<SEC-DOCUMENT>0000059478-21-000216.txt : 20211027
<SEC-HEADER>0000059478-21-000216.hdr.sgml : 20211027
<ACCEPTANCE-DATETIME>20211027090659
ACCESSION NUMBER:		0000059478-21-000216
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		68
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211027
DATE AS OF CHANGE:		20211027

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELI LILLY & Co
		CENTRAL INDEX KEY:			0000059478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				350470950
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06351
		FILM NUMBER:		211350953

	BUSINESS ADDRESS:	
		STREET 1:		LILLY CORPORATE CTR
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285
		BUSINESS PHONE:		3172762000

	MAIL ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LILLY ELI & CO
		DATE OF NAME CHANGE:	19941024
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>lly-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:83f390d0-6781-4e7e-a1f5-5192701136a4,g:3039e280-7bbd-437e-b91e-6280679dfdce,d:48af34e12713400c858f7a29183e5680--><html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:lly="http://www.lilly.com/20210930" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lly-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" format="ixt:fixed-false" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80L2ZyYWc6YzE4M2RjOThlOWViNDM1MjgyYzgyM2I5NWZiNTMzZDEvdGFibGU6NjJkNDVlN2Q0MWNmNDY2Njg0ZGFmN2Q0NWE3YTk1ZWMvdGFibGVyYW5nZTo2MmQ0NWU3ZDQxY2Y0NjY2ODRkYWY3ZDQ1YTdhOTVlY18zLTEtMS0xLTE_2d2a7254-7d9a-4aaa-9102-df902cb79d94">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80L2ZyYWc6YzE4M2RjOThlOWViNDM1MjgyYzgyM2I5NWZiNTMzZDEvdGFibGU6NjJkNDVlN2Q0MWNmNDY2Njg0ZGFmN2Q0NWE3YTk1ZWMvdGFibGVyYW5nZTo2MmQ0NWU3ZDQxY2Y0NjY2ODRkYWY3ZDQ1YTdhOTVlY180LTEtMS0xLTE_7d5d6d3e-b874-4096-9353-4e38adb404e5">2021</ix:nonNumeric><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80L2ZyYWc6YzE4M2RjOThlOWViNDM1MjgyYzgyM2I5NWZiNTMzZDEvdGFibGU6NjJkNDVlN2Q0MWNmNDY2Njg0ZGFmN2Q0NWE3YTk1ZWMvdGFibGVyYW5nZTo2MmQ0NWU3ZDQxY2Y0NjY2ODRkYWY3ZDQ1YTdhOTVlY181LTEtMS0xLTE_c815e478-01e0-41a7-96a3-28346cc5ed9b">Q3</ix:nonNumeric><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80L2ZyYWc6YzE4M2RjOThlOWViNDM1MjgyYzgyM2I5NWZiNTMzZDEvdGFibGU6NjJkNDVlN2Q0MWNmNDY2Njg0ZGFmN2Q0NWE3YTk1ZWMvdGFibGVyYW5nZTo2MmQ0NWU3ZDQxY2Y0NjY2ODRkYWY3ZDQ1YTdhOTVlY182LTEtMS0xLTE_f8d4b19c-ecbc-4209-83a2-a5e84f2d07f9">0000059478</ix:nonNumeric><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" format="ixt:date-month-day" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80L2ZyYWc6YzE4M2RjOThlOWViNDM1MjgyYzgyM2I5NWZiNTMzZDEvdGFibGU6NjJkNDVlN2Q0MWNmNDY2Njg0ZGFmN2Q0NWE3YTk1ZWMvdGFibGVyYW5nZTo2MmQ0NWU3ZDQxY2Y0NjY2ODRkYWY3ZDQ1YTdhOTVlY183LTEtMS0xLTE_c510a59d-5daa-4957-a37e-34563ce60f09">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i13bb526970b946c4a88c0fdfe320bd02_D20191201-20191231" format="ixt-sec:durday" name="lly:LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83Ni9mcmFnOmQ5YTM1OTUwMDNmOTRjMWY5NGM2NTcxYjIwNGMxNzU0L3RleHRyZWdpb246ZDlhMzU5NTAwM2Y5NGMxZjk0YzY1NzFiMjA0YzE3NTRfNTA3_71b706d2-671a-4cfb-9a07-6a78cd599e24">21</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lly-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f70d4ddb50548fc9ed454e70437d29f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee28461a11ce40dd892a5d1af3d82bc3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.000NotesDueJune22022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a43a3f2ce8e49b3b401dcf8182bda5e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb1af12eeba04c0f906f5e5eb7425b07_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i753e0f88d69d41e891ceddd7541604a2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66895af514214364a9f5110c5ce8708d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7531f4ca382a43839cf3a3b4014bb13b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A5000NotesDue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i972a26e5571a4689b6a657c98879bc5b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd06d4fd694d41f1b11ae0159a256cbf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff4a44c5161c49a984d21cfcdf9ec6cc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec85e79d1f4b4520aaed094ce2211f85_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26ec5aeeab074242968c82cb92e236a7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i738a150fa85d48f491f84c759c959068_I20211022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ie526750480d147ff852c5266a9af6876_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie146f46cbfc341289d8af574772b4b88_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6269e3039a904047803aaf8c59d2c31e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i277f40e31a78476c8a25e89e3ad7fad7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i480c67fa255d4952aec1ce6fdc96a5cf_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie79822b045d24ca8816e16c558b018d9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c4de3b4868049e78934ed4495abd9dc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i292925605a554dd98b2bb9c1601dcacd_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cc02b3f1ff146b89aaf8d18611bff3a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9b17be62717498291500daeab724167_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i128373a43773438d93068364bbda7364_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i646c747914e84ad991f450bbec883d19_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i527414e868ec4177853d359e75ca6df1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cd72451146c46faa7d53de5bc28c3ac_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2dc23546086416285bbd41e25d62584_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74a77b8d5d984968b3c4578e17bbb5e9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36d3b669185e44dbbd9e6e8943ab4f6a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie279100c0102406e93bb14b4657500dc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28b47563db924e53a3b01da85a1c1857_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b458bdf7deb40b29fead2a4923fcdc0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic401234ddcb24a04b3a48f1e46bb9d26_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9230f02f9af8414aaa820e4637091e33_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i661e35a5d390434383f2e73f7a2a947c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9b807fcb6dd415889f60755aa586d46_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7557d0c1a88148acb26d4de3f94524bd_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2f9c0959ab041ef9cd49b71327449cd_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e006e6aa4cf4c4c8d995f6d7ef007b3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id48ee4fdf79b43f68e80f1116057e733_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d263bfcfede470e849adc44fbd95b02_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4489a9298a74411cb30a8b6d1d8c0a5a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i408826e558824625a2ca711ba35a4da0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d29538f03db4d85830f1a00e8cc2a3d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9112ede45bca4fa485446dc88c3c5484_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b653f1fba914f8dbac7b520ac3265a7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83143935f8da447d9261cebfc72ce7ff_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bb41cf2a9504b31b3ee0af14c18f87f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22679a982313462397a5663f58993f05_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d120ba2343e410780602579de874a5f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0287914b178a46d4be80deab95a97314_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie425975ac2314fc3bf1853a1bc359060_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5af76f55c3349ba859b1f9206178021_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8b0a3ca285542978d0be33bc0249ffb_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i612deeb868604a2c937e486f25fce6f6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a83d082225245798aa0f1e672ee7810_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05ea4e8d0df642af8b6a87953f1f8e23_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i177bd18351114d5c8ae70dbc77c8660c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4622633489fa4632a9800fb6fb1326c9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i831186dd08c8458bb74c88268733509a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2781ee2a1570463cb045238d0fe460f5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id986361421254ab4997b4c92dec009d3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i252777c0f5ec42bb81ec84d8bffeaebc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0f254d6b3ea463b8d26b218473a23dd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b73aed77d4d4a3aa3b99395305f0cb5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i252f3fa632ef43be9ad24db3bffe5ad8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22b957be322b4417a234d68dfb557223_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iead50fa9bd39400bb6f8a9b5d3d03acd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90982ebb563845899ddc7a66f27f1455_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a74fbbdc9ac408e8912ccf4e1576ae8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice93dc7ac1da463ea4ecca4d2fba8434_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0aebdc3dbd54d82a80cf1b888beb150_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76fda2c740f94c7ca2ee9b4ceda0b709_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd1b1734812948e294108968f3a834d3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i218e2fbd7bbc48deba986aa580060342_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44128d85d4474ad681fc84f6f83f73b7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i741888a65d6744479381fb901e13925c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdd23d64b8ba4239ab77fe5df21cd6d5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08ae5e3d75fc49a3b01da53199cc2e26_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79216bede2b24f049a04d252ea215271_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic89977d02ab1401dbc23753322c8563b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idac57d16ce9f4dcb9b27d234834a1cc0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3751844cca5948b7a2fad81b7407b645_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9740fd412b0b4c8b8920a13188bc08f6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i008aee30db1f4ed2b8bb7a205e2a213a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6e915f6611043fda08216f49f3b300a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib870f3d12a3f45ffba916dc4a4d8bc56_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8622b2e9dd4842da9e583319c95a3d10_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82cca299a87747259a76bff17b9d3f03_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b10af06686e401d9bc0772daa1af568_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2afe7200511442b9be37640fe7d2a7f4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33cd075c62264add8dfcb7b313a654d0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba7b305393e54b31bccb95fbd0f79f67_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69d6b9eefe5e435997214a4dc60d7f32_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i61a4e12edfa84ace81f68212f895f984_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c7c7535680c41bdb5edaa1a9d31b011_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75ef086b481246719964b43441307bdb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5618c9f0179444b3b10b8ab8e3e9bef3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i619decfb20794db0b459aef3c32bc5e6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ac5fda408e6497890499865b967861b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a9cefb7c292416bb0d6ebbb330edbc3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c1d6f95905448d385eb2e6e6dae543f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i143a18efe3784ef881f53727b5686001_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4197f4f08df34479bd091bfc5c54df55_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3615f0b224ea424280772b92ec8e7d2e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc03cbb9d199450ea24aed63300c9230_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i636a3552add040f5ad7def2b7dd765bc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0bcc0407fc64c0286f70bd29d8897e6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if95e2942890f4e65b9ee7a2130447a4a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e2e117448cb42c2a288857bc438f50f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f0f99a60bc04551b5ae2d2be7ceceb1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2467cd73fd4349ddbfa9e1baf740e12c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7a26c27a65f403eb8beb3df6550f89c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fa2f284977c46d9989820ed12d7553f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1cd05c961fe4864a7ad4058c5bb2cbe_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc63f2b4f3ad4a38885421b13733cfbd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1843d4702b74c9b8adbaf5ab7aae759_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf7ecd718b194d13826533eda4fbf459_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dc7e770251b4603b707a2b28a01efc6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6efe748f82424164bff261d4d56704a4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e1edb9e5a264ddaa2145ab88b861f25_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e0bd74a50404b86b9780ef0d7574708_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23405a005d0043188b612fbd2cb9a01c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f5d4c7e9fc24d87a56948514836e08b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcd5ed73cc264b21bfcf6eb9c75a76f1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc683f8f7aec487db1c97534775202e0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i013c2fd777cb4ad78b3588d03b646777_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4c206cb2e614db381ab7a7d1967bd03_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad1245294846401dbd994a69555c3b22_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id662cd6af0a1437492d74860015d4dd3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic60d8559880548869550b76fd7e1622c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81fb83afd9174a4584c76d363f319ed7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cfded4b3a63477dab06f1ce39f440c2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b041f3ba59449439e77c6a72a154148_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71a09b1522b247eb870ad3c04226f894_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if07f1bed036f4a8cab6b04215059a9a0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a81a76397d14cf3920f2f8dc0aff2ad_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66fe92bb4b37478283f0fcde0b4655e7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35a15d4ca7a14c94906cb2cb75408325_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e81fb756b57423eb9b5630c52df179d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i833d461ea6104a85b39825c841b91425_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f9102a7fb8049fa9237e84cee584b52_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fc787ae1bbb4d8cb11f4f23e454b76c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65bdcc2ecaf44f2393df1548f2ca567b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91e9f2f10aae452e851237fa01acebad_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f970f1846c9427d96a62ed28a252336_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i808fde7a4bcc424abe955ca582b6c429_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cb18d4711ef487292258d52ebcbb56f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85255af923d2412cadfe050e3f55be5a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55b77fb4de574805b40a93cc0c77e784_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i610e677c79024836a14be2d01ea5588e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6adc0c0529714689a5664f338caae315_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac732504ce454cb9af710f8437b31b72_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad7f4df9b6b44f7b8942015b498f808e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9596c4e04274bb8b84585df2008c087_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3cadcc0ccc047aeadd216305626ae7e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b7407649b1a42b38ee51c3819e286b9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74f827e23ec74d3592ec62c9d8a24045_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f64171c60cb40589455a45ddebdb7f0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87336623af3c4094ae1f02a8981d1c87_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44aed9a2ff864ffbb9dabb42a9652a4d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ae25d95b4f8443e97e0378c32d9625a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34c6cc4dbeb24eeb82e00b1ebe898947_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99138be47ed847849c3df6c670763516_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafb2cb4b4ba94633a0d9effd3535a22d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94a1de0c39bb4d91a6b8220fd88cc995_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i897388675b95435fb4f36e6b1e6cd6f9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8207dcbe71c47eca3c2f1096df4b7a8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id34b15be682a4e5cafaba09fd90dc0a3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33b4d90ccdd9479fa1adc0ede684c6b6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dbd0fc64d85402a8c6614d6d2cc1b34_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i252c837f8bcb4ac0b13f2285fadeb589_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7569cb5db95e4d16ab9bf1906d28a414_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e344efb8a154f9293c35b2a2071dea2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bc5a0211b694ef1ad818a7c769134c9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79cde695c635485fb5969cbeffb8ee65_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79a992ad9b904ca59f6786e45f7b37de_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id598f2d470ee46d09e2445b9507ad3f2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8103205049b472f8eae31d6a58e53a8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if532b94bdbac4bce82537f40e4a0cf51_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafbd8b57ba564ee298f69bd41e7e8601_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e4c02ed82d7415eb7c1bcf15c6c21b8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d59e5583c8648d7b78f39b5a5466a11_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6aab2127a004f0ba2023cc7bf0b485e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia56673e90d78440b919786ca8b4e5230_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0f342cfe7ed447c972ee626e06d8847_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f56993e98d5433a8d3954524f86fd8d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77fbbc9968cf4bb18902690fe1fd8686_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad10567d7217449bb0a0eacc29b03bb1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28a2e586d3c54230929df1bb15cecbc0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb79dda4914c4c118d30138f4db6d0c9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia634a6f32f8d47e087b88320b460594d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc9c80adfe494319a49b462b4c84e227_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89bc1277904f44ebb00cc1c346f34407_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc39388717ab43b39a31ccad3c4b5ae1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i391eae2ff09a4964b6b7b192b55be566_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i252d50dbb8234dcaa62617a57a7f132c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87081eb668e448cca72a3cfd33b884eb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3510314a6b1348e1ad1a289c769221a5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69df563139e5499c9977856b5c047b89_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3eefcda66434dc7bdb28af6eacee5ae_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide62ca0bafc24f6189c5766c74864a61_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fc211aaf0c04cde8b946bf6a6c2101c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ae2f07cc5ec45d7b4df160393ddcfeb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17c7b300da94407dacde87022ba06fe4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a964d449ac84c94b6a4e507792eaf2d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e0ddfd3674c4908827fced5b7901b52_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65e6b9bae263441f8bb7c2a734d070c0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i603eda46c0be4d8b86ba9ef36bd2af4d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fbcaa2d029c4c05bafbb0400bfe6df8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1492ec6093ff478e916d7d23f4f020ab_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60dde10942844b47a3c7d72ca1e89c00_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9a4c536cd364a3fb26c3f2186868f7d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3881ab6fddaf4d0397d1251b9b335eaf_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5821c8abb9f442939c46c5f2ea55e15a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f20b6672fbd429cbc47b24cc460ae1b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bac77c719ed47c6b5e1daba371ea914_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcff59ffda63475ea32a7379c4669b03_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2f4b471c7e348ca914c418fd367c183_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd4429e99d4349deb077d59d1dad17eb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceae9cbc8e6f428cac0b0351b0034ee5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92d973cd4a0a4537962a3af58489887b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifebda85ec8dd4ce192a74a6531b9d614_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe8ab0e4d8fd4cfd9126dfb95a32ada2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3921ded1beba40848d3de915564681a9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7659a70032347a1a0b90552b4d62ed3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i186444e26ab54d898b6b15b3ec836f25_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i453051ae80004c3eaa95fb204101dd02_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31a4994fe4e0451d9b0de9fc4cc45241_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib39a29f5f552438ea4ed0f6636e277a8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i052653fc20254249a0de9e128a7c2a7b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i089ee5a884734f048eeee3e2567bf7ce_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i292fa580da6a4de9822a300c2b0366fa_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a55f0b0a5af4394ad7de980181c592f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a2b9316931c41cbad3fbe52783bbc71_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cc53c31079d4498baf5c2908aa20aa4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71b81d21fbe94b4e98b74b22e329e4fe_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i083918a48bb449d78ad626ecb038546e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1915b82ef0745bc9e6902e358dcf426_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1382419146344dc79bef45e72e6ff200_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7998ccfffad54f5a9b058726aa6b7326_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55ecf9bd230b4e6f9a61f2f6dd604b6a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd86bf7f1e8344b3a7dbfbaf21dd0e6a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51349dbae1e142efbd09be3fc1d7902d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie18eb8b2caaa4e6bba191b1bd794bac5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i517eba3441bc456fbc2a2c195f1e25bf_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe5334101eb14c808e2139001ea4c06e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia255d15fc6ff4cff922a9ee2fb0c0e96_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bb5a4110102404cbfd2c7b4ba607883_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cf54671a7af41728bdbea955e0f5c5f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8890bd1f5f1a4efaaaca2db702f79703_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i959c1d63793f4187b23a4c1b7682d284_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbe2a3bad44c450a8397960daacfd707_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19c6a9959ea140fd9890927f182fe605_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic46899cdc2a5456f9e0611bd0426b4fd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf2deaf4d18c449490361e41a4ac0cef_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i289d3252ca6a485f820ef1ea3ad85c12_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i784dad6404be43dfb6fc2b79158399e7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaa3e0c977aa4404a714b3813766c78f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82485c3a3fba4749bfbbb721e21e7f30_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58158972e0264a6fa5cee16276b66a34_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3ec4f79f58b44a296e438bfeb9305c9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddc5a8ab9f9e49e9b1727ce623456ec5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fe1bbef48c94f69a1e7eb1738576328_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41665e7d5323479fa5a85ac7afd7a612_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id54a327ff97d4ef9958f15bb7ed74770_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd448a0d7d984d978046eded1bdbef98_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if41782491b964242bf0779976ed75cfc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0fa9309b68448efb27e0f24f9cfa0a4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecf6d4dabc7f494caae8aa84b2e0e2bc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida742051726641c1a38ba8085a59818b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8afbe65684454a96aad4f5fcc43bb2f2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c156843918049c3b017e903d0c8b152_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c0e23525a404bd980161347b9d48297_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f487e07da6a4df7beced03386ce2cb2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifda1418c5f224ffabb56a4cd20894bb4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21f5c26534d04950a2d18f70db623648_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd90c62ee1c04e2e80e99978c6745eb9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i392ba95f36004b559b3dabf4a7d68df7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78362cdcc41745bb8bda6133796f6fd2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b810a3d51924e95aeb4d64791147211_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d57ac52c7bb44dba43dbba774be4bf2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f3d83ab14504b6689cc76eec030040f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a6c69c487df42779007c37685f53e85_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c5cb50d0a384037b1da389f2a6e0996_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5877d4ccd49f4569b4e2595a05ac782b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee73ab780a8f46d8b5fd8ade8860c89a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfc25dba031242f7b3f38ee74a40876d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7646113be96547db8a4bb44230ae23e6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe4ca92881b34f2d87b3d3d4afee83d4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f931c0b571a4fe0ba04399bb7cf2882_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6079c23287c458d90dcf5793335aca1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45f071d62d774401ae3df21bca257b94_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6bfac32d58a4b7db6eb70dfb23fd9fd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic485be951f44461b83f7178570da126d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i399cec6d60df445682e5e26167ab0fa6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib84ab601c2e045f9b4f9ff1a30e0787a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f09f9b3b0ed4eeaadea6c487497dc7e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0327ede8f6347659e88e5324c757fc9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9fdd628b285469fb2e83ec947cf3bb1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i397a56587b474dc5810261bc659887e2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacfcc3433c15426bac8a79d18149a311_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fda94809a0f43ca9938efc6f0994e74_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd07e050427d4b0495759b6f44c3273e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4d463248ad74b09a08446c68620a3e1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0185d32bea7d4ee0b0b5e34fbac1fa96_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03a83d2e4f15480780af7cc663a095e8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafb64cc18d0c4af79c7b894a05a665e1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d04d41e5ada46e1a63e592fc6a9b2d2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i652338f7e46b486589e3d75d6a3de4a0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i705897b88c1c4bc9ae28abf5053986a2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73e2acd9dcfc42759dfd0fcf3b77d702_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if46b1191ac1c46e9b91d7193b8f302bd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica3c1e4736274954a8d703df9c2b167a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a497c7c118f46e98f40fdba8afad80b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa5c550586744b789a920295b90fe29b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99d38563475f4c678f23755bdbf34b9e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc96b44a7e7c4b2d9067f6309c9e0981_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4dee8841aff467e8d34d2a66b5ede53_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aa0f1db9a924a86a4539ed44bb03cf4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55ad0c64dc4445c8b5360106446e4e0e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i619fc1a06c8e4e23955358634606df7a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b9c66fd8850463dabe617b7427612b9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90fe301cd12a458a8609a9e6744b77c2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc36beb9b14e4b9783e4927f8ff53209_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fc16180ac704e6f8cae3536cc15fc44_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1974eeef369549dc94df5ceef4375ee4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4683a7953b994727aa54bdf352b5d02d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cda66e9d3f64ed7b5ab5be8945ea9dd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0289a925449c4af893800c44334d7179_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i760c1d6d41874cbba99a6b0a36e9dbfc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9171d813dd8744aa8ebf6be081733303_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia12001823d9949fbaf94effdadcee1f0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i374b134314ff4f75bf1e218faeb7a140_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a772071ec7b42b5a35616776c47cc46_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a60daf847d84c269726d5443505a7f6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea2febe706a44680bc01a519177d071a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d5607f6891d49dea32ba497824c5cf6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47a1977d3def441282bd0a67b40c3f58_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6922b33207dc47c696a18cd215b4fc89_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99b621e206fb43b2af4e311739f64ce3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i721201b823f24281ab0040324500b66f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i390fccc895414dbc80bc7b21902083d8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3b5806021254319908670087ba01693_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12d8057fb6f44881adf62c66da12a47b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d2c31facfd84348940f0a8c61dbc204_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5f004ac1b604026a7bc7798d77ef19e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i469dc8fbbc274df3ac3a499298b1aaa1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia11ae3c44d264cff812e96e38e8bcecc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77eccb6aa9be4aadabe9b433c7c2d2c4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cd766bc4a6a436d9bc943dc45e61200_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i738ee12d2f674f3d8ecab5b26681f558_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90f1e252129e42289186cf041bf33a8e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a6eb6ab1d454923bb5c11298dc3ad33_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44f8e7433d104910ac58ce5909942f8d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fda936960b8455e927557e937bd1b99_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bf37d8e1a9840ff840b07a02b3d5386_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i800cc0342090483daa741525f8744ff3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5551db7f547e415f84b80f7c3b385f9b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e75cf8e17334bd7905b58023a170fa9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabc3b21ccc994e3890088301e3cfc653_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4683cd0b47d404d9b3503f7a600a568_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2e4795f073d468fac40d557656ecda2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id06212a669134804953343ff9b9678f8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie85525da43ff40e380aee019e6218166_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if93d6526b32048608464727fad92c9bb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d1869f9b9284dfcbe120478faa3f6cc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i184a7a62437441fe889424d1df050960_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1d8fa886c14458d88747c5a3f5ebeac_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b1a3020e2314eaaacf0bd2fc78d63c1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bc589b7bd644e10835ebc480ec4a412_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18de420a47cf41a793c58b470768a0e8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb9be07b275a40f8852a6c540fe99af8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2861a0c3822428d869e6001e7582ec3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id05ffc1309fe428888516a9c3f40e7a7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id34d06576e4145798da69e8840b8ea78_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if71dd64ea4de44d9afaf6d6a512ba1db_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12b21ce236de4ed8bf7e747d6eea29ff_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1523e93b1ffd4b70acacf4087551c5db_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2bc530014104c0cb422de56d4d03e82_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9e84e4ca8de4c4b97234a747132a31e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38c6380bb9864e3587fe92837bf5d091_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc35c7271a8a4943a6227055ab125eb0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a99b6d9c4c747ce99e9e703d54444b3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i491c10fe08e342f4a4ac07e509c92936_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i816868a48c8b48099f4d274ded2ea7ed_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc3314eed4cb4b9d8584ffe6c2837839_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i624804e1e29b4c2f970fd6fb40049075_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76a9135fab1f4504b803607fb262021d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e0b11e3d0d14a5baf6de15812c649f2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd82f3451e814629b0bd328a44af9778_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i399f4d91b8034567938ddf63d2231514_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b3ace2be01a4932a527ada8b0e95c08_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cec004919c74d1abb18678fa0d18ec8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie56c114480404e369f4c566552d2726d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i273b596e58b94897a35fd6eaf5a112bb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if68930386e0e490d9cc62c2853246366_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2219da41e098458f8e17480a24f019ae_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc7fc4722f76404a8a37d85632337dbc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00900522405a4bb38276038085c324e4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86b2429251b54a7389aab14092777b48_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffa2fbcd9aae4080910c4a7ea104fd94_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id60f7f14418c463da58451d606950976_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie16f11aac59c4ca3a1b1d3532c9651a5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a99b63187cb430c89fd5d3823917b2d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dd55add52d845c6a51186e6507d9fd1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i610c7613e7d44f308a44a6dc9bbbaaf3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96c837650d554f56a6200ace6566fe10_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic36dcc53ac3e4228adb3e7a26ca46465_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i133749f5535c426db6fff5b68d432a9a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib066c49389e847e08dd9e47b3dd013ff_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00cdf12927374e9ea2bd4fd171d087a8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8046f99bbe284c3ba18f324d7e76338d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia784a32e102a4a3c897cd146133b8efa_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f926fe8ad974b88bb900b9493519ef1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6aab15dd89e4fb29adda466320b7ab7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2214d9b014994300805fe9c16ab74705_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba10a9ccc98d4a24b8827dac6bfff7da_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9600095f80154ce7888d5d052fbc1c34_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2d77207bbde4ab49c305e35c7f2a45f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i197272b1a6734b7c91e241f32e6dd646_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd45ae5c53e04751870a061d88a445ce_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31c1a896fd4244b5a8e15e4ac8abb96b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f6f899a265e4b63b17af12da3b7c5b8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i847263e5354d4a72a9f742d7dbe5f329_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c361d809be0426984f9993fb59eccd6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i608a490542db4b6893542e7e7a64f228_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dc52535a84848d5a963a822901590da_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcf246e7d1304af48b16a8f5ee00dc49_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a2c4c9002a344d1bd2cb16fc80b4bf3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33e9f09317ba4403a2235be6dea1faa9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39c4874639894af4bbd798a405ef14f9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide834e2a43444a5cb9b3500607e4ff20_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b5acdd57ce5404da6a626cbe3b64a5e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if99f841c17e145b28e1c88eceea31bab_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i863ea645f4b549408c451c4882b42085_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic231bc3ee12e4b1285ddceb9e02b4a26_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ef4e15111c14cd19aa8255c772b5d92_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2a183d7003942d49ed5ae4cef5356cb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i428cf713dc7b4901beedaa25a7950476_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b9750abc82c4253b256ba599ee15596_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2b62bc7ef73412295dc475eeadec217_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3c0a13a33a349aa92d5012e4b636a7a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i669cb3004ae84cf6960440516244078b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id268ee0f04df42a4a96c475b5cfcbcc9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib82ffaddfbef4082af244efc218be24a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14d504c5ac9c4198822bc799884207ec_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idce8121dee4344e18147fc49a8d5a07b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib632c646a6e9448cbae9a56d4a57fbfc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbc00e7246a6407b8cc8a82ca741b867_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5391e5cb27db47b8ba06894098bd568e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9971c726971d4e269f7742be265aaaa7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f70dfeee6ed4ead97768caa6e0b0573_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37a3d265d5664f4fac0555e3347dda9a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id317a865e2e349898f18728c5ca604b3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d381b3aade5467ea39cf273c6cc47ae_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dd27416e4d244238ac2cf4eafcbc5e3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i468cf70e06e74d9abb4442d6f2e6ac71_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34f0affb1412406985b955e8954cdf8e_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69178206ce654ab9873b9e9c1d36fa34_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="right"><xbrli:measure>lly:right</xbrli:measure></xbrli:unit><xbrli:context id="ibb396fb0bb334dbdb983642373e2383a_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0548c5b9afb4dfb8d20e8ccf806b912_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3663573ba3c48a5bdcf5eb80a22298a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b575113de824b30a1c74f39db88aefd_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:PrecisionBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6e905c8a80b4d38b9c543fb5bf2ef03_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9500cb4fcb444bd2b15d0629279eaf70_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:AsahiKaseiPharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa35124ffe304988988994e711548e86_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:RigelPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a14466d4a0e4b20bc65b50a6842b2f5_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:MiNATherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i870c4b4df8a341cc9b9dab7c879317b8_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:ProtomerTechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dd9b9e634e34e57897aaaf824716990_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:KumquatBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide01e64c4e60431ba5c28356bcc7cb42_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:LyciaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ed04cd38d964fc2af21956c88de5379_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:ProQRTherapeuticsNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i531eb44bb094404198d87fc5156c354e_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:SitryxTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ca3bd941a584b85b1b0b4d72b454dda_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:AbCelleraBiologicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibab640a2f0fa4cf195eec35598754f90_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a26ac8fb34d4458b120b7a6bc3235c0_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:PetraPharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20e4f1b2ae08456c8caf48e2e1fdbe90_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:EvoxTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cb5bd55318443f49ec7b5fbcc892280_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:AbCelleraBiologicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2711efdfc53c49bd9e0e8915915d9f02_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1acc40e06de4a0f94f52199958700b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb083c377a2b4107a6eb8d5b758dee94_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc5eafc995df4bbc9a45fd9e9b60dd25_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba9b3f1d338b4eda841d752024c756c7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46d24272d19741b5a607f6c2f4e46637_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5010b2b7e5545ed8348dbdee8d74c25_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae1bfc71fb534381a72a38855339542f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic26a9205f4884f5fafe309bf577ca246_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if23d24438d434f35937e458ed4abff61_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib280a0fecb8d4d45a80cbda714aed6f5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3551bdde470b46ae9c137fe74872a446_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27a8de99546f46b5b97d0667185d1775_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ac78500f4494fa597feac64cdfc42b7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i832240d2148c4ade980357dce8b58dcf_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ba69dd64a4449d7b5cc355b8cdb4e0c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1df26c2f1ab404684e40f47a90f31a2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1c05dd0b56b403e9e561ab09c6adf97_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib67b5243a6ad40ec868a47e512875138_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:NonCHINAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fabc22c5af942a5bb088863f27e3c17_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cdf764053f54a69bddcc58019bd9a9c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ed81d6975474a5abcbc174337c27bd4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie35017a9e84c4b85960feecbdacbbfd4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a58e1d1992e4f0e821edbda0434c22b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i212f03ee260a4a1d8b38aa6b588dc87e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e7d5f5212014d5fb1eecf77eb35a41b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9d50a42ad904e8cbe293593bfa34095_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsContingentUponInitiationOfPhaseITrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:PetraPharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea65191ac5fc4dbb8e7121cae60f91a9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:PetraPharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3e68e01c19a4aaa93a9c6e8d4d5ca0f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUsDollarSellEuroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i3c88f68cc2d7438497246b3d6404eead_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyEuroSellUsDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a4f51f3d44f4d129128571ca91c4045_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSDollarSellChineseYuanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cny"><xbrli:measure>iso4217:CNY</xbrli:measure></xbrli:unit><xbrli:context id="ia65189ebfe674bcdaa496351f69f95ed_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSdollarSellJapaneseYenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="i608ccb2010534f3489d040d1051be217_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyBritishPoundandSellUSDollarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51538ef7c00c4b7ca042552f8fcf1b56_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2282403149944b6a454777d0cbe119e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifec1b340db5a429986bb4f14e4d51236_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapU.S.DollarsToEuroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id050ee0435604da9889144406e53ddb1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapSwissFrancsToU.S.DollarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a30bd1d6f09458d9b484f6eede92a0b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0197954b7f246438579f727a96ba302_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A5000NotesDue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a56fd67eaa446d58b10847878682132_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf519817e48d4e2aa20f61c0464569ac_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if42acdc6f14644c49737fbdd91a729b4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0007a0646ac4490fab4a90fe8acda870_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic965f0de559d414494ead6ebab58b9b6_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib811247eae3e4f2c950b855814774a4e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdef17a4b3924ef18dc393a876d0f969_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59558243da25489986f3aa7a759e9236_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i630bb94f7a0241fc85ecb2d9d7c1705e_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i246b98760440439aa55a1d9c36f1efc2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83977bd0653b402a9c4271c7b321f9a4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39101bb15f78410c92851ae13eb04f8f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc0dc774626d4895bcd260e8b1e00a1c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49a37f83c03b41ed93d44441b19d8ce5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i864b815909f7410a8ae48163786157ed_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a61299558154a88a75737f4e52e86db_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2460f130430a483aa8e55f391938b835_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cc83e8355fd4482bebf96cb53270e2a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d6ca7bce852474597f1638b0244034b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4372afcae30c4182a4a4b043e87b2b28_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8b918e825124054b3c412a4eb18978d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75f82b84a5c44509970d0b0205ee4b7a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c88bbe6ccfc45ef949dcef76b904617_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i937f1bdb1bc1479a931e868c6d681bbe_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd44da12be9b4958bc40d1622ff85d3d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0315d885ffd4214b0351c0717eb4c2d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaeede8153e14149b4dd378cfd5bb59e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f55cc8a2fb64fcb9720f4b9b61421d6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8ef8f194e1446699469424765ff1fa8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if92f732c456441e6ad74d4c284c639fb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67dbdc3d2d474dbabc54a7a74c1ea885_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie121f355ecb34b25b0508086f86f2a6c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ba09cfe8cfa4f10bc560bc45b9319b5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i864500d9b5b94bfaaa7d9ea71c3b0c26_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42cf035468e94826ad3cde71dde916af_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id79d99cd800d4ad28394d8150c6332df_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2a25406ea954c5f8992888e7c738569_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e8ec6c42f514d1e80c619a050d59507_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab73c3bd3fe34c699b5cb054ccb42a6b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf8e31e25410469a84688b7fb5b87b90_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44ef377c866e48298d0988babb457ef5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ad610fc9575465b996c10f1fb676d8e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e0450a0148940568359bd2bb4fd1c7a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie387bef8710440e4832f0dd71a46bba0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05166d7e427248f89521f9a6bcdaa937_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i519a8c1745264739b16980e97bd28088_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6137cc328cc64a7b8e6dc90a371cff51_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ac4ef28e5ea4608a5b80501977931f5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1b8587493d44060ac22b7dfc95bcf5b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i254a65a32a434ab6b7ef57c8e79f3444_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0eea1fbbff8437281fea8e1a0f1bef3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a167b8fec544f85a40ec24ff3dca2ae_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8271ad9786914a7b9146b4cac43d9253_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9346e5ce6da0496eb9220c6582e6049a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68599e7c7d4b45eca411fa801f914c08_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3674d32a89aa4e689ac0f2091ddd444f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i600421af4c80421291f0d5e08ea11d36_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i027d17439d6c44daaa8479672e90cc93_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec3eb54ea13545388e93581cfd374f6b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a3380d8d6904862a95b183e88d6721d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f93a011c64e4f2c94195e681aac557a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife05bc1f99a24066a3787f493ad65c20_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i667849e28703418487b214fec3474bdf_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i175f9851b84d40c69587dda3c8dc10b9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida2502dbdf2544cb9724ce9126589989_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e73b6978a284142bdbfa2193963e239_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7df8c985cdf740f7bae9773aa95472ab_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59605113a4b745c8bb79328b1a984d9e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bf8581a0b224377866093121945c682_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i994afc29ec17435a9bee9daefa8e55bb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8242f0bb64934a2f96b9efb3621ba78f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac3d68dc29d04fa68b9b49b08724abb8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1917512fec5348218ab246fc29ac8b87_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03ec7add2c2b40edbdc4d76abab59030_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ee0ce7fbbd74335ae49c786f5ce512f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52017fe562964955b55493c294addb61_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id52dc374b89b4866b4adf274c2fa1a1e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5c4cc06a6de46e1aad4f9ff97b84c27_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i225a1a562a4642abb6920b01f2fbb477_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5501586573ce4f1cbc984235a5fde549_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i770397553c8b4514ae29bcfa65ceee7b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b9c433fde8f4a7b8dc0cbfd63eae7e9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6bfbe4f40464147acb2b478e7971494_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7edbfa9acbdb4bc6a481ff5ca1ce3c46_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f2ea2a6d6594fc5a90ebcefa22bf6ed_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad249b87b2f44e35b139a24f5d4d84db_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87dfd73c05814b0fbc8871daab747004_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cb6f993649c432f91ab9ca4b71ffef8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fe77029755145319472019556e746c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96ca3e07a01148b094a43c55448e4efb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1e0615e204f473cba443f60b3f7de5f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05295ce03244400fa6766b9e219b8bf3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fa9cde6db5c48a49a12b2bf050fed02_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08e5d8fcb3fd44119480db6dbff280ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied8184781f424f29a27dadddc6ed8731_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a9d1a3a1cff4a65a746020df220cf2f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65469da25ad54c90b48a89c0f3bf3d24_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id88987a437d54b93a06bb21dda0b2e94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic54aa0ee54c84aa7b85f303e4d069d0d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae50a005012c4da184ec9eab81c511a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id30187a0d3b642f182acd93577234424_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if108dc8c33db49f1b50918a4d21f04b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1d6a3638c5d4a708badbca1668d1e74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafebeab06586446d912397c6fb09946f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i559d13b3f37b4eb4ab054a4bce781df7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id471726344764ff2b385dbc67cf0ff8c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i579833d7d4e94e06b8586597ea11d6be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i529b971a380a4005bfd7acd5587ded3e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc82ddb19c4945f884bbc5cd15cb96f4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f53adcd59224d2687568795466dfc6f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f2b5896fbb642c0a0b59d18c9b0e845_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10c6b8bdcad04d0d88e821b45c159a43_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i034058bf069a4dbcaae7e84a4aa255ae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0365c0c3dd2458dae2cab0433af8f3e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19165abf56a04452a4c3551fe3755e80_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i289304fc14e749fea082a39de3765686_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38b1cd4f68cc409893c60409151dc138_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0246f3af391442d94cfbdb8ee92c330_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i647c8bc2ff894d94933a6d11cfd86f10_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07aa6c9aa38745159a6c6e80527e089c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0d94775a2e4434f8f30c1ad2daaa4be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb3a371deaa94088a0072db110d4390c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bf5bc5acb2d44fdb267cb99d8658e57_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61279d09c7f74590ba3c78f533210f01_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09e35a2009cd4049b44091d2fbad8303_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e126e3688134c3599ff5a999c9c666e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d5ca9edfa0a4d2e8a076d65f4bf86f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bfadc646ecc4dc6b43cf57447e0394b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32ae0f6ced194431824adea4c4770c08_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bf0bd0fc1154e00a1a1c2c3d2110606_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fff8d67cdfe4a6694c7c5b6f0cb54c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44c59f63225e4451a3244ff421561da5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90ec35ef834d4369a726dac716752c0a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if06045f0fcf1478f9c730dddb34ab7ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2da876ea43f4439ebedccb5d73cf5b3b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib359550524f54c8f8a3d1f33d72a5dda_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i505924e93d794dcfb0c5b8f9156cc31d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib69916829c7f4e9fbfb75dc86bee47ef_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide74b136d9db45dc9cd0829ce1591b43_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66fa7e1e841c4a48bef41810792cf5e1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95b523dd0c89497e8d0a8474b6749ceb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffd5ed0fac1144d3bbe9bcce7cd1dcab_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c09bc5eb3b44d3b988ac6fdb7749025_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i070877701c5a412581e58eb922963dfb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5427871777084be79a6dd7b683f42940_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdeeaeee0d0d4d56bc48afc50bdbf622_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f9e2597f06c4231ae5d5e3a773d4991_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i971a91d6ce39447f86a1c28fa9944956_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aed62f649184956b1971ad38859077d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic36d644f83d345269c981d8628439fe7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8af5b44af8147c684f333006fbe7f0c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f931a8eb6e44ca2a36918808b02f5e3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97d367acc5bc4a7693028a8fc46010a4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89eb7f65122e4d24b2f6d71a3d2035ca_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i378115cc1767432b9131fab24760be6c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79a2635cf98d414eb4d6df658c5f7006_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i610fa7df3a574a30bb25b81f30f3394e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i544e08e2a3a1491f9a0fa4048ca7ab95_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0b124c9b6104c87b8aeb05c89cb6f96_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd3f4727952e4020b12ae68aacca865d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id907a8104c9441f294b2de3071a1225c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81adb51d1b8642b89fde93b4d30867a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie853d3ba19364e30b51bd241ce67c53e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4754a075a4b41139b71c1d8bd51b1d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d66e7dd621e49b19263feb5a5399308_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70f111854ded42afbf8cf34c68376b8b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic96c9ad703a245439fd588caaf8599df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3066f646c41949fea57b1468cb30aa61_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3114cab844d04fb094abf5ed273c4e1a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i462ca7b5109d432893cd43002d27ce96_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i143e36fc013841a18710bf40ddbee422_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ce61f92b7b2406a94a6f87d2dd9623e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i667fa4a2085f406eb99b492e2438f438_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c435b9259f241fbad90a81868ac7e93_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38d8fd0978ab4d4893660a6cce21b4ac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0716e0eaab47406db717f55a7cbf94ae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12ec379ba231490e890d0b394891be1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29cc6f270f8e4052ada8d9109a7be71d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90ded503eb9c4993b67215c3faca3095_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f59e5a852fa4290a1df65e6c201066d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d085d14349d484c957844f0450fce23_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i646f429e54744f22989e1d0d53220bc3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i350054955cb548ee9fa3d529afd9be07_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1213fc8d77534b999d9ec3dd2556fa3d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id562cb2b7ee2435a966ee63e3c0c3331_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8744c9db8c224530b3a70c3dc9a6e821_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i176730f8aadd46128632c5ba433875c6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26ed7f2fc0cc4fc2b518e980d510d435_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f0d0b356cce49a8934e6af36a6e9f3f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e32aff16cce45f1bbc5d66e0afc2090_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6733dbedc8dc49a5a3099a9d0ba22916_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbc6413f2deb444f9703aae3ad14ffef_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07abba9f0ad143a1bd6ac13320789ca2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c740c841315439ab33499536b4e70a2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>lly:patent</xbrli:measure></xbrli:unit><xbrli:context id="i3396e46f9d1e40d387eef70e8d15804f_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifba4f334917d401c815c949e200f615c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04488b288a30423980051e6f31d6daef_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a8ded4399f14dd3a19c466a1b1af3e9_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieee62783e4544f66ab4860b55a43cd90_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="decision"><xbrli:measure>lly:decision</xbrli:measure></xbrli:unit><xbrli:context id="i7c00bf1eb48e4add853803f501de39e3_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa01b284a88a485895b7e8d41c34e4e9_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>lly:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="ie7da18cbbc67441ea99ca54c41121ad6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if922480499654c8fa72000e69a03bbe5_I20111231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ec7a80a2fc74972819c8c8d4ae943cb_I20120731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:WhyteEtAlVEliLillyEtAlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2d0b9f9d00c4789a57ac22dffd8de57_I20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:WeilerVTakedaCanadaIncEtAlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id492c2aa322440ef91df2d2864ae3436_I20130131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EppVTakedaCanadaIncEtAlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02631251065446e8b80c3ef3bde18d1e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>lly:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="id08a7fa5ef244fbdb2e5f2a1bf85908a_D20090301-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a6d539b9e9b4a2e9a56aa47022fef97_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:LosAngelesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57962c6f806042039b9a5e06a4c746f8_D20090301-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:LosAngelesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cebe969b12a4a35a83f8a3e3a6c1d34_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:SouthernDistrictOfCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a303e3d333446bd9c148cdb72de62b9_D20090301-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:SouthernDistrictOfCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6b528e1289547a7a6c8125628509fe4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i823025d06a794591a0b79f3627915cb6_D20090301-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide3640818e464610a65948e49215fb32_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreaticCancerOrThyroidCancerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec6231ab796440cea08cae552c4f7aec_D20090301-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreaticCancerOrThyroidCancerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e401371e97c43e0b9c5ea15f0b54e42_D20090301-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreatitisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b351247f73c46c28ff4f882e37804b1_D20090301-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:AmpullaryCancerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-03-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="claimant"><xbrli:measure>lly:claimant</xbrli:measure></xbrli:unit><xbrli:context id="id877b0b6a111490cbd371689fd76bb41_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0974ec7e0d754316996a9ed48591b15f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="site"><xbrli:measure>lly:site</xbrli:measure></xbrli:unit><xbrli:context id="ic2caaa0461b646bfa03a4e4b72b0fd0c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="brl"><xbrli:measure>iso4217:BRL</xbrli:measure></xbrli:unit><xbrli:context id="i4c05f03242a6456dbd827f3bfc73638e_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5389c2f3f2b4fecaa12712374100b27_D20210930-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-30</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5db0916c42c432ab0d7c4f60ea69486_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b7f344f3e4a4d4489bf483eb893bcbc_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fa1d97abf9842288bcab6b2233d933e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67de38ae9b6847fc8362e05564887711_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogHumulinAndForteoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>lly:claim</xbrli:measure></xbrli:unit><xbrli:context id="i2330339854444106911984ac8d431494_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:InsulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13bb526970b946c4a88c0fdfe320bd02_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:DrReddysLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeb5ba7c9ba14c15ba0052fa193204e3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55fb2a4e7d5a40df8b249f3933bb08b6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44dd2692507f4266b4a6a0fbf0fee907_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic193e7bc5e094826be326aee4fe41f2e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc4a62ea3c3045fcb1975315d8b1874c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdb47e6e63294d44a8f97f9e50e54a83_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75e7048b106947fda1b1b5e4eabdc0fc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4b8f930c8cb4479ac83208582a7d734_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fcde9e91e224331bee5a8adc7892978_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6bf89817cf74679b6916eddd60558c9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd2e85aa71f446bdbb141da8010fbe3d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic375cded995a4df69d3eae9edc6766c7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d2760fb44974a73a735787c71ae8f1a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b11f523dfe64ce792a038f20fbc68b5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a35afc361544badb9c16d04e8aad497_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i717939ea3d4e4bb3b1b65e0a974da3c2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37fc3dd032964801aa1348f510cb122b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bee3c9d23994e78baa2eba95869bd9b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1106ce810ad4da5852f6b633b316eee_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dc5691b17b74c35ad24aafdbf59f3fe_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3759b3a7e2f43dcb3def496f0e66523_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b09b2d2f1f840c7ae5d5461b2c17a11_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbffb928c8ef4db9847f4474b9b3c4f7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i749e85ac79ee42a29981a1a54fe12f89_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2e49dd86e464c6b8eb00c81c2ba5106_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28164fe940424f16b215cb55adf86237_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95f3c6593b4b487dae8900c3ac61ac05_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92bb29baa2584750986eee75a3d6e4ce_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id65902a544ed43ceb02d93ffc0a552e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a29af9f964348b0945d6e3a688d0920_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id528bf4c135048229335007002573a24_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1814bfd7e734e99af54e8b90a4f5ba1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic30630769098404a82485baedba6de39_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i343f9384f69a4fbea834e4b74393c357_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55f74de7b4534040af7ed40631285711_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42d644c1be1b47929fd7f33b4aa7934f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb7a26b32e694ddf89ed67424b0f6153_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d711cf47db44ea8a7769cdcc03215c2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1398a4cb6b3b4f82aaf46f5f2990e359_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b2773f7cce247f2b474587bc25ee417_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11592af1b8584d8e941ac285b2b9ff5f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if60b5c4e32da4c9aaf3a96926acf3f56_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f358682845c429a9e682d2659872229_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd8c50c7162047369d212f2103eba93f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia57652e4c70f423c8b2fd6f637a90a05_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib297cf9f9edb4c749f2a81b2e539ced2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22630c35f56443229b86ee022e4155d1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b485bf17c5749a699e26a1df2e648da_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ff88e97ce21499da1d1b1bdb8a2824f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if57b47926a4847e78d8dcd2326b16c65_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dbc75b54c4a4c39a56bbd8e3006acba_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i412a43d01f8c4978b95b1d9b22b6028e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8ed2c03cd8446b992f8ed65b4226a3e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia29720c84e08498b8a3c6e661a3fe7bd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15dc1b0ac6eb41bab90c9964ded2067d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ecbb90470a94e7780adb982e83ad4eb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c3769918b9d406e90beab010e76b7de_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3be6ddfb286c465fa67388157f156b71_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b999b38b45f48d6b4eacb839d5ae8ef_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e909ad38be242f4935ee1c7e0dfc3c7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf900552e5704e3b83f6dd3f56cfb8b1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc20efde344e4966b2390b23bdfad980_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i846634e73e214b8b9dde808125858a45_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifed88205905a4275ba8c331b5dbd8547_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaec30f04bf644fea6c5f2229258f4b8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i129d769168bb4388b55fa2891a6051bc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9611b430044e49a384caf7309cee05ff_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d84b8a802d54abdb0af6d412798b456_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e9e954fc084405785c8bdfb174f2726_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99b24dcf85424c689a8236968bfe8b4d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjEtMTUtMS0xLTE_4a039bb4-7d57-4cc6-8345-e8a588bc0e9d id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtMTMtMS0xLTE_6d009de1-88d9-4000-b2d9-620f045c6496 id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy0xMy0xLTEtMQ_ff7fe7bf-ba9f-4686-897f-21f2098bcd8a id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjEtMTMtMS0xLTE_eed90e6f-7db6-4694-8923-b3ee18dc613a id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy0xMy0xLTEtMQ_b2dd5832-acf7-498f-805b-6e6692197d01 id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtMTMtMS0xLTE_46112e1c-12d7-46c8-be5f-d81e03cd4a21 id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOC0xNS0xLTEtMQ_e5260fcd-2cb4-4b54-bb00-7081c06c9b68 id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy0xNS0xLTEtMQ_11779181-5463-4bed-be4b-1ac758305555 id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNy0xNS0xLTEtMQ_ec16c59e-9d22-4e6d-b90e-d91e2ddf8102 id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOS0xNS0xLTEtMQ_0d17fa04-e5b1-4fd4-b3d0-b5a50e67f519 id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtMTMtMS0xLTE_c9e80bc4-8a71-4fb6-87d4-1656f4ee2264 id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtMTUtMS0xLTE_4439dc84-d22d-4752-923a-26a9bc5cdf2b id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtMTUtMS0xLTE_2bef079f-6b48-4928-a3b6-b6990292d907 id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNy0xMy0xLTEtMQ_1e99a41f-b073-458d-8bf2-86a4fd6bb7f1 id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtMTUtMS0xLTE_2cdb2d62-671e-48fd-a8a2-6a96a76d2aa9 id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjAtMTUtMS0xLTE_42356bcd-102e-4951-908b-9fbe63c054f2 id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOC0xMy0xLTEtMQ_4a20c478-f442-4f2e-b927-524ce344d68c id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjItMTMtMS0xLTE_f6b0cbf1-8ea9-4e3c-8fda-d4606c6d2fea id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtMTMtMS0xLTE_7bfab548-476d-464d-b4f0-7f48f5e144be id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtMTMtMS0xLTE_7e106991-453e-4af5-b4d7-11292ad1f604 id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtMTMtMS0xLTE_b13827a8-af2d-4a7d-87ea-2fb03492aaf7 id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy0xNS0xLTEtMQ_cf430d6f-18f9-497d-bc39-23d0fb10324b id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtMTUtMS0xLTE_6bfefc11-3f8e-46b8-8bab-7377c0bd95f0 id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtMTUtMS0xLTE_52d0cae5-5189-43c9-a3ba-a9fa5a6931fe id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjAtMTMtMS0xLTE_ae12d3ca-246d-4b32-8d5d-2b62d86d16c2 id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjItMTUtMS0xLTE_7abe819a-50fc-4c27-8850-eae51083415c id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOS0xMy0xLTEtMQ_cb23c7b5-c41a-4e13-ae27-b624034d3d92 id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtMTUtMS0xLTE_bc0dde86-46f2-4741-980a-39ace0aca559" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i48af34e12713400c858f7a29183e5680_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDM0_adb3021a-e2e4-458e-826b-0e5e73b3b007">10-Q</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" format="ixt:fixed-true" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDM2_7b706731-56eb-40a1-aa0c-5985c4520aed"><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDM2_ca9e0923-21e1-496f-a02d-679b615f644f">Quarterly</ix:nonNumeric></ix:nonNumeric> Report Pursuant to Section&#160;13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMTA_ac0fdd48-7c72-4272-bae2-3540a618976b">September&#160;30, 2021</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER <ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDM4_4eb20bdd-67fe-4a08-aa77-5034541c66d8">001-6351</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDM5_77e58531-ec70-4c54-b2e4-74603b597aa7">ELI LILLY AND COMPANY</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6Mzg2NDgzM2VhYTdiNGM0YTk1YzM0M2YzNmE1ZGFjYTgvdGFibGVyYW5nZTozODY0ODMzZWFhN2I0YzRhOTVjMzQzZjM2YTVkYWNhOF8wLTAtMS0xLTE_a2e1e443-4d97-47de-a6c1-d73cb28e6868">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6Mzg2NDgzM2VhYTdiNGM0YTk1YzM0M2YzNmE1ZGFjYTgvdGFibGVyYW5nZTozODY0ODMzZWFhN2I0YzRhOTVjMzQzZjM2YTVkYWNhOF8wLTItMS0xLTE_31231fc9-660c-43a4-8fdb-c60a87cd958b">35-0470950</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identification No.)</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDQy_be9ca824-c7f6-4e0b-900b-8067e6003502">Lilly Corporate Center</ix:nonNumeric>, <ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDQw_582d1ebb-c06a-4b6b-a3bb-1021c4170cf9">Indianapolis</ix:nonNumeric>, <ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDQz_ed3f926e-e5eb-4d04-b906-bc24d5d1a3f8">Indiana</ix:nonNumeric> <ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDQ0_7a254437-8ea5-42a9-bc84-d19f458d55b9">46285</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address and zip code of principal executive offices)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code (<ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDQ1_42050a59-75a5-4cf0-b270-3d055e8a27f9">317</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDQ2_80123cfa-6062-437e-8b59-f65bd7ffc96a">276-2000</ix:nonNumeric> </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Exchange Act:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbols</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Each Exchange On Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5f70d4ddb50548fc9ed454e70437d29f_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18xLTAtMS0xLTE_c382913e-1a3d-4197-a50f-183877d3b9fe">Common Stock (no par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5f70d4ddb50548fc9ed454e70437d29f_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18xLTEtMS0xLTE_c61557d6-7e69-4c5a-a233-c26f4d0c6ef6">LLY</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5f70d4ddb50548fc9ed454e70437d29f_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18xLTItMS0xLTE_65afef7b-2c80-47f8-abb4-91aced52358e">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iee28461a11ce40dd892a5d1af3d82bc3_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18yLTAtMS0xLTE_1a1bfc7c-064b-4c9b-b958-bbc1c0594a43">1.000% Notes due 2022</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iee28461a11ce40dd892a5d1af3d82bc3_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18yLTEtMS0xLTE_30948371-ec84-4cd0-b6a8-3dbd7ac0d9e1">LLY22</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iee28461a11ce40dd892a5d1af3d82bc3_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18yLTItMS0xLTE_9fc5dee8-4ffe-43a9-ac78-b0c28ab56677">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3a43a3f2ce8e49b3b401dcf8182bda5e_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18zLTAtMS0xLTE_c5aabe85-9111-4292-9591-2b80015e698f">7 1/8% Notes due 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3a43a3f2ce8e49b3b401dcf8182bda5e_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18zLTEtMS0xLTE_f552ca04-13d3-40eb-b7a2-39bf08645348">LLY25</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3a43a3f2ce8e49b3b401dcf8182bda5e_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18zLTItMS0xLTE_26be8a93-7fd0-4e2a-b120-0bb24ca46f3f">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb1af12eeba04c0f906f5e5eb7425b07_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN180LTAtMS0xLTE_dd0acf62-bbf3-43e6-80a3-9080a67d6442">1.625% Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb1af12eeba04c0f906f5e5eb7425b07_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN180LTEtMS0xLTE_5605af12-bedf-4010-a351-a72f1eeaabfb">LLY26</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb1af12eeba04c0f906f5e5eb7425b07_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN180LTItMS0xLTE_84e53497-ace4-4136-9aa1-4ac271b28856">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i753e0f88d69d41e891ceddd7541604a2_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN181LTAtMS0xLTE_2172b1d5-480c-47e5-a41e-44679705dd73">2.125% Notes due 2030</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i753e0f88d69d41e891ceddd7541604a2_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN181LTEtMS0xLTE_01e947eb-409c-44a6-9a0c-f2c3f84ac87b">LLY30</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i753e0f88d69d41e891ceddd7541604a2_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN181LTItMS0xLTE_069bf895-a39e-473b-8bc0-b2c031c2d619">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i66895af514214364a9f5110c5ce8708d_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN182LTAtMS0xLTE_74706c88-48fd-44af-a901-42b0870dbe95">0.625% Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i66895af514214364a9f5110c5ce8708d_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN182LTEtMS0xLTE_cd1da11d-1a01-43ef-9393-6fd3f6aaa924">LLY31</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i66895af514214364a9f5110c5ce8708d_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN182LTItMS0xLTE_1d681337-2ca8-4829-8eb6-7372c07afb6b">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7531f4ca382a43839cf3a3b4014bb13b_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN183LTAtMS0xLTMxNzgy_89c591b2-15ea-4891-b871-617c61ff1300">0.500% Notes due 2033</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7531f4ca382a43839cf3a3b4014bb13b_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN183LTEtMS0xLTMxNzgy_1042648d-6c35-4a9e-af66-df6aabd176cf">LLY33</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7531f4ca382a43839cf3a3b4014bb13b_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN183LTItMS0xLTMxNzgy_39b77007-b947-4ee8-8d1e-3673d02b9dfd">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i972a26e5571a4689b6a657c98879bc5b_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN183LTAtMS0xLTE_5a2dad99-63cf-4a12-b227-c35448074bfd">6.77%&#160;Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i972a26e5571a4689b6a657c98879bc5b_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN183LTEtMS0xLTE_a64b01d9-af21-4d2c-b47c-71d03fdb252e">LLY36</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i972a26e5571a4689b6a657c98879bc5b_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN183LTItMS0xLTE_76c09442-918c-4d42-b80c-305b0120aba8">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idd06d4fd694d41f1b11ae0159a256cbf_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN185LTAtMS0xLTMxNzg0_9de8bb6e-6e58-4cea-a7ab-863470ea953a">1.625% Notes due 2043</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idd06d4fd694d41f1b11ae0159a256cbf_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN185LTEtMS0xLTMxNzg0_c34febc0-46e2-47b3-89fa-16257289c14e">LLY43</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idd06d4fd694d41f1b11ae0159a256cbf_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN185LTItMS0xLTMxNzg0_eadf7203-ce56-4873-9cf4-4bac758559c5">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff4a44c5161c49a984d21cfcdf9ec6cc_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN184LTAtMS0xLTE_e14bf815-0f39-4df3-941e-087d8102fcdd">1.700% Notes due 2049</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff4a44c5161c49a984d21cfcdf9ec6cc_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN184LTEtMS0xLTE_4333a664-b7fc-4a2e-9784-3a26f65a7634">LLY49A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff4a44c5161c49a984d21cfcdf9ec6cc_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN184LTItMS0xLTE_81acc779-7e25-443b-aed1-676547b27c3a">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iec85e79d1f4b4520aaed094ce2211f85_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18xMS0wLTEtMS0zMTc4Ng_4483e6d9-0540-4f12-be29-fbe104694bc5">1.125% Notes due 2051</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iec85e79d1f4b4520aaed094ce2211f85_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18xMS0xLTEtMS0zMTc4Ng_c430338a-1d30-4281-9a40-6b79c2352596">LLY51</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iec85e79d1f4b4520aaed094ce2211f85_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18xMS0yLTEtMS0zMTc4Ng_66c76faf-37a7-4765-8c6b-92462359843d">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i26ec5aeeab074242968c82cb92e236a7_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18xMi0wLTEtMS0zMTc4OA_e2f2ef25-dcae-4bc4-bc45-2b1007cfdfba">1.375% Notes due 2061</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i26ec5aeeab074242968c82cb92e236a7_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18xMi0xLTEtMS0zMTc4OA_4d408d15-9570-483c-b2d6-b5ca557e72fb">LLY61</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i26ec5aeeab074242968c82cb92e236a7_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18xMi0yLTEtMS0zMTc4OA_2ff67aa7-a04c-4633-a417-23ca49e323e7">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2)&#160;has been subject to such filing requirements for the past 90 days.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDQx_b938ede1-2717-492b-8aef-7b9479ed72bd">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDM1_616f66ad-eb54-4cff-8374-0a483436dce6">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZGZlNDBmNjI2YmJjNDY2Zjg2ZTVmYzhkYTVhYjVjMDIvdGFibGVyYW5nZTpkZmU0MGY2MjZiYmM0NjZmODZlNWZjOGRhNWFiNWMwMl8wLTAtMS0xLTE_d6e242be-699a-4a20-a95f-8a025e4748c6">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZGZlNDBmNjI2YmJjNDY2Zjg2ZTVmYzhkYTVhYjVjMDIvdGFibGVyYW5nZTpkZmU0MGY2MjZiYmM0NjZmODZlNWZjOGRhNWFiNWMwMl8xLTctMS0xLTE_85d39978-42ea-4d33-89d4-9b8a8aa1f72f">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZGZlNDBmNjI2YmJjNDY2Zjg2ZTVmYzhkYTVhYjVjMDIvdGFibGVyYW5nZTpkZmU0MGY2MjZiYmM0NjZmODZlNWZjOGRhNWFiNWMwMl8yLTctMS0xLTE_27696ad2-d0bd-4cb7-ab5b-b69c9fb06f20">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDQ3_5fdba16c-70b5-4e53-bd26-f470c4b99529">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares of common stock outstanding as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">October&#160;22, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Shares Outstanding</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i738a150fa85d48f491f84c759c959068_I20211022" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6MzM3NzA5MTlhN2Q3NGNlYThiMmRlNmNlMTZmZmY4YjQvdGFibGVyYW5nZTozMzc3MDkxOWE3ZDc0Y2VhOGIyZGU2Y2UxNmZmZjhiNF8xLTItMS0xLTE_9b8f825c-77c3-473a-84b8-95a974f53f73">956,592,393</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i48af34e12713400c858f7a29183e5680_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eli Lilly and Company</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Quarter Ended September&#160;30, 2021 </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.750%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_13">PART I. Financial Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_13">5</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_16">Item 1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_19">Consolidated Condensed Statements of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_22">Consolidated Condensed Statements of Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_25">Consolidated Condensed Balance Sheets</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_31">Consolidated Condensed Statements of Equity</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_31">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_34">Consolidated Condensed Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_34">10</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_37">Notes to Consolidated Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_37">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_88">Item 2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_88">Management's Discussion and Analysis of Results of Operations and Financial Condition</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_88">40</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_91">Executive Overview</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_91">40</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_94">Revenue</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_94">49</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_100">Gross Margin, Costs, and Expenses</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_100">54</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_106">Financial Condition and Liquidity</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_106">56</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_109">Financial Expectations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_109">57</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_112">Available Information on our Website</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_112">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_115">Item 4.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_115">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_115">58</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_118">PART II. Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_118">59</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_121">Item 1.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_121">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_121">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_124">Item 1A.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_124">Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_124">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_127">Item 2.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_127">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_127">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_133">Item 6.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_133">Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_133">60</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_139">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i48af34e12713400c858f7a29183e5680_139">60</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i48af34e12713400c858f7a29183e5680_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-style:italic;font-weight:400;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. In particular, information appearing under &#8220;Management's Discussion and Analysis of Results of Operations and Financial Condition&#8221; includes forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical or current facts, and generally can be identified by the use of words such as &#8220;may,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;continue,&#8221; or similar expressions or future or conditional verbs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">Forward-looking statements inherently involve many risks and uncertainties that could cause actual results to differ materially from those expressed in forward-looking statements. Where, in any forward-looking statement, we express an expectation or belief as to future results or events, it is based on management's current plans and expectations, expressed in good faith and believed to have a reasonable basis. However, we can give no assurance that any such expectation or belief will result or will be achieved or accomplished. Investors therefore should not place undue reliance on forward-looking statements. The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">the impact of the evolving COVID-19 pandemic and the global response thereto;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">uncertainties related to our efforts to develop potential treatments for COVID-19;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">the impact of acquisitions and business development transactions and related integration costs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">the expiration of intellectual property protection for certain of our products and competition from generic and/or biosimilar products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">our ability to protect and enforce patents and other intellectual property;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">changes in patent law or regulations related to data package exclusivity;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">competitive developments affecting current products and our pipeline;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">market uptake of recently launched products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">information technology system inadequacies, breaches, or operating failures;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our IT systems, networks, and facilities, or those of third parties with whom we share our data;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">unexpected safety or efficacy concerns associated with our products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as we are largely self-insured;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">issues with product supply and regulatory approvals stemming from manufacturing difficulties or disruptions, including as a result of regulatory actions relating to our facilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">reliance on third-party relationships and outsourcing arrangements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">regulatory changes or other developments;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">regulatory actions regarding currently marketed products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">devaluations in foreign currency exchange rates or changes in interest rates, and inflation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">changes in tax law, tax rates, or events that differ from our assumptions related to tax positions; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">asset impairments and restructuring charges;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">the impact of global macroeconomic conditions and trade disruptions or disputes; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;padding-left:14.54pt">regulatory compliance problems or government investigations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">More information on factors that could cause actual results or events to differ materially from those anticipated is included from time to time in our reports filed with the SEC, including in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2020, particularly under the caption &#8220;Risk Factors&#8221;.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.9pt;font-weight:400;line-height:120%">All forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this Quarterly Report on Form 10-Q. Except as is required by law, we expressly disclaim any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this Quarterly Report on Form 10-Q. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i48af34e12713400c858f7a29183e5680_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:120%;text-decoration:underline">PART I. Financial Information</span></div><div id="i48af34e12713400c858f7a29183e5680_16"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;1. Financial Statements</span></div><div id="i48af34e12713400c858f7a29183e5680_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars and shares in millions, except per-share data)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:53.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.181%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue (Note 2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMi0xLTEtMS0x_6aeb8430-dd3c-44ab-aa58-9ce5c77bf6a9">6,772.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMi0zLTEtMS0x_acd27e42-404e-4fb3-9253-a5d40b075fe6">5,740.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMi01LTEtMS0x_5bdd77e2-deaa-444f-aa4a-9a210a3243ac">20,318.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMi03LTEtMS0x_35de0b63-a9e5-44e5-a748-93e721083fac">17,099.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs, expenses, and other:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNC0xLTEtMS0x_2450fdf9-f95e-4642-90f4-c4552791a1ab">1,430.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNC0zLTEtMS0x_4e2241e0-f7b7-4a52-a9b9-dd05e13c98be">1,326.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNC01LTEtMS0x_8a9eaf21-35b8-41e4-93e1-36a64e0982ad">5,262.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNC03LTEtMS0x_b3ff789a-dab4-4152-a5db-71566736c235">3,763.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNS0xLTEtMS0x_3ad3de67-5405-42ea-ba44-8fb47d397dc2">1,708.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNS0zLTEtMS0x_ee61019f-b124-4500-b377-1e1890e34587">1,465.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNS01LTEtMS0x_2851d719-8873-448d-aa73-8b7c87827c57">5,066.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNS03LTEtMS0x_4c14624c-0605-4982-9d35-1763400bd254">4,247.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing, selling, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNi0xLTEtMS0x_c4d03752-9cbb-40a8-b380-ad039a587558">1,577.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNi0zLTEtMS0x_a6a9f990-79af-4d69-836b-7de9489a218a">1,569.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNi01LTEtMS0x_4d6e4b4c-5cf3-42f9-930e-0dea7b11fc2b">4,839.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNi03LTEtMS0x_b24cc544-35b1-42ee-94a6-4f960dacb812">4,567.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development (Note 3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNy0xLTEtMS0x_ca0d0149-f521-4af5-8a2c-09ad60317e17">174.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNy0zLTEtMS0x_9fa2bb95-129a-4f30-9058-aa4b73f0bcf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNy01LTEtMS0x_c04be530-a582-47e4-8ba9-68a4bb76dee8">498.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNy03LTEtMS0x_2b31f7cb-e289-44c9-adc9-8dcfc07687fe">294.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring, and other special charges (Note 5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfOC0xLTEtMS0x_e8f704f0-82ee-411a-9fac-6ae1951528b0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfOC0zLTEtMS0x_debab27b-55f7-4ece-8244-ede7484909ef">101.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfOC01LTEtMS0x_4b5c5abb-3e3e-482e-bf1d-9d9eb8a13f2d">211.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfOC03LTEtMS0x_0994ef60-2e2b-4540-bf15-87f330dc6a87">161.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense (Note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfOS0xLTEtMS0x_ad5733dc-bbb4-4d96-894e-91b7f2df9089">635.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfOS0zLTEtMS0x_c36f78f0-b792-4e63-b896-60c712da1b85">158.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfOS01LTEtMS0x_519470d4-2aae-4079-b8f2-04275653e4f5">124.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfOS03LTEtMS0x_80b430be-1e60-45c5-b8d8-943ec8cb8ed1">694.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="lly:CostOfSalesOperatingExpensesAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTAtMS0xLTEtMQ_1aa77ffa-dee2-48ee-9ba2-3b5197e4211c">5,527.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="lly:CostOfSalesOperatingExpensesAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTAtMy0xLTEtMQ_ac13915e-0efb-45b5-9710-6f721449d048">4,303.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="lly:CostOfSalesOperatingExpensesAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTAtNS0xLTEtMQ_d96d074f-aba2-4677-97e0-685310d463b0">16,002.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="lly:CostOfSalesOperatingExpensesAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTAtNy0xLTEtMQ_167f4a8f-87e2-458f-9d9b-44b8b3beabbc">12,339.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTEtMS0xLTEtMQ_5ba62958-7021-4bbd-b583-631e6c5f47e2">1,245.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTEtMy0xLTEtMQ_5b308398-663a-4b4d-a7f1-feb644108d7d">1,437.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTEtNS0xLTEtMQ_b510b444-615d-4832-92db-b5458b47072c">4,315.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTEtNy0xLTEtMQ_64aade7f-4134-4f1b-b190-0462f866cbce">4,760.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes (Note 7)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTItMS0xLTEtMQ_df685639-aeb9-4ecf-a271-7faf1715983d">135.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTItMy0xLTEtMQ_e457ab0e-3672-4277-8a32-283f81cd9ae2">228.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTItNS0xLTEtMQ_48550cd0-49c3-4be8-b938-416fb2af7d8e">460.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTItNy0xLTEtMQ_97b1a3f0-8c07-42ad-9ebb-0d9222187529">683.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTMtMS0xLTEtMQ_cfd3584d-b56b-4e13-8892-db2023353fec">1,110.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTMtMy0xLTEtMQ_b2df48c3-3c8e-4e98-a604-230a293e0fda">1,208.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTMtNS0xLTEtMQ_9d9c01e8-30fe-4af4-a5d8-77d110a52905">3,855.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTMtNy0xLTEtMQ_8e0722b4-dd6b-4494-9a41-b76186fad467">4,076.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTgtMS0xLTEtMQ_0b8f33f8-1334-4126-8acc-5c99751b30f3">1.22</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTgtMy0xLTEtMQ_be253913-3d2d-48d3-99fd-7ad1dfbb7d91">1.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTgtNS0xLTEtMQ_449bdca5-fc31-4c6b-8b9a-1ee5c9fa57fd">4.25</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTgtNy0xLTEtMQ_b2912f51-2185-4dde-b499-588c8c98965c">4.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjAtMS0xLTEtMQ_6edd7764-0eac-457d-9093-092e4476bbaf">1.22</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjAtMy0xLTEtMQ_1809cfb1-8234-4674-9321-eb1273eeecd5">1.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjAtNS0xLTEtMQ_8cb935fc-24e6-4f66-827b-06037e7bdb2c">4.23</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjAtNy0xLTEtMQ_fd2d9614-1d60-4a77-af9d-2dcbd278f001">4.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in calculation of earnings per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjQtMS0xLTEtMQ_34fc6d9f-b73b-46b9-bb03-645405a5e299">906.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjQtMy0xLTEtMQ_03072602-53b1-40e6-b2fb-974f4f8fcf45">907.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjQtNS0xLTEtMQ_bd017fde-2b27-4f2d-aad0-ba809d1cc720">907.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjQtNy0xLTEtMQ_d5d6dfab-16d0-4154-9276-5d213a46e2a8">907.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjUtMS0xLTEtMQ_fd786269-6e83-46fe-8d74-e4c006f453cb">910.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjUtMy0xLTEtMQ_40383998-5b8e-4d78-9789-86f231802724">911.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjUtNS0xLTEtMQ_00882621-3a68-4235-9d82-2072b62f7237">911.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjUtNy0xLTEtMQ_bf5777a3-a4dd-44f8-91bd-5da720f3b425">911.9</ix:nonFraction></span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i48af34e12713400c858f7a29183e5680_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Comprehensive Income (Loss)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:55.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfMi0xLTEtMS0x_cfd3584d-b56b-4e13-8892-db2023353fec">1,110.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfMi0zLTEtMS0x_b2df48c3-3c8e-4e98-a604-230a293e0fda">1,208.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfMi01LTEtMS0x_ccb5166e-02ef-4b55-a83a-a814596383f9">3,855.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfMi03LTEtMS0x_1181b960-27ea-45cd-9b6c-1981e62b1388">4,076.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax (Note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfMy0xLTEtMS0x_f3d6ad8b-0fac-452f-90bc-f98903c71b32">114.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfMy0zLTEtMS0x_96417fcf-1898-4487-9014-84f5a5c8f80d">127.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfMy01LTEtMS0x_20573a15-0396-45ea-944a-b50c2dcb3e58">323.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfMy03LTEtMS0x_b454d558-6681-45b0-8d00-d44cba898998">31.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfNC0xLTEtMS0x_137a9f4b-8805-4541-afc7-56f36d41793d">1,224.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfNC0zLTEtMS0x_4f0141d1-a1e5-45ae-ad99-d8022b943c14">1,336.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfNC01LTEtMS0x_6bfba242-fdce-47cf-a895-705ccafaed59">4,179.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfNC03LTEtMS0x_61bc5c84-a765-4576-a8d0-9aeaca1184cb">4,045.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i48af34e12713400c858f7a29183e5680_25"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents (Note 6)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMy0xLTEtMS0x_eb254b0c-5207-473a-adb1-781a6d17562f">3,788.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMy0zLTEtMS0x_64f312ae-4b59-475a-a998-bb7d3fdbdb72">3,657.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments (Note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNC0xLTEtMS0x_01d00118-b4d2-4fa6-bf36-80c8625ef6d2">37.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNC0zLTEtMS0x_834ed4fc-3ccf-4908-ab0c-a84ca1302798">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net of allowances of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> $<ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNS0wLTEtMS0xL3RleHRyZWdpb246MzM4NmM1ODY4MjBmNDFjYzg5ZjRkZmQ5YjQ2ZTFmZWVfNDY_1a6fb4cd-2286-4de1-99da-27716e318084">24.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2021)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and $<ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNS0wLTEtMS0xL3RleHRyZWdpb246MzM4NmM1ODY4MjBmNDFjYzg5ZjRkZmQ5YjQ2ZTFmZWVfNjA_92157756-a1ab-4bd7-9133-e46081625d2c">25.9</ix:nonFraction> (2020)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNS0xLTEtMS0x_0870d42b-a566-4c11-bec3-12a45d5a4b2e">5,914.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNS0zLTEtMS0x_3a509a43-9037-4f79-9f91-1b92468b2a33">5,875.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNi0xLTEtMS0x_67040dce-b835-40da-ac87-5c55c22bc3b4">1,110.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNi0zLTEtMS0x_f044ec56-cd7c-4f76-8106-19ce43767ebe">1,053.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNy0xLTEtMS0x_1aeab4bb-4ccc-4d09-9946-3965ae57e684">3,907.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNy0zLTEtMS0x_250b3dae-bf1c-49f0-beed-c7d24997e6f9">3,980.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfOC0xLTEtMS0x_0099710c-e745-4000-8f8d-a32c75676c9a">3,050.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfOC0zLTEtMS0x_c52c4f92-8b55-46ce-bbe0-84696cc69df5">2,871.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfOS0xLTEtMS0x_2bb75d83-0f92-45f4-a6e7-c3bd5936a3db">17,808.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfOS0zLTEtMS0x_91dab63d-c9c7-47c5-93d5-44bbf065f4e2">17,462.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments (Note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTAtMS0xLTEtMQ_24ad9b03-4781-43be-ba4d-dc5310ec4c59">3,350.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTAtMy0xLTEtMQ_5af00377-d991-4423-80da-ba6590672526">2,966.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTEtMS0xLTEtMQ_cc695948-4b67-43db-8ae9-9fb4e1a786b7">3,884.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTEtMy0xLTEtMQ_b7d7803b-fb68-4de8-a740-b8026229f509">3,766.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTItMS0xLTEtMQ_4df70616-d9de-4bcb-b259-a0b3662cc883">7,887.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTItMy0xLTEtMQ_848feb6e-3920-46a4-ace8-bc842cf77a56">7,450.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTMtMS0xLTEtMQ_a45709e0-17e7-440c-825d-b8d4374db0a8">2,625.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTMtMy0xLTEtMQ_51904687-b14c-46eb-aad2-6d5fa7620ab3">2,830.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> $<ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTQtMC0xLTEtMS90ZXh0cmVnaW9uOjc2NDEzNGFkNGY5ZjQyNGI5NjUwYjIxYmU5NWNkNGFmXzYz_b89867a5-49e5-4b54-852a-cfe23c40a1c7">9,962.8</ix:nonFraction> (2021) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and $<ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTQtMC0xLTEtMS90ZXh0cmVnaW9uOjc2NDEzNGFkNGY5ZjQyNGI5NjUwYjIxYmU5NWNkNGFmXzc3_4fd5196a-7988-491e-a8fc-e05c6f841334">9,570.7</ix:nonFraction> (2020)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTQtMS0xLTEtMQ_26a71930-dbe4-4805-864c-c8d027aa5a4d">8,920.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTQtMy0xLTEtMQ_6f09a6e6-d2cd-4f31-b072-c7b036ee9833">8,681.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTUtMS0xLTEtMQ_7778efdc-1de6-4037-a635-256e1dbe099c">3,710.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTUtMy0xLTEtMQ_a2020b07-b7e8-4e91-a893-c81ee12ae4fe">3,475.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTYtMS0xLTEtMQ_fd2898b3-b014-492b-94cd-51c5c78b6c4b">48,187.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTYtMy0xLTEtMQ_11009ad8-7265-467f-be75-f698fbc98648">46,633.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings and current maturities of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTktMS0xLTEtMQ_2521087c-e3eb-4107-b662-eb1627522656">1,563.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTktMy0xLTEtMQ_10b8920f-d7c9-45f1-89f2-a58bed64f25d">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjAtMS0xLTEtMQ_b44c2e82-dce8-49ef-a7e9-621fa848c62c">1,566.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjAtMy0xLTEtMQ_38e694f1-fc2a-43e8-b528-c8e5f055b79f">1,606.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjEtMS0xLTEtMQ_92607218-efe9-4bcf-b865-24a3b4a148cb">836.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjEtMy0xLTEtMQ_7787c8a4-406e-428b-ad4a-92106efdb4f7">997.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales rebates and discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="lly:SalesRebatesAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjItMS0xLTEtMQ_291a0eaa-7bef-42de-9b61-6c21d3195e5c">7,185.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="lly:SalesRebatesAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjItMy0xLTEtMQ_e0960acb-f51d-4da8-a669-99e85a0db439">5,853.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjMtMS0xLTEtMQ_5f3c371b-4b69-425b-9b4a-2135bce5afd7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjMtMy0xLTEtMQ_d46634bf-093b-4407-8fef-ffc6d5382406">770.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjQtMS0xLTEtMQ_d085075a-a305-4cd4-bf31-88b784ae0b7d">203.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjQtMy0xLTEtMQ_0875ea10-3858-4398-adbb-d4f55bfef975">495.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjUtMS0xLTEtMQ_140855e7-c0d8-41f6-99ac-78b996c1841a">2,326.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjUtMy0xLTEtMQ_25b9579a-1b5c-4c17-9c45-bbd070daac1d">2,750.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjYtMS0xLTEtMQ_28bcea19-8eaa-4438-a7bb-efa8998aa9be">13,682.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjYtMy0xLTEtMQ_35d078ba-6f79-4b36-b77f-54848b3e1bb5">12,481.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjgtMS0xLTEtMQ_1fb454ff-3489-421b-900b-5886451d184f">15,522.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjgtMy0xLTEtMQ_68b90dfa-d3a5-4e96-b364-b828bfa36c8f">16,586.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement benefits (Note 8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjktMS0xLTEtMQ_674b3e70-50b8-4ad2-a548-9a38616d7e1c">3,878.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjktMy0xLTEtMQ_d03af194-4b73-462f-927b-a9de78c610a3">4,094.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzAtMS0xLTEtMQ_fa617148-d515-4435-8bf5-c25ba260066b">3,768.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzAtMy0xLTEtMQ_deb8f35a-4b58-4521-86bb-24241d83f276">3,837.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzEtMS0xLTEtMQ_bb440fb0-d27d-4a33-9447-792a06063a18">1,632.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzEtMy0xLTEtMQ_452af235-70ec-4103-9cf2-3c3fbcb076bb">2,099.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzItMS0xLTEtMQ_4813dec0-4510-4547-9db7-97fd092b9f35">1,748.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzItMy0xLTEtMQ_823f9915-15e6-457c-b866-e03fc6f5ebfb">1,707.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzMtMS0xLTEtMQ_78625911-05bb-44b0-8c39-fd59b98ea4c0">26,550.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzMtMy0xLTEtMQ_2d503620-3e60-47eb-ae6d-99d38f1c52c0">28,326.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Commitments and Contingencies (Note 9)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzQtMS0xLTEtMQ_f9f3845f-b417-4c76-b300-8e45af121fb2"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzQtMy0xLTEtMQ_9c5c0544-cdd9-473b-b275-d419b7f2694d"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Eli Lilly and Company Shareholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzYtMS0xLTEtMQ_e39e9ec3-3687-4fcb-9921-5985db63cfed">598.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzYtMy0xLTEtMQ_a1120ec7-b077-4b43-9a75-6619819b1597">598.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzctMS0xLTEtMQ_ab396775-c581-4324-a8e0-f97da2428d19">6,758.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzctMy0xLTEtMQ_bbbb2691-6681-488a-8509-dd092dd4ee20">6,778.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzgtMS0xLTEtMQ_0a7fddfe-feb0-4e3f-b30d-46d3608c2057">9,639.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzgtMy0xLTEtMQ_36756b14-86b3-4047-8246-25a7e0fbf8e8">7,830.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit trust</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzktMS0xLTEtMQ_4bedf658-fe61-4478-b97d-53a68c16527f">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzktMy0xLTEtMQ_53c56fc5-0d3f-45d5-97e8-ca6b62c47994">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss (Note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDAtMS0xLTEtMQ_969296be-0f8c-422b-8c6e-a9d99899b2bb">6,172.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDAtMy0xLTEtMQ_320ac504-d73e-440d-990f-c38c82645f2c">6,496.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of common stock in treasury</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDEtMS0xLTEtMQ_64f1d5b1-4fe4-4de0-848d-9478d684eeb3">52.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDEtMy0xLTEtMQ_b9ad3000-9cad-4ce8-a540-53b595f26fc5">55.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Eli Lilly and Company shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDItMS0xLTEtMQ_d66a1c64-8516-4639-a10f-87d050326424">7,757.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDItMy0xLTEtMQ_3cb6db63-b6bb-4759-8f26-5e54b1410f5f">5,641.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDMtMS0xLTEtMQ_f92caa9d-945c-4282-84a8-814d917b231b">197.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDMtMy0xLTEtMQ_cf3df9cc-4fb1-4ccf-9f1b-ebd9726ea907">183.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDQtMS0xLTEtMQ_f2dbb74b-441d-4c3f-9fae-330291c55502">7,954.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDQtMy0xLTEtMQ_d5426f64-a79a-467e-a8da-17d621b306f9">5,825.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDUtMS0xLTEtMQ_3bfc63ea-3730-46b9-9f66-6d311025b324">48,187.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDUtMy0xLTEtMQ_89afda48-8a08-4142-8001-f4a91b8d50c8">46,633.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i48af34e12713400c858f7a29183e5680_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:23.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.760%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Equity of Eli Lilly and Company Shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(Dollars in millions, except per-share data, and shares in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Employee Benefit Trust</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock in Treasury</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Noncontrolling Interests</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at July 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6269e3039a904047803aaf8c59d2c31e_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy0xLTEtMS0x_9bf6a804-abdc-4ddb-a962-b88bdb60294a">956,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6269e3039a904047803aaf8c59d2c31e_I20200630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy0zLTEtMS0x_4460a629-36e4-42ac-b5bc-101f4f53d56b">598.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i277f40e31a78476c8a25e89e3ad7fad7_I20200630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy01LTEtMS0x_fd36ba59-8a5b-45f4-9fd3-96b0a12dcf3f">6,629.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i480c67fa255d4952aec1ce6fdc96a5cf_I20200630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy03LTEtMS0x_2ad5213e-ede3-4874-a0d4-23b946f18779">6,617.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie79822b045d24ca8816e16c558b018d9_I20200630" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy05LTEtMS0x_503efdc8-e8bf-49a5-9680-b9d493fb4419">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4de3b4868049e78934ed4495abd9dc_I20200630" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy0xMS0xLTEtMQ_02ea13bf-2be8-4d34-8041-630729360782">6,682.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i292925605a554dd98b2bb9c1601dcacd_I20200630" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy0xMy0xLTEtMQ_b2dd5832-acf7-498f-805b-6e6692197d01">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292925605a554dd98b2bb9c1601dcacd_I20200630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy0xNS0xLTEtMQ_11779181-5463-4bed-be4b-1ac758305555">55.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc02b3f1ff146b89aaf8d18611bff3a_I20200630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy0xNy0xLTEtMQ_68b5f7f4-c96d-4142-982e-24552096fc58">179.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9b17be62717498291500daeab724167_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfNC03LTEtMS0x_9ab8b39d-e518-4fbe-b35e-d7d9b089c1e3">1,208.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i128373a43773438d93068364bbda7364_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfNC0xNy0xLTEtMQ_3255a2ce-decb-4c23-9a90-31b60121250b">4.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646c747914e84ad991f450bbec883d19_D20200701-20200930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfNS0xMS0xLTEtMQ_074f4485-601f-447f-ae4c-5b264c965169">127.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash dividends declared per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfNy0wLTEtMS0xL3RleHRyZWdpb246MTU5ZjIxMWYzN2NmNDEyZjk3YzFiNDJkNjA4NTVkZWVfMzk_0852a533-cf39-4099-ae46-2e97bdc30154">0.74</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9b17be62717498291500daeab724167_D20200701-20200930" decimals="-5" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfNy03LTEtMS0x_0b16bf5f-b27b-47ef-9ea1-a3ce2315edd3">671.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i527414e868ec4177853d359e75ca6df1_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfOS0xLTEtMS0x_74146e4f-89d5-49a7-890d-84585e2ef278">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cd72451146c46faa7d53de5bc28c3ac_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfOS01LTEtMS0x_d10706e2-ed1b-4b55-b5b4-973b2dc99b7e">2.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cd72451146c46faa7d53de5bc28c3ac_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTAtNS0xLTEtMQ_30cf8996-7ea5-4cc2-acf8-67558e819667">71.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i128373a43773438d93068364bbda7364_D20200701-20200930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTMtMTctMS0xLTE_75cb5388-6f61-4387-acdd-d9869f1ecf61">5.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2dc23546086416285bbd41e25d62584_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtMS0xLTEtMQ_745d0356-2fc7-42d8-a2d1-f6c3edc7fc5c">956,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2dc23546086416285bbd41e25d62584_I20200930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtMy0xLTEtMQ_e7d09c11-ca02-4e69-b530-d68a18dfdced">598.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a77b8d5d984968b3c4578e17bbb5e9_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtNS0xLTEtMQ_11dc22c0-de0d-4a87-b600-5fb3e0db1d9f">6,698.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36d3b669185e44dbbd9e6e8943ab4f6a_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtNy0xLTEtMQ_8ff65bbd-e0ad-4b55-b334-9de5c5cdc853">7,154.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie279100c0102406e93bb14b4657500dc_I20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtOS0xLTEtMQ_e0c710a8-a100-4a9c-aed8-941793ea6e1e">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28b47563db924e53a3b01da85a1c1857_I20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtMTEtMS0xLTE_d0171b74-adc6-48b9-8f0a-aa917f38db04">6,555.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b458bdf7deb40b29fead2a4923fcdc0_I20200930" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtMTMtMS0xLTE_7e106991-453e-4af5-b4d7-11292ad1f604">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b458bdf7deb40b29fead2a4923fcdc0_I20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtMTUtMS0xLTE_2bef079f-6b48-4928-a3b6-b6990292d907">55.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic401234ddcb24a04b3a48f1e46bb9d26_I20200930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtMTctMS0xLTE_fbd77ed0-a6f5-4cd7-a99b-a574d940a201">169.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at July 1, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9230f02f9af8414aaa820e4637091e33_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtMS0xLTEtMQ_0753c190-d743-47f8-aa97-ee1a3507346e">957,038</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9230f02f9af8414aaa820e4637091e33_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtMy0xLTEtMQ_985f9019-3356-49f6-9774-99ef932500df">598.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i661e35a5d390434383f2e73f7a2a947c_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtNS0xLTEtMQ_3b0b9786-3edb-417e-bd32-8ca1264beaf4">6,669.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b807fcb6dd415889f60755aa586d46_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtNy0xLTEtMQ_a8ee0614-85b2-450c-b205-6e9e2b4b5683">8,530.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7557d0c1a88148acb26d4de3f94524bd_I20210630" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtOS0xLTEtMQ_f76a1ebb-4efc-425c-9218-8b66bf8db7b5">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2f9c0959ab041ef9cd49b71327449cd_I20210630" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtMTEtMS0xLTE_a695eb47-8103-4ce7-b515-a149f6b07276">6,287.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e006e6aa4cf4c4c8d995f6d7ef007b3_I20210630" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtMTMtMS0xLTE_46112e1c-12d7-46c8-be5f-d81e03cd4a21">463</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e006e6aa4cf4c4c8d995f6d7ef007b3_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtMTUtMS0xLTE_bc0dde86-46f2-4741-980a-39ace0aca559">52.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id48ee4fdf79b43f68e80f1116057e733_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtMTctMS0xLTE_00cf3841-0137-4df4-acfd-52ef412e4354">219.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d263bfcfede470e849adc44fbd95b02_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTctNy0xLTEtMQ_8ab66daa-f859-49db-921e-ff91bb62b3d6">1,110.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4489a9298a74411cb30a8b6d1d8c0a5a_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTctMTctMS0xLTE_3a91288c-2b55-45da-8010-8a4da8369ca4">22.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i408826e558824625a2ca711ba35a4da0_D20210701-20210930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTgtMTEtMS0xLTE_e269fe50-8916-4ae3-b523-7084355771f8">114.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d29538f03db4d85830f1a00e8cc2a3d_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjItMS0xLTEtMQ_f744bc32-1d7d-457e-8079-6980e67d56c5">14</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d29538f03db4d85830f1a00e8cc2a3d_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjItMy0xLTEtMQ_f8252ae7-1927-4ff8-9446-a9d022d3f0c7">0.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9112ede45bca4fa485446dc88c3c5484_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjItNS0xLTEtMQ_58a34db2-bc5b-4b37-a53d-0be8e5434f09">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9112ede45bca4fa485446dc88c3c5484_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjMtNS0xLTEtMQ_9961e108-94d9-44cd-bcd3-a3c5d2e9c14c">90.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d263bfcfede470e849adc44fbd95b02_D20210701-20210930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjQtNy0xLTEtMQ_a6dfc2b0-0bea-466e-9d94-ec3dc04b1547">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4489a9298a74411cb30a8b6d1d8c0a5a_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjQtMTctMS0xLTE_4b4b6c03-e470-44d6-b526-6401042fe769">0.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b653f1fba914f8dbac7b520ac3265a7_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtMS0xLTEtMQ_4aede6db-b565-42b2-86d7-8441785ec6f3">957,052</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b653f1fba914f8dbac7b520ac3265a7_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtMy0xLTEtMQ_1707f197-b093-4012-8e5d-70b509beef0b">598.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83143935f8da447d9261cebfc72ce7ff_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtNS0xLTEtMQ_83fbb6c3-2052-44d4-b0ca-705fd5743ba3">6,758.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb41cf2a9504b31b3ee0af14c18f87f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtNy0xLTEtMQ_f49488fa-c28e-4d58-97be-684c35910b70">9,639.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22679a982313462397a5663f58993f05_I20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtOS0xLTEtMQ_9b5ef9be-482a-44a2-a11e-0c386e72237e">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d120ba2343e410780602579de874a5f_I20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtMTEtMS0xLTE_89166a32-b029-4f7b-8559-ded28cf43975">6,172.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0287914b178a46d4be80deab95a97314_I20210930" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtMTMtMS0xLTE_b13827a8-af2d-4a7d-87ea-2fb03492aaf7">463</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0287914b178a46d4be80deab95a97314_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtMTUtMS0xLTE_2cdb2d62-671e-48fd-a8a2-6a96a76d2aa9">52.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie425975ac2314fc3bf1853a1bc359060_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtMTctMS0xLTE_b13f101a-9ac2-40e0-9895-b79a427ed8b6">197.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc" footnoteRole="http://www.xbrl.org/2003/role/footnote">As of September&#160;30, 2021, there were $<ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfMTMxOTQxMzk1MzQ4MzY_b1620fc8-c38a-4f9d-97fb-c83256c887f8">500.0</ix:nonFraction> million remaining under our $<ix:nonFraction unitRef="usd" contextRef="ic5af76f55c3349ba859b1f9206178021_I20180630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfMTMxOTQxMzk1MzQ4NjA_03e20580-3467-49be-87db-4ebc6842bd6c">8.00</ix:nonFraction> billion share repurchase program authorized in June 2018 and $<ix:nonFraction unitRef="usd" contextRef="if8b0a3ca285542978d0be33bc0249ffb_I20210531" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfMTMxOTQxMzk1MzQ5MTc_f367f371-ddfb-48f3-9820-91e978519ce1">5.00</ix:nonFraction> billion  remaining under our $<ix:nonFraction unitRef="usd" contextRef="if8b0a3ca285542978d0be33bc0249ffb_I20210531" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfMTMxOTQxMzk1MzQ5NDM_f367f371-ddfb-48f3-9820-91e978519ce1">5.00</ix:nonFraction> billion share repurchase program authorized in May 2021. </ix:footnote></span></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Equity of Eli Lilly and Company Shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(Dollars in millions, except per-share data, and shares in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Employee Benefit Trust</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Stock in Treasury</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Noncontrolling Interests</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i612deeb868604a2c937e486f25fce6f6_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy0xLTEtMS0x_e6c6bbcc-f973-43e0-9464-d0c619076356">958,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i612deeb868604a2c937e486f25fce6f6_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy0zLTEtMS0x_7a7302e0-9b6d-47f2-b739-3ad306052332">598.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a83d082225245798aa0f1e672ee7810_I20191231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy01LTEtMS0x_fc179345-0aed-4bc9-8ab8-0f8cb01f65ea">6,685.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05ea4e8d0df642af8b6a87953f1f8e23_I20191231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy03LTEtMS0x_82d1dfaf-b2e9-4cbf-8053-aa974848a382">4,920.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i177bd18351114d5c8ae70dbc77c8660c_I20191231" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy05LTEtMS0x_13807d6a-aa75-4adc-afc0-db398fb00b4f">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4622633489fa4632a9800fb6fb1326c9_I20191231" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy0xMS0xLTEtMQ_f38b6f0f-050c-4a9e-8e2b-796fc8a59dc6">6,523.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i831186dd08c8458bb74c88268733509a_I20191231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy0xMy0xLTEtMQ_ff7fe7bf-ba9f-4686-897f-21f2098bcd8a">530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i831186dd08c8458bb74c88268733509a_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy0xNS0xLTEtMQ_cf430d6f-18f9-497d-bc39-23d0fb10324b">60.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2781ee2a1570463cb045238d0fe460f5_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy0xNy0xLTEtMQ_b013564b-1af2-49fb-baae-5472783800c1">92.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id986361421254ab4997b4c92dec009d3_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNC03LTEtMS0x_05d4c4c5-a1c4-478c-a41f-e115415b9942">4,076.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252777c0f5ec42bb81ec84d8bffeaebc_D20200101-20200930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNC0xNy0xLTEtMQ_2b5a5e89-7f34-4238-80eb-7974bcccfd8f">95.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0f254d6b3ea463b8d26b218473a23dd_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNS0xMS0xLTEtMQ_e6f9036f-ede8-4288-ab52-7705d109bf34">31.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash dividends declared per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNi0wLTEtMS0xL3RleHRyZWdpb246YjcyMjk5YTAwZDk2NDA1N2E3YjI4ZGQ3NTljMGY1M2VfMzk_389f56b8-b791-4f0a-b0d5-a945e04e9189">1.48</ix:nonFraction> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id986361421254ab4997b4c92dec009d3_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNi03LTEtMS0x_bc114d0b-e96f-472d-aa7c-d8bda2e9353c">1,345.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retirement of treasury shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5b73aed77d4d4a3aa3b99395305f0cb5_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesRetired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNy0xLTEtMS0x_29786c6c-6eda-4cbe-bdef-5a26c8312f0b">3,627</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b73aed77d4d4a3aa3b99395305f0cb5_D20200101-20200930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNy0zLTEtMS0x_582274dd-8d67-4dd3-886d-40c66875741d">2.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id986361421254ab4997b4c92dec009d3_D20200101-20200930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNy03LTEtMS0x_c6bf48aa-8c83-4308-a6ae-a1896f94e823">497.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i252f3fa632ef43be9ad24db3bffe5ad8_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesRetired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNy0xMy0xLTEtMQ_1e99a41f-b073-458d-8bf2-86a4fd6bb7f1">3,627</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252f3fa632ef43be9ad24db3bffe5ad8_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNy0xNS0xLTEtMQ_ec16c59e-9d22-4e6d-b90e-d91e2ddf8102">500.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of treasury shares </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i252f3fa632ef43be9ad24db3bffe5ad8_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOC0xMy0xLTEtMQ_4a20c478-f442-4f2e-b927-524ce344d68c">3,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i252f3fa632ef43be9ad24db3bffe5ad8_D20200101-20200930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOC0xNS0xLTEtMQ_e5260fcd-2cb4-4b54-bb00-7081c06c9b68">500.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b73aed77d4d4a3aa3b99395305f0cb5_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOS0xLTEtMS0x_bde450ac-46e3-4134-b2b1-b15c34c842c6">2,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b73aed77d4d4a3aa3b99395305f0cb5_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOS0zLTEtMS0x_315a66c8-dc5c-445a-94b6-14006e92be0a">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22b957be322b4417a234d68dfb557223_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOS01LTEtMS0x_8ada6546-763a-4b05-8898-22ebb182b744">206.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i252f3fa632ef43be9ad24db3bffe5ad8_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOS0xMy0xLTEtMQ_cb23c7b5-c41a-4e13-ae27-b624034d3d92">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252f3fa632ef43be9ad24db3bffe5ad8_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOS0xNS0xLTEtMQ_0d17fa04-e5b1-4fd4-b3d0-b5a50e67f519">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22b957be322b4417a234d68dfb557223_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTAtNS0xLTEtMQ_618b5d71-8f47-4164-b10e-e1ecbc645751">220.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22b957be322b4417a234d68dfb557223_D20200101-20200930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTMtNS0xLTEtMQ_58ecc180-110f-4743-92db-8ca04c869551">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i252777c0f5ec42bb81ec84d8bffeaebc_D20200101-20200930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTMtMTctMS0xLTE_629aa5e0-19c1-4fbd-9449-b59bf78b0356">19.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2dc23546086416285bbd41e25d62584_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtMS0xLTEtMQ_4a869520-b7e8-4b23-8d17-59800f2ed165">956,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2dc23546086416285bbd41e25d62584_I20200930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtMy0xLTEtMQ_80621e44-fa9b-461a-aa7e-7ce5f473d50a">598.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a77b8d5d984968b3c4578e17bbb5e9_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtNS0xLTEtMQ_a12890a2-510e-42fd-95f2-5af8dff26a90">6,698.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36d3b669185e44dbbd9e6e8943ab4f6a_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtNy0xLTEtMQ_8ff65bbd-e0ad-4b55-b334-9de5c5cdc853">7,154.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie279100c0102406e93bb14b4657500dc_I20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtOS0xLTEtMQ_6704c959-1465-4e27-ad0e-562e56f998de">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28b47563db924e53a3b01da85a1c1857_I20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtMTEtMS0xLTE_b700a4bc-fe83-4689-a2e7-ad9f0552941b">6,555.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b458bdf7deb40b29fead2a4923fcdc0_I20200930" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtMTMtMS0xLTE_6d009de1-88d9-4000-b2d9-620f045c6496">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b458bdf7deb40b29fead2a4923fcdc0_I20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtMTUtMS0xLTE_6bfefc11-3f8e-46b8-8bab-7377c0bd95f0">55.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic401234ddcb24a04b3a48f1e46bb9d26_I20200930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtMTctMS0xLTE_b05aa41e-5cb8-46f6-9c36-d989291f5fd1">169.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iead50fa9bd39400bb6f8a9b5d3d03acd_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtMS0xLTEtMQ_c65349cd-9818-4a7f-ad01-643066d476d5">957,077</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iead50fa9bd39400bb6f8a9b5d3d03acd_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtMy0xLTEtMQ_8c1b8e92-1c92-431a-b046-df2039cb61ba">598.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90982ebb563845899ddc7a66f27f1455_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtNS0xLTEtMQ_a0a1ce21-12f7-44d7-b759-4325a7f162af">6,778.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a74fbbdc9ac408e8912ccf4e1576ae8_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtNy0xLTEtMQ_1bae4dfc-0540-4fb4-94e0-4b1e058ca15f">7,830.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice93dc7ac1da463ea4ecca4d2fba8434_I20201231" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtOS0xLTEtMQ_b60167ab-616b-4452-87c8-b69566baf831">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0aebdc3dbd54d82a80cf1b888beb150_I20201231" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtMTEtMS0xLTE_863acd1b-2738-47cc-a8ab-2dab63134f39">6,496.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i76fda2c740f94c7ca2ee9b4ceda0b709_I20201231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtMTMtMS0xLTE_7bfab548-476d-464d-b4f0-7f48f5e144be">487</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76fda2c740f94c7ca2ee9b4ceda0b709_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtMTUtMS0xLTE_4439dc84-d22d-4752-923a-26a9bc5cdf2b">55.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd1b1734812948e294108968f3a834d3_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtMTctMS0xLTE_2b9a8f35-5867-4372-afd1-949017ec6d47">183.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i218e2fbd7bbc48deba986aa580060342_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTctNy0xLTEtMQ_e8c56663-5c45-4525-b902-a9856c3ca957">3,855.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44128d85d4474ad681fc84f6f83f73b7_D20210101-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTctMTctMS0xLTE_f16f615e-2d0e-4e35-b537-cfd98bad6c89">25.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i741888a65d6744479381fb901e13925c_D20210101-20210930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTgtMTEtMS0xLTE_99364500-5ee6-4d81-86d7-a6bc99cb1ab7">323.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash dividends declared per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTktMC0xLTEtMS90ZXh0cmVnaW9uOjBlNTQ0NGIzNzhmNjQ0NzZiMzg4NmJkNzY2NjIxNDc4XzM5_42c0428f-57b5-4724-86c1-21f4f65e4b10">1.70</ix:nonFraction> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i218e2fbd7bbc48deba986aa580060342_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTktNy0xLTEtMQ_2a91b842-d616-472b-983f-c500b8e9a9ff">1,542.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retirement of treasury shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icdd23d64b8ba4239ab77fe5df21cd6d5_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesRetired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjAtMS0xLTEtMQ_74469328-cffa-47da-9111-4e7c6b8d3ba4">2,467</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdd23d64b8ba4239ab77fe5df21cd6d5_D20210101-20210930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjAtMy0xLTEtMQ_55531944-a889-447a-8035-bacf149200d6">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i218e2fbd7bbc48deba986aa580060342_D20210101-20210930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjAtNy0xLTEtMQ_4baa87c1-8a19-4856-89a7-ac5f41293e2e">498.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i08ae5e3d75fc49a3b01da53199cc2e26_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesRetired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjAtMTMtMS0xLTE_ae12d3ca-246d-4b32-8d5d-2b62d86d16c2">2,467</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ae5e3d75fc49a3b01da53199cc2e26_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjAtMTUtMS0xLTE_42356bcd-102e-4951-908b-9fbe63c054f2">500.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08ae5e3d75fc49a3b01da53199cc2e26_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjEtMTMtMS0xLTE_eed90e6f-7db6-4694-8923-b3ee18dc613a">2,467</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08ae5e3d75fc49a3b01da53199cc2e26_D20210101-20210930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjEtMTUtMS0xLTE_4a039bb4-7d57-4cc6-8345-e8a588bc0e9d">500.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of stock under employee stock plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icdd23d64b8ba4239ab77fe5df21cd6d5_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjItMS0xLTEtMQ_98f02d12-1663-4111-a71e-8e22f7e287f6">2,442</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdd23d64b8ba4239ab77fe5df21cd6d5_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjItMy0xLTEtMQ_69d94a7d-01d5-4e07-bcf7-27e11f8911db">1.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79216bede2b24f049a04d252ea215271_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjItNS0xLTEtMQ_e8ede1e4-cd8d-4eb7-aedd-67ad42df7a06">287.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i08ae5e3d75fc49a3b01da53199cc2e26_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjItMTMtMS0xLTE_f6b0cbf1-8ea9-4e3c-8fda-d4606c6d2fea">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ae5e3d75fc49a3b01da53199cc2e26_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjItMTUtMS0xLTE_7abe819a-50fc-4c27-8850-eae51083415c">3.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79216bede2b24f049a04d252ea215271_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjMtNS0xLTEtMQ_92764229-f6c3-47c8-8a6c-ce9842d90db3">267.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79216bede2b24f049a04d252ea215271_D20210101-20210930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjQtNS0xLTEtMQ_444e108c-d08f-4bb2-837f-1d64d73dbf7d">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i218e2fbd7bbc48deba986aa580060342_D20210101-20210930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjQtNy0xLTEtMQ_039ce9e9-0ca3-4c98-a1cc-f5253de6634c">5.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44128d85d4474ad681fc84f6f83f73b7_D20210101-20210930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjQtMTctMS0xLTE_6bbad395-2979-46b0-86c5-9c8cf19bf0c9">11.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b653f1fba914f8dbac7b520ac3265a7_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtMS0xLTEtMQ_69d2db7e-143a-4fd8-96b2-89302e6f4c14">957,052</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b653f1fba914f8dbac7b520ac3265a7_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtMy0xLTEtMQ_931daebc-a26e-43db-ba49-bee4e869a799">598.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83143935f8da447d9261cebfc72ce7ff_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtNS0xLTEtMQ_ff082a01-21c3-4b95-a0dc-a78d035d1173">6,758.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb41cf2a9504b31b3ee0af14c18f87f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtNy0xLTEtMQ_8ae1c49a-0b75-4fe8-96cd-ebd7574132c0">9,639.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22679a982313462397a5663f58993f05_I20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtOS0xLTEtMQ_2bbf7361-3d51-4547-b18b-7d4e52e38f25">3,013.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d120ba2343e410780602579de874a5f_I20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtMTEtMS0xLTE_004f39fb-ecc6-4923-af83-20597f879729">6,172.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0287914b178a46d4be80deab95a97314_I20210930" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtMTMtMS0xLTE_c9e80bc4-8a71-4fb6-87d4-1656f4ee2264">463</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0287914b178a46d4be80deab95a97314_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtMTUtMS0xLTE_52d0cae5-5189-43c9-a3ba-a9fa5a6931fe">52.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie425975ac2314fc3bf1853a1bc359060_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtMTctMS0xLTE_0deba168-6ab7-44a8-a2a2-ccbf4a8a7e8c">197.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> As of September&#160;30, 2021, there were $<ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfNDUx_b1620fc8-c38a-4f9d-97fb-c83256c887f8">500.0</ix:nonFraction> million remaining under our $<ix:nonFraction unitRef="usd" contextRef="ic5af76f55c3349ba859b1f9206178021_I20180630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfNDc0_03e20580-3467-49be-87db-4ebc6842bd6c">8.00</ix:nonFraction> billion share repurchase program authorized in June 2018 and $<ix:nonFraction unitRef="usd" contextRef="if8b0a3ca285542978d0be33bc0249ffb_I20210531" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfNTI5_f367f371-ddfb-48f3-9820-91e978519ce1">5.00</ix:nonFraction> billion  remaining under our $<ix:nonFraction unitRef="usd" contextRef="if8b0a3ca285542978d0be33bc0249ffb_I20210531" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfNjI4_f367f371-ddfb-48f3-9820-91e978519ce1">5.00</ix:nonFraction> billion share repurchase program authorized in May 2021. </span></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i48af34e12713400c858f7a29183e5680_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Condensed Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELI LILLY AND COMPANY AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities</span></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMy0xLTEtMS0x_a61fdd3d-6078-4a22-b43e-6ab80af7b66e">3,855.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMy0zLTEtMS0x_d735664a-860f-4b2c-987b-f34b51d92b3d">4,076.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfNi0xLTEtMS0x_4d98d016-279f-431e-9da3-b36619cc77d0">1,101.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfNi0zLTEtMS0x_9c6310eb-ff02-45dd-a6c9-fccb488ca7bb">956.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfNy0xLTEtMS0x_5e9ef2ac-d861-418c-9c68-50e875bbcb81">709.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfNy0zLTEtMS0x_eb6debc5-85c3-42bc-8d32-55f20d6a211a">66.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment loss (Note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfOC0xLTEtMS0x_e08536f0-5805-42d8-8e43-c5b83c26770f">405.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfOC0zLTEtMS0x_3875aba8-1ffe-4bee-889a-2f55b30baeb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfOS0xLTEtMS0x_9b1c83aa-224e-4efb-b76e-f8b851c4b5e4">267.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfOS0zLTEtMS0x_a4138cf3-45d0-4841-bbec-5f147f9e8898">220.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTEtMS0xLTEtMQ_625bd6cc-1a54-48bf-973d-43352ec73629">271.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTEtMy0xLTEtMQ_29456d63-92f0-4b09-af07-5c8575acb5e8">909.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development (Note 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTItMS0xLTEtMQ_c86ace15-bd57-403d-a137-8ef50efc0b3f">498.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="lly:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTItMy0xLTEtMQ_f9653e83-918c-42ff-8244-0eef9e004bb3">294.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other changes in operating assets and liabilities, net of acquisitions and divestitures</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTMtMS0xLTEtMQ_90c0c61f-1361-4885-bd54-5a5394fb6957">548.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTMtMy0xLTEtMQ_5687113c-fe05-420f-bb61-ce040a3a0745">232.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash operating activities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTQtMS0xLTEtMQ_d4c3e449-1c86-49d9-8fbb-60a1a8831c82">504.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTQtMy0xLTEtMQ_8f5b19ea-7efb-4482-98bb-a6544c6ed872">212.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Provided by Operating Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTUtMS0xLTEtMQ_1a6a5c37-b605-49c5-8d6a-0b587b195513">5,104.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTUtMy0xLTEtMQ_07b208be-3192-4a14-bfd4-4e6d00bec174">4,684.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTctMS0xLTEtMQ_4e6b809b-ca86-4ab0-bac7-cf764962bd72">1,018.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTctMy0xLTEtMQ_54d110d4-5c41-4590-b53d-9ccf105058a6">933.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTgtMS0xLTEtMQ_c4307dbd-3981-40f2-90c5-d48c89247bf2">46.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTgtMy0xLTEtMQ_cfc03f2c-2b1a-403d-8525-815bab557fbe">118.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTktMS0xLTEtMQ_93247dd8-5c02-4d8e-9c39-d313cc0915b9">27.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTktMy0xLTEtMQ_b17bf0fd-02f4-4b78-bdb7-7738f24f9e6f">11.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of noncurrent investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromSaleOfLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjAtMS0xLTEtMQ_aa6f8732-ffc3-43c0-8153-91219d29be58">537.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:ProceedsFromSaleOfLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjAtMy0xLTEtMQ_85c815bf-8b12-4637-9ec2-25a439a53823">574.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of noncurrent investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjEtMS0xLTEtMQ_d7db5249-047b-454f-a63f-01017192880e">710.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjEtMy0xLTEtMQ_80e8ab32-4b57-4741-abbb-f6a608fc8677">223.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisitions, net of cash acquired (Note 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjItMS0xLTEtMQ_38fe2d78-0d4f-4cc5-9bf8-2f4b88a9124b">747.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjItMy0xLTEtMQ_dfc4508f-c091-4679-aca3-9c418e6e3e9c">849.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of in-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="lly:PurchasedInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjQtMS0xLTEtMQ_d3bb94c7-3b3b-4eaf-94fa-c4a60c8db772">460.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="lly:PurchasedInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjQtMy0xLTEtMQ_5930c56a-dd17-4723-927f-776f23666242">276.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investing activities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjUtMS0xLTEtMQ_a7eb945c-288d-4b7b-8339-056ba9ff403e">2.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjUtMy0xLTEtMQ_88af6585-3f52-43c6-86cd-7e2f9bb9f860">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Used for Investing Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjYtMS0xLTEtMQ_344ac4cf-eb2f-4b54-a542-44430a8489e0">2,383.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjYtMy0xLTEtMQ_dec20764-d814-4302-9d6a-6d6960487b62">1,584.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjgtMS0xLTEtMQ_e0c98ee0-5d62-496b-b88c-d0221731c0ab">2,313.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjgtMy0xLTEtMQ_439cda2f-a317-4cbc-9ba7-f43b8051ece1">2,017.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjktMS0xLTEtMQ_f5b46d46-d2bb-4269-9c77-8e6d6eb3b403">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjktMy0xLTEtMQ_d597c373-4ea4-47ad-bf12-2492a18e6f77">914.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzAtMS0xLTEtMQ_1fdf7a8c-6c16-469a-af87-f16587dfe24e">2,410.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzAtMy0xLTEtMQ_b3e16eec-928e-4798-9ed1-1d315625dea4">2,062.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzEtMS0xLTEtMQ_39ed2f4e-cd0c-4bc7-866b-cff0a3f7fafe">1,905.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzEtMy0xLTEtMQ_56f4f7b9-1d2b-4ea2-aa8d-af14a4fbeaf7">276.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzItMS0xLTEtMQ_87fd0d08-1898-4235-83ea-9f9f7bf63a8b">500.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzItMy0xLTEtMQ_8bd5fcb3-0cfe-4bad-b081-ae344825d61c">500.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other financing activities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzQtMS0xLTEtMQ_bd704200-1a77-4b94-ac0f-c14f072fcc7b">295.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzQtMy0xLTEtMQ_138d0004-cf91-4c1f-bf23-549a2e2950e9">200.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Cash Used for Financing Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzUtMS0xLTEtMQ_5252cb44-2e35-4b1d-b6e0-f9529a8a3156">2,604.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzUtMy0xLTEtMQ_99110c56-2207-4388-93b0-818b8f93b29a">1,845.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzYtMS0xLTEtMQ_e38e73d9-9805-41b5-b188-9a7fa48d5633">15.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzYtMy0xLTEtMQ_ea5994dd-cd80-48c9-9aef-bc60df0ad4dc">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzgtMS0xLTEtMQ_21f47b8d-0688-4af8-93b2-fc108c6a858a">131.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzgtMy0xLTEtMQ_a686ccef-6092-4e00-9155-8ec9f2380bb0">1,257.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at January&#160;1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzktMS0xLTEtMQ_1b1d86fb-b393-48bb-aca4-b42a5c145e14">3,657.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic89977d02ab1401dbc23753322c8563b_I20191231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzktMy0xLTEtMQ_1ba9a186-455a-41bf-999c-99bf4ad03399">2,337.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and Cash Equivalents at September 30</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfNDAtMS0xLTEtMQ_261ca41e-a0da-44f5-943f-565ca3a92467">3,788.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idac57d16ce9f4dcb9b27d234834a1cc0_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfNDAtMy0xLTEtMQ_b0ca7367-3719-4ad5-9c7c-ecc10b2c4fd8">3,595.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated condensed financial statements.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i48af34e12713400c858f7a29183e5680_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Condensed Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Tables present dollars in millions, except per-share data)</span></div><div id="i48af34e12713400c858f7a29183e5680_40"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1: <ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80MC9mcmFnOmRmZGRmOTllMDZiYzQ4MjlhNTRjYjJiMDg0ZWRlNTU4L3RleHRyZWdpb246ZGZkZGY5OWUwNmJjNDgyOWE1NGNiMmIwODRlZGU1NThfMjQzNw_a1fb07d7-5c21-4c94-b68c-11414a6db880" continuedAt="i7fa0534135e447b89cc818f126e6a2f9" escape="true">Basis of Presentation </ix:nonNumeric></span></div><ix:continuation id="i7fa0534135e447b89cc818f126e6a2f9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the consolidated condensed financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2020. We issue our financial statements by filing them with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis; that is, based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i48af34e12713400c858f7a29183e5680_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2: <ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RleHRyZWdpb246ZjQ4NTU3MjI0MjQ2NGE2YTg5MmUwYmNiYzA0YTMyODNfMzUxMA_022d6599-e2b2-4396-b788-580ad4cdfa17" continuedAt="ic3b6d4d127c84bb7b0ff492386157c58" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="ic3b6d4d127c84bb7b0ff492386157c58" continuedAt="i99301c7591624977899342c7689b6685"><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RleHRyZWdpb246ZjQ4NTU3MjI0MjQ2NGE2YTg5MmUwYmNiYzA0YTMyODNfMzUyNg_82f83a83-1a65-4067-8c20-badf64689066" continuedAt="ia0a612f8eced4a5b8fbc40af9cf4cd2c" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated condensed statements of operations:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3751844cca5948b7a2fad81b7407b645_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfMi0xLTEtMS0x_0bebfc4b-4c23-4bb9-b2ff-4d70f71b686d">6,189.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9740fd412b0b4c8b8920a13188bc08f6_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfMi0zLTEtMS0x_41a493d9-5f08-469b-9412-bbc0f4bb4dd0">5,281.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i008aee30db1f4ed2b8bb7a205e2a213a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfMi01LTEtMS0x_ca966531-d949-4e87-868d-efe9e36b3cb6">18,579.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6e915f6611043fda08216f49f3b300a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfMi03LTEtMS0x_05b4d1ca-b48a-4c41-b91e-52ff3676d93c">15,762.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib870f3d12a3f45ffba916dc4a4d8bc56_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfMy0xLTEtMS0x_e91b5415-dee5-48b6-bbb8-001f627488c5">583.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8622b2e9dd4842da9e583319c95a3d10_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfMy0zLTEtMS0x_69745157-f0ea-445e-aa79-d6316cbcae19">459.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82cca299a87747259a76bff17b9d3f03_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfMy01LTEtMS0x_be2d6dde-05e1-4827-a3ec-75147d8de70b">1,739.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b10af06686e401d9bc0772daa1af568_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfMy03LTEtMS0x_3b5b9db7-5096-41c5-8fc8-0472f55a0297">1,337.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfNC0xLTEtMS0x_139b6588-f55a-4d1c-a4b8-8fa8816896ac">6,772.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfNC0zLTEtMS0x_59337a68-552e-477d-bf03-1e7ff266959f">5,740.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfNC01LTEtMS0x_4f71a1a2-f950-40ac-99a3-90eaa65b3a92">20,318.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfNC03LTEtMS0x_33917439-7ffe-40c6-9fa0-01fd8f68fde4">17,099.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $<ix:nonFraction unitRef="usd" contextRef="i2afe7200511442b9be37640fe7d2a7f4_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RleHRyZWdpb246ZjQ4NTU3MjI0MjQ2NGE2YTg5MmUwYmNiYzA0YTMyODNfMjM4_180e556d-11d3-42f2-bbc5-ca162b9e59c3">62.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i33cd075c62264add8dfcb7b313a654d0_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RleHRyZWdpb246ZjQ4NTU3MjI0MjQ2NGE2YTg5MmUwYmNiYzA0YTMyODNfMjQ1_a17e9349-6c64-4584-ab9d-2a3c4057fd29">136.1</ix:nonFraction> million during the three and nine months ended September&#160;30, 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="iba7b305393e54b31bccb95fbd0f79f67_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RleHRyZWdpb246ZjQ4NTU3MjI0MjQ2NGE2YTg5MmUwYmNiYzA0YTMyODNfMzA3_a4345444-e0ea-4b70-94c2-d3ca11680d84">31.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i69d6b9eefe5e435997214a4dc60d7f32_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RleHRyZWdpb246ZjQ4NTU3MjI0MjQ2NGE2YTg5MmUwYmNiYzA0YTMyODNfMzE0_1e3279fc-fdd0-4784-a036-61b4b157bb11">101.5</ix:nonFraction> million during the three and nine months ended September 30, 2020, respectively.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to certain of our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustments to Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to increase (decrease) revenue recognized as a result of changes in estimates for our most significant United States (U.S.) sales returns, rebates, and discounts liability balances for products shipped in previous periods were less than <ix:nonFraction unitRef="number" contextRef="i61a4e12edfa84ace81f68212f895f984_D20210701-20210930" decimals="2" format="ixt:num-dot-decimal" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RleHRyZWdpb246ZjQ4NTU3MjI0MjQ2NGE2YTg5MmUwYmNiYzA0YTMyODNfODc5NjA5MzAyNjUwMQ_7b1c303d-1129-467f-8c48-0d90d3d74523"><ix:nonFraction unitRef="number" contextRef="i6c7c7535680c41bdb5edaa1a9d31b011_D20210101-20210930" decimals="2" format="ixt:num-dot-decimal" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RleHRyZWdpb246ZjQ4NTU3MjI0MjQ2NGE2YTg5MmUwYmNiYzA0YTMyODNfODc5NjA5MzAyNjUwMQ_c80214d9-4629-46a6-b84b-1efe69fada68">1</ix:nonFraction></ix:nonFraction> percent of U.S. revenue during each of the three and nine months ended September&#160;30, 2021, and approximately (<ix:nonFraction unitRef="number" contextRef="i75ef086b481246719964b43441307bdb_D20200701-20200930" decimals="2" sign="-" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RleHRyZWdpb246ZjQ4NTU3MjI0MjQ2NGE2YTg5MmUwYmNiYzA0YTMyODNfMTU2MA_6a397baa-2016-4281-8103-300ab76039c4">1</ix:nonFraction>) percent and <ix:nonFraction unitRef="number" contextRef="i5618c9f0179444b3b10b8ab8e3e9bef3_D20200101-20200930" decimals="2" format="ixt:num-dot-decimal" name="lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RleHRyZWdpb246ZjQ4NTU3MjI0MjQ2NGE2YTg5MmUwYmNiYzA0YTMyODNfMTU2Nw_b22092d7-9960-4fad-8892-3e30b3389c26">1</ix:nonFraction> percent of U.S. revenue for the three and nine months ended September 30, 2020, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. </span></div><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RleHRyZWdpb246ZjQ4NTU3MjI0MjQ2NGE2YTg5MmUwYmNiYzA0YTMyODNfMzUwNg_c7cd3b8c-c483-4230-b9bf-b3d668e44b4b" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1ZWVkOWJmYzU1ODQxZWViOTBhMjljMzQzMDAzYzRlL3RhYmxlcmFuZ2U6NzVlZWQ5YmZjNTU4NDFlZWI5MGEyOWMzNDMwMDNjNGVfMS0xLTEtMS0x_3de6dab0-0080-4307-9fe2-f71a0452c1f8">278.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1ZWVkOWJmYzU1ODQxZWViOTBhMjljMzQzMDAzYzRlL3RhYmxlcmFuZ2U6NzVlZWQ5YmZjNTU4NDFlZWI5MGEyOWMzNDMwMDNjNGVfMS0zLTEtMS0x_bd2fa686-e22b-4282-8fa5-b1524ee6804b">276.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021 and 2020, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i99301c7591624977899342c7689b6685" continuedAt="ice4a2a246e024a5ab06a12fb397a04d4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disaggregation of Revenue</span></div><ix:continuation id="ia0a612f8eced4a5b8fbc40af9cf4cd2c" continuedAt="i864b0a004ce8452297e95bdbd44b7372"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product for the three months ended September 30, 2021 and 2020:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i619decfb20794db0b459aef3c32bc5e6_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNS0xLTEtMS0x_d59e78b6-2212-43a6-beb6-a7b33237c2d5">1,201.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac5fda408e6497890499865b967861b_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNS0yLTEtMS0x_465e60e1-e082-4a5f-806a-60de75b76ee3">398.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a9cefb7c292416bb0d6ebbb330edbc3_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNS0zLTEtMS0x_edc084dc-e191-410f-b0b0-f04a6bd6e4ce">1,600.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c1d6f95905448d385eb2e6e6dae543f_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNS01LTEtMS0x_03f67b95-c383-42af-8d87-160fa1cef097">791.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i143a18efe3784ef881f53727b5686001_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNS02LTEtMS0x_b4ecd5d9-46e2-4659-932e-40d8b16fae4f">315.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4197f4f08df34479bd091bfc5c54df55_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNS03LTEtMS0x_fca2c5d6-4f05-4044-86ba-9b2629d133e7">1,106.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3615f0b224ea424280772b92ec8e7d2e_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNi0xLTEtMS0x_1e7abe53-bd3f-49a3-a96d-8e5cebb2030e">347.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc03cbb9d199450ea24aed63300c9230_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNi0yLTEtMS0x_f5ed7522-8677-4d53-8996-958bcee6d2b7">279.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i636a3552add040f5ad7def2b7dd765bc_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNi0zLTEtMS0x_952f3ee6-f5f6-47b7-9985-539b5da98bcd">626.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0bcc0407fc64c0286f70bd29d8897e6_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNi01LTEtMS0x_fc4e26e0-8003-4558-abdf-10f17c8de3ed">390.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95e2942890f4e65b9ee7a2130447a4a_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNi02LTEtMS0x_caad2d3d-63b4-46c1-a965-81e6870634d0">266.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2e117448cb42c2a288857bc438f50f_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNi03LTEtMS0x_1de8228b-08fd-467f-8bd0-a11bc60d23d8">656.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f0f99a60bc04551b5ae2d2be7ceceb1_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy0xLTEtMS0zMDIzNA_72ea39d6-78d9-4cf8-8f19-c5340e3dd9b4">221.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2467cd73fd4349ddbfa9e1baf740e12c_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy0yLTEtMS0zMDIzNA_097dd879-e794-4783-b09c-eddd7d691988">169.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a26c27a65f403eb8beb3df6550f89c_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy0zLTEtMS0zMDIzNA_04c477ea-eaef-468e-bd0a-1e4307125c36">390.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fa2f284977c46d9989820ed12d7553f_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy01LTEtMS0zMDIzNA_d4157852-4c91-4742-81a4-4a5bf33479af">163.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1cd05c961fe4864a7ad4058c5bb2cbe_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy02LTEtMS0zMDIzNA_acd59dc9-0a3f-4a1b-8c2f-8817c1dff27c">147.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc63f2b4f3ad4a38885421b13733cfbd_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy03LTEtMS0zMDIzNA_9f8a6083-9cea-4827-bac7-176607621836">310.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1843d4702b74c9b8adbaf5ab7aae759_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy0xLTEtMS0x_c591220a-4f49-42d0-879c-3ddf6fbce04c">193.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf7ecd718b194d13826533eda4fbf459_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy0yLTEtMS0x_7d7c171e-f926-4cec-8196-fbf7bf8fcaa3">93.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dc7e770251b4603b707a2b28a01efc6_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy0zLTEtMS0x_8e82f5a7-dcf8-4247-8182-a90f94930f33">286.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6efe748f82424164bff261d4d56704a4_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy01LTEtMS0x_7db2a0bd-3449-474c-9405-d490b400575f">214.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1edb9e5a264ddaa2145ab88b861f25_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy02LTEtMS0x_59f3d1dc-951f-4b6d-86c3-c5371dc54197">91.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0bd74a50404b86b9780ef0d7574708_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy03LTEtMS0x_2507d52b-1f55-49bc-b10a-2c5d14a0f1b5">305.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23405a005d0043188b612fbd2cb9a01c_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfOS0xLTEtMS0x_9f173bbb-3f0c-4b33-9b31-7aacd43eb2cd">114.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f5d4c7e9fc24d87a56948514836e08b_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfOS0yLTEtMS0x_65d3f4dc-6e79-419b-89a7-55d446a7572c">78.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd5ed73cc264b21bfcf6eb9c75a76f1_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfOS0zLTEtMS0x_08954fd5-21c2-43c9-a017-6383ee01c53a">192.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc683f8f7aec487db1c97534775202e0_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfOS01LTEtMS0x_e77599b2-37e4-44df-bbfc-d56d857a5328">178.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i013c2fd777cb4ad78b3588d03b646777_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfOS02LTEtMS0x_c0feb8a0-30cc-4a3b-9f2c-ac1b96209e94">69.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c206cb2e614db381ab7a7d1967bd03_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfOS03LTEtMS0x_0bd9260f-d6a2-4422-97f0-67a0f7762c19">248.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1245294846401dbd994a69555c3b22_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTAtMS0xLTEtMQ_dde0f8f4-8942-40e1-9a88-8ba97505d5b7">65.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id662cd6af0a1437492d74860015d4dd3_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTAtMi0xLTEtMQ_296e3256-6643-4b96-938f-14ecc961bff8">112.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic60d8559880548869550b76fd7e1622c_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTAtMy0xLTEtMQ_a2c269f7-640b-48d9-99de-f91a2eb85f7f">177.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81fb83afd9174a4584c76d363f319ed7_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTAtNS0xLTEtMQ_45683a48-0bfe-4780-8cc9-6ae37eb3e26f">61.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cfded4b3a63477dab06f1ce39f440c2_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTAtNi0xLTEtMQ_10136077-00af-4266-b4b4-2e7be2eeaead">93.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b041f3ba59449439e77c6a72a154148_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTAtNy0xLTEtMQ_b27f08a0-bc74-4eb0-bc5a-dfafc75ae20a">154.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Diabetes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a09b1522b247eb870ad3c04226f894_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTEtMS0xLTEtMQ_9cc4beaa-8e82-4865-9857-d969f10b96f0">2,143.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07f1bed036f4a8cab6b04215059a9a0_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTEtMi0xLTEtMQ_9cdf0a13-90f1-4a6a-b37a-606779fe3034">1,131.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a81a76397d14cf3920f2f8dc0aff2ad_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTEtMy0xLTEtMQ_39b04d96-8007-43a1-b2c1-c77d8b788618">3,274.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66fe92bb4b37478283f0fcde0b4655e7_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTEtNS0xLTEtMQ_355f2db2-7267-4b69-97e8-906fe33cbe06">1,798.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35a15d4ca7a14c94906cb2cb75408325_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTEtNi0xLTEtMQ_c12811cd-3c36-4894-a3f2-a7f2e3f4cbc9">984.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e81fb756b57423eb9b5630c52df179d_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTEtNy0xLTEtMQ_5c913652-c231-4b4a-8119-e686ddda411f">2,783.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i833d461ea6104a85b39825c841b91425_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTQtMS0xLTEtMQ_2b0c6094-9152-4d7e-8af0-93a474e946e1">297.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f9102a7fb8049fa9237e84cee584b52_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTQtMi0xLTEtMQ_78972bf2-5702-43a1-8a80-286120813453">159.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fc787ae1bbb4d8cb11f4f23e454b76c_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTQtMy0xLTEtMQ_69d5ae31-aac0-44a4-86fa-5dafdec18fc5">457.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65bdcc2ecaf44f2393df1548f2ca567b_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTQtNS0xLTEtMQ_e58a5614-1349-4f78-b559-ff978b54cdf5">291.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e9f2f10aae452e851237fa01acebad_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTQtNi0xLTEtMQ_ce855260-5d02-4acd-9c5c-defc80425698">286.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f970f1846c9427d96a62ed28a252336_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTQtNy0xLTEtMQ_f2eca35e-809d-4592-a2c6-d652fcb467a4">578.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808fde7a4bcc424abe955ca582b6c429_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTUtMS0xLTEtMQ_6798ec32-2e55-4aad-9c78-3731f89c9a6b">199.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb18d4711ef487292258d52ebcbb56f_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTUtMi0xLTEtMQ_09b4d604-901b-4c2c-b951-0979d15b9891">135.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85255af923d2412cadfe050e3f55be5a_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTUtMy0xLTEtMQ_3fcfd93b-7610-41d4-a847-9eeba60a8797">335.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55b77fb4de574805b40a93cc0c77e784_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTUtNS0xLTEtMQ_cd44d13f-4a36-4bba-9f13-5f7beddc94ee">158.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i610e677c79024836a14be2d01ea5588e_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTUtNi0xLTEtMQ_474bf45e-2bc7-46ac-a2ba-666f19dfb7c3">75.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6adc0c0529714689a5664f338caae315_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTUtNy0xLTEtMQ_9055d34c-16f5-4f37-81f4-552cabb37319">234.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac732504ce454cb9af710f8437b31b72_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTYtMS0xLTEtMQ_2cc7cce4-752b-4688-b6c0-743703529e75">84.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad7f4df9b6b44f7b8942015b498f808e_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTYtMi0xLTEtMQ_bad36f12-0775-46bf-85e8-336b49cbcf94">168.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9596c4e04274bb8b84585df2008c087_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTYtMy0xLTEtMQ_1f86c386-3ee4-4368-9837-f380a82e45e2">253.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3cadcc0ccc047aeadd216305626ae7e_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTYtNS0xLTEtMQ_07b7b0e1-d16f-4ffd-8521-5bcbb091565b">94.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b7407649b1a42b38ee51c3819e286b9_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTYtNi0xLTEtMQ_0517fe89-e236-422b-99ef-b8fa579293e5">158.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f827e23ec74d3592ec62c9d8a24045_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTYtNy0xLTEtMQ_255c6448-7883-4229-bfb7-3d7851d88f6f">252.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f64171c60cb40589455a45ddebdb7f0_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTctMS0xLTEtMQ_dbc7a650-e747-49a1-b18e-584822fed171">114.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87336623af3c4094ae1f02a8981d1c87_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTctMi0xLTEtMQ_1357c7d0-9a30-4a71-9d9e-c21ccd91b907">20.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44aed9a2ff864ffbb9dabb42a9652a4d_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTctMy0xLTEtMQ_207bccec-9349-4fbb-b328-0f662719c871">134.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ae25d95b4f8443e97e0378c32d9625a_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTctNS0xLTEtMQ_dcbe035a-c9f8-46bc-9505-42786393b005">122.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c6cc4dbeb24eeb82e00b1ebe898947_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTctNi0xLTEtMQ_35d0f556-455a-484c-b893-70a4e81145de">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99138be47ed847849c3df6c670763516_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTctNy0xLTEtMQ_afc9d3a3-91bc-4c79-bcd1-5be707e251c3">136.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafb2cb4b4ba94633a0d9effd3535a22d_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTgtMS0xLTEtMQ_afccdbc0-cb9e-450d-ae08-aafa732349be">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94a1de0c39bb4d91a6b8220fd88cc995_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTgtMi0xLTEtMQ_e889874a-3b4d-43b4-85af-abe821cc0439">125.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i897388675b95435fb4f36e6b1e6cd6f9_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTgtMy0xLTEtMQ_39d3e977-4a04-4ba9-81e2-587ec283cc4b">125.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8207dcbe71c47eca3c2f1096df4b7a8_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTgtNS0xLTEtMQ_212de80d-d46a-46f7-95b4-0ab0d455a982">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34b15be682a4e5cafaba09fd90dc0a3_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTgtNi0xLTEtMQ_e66e90c8-79a7-4a5c-a7c4-e3be41d15076">84.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4d90ccdd9479fa1adc0ede684c6b6_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTgtNy0xLTEtMQ_54ee13a5-40a6-4053-a4a5-53eee5f277c2">84.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Oncology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dbd0fc64d85402a8c6614d6d2cc1b34_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTktMS0xLTEtMQ_ed079269-9c1b-4ed6-9a1e-cb3a887f7dc9">35.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252c837f8bcb4ac0b13f2285fadeb589_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTktMi0xLTEtMQ_20ca714c-a959-4915-995c-ab667b245811">65.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7569cb5db95e4d16ab9bf1906d28a414_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTktMy0xLTEtMQ_050ea72d-15ad-46d9-9f24-75716f0b07f8">100.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e344efb8a154f9293c35b2a2071dea2_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTktNS0xLTEtMQ_e67c8c99-31dc-4476-8291-735a516c64e5">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc5a0211b694ef1ad818a7c769134c9_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTktNi0xLTEtMQ_f39ce5ce-e1c5-41f1-a5e5-dad9450c367d">32.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79cde695c635485fb5969cbeffb8ee65_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTktNy0xLTEtMQ_759e1e2a-7ac1-4dbd-a0b9-81e0e54af977">47.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Oncology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79a992ad9b904ca59f6786e45f7b37de_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjAtMS0xLTEtMQ_609d4f29-c70b-4db0-8c94-6aca7ef8d6ef">730.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id598f2d470ee46d09e2445b9507ad3f2_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjAtMi0xLTEtMQ_8744d27f-3782-43e5-b043-3ee2bdbde78b">675.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8103205049b472f8eae31d6a58e53a8_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjAtMy0xLTEtMQ_27700197-1972-4b12-ac86-9b5fe303c638">1,406.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if532b94bdbac4bce82537f40e4a0cf51_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjAtNS0xLTEtMQ_eca1ae2c-3111-452c-a61c-ff14493f0a35">682.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafbd8b57ba564ee298f69bd41e7e8601_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjAtNi0xLTEtMQ_503ed0c6-ecee-437a-bf30-80bfc06fee56">650.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4c02ed82d7415eb7c1bcf15c6c21b8_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjAtNy0xLTEtMQ_dd155eac-1731-42d2-90e2-e5645520587c">1,333.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d59e5583c8648d7b78f39b5a5466a11_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjMtMS0xLTEtMQ_20158550-7403-4999-8c0e-ba884d7a76ee">422.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6aab2127a004f0ba2023cc7bf0b485e_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjMtMi0xLTEtMQ_a42332f5-281b-44ef-b1c1-38a52c3dd4ce">170.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia56673e90d78440b919786ca8b4e5230_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjMtMy0xLTEtMQ_0f071850-945c-48a0-a795-2dd2a6627e54">593.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0f342cfe7ed447c972ee626e06d8847_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjMtNS0xLTEtMQ_40660ae6-0c59-4fdd-91b2-5989b2702686">326.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f56993e98d5433a8d3954524f86fd8d_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjMtNi0xLTEtMQ_1b5cf3e7-f24d-40f8-aebf-90920f376790">128.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77fbbc9968cf4bb18902690fe1fd8686_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjMtNy0xLTEtMQ_4698ffc1-2d20-4fb6-882a-268256cac90f">454.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad10567d7217449bb0a0eacc29b03bb1_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjQtMS0xLTEtMQ_321e7864-67d9-4b6f-9d90-08d246a427d1">194.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28a2e586d3c54230929df1bb15cecbc0_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjQtMi0xLTEtMQ_159f018e-e75a-4d04-b20e-69ebacf382ed">212.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb79dda4914c4c118d30138f4db6d0c9_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjQtMy0xLTEtMQ_58a3f336-9243-4044-9159-317fb0607fdd">406.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia634a6f32f8d47e087b88320b460594d_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjQtNS0xLTEtMQ_134463ea-ea4f-47f9-8b5f-735bdff2d039">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc9c80adfe494319a49b462b4c84e227_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjQtNi0xLTEtMQ_a12a5c38-42d0-493e-9ef1-23bc31379d9d">147.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89bc1277904f44ebb00cc1c346f34407_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjQtNy0xLTEtMQ_1bf30166-cd31-47d3-81ad-f9d8858e6723">162.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Immunology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc39388717ab43b39a31ccad3c4b5ae1_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjUtMS0xLTEtMQ_486ce1be-dddc-4d7b-b194-3427b21d73ec">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i391eae2ff09a4964b6b7b192b55be566_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjUtMi0xLTEtMQ_1983c21a-2943-4911-828a-dfbeee300b44">4.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252d50dbb8234dcaa62617a57a7f132c_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjUtMy0xLTEtMQ_15389c95-ab2b-47d9-88ef-edb0c2ac74bc">4.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87081eb668e448cca72a3cfd33b884eb_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjUtNS0xLTEtMQ_9b59f405-bc62-4230-852d-a385d40241bf">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3510314a6b1348e1ad1a289c769221a5_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjUtNi0xLTEtMQ_1bfe96cc-f878-4b39-95e0-b67bdba8e7f9">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69df563139e5499c9977856b5c047b89_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjUtNy0xLTEtMQ_b7b8c522-5189-4074-8b61-d94ee3a3ae28">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Immunology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3eefcda66434dc7bdb28af6eacee5ae_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjYtMS0xLTEtMQ_f86bc3ba-c150-4528-9c7c-41182d0bd320">616.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide62ca0bafc24f6189c5766c74864a61_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjYtMi0xLTEtMQ_14b31436-b06c-4108-aaed-483bd85e13ef">388.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fc211aaf0c04cde8b946bf6a6c2101c_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjYtMy0xLTEtMQ_4f7c7e4a-c4e4-4b6f-bff1-3c041ced1f08">1,004.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ae2f07cc5ec45d7b4df160393ddcfeb_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjYtNS0xLTEtMQ_3f1df87d-69a4-42bb-8f66-95a7b121ae4e">346.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c7b300da94407dacde87022ba06fe4_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjYtNi0xLTEtMQ_48e39929-0c68-4031-b81d-2106b6369544">280.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a964d449ac84c94b6a4e507792eaf2d_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjYtNy0xLTEtMQ_61378411-086a-4bfe-a8e1-6e550c8dda1f">627.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e0ddfd3674c4908827fced5b7901b52_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtMS0xLTEtMzAyNDI_c67dab2c-f924-41e0-9672-5f4de2d68c71">99.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65e6b9bae263441f8bb7c2a734d070c0_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtMi0xLTEtMzAyNDI_8539d989-b50c-4864-ade9-a6f48c2c636c">40.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i603eda46c0be4d8b86ba9ef36bd2af4d_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtMy0xLTEtMzAyNDI_99b2375b-8ae0-4c4a-ba6d-c08972ad9239">140.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fbcaa2d029c4c05bafbb0400bfe6df8_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtNS0xLTEtMzAyNDI_349740f2-e6f7-471a-b1df-67caaa79fa3c"><ix:nonFraction unitRef="usd" contextRef="i4fbcaa2d029c4c05bafbb0400bfe6df8_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtNS0xLTEtMzAyNDI_6091d61a-51b8-430c-861a-b412afc2b445">81.4</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1492ec6093ff478e916d7d23f4f020ab_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtNi0xLTEtMzAyNDI_8a5273a3-2af5-4eac-a092-45c5e31de5dc"><ix:nonFraction unitRef="usd" contextRef="i1492ec6093ff478e916d7d23f4f020ab_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtNi0xLTEtMzAyNDI_dd55312e-517c-4205-af6e-7db820c3950a">10.1</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60dde10942844b47a3c7d72ca1e89c00_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtNy0xLTEtMzAyNDI_39d9f907-ad06-4633-a6f6-0ecf4718cef1">91.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9a4c536cd364a3fb26c3f2186868f7d_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtMS0xLTEtMQ_42d1dc3f-30b4-431b-b3b9-4e8edf21e3d2">7.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3881ab6fddaf4d0397d1251b9b335eaf_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtMi0xLTEtMQ_272ac533-d017-476e-9809-19843c857679">125.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5821c8abb9f442939c46c5f2ea55e15a_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtMy0xLTEtMQ_b4a4db5f-3858-4aa9-9845-802943067f62">132.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f20b6672fbd429cbc47b24cc460ae1b_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtNS0xLTEtMQ_ba9f3be3-ba6c-48f8-98ab-e8bfb2b39f3a">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bac77c719ed47c6b5e1daba371ea914_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtNi0xLTEtMQ_c6b99f78-753a-48b7-a3e5-551e4979ac50">175.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcff59ffda63475ea32a7379c4669b03_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtNy0xLTEtMQ_bee46743-dfae-405f-9786-4b9a164a9186">186.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f4b471c7e348ca914c418fd367c183_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzEtMS0xLTEtMQ_9dc074c5-d907-4c53-88e5-d85a4f119c0c">13.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd4429e99d4349deb077d59d1dad17eb_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzEtMi0xLTEtMQ_78436f1d-4079-4114-bfe7-0505adfdabe0">88.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceae9cbc8e6f428cac0b0351b0034ee5_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzEtMy0xLTEtMQ_53631442-93e6-444f-9bc5-f8c2adb6f2a7">101.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92d973cd4a0a4537962a3af58489887b_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzEtNS0xLTEtMQ_8f9a28e6-1751-4acd-9d6d-5db135ab3527">21.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifebda85ec8dd4ce192a74a6531b9d614_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzEtNi0xLTEtMQ_d0d8b7a1-796f-41ee-89fe-f185a75c161c">91.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe8ab0e4d8fd4cfd9126dfb95a32ada2_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzEtNy0xLTEtMQ_64151707-2980-406e-886a-bf0f02486d53">112.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3921ded1beba40848d3de915564681a9_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzMtMS0xLTEtMQ_8ec30cb3-871f-458f-b6e2-3c0510c0b997">24.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7659a70032347a1a0b90552b4d62ed3_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzMtMi0xLTEtMQ_449430ae-5a8e-4bc7-9551-1a5089636309">51.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i186444e26ab54d898b6b15b3ec836f25_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzMtMy0xLTEtMQ_f17090db-b164-4cec-b57f-b91d48a10fd2">76.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i453051ae80004c3eaa95fb204101dd02_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzMtNS0xLTEtMQ_ffe2fd1a-22c4-4f3e-87c5-79c384363aa2">26.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31a4994fe4e0451d9b0de9fc4cc45241_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzMtNi0xLTEtMQ_4d250ba0-46d1-4cac-bd57-37413988adf2">53.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib39a29f5f552438ea4ed0f6636e277a8_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzMtNy0xLTEtMQ_d8ffb844-705d-444d-af42-b672a1ec43b4">79.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Neuroscience</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i052653fc20254249a0de9e128a7c2a7b_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzQtMS0xLTEtMQ_c3aacfda-9566-43c8-8f47-88529f5780f1">144.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i089ee5a884734f048eeee3e2567bf7ce_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzQtMi0xLTEtMQ_d2b22e32-1014-409e-bd0a-e893ced779ca">305.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292fa580da6a4de9822a300c2b0366fa_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzQtMy0xLTEtMQ_d7075acf-7ae5-4ca2-9682-a4ecf16a0ef2">450.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a55f0b0a5af4394ad7de980181c592f_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzQtNS0xLTEtMQ_62f89521-7a21-420e-8495-5b5d41a19c6d">140.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2b9316931c41cbad3fbe52783bbc71_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzQtNi0xLTEtMQ_520cebcd-f45f-4993-a367-2cdabd1b163f">330.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cc53c31079d4498baf5c2908aa20aa4_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzQtNy0xLTEtMQ_8e59a9fd-8236-496d-8c46-85517fcfb9d1">470.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 Antibodies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71b81d21fbe94b4e98b74b22e329e4fe_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzgtMS0xLTEtMQ_719e4dcf-db3f-4327-b74b-e8a13e0ff261">215.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i083918a48bb449d78ad626ecb038546e_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzgtMi0xLTEtMQ_1cda5468-9c90-4840-a158-01c22c25e6a9">1.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1915b82ef0745bc9e6902e358dcf426_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzgtMy0xLTEtMQ_6dc441b1-235f-4a1f-bcdc-e193e5d2b244">217.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1382419146344dc79bef45e72e6ff200_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzgtNS0xLTEtMQ_28eac30f-7154-4066-9d49-7c58f3ad1981">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7998ccfffad54f5a9b058726aa6b7326_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzgtNi0xLTEtMQ_f16f27da-8314-4541-8d2b-8a336255448a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55ecf9bd230b4e6f9a61f2f6dd604b6a_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzgtNy0xLTEtMQ_378eada0-977f-4253-a5ef-e8a2731a3218">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd86bf7f1e8344b3a7dbfbaf21dd0e6a_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzktMS0xLTEtMQ_754d7448-e56b-4b11-8b6a-b22fa87da68f">109.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51349dbae1e142efbd09be3fc1d7902d_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzktMi0xLTEtMQ_cb147a87-d4f0-47af-9a52-aaf5b6157910">91.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie18eb8b2caaa4e6bba191b1bd794bac5_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzktMy0xLTEtMQ_7808cba8-fe2e-45f4-ae3e-a221eff92e2b">200.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517eba3441bc456fbc2a2c195f1e25bf_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzktNS0xLTEtMQ_58899e93-4d7b-4504-a387-423e445fc45d">144.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe5334101eb14c808e2139001ea4c06e_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzktNi0xLTEtMQ_0a319970-ca3c-4e8c-b100-30929b41106d">122.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia255d15fc6ff4cff922a9ee2fb0c0e96_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzktNy0xLTEtMQ_17c261cb-801a-44bc-a2e5-3bd78dc95eed">266.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bb5a4110102404cbfd2c7b4ba607883_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDAtMS0xLTEtMQ_6c818eb2-883a-4208-8119-ed690237dc16">6.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cf54671a7af41728bdbea955e0f5c5f_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDAtMi0xLTEtMQ_4f1a3d05-7601-427c-989e-5aead6fda2e4">137.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8890bd1f5f1a4efaaaca2db702f79703_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDAtMy0xLTEtMQ_7889c926-be9a-40e8-a1b8-50de91ce2d02">130.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959c1d63793f4187b23a4c1b7682d284_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDAtNS0xLTEtMQ_cbd0dddf-db00-4378-876b-3e257f5611b0">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbe2a3bad44c450a8397960daacfd707_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDAtNi0xLTEtMQ_72889837-ec62-481b-b32e-0ba50bfda2e1">147.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19c6a9959ea140fd9890927f182fe605_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDAtNy0xLTEtMQ_4745ec45-04bf-4b3d-98f4-64bd8805fdae">162.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic46899cdc2a5456f9e0611bd0426b4fd_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDEtMS0xLTEtMQ_71529216-f3ef-40f6-8584-e164a553a5a2">36.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf2deaf4d18c449490361e41a4ac0cef_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDEtMi0xLTEtMQ_fd30446a-2dc3-4700-a20e-64ec2349aaa6">52.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i289d3252ca6a485f820ef1ea3ad85c12_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDEtMy0xLTEtMQ_0630543a-b0f6-4566-bbb1-cb8ee33e08d2">88.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784dad6404be43dfb6fc2b79158399e7_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDEtNS0xLTEtMQ_ab2ecb1a-13ba-401f-9690-d53b6471c0d5">33.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaa3e0c977aa4404a714b3813766c78f_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDEtNi0xLTEtMQ_460636c4-6443-4704-91df-68a980db8d90">63.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82485c3a3fba4749bfbbb721e21e7f30_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDEtNy0xLTEtMQ_96efc2ba-e5bc-4391-beb5-05bcddf270ba">97.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58158972e0264a6fa5cee16276b66a34_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDItMS0xLTEtMQ_8e528a55-bdfe-489d-9bfb-c51f348f7110">354.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3ec4f79f58b44a296e438bfeb9305c9_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDItMi0xLTEtMQ_fab602ef-ff21-4698-abd8-b57a782c939f">282.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc5a8ab9f9e49e9b1727ce623456ec5_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDItMy0xLTEtMQ_4c657260-75ff-4605-9afb-c5443e18faee">637.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe1bbef48c94f69a1e7eb1738576328_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDItNS0xLTEtMQ_a3e3e369-c7c9-49f6-87b3-160b7b5dec7a">193.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41665e7d5323479fa5a85ac7afd7a612_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDItNi0xLTEtMQ_c5c17eb1-a678-42b1-bd95-5f168e74cf6f">333.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id54a327ff97d4ef9958f15bb7ed74770_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDItNy0xLTEtMQ_b12a47c4-ff44-4323-9e21-4f9ba5c6e8d5">526.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd448a0d7d984d978046eded1bdbef98_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDMtMS0xLTEtMQ_a14094ca-d373-4d11-9f3e-b14de5c68431">3,989.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if41782491b964242bf0779976ed75cfc_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDMtMi0xLTEtMQ_ba2ed9fe-9624-4ddc-b5a2-409e7d7e18ac">2,783.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDMtMy0xLTEtMQ_686ead47-4daf-4162-93ce-47b333b3b580">6,772.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0fa9309b68448efb27e0f24f9cfa0a4_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDMtNS0xLTEtMQ_e9fdcf8f-a448-4faa-b719-f1db7fc197f1">3,161.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf6d4dabc7f494caae8aa84b2e0e2bc_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDMtNi0xLTEtMQ_9da00898-6dd5-45c3-b1aa-ecd87b55992f">2,579.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDMtNy0xLTEtMQ_54cf53b5-f5e5-41f6-b1ba-e2ae37c0b222">5,740.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)   </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to Emergency Use Authorization (EUA).</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs. </span></div></ix:continuation></ix:continuation><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span><br/></span></div><ix:continuation id="ice4a2a246e024a5ab06a12fb397a04d4" continuedAt="i05e53edb6a7b4c72a298c34186d9701f"><ix:continuation id="i864b0a004ce8452297e95bdbd44b7372" continuedAt="ibc09f7c4f95542da958807bb12d9da69"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product for the nine months ended September 30, 2021 and 2020:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.298%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida742051726641c1a38ba8085a59818b_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNS0xLTEtMS0x_8aad5ef2-0b8c-44a0-8e6e-8630589c2ea7">3,465.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8afbe65684454a96aad4f5fcc43bb2f2_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNS0yLTEtMS0x_ded1ddf9-99df-4d11-95fa-96de5fce663e">1,122.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c156843918049c3b017e903d0c8b152_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNS0zLTEtMS0x_76ce43ab-0513-4887-893d-5442a0a8f52e">4,588.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c0e23525a404bd980161347b9d48297_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNS01LTEtMS0x_e04b6e2a-6b7d-4a82-bbfe-fc6d934993f9">2,673.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f487e07da6a4df7beced03386ce2cb2_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNS02LTEtMS0x_cda15270-0560-4341-b7d4-548eb232b098">892.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifda1418c5f224ffabb56a4cd20894bb4_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNS03LTEtMS0x_ed5b4f10-e2c8-4e67-a59a-cbfc18262958">3,565.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21f5c26534d04950a2d18f70db623648_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNi0xLTEtMS0x_c2c55b82-46ce-4f46-bca2-748e731fd7e3">1,009.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd90c62ee1c04e2e80e99978c6745eb9_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNi0yLTEtMS0x_cb375e2a-c88d-4aaf-840c-a5d568a74360">842.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392ba95f36004b559b3dabf4a7d68df7_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNi0zLTEtMS0x_1e662a27-8d5b-40fc-9f4f-a104046206ea">1,851.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78362cdcc41745bb8bda6133796f6fd2_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNi01LTEtMS0x_a2c3c5f9-578b-47fc-8ee0-a0de0c4dac89">1,070.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b810a3d51924e95aeb4d64791147211_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNi02LTEtMS0x_06cbd221-3c92-4237-a79b-3d9c47f66577">837.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d57ac52c7bb44dba43dbba774be4bf2_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNi03LTEtMS0x_7f734537-3de3-489b-9ae8-a08f636c0442">1,907.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3d83ab14504b6689cc76eec030040f_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy0xLTEtMS0zMDI1OA_7b89ebe0-faf4-4c0a-8726-9305cda30758">566.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a6c69c487df42779007c37685f53e85_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy0yLTEtMS0zMDI1OA_3539b872-6c40-47fd-97f8-5ad7cf7b134c">492.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c5cb50d0a384037b1da389f2a6e0996_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy0zLTEtMS0zMDI1OA_2fe7df2b-2d70-415d-b85d-21a4ed6a2917"><ix:nonFraction unitRef="usd" contextRef="i0c5cb50d0a384037b1da389f2a6e0996_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy0zLTEtMS0zMDI1OA_90845ff0-de10-47e8-800d-e192fb7b3100">1,058.9</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5877d4ccd49f4569b4e2595a05ac782b_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy01LTEtMS0zMDI1OA_727c0cb3-01a7-40a7-94c0-e0876048ff59">453.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee73ab780a8f46d8b5fd8ade8860c89a_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy02LTEtMS0zMDI1OA_51d26a21-0335-45c4-bded-dbe430b728b7">387.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc25dba031242f7b3f38ee74a40876d_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy03LTEtMS0zMDI1OA_9ee139b7-1f1d-4453-9546-e4cd3f70f1d0">840.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7646113be96547db8a4bb44230ae23e6_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy0xLTEtMS0x_d7ad04ec-8185-43e9-a9c4-c79866b6f5d3">633.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe4ca92881b34f2d87b3d3d4afee83d4_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy0yLTEtMS0x_12795a2a-0e15-47e6-bd19-62b7adf3b772">290.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f931c0b571a4fe0ba04399bb7cf2882_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy0zLTEtMS0x_fabb4110-1559-4d92-8e32-920e13cc04fd">923.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6079c23287c458d90dcf5793335aca1_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy01LTEtMS0x_aef9b0ae-2f7f-445a-8119-d322db16546f">642.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f071d62d774401ae3df21bca257b94_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy02LTEtMS0x_85284325-790b-49b3-91ee-666d28bc402a">292.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6bfac32d58a4b7db6eb70dfb23fd9fd_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy03LTEtMS0x_d7b5575c-0c49-4cdb-9f75-1d92e5e3b55f">935.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic485be951f44461b83f7178570da126d_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfOS0xLTEtMS0x_8ed96778-9181-445b-b7e5-900679f61661">423.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399cec6d60df445682e5e26167ab0fa6_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfOS0yLTEtMS0x_513b64cb-6be0-440c-805c-d821704a95ad">226.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib84ab601c2e045f9b4f9ff1a30e0787a_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfOS0zLTEtMS0x_fb9d9946-288e-4fd4-b533-a14533f1ea7a">650.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f09f9b3b0ed4eeaadea6c487497dc7e_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfOS01LTEtMS0x_dbc6c011-711c-45b7-9650-fe0cbe6ea97e">638.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0327ede8f6347659e88e5324c757fc9_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfOS02LTEtMS0x_1ce795bc-e7af-41af-b63d-c5a186863906">203.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9fdd628b285469fb2e83ec947cf3bb1_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfOS03LTEtMS0x_d0d78fdd-45bd-4c66-8e65-823515fdc548">842.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i397a56587b474dc5810261bc659887e2_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTAtMS0xLTEtMQ_ed4accfc-cc2e-4e11-bfba-007ed8793610">185.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacfcc3433c15426bac8a79d18149a311_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTAtMi0xLTEtMQ_53516c02-49c8-48cd-b927-2343d61a079d">302.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fda94809a0f43ca9938efc6f0994e74_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTAtMy0xLTEtMQ_4b463fd5-d756-4b6a-ab42-14e66107b85e">488.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd07e050427d4b0495759b6f44c3273e_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTAtNS0xLTEtMQ_d13daaa9-bade-4711-816c-262ef333e024">185.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4d463248ad74b09a08446c68620a3e1_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTAtNi0xLTEtMQ_b3732117-35cd-47a1-98cf-02ee69a6d648">254.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0185d32bea7d4ee0b0b5e34fbac1fa96_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTAtNy0xLTEtMQ_6272786a-bf87-45f6-ad76-c05177c37f61">439.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Diabetes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a83d2e4f15480780af7cc663a095e8_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTEtMS0xLTEtMQ_1aef078b-19f1-412a-9ba8-42d76113f31e">6,284.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafb64cc18d0c4af79c7b894a05a665e1_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTEtMi0xLTEtMQ_384e64d7-d868-4b89-8a03-8e309157833f">3,276.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d04d41e5ada46e1a63e592fc6a9b2d2_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTEtMy0xLTEtMQ_08cf7b84-32ed-457f-a476-3efbf1a9efa2">9,560.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i652338f7e46b486589e3d75d6a3de4a0_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTEtNS0xLTEtMQ_0f796504-77b3-42ce-8dde-a740f7de07d1">5,663.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i705897b88c1c4bc9ae28abf5053986a2_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTEtNi0xLTEtMQ_ea3798af-83ad-4ef4-9fee-d9e2b0c9e094">2,868.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e2acd9dcfc42759dfd0fcf3b77d702_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTEtNy0xLTEtMQ_257dd121-faf8-49e2-ae31-e5bbf596031a">8,530.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if46b1191ac1c46e9b91d7193b8f302bd_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTQtMS0xLTEtMQ_f8158f3d-24bd-47a2-97fe-c19b3dfcedea">911.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica3c1e4736274954a8d703df9c2b167a_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTQtMi0xLTEtMQ_401620f9-b55a-4461-bfa9-2c97ec1fdf0c">714.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a497c7c118f46e98f40fdba8afad80b_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTQtMy0xLTEtMQ_088434a9-726e-4c9f-a42f-6477dc490f2b">1,626.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa5c550586744b789a920295b90fe29b_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTQtNS0xLTEtMQ_7910288c-1fb8-4363-ac8a-46b97170adfd">933.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99d38563475f4c678f23755bdbf34b9e_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTQtNi0xLTEtMQ_8304fc29-390f-42f1-a8c7-e5f29bf26a11">743.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc96b44a7e7c4b2d9067f6309c9e0981_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTQtNy0xLTEtMQ_33278e34-06d2-4b98-8ccb-c8b498d0ff3b">1,677.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4dee8841aff467e8d34d2a66b5ede53_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTUtMS0xLTEtMQ_69f95715-cb83-46fd-ae14-8603597059a1">582.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aa0f1db9a924a86a4539ed44bb03cf4_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTUtMi0xLTEtMQ_a6f8a1e4-6e7c-434c-b17f-0f98cbff1b01">363.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55ad0c64dc4445c8b5360106446e4e0e_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTUtMy0xLTEtMQ_e7e3464a-f866-4ed2-914a-cbb221916f7c">945.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i619fc1a06c8e4e23955358634606df7a_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTUtNS0xLTEtMQ_28ee84cc-fa79-4425-a3ee-80f9ab577981">430.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b9c66fd8850463dabe617b7427612b9_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTUtNi0xLTEtMQ_b41e5855-0495-4018-bb5b-96274b251306">201.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90fe301cd12a458a8609a9e6744b77c2_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTUtNy0xLTEtMQ_693e4402-d4ee-4ef0-b3e3-49d7c1053741">631.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc36beb9b14e4b9783e4927f8ff53209_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTYtMS0xLTEtMQ_787b6cb5-6ed1-43ed-9b78-141ece7b5545">266.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fc16180ac704e6f8cae3536cc15fc44_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTYtMi0xLTEtMQ_962932c1-ba21-403b-a5dd-6c12798987b5">496.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1974eeef369549dc94df5ceef4375ee4_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTYtMy0xLTEtMQ_27834960-6aba-4ee0-9f4b-3613d5f3253a">762.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4683a7953b994727aa54bdf352b5d02d_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTYtNS0xLTEtMQ_74d2211f-14f2-4fca-9b26-5d9287f2bec3">277.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cda66e9d3f64ed7b5ab5be8945ea9dd_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTYtNi0xLTEtMQ_696dd423-a903-44e0-bdb2-670da71284ed">470.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0289a925449c4af893800c44334d7179_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTYtNy0xLTEtMQ_4a37b3f4-546f-475f-88d8-dcd827d2ef1d">748.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i760c1d6d41874cbba99a6b0a36e9dbfc_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTctMS0xLTEtMQ_51f12bde-9720-4a87-a011-a7ffce3769ad">357.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9171d813dd8744aa8ebf6be081733303_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTctMi0xLTEtMQ_365f403f-aba2-4941-b9a6-f6f9d2151026">45.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia12001823d9949fbaf94effdadcee1f0_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTctMy0xLTEtMQ_620f0e68-9b23-4e9d-961e-bfb2a07b7b84">403.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374b134314ff4f75bf1e218faeb7a140_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTctNS0xLTEtMQ_afbe7492-ccd2-4c45-89e4-ef70ee3e920a">356.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a772071ec7b42b5a35616776c47cc46_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTctNi0xLTEtMQ_9a107846-dafa-4900-b6b7-c9a50aa8b913">40.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a60daf847d84c269726d5443505a7f6_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTctNy0xLTEtMQ_edd95175-dc7d-45b6-808f-10aab9de3b69">396.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea2febe706a44680bc01a519177d071a_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTgtMS0xLTEtMQ_5ac0d262-c2c6-4f8c-83d9-969687cda761">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5607f6891d49dea32ba497824c5cf6_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTgtMi0xLTEtMQ_35bade17-f1f3-43f5-85cf-08a1e6c414ab">340.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47a1977d3def441282bd0a67b40c3f58_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTgtMy0xLTEtMQ_35b87a5c-eeef-4e28-a91e-bf8e3d692b4c">340.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6922b33207dc47c696a18cd215b4fc89_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTgtNS0xLTEtMQ_ab4e609c-98d3-4268-ab25-0384885bd22c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99b621e206fb43b2af4e311739f64ce3_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTgtNi0xLTEtMQ_773e73cd-497d-44a6-8372-ba9883d32370">205.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721201b823f24281ab0040324500b66f_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTgtNy0xLTEtMQ_d4462724-0964-4cfa-9bff-2c477e651b55">205.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Oncology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i390fccc895414dbc80bc7b21902083d8_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTktMS0xLTEtMQ_2e2eadd1-caf1-445e-b598-e50d8255f92c">83.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b5806021254319908670087ba01693_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTktMi0xLTEtMQ_3599b1ff-e552-4967-9972-658a704cac0f">169.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12d8057fb6f44881adf62c66da12a47b_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTktMy0xLTEtMQ_efb5bd2e-2ddd-4899-8b05-5eb32d7ffc98">253.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d2c31facfd84348940f0a8c61dbc204_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTktNS0xLTEtMQ_313489a3-e86f-44c5-bccc-727141b4cce3">26.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f004ac1b604026a7bc7798d77ef19e_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTktNi0xLTEtMQ_caf195c4-8a9d-4bb5-b78b-4b8e7a30872a">118.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i469dc8fbbc274df3ac3a499298b1aaa1_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTktNy0xLTEtMQ_d21214c5-7906-4d81-bc7a-4b85adc310c0">144.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Oncology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11ae3c44d264cff812e96e38e8bcecc_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjAtMS0xLTEtMQ_1648af9b-961f-4868-8d32-28377d92cb09">2,201.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77eccb6aa9be4aadabe9b433c7c2d2c4_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjAtMi0xLTEtMQ_ce362396-a850-41b0-a344-6d9d348fe729">2,130.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cd766bc4a6a436d9bc943dc45e61200_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjAtMy0xLTEtMQ_012afa4a-b361-47a6-be89-f93a972f174d">4,332.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i738ee12d2f674f3d8ecab5b26681f558_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjAtNS0xLTEtMQ_7e5e2d46-6b7f-47c8-a79e-e823a4512fdc">2,023.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90f1e252129e42289186cf041bf33a8e_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjAtNi0xLTEtMQ_0a4ff36d-1d0a-4a43-8ff5-a2deb04e3937">1,780.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a6eb6ab1d454923bb5c11298dc3ad33_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjAtNy0xLTEtMQ_cf2afdb8-86e4-4913-b174-cd653a16def3">3,803.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44f8e7433d104910ac58ce5909942f8d_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjMtMS0xLTEtMQ_a63f3b37-3c2b-46b4-b662-663a8ccecac1">1,071.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fda936960b8455e927557e937bd1b99_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjMtMi0xLTEtMQ_23ce7a1a-21b8-472b-aae3-c16312efebf5">493.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bf37d8e1a9840ff840b07a02b3d5386_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjMtMy0xLTEtMQ_f4d14a6f-2d49-4f35-9fd4-35fc08bc4771">1,565.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i800cc0342090483daa741525f8744ff3_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjMtNS0xLTEtMQ_c5d1d5bf-38bc-477e-ac79-24f31e21e013">942.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5551db7f547e415f84b80f7c3b385f9b_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjMtNi0xLTEtMQ_fd643c21-8abe-4b86-b5e4-b0af46ccfe62">350.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e75cf8e17334bd7905b58023a170fa9_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjMtNy0xLTEtMQ_3eafd05b-55cd-4ba5-bbea-62c127841f34">1,293.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabc3b21ccc994e3890088301e3cfc653_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjQtMS0xLTEtMQ_9aaef09f-7edf-4aa5-a428-420e5f6b4925">236.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4683cd0b47d404d9b3503f7a600a568_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjQtMi0xLTEtMQ_1ab71337-3957-4149-8e2d-ba283203ea44">572.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e4795f073d468fac40d557656ecda2_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjQtMy0xLTEtMQ_a36d1910-0a3c-40aa-8a71-bb7cc4534aac">809.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id06212a669134804953343ff9b9678f8_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjQtNS0xLTEtMQ_f0b1e825-3044-4a3c-b53e-f8b95e5a67e0">39.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie85525da43ff40e380aee019e6218166_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjQtNi0xLTEtMQ_fa50c9b8-49e7-4eb1-abe6-826f5693de13">407.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if93d6526b32048608464727fad92c9bb_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjQtNy0xLTEtMQ_b84ef628-f2c3-4afe-b03a-8d64c12a5284">446.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Immunology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d1869f9b9284dfcbe120478faa3f6cc_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjUtMS0xLTEtMQ_32b18b94-aa1c-489c-a221-0b7b3141153d">15.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i184a7a62437441fe889424d1df050960_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjUtMi0xLTEtMQ_4b72f47c-69ff-4eb1-9057-89d9bc57fc9e">14.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d8fa886c14458d88747c5a3f5ebeac_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjUtMy0xLTEtMQ_8339d9d6-e57a-4015-906e-12ae92e1226a">29.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b1a3020e2314eaaacf0bd2fc78d63c1_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjUtNS0xLTEtMQ_8838b3bb-e494-4711-bdf3-de6961969223">13.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bc589b7bd644e10835ebc480ec4a412_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjUtNi0xLTEtMQ_7c395a20-399b-49b8-9529-29a36a09275e">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18de420a47cf41a793c58b470768a0e8_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjUtNy0xLTEtMQ_c88544eb-7a07-4897-acfa-dbe19a4ea5d1">21.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Immunology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb9be07b275a40f8852a6c540fe99af8_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjYtMS0xLTEtMQ_9f226424-53f4-4103-8e4b-2c00263d17c6">1,323.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2861a0c3822428d869e6001e7582ec3_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjYtMi0xLTEtMQ_10fae536-ff59-4fcd-89e1-5645477fa97b">1,080.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id05ffc1309fe428888516a9c3f40e7a7_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjYtMy0xLTEtMQ_8dac8ecb-82ca-499f-ba8a-1347f1533147">2,404.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34d06576e4145798da69e8840b8ea78_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjYtNS0xLTEtMQ_84b57652-d993-496e-9e82-0e00533eb79c">995.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if71dd64ea4de44d9afaf6d6a512ba1db_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjYtNi0xLTEtMQ_2ce47fc5-5b52-4ec3-88ba-eb1ffa761a06">766.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12b21ce236de4ed8bf7e747d6eea29ff_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjYtNy0xLTEtMQ_a1b3085c-e82d-4922-8570-214d9bf75b9b">1,761.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1523e93b1ffd4b70acacf4087551c5db_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjktMS0xLTEtMQ_23233f43-ca2a-4119-a7f6-e94458d80643">30.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2bc530014104c0cb422de56d4d03e82_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjktMi0xLTEtMQ_b0f72fd8-b682-4d0a-8c7a-baa0946f58cf">454.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9e84e4ca8de4c4b97234a747132a31e_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjktMy0xLTEtMQ_2204760b-8fdb-49b1-8893-c35c5431cf30">484.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38c6380bb9864e3587fe92837bf5d091_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjktNS0xLTEtMQ_1d406bfe-951c-426b-887d-c88030cc599d">30.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc35c7271a8a4943a6227055ab125eb0_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjktNi0xLTEtMQ_4305871e-946c-4c3c-8281-3eaff70f2806">546.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a99b6d9c4c747ce99e9e703d54444b3_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjktNy0xLTEtMQ_ff4cf130-2110-47ee-ba4d-b32b26ffbea3">576.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i491c10fe08e342f4a4ac07e509c92936_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzAtMS0xLTEtMQ_cd487a77-5859-48ab-aeea-db03cf40b356">313.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816868a48c8b48099f4d274ded2ea7ed_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzAtMi0xLTEtMQ_6f46a4d5-9f83-44bb-be69-eae4cb4c5c0b">102.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc3314eed4cb4b9d8584ffe6c2837839_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzAtMy0xLTEtMQ_64772018-cc59-4d94-a6ed-5a3e435cfdb9">415.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i624804e1e29b4c2f970fd6fb40049075_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzAtNS0xLTEtMQ_7a76500b-a890-4e5f-8540-36cd6ec53b36">229.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a9135fab1f4504b803607fb262021d_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzAtNi0xLTEtMQ_e3a1f27a-7a82-4d02-a281-19f2bafea4ba">23.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e0b11e3d0d14a5baf6de15812c649f2_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzAtNy0xLTEtMQ_b82dd3ec-9719-4e96-953e-97cb9358e20d">252.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd82f3451e814629b0bd328a44af9778_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzEtMS0xLTEtMQ_76c23481-d653-4a06-ba39-479e481f1d32">28.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399f4d91b8034567938ddf63d2231514_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzEtMi0xLTEtMQ_ddbf4e1a-51bd-4d0d-8b4d-71fd94793a10">264.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b3ace2be01a4932a527ada8b0e95c08_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzEtMy0xLTEtMQ_c927db52-38ef-4f6d-bf86-36ed31ba8e70">292.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cec004919c74d1abb18678fa0d18ec8_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzEtNS0xLTEtMQ_f2c3c71a-79a0-48e3-b59e-88504fd3c0cc">41.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie56c114480404e369f4c566552d2726d_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzEtNi0xLTEtMQ_f4616900-1e60-46a5-97be-64cc734166c0">266.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i273b596e58b94897a35fd6eaf5a112bb_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzEtNy0xLTEtMQ_6963d16f-431e-43a3-b5d9-14168f6694cf">307.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if68930386e0e490d9cc62c2853246366_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzMtMS0xLTEtMQ_1a71cd4f-484a-42ef-abb0-22f7caab7e5a">81.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2219da41e098458f8e17480a24f019ae_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzMtMi0xLTEtMQ_7f8a7049-dff9-48b7-8174-aa5af1306c06">154.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc7fc4722f76404a8a37d85632337dbc_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzMtMy0xLTEtMQ_8f141480-ddf2-41cd-8b41-50ad532a94c8">235.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00900522405a4bb38276038085c324e4_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzMtNS0xLTEtMQ_6d7ea537-e9ee-4726-b023-831248e1aa3d">53.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b2429251b54a7389aab14092777b48_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzMtNi0xLTEtMQ_60f09845-fc91-48f5-892c-c85c7d03e129">165.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffa2fbcd9aae4080910c4a7ea104fd94_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzMtNy0xLTEtMQ_5f3558b8-9f6a-4a31-bfda-872bf4a87a2c">219.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Neuroscience</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id60f7f14418c463da58451d606950976_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzQtMS0xLTEtMQ_8375e427-7998-4b5b-914e-5e735d6dc9fb">453.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16f11aac59c4ca3a1b1d3532c9651a5_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzQtMi0xLTEtMQ_7f4231fb-25cb-4c67-992a-21adad845690">974.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a99b63187cb430c89fd5d3823917b2d_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzQtMy0xLTEtMQ_56704494-d3ac-43c5-9f2a-3fc2f2924af0">1,427.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dd55add52d845c6a51186e6507d9fd1_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzQtNS0xLTEtMQ_67ab4009-fc4d-4aa5-a78b-9fc9ed97d3b2">354.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i610c7613e7d44f308a44a6dc9bbbaaf3_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzQtNi0xLTEtMQ_90dc66c9-e598-4e76-a22e-fc9db1124ed6">1,002.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c837650d554f56a6200ace6566fe10_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzQtNy0xLTEtMQ_c4fe0aab-9dab-44f7-8dc6-fadde87ce026">1,356.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 Antibodies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36dcc53ac3e4228adb3e7a26ca46465_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzctMS0xLTEtMQ_b42d3734-dddc-4686-8ecd-0f821c8ae66e">949.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i133749f5535c426db6fff5b68d432a9a_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzctMi0xLTEtMQ_ded315eb-e280-42a8-b023-9d71666e15d3">226.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib066c49389e847e08dd9e47b3dd013ff_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzctMy0xLTEtMQ_7ca45fe7-aa06-44e6-a905-cad8a1994487">1,176.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00cdf12927374e9ea2bd4fd171d087a8_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzctNS0xLTEtMQ_38a53cdb-9414-49fc-9aa6-ce58d232690f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8046f99bbe284c3ba18f324d7e76338d_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzctNi0xLTEtMQ_c92f275f-6e98-4ee6-a84f-5d103eb34b96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia784a32e102a4a3c897cd146133b8efa_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzctNy0xLTEtMQ_0e92b41a-8950-499f-8c2d-b1d0b6235faa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f926fe8ad974b88bb900b9493519ef1_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzgtMS0xLTEtMQ_64c2b720-015d-4ec1-9583-36334bbf7697">330.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6aab15dd89e4fb29adda466320b7ab7_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzgtMi0xLTEtMQ_82eb2d9c-a87a-4673-b993-5e9e805e5878">287.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2214d9b014994300805fe9c16ab74705_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzgtMy0xLTEtMQ_cca31554-fd45-4108-a09f-10957d95ea65">617.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba10a9ccc98d4a24b8827dac6bfff7da_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzgtNS0xLTEtMQ_c2c4169e-8867-4328-a17b-d53284816220">386.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9600095f80154ce7888d5d052fbc1c34_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzgtNi0xLTEtMQ_7247739e-d6fa-4991-ac11-b26c8b60f71c">405.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2d77207bbde4ab49c305e35c7f2a45f_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzgtNy0xLTEtMQ_cf7407ac-e6c3-48e8-95d8-7a043b959c99">791.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i197272b1a6734b7c91e241f32e6dd646_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzktMS0xLTEtMQ_fc6642a7-c537-41cd-a50b-db600e0782b6">3.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd45ae5c53e04751870a061d88a445ce_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzktMi0xLTEtMQ_96175141-babf-4e8d-bee1-293f1f2ac9f2">541.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c1a896fd4244b5a8e15e4ac8abb96b_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzktMy0xLTEtMQ_89ed1b9a-a773-4b86-96f9-daa4b9fb2f0e">538.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f6f899a265e4b63b17af12da3b7c5b8_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzktNS0xLTEtMQ_a2683b5c-d239-4da2-821c-68592e5e9aa6">64.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i847263e5354d4a72a9f742d7dbe5f329_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzktNi0xLTEtMQ_de0c9493-15c8-4188-9e00-a5906f41105a">421.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c361d809be0426984f9993fb59eccd6_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzktNy0xLTEtMQ_147fffe2-c048-4941-87a8-ef970d164167">486.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608a490542db4b6893542e7e7a64f228_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDAtMS0xLTEtMQ_fbae7da6-fe49-4608-8c80-49edc25c9a92">96.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dc52535a84848d5a963a822901590da_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDAtMi0xLTEtMQ_0e14a9f8-d2cf-473d-9624-a1449d02332a">164.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcf246e7d1304af48b16a8f5ee00dc49_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDAtMy0xLTEtMQ_50ba2c21-b365-4fef-bd43-9638a5ee6176">260.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2c4c9002a344d1bd2cb16fc80b4bf3_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDAtNS0xLTEtMQ_e3f22b9a-0026-4350-82fa-2a85f40425e7">144.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33e9f09317ba4403a2235be6dea1faa9_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDAtNi0xLTEtMQ_7bf99392-08e4-49b4-86d9-659256ef20af">225.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39c4874639894af4bbd798a405ef14f9_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDAtNy0xLTEtMQ_3622f10d-87fc-4ca4-a2c2-03e0ba195c66">369.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide834e2a43444a5cb9b3500607e4ff20_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDEtMS0xLTEtMQ_dfc897f4-f881-4983-821e-e2b96c9363ef">1,373.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b5acdd57ce5404da6a626cbe3b64a5e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDEtMi0xLTEtMQ_6f851df5-544f-472a-81e1-89ba1b6bb787">1,220.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99f841c17e145b28e1c88eceea31bab_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDEtMy0xLTEtMQ_22b955ee-a40e-4177-bde4-9ccd1ee84e7a">2,593.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863ea645f4b549408c451c4882b42085_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDEtNS0xLTEtMQ_e9e618dc-40e9-493c-a3c6-15f0896e81b2">595.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic231bc3ee12e4b1285ddceb9e02b4a26_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDEtNi0xLTEtMQ_6f10985c-abe6-4dad-99c7-fdb88bcdf2a8">1,052.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef4e15111c14cd19aa8255c772b5d92_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDEtNy0xLTEtMQ_ee377515-7b93-4214-ae73-eab13cc0349a">1,647.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2a183d7003942d49ed5ae4cef5356cb_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDItMS0xLTEtMQ_c60a9997-535a-48ff-a6a1-fbb8c907e340">11,635.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i428cf713dc7b4901beedaa25a7950476_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDItMi0xLTEtMQ_77a9283f-3274-49a4-b88e-050cfb3a59b6">8,683.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDItMy0xLTEtMQ_f80ed7e4-c037-4c63-ad22-a4e0e26f712f">20,318.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b9750abc82c4253b256ba599ee15596_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDItNS0xLTEtMQ_21e2a9ba-164e-4e89-8476-ee3baaa26f75">9,631.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b62bc7ef73412295dc475eeadec217_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDItNi0xLTEtMQ_7f031149-2486-4b9c-86c5-145d88775c82">7,468.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDItNy0xLTEtMQ_2210ee6b-aa03-48b7-a8ba-062d362ad625">17,099.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy, and Trijardy XR.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to EUA.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs. </span></div></ix:continuation></ix:continuation><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i05e53edb6a7b4c72a298c34186d9701f"><ix:continuation id="ibc09f7c4f95542da958807bb12d9da69"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:51.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.101%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd448a0d7d984d978046eded1bdbef98_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfMy0xLTEtMS0x_1c6c1fd8-e703-4e88-b805-c758b4399da0">3,989.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0fa9309b68448efb27e0f24f9cfa0a4_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfMy0zLTEtMS0x_1a2c1c4e-8010-4644-a59e-391df1a84c06">3,161.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2a183d7003942d49ed5ae4cef5356cb_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfMy01LTEtMS0x_c079cfcb-c22f-4895-b4f6-715e41b76e3c">11,635.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b9750abc82c4253b256ba599ee15596_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfMy03LTEtMS0x_43e27256-d941-46be-a35a-1a835f2de20e">9,631.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3c0a13a33a349aa92d5012e4b636a7a_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNC0xLTEtMS0x_6bb1e6d0-c8d3-4e48-8274-361b4b0a18e0">1,098.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i669cb3004ae84cf6960440516244078b_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNC0zLTEtMS0x_4def9408-a1be-4d9b-9d75-86afdbf040bc">1,046.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id268ee0f04df42a4a96c475b5cfcbcc9_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNC01LTEtMS0x_176838e1-12d1-4091-a3ed-bff282160006">3,629.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib82ffaddfbef4082af244efc218be24a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNC03LTEtMS0x_b546e18c-cec1-4d60-a08d-9ad1032daf55">2,984.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d504c5ac9c4198822bc799884207ec_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNS0xLTEtMS0x_e218e7d1-9025-4e68-85e2-e416557d4671">595.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idce8121dee4344e18147fc49a8d5a07b_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNS0zLTEtMS0x_d89e3af6-e1be-4f20-8e42-d9524af0debe">660.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib632c646a6e9448cbae9a56d4a57fbfc_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNS01LTEtMS0x_a71498cf-18b3-4bc2-9056-14c738c40107">1,832.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc00e7246a6407b8cc8a82ca741b867_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNS03LTEtMS0x_b13f3a25-37e5-437c-937b-3a15d9b321a2">1,919.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5391e5cb27db47b8ba06894098bd568e_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNi0xLTEtMS0x_9a4ceeab-5b14-4bff-8964-a0214ca9375e">400.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9971c726971d4e269f7742be265aaaa7_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNi0zLTEtMS0x_0558a0fa-9465-45ca-ae4e-cc43db8800a9">289.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f70dfeee6ed4ead97768caa6e0b0573_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNi01LTEtMS0x_0c5e7239-d1fa-4e33-99a7-8e39da1cad62">1,285.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a3d265d5664f4fac0555e3347dda9a_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNi03LTEtMS0x_a7d9ddd9-f7c9-46b9-8321-8c3d30aac593">796.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id317a865e2e349898f18728c5ca604b3_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNy0xLTEtMS0x_ceaeb1ad-68f5-4c45-b9b5-d53f539e5180">689.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d381b3aade5467ea39cf273c6cc47ae_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNy0zLTEtMS0x_0a276c39-ba7d-4b5d-a585-d8bffc83d1d3">583.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dd27416e4d244238ac2cf4eafcbc5e3_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNy01LTEtMS0x_2a551a8e-e413-414e-83e7-09777d41a662">1,936.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i468cf70e06e74d9abb4442d6f2e6ac71_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNy03LTEtMS0x_271afaca-f429-4ddd-90b2-3f68a653429d">1,768.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfOC0xLTEtMS0x_be49abdb-fa01-49cd-ae96-b7783a4b2cb8">6,772.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfOC0zLTEtMS0x_4da3d3d7-0177-43af-8875-33f91bcea104">5,740.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfOC01LTEtMS0x_19298224-bd8c-42a4-ac68-0f0f4bbc3a3a">20,318.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfOC03LTEtMS0x_9e772ce6-bc85-499a-88f1-aae0afab800a">17,099.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue is attributed to the countries based on the location of the customer.</span></div></ix:continuation></ix:continuation><div style="margin-bottom:12pt;margin-top:3pt"><span><br/></span></div><div id="i48af34e12713400c858f7a29183e5680_49"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;3:&#160;<ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNjg1Nw_5ff41fcb-206d-465f-90f9-ec9f74a6be80" continuedAt="i5ea34be438814b8c9bb77a8d9f055d3e" escape="true"><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:AssetAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNjg1Nw_60f716e0-209d-4fee-80e2-fcb110b6815b" continuedAt="i834a1dfbbaaa4830bf6656057a8acafd" escape="true">Acquisitions</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i5ea34be438814b8c9bb77a8d9f055d3e" continuedAt="i4212cf8574e14bd19a2c899238dcdb6e"><ix:continuation id="i834a1dfbbaaa4830bf6656057a8acafd" continuedAt="i8c56dfc625b349e8b3952947f1b348bc"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021 and February 2020, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail) and Dermira, Inc. (Dermira), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. <ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNjg0MQ_f020c5fc-4f86-4cf2-8c95-9d4b3bba0484" continuedAt="ifde5f2cf7ec142629676413c0e3ce2e7" escape="true">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated condensed financial statements from the date of acquisition.</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired assets in development which are further discussed in this note below in Asset Acquisitions. <ix:continuation id="ifde5f2cf7ec142629676413c0e3ce2e7">Upon each acquisition, the cost allocated to acquired in-process research and development (IPR&amp;D) was immediately expensed because the compound had no alternative future use.</ix:continuation> We recognized acquired IPR&amp;D charges of $<ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfMTI0NQ_75b06413-023f-4751-9e49-db532a25d9ec">174.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfMTI1Mg_43af69eb-73ce-43cb-9e99-4737b87a0399">498.3</ix:nonFraction> million for the three and nine months ended September&#160;30, 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfMTMxOA_8c856173-e5f4-4ecc-be06-5c3163ba2007">294.1</ix:nonFraction> million for the nine months ended September 30, 2020. There were <ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfODc5NjA5MzAzMDEwMA_7b832bf9-a4b7-4c7a-8703-9c2e37a6e9f9">no</ix:nonFraction> acquired IPR&amp;D charges recognized in the three months ended September 30, 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions of Businesses</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Prevail Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $<ix:nonFraction unitRef="usdPerShare" contextRef="i34f0affb1412406985b955e8954cdf8e_I20210131" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfMTU0MQ_6e9bff1a-4ae7-4fca-aecb-a80868a8652f">22.50</ix:nonFraction> per share in cash (or an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i69178206ce654ab9873b9e9c1d36fa34_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfMTU4Mg_37a34817-e5b8-4543-8360-760a11bfaf58">747.4</ix:nonFraction> million, net of cash acquired) plus <ix:nonFraction unitRef="right" contextRef="i69178206ce654ab9873b9e9c1d36fa34_D20210101-20210131" decimals="INF" format="ixt-sec:numwordsen" name="lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfMTYyMQ_816fe77e-4a25-4236-8823-bf1844317a77">one</ix:nonFraction> non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $<ix:nonFraction unitRef="usdPerShare" contextRef="i34f0affb1412406985b955e8954cdf8e_I20210131" decimals="INF" name="lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfMTczOA_dfdef7ed-d963-44cc-8ada-63d417dd9a8f">4.00</ix:nonFraction> per share in cash (or an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="i34f0affb1412406985b955e8954cdf8e_I20210131" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfMTc5Mw_5762f5ab-c9fc-4f79-ac0c-be0f4b15dbe5">160</ix:nonFraction>&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately <ix:nonFraction unitRef="usdPerShare" contextRef="i34f0affb1412406985b955e8954cdf8e_I20210131" decimals="3" name="lly:BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfMjIxMA_b121ca4c-4112-4019-8930-857232cea2bc">8.3</ix:nonFraction> cents per month until December 1, 2028, at which point the CVR will expire without payment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail&#8217;s portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson&#8217;s disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4212cf8574e14bd19a2c899238dcdb6e" continuedAt="i18d588519c6d48869b67f84f229dc721"><ix:continuation id="i8c56dfc625b349e8b3952947f1b348bc" continuedAt="i05c06743c89e499eaa9ab635bcefe42f"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our access to Prevail information was limited prior to the acquisition. As a consequence, we are in the process of determining fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized.</span></div><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNjg2OA_ff65be0a-86f6-4b2f-b172-f9d8912a576f" continuedAt="i554094c671314314bd9c44f840f7868f" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at January 22, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34f0affb1412406985b955e8954cdf8e_I20210131" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOmRkYzg1Y2ViMTg4ZDQ5MjY5OGZkYTlmMTMwZDBkOWNlL3RhYmxlcmFuZ2U6ZGRjODVjZWIxODhkNDkyNjk4ZmRhOWYxMzBkMGQ5Y2VfMS0xLTEtMS0x_fb89b3d9-b060-4a6b-9692-262087b0bc1d">90.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34f0affb1412406985b955e8954cdf8e_I20210131" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOmRkYzg1Y2ViMTg4ZDQ5MjY5OGZkYTlmMTMwZDBkOWNlL3RhYmxlcmFuZ2U6ZGRjODVjZWIxODhkNDkyNjk4ZmRhOWYxMzBkMGQ5Y2VfMi0xLTEtMS0x_54f59bd8-0557-4204-965b-0b00f57dcb0e">824.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34f0affb1412406985b955e8954cdf8e_I20210131" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOmRkYzg1Y2ViMTg4ZDQ5MjY5OGZkYTlmMTMwZDBkOWNlL3RhYmxlcmFuZ2U6ZGRjODVjZWIxODhkNDkyNjk4ZmRhOWYxMzBkMGQ5Y2VfMy0xLTEtMS0x_e03993e2-acbd-4384-bf9a-0aefcd224bae">118.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34f0affb1412406985b955e8954cdf8e_I20210131" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOmRkYzg1Y2ViMTg4ZDQ5MjY5OGZkYTlmMTMwZDBkOWNlL3RhYmxlcmFuZ2U6ZGRjODVjZWIxODhkNDkyNjk4ZmRhOWYxMzBkMGQ5Y2VfNC0xLTEtMS0x_0d115117-1438-4dd9-a838-7ea6c0ef3b97">98.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34f0affb1412406985b955e8954cdf8e_I20210131" decimals="-5" sign="-" name="lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOmRkYzg1Y2ViMTg4ZDQ5MjY5OGZkYTlmMTMwZDBkOWNlL3RhYmxlcmFuZ2U6ZGRjODVjZWIxODhkNDkyNjk4ZmRhOWYxMzBkMGQ5Y2VfNS0xLTEtMS0x_06cd71ec-329d-4666-a5cf-e2b601b7362e">31.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34f0affb1412406985b955e8954cdf8e_I20210131" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOmRkYzg1Y2ViMTg4ZDQ5MjY5OGZkYTlmMTMwZDBkOWNlL3RhYmxlcmFuZ2U6ZGRjODVjZWIxODhkNDkyNjk4ZmRhOWYxMzBkMGQ5Y2VfNi0xLTEtMS0x_efcf26ab-4c96-46f2-a050-b2fce79ba05a">903.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69178206ce654ab9873b9e9c1d36fa34_D20210101-20210131" decimals="-5" name="us-gaap:CashAcquiredFromAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOmRkYzg1Y2ViMTg4ZDQ5MjY5OGZkYTlmMTMwZDBkOWNlL3RhYmxlcmFuZ2U6ZGRjODVjZWIxODhkNDkyNjk4ZmRhOWYxMzBkMGQ5Y2VfOC0xLTEtMS0x_7d039795-f143-4713-9789-66e743978f4e">90.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34f0affb1412406985b955e8954cdf8e_I20210131" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOmRkYzg1Y2ViMTg4ZDQ5MjY5OGZkYTlmMTMwZDBkOWNlL3RhYmxlcmFuZ2U6ZGRjODVjZWIxODhkNDkyNjk4ZmRhOWYxMzBkMGQ5Y2VfOS0xLTEtMS0x_942d00eb-fe68-4b25-8102-09c65f0eb857">65.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69178206ce654ab9873b9e9c1d36fa34_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOmRkYzg1Y2ViMTg4ZDQ5MjY5OGZkYTlmMTMwZDBkOWNlL3RhYmxlcmFuZ2U6ZGRjODVjZWIxODhkNDkyNjk4ZmRhOWYxMzBkMGQ5Y2VfMTAtMS0xLTEtMQ_65f66b5a-7e87-46b1-bcc7-efe2843c5c6c">747.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to PR001.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is not deductible for tax purposes. </span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i554094c671314314bd9c44f840f7868f" continuedAt="i19afad06ecec4d0c89db630b571235e1">(3) </ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i19afad06ecec4d0c89db630b571235e1">See Note 6 for a discussion on the estimation of the CVR liability.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included as this acquisition did not have a material impact on our consolidated condensed statements of operations for the three and nine months ended September 30, 2021 and 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Dermira Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we acquired all shares of Dermira for a purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="ibb396fb0bb334dbdb983642373e2383a_D20200201-20200229" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNDM2OA_f4c9757d-18bc-4bb9-abeb-606dc4c00a37">849.3</ix:nonFraction> million, net of cash acquired. Under the terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the FDA. We also acquired Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the nine months ended September&#160;30, 2021, we sold the rights to Qbrexza. See Note 5 for additional information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $<ix:nonFraction unitRef="usd" contextRef="ib0548c5b9afb4dfb8d20e8ccf806b912_I20200229" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNTA5NQ_8babb782-6f46-413a-8d24-091b2a1b7dd9">86.8</ix:nonFraction> million, other intangibles of $<ix:nonFraction unitRef="usd" contextRef="ib0548c5b9afb4dfb8d20e8ccf806b912_I20200229" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNTEyMA_3c117bd2-246b-4869-b5e8-f58757724780">1.20</ix:nonFraction> billion primarily related to lebrikizumab, deferred income tax liabilities of $<ix:nonFraction unitRef="usd" contextRef="ib0548c5b9afb4dfb8d20e8ccf806b912_I20200229" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNTE5Mw_cea203c3-c4d2-49f6-a67d-38383601da0e">49.5</ix:nonFraction> million, and long-term debt of $<ix:nonFraction unitRef="usd" contextRef="ib0548c5b9afb4dfb8d20e8ccf806b912_I20200229" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNTIxOQ_5d4d031b-9430-4add-bc08-d3794ac29b13">375.5</ix:nonFraction> million. After the acquisition, we repaid $<ix:nonFraction unitRef="usd" contextRef="ia3663573ba3c48a5bdcf5eb80a22298a_D20200101-20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNTI1Ng_371d0a9e-3783-4b0c-b53a-13c82bad34b7">276.2</ix:nonFraction> million of long-term debt assumed as part of our acquisition of Dermira.</span></div></ix:continuation></ix:continuation><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i18d588519c6d48869b67f84f229dc721"><ix:continuation id="i05c06743c89e499eaa9ab635bcefe42f"><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNjg1NQ_02848d64-1945-431d-b6aa-0f6a8d85a805" continuedAt="if4a0a1048bd64d2fb4bcab63c8dfc6f4" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our asset acquisitions during the nine months ended September&#160;30, 2021 and 2020:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.916%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s) or Therapy</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biosciences, Inc. </span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential in vivo therapies for genetic disorders</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b575113de824b30a1c74f39db88aefd_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfMS02LTEtMS0x_4540b202-5b19-4515-b504-116a206ef6b8">107.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merus N.V. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CD3-engaging T-cell re-directing bispecific antibodies for the potential treatment of cancer</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6e905c8a80b4d38b9c543fb5bf2ef03_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfMi02LTEtMS0x_51985457-d6be-4730-a271-bd6c534e5db2">46.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asahi Kasei Pharma Corporation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AK1780, an orally bioavailable P2X7 receptor antagonist for the potential treatment of chronic pain conditions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9500cb4fcb444bd2b15d0629279eaf70_D20210101-20210131" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfMy02LTEtMS0x_e8273ed0-6abe-4580-b4a3-2344364696b5">20.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigel Pharmaceuticals, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa35124ffe304988988994e711548e86_D20210301-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfNC02LTEtMS0x_1b4564b4-b604-4962-8db0-c261e8b3d7da">125.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiNA Therapeutics Limited</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a14466d4a0e4b20bc65b50a6842b2f5_D20210501-20210531" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfNS02LTEtMS0x_7841ccc7-0f50-4a77-83fa-f389371013a2">25.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Protomer Technologies Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glucose-sensing insulin program</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870c4b4df8a341cc9b9dab7c879317b8_D20210701-20210731" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfNi02LTEtMS03ODk_99598d96-da9f-4587-8235-a8110f2123e2">57.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kumquat Biosciences Inc. </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical small molecules that stimulate tumor-specific immune responses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dd9b9e634e34e57897aaaf824716990_D20210701-20210731" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfNy02LTEtMS04MjU_558ef509-5f74-46af-a83f-30c9d9287114">55.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lycia Therapeutics, Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Several potential modalities across a spectrum of therapeutic areas and diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide01e64c4e60431ba5c28356bcc7cb42_D20210801-20210831" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfOC02LTEtMS0xMDU5_30573df8-1cea-41f7-868e-58fdf09aaa58">35.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ProQR Therapeutics N.V.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for genetic disorders in the liver and nervous system</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ed04cd38d964fc2af21956c88de5379_D20210901-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfOS02LTEtMS05NTI_8e789121-02ef-47eb-a2e3-2183977e0ad0">26.7</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sitryx Therapeutics Limited</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for autoimmune diseases</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531eb44bb094404198d87fc5156c354e_D20200301-20200331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfNy02LTEtMS0x_5d3c545b-2f89-472a-85ca-435db8d4a1e5">52.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbCellera Biologics Inc. (AbCellera)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ca3bd941a584b85b1b0b4d72b454dda_D20200301-20200331" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfOC02LTEtMS0x_7bd29c66-c51c-4da2-a8b1-e53e47f54274">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibab640a2f0fa4cf195eec35598754f90_D20200501-20200531" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfOS02LTEtMS0x_7a2ec042-74f3-437a-88d6-f9953fcd587e">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Petra Pharma Corporation (Petra)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutant-selective PI3K</span><span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#945;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> inhibitor that could lead to potential new medicine </span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a26ac8fb34d4458b120b7a6bc3235c0_D20200501-20200531" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfMTAtNi0xLTEtMQ_4298c956-f21d-42e2-a2ec-b968ca7f84d7">174.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evox Therapeutics Limited</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets for the potential treatment of neurological disorders</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2020</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e4f1b2ae08456c8caf48e2e1fdbe90_D20200601-20200630" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfMTEtNi0xLTEtMQ_90b6e7a6-643c-4346-9d12-fc75c3188679">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. </span></div></ix:nonNumeric><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="if4a0a1048bd64d2fb4bcab63c8dfc6f4" continuedAt="i0540931d5f0447e99ddbbdbf9bf4eb70">(2)</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i0540931d5f0447e99ddbbdbf9bf4eb70"> We recognized an acquired IPR&amp;D expense of $<ix:nonFraction unitRef="usd" contextRef="i3cb5bd55318443f49ec7b5fbcc892280_D20200501-20200531" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNTY1OA_c8b6e030-a78e-4d69-9e8f-d82ccaf5d70c">25.0</ix:nonFraction> million in May 2020 upon closing of the transaction.</ix:continuation> </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i48af34e12713400c858f7a29183e5680_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4: <ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfMTIyODg_9e45c00f-6b24-4407-b715-b90f8bba46dd" continuedAt="ia8575e906f814e83bed4c2630a2e204a" escape="true">Collaborations and Other Arrangements</ix:nonNumeric></span></div><ix:continuation id="ia8575e906f814e83bed4c2630a2e204a" continuedAt="i8499ea13053a48be967471246f47fce8"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Boehringer Ingelheim Diabetes Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim&#8217;s oral diabetes products: Jardiance,  Glyxambi, Synjardy, Trijardy XR, Trajenta, and Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as our basal insulin, Basaglar. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. Jentadueto is included in the Trajenta product family. </span></div><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfMTIyOTg_4882a120-8afa-4430-a71c-94f021e45419" continuedAt="i0d622e615e824e928f89b6e59c8880f7" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the net amount of significant milestones capitalized (deferred) at September 30, 2021 and December 31, 2020 for the compounds included in this collaboration: </span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Milestones Capitalized (Deferred) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as of:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Family</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2711efdfc53c49bd9e0e8915915d9f02_I20210930" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOmM0Zjg4MzgxMjVkNDQyNThhYjBiMzIxNTRjYTk2ZjE5L3RhYmxlcmFuZ2U6YzRmODgzODEyNWQ0NDI1OGFiMGIzMjE1NGNhOTZmMTlfMi0xLTEtMS0x_0153cb53-0bdc-4133-823c-be62ed38488a">141.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1acc40e06de4a0f94f52199958700b4_I20201231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOmM0Zjg4MzgxMjVkNDQyNThhYjBiMzIxNTRjYTk2ZjE5L3RhYmxlcmFuZ2U6YzRmODgzODEyNWQ0NDI1OGFiMGIzMjE1NGNhOTZmMTlfMi0yLTEtMS0x_fd2c5995-c612-4cf0-8b15-48e9a92e594a">156.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb083c377a2b4107a6eb8d5b758dee94_I20210930" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOmM0Zjg4MzgxMjVkNDQyNThhYjBiMzIxNTRjYTk2ZjE5L3RhYmxlcmFuZ2U6YzRmODgzODEyNWQ0NDI1OGFiMGIzMjE1NGNhOTZmMTlfMy0xLTEtMS0x_bd98ad74-7dc9-4d09-ad8d-d8cb0f10ea10">95.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc5eafc995df4bbc9a45fd9e9b60dd25_I20201231" decimals="-5" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOmM0Zjg4MzgxMjVkNDQyNThhYjBiMzIxNTRjYTk2ZjE5L3RhYmxlcmFuZ2U6YzRmODgzODEyNWQ0NDI1OGFiMGIzMjE1NGNhOTZmMTlfMy0yLTEtMS0x_272e16f6-830d-4c5c-9d5c-3b2b5bad2e31">114.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba9b3f1d338b4eda841d752024c756c7_I20210930" decimals="-5" sign="-" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOmM0Zjg4MzgxMjVkNDQyNThhYjBiMzIxNTRjYTk2ZjE5L3RhYmxlcmFuZ2U6YzRmODgzODEyNWQ0NDI1OGFiMGIzMjE1NGNhOTZmMTlfNC0xLTEtMS0x_4b72bbe4-ca30-43d3-b205-1b6ab166373e">154.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46d24272d19741b5a607f6c2f4e46637_I20201231" decimals="-5" sign="-" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOmM0Zjg4MzgxMjVkNDQyNThhYjBiMzIxNTRjYTk2ZjE5L3RhYmxlcmFuZ2U6YzRmODgzODEyNWQ0NDI1OGFiMGIzMjE1NGNhOTZmMTlfNC0yLTEtMS0x_877bbaaa-fcc7-40d5-8533-c55d7e2322ea">168.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In  connection with the regulatory approvals of Jardiance and Trajenta, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. In connection with the regulatory approvals of Basaglar, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Jardiance product family, we and Boehringer Ingelheim share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue. Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family. Beginning January 1, 2021, the royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds. We pay to Boehringer Ingelheim a royalty on net sales for Basaglar in the U.S. We record our sales of Basaglar to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales.</span></div><ix:continuation id="i0d622e615e824e928f89b6e59c8880f7" continuedAt="i5af91af58a284d1296502553546c865f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and our net product revenue recognized with respect to Basaglar:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Family</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a26c27a65f403eb8beb3df6550f89c_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfMi0xLTEtMS0x_04c477ea-eaef-468e-bd0a-1e4307125c36">390.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc63f2b4f3ad4a38885421b13733cfbd_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfMi0zLTEtMS0x_9f8a6083-9cea-4827-bac7-176607621836">310.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c5cb50d0a384037b1da389f2a6e0996_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfMi01LTEtMS0x_2fe7df2b-2d70-415d-b85d-21a4ed6a2917"><ix:nonFraction unitRef="usd" contextRef="i0c5cb50d0a384037b1da389f2a6e0996_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfMi01LTEtMS0x_90845ff0-de10-47e8-800d-e192fb7b3100">1,058.9</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc25dba031242f7b3f38ee74a40876d_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfMi03LTEtMS0x_9ee139b7-1f1d-4453-9546-e4cd3f70f1d0">840.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd5ed73cc264b21bfcf6eb9c75a76f1_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfMy0xLTEtMS0x_08954fd5-21c2-43c9-a017-6383ee01c53a">192.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c206cb2e614db381ab7a7d1967bd03_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfMy0zLTEtMS0x_0bd9260f-d6a2-4422-97f0-67a0f7762c19">248.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib84ab601c2e045f9b4f9ff1a30e0787a_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfMy01LTEtMS0x_fb9d9946-288e-4fd4-b533-a14533f1ea7a">650.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9fdd628b285469fb2e83ec947cf3bb1_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfMy03LTEtMS0x_d0d78fdd-45bd-4c66-8e65-823515fdc548">842.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5010b2b7e5545ed8348dbdee8d74c25_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfNC0xLTEtMS0x_a6a533a7-798e-4a59-bb9f-abd130fd9ef1">96.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae1bfc71fb534381a72a38855339542f_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfNC0zLTEtMS0x_39d29c23-6988-4775-883d-1f62eba842c4">91.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic26a9205f4884f5fafe309bf577ca246_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfNC01LTEtMS0x_e0da7e08-80cc-4dcb-9b72-7893f48c9f1f">279.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if23d24438d434f35937e458ed4abff61_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfNC03LTEtMS0x_28cb9d23-c1bb-44bc-b209-8805e9f51135">261.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8499ea13053a48be967471246f47fce8" continuedAt="ie436567c42d34d8e93da01f1532a7e38"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Olumiant</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to its Janus tyrosine kinase (JAK) inhibitor compound, now known as Olumiant (baricitinib), and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double digit royalty payments on global net sales with rates ranging up to <ix:nonFraction unitRef="number" contextRef="ib280a0fecb8d4d45a80cbda714aed6f5_D20210101-20210930" decimals="2" format="ixt:num-dot-decimal" name="lly:CollaborativeArrangementRightsAndObligationsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfNDY4NQ_007a5b43-709e-4ff2-b5ff-2a7a78e3764f">20</ix:nonFraction> percent. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. In 2020, the agreement was amended to include the treatment of COVID-19, with Incyte obtaining the right to receive an additional royalty ranging up to the low teens on global net sales for the treatment of COVID-19 that exceed a specified aggregate global net sales threshold. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i3551bdde470b46ae9c137fe74872a446_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfNTIxOA_4361265b-fc22-4084-bd3f-788573004717"><ix:nonFraction unitRef="usd" contextRef="i27a8de99546f46b5b97d0667185d1775_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfNTIxOA_bfbb2bde-b1f5-4bc2-8ac5-6c202afbfa33">210.0</ix:nonFraction></ix:nonFraction> million were capitalized as intangible assets as of September 30, 2021 and December 31, 2020 and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, Incyte is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i7ac78500f4494fa597feac64cdfc42b7_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfNTU3Mg_970a736c-7f73-4c96-b2ff-4f2471abe605">100.0</ix:nonFraction> million of additional payments from us contingent upon certain success-based regulatory milestones. Incyte is also eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i832240d2148c4ade980357dce8b58dcf_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfNTcwOA_ab4cc65a-024e-4ba4-a261-a4c08261efe7">150.0</ix:nonFraction> million of potential sales-based milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Olumiant, including sales of baricitinib that were made pursuant to EUA, to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. <ix:continuation id="i5af91af58a284d1296502553546c865f" continuedAt="i11f8e43b615d45d0a74ec3eb3d131949">The following table summarizes our net product revenue recognized with respect to Olumiant:</ix:continuation></span></div><div style="margin-top:11pt;text-align:center"><ix:continuation id="i11f8e43b615d45d0a74ec3eb3d131949" continuedAt="i6244ed55d1764a87b91b60830d8bae75"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:49.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb79dda4914c4c118d30138f4db6d0c9_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjJiYWFiYjMzOTUxMTRlOTM4ZjIyYzk1ZTkyM2IxYmU3L3RhYmxlcmFuZ2U6MmJhYWJiMzM5NTExNGU5MzhmMjJjOTVlOTIzYjFiZTdfMi0xLTEtMS0x_58a3f336-9243-4044-9159-317fb0607fdd">406.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89bc1277904f44ebb00cc1c346f34407_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjJiYWFiYjMzOTUxMTRlOTM4ZjIyYzk1ZTkyM2IxYmU3L3RhYmxlcmFuZ2U6MmJhYWJiMzM5NTExNGU5MzhmMjJjOTVlOTIzYjFiZTdfMi0zLTEtMS0x_1bf30166-cd31-47d3-81ad-f9d8858e6723">162.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e4795f073d468fac40d557656ecda2_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjJiYWFiYjMzOTUxMTRlOTM4ZjIyYzk1ZTkyM2IxYmU3L3RhYmxlcmFuZ2U6MmJhYWJiMzM5NTExNGU5MzhmMjJjOTVlOTIzYjFiZTdfMi01LTEtMS0x_a36d1910-0a3c-40aa-8a71-bb7cc4534aac">809.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if93d6526b32048608464727fad92c9bb_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjJiYWFiYjMzOTUxMTRlOTM4ZjIyYzk1ZTkyM2IxYmU3L3RhYmxlcmFuZ2U6MmJhYWJiMzM5NTExNGU5MzhmMjJjOTVlOTIzYjFiZTdfMi03LTEtMS0x_b84ef628-f2c3-4afe-b03a-8d64c12a5284">446.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 antibodies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a worldwide license and collaboration agreement with AbCellera to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab, for which we hold development and commercialization rights. AbCellera has the right to receive tiered royalty payments on global net sales of bamlanivimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera are recorded as cost of sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a license and collaboration agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including etesevimab, for which we hold development and commercialization rights outside of mainland China and the Special Administrative Regions of Hong Kong and Macau, and for which Junshi Biosciences currently maintains all rights in mainland China and the Special Administrative Regions of Hong Kong and Macau. Junshi Biosciences has the right to receive royalty payments in the mid-teens on our net sales of etesevimab. Junshi Biosciences also has the right to receive certain development, success-based regulatory and sales-based milestones. In connection with the regulatory authorizations of etesevimab (for administration with bamlanivimab) as well as achievement of a sales-based milestone, milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i7ba69dd64a4449d7b5cc355b8cdb4e0c_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfNzMyMQ_27b8ecbf-591f-4ec9-a891-9f52ed4b8a2b">95.0</ix:nonFraction> million were capitalized as intangible assets as of September&#160;30, 2021 and are being amortized to cost of sales over the estimated useful life of etesevimab. As of September&#160;30, 2021, Junshi Biosciences is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ie1df26c2f1ab404684e40f47a90f31a2_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfNzYxMg_58adc924-de86-4562-81f4-58e8e7ad764b">100.0</ix:nonFraction> million of potential sales-based milestones. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to EUAs, we recognized $<ix:nonFraction unitRef="usd" contextRef="id1915b82ef0745bc9e6902e358dcf426_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfNzY4NQ_6dc441b1-235f-4a1f-bcdc-e193e5d2b244">217.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib066c49389e847e08dd9e47b3dd013ff_D20210101-20210930" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfNzY5Mg_23f02272-3971-4551-8d3d-f198b808c301">1.18</ix:nonFraction> billion of net product revenue associated with our sales of our COVID-19 antibodies during the three and nine months ended September&#160;30, 2021, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sintilimab Injection</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Innovent Biologics, Inc. (Innovent) to jointly develop and commercialize sintilimab injection in China, where it is branded and trademarked as Tyvyt. In 2019, we and Innovent began co-commercializing Tyvyt in China. In 2020, we obtained an exclusive license for sintilimab injection from Innovent for geographies outside of China. Innovent, with collaboration from us, has filed the initial registration of sintilimab injection in the U.S., and we will pursue initial registration of sintilimab injection in other markets and all other subsequent registrations of sintilimab injection. We have exclusive commercialization rights outside of China.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a regulatory approval for Tyvyt in China in the second quarter of 2021, we capitalized a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="ic1c05dd0b56b403e9e561ab09c6adf97_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfODY0OQ_c63a38b4-b02f-48e5-8a0b-0c9b442c2b64">40.0</ix:nonFraction> million as an intangible asset which is being amortized to cost of sales through the term of the collaboration.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie436567c42d34d8e93da01f1532a7e38"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, Innovent is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ib67b5243a6ad40ec868a47e512875138_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfODgyNw_cd0c830a-eb98-4dac-bb69-3c3d19e5a0f9">825.0</ix:nonFraction> million for geographies outside of China and up to $<ix:nonFraction unitRef="usd" contextRef="i3fabc22c5af942a5bb088863f27e3c17_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfODg3Mw_23fb8db9-97a9-4e62-bddf-1fb6e92f74f3">195.0</ix:nonFraction> million in China in success-based regulatory and sales-based milestones. Innovent is also eligible to receive tiered double digit royalties on net sales for geographies outside of China. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Tyvyt to third parties as net product revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. We report as collaboration and other revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties. <ix:continuation id="i6244ed55d1764a87b91b60830d8bae75" continuedAt="i77fcaac107e040098b695dc81e82ed56">The following table summarizes our revenue recognized in China with respect to Tyvyt:</ix:continuation></span></div><div style="margin-top:11pt;text-align:center"><ix:continuation id="i77fcaac107e040098b695dc81e82ed56"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:49.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyvyt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i897388675b95435fb4f36e6b1e6cd6f9_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjM4YjQzYzdmNWFlYjQzODM5YTcxMTAyZjc3NTQ5YzlkL3RhYmxlcmFuZ2U6MzhiNDNjN2Y1YWViNDM4MzlhNzExMDJmNzc1NDljOWRfMi0xLTEtMS0x_39d3e977-4a04-4ba9-81e2-587ec283cc4b">125.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4d90ccdd9479fa1adc0ede684c6b6_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjM4YjQzYzdmNWFlYjQzODM5YTcxMTAyZjc3NTQ5YzlkL3RhYmxlcmFuZ2U6MzhiNDNjN2Y1YWViNDM4MzlhNzExMDJmNzc1NDljOWRfMi0zLTEtMS0x_54ee13a5-40a6-4053-a4a5-53eee5f277c2">84.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47a1977d3def441282bd0a67b40c3f58_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjM4YjQzYzdmNWFlYjQzODM5YTcxMTAyZjc3NTQ5YzlkL3RhYmxlcmFuZ2U6MzhiNDNjN2Y1YWViNDM4MzlhNzExMDJmNzc1NDljOWRfMi01LTEtMS0x_35b87a5c-eeef-4e28-a91e-bf8e3d692b4c">340.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721201b823f24281ab0040324500b66f_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjM4YjQzYzdmNWFlYjQzODM5YTcxMTAyZjc3NTQ5YzlkL3RhYmxlcmFuZ2U6MzhiNDNjN2Y1YWViNDM4MzlhNzExMDJmNzc1NDljOWRfMi03LTEtMS0x_d4462724-0964-4cfa-9bff-2c477e651b55">205.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tanezumab</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain and cancer pain. In October 2021, we and Pfizer discontinued the global clinical development program of tanezumab for the treatment of osteoarthritis pain and cancer pain following the receipt of a Complete Response Letter from the FDA and a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lebrikizumab</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Dermira, we have a worldwide licensing agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively Roche), which provides us the global development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future global net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of September&#160;30, 2021, Roche is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i6cdf764053f54a69bddcc58019bd9a9c_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfMTA5MjA_125190d1-64cf-452d-9a23-75dcdb24dd09">180.0</ix:nonFraction> million of payments from us contingent upon the achievement of success-based regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i6ed81d6975474a5abcbc174337c27bd4_I20210930" decimals="-7" format="ixt:num-dot-decimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfMTEwMjQ_5a4f7333-f988-4458-9a00-b4b432c5b568">1.03</ix:nonFraction> billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Dermira, we have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of September&#160;30, 2021, we are eligible to receive additional payments of $<ix:nonFraction unitRef="usd" contextRef="ie35017a9e84c4b85960feecbdacbbfd4_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfMTE2ODA_731d4895-c447-42c8-b014-1a33f2611a8a">85.0</ix:nonFraction> million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i3a58e1d1992e4f0e821edbda0434c22b_I20210930" decimals="-7" format="ixt:num-dot-decimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfMTE3Nzg_4da35d6a-088b-4449-a702-e8ba65b2af95">1.25</ix:nonFraction> billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December 31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i212f03ee260a4a1d8b38aa6b588dc87e_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfMTE5MDg_3f9efa4e-2019-498f-9369-672822c59664">15.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2e7d5f5212014d5fb1eecf77eb35a41b_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfMTE5MTU_ab44b1af-2144-4c29-8ecb-b5b3ae3fe540">29.7</ix:nonFraction> million, respectively, were recorded as contract liabilities on the consolidated condensed balance sheets and are expected to be recognized as collaboration and other revenue over the remaining Phase III development period. During the three and nine months ended September&#160;30, 2021 and 2020, milestones received and collaboration and other revenue recognized were not material. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Petra</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Petra, we are required to make milestone payments to Petra shareholders contingent upon the occurrence of certain future events linked to the success of the mutant-selective PI3K</span><span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#945;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> inhibitor. Our more significant, near term milestones include a development milestone of approximately $<ix:nonFraction unitRef="usd" contextRef="ia9d50a42ad904e8cbe293593bfa34095_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfODc5NjA5MzA0MTQ5NQ_f05b3369-78c2-4854-b661-48527a36eed6">205</ix:nonFraction>&#160;million in 2022 contingent upon initiation of its Phase I trial and a further development milestone of approximately $<ix:nonFraction unitRef="usd" contextRef="iea65191ac5fc4dbb8e7121cae60f91a9_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="lly:CollaborativeArrangementRightsAndObligationsRightsObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfODc5NjA5MzA0MTUxMQ_232db588-8a56-456a-9351-18adac89539c">164</ix:nonFraction>&#160;million in 2023 contingent upon achieving clinical proof of concept.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i48af34e12713400c858f7a29183e5680_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5: <ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RleHRyZWdpb246MDU4YzIzYTFmMTc2NDliZDk0MjE0ZThkYjEwYjI0M2NfMjA4NA_72c35c86-4438-46ec-ac86-b939b32c9eed" continuedAt="iff9dda34f57342b79012f2ac932480da" escape="true">Asset Impairment, Restructuring, and Other Special Charges</ix:nonNumeric></span></div><ix:continuation id="iff9dda34f57342b79012f2ac932480da" continuedAt="ie717a25dc9684d2a8bde2a3458116a6b"><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RleHRyZWdpb246MDU4YzIzYTFmMTc2NDliZDk0MjE0ZThkYjEwYjI0M2NfMjA3NQ_7bb77a05-cdf7-471c-8cfd-f0f9150488ea" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below. </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:51.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.948%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfMi0xLTEtMS0x_6bade988-0068-4a6c-b48e-da92511095ed">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfMi0zLTEtMS0x_213c965f-4235-438e-82fb-1848c49b9b05">144.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfMi01LTEtMS0x_d7cde435-10b9-4f53-8a16-f9ab3782b8c4">11.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfMi03LTEtMS0x_b4a2c792-926d-4bf0-a50c-c1326573d977">154.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment (recovery) and other special charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfMy0xLTEtMS0x_6a3037fe-06f1-474c-8af7-c7fe4b261441">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" sign="-" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfMy0zLTEtMS0x_ed30cd26-d7ac-403f-8beb-f41ed04375ba">43.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfMy01LTEtMS0x_b0f0d5d0-41bb-4907-b4ae-17b72558ec6b">200.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfMy03LTEtMS0x_0b819744-ef8f-4244-8cac-c8d582994d5c">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total asset impairment, restructuring, and other special charges</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfNC0xLTEtMS0x_e8f704f0-82ee-411a-9fac-6ae1951528b0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfNC0zLTEtMS0x_debab27b-55f7-4ece-8244-ede7484909ef">101.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfNC01LTEtMS0x_4b5c5abb-3e3e-482e-bf1d-9d9eb8a13f2d">211.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfNC03LTEtMS0x_0994ef60-2e2b-4540-bf15-87f330dc6a87">161.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairment, restructuring, and other special charges recognized during the nine months ended September&#160;30, 2021 were primarily related to an intangible asset impairment of $<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RleHRyZWdpb246MDU4YzIzYTFmMTc2NDliZDk0MjE0ZThkYjEwYjI0M2NfNTUz_f5338a35-35da-46fe-b0c6-b9de6d1b0d68">108.1</ix:nonFraction>&#160;million resulting from the sale of the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance costs recognized during the three and nine months ended September&#160;30, 2020 were incurred as a result of actions taken worldwide to reduce our cost structure. Substantially all of the severance costs incurred during the three and nine months ended September&#160;30, 2020 have been paid. </span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie717a25dc9684d2a8bde2a3458116a6b" continuedAt="i85b9a3f30b9a4145899220db0a967b8f">We recognized a net inventory impairment charge related to our COVID-19 antibodies of $<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RleHRyZWdpb246MDU4YzIzYTFmMTc2NDliZDk0MjE0ZThkYjEwYjI0M2NfODc5NjA5MzAyODc1Mg_da7e9c4e-b137-44d0-a319-81f46e61279c">435.1</ix:nonFraction>&#160;million during the nine months ended September 30, 2021 in cost of sales in our consolidated condensed statements of operations. As part of our response to the COVID-19 pandemic, and at the request of the U.S. and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic has continued to evolve during 2021, we incurred a net inventory impairment charge primarily due to the combination of changes to current and forecasted demand from U.S. and international governments,</ix:continuation></span><span style="color:#212121;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i85b9a3f30b9a4145899220db0a967b8f"> including changes to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i48af34e12713400c858f7a29183e5680_64"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6: <ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ4MTU_08dde6ca-240c-421f-b6ed-1858529fb45d" continuedAt="ie1cba1ab9cfd424fb2e10ba347591370" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="ie1cba1ab9cfd424fb2e10ba347591370" continuedAt="ic41dc5ebbbc8491699d60f9508d729b5"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity investments are accounted for using three different methods depending on the type of equity investment:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review equity investments other than public equity investments for indications of impairment and observable price changes on a regular basis.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic41dc5ebbbc8491699d60f9508d729b5" continuedAt="ibd40eadc90ea41988a9eaf47bed04e85"><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ4NDE_3cad7bdc-9bec-4377-91ed-6a4bd23d9a96" continuedAt="iea7eb1f9e63f40d98f264dea65cfe918" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iea7eb1f9e63f40d98f264dea65cfe918">We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months.</ix:continuation> At September&#160;30, 2021, we had outstanding foreign currency forward commitments to purchase <ix:nonFraction unitRef="usd" contextRef="ib3e68e01c19a4aaa93a9c6e8d4d5ca0f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDMwNw_e47ff949-03f3-4765-bd45-5343c185c10d">707.3</ix:nonFraction> million U.S. dollars and sell <ix:nonFraction unitRef="eur" contextRef="ib3e68e01c19a4aaa93a9c6e8d4d5ca0f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDMzMg_4b3745e7-175e-40a7-ae28-28918c4ddde2">604.5</ix:nonFraction> million euro, commitments to purchase <ix:nonFraction unitRef="eur" contextRef="i3c88f68cc2d7438497246b3d6404eead_I20210930" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDM2NQ_0f09828d-8fdb-48ce-8543-7f96263debef">2.54</ix:nonFraction> billion euro and sell <ix:nonFraction unitRef="usd" contextRef="i3c88f68cc2d7438497246b3d6404eead_I20210930" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:DerivativeAssetNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDM4Mg_9553632a-9fd4-4a39-bfc0-bb8ae92f1086">2.98</ix:nonFraction> billion U.S. dollars, commitments to purchase <ix:nonFraction unitRef="usd" contextRef="i9a4f51f3d44f4d129128571ca91c4045_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMjQxODkyNTU4MzQwMTM_41ce16c3-c1d3-4a96-a7a5-9c760a52f476">151.6</ix:nonFraction> million U.S. dollars and sell <ix:nonFraction unitRef="cny" contextRef="i9a4f51f3d44f4d129128571ca91c4045_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMjQxODkyNTU4MzQwNDM_caabe4e2-4bff-47a8-9110-2411b6d35436">980.0</ix:nonFraction> million Chinese yuan, commitments to purchase <ix:nonFraction unitRef="usd" contextRef="ia65189ebfe674bcdaa496351f69f95ed_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDQyMw_35479ae1-20c4-4ccd-bf8b-cd75f518194f">144.7</ix:nonFraction> million U.S. dollars and sell <ix:nonFraction unitRef="jpy" contextRef="ia65189ebfe674bcdaa496351f69f95ed_I20210930" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:DerivativeAssetNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDQ0OA_b77c4f52-9bf7-4c59-b896-60bbccfeb8ad">16.13</ix:nonFraction> billion Japanese yen, and commitments to purchase <ix:nonFraction unitRef="gbp" contextRef="i608ccb2010534f3489d040d1051be217_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDQ5Mw_64043cac-ebbe-46ac-bdcc-4bdefe3d4a0e">155.5</ix:nonFraction> million British pounds and sell <ix:nonFraction unitRef="usd" contextRef="i608ccb2010534f3489d040d1051be217_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDUyMA_877d3e63-b1fd-4e6a-8771-9f69f9091167">212.6</ix:nonFraction> million U.S. dollars, which all have settlement dates within <ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" format="ixt-sec:durday" name="us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDU2Mg_2a3e3b6f-2a92-43e0-87aa-a87ed7a48be8">180</ix:nonNumeric> days.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes had carrying amounts of $<ix:nonFraction unitRef="usd" contextRef="i51538ef7c00c4b7ca042552f8fcf1b56_I20210930" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDc1Nw_a774b920-5f28-4a8c-a111-f13ff3a32a64">8.08</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="if2282403149944b6a454777d0cbe119e_I20201231" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDc2NA_1dd7a349-db3f-428a-88d2-7cc4913d264a">6.02</ix:nonFraction> billion as of September&#160;30, 2021 and December&#160;31, 2020, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDgwNw_4d174bfa-26cf-46f0-838f-4a30fb57561d">5.95</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDgxNA_36312693-0f16-4132-a6e9-59c07b1cc5a7">4.50</ix:nonFraction> billion have been designated as, and are effective as, economic hedges of net investments in certain of our foreign operations as of September&#160;30, 2021 and December&#160;31, 2020, respectively. At September&#160;30, 2021, we had outstanding cross-currency swaps with notional amounts of $<ix:nonFraction unitRef="usd" contextRef="ifec1b340db5a429986bb4f14e4d51236_I20210930" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNTA1Nw_785eaf60-37aa-4cd5-8f47-ef485ce60178">2.69</ix:nonFraction> billion swapping U.S. dollars to euro and $<ix:nonFraction unitRef="usd" contextRef="id050ee0435604da9889144406e53ddb1_I20210930" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNTA5NA_893f6bb0-3bcc-4900-80ab-fa444a93a409">1.00</ix:nonFraction> billion swapping Swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed-rate debt to foreign-denominated fixed-rate debt, have also been designated as, and are effective as, economic hedges of net investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated condensed statements of cash flows. At September&#160;30, 2021, substantially all of our total long-term debt is at a fixed rate. We have converted approximately <ix:nonFraction unitRef="number" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="2" format="ixt:num-dot-decimal" name="lly:DescriptionOfDerivativeActivityVolumePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNjg3Ng_611f0811-419b-4620-891a-ebed997c68b4">12</ix:nonFraction> percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss), and upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt. As of September&#160;30, 2021, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $<ix:nonFraction unitRef="usd" contextRef="i3a30bd1d6f09458d9b484f6eede92a0b_I20210930" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNzU4NQ_47df96c9-aae0-488b-b0e9-4fd7868f2968">1.75</ix:nonFraction> billion, which have settlement dates ranging between 2023 and 2025.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibd40eadc90ea41988a9eaf47bed04e85" continuedAt="idfcf1c4cb2be4031a39a5878787339d1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we issued euro-denominated notes consisting of &#8364;<ix:nonFraction unitRef="eur" contextRef="ie0197954b7f246438579f727a96ba302_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODc5NjA5MzA0NTIxNQ_a6836399-a938-4866-86b9-7a67f62abd56">600.0</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="ie0197954b7f246438579f727a96ba302_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODc5NjA5MzA0NTI1OA_008a36f8-b646-4a0e-8a27-73f96727d89b">0.50</ix:nonFraction> percent fixed-rate notes due in September 2033, with interest to be paid annually. The net proceeds from the offering will be used to fund, in whole or in part, eligible projects designed to advance one or more of our environmental, social, and governance objectives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we issued euro-denominated notes consisting of &#8364;<ix:nonFraction unitRef="eur" contextRef="i4a56fd67eaa446d58b10847878682132_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODc5NjA5MzA0NTIzNw_b3e01b85-c655-4be0-91cc-204abd02b8c0">500.0</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="i4a56fd67eaa446d58b10847878682132_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODc5NjA5MzA0NTI1Mg_434cd5d2-e95e-4194-b9aa-8a60e48dd55c">1.125</ix:nonFraction> percent fixed-rate notes due in September 2051 and &#8364;<ix:nonFraction unitRef="eur" contextRef="icf519817e48d4e2aa20f61c0464569ac_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODc5NjA5MzA0NTI5OQ_8edbd230-8ba1-471f-9520-ea59d93b6a6d">700.0</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="icf519817e48d4e2aa20f61c0464569ac_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODc5NjA5MzA0NTMxNA_642b6c1d-8f7b-4b59-aa21-8ffc50eef769">1.375</ix:nonFraction> percent fixed-rate notes due in September 2061, with interest to be paid annually, and British pound-denominated notes consisting of &#163;<ix:nonFraction unitRef="gbp" contextRef="if42acdc6f14644c49737fbdd91a729b4_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODc5NjA5MzA0NTMzNg_d54ec132-82f1-40cc-9a72-59fc9ba4ec3e">250.0</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="if42acdc6f14644c49737fbdd91a729b4_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODc5NjA5MzA0NTM1MQ_b4e41c02-b84c-475c-9df6-0de5a7db9d2e">1.625</ix:nonFraction> percent fixed-rate notes due in September 2043, with interest to be paid annually. We paid $<ix:nonFraction unitRef="usd" contextRef="i0007a0646ac4490fab4a90fe8acda870_D20210901-20210930" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODc5NjA5MzA0NTM3Mw_7b7213fc-c5a6-496c-9aab-ee33e93f3df7">1.91</ix:nonFraction>&#160;billion of the net cash proceeds from the offering to purchase and redeem certain higher interest rate U.S. dollar-denominated notes with an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i0007a0646ac4490fab4a90fe8acda870_D20210901-20210930" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:ExtinguishmentOfDebtAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODc5NjA5MzA0NTM4OA_2190392a-db4e-4199-ad29-8bd1718753b3">1.50</ix:nonFraction>&#160;billion, resulting in a debt extinguishment loss of $<ix:nonFraction unitRef="usd" contextRef="i0007a0646ac4490fab4a90fe8acda870_D20210901-20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODc5NjA5MzA0NTQwMw_a759ec46-80a7-4434-9d54-af07914e6b90">405.2</ix:nonFraction>&#160;million. This loss was included in other-net, (income) expense in our consolidated statement of operations during the three and nine months ended September 30, 2021. The $<ix:nonFraction unitRef="usd" contextRef="i0007a0646ac4490fab4a90fe8acda870_D20210901-20210930" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:ExtinguishmentOfDebtAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTIwOTQ2Mjc5MzA3MjU_2190392a-db4e-4199-ad29-8bd1718753b3">1.50</ix:nonFraction>&#160;billion principal amount of higher interest rate U.S. dollar-denominated notes that were redeemed primarily included $<ix:nonFraction unitRef="usd" contextRef="ic965f0de559d414494ead6ebab58b9b6_D20210901-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ExtinguishmentOfDebtAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfOTM0NTg0ODg2MTQwNw_f15b1402-6965-4666-99a9-bb5a40960f37">541.8</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="ib811247eae3e4f2c950b855814774a4e_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfOTM0NTg0ODg2MTQ1NQ_6aa82544-7ead-4286-8210-3b6521a9dc6a">3.95</ix:nonFraction> percent notes due 2049, $<ix:nonFraction unitRef="usd" contextRef="ifdef17a4b3924ef18dc393a876d0f969_D20210901-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ExtinguishmentOfDebtAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfOTM0NTg0ODg2MTQyMw_bdca5a18-512a-4aad-a887-8c5c645ed1eb">408.7</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="i59558243da25489986f3aa7a759e9236_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfOTM0NTg0ODg2MTQ2Mg_06e54607-214f-4e4e-97ed-0e1555eaf26a">4.15</ix:nonFraction> percent notes due 2059, and $<ix:nonFraction unitRef="usd" contextRef="i630bb94f7a0241fc85ecb2d9d7c1705e_D20210901-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ExtinguishmentOfDebtAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfOTM0NTg0ODg2MTQzOQ_c03913d9-cd5e-4fc3-bad6-d854a7e2b731">219.4</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="i246b98760440439aa55a1d9c36f1efc2_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfOTM0NTg0ODg2MTQ2OQ_0b994f5a-6bcb-4ff7-9381-7405207c04d7">3.375</ix:nonFraction> percent notes due 2029. We used the remaining net proceeds from the offering to prefund certain 2022 debt maturities and for general corporate purposes. </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Effect of Risk-Management Instruments on the Consolidated Condensed Statements of Operations</span></div><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ4MDg_f813520e-21c1-4bee-8021-d9071b6a83d3" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:59.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.221%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83977bd0653b402a9c4271c7b321f9a4_D20210701-20210930" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfMy0xLTEtMS0x_b10530bd-783c-4d7c-8d13-70b1d5d320b8">10.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39101bb15f78410c92851ae13eb04f8f_D20200701-20200930" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfMy0zLTEtMS0x_417c5a2f-02d3-4bcd-80db-b8d74581dfa9">14.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc0dc774626d4895bcd260e8b1e00a1c_D20210101-20210930" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfMy01LTEtMS0x_0f03f7f2-cbad-4724-b25b-8507a36431f7">60.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49a37f83c03b41ed93d44441b19d8ce5_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfMy03LTEtMS0x_32ddfa7d-23f0-434c-a76f-e56f1abe4135">110.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i864b815909f7410a8ae48163786157ed_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNC0xLTEtMS0x_851d62c7-a278-426a-ae5a-32310cd7d910">10.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a61299558154a88a75737f4e52e86db_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNC0zLTEtMS0x_50396fa3-055c-4c1a-99a7-e9b7f7e2036e">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2460f130430a483aa8e55f391938b835_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNC01LTEtMS0x_65732ad2-787d-43a4-be16-c9c6f9d32b6b">60.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cc83e8355fd4482bebf96cb53270e2a_D20200101-20200930" decimals="-5" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNC03LTEtMS0x_db3bc860-5234-4c42-ba74-07eb025f49bb">110.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i864b815909f7410a8ae48163786157ed_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNi0xLTEtMS0x_28d76808-7664-470d-8150-6022d5e518fa">4.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a61299558154a88a75737f4e52e86db_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNi0zLTEtMS0x_f5eece09-d1c3-46c1-ba4a-d3debfb7c106">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2460f130430a483aa8e55f391938b835_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNi01LTEtMS0x_13164f51-207c-4d68-b75b-38c1f718d2fd">12.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cc83e8355fd4482bebf96cb53270e2a_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNi03LTEtMS0x_44ba6bd1-7308-4209-a06e-81b37377a8eb">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ca7bce852474597f1638b0244034b_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNy0xLTEtMS0x_a91eae9e-a73a-4617-9ce0-ffbeddae511e">10.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4372afcae30c4182a4a4b043e87b2b28_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNy0zLTEtMS0x_42a48ffc-de1c-4570-84c3-f78657b8bb7e">30.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8b918e825124054b3c412a4eb18978d_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNy01LTEtMS0x_f3ce665e-2eab-4b0f-bfa9-bad07ae8783f">58.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75f82b84a5c44509970d0b0205ee4b7a_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNy03LTEtMS0x_a9ce3769-ac6c-4908-9203-36834be75e7d">54.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c88bbe6ccfc45ef949dcef76b904617_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfOC0xLTEtMS0x_431cb638-16fd-4e75-a37a-dcf2ec2fb699">50.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i937f1bdb1bc1479a931e868c6d681bbe_D20200701-20200930" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfOC0zLTEtMS0x_98f347bb-595a-4dc0-aa12-da0b0a5e4bca">54.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd44da12be9b4958bc40d1622ff85d3d_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfOC01LTEtMS0x_3e7e6830-43ab-4f42-b79c-b663933c4c7c">110.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0315d885ffd4214b0351c0717eb4c2d_D20200101-20200930" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfOC03LTEtMS0x_a5f87b6d-9913-4cfd-b7b8-f7c145a20401">82.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" sign="-" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfOS0xLTEtMS0x_6dae6a37-b682-4233-9da2-b3ccccfe3a4e">65.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfOS0zLTEtMS0x_ea266c0e-b2c8-4cac-8493-e31d87f6c5c3">80.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" sign="-" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfOS01LTEtMS0x_98967c3b-e149-45f4-9f09-e3190dc2028e">181.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="lly:DerivativeInstrumentsGainLossRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfOS03LTEtMS0x_a447d0e9-eeb7-4a67-b977-3725757baddc">125.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021 and 2020, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idfcf1c4cb2be4031a39a5878787339d1" continuedAt="ic0343cc20a234ac3931a227360c0ae84"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ4MjM_edb4428e-e3c9-4947-92b1-7a62f9aec61a" escape="true"><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ4NjI_1a88ba55-0089-4ff0-85b4-4489506e5c82" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"></td><td style="width:59.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.231%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.231%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaeede8153e14149b4dd378cfd5bb59e_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfMy0xLTEtMS0x_2fc85ca3-9e6d-439b-966e-b7ebe4ef1d44">119.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f55cc8a2fb64fcb9720f4b9b61421d6_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfMy0zLTEtMS0x_0eee6e25-ac35-4800-be30-c5d242440c0d">181.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8ef8f194e1446699469424765ff1fa8_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfMy01LTEtMS0x_7c9b950b-b313-4839-8dba-0ca2be7c5080">268.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if92f732c456441e6ad74d4c284c639fb_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfMy03LTEtMS0x_6476cb7a-b1ea-49d2-a596-da1bfcc9a92c">186.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67dbdc3d2d474dbabc54a7a74c1ea885_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfNC0xLTEtMS0x_7f7af1ba-20b3-4dfc-84af-24c06a059159">66.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie121f355ecb34b25b0508086f86f2a6c_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfNC0zLTEtMS0x_af50af7a-12ff-4a42-a9a8-fdf43d1bb58e">110.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ba09cfe8cfa4f10bc560bc45b9319b5_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfNC01LTEtMS0x_a0f45580-1b4e-4684-a7c9-c944afb28922">170.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i864500d9b5b94bfaaa7d9ea71c3b0c26_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfNC03LTEtMS0x_9b889061-798f-4fa3-b7e3-9c51d908fad3">55.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42cf035468e94826ad3cde71dde916af_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfNy0xLTEtMS0x_6e39fbb5-ec66-4a50-becd-f1be3e7717d2">19.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id79d99cd800d4ad28394d8150c6332df_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfNy0zLTEtMS0x_f3a46a42-85ae-4ec0-a2c2-7c0bd58a856d">99.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2a25406ea954c5f8992888e7c738569_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfNy01LTEtMS0x_4dd827ce-57d4-4702-bad6-4dc60149cf8a">149.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e8ec6c42f514d1e80c619a050d59507_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfNy03LTEtMS0x_e24699ee-0b05-41f1-8636-23b8232e8a3f">231.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67dbdc3d2d474dbabc54a7a74c1ea885_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfOC0xLTEtMS0x_6f3ce22f-f547-4ac1-aaeb-20536309c5d4">3.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie121f355ecb34b25b0508086f86f2a6c_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfOC0zLTEtMS0x_08df76dd-2aa0-46df-b96a-9cb534f87d17">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ba09cfe8cfa4f10bc560bc45b9319b5_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfOC01LTEtMS0x_83bc563f-a63a-473c-b8d9-65ab1beecb8b">22.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i864500d9b5b94bfaaa7d9ea71c3b0c26_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfOC03LTEtMS0x_1b3cd0de-8d04-4906-b5b8-bb8c290f2d55">58.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the next 12&#160;months, we expect to reclassify $<ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODM1Mg_79472be9-1b19-4a0a-bd1f-f3c9067bece6">16.4</ix:nonFraction>&#160;million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other&#8211;net, (income) expense. During the three and nine months ended September&#160;30, 2021 and 2020, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material.</span></div></ix:continuation><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic0343cc20a234ac3931a227360c0ae84" continuedAt="i5a16f6c8dcd44bd396b62f6eb32d3ddc"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ4MjQ_3d3ed61d-d71c-4984-9770-e4204d6848b5" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize certain fair value information at September&#160;30, 2021 and December&#160;31, 2020 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:34.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab73c3bd3fe34c699b5cb054ccb42a6b_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMy0xLTEtMS0x_bd11384a-eff4-4e3c-af73-c1b089ecdfaf">2,373.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf8e31e25410469a84688b7fb5b87b90_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMy0zLTEtMS0x_7b92a418-4fdb-43af-975a-cf42f4f1d270">2,373.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44ef377c866e48298d0988babb457ef5_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMy01LTEtMS0x_90d237d9-5825-4135-b952-1142fb675fd5">2,373.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ad610fc9575465b996c10f1fb676d8e_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMy03LTEtMS0x_274ab38a-4b4a-42e9-be72-37da0e110b94">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e0450a0148940568359bd2bb4fd1c7a_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMy05LTEtMS0x_f06edd41-c540-4b90-a2f6-7876899bc970">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie387bef8710440e4832f0dd71a46bba0_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMy0xMS0xLTEtMQ_6098ce4a-add7-4294-8284-35c76bfe92a6">2,373.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05166d7e427248f89521f9a6bcdaa937_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNi0xLTEtMS0x_345e0282-2ecb-4ad5-aac7-b6a8140b59b0">11.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i519a8c1745264739b16980e97bd28088_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNi0zLTEtMS0x_d2aecea0-fe11-4ff1-b8bb-d32c639d1a13">11.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6137cc328cc64a7b8e6dc90a371cff51_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNi01LTEtMS0x_c24f751d-3055-4c29-9f74-31fc671ce9a1">11.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ac4ef28e5ea4608a5b80501977931f5_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNi03LTEtMS0x_c7ff46a1-49ce-4fa2-8039-df385fd68169">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1b8587493d44060ac22b7dfc95bcf5b_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNi05LTEtMS0x_f79078b9-a734-4c8b-add1-feddcfd0f7d0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i254a65a32a434ab6b7ef57c8e79f3444_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNi0xMS0xLTEtMQ_e2b9cc22-4f6e-4eaa-b06a-be5b2b54c36b">11.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eea1fbbff8437281fea8e1a0f1bef3_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNy0xLTEtMS0x_72bdbfb3-c1bb-4caa-b675-da77de5113f4">6.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a167b8fec544f85a40ec24ff3dca2ae_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNy0zLTEtMS0x_46cade2e-33fb-4514-920d-ff3ff08f43b0">6.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8271ad9786914a7b9146b4cac43d9253_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNy01LTEtMS0zMDQwNg_863371ed-1924-4ca2-85d1-57863f3050d3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9346e5ce6da0496eb9220c6582e6049a_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNy03LTEtMS0x_d74d4f87-784f-40f5-a9f0-87ce773d059e">6.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68599e7c7d4b45eca411fa801f914c08_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNy05LTEtMS0zMTc2NQ_2c648535-c119-4923-91ec-67391191654e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3674d32a89aa4e689ac0f2091ddd444f_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNy0xMS0xLTEtMQ_49aa75ad-bf4d-4aff-97e6-e7b671149772">6.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i600421af4c80421291f0d5e08ea11d36_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOC0xLTEtMS0x_22a7e579-2de0-4bec-9f19-9615b440f2c7">0.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027d17439d6c44daaa8479672e90cc93_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOC0zLTEtMS0x_bde194ac-3c9f-4ad8-a17f-cea68911e39f">0.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec3eb54ea13545388e93581cfd374f6b_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOC01LTEtMS0x_1f0325c2-a721-4577-9441-9ede384ebe95">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3380d8d6904862a95b183e88d6721d_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOC03LTEtMS0x_c660f6af-e2a4-4e69-9982-f4b64250ac4c">0.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f93a011c64e4f2c94195e681aac557a_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOC05LTEtMS0x_c3e40e5a-e033-4880-89a7-61fcc07239b5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife05bc1f99a24066a3787f493ad65c20_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOC0xMS0xLTEtMQ_f0662b14-f548-4fcb-ba9a-7c05e267f5a9">0.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667849e28703418487b214fec3474bdf_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOS0xLTEtMS0x_0d98fce7-7171-4df1-b3d1-7e08eadedf79">3.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i175f9851b84d40c69587dda3c8dc10b9_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOS0zLTEtMS0x_a23863eb-fe69-4e5b-9344-165a34ceecd9">3.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida2502dbdf2544cb9724ce9126589989_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOS01LTEtMS0x_94bfc1b4-c807-40f9-b352-5559c270e94c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e73b6978a284142bdbfa2193963e239_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOS03LTEtMS0x_5768357b-843c-4a7c-b232-26472801c88e">3.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df8c985cdf740f7bae9773aa95472ab_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOS05LTEtMS0x_96068ad9-fe56-4c4d-9171-7e36b539a697">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59605113a4b745c8bb79328b1a984d9e_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOS0xMS0xLTEtMQ_d958215b-85c7-433b-9443-b7c1ee667800">3.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf8581a0b224377866093121945c682_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTAtMS0xLTEtMQ_cd80f676-11b2-47ae-90ef-2cffd86cf63b">15.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i994afc29ec17435a9bee9daefa8e55bb_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTAtMy0xLTEtMQ_3f839b46-0276-406a-8869-689a82ccd638">15.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8242f0bb64934a2f96b9efb3621ba78f_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTAtNS0xLTEtMQ_0396bd62-2ccd-4808-b4f3-374d4328d11e">6.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac3d68dc29d04fa68b9b49b08724abb8_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTAtNy0xLTEtMQ_c0926dbd-f1cd-42cb-a71b-526625a2ec85">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1917512fec5348218ab246fc29ac8b87_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTAtOS0xLTEtMQ_1f7cf6dc-36dd-4e13-a3ba-ad6cbc145d4d">8.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03ec7add2c2b40edbdc4d76abab59030_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTAtMTEtMS0xLTE_ecbf3bf8-d55a-4c78-b9e1-86d542641f12">15.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab73c3bd3fe34c699b5cb054ccb42a6b_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTItMS0xLTEtMQ_29abac4c-6a50-49ca-b886-c964d7781ec6">37.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05166d7e427248f89521f9a6bcdaa937_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTUtMS0xLTEtMQ_2e736d90-6123-4ad8-8604-6ce61ffd7a01">129.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i519a8c1745264739b16980e97bd28088_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTUtMy0xLTEtMQ_a84457b8-db14-4f58-968a-82d873c5544b">129.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6137cc328cc64a7b8e6dc90a371cff51_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTUtNS0xLTEtMQ_abd375ad-4c7f-4d82-9e39-d58b1cf74776">129.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ac4ef28e5ea4608a5b80501977931f5_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTUtNy0xLTEtMQ_801ead89-5011-42b2-947f-ff8c6185d818">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1b8587493d44060ac22b7dfc95bcf5b_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTUtOS0xLTEtMQ_e48f5994-14ae-4e54-b7a3-a6b7508b9cee">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i254a65a32a434ab6b7ef57c8e79f3444_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTUtMTEtMS0xLTE_128bb1ef-633e-41d1-8aef-815be56a5829">129.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eea1fbbff8437281fea8e1a0f1bef3_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTctMS0xLTEtMQ_8885cb74-5dc2-467e-9231-52064eefef75">219.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a167b8fec544f85a40ec24ff3dca2ae_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTctMy0xLTEtMQ_5de15221-a63f-4f07-9177-9d9e485aabfc">215.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8271ad9786914a7b9146b4cac43d9253_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTctNS0xLTEtMQ_7e57ab2b-167b-407d-8cfd-0e070a5c5f73">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9346e5ce6da0496eb9220c6582e6049a_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTctNy0xLTEtMQ_b943cc0b-09a3-41bc-bdb2-8e0d3eb3000c">219.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68599e7c7d4b45eca411fa801f914c08_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTctOS0xLTEtMQ_d6fe598e-7527-4a65-b3bf-4399d9ba359c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3674d32a89aa4e689ac0f2091ddd444f_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTctMTEtMS0xLTE_d7ead940-2f50-4ba5-9f84-b3f5101851ea">219.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i600421af4c80421291f0d5e08ea11d36_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTgtMS0xLTEtMQ_297940fc-fa09-4083-ac99-99846c411c06">110.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027d17439d6c44daaa8479672e90cc93_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTgtMy0xLTEtMQ_3c18c740-a314-4cd3-87ac-7ce8f26237bc">107.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec3eb54ea13545388e93581cfd374f6b_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTgtNS0xLTEtMQ_5153fa82-3eec-48dc-963a-821b0dcacc48">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3380d8d6904862a95b183e88d6721d_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTgtNy0xLTEtMQ_ad9432d3-c207-4140-aa8e-9a4d70992d76">110.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f93a011c64e4f2c94195e681aac557a_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTgtOS0xLTEtMQ_fe83aac7-d835-44cd-af65-fe4ed29e70b2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife05bc1f99a24066a3787f493ad65c20_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTgtMTEtMS0xLTE_c768fc4f-b3f6-4d19-83a2-54c7b71991a1">110.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667849e28703418487b214fec3474bdf_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTktMS0xLTEtMQ_00a78140-05c2-452e-bac8-9433c47daf41">19.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i175f9851b84d40c69587dda3c8dc10b9_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTktMy0xLTEtMQ_4268b94c-71ba-4cec-b17f-b7ee93cbceff">19.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida2502dbdf2544cb9724ce9126589989_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTktNS0xLTEtMQ_db97b18b-f08e-4ae3-8235-a5280d0b92df">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e73b6978a284142bdbfa2193963e239_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTktNy0xLTEtMQ_a9cbf156-f004-41be-bc97-56458e0bbf8e">19.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df8c985cdf740f7bae9773aa95472ab_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTktOS0xLTEtMQ_7fa13799-0098-420a-94a7-c6c71be0d610">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59605113a4b745c8bb79328b1a984d9e_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTktMTEtMS0xLTE_c52f07ef-a295-4cf8-82b0-53b1598cb9d7">19.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ee0ce7fbbd74335ae49c786f5ce512f_I20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjAtMS0xLTEtMQ_3e1718db-6e88-4e25-b0d0-c0fe6fd02c60">105.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52017fe562964955b55493c294addb61_I20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjAtMy0xLTEtMQ_eb608ed0-20d8-4fff-91aa-56a729a35622">21.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id52dc374b89b4866b4adf274c2fa1a1e_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjAtNS0xLTEtMQ_1fe4a1f0-15b3-4003-a099-ed20912b76f7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5c4cc06a6de46e1aad4f9ff97b84c27_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjAtNy0xLTEtMQ_aacdd2c0-8e0b-4f08-8f72-81f8f558cc14">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i225a1a562a4642abb6920b01f2fbb477_I20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjAtOS0xLTEtMQ_8d167f41-4b68-469a-884a-573ef17ddfe6">105.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5501586573ce4f1cbc984235a5fde549_I20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjAtMTEtMS0xLTE_6ea812df-ad15-4a34-88d1-433dfbc2d061">105.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770397553c8b4514ae29bcfa65ceee7b_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjEtMS0xLTEtMQ_4892055f-848c-4124-98be-c648a9a2d8d8">1,482.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b9c433fde8f4a7b8dc0cbfd63eae7e9_I20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjEtMy0xLTEtMQ_0c48f03a-11bc-45d9-9bae-a7ed8c8e3030">420.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6bfbe4f40464147acb2b478e7971494_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjEtNS0xLTEtMQ_2b7f5f10-fdac-432f-923d-1048e1456de7">1,482.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7edbfa9acbdb4bc6a481ff5ca1ce3c46_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjEtNy0xLTEtMQ_497f69ba-d2ae-4049-8a92-a44073146f78">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2ea2a6d6594fc5a90ebcefa22bf6ed_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjEtOS0xLTEtMQ_4f970d2d-44a5-47ca-a42b-599e5e059838">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad249b87b2f44e35b139a24f5d4d84db_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjEtMTEtMS0xLTE_5a9184f4-085b-4e67-8608-7fceb86fb060">1,482.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab73c3bd3fe34c699b5cb054ccb42a6b_I20210930" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjItMS0xLTEtMQ_3f95a4d3-c1c2-4756-9b21-361f46d9c936">556.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87dfd73c05814b0fbc8871daab747004_I20210930" decimals="-5" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjMtMS0xLTEtMQ_9ed3bc51-cc02-40a3-85f4-5ecb7a7ff5d8">725.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab73c3bd3fe34c699b5cb054ccb42a6b_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjQtMS0xLTEtMQ_ff921f6f-11c3-40da-8688-7fd3b4b4e5f1">3,350.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cb6f993649c432f91ab9ca4b71ffef8_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjctMS0xLTEtMQ_7ffc9201-c649-434b-bd23-40367b48863d">2,097.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fe77029755145319472019556e746c7_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjctMy0xLTEtMQ_baa3ac97-1435-4859-b3a0-de5092cfd8c6">2,097.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ca3e07a01148b094a43c55448e4efb_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjctNS0xLTEtMQ_21543e09-312d-4b2f-a9f7-246c9357ccaa">2,097.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1e0615e204f473cba443f60b3f7de5f_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjctNy0xLTEtMQ_92d587c4-5752-4116-b954-7555ce87bc9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05295ce03244400fa6766b9e219b8bf3_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjctOS0xLTEtMQ_95e4f2dd-b375-4934-9203-9fdba245b3e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fa9cde6db5c48a49a12b2bf050fed02_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjctMTEtMS0xLTE_bf57940b-d57b-4660-ba7a-a06d15725065">2,097.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e5d8fcb3fd44119480db6dbff280ce_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzAtMS0xLTEtMQ_5f5fe95c-f24f-40ec-8620-8ecc98996ba8">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8184781f424f29a27dadddc6ed8731_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzAtMy0xLTEtMQ_351197c0-ae73-449b-ab48-4cf440ba636a">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9d1a3a1cff4a65a746020df220cf2f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzAtNS0xLTEtMQ_56a9eefa-cfca-4bf4-8ec5-c5d64621f6e0">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65469da25ad54c90b48a89c0f3bf3d24_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzAtNy0xLTEtMQ_221fd8d0-a30b-40db-9cd9-110dd88840ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id88987a437d54b93a06bb21dda0b2e94_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzAtOS0xLTEtMQ_95c1c6cd-8f0d-495c-b36d-6f5a7415800d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic54aa0ee54c84aa7b85f303e4d069d0d_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzAtMTEtMS0xLTE_1cfa14e9-9722-42fa-95ee-232a35419ec9">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae50a005012c4da184ec9eab81c511a8_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzEtMS0xLTEtMQ_ff73ec80-6fac-4fc2-9d4e-66272020af71">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id30187a0d3b642f182acd93577234424_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzEtMy0xLTEtMQ_c76ad34a-46a5-4eb7-940b-0c8f2a5496fe">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if108dc8c33db49f1b50918a4d21f04b6_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzEtNS0xLTEtMQ_2e4f7eb9-8aa8-400b-bf88-cca6836e209b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d6a3638c5d4a708badbca1668d1e74_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzEtNy0xLTEtMQ_d4a986d5-c7f7-4b36-a775-729e47e813ef">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafebeab06586446d912397c6fb09946f_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzEtOS0xLTEtMQ_04f7706c-5311-48c0-8119-f41703e5359c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i559d13b3f37b4eb4ab054a4bce781df7_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzEtMTEtMS0xLTE_8a6ff988-7954-41ed-b9d7-4de3056d2684">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id471726344764ff2b385dbc67cf0ff8c_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzItMS0xLTEtMQ_02acb382-76fa-47a2-82f3-cb0368b1d728">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i579833d7d4e94e06b8586597ea11d6be_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzItMy0xLTEtMQ_df3cc659-0bb7-45b8-991f-a9328e6a2728">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i529b971a380a4005bfd7acd5587ded3e_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzItNS0xLTEtMQ_6b668a60-c635-4937-8b22-35745822b13b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc82ddb19c4945f884bbc5cd15cb96f4_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzItNy0xLTEtMQ_929ab758-6193-43ec-9c29-b0c21de1ef91">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f53adcd59224d2687568795466dfc6f_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzItOS0xLTEtMQ_9914f7c5-885f-43ef-b26a-bcf506f7812e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2b5896fbb642c0a0b59d18c9b0e845_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzItMTEtMS0xLTE_91fee13c-0c93-4359-a2bc-e2b8d20bef4a">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c6b8bdcad04d0d88e821b45c159a43_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzMtMS0xLTEtMQ_f84baa54-cc53-4001-9244-981259f39dd6">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i034058bf069a4dbcaae7e84a4aa255ae_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzMtMy0xLTEtMQ_df352e52-b081-4115-aac5-1b45c278d866">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0365c0c3dd2458dae2cab0433af8f3e_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzMtNS0xLTEtMQ_7b200eff-0d5e-4cae-a429-40a0330fbcc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19165abf56a04452a4c3551fe3755e80_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzMtNy0xLTEtMQ_32418277-399d-493e-9558-bd492593c9dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i289304fc14e749fea082a39de3765686_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzMtOS0xLTEtMQ_e82927f7-7bd4-4507-a922-89c8234e4ed3">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38b1cd4f68cc409893c60409151dc138_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzMtMTEtMS0xLTE_e54449bf-2127-4638-9029-ace0f080e03d">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cb6f993649c432f91ab9ca4b71ffef8_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzUtMS0xLTEtMQ_f06afd6e-4f8c-45e0-9f21-4023a5b0a057">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e5d8fcb3fd44119480db6dbff280ce_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzgtMS0xLTEtMQ_db5c1142-0225-425f-bac5-2f75f3dbe327">78.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8184781f424f29a27dadddc6ed8731_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzgtMy0xLTEtMQ_da910a6b-a034-4bf2-a021-34da31ff4430">74.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9d1a3a1cff4a65a746020df220cf2f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzgtNS0xLTEtMQ_a4c0b59e-361e-46e4-92a7-9acf2c65e277">78.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65469da25ad54c90b48a89c0f3bf3d24_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzgtNy0xLTEtMQ_ddbad957-10c1-48cf-adac-1044d7031c7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id88987a437d54b93a06bb21dda0b2e94_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzgtOS0xLTEtMQ_5dec742f-d381-4188-a2c5-2bcb204d192c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic54aa0ee54c84aa7b85f303e4d069d0d_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzgtMTEtMS0xLTE_7e204cdd-9495-489f-8463-8210956a8e5c">78.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae50a005012c4da184ec9eab81c511a8_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzktMS0xLTEtMQ_235c5f36-65f7-40a4-84d4-c749ab338e3e">137.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id30187a0d3b642f182acd93577234424_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzktMy0xLTEtMQ_8befb4eb-3d53-45db-ae43-2566362c642f">126.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if108dc8c33db49f1b50918a4d21f04b6_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzktNS0xLTEtMQ_2937eb20-f85b-4454-823c-8d1fc72c1a46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d6a3638c5d4a708badbca1668d1e74_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzktNy0xLTEtMQ_1d60fa53-d6eb-4832-b45a-8a5cef44e965">137.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafebeab06586446d912397c6fb09946f_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzktOS0xLTEtMQ_962761fc-e85e-4b74-adfe-d95b71b6a2b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i559d13b3f37b4eb4ab054a4bce781df7_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzktMTEtMS0xLTE_5242c572-16d1-4aac-b007-ca988b6f2259">137.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0246f3af391442d94cfbdb8ee92c330_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDAtMS0xLTEtMQ_84efd655-bf09-4ed8-b623-4a7f85e7641e">106.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i647c8bc2ff894d94933a6d11cfd86f10_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDAtMy0xLTEtMQ_af501f7f-41d0-4c5d-b245-bbb419cee4f9">101.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07aa6c9aa38745159a6c6e80527e089c_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDAtNS0xLTEtMQ_54b99fb8-1c22-4ee2-8b21-eda526e7999f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0d94775a2e4434f8f30c1ad2daaa4be_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDAtNy0xLTEtMQ_5defc809-176c-4571-8694-138acbc79512">106.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb3a371deaa94088a0072db110d4390c_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDAtOS0xLTEtMQ_fa66b6d0-e930-442d-bd9a-01dec0df81cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bf5bc5acb2d44fdb267cb99d8658e57_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDAtMTEtMS0xLTE_e086806e-5692-401d-924a-c0fcebe8cb5b">106.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id471726344764ff2b385dbc67cf0ff8c_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDEtMS0xLTEtMQ_c1446edb-3ecf-48a6-a95b-e019e87a651d">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i579833d7d4e94e06b8586597ea11d6be_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDEtMy0xLTEtMQ_860dea17-95c3-4760-a6b4-362441334f6a">23.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i529b971a380a4005bfd7acd5587ded3e_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDEtNS0xLTEtMQ_088e2f24-90f3-49b8-98aa-f8d67b9f0222">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc82ddb19c4945f884bbc5cd15cb96f4_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDEtNy0xLTEtMQ_07870655-aabc-4090-80df-f94a525a8b29">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f53adcd59224d2687568795466dfc6f_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDEtOS0xLTEtMQ_c8ded427-3729-469b-b719-0f38ef54f402">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2b5896fbb642c0a0b59d18c9b0e845_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDEtMTEtMS0xLTE_1e5ebcbc-af02-4849-8e8a-849f69e3c68e">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61279d09c7f74590ba3c78f533210f01_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDItMS0xLTEtMQ_f6121407-1532-44bd-ab06-b80575a5c1db">110.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09e35a2009cd4049b44091d2fbad8303_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDItMy0xLTEtMQ_1a6e28f4-7ad5-4608-8536-f6fdc488bf6f">31.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e126e3688134c3599ff5a999c9c666e_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDItNS0xLTEtMQ_1786a3e0-001d-400b-8ec6-e930d5516a6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d5ca9edfa0a4d2e8a076d65f4bf86f7_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDItNy0xLTEtMQ_112660a2-d39e-42e2-b32b-a0e933d60e29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfadc646ecc4dc6b43cf57447e0394b_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDItOS0xLTEtMQ_36b51613-b918-4dfd-b338-28bff72a1fd7">110.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32ae0f6ced194431824adea4c4770c08_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDItMTEtMS0xLTE_e3dc63c1-03ce-49a6-bbbe-9d4d9bb7b950">110.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bf0bd0fc1154e00a1a1c2c3d2110606_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDMtMS0xLTEtMQ_3b8de3f7-f7d7-45ff-af70-6be43f4e9dff">1,664.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fff8d67cdfe4a6694c7c5b6f0cb54c7_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDMtMy0xLTEtMQ_03cfd17e-1b98-44f8-8ad8-0818c75d4a7f">311.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44c59f63225e4451a3244ff421561da5_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDMtNS0xLTEtMQ_aa5fa329-760e-47a7-b9ca-cd9f0096b810">1,664.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90ec35ef834d4369a726dac716752c0a_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDMtNy0xLTEtMQ_a0cd427b-2a3e-411a-86f8-416f7fb52a90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06045f0fcf1478f9c730dddb34ab7ef_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDMtOS0xLTEtMQ_e50ee9e1-47a6-45fc-8fa5-9ace36999149">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da876ea43f4439ebedccb5d73cf5b3b_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDMtMTEtMS0xLTE_bf289067-a3dc-4ef7-92ff-2c68ee933736">1,664.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cb6f993649c432f91ab9ca4b71ffef8_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDQtMS0xLTEtMQ_52fa221d-c547-4c2d-a217-972dd81d1917">373.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib359550524f54c8f8a3d1f33d72a5dda_I20201231" decimals="-5" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDUtMS0xLTEtMQ_308dd6f2-906e-477e-872a-338016d8c564">471.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cb6f993649c432f91ab9ca4b71ffef8_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDYtMS0xLTEtMQ_5481cc60-2e84-4e68-97e4-8fa4c7e28162">2,966.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><ix:continuation id="i5a16f6c8dcd44bd396b62f6eb32d3ddc" continuedAt="i192ae88a796640ffba11240c4de674d5"><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ4Mjk_a9d6fc9d-caa0-46da-906a-74b73a0ad1eb" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.916%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab73c3bd3fe34c699b5cb054ccb42a6b_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjY5ZDk1ZjQ4Njg5NTQ0YjBhNWU3MTM3NzY0NjhjMTk0L3RhYmxlcmFuZ2U6NjlkOTVmNDg2ODk1NDRiMGE1ZTcxMzc3NjQ2OGMxOTRfNi0xLTEtMS0x_ba8a4079-b25f-4304-a22f-404db10405df">17,085.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44ef377c866e48298d0988babb457ef5_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjY5ZDk1ZjQ4Njg5NTQ0YjBhNWU3MTM3NzY0NjhjMTk0L3RhYmxlcmFuZ2U6NjlkOTVmNDg2ODk1NDRiMGE1ZTcxMzc3NjQ2OGMxOTRfNi0zLTEtMS0x_d10a8181-4e06-45a2-9ae4-16016b808448">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ad610fc9575465b996c10f1fb676d8e_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjY5ZDk1ZjQ4Njg5NTQ0YjBhNWU3MTM3NzY0NjhjMTk0L3RhYmxlcmFuZ2U6NjlkOTVmNDg2ODk1NDRiMGE1ZTcxMzc3NjQ2OGMxOTRfNi01LTEtMS0x_7b34dd29-8295-431a-87a1-cb81bef0a7e4">18,354.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e0450a0148940568359bd2bb4fd1c7a_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjY5ZDk1ZjQ4Njg5NTQ0YjBhNWU3MTM3NzY0NjhjMTk0L3RhYmxlcmFuZ2U6NjlkOTVmNDg2ODk1NDRiMGE1ZTcxMzc3NjQ2OGMxOTRfNi03LTEtMS0x_5986a2ca-e309-4c98-b9c0-1f7a7ec6d34e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie387bef8710440e4832f0dd71a46bba0_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjY5ZDk1ZjQ4Njg5NTQ0YjBhNWU3MTM3NzY0NjhjMTk0L3RhYmxlcmFuZ2U6NjlkOTVmNDg2ODk1NDRiMGE1ZTcxMzc3NjQ2OGMxOTRfNi05LTEtMS0x_822dbe6b-b683-4b89-ac52-49e4c5f204ef">18,354.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7cb6f993649c432f91ab9ca4b71ffef8_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjY5ZDk1ZjQ4Njg5NTQ0YjBhNWU3MTM3NzY0NjhjMTk0L3RhYmxlcmFuZ2U6NjlkOTVmNDg2ODk1NDRiMGE1ZTcxMzc3NjQ2OGMxOTRfNy0xLTEtMS0x_23c01535-0cf1-45cb-87d9-f7767f66333c">16,595.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ca3e07a01148b094a43c55448e4efb_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjY5ZDk1ZjQ4Njg5NTQ0YjBhNWU3MTM3NzY0NjhjMTk0L3RhYmxlcmFuZ2U6NjlkOTVmNDg2ODk1NDRiMGE1ZTcxMzc3NjQ2OGMxOTRfNy0zLTEtMS0x_5b4f1eee-fc34-4f4f-ba2c-352fc252870e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1e0615e204f473cba443f60b3f7de5f_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjY5ZDk1ZjQ4Njg5NTQ0YjBhNWU3MTM3NzY0NjhjMTk0L3RhYmxlcmFuZ2U6NjlkOTVmNDg2ODk1NDRiMGE1ZTcxMzc3NjQ2OGMxOTRfNy01LTEtMS0x_85bb53df-ba84-4ca0-bd59-52865bab3be9">19,038.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05295ce03244400fa6766b9e219b8bf3_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjY5ZDk1ZjQ4Njg5NTQ0YjBhNWU3MTM3NzY0NjhjMTk0L3RhYmxlcmFuZ2U6NjlkOTVmNDg2ODk1NDRiMGE1ZTcxMzc3NjQ2OGMxOTRfNy03LTEtMS0x_a5827d87-8d28-493f-9fe4-6bb203ca956a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fa9cde6db5c48a49a12b2bf050fed02_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjY5ZDk1ZjQ4Njg5NTQ0YjBhNWU3MTM3NzY0NjhjMTk0L3RhYmxlcmFuZ2U6NjlkOTVmNDg2ODk1NDRiMGE1ZTcxMzc3NjQ2OGMxOTRfNy05LTEtMS0x_ffaea9df-cc0d-4193-b39b-4b0bdf07096d">19,038.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><ix:continuation id="i192ae88a796640ffba11240c4de674d5" continuedAt="i213ea745cacf4ef4ab3ff0eea7c76d25"><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ4NjU_d293b8a1-f9b7-4a50-91ad-c1ca119bf348" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505924e93d794dcfb0c5b8f9156cc31d_I20210930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNS0xLTEtMS0x_950594e0-225c-4649-bcd3-f765de28663e">8.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib69916829c7f4e9fbfb75dc86bee47ef_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNS0zLTEtMS0x_f7eec9bb-4627-4df5-a4f0-95da365416f8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide74b136d9db45dc9cd0829ce1591b43_I20210930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNS01LTEtMS0x_59289fcc-53f5-49d0-a9ba-b9b91192f83c">8.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66fa7e1e841c4a48bef41810792cf5e1_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNS03LTEtMS0x_30fcdec2-d71f-49a9-872b-c3c2704ef449">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95b523dd0c89497e8d0a8474b6749ceb_I20210930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNS05LTEtMS0x_6c17c171-488b-46c8-8f40-c54b34745b19">8.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505924e93d794dcfb0c5b8f9156cc31d_I20210930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNi0xLTEtMS0x_af304bea-1572-4ec6-acf3-87b73e25ba47">87.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib69916829c7f4e9fbfb75dc86bee47ef_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNi0zLTEtMS0x_cb935489-8cfc-489e-8ef3-19f29bc208a3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide74b136d9db45dc9cd0829ce1591b43_I20210930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNi01LTEtMS0x_169637bd-1591-4a43-8dbb-bb372fc13f54">87.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66fa7e1e841c4a48bef41810792cf5e1_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNi03LTEtMS0x_8d2aa148-7e30-40c2-9b3a-5f2c94e452a3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95b523dd0c89497e8d0a8474b6749ceb_I20210930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNi05LTEtMS0x_66913aaf-c65a-47be-9fec-1b3d4b2cc87b">87.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i505924e93d794dcfb0c5b8f9156cc31d_I20210930" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfOC0xLTEtMS0x_8a9833e2-d8d3-463a-8dfc-44807c7d8a0f">2.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib69916829c7f4e9fbfb75dc86bee47ef_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfOC0zLTEtMS0x_bf1dc077-4f21-4c61-aca7-c09fd0bb2c3f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide74b136d9db45dc9cd0829ce1591b43_I20210930" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfOC01LTEtMS0x_23e0c649-9346-4dcc-ac0e-68cfbced4ede">2.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66fa7e1e841c4a48bef41810792cf5e1_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfOC03LTEtMS0x_59575745-174e-4116-8f3a-dbd0d75cca7d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95b523dd0c89497e8d0a8474b6749ceb_I20210930" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfOC05LTEtMS0x_7dcbb21a-8bff-412c-85f1-0c63769d9772">2.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffd5ed0fac1144d3bbe9bcce7cd1dcab_I20210930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTItMS0xLTEtMQ_007df8ee-2114-4dc2-b697-f573c7463ed4">77.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c09bc5eb3b44d3b988ac6fdb7749025_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTItMy0xLTEtMQ_e999e37d-a4ba-4be9-9667-6832a78fa62e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i070877701c5a412581e58eb922963dfb_I20210930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTItNS0xLTEtMQ_3572e437-5549-494f-93f2-504acf1037d2">77.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5427871777084be79a6dd7b683f42940_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTItNy0xLTEtMQ_7776ab5f-64c6-46d6-b963-b672bebe68a4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdeeaeee0d0d4d56bc48afc50bdbf622_I20210930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTItOS0xLTEtMQ_69c23d69-ae37-4568-8940-d2ddb9f0c152">77.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e2597f06c4231ae5d5e3a773d4991_I20210930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTUtMS0xLTEtMQ_a5321c2e-2f3b-4536-a4b4-9c26d60db3e4">18.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971a91d6ce39447f86a1c28fa9944956_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTUtMy0xLTEtMQ_13edb567-083e-42f2-89dd-f5f064be7f9a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aed62f649184956b1971ad38859077d_I20210930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTUtNS0xLTEtMQ_1c95f434-8e50-4f54-bb4b-5f85d0ac0fdd">18.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36d644f83d345269c981d8628439fe7_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTUtNy0xLTEtMQ_b58d0a7e-6b74-4e87-8fd2-18b975602a6d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8af5b44af8147c684f333006fbe7f0c_I20210930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTUtOS0xLTEtMQ_4cc69e8b-5bfb-4c11-9feb-92b8bd7eeb56">18.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9e2597f06c4231ae5d5e3a773d4991_I20210930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTYtMS0xLTEtMQ_46cd8efd-fb5f-435c-a5ce-cfa8f2fdedd0">38.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971a91d6ce39447f86a1c28fa9944956_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTYtMy0xLTEtMQ_c7f29217-5a8c-424b-8951-4bbe21847dd5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aed62f649184956b1971ad38859077d_I20210930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTYtNS0xLTEtMQ_08d2f569-47a5-41f3-a72e-a1b4098628b7">38.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36d644f83d345269c981d8628439fe7_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTYtNy0xLTEtMQ_ed624983-e0f4-4325-9477-8580bf149239">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8af5b44af8147c684f333006fbe7f0c_I20210930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTYtOS0xLTEtMQ_9cfb5fcc-fa0a-469b-9ece-716bb8f42199">38.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f9e2597f06c4231ae5d5e3a773d4991_I20210930" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTctMS0xLTEtMQ_b114a70e-4c81-42fd-853f-effcd07824d0">17.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971a91d6ce39447f86a1c28fa9944956_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTctMy0xLTEtMQ_c8937584-479f-443e-b629-4349e4e7ca4a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3aed62f649184956b1971ad38859077d_I20210930" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTctNS0xLTEtMQ_e22da6f2-66d1-4152-b70b-cbbfe811914d">17.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36d644f83d345269c981d8628439fe7_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTctNy0xLTEtMQ_eb141ded-09ec-4b98-8b63-c8078534a96f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8af5b44af8147c684f333006fbe7f0c_I20210930" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTctOS0xLTEtMQ_2b8ae683-7ba5-44ef-aae1-ba35de8b850e">17.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f9e2597f06c4231ae5d5e3a773d4991_I20210930" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTgtMS0xLTEtMQ_5ef55294-7dd1-47d2-99e6-6f4521c5605b">9.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971a91d6ce39447f86a1c28fa9944956_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTgtMy0xLTEtMQ_d25efbda-9631-4854-907c-8cf1cda564cd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3aed62f649184956b1971ad38859077d_I20210930" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTgtNS0xLTEtMQ_f1ab80d2-08d2-4804-aaaa-eec52ed90089">9.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36d644f83d345269c981d8628439fe7_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTgtNy0xLTEtMQ_cc70a4cd-9b6c-4899-a1fb-f4f3db764c8e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8af5b44af8147c684f333006fbe7f0c_I20210930" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTgtOS0xLTEtMQ_7fcddd43-db4e-49f5-8754-98a7a7988177">9.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f931a8eb6e44ca2a36918808b02f5e3_I20210930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjAtMS0xLTEtMQ_4f33e7d6-ef05-4a69-9d5f-2f3a6db644ee">10.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97d367acc5bc4a7693028a8fc46010a4_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjAtMy0xLTEtMQ_a821aa44-6488-4cd9-82b3-0eb464eafafd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89eb7f65122e4d24b2f6d71a3d2035ca_I20210930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjAtNS0xLTEtMQ_048e68d2-73bb-47e8-ae2a-a691e890a50f">10.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378115cc1767432b9131fab24760be6c_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjAtNy0xLTEtMQ_6b92b405-5773-475c-ad31-23bcb8aba69b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79a2635cf98d414eb4d6df658c5f7006_I20210930" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjAtOS0xLTEtMQ_46734113-e4ae-4424-9f94-83c0f701d5c7">10.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f931a8eb6e44ca2a36918808b02f5e3_I20210930" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjEtMS0xLTEtMQ_2e2c0c58-6b2d-43cd-bd12-7cfa158d899f">23.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97d367acc5bc4a7693028a8fc46010a4_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjEtMy0xLTEtMQ_c4b56589-276d-4616-b39d-d13ae99ee8f2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89eb7f65122e4d24b2f6d71a3d2035ca_I20210930" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjEtNS0xLTEtMQ_c0678df0-a78e-4324-bfa7-8ffb94f09bf6">23.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378115cc1767432b9131fab24760be6c_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjEtNy0xLTEtMQ_21886843-4525-463a-8c9c-108c141f8ec6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79a2635cf98d414eb4d6df658c5f7006_I20210930" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjEtOS0xLTEtMQ_625df700-577b-4034-85d8-5ccf9890e85c">23.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i610fa7df3a574a30bb25b81f30f3394e_I20210930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjMtMS0xLTEtMQ_aaf89376-2159-4b21-ab3d-0af4c1dbcbad">5.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544e08e2a3a1491f9a0fa4048ca7ab95_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjMtMy0xLTEtMQ_ad8fa7fe-c741-46f2-ba81-f5222d4d12a1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b124c9b6104c87b8aeb05c89cb6f96_I20210930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjMtNS0xLTEtMQ_84d435b2-28ac-4b44-a8da-0ca1fef45ff9">5.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd3f4727952e4020b12ae68aacca865d_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjMtNy0xLTEtMQ_73ba7e05-b99f-4035-9bff-ad859236d1c4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id907a8104c9441f294b2de3071a1225c_I20210930" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjMtOS0xLTEtMQ_8a89e176-a233-48fd-90bf-c658af101519">5.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i610fa7df3a574a30bb25b81f30f3394e_I20210930" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjQtMS0xLTEtMQ_87c95159-a42a-4231-a30c-c215840a4c09">25.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544e08e2a3a1491f9a0fa4048ca7ab95_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjQtMy0xLTEtMQ_ebfa0b97-64cf-427a-a080-d103983220f7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0b124c9b6104c87b8aeb05c89cb6f96_I20210930" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjQtNS0xLTEtMQ_e445a71c-7837-407f-bf59-4a978098c9e8">25.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd3f4727952e4020b12ae68aacca865d_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjQtNy0xLTEtMQ_ad3ca60a-63f0-4e70-a835-3bfc85c2ef1d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id907a8104c9441f294b2de3071a1225c_I20210930" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjQtOS0xLTEtMQ_7e365f81-6ae8-4a3e-a3af-ce72d91250d4">25.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liability:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab73c3bd3fe34c699b5cb054ccb42a6b_I20210930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjktMS0xLTEtMQ_82f306c1-45c1-4320-9859-ab461044b2dc">70.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44ef377c866e48298d0988babb457ef5_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjktMy0xLTEtMQ_ae0cb087-a092-425e-a5dc-bddc363160e1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ad610fc9575465b996c10f1fb676d8e_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjktNS0xLTEtMQ_6bb8f014-b44f-4a72-ad11-80c5c2058b0e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e0450a0148940568359bd2bb4fd1c7a_I20210930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjktNy0xLTEtMQ_c156b692-d4cb-4729-99de-1b9a1bf44444">70.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie387bef8710440e4832f0dd71a46bba0_I20210930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjktOS0xLTEtMQ_4139a395-fa39-466a-9ccf-207363ce0859">70.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81adb51d1b8642b89fde93b4d30867a1_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMzUtMS0xLTEtMQ_0c191769-a03d-41a1-bde6-044a66032b51">158.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie853d3ba19364e30b51bd241ce67c53e_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMzUtMy0xLTEtMQ_7ceb754b-031f-4200-b26c-a50ad0b3afe3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4754a075a4b41139b71c1d8bd51b1d1_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMzUtNS0xLTEtMQ_fc1a556d-d0fd-4b4c-afba-1a3f2076afe3">158.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d66e7dd621e49b19263feb5a5399308_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMzUtNy0xLTEtMQ_69867c8b-56c0-438a-9925-af889f54f474">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70f111854ded42afbf8cf34c68376b8b_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMzUtOS0xLTEtMQ_0baf0bd3-e030-4c0b-a655-c5202a2d1475">158.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96c9ad703a245439fd588caaf8599df_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMzktMS0xLTEtMQ_fb02fd92-b281-4df5-b615-35f01df1d7fd">38.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3066f646c41949fea57b1468cb30aa61_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMzktMy0xLTEtMQ_480ed097-bb00-40d6-aab0-18cf66ce7f7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3114cab844d04fb094abf5ed273c4e1a_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMzktNS0xLTEtMQ_47e3e20d-0f7b-4f96-9c72-4dd5b406e9a0">38.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462ca7b5109d432893cd43002d27ce96_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMzktNy0xLTEtMQ_4000dfc7-950e-4b6c-8bef-975a453dfd9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i143e36fc013841a18710bf40ddbee422_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMzktOS0xLTEtMQ_5d42fd63-d6df-4894-9353-203dd964376c">38.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96c9ad703a245439fd588caaf8599df_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDAtMS0xLTEtMQ_20da0f9d-265c-495d-8be1-4fe3eb1cdb67">97.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3066f646c41949fea57b1468cb30aa61_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDAtMy0xLTEtMQ_9fd59462-2f30-4eed-b9d3-70e275968933">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3114cab844d04fb094abf5ed273c4e1a_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDAtNS0xLTEtMQ_3f0386a0-beae-4d0f-abfe-6a2879f72b73">97.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462ca7b5109d432893cd43002d27ce96_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDAtNy0xLTEtMQ_1ffa9acc-4538-475d-9494-82caa602d197">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i143e36fc013841a18710bf40ddbee422_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDAtOS0xLTEtMQ_2216c89f-dca5-49e3-81bd-dc67b8a75408">97.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ce61f92b7b2406a94a6f87d2dd9623e_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDMtMS0xLTEtMQ_2c963f87-2e2f-482e-a430-9cc1c3cc3185">92.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa4a2085f406eb99b492e2438f438_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDMtMy0xLTEtMQ_50778011-1f00-4064-8297-291e73a1b932">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c435b9259f241fbad90a81868ac7e93_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDMtNS0xLTEtMQ_38d6d3f0-a5e1-4733-9fb9-1dcd9723737f">92.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8fd0978ab4d4893660a6cce21b4ac_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDMtNy0xLTEtMQ_e9ec1758-5b56-4bc1-8d9c-5a341f442f01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0716e0eaab47406db717f55a7cbf94ae_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDMtOS0xLTEtMQ_1ae52815-15d4-4f26-96ec-8b8ab89405a2">92.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ce61f92b7b2406a94a6f87d2dd9623e_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDQtMS0xLTEtMQ_dc8c574d-8cb3-40aa-8d65-d9681663c10a">97.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667fa4a2085f406eb99b492e2438f438_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDQtMy0xLTEtMQ_6ce30aab-cba3-45df-8767-2a8b3659eff0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c435b9259f241fbad90a81868ac7e93_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDQtNS0xLTEtMQ_1227abe3-bce7-40b8-818d-3b042dc62eb1">97.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8fd0978ab4d4893660a6cce21b4ac_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDQtNy0xLTEtMQ_96d6807e-c55d-4b46-8c7a-56f8342b9d2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0716e0eaab47406db717f55a7cbf94ae_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDQtOS0xLTEtMQ_f1a94ed6-31cf-44e8-b458-79ec29c934b3">97.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12ec379ba231490e890d0b394891be1b_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDYtMS0xLTEtMQ_b68a02a8-c477-4238-b759-a0c577e09284">34.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29cc6f270f8e4052ada8d9109a7be71d_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDYtMy0xLTEtMQ_4079d3bf-cf06-4f89-9551-76e7987dcbc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90ded503eb9c4993b67215c3faca3095_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDYtNS0xLTEtMQ_8cf37fbe-a655-467e-87ec-a00b565508dd">34.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f59e5a852fa4290a1df65e6c201066d_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDYtNy0xLTEtMQ_92c2c48c-51b2-4bd2-aeaf-899a90b4efbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d085d14349d484c957844f0450fce23_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDYtOS0xLTEtMQ_73d90ae2-5f17-4e12-bd04-a9e35fbb2a2e">34.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12ec379ba231490e890d0b394891be1b_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDctMS0xLTEtMQ_a30f4197-944d-408b-93cc-2fee3bf28293">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29cc6f270f8e4052ada8d9109a7be71d_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDctMy0xLTEtMQ_7301795a-c109-48ef-b4df-cbfd82a10fa1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90ded503eb9c4993b67215c3faca3095_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDctNS0xLTEtMQ_b528b910-4831-4836-81b1-2aefb2a15407">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f59e5a852fa4290a1df65e6c201066d_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDctNy0xLTEtMQ_8cec31fe-9368-45e2-b2e2-ca83ffe9bbe1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d085d14349d484c957844f0450fce23_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDctOS0xLTEtMQ_78a553f9-e8a4-4f7f-877a-0775e4105f4a">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646f429e54744f22989e1d0d53220bc3_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDktMS0xLTEtMQ_0b2f2ea5-b376-4137-a8fc-2cf623f943dd">41.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i350054955cb548ee9fa3d529afd9be07_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDktMy0xLTEtMQ_0f5ab5e1-6e4c-454c-8234-c1a891928179">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1213fc8d77534b999d9ec3dd2556fa3d_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDktNS0xLTEtMQ_769f2666-6c4e-4c4b-8b2c-ae246252b81c">41.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id562cb2b7ee2435a966ee63e3c0c3331_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDktNy0xLTEtMQ_794ac8c0-7dc1-4993-9917-1bd0b07a0c77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8744c9db8c224530b3a70c3dc9a6e821_I20201231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDktOS0xLTEtMQ_9f3ef571-e8bb-4453-bb06-1e4233043903">41.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646f429e54744f22989e1d0d53220bc3_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNTAtMS0xLTEtMQ_319efccd-153e-492d-8dc1-1fc09406feab">15.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i350054955cb548ee9fa3d529afd9be07_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNTAtMy0xLTEtMQ_9a4f095b-ffef-4670-96dd-80851d55c558">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1213fc8d77534b999d9ec3dd2556fa3d_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNTAtNS0xLTEtMQ_695107dd-daf9-4263-a5df-78a9063a3ae5">15.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id562cb2b7ee2435a966ee63e3c0c3331_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNTAtNy0xLTEtMQ_f530dbda-9d86-4796-85fe-cfc9d35e187a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8744c9db8c224530b3a70c3dc9a6e821_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNTAtOS0xLTEtMQ_29bb8871-e6ae-4052-bb24-e5013f756312">15.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i213ea745cacf4ef4ab3ff0eea7c76d25" continuedAt="iea658faec03a496aa564f53d70f4954a"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. Fair values are not readily available for certain equity investments measured under the measurement alternative. As of September 30, 2021, we had approximately $<ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTAyNzQ_7881f4df-c584-4950-bdb8-4d8f0e1488d1">781</ix:nonFraction> million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to <ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" format="ixt-sec:duryear" name="lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTAzOTM_46781d2d-34a0-4cf9-80e0-b18264b03dab">10</ix:nonNumeric> years. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liability relates to our liability arising in connection with the CVR issued as a result of the Prevail acquisition. The fair value of the CVR liability was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant's view of the expected cash payment associated with the first potential regulatory approval of a Prevail compound in the applicable countries based on probabilities of technical success, timing of the potential approval events for the compounds, and an estimated discount rate. See Note 3 for additional information related to the CVR arrangement. </span></div><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ4NTA_ce7a1e98-0a3c-427e-b59b-29dd3d3618eb" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of September&#160;30, 2021:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:40.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&#160;Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More&#160;Than<br/>10 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjZjZDIwMDYyNWRhMTQ0NDI4OTFiYjE3ZTU3MWMxMmZiL3RhYmxlcmFuZ2U6NmNkMjAwNjI1ZGExNDQ0Mjg5MWJiMTdlNTcxYzEyZmJfMi0xLTEtMS0x_7ea86a0a-0719-4afd-8069-bf8f19bbac8a">501.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjZjZDIwMDYyNWRhMTQ0NDI4OTFiYjE3ZTU3MWMxMmZiL3RhYmxlcmFuZ2U6NmNkMjAwNjI1ZGExNDQ0Mjg5MWJiMTdlNTcxYzEyZmJfMi0zLTEtMS0x_409b27ab-7760-4edb-aadc-3ed5d6b49313">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjZjZDIwMDYyNWRhMTQ0NDI4OTFiYjE3ZTU3MWMxMmZiL3RhYmxlcmFuZ2U6NmNkMjAwNjI1ZGExNDQ0Mjg5MWJiMTdlNTcxYzEyZmJfMi01LTEtMS0x_1ad4f1ee-cef6-4f75-9467-be7ce17b0de8">157.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjZjZDIwMDYyNWRhMTQ0NDI4OTFiYjE3ZTU3MWMxMmZiL3RhYmxlcmFuZ2U6NmNkMjAwNjI1ZGExNDQ0Mjg5MWJiMTdlNTcxYzEyZmJfMi03LTEtMS0x_5582218c-dcfa-429a-abd5-ebb959545f3d">153.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjZjZDIwMDYyNWRhMTQ0NDI4OTFiYjE3ZTU3MWMxMmZiL3RhYmxlcmFuZ2U6NmNkMjAwNjI1ZGExNDQ0Mjg5MWJiMTdlNTcxYzEyZmJfMi05LTEtMS0x_54699860-c3cc-4a3f-a4e1-b6ea9b67dbdc">168.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net gains (losses) recognized in our consolidated condensed statements of operations for equity securities were $(<ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTEyOTI_24325b8f-1a14-4019-b214-3654e29213fb">246.8</ix:nonFraction>)&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTEyOTk_9bb989c5-5748-406b-94b6-84153fbf64f9">270.1</ix:nonFraction> million for the three and nine months ended September&#160;30, 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTEzNTk_baa8b4f0-0203-4af5-a6b9-d11df3a016fb">141.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTEzNjY_c284ce25-ba65-439c-9916-43c9c9cc69ed">905.1</ix:nonFraction> million for the three and nine months ended September 30, 2020, respectively. The net gains/losses recognized during the three and nine months ended September&#160;30, 2021 and 2020 on equity securities sold during the respective periods were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded during the three and nine months ended September&#160;30, 2021 and 2020 were not material.</span></div><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ4NTE_1ae438c3-88e4-4811-a6c0-f64222d52972" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhMDc2OTc1NDkxMDRmNzU4ODZlNmZjYTJjZDg5NTBlL3RhYmxlcmFuZ2U6NWEwNzY5NzU0OTEwNGY3NTg4NmU2ZmNhMmNkODk1MGVfMS0xLTEtMS0x_97ecbd3d-2986-4c0f-9e10-5dcee2f8299b">12.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhMDc2OTc1NDkxMDRmNzU4ODZlNmZjYTJjZDg5NTBlL3RhYmxlcmFuZ2U6NWEwNzY5NzU0OTEwNGY3NTg4NmU2ZmNhMmNkODk1MGVfMS0zLTEtMS0x_1ba8175a-a546-49e6-91cf-f07ed228475c">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhMDc2OTc1NDkxMDRmNzU4ODZlNmZjYTJjZDg5NTBlL3RhYmxlcmFuZ2U6NWEwNzY5NzU0OTEwNGY3NTg4NmU2ZmNhMmNkODk1MGVfMi0xLTEtMS0x_9d82ab89-6c93-4ff2-bda4-e9802244dd2a">4.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhMDc2OTc1NDkxMDRmNzU4ODZlNmZjYTJjZDg5NTBlL3RhYmxlcmFuZ2U6NWEwNzY5NzU0OTEwNGY3NTg4NmU2ZmNhMmNkODk1MGVfMi0zLTEtMS0x_237498b0-cd1f-4c14-ab1f-a3149e2f889f">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" name="lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhMDc2OTc1NDkxMDRmNzU4ODZlNmZjYTJjZDg5NTBlL3RhYmxlcmFuZ2U6NWEwNzY5NzU0OTEwNGY3NTg4NmU2ZmNhMmNkODk1MGVfMy0xLTEtMS0x_27114f7c-1ad8-4474-972a-e40991f4b5e7">293.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" name="lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhMDc2OTc1NDkxMDRmNzU4ODZlNmZjYTJjZDg5NTBlL3RhYmxlcmFuZ2U6NWEwNzY5NzU0OTEwNGY3NTg4NmU2ZmNhMmNkODk1MGVfMy0zLTEtMS0x_5b79a27d-b47d-48b5-a156-ef8961879f4f">348.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhMDc2OTc1NDkxMDRmNzU4ODZlNmZjYTJjZDg5NTBlL3RhYmxlcmFuZ2U6NWEwNzY5NzU0OTEwNGY3NTg4NmU2ZmNhMmNkODk1MGVfNC0xLTEtMS0x_202cc4ad-9793-4668-9cc7-54e312c51645">208.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhMDc2OTc1NDkxMDRmNzU4ODZlNmZjYTJjZDg5NTBlL3RhYmxlcmFuZ2U6NWEwNzY5NzU0OTEwNGY3NTg4NmU2ZmNhMmNkODk1MGVfNC0zLTEtMS0x_faacf704-8d1f-4c7a-87ae-5bf88f885678">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the three and nine months ended September&#160;30, 2021 and 2020.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iea658faec03a496aa564f53d70f4954a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately <ix:nonFraction unitRef="number" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTMyMjk_59c1868c-f99e-4424-b3ab-036ce4e6388f">97</ix:nonFraction> percent&#160;of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of September&#160;30, 2021, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities.</span></div><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:GainLossOnInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ4MTQ_9cceb8fc-1b97-4856-bef4-fc4666ae72a5" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:60.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfMi0xLTEtMS0x_3c651f8f-7729-47a9-b5a2-5d8c70ec4dda">49.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfMi0zLTEtMS0x_98d740cb-e609-4aed-a578-8046f7708adf">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfMi01LTEtMS0x_58edee61-1d0d-4e36-82bd-9c18b8120324">137.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfMi03LTEtMS0x_4df6f231-2e73-4d6f-9766-16a22bfd5632">246.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfMy0xLTEtMS0x_83c2cc34-14b0-434d-950d-71cc051071c6">0.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfMy0zLTEtMS0x_c57ca2f5-c19e-4581-b7bb-4731b05d8725">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfMy01LTEtMS0x_679140e2-9f25-4ea9-a044-5dfa5948f417">2.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfMy03LTEtMS0x_7d26cd83-b046-487b-a6c4-ec5f35c19a1a">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfNC0xLTEtMS0x_5e3ffca0-4a22-452a-80d7-0b2532003138">0.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfNC0zLTEtMS0x_a74493d9-fc1a-4f3e-8d62-b2ca929a3eb8">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfNC01LTEtMS0x_3434894a-e0d0-4257-857a-0c5e235c3508">1.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfNC03LTEtMS0x_685c3cb2-25bc-4d90-830c-3b7628c76835">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable Factoring Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and, risk related to, the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $<ix:nonFraction unitRef="usd" contextRef="ie526750480d147ff852c5266a9af6876_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ1MjM_0b5818f3-44ed-4276-8bdd-cec32f57b76c">617.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ1MzA_3e309e13-fec0-4bc2-8619-baa7817aa83d">754.9</ix:nonFraction> million&#160;of accounts receivable as of September&#160;30, 2021 and December 31, 2020, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated condensed results of operations for the three and nine months ended September&#160;30, 2021 and 2020&#160;were&#160;not material.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i48af34e12713400c858f7a29183e5680_67"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7: <ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82Ny9mcmFnOjc0Y2Y2MmRkZDdmNDQxNjM5NjJlODA2ZmI1MDcxNDg2L3RleHRyZWdpb246NzRjZjYyZGRkN2Y0NDE2Mzk2MmU4MDZmYjUwNzE0ODZfOTA2_4efd0885-a71d-411f-84d1-fa548ec87e77" continuedAt="i8de8537d0005472e980a3b70cff1ba6a" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="i8de8537d0005472e980a3b70cff1ba6a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was <ix:nonFraction unitRef="number" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82Ny9mcmFnOjc0Y2Y2MmRkZDdmNDQxNjM5NjJlODA2ZmI1MDcxNDg2L3RleHRyZWdpb246NzRjZjYyZGRkN2Y0NDE2Mzk2MmU4MDZmYjUwNzE0ODZfNTQ_739d46a7-1d61-4943-8dce-512857968b47">10.9</ix:nonFraction> percent for the three months ended September&#160;30, 2021, compared with <ix:nonFraction unitRef="number" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82Ny9mcmFnOjc0Y2Y2MmRkZDdmNDQxNjM5NjJlODA2ZmI1MDcxNDg2L3RleHRyZWdpb246NzRjZjYyZGRkN2Y0NDE2Mzk2MmU4MDZmYjUwNzE0ODZfMTAy_04650a8e-dbd2-4ef8-a0d4-47ead92fe7ad">15.9</ix:nonFraction> percent for the three months ended September 30, 2020. The lower effective tax rate for the three months ended September 30, 2021 was primarily due to the income tax impact of a debt extinguishment loss and unfavorable mark-to-market adjustments on investments in equity securities, partially offset by a lower net discrete tax benefit compared to the three months ended September 30, 2020. The effective tax rate was <ix:nonFraction unitRef="number" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82Ny9mcmFnOjc0Y2Y2MmRkZDdmNDQxNjM5NjJlODA2ZmI1MDcxNDg2L3RleHRyZWdpb246NzRjZjYyZGRkN2Y0NDE2Mzk2MmU4MDZmYjUwNzE0ODZfMTc0_a44a4760-b79e-46f4-a4e0-9debc701bb04">10.7</ix:nonFraction> percent for the nine months ended September&#160;30, 2021, compared with <ix:nonFraction unitRef="number" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82Ny9mcmFnOjc0Y2Y2MmRkZDdmNDQxNjM5NjJlODA2ZmI1MDcxNDg2L3RleHRyZWdpb246NzRjZjYyZGRkN2Y0NDE2Mzk2MmU4MDZmYjUwNzE0ODZfMjIw_6a044663-9185-4b44-992e-0da0b21ff8b0">14.4</ix:nonFraction> percent for the nine months ended September 30, 2020. The lower effective tax rate for the nine months ended September 30, 2021 was primarily due to the income tax impacts of a net inventory impairment charge related to our COVID-19 antibodies and a debt extinguishment loss, as well as higher acquired IPR&amp;D charges and lower favorable mark-to-market adjustments on investments in equity securities compared to the nine months ended September 30, 2020, partially offset by a lower net discrete tax benefit compared to the nine months ended September 30, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. examination of tax years 2016-2018 began in the fourth quarter of 2019 and remains ongoing. The resolution of this audit period will likely extend beyond the next 12 months.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i48af34e12713400c858f7a29183e5680_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8: <ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RleHRyZWdpb246MjdjMThmNzdiMTJmNGFiOTg4NTJhMmNiZTczZmYxNThfNTY4_ed146df8-c285-4623-b480-d8e9261e179d" continuedAt="i769d958648ab4c8980de1462fa14a7d6" escape="true">Retirement Benefits</ix:nonNumeric></span></div><ix:continuation id="i769d958648ab4c8980de1462fa14a7d6"><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RleHRyZWdpb246MjdjMThmNzdiMTJmNGFiOTg4NTJhMmNiZTczZmYxNThfNTc4_bf1492e2-f519-4982-970f-ab86640d1808" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health benefit (income) cost included the following components:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176730f8aadd46128632c5ba433875c6_D20210701-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNC0xLTEtMS0x_2170b97d-ec07-4a2b-ad5d-306df2ffb360">92.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26ed7f2fc0cc4fc2b518e980d510d435_D20200701-20200930" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNC0zLTEtMS0x_fa06dd48-5208-4f28-be37-449682f657a1">81.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f0d0b356cce49a8934e6af36a6e9f3f_D20210101-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNC01LTEtMS0x_14885291-dbfa-40bd-99ee-552ac10ab210">277.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e32aff16cce45f1bbc5d66e0afc2090_D20200101-20200930" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNC03LTEtMS0x_25498fcf-619a-4cba-a90e-9c6aa45f32c5">243.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176730f8aadd46128632c5ba433875c6_D20210701-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNS0xLTEtMS0x_c5b00772-d1d4-4a88-a5cf-ebb79ce6e866">84.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26ed7f2fc0cc4fc2b518e980d510d435_D20200701-20200930" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNS0zLTEtMS0x_81e58652-fc81-4487-a6f7-188ef7b3aad1">106.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f0d0b356cce49a8934e6af36a6e9f3f_D20210101-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNS01LTEtMS0x_ef673883-bc99-4e80-98e6-b7369a46732b">253.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e32aff16cce45f1bbc5d66e0afc2090_D20200101-20200930" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNS03LTEtMS0x_d26c7feb-63fb-4e96-a5c2-73af660705c5">319.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176730f8aadd46128632c5ba433875c6_D20210701-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNi0xLTEtMS0x_53036c34-e90d-47c7-8d02-426fe762163b">237.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26ed7f2fc0cc4fc2b518e980d510d435_D20200701-20200930" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNi0zLTEtMS0x_7339e453-ce09-4310-9a5c-0a5c28c751b8">229.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f0d0b356cce49a8934e6af36a6e9f3f_D20210101-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNi01LTEtMS0x_02b23bae-d414-4953-ad18-b0d4a41e3851">712.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e32aff16cce45f1bbc5d66e0afc2090_D20200101-20200930" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNi03LTEtMS0x_17397a91-bde0-4f97-afaa-1f71fe59eb5b">671.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176730f8aadd46128632c5ba433875c6_D20210701-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNy0xLTEtMS0x_65acb032-20f4-41a0-a0a2-efd48fbc5627">1.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26ed7f2fc0cc4fc2b518e980d510d435_D20200701-20200930" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNy0zLTEtMS0x_6fd5f106-5c2b-41c9-9af7-6936456da6ef">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f0d0b356cce49a8934e6af36a6e9f3f_D20210101-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNy01LTEtMS0x_e05669f4-0bcb-432f-be03-f2d4d87e0bb9">3.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e32aff16cce45f1bbc5d66e0afc2090_D20200101-20200930" decimals="-5" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNy03LTEtMS0x_7d080bd7-a9c9-405f-bacc-2b87bfb271c2">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176730f8aadd46128632c5ba433875c6_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfOC0xLTEtMS0x_1dfc4c06-624f-4962-b417-54fef41820ae">121.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26ed7f2fc0cc4fc2b518e980d510d435_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfOC0zLTEtMS0x_ac0d8f3d-3575-4d66-b16f-d10b42667d64">58.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f0d0b356cce49a8934e6af36a6e9f3f_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfOC01LTEtMS0x_310e531d-331d-488e-a6b7-39ef3ebb70e2">366.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e32aff16cce45f1bbc5d66e0afc2090_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfOC03LTEtMS0x_8b65f93f-4ba1-4d56-a2c8-7bafe73abe9e">286.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176730f8aadd46128632c5ba433875c6_D20210701-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfMTAtMS0xLTEtMQ_2ae7a7a6-3a80-4d04-a463-4c2dc5a54ba8">62.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26ed7f2fc0cc4fc2b518e980d510d435_D20200701-20200930" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfMTAtMy0xLTEtMQ_164876c2-fc06-4cc9-8f24-dc0cb990596e">18.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f0d0b356cce49a8934e6af36a6e9f3f_D20210101-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfMTAtNS0xLTEtMQ_4b7dee25-f881-4100-907d-9db2289233fe">188.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e32aff16cce45f1bbc5d66e0afc2090_D20200101-20200930" decimals="-5" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfMTAtNy0xLTEtMQ_39541f23-53fa-4bb5-94eb-648f6c6a918f">180.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit income:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6733dbedc8dc49a5a3099a9d0ba22916_D20210701-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNC0xLTEtMS0x_b0d97473-dd12-4b1b-89e2-79b11767a0bf">12.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc6413f2deb444f9703aae3ad14ffef_D20200701-20200930" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNC0zLTEtMS0x_0ce61c49-2667-47b1-9aca-1f63ea0e9b65">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07abba9f0ad143a1bd6ac13320789ca2_D20210101-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNC01LTEtMS0x_668b23d3-0ba9-41b2-a8bd-98034b92f199">37.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c740c841315439ab33499536b4e70a2_D20200101-20200930" decimals="-5" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNC03LTEtMS0x_c831e5f9-d653-4906-b1b3-1b02a5573885">30.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6733dbedc8dc49a5a3099a9d0ba22916_D20210701-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNS0xLTEtMS0x_612ab707-d677-4cf2-b710-04e2140f4632">8.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc6413f2deb444f9703aae3ad14ffef_D20200701-20200930" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNS0zLTEtMS0x_bc542ae2-fefc-4bb5-bacb-832e29bd5dd8">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07abba9f0ad143a1bd6ac13320789ca2_D20210101-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNS01LTEtMS0x_99f65d77-e75f-4589-833a-122efe698d4b">24.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c740c841315439ab33499536b4e70a2_D20200101-20200930" decimals="-5" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNS03LTEtMS0x_7f3e8531-7e80-4da7-a9b2-24495184c895">32.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6733dbedc8dc49a5a3099a9d0ba22916_D20210701-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNi0xLTEtMS0x_7a0cb6fe-5215-44fc-a306-bf34a710a254">36.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc6413f2deb444f9703aae3ad14ffef_D20200701-20200930" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNi0zLTEtMS0x_b9ac9b8d-acee-40c9-b44c-1894d8eead31">40.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07abba9f0ad143a1bd6ac13320789ca2_D20210101-20210930" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNi01LTEtMS0x_3af34503-a0c3-4765-b35c-0e5f45806680">109.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c740c841315439ab33499536b4e70a2_D20200101-20200930" decimals="-5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNi03LTEtMS0x_bb49484c-8e55-4aa1-a76c-f3b1531832c3">115.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6733dbedc8dc49a5a3099a9d0ba22916_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNy0xLTEtMS0x_2021705c-209f-4407-9714-4161490d820a">14.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc6413f2deb444f9703aae3ad14ffef_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNy0zLTEtMS0x_9820dc5d-0816-4966-849c-ba4d948b49d5">21.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07abba9f0ad143a1bd6ac13320789ca2_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNy01LTEtMS0x_2d21bfda-a43d-43d9-9f10-1e7b17833123">44.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c740c841315439ab33499536b4e70a2_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNy03LTEtMS0x_f3562612-ec8c-4eb2-a4bc-d66332db3db4">51.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6733dbedc8dc49a5a3099a9d0ba22916_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfOC0xLTEtMS0x_d4995a4e-e0dc-4f05-b64e-67cb9871f58a">0.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc6413f2deb444f9703aae3ad14ffef_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfOC0zLTEtMS0x_fbdb5fe8-9b4b-4628-ad51-4c8537142bf8">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07abba9f0ad143a1bd6ac13320789ca2_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfOC01LTEtMS0x_b77035bf-acb9-429a-bf89-c5889e2856f3">2.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c740c841315439ab33499536b4e70a2_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfOC03LTEtMS0x_79260b10-aa49-47d8-9075-5c0bc7c038bc">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit income</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6733dbedc8dc49a5a3099a9d0ba22916_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfMTAtMS0xLTEtMQ_5c96aa8e-c809-4e4a-9417-140f6db21fc0">30.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc6413f2deb444f9703aae3ad14ffef_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfMTAtMy0xLTEtMQ_e9299ff3-eece-4e86-831f-9b7a66479463">40.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07abba9f0ad143a1bd6ac13320789ca2_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfMTAtNS0xLTEtMQ_bb856d25-28ac-4499-81dd-c134516cb45c">90.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c740c841315439ab33499536b4e70a2_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfMTAtNy0xLTEtMQ_746240e3-f531-42d5-8d78-fae5f5481f39">101.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div><span><br/></span></div><div id="i48af34e12713400c858f7a29183e5680_73"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9: <ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMjk0NTQ_0b0d96d7-e047-42a0-8465-548e4a95a69c" continuedAt="i009b4fc9df854a64ae4a2010d25ace19" escape="true">Contingencies</ix:nonNumeric></span></div><ix:continuation id="i009b4fc9df854a64ae4a2010d25ace19" continuedAt="i6bbe8269f537463d88392d7764197ddd"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the final outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated condensed balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6bbe8269f537463d88392d7764197ddd" continuedAt="iae2c5e1c851842bdb0c131fa370f7b69"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently and previously marketed products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Alimta Patent Litigation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alimta (pemetrexed) is protected by a vitamin regimen patent until November 2021, plus pediatric exclusivity through May 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we settled a lawsuit we filed against Eagle Pharmaceuticals, Inc. (Eagle) in response to its application to market a product using an alternative form of pemetrexed. Per the settlement agreement, Eagle has a limited initial entry into the market with its product starting February 2022 (up to an approximate three-week supply) and subsequent unlimited entry starting April 2022.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Litigation</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was protected by the vitamin regimen patent through June 2021. Despite the recent patent expiration, a number of legal proceedings that were initiated prior to expiration are ongoing</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Emgality Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, we were</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> named as a defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA, Inc. (collectively, Teva) in the U.S. District Court for the District of Massachusetts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">seeking a ruling that various claims in <ix:nonFraction unitRef="patent" contextRef="i3396e46f9d1e40d387eef70e8d15804f_I20180930" decimals="INF" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfNDUyNQ_095b6c2d-7ac3-41ee-81d8-75d61cc896c0">nine</ix:nonFraction> different Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in adults. Trial is expected in March 2022. In June 2021, we were named as a defendant in a second litigation filed by Teva in the U.S. District Court for the District of Massachusetts seeking a ruling that <ix:nonFraction unitRef="patent" contextRef="ifba4f334917d401c815c949e200f615c_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfNDg1NA_5381c53d-7f9c-4197-bb15-1d1347be4c98">two</ix:nonFraction> of Teva&#8217;s patents, which are directed toward use of the active ingredient in Emgality to treat migraine, would be infringed by our continued sales of Emgality.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, the U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) granted our request to initiate an&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes review</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(IPR) to reexamine the validity of the <ix:nonFraction unitRef="patent" contextRef="i3396e46f9d1e40d387eef70e8d15804f_I20180930" decimals="INF" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfNTE3OQ_095b6c2d-7ac3-41ee-81d8-75d61cc896c0">nine</ix:nonFraction> Teva patents asserted against us in the litigation. In February 2020, the PTAB ruled in our favor and found that the claims asserted against us in <ix:nonFraction unitRef="patent" contextRef="i04488b288a30423980051e6f31d6daef_D20200201-20200229" decimals="INF" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatentsClaimsDismissed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfNTMzMA_e33f9a88-361d-4bb1-ab5d-eda6abe08931">six</ix:nonFraction> of Teva's <ix:nonFraction unitRef="patent" contextRef="i9a8ded4399f14dd3a19c466a1b1af3e9_I20200229" decimals="INF" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfNTM0Mw_52cc950a-c1ae-4dae-bc8a-96fb3ef1ced3">nine</ix:nonFraction> patents were invalid. In March 2020, the PTAB ruled against us on the remaining <ix:nonFraction unitRef="patent" contextRef="ieee62783e4544f66ab4860b55a43cd90_D20200301-20200331" decimals="INF" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatentsRuledUnpatentable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfNTQyNw_f8a16e9f-b087-41e2-b6e6-fae725707624">three</ix:nonFraction> Teva patents, finding that we failed to show that the remaining <ix:nonFraction unitRef="patent" contextRef="ieee62783e4544f66ab4860b55a43cd90_D20200301-20200331" decimals="INF" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatentsRuledUnpatentable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfNTQ5NA_0fc9de65-d2cb-449a-8a40-9469cabbde68">three</ix:nonFraction> patents were unpatentable based on the subset of invalidity arguments available in an IPR proceeding. In April 2020, we appealed the PTAB&#8217;s March 2020 ruling, and Teva appealed the PTAB&#8217;s February 2020 ruling to the U.S. Court of Appeals for the Federal Circuit. In August 2021, the appeals court affirmed all <ix:nonFraction unitRef="decision" contextRef="i7c00bf1eb48e4add853803f501de39e3_I20210831" decimals="INF" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfDecisionsAffirmed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfODc5NjA5MzA1OTYxOQ_68ad7dd7-d02a-4be1-9d45-66e6caf674b9">nine</ix:nonFraction> of the PTAB's decisions. Neither Lilly nor Teva appealed the rulings and accordingly those decisions are final, and the parties have agreed to a stipulation which removes the <ix:nonFraction unitRef="patent" contextRef="ifa01b284a88a485895b7e8d41c34e4e9_D20210801-20210831" decimals="INF" format="ixt-sec:numwordsen" name="lly:LossContingencyNumberOfPatentsClaimsDismissed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfODc5NjA5MzA1OTU3OA_ac68cdd3-9c50-4775-b3d8-00f0d3a6af76">six</ix:nonFraction> invalidated patents from the district court litigation. This IPR matter is now closed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Jardiance Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Boehringer Ingelheim (BI), our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court of Delaware alleging infringement arising from submissions of Abbreviated New Drug Applications (ANDA) by a number of generic companies seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, the generic companies' ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. This litigation has been stayed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Taltz Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we petitioned the High Court of Ireland to declare invalid the patent that Novartis Pharma AG (Novartis) purchased from Genentech, Inc. in 2020. Novartis responded by filing a claim against us alleging patent infringement related to our commercialization of Taltz and seeking damages for past infringement and an injunction against future infringement. This matter is ongoing. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iae2c5e1c851842bdb0c131fa370f7b69" continuedAt="i824dede0ac9b40b38043582aaa252dfc"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021 and June 2021, Novartis petitioned the Court of Rome Intellectual Property Division and the Commercial Court of Vienna, respectively, in preliminary injunction infringement proceedings against us related to our commercialization of Taltz. In June 2021, the Court of Rome Intellectual Property Division dismissed Novartis&#8217; preliminary injunction action. Novartis has appealed the ruling and in October 2021 the panel hearing Novartis' appeal appointed a technical expert to assess the merits of the case. Both matters are ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Zyprexa Canada Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the mid-2000&#8217;s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012, the Canadian Federal Court of Appeals denied our appeal of a lower court's decision that certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trade-Mark Act, and common law. In March 2021, the Ontario Superior Court granted our motion for summary judgement, thereby dismissing Apotex&#8217;s case. Apotex appealed that ruling to the Court of Appeal for Ontario in April 2021 and a hearing is scheduled for February 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Actos&#174;  Product Liability</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named along with Takeda Chemical Industries, Ltd. and Takeda affiliates (collectively, Takeda) as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="ie7da18cbbc67441ea99ca54c41121ad6_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfODcwOQ_f2cc5a9b-e9d5-4475-9bab-47b5179b4f87">four</ix:nonFraction> purported product liability class actions in Canada related to Actos, which we commercialized with Takeda in Canada until 2009, including <ix:nonFraction unitRef="lawsuit" contextRef="if922480499654c8fa72000e69a03bbe5_I20111231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfODg1MA_f722d776-da07-4a84-aa13-10b7ba59295b">one</ix:nonFraction> in Ontario filed December 2011 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), <ix:nonFraction unitRef="lawsuit" contextRef="i9ec7a80a2fc74972819c8c8d4ae943cb_I20120731" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfODk1Ng_96ed2e32-fa7a-4462-978a-bff927f9972e">one</ix:nonFraction> in Quebec filed July 2012 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Whyte et al. v. Eli Lilly et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), <ix:nonFraction unitRef="lawsuit" contextRef="ia2d0b9f9d00c4789a57ac22dffd8de57_I20171130" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfOTAyMQ_65d15133-7749-4bb9-bce0-27c727bf69c1">one</ix:nonFraction> in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Saskatchewan filed November 2017 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Weiler v. Takeda Canada Inc. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and <ix:nonFraction unitRef="lawsuit" contextRef="id492c2aa322440ef91df2d2864ae3436_I20130131" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfOTEwMw_0a5cae28-cfa9-43c7-9fbe-0fa736b2496e">one</ix:nonFraction> in Alberta filed January 2013 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Epp v. Takeda Canada Inc. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In general, plaintiffs in these actions alleged that Actos caused or contributed to their bladder cancer. An agreement to settle these actions became effective in May 2021, and the settlement claims administration process is ongoing. The lawsuits have been dismissed or discontinued.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Byetta&#174; Product Liability</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in approximately <ix:nonFraction unitRef="lawsuit" contextRef="i02631251065446e8b80c3ef3bde18d1e_I20210930" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfOTU2MA_c3075e80-f89f-4d67-8dda-f5d9ea8ec624">570</ix:nonFraction> Byetta product liability lawsuits in the U.S. which were initiated in March 2009 and involve approximately <ix:nonFraction unitRef="plaintiff" contextRef="id08a7fa5ef244fbdb2e5f2a1bf85908a_D20090301-20210930" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfOTYzMw_e1c7fb4d-358c-445d-8416-fcc6e5149a92">805</ix:nonFraction> plaintiffs. Approximately <ix:nonFraction unitRef="lawsuit" contextRef="i5a6d539b9e9b4a2e9a56aa47022fef97_I20210930" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfOTY2Mg_250676b7-f725-4c10-882b-5824b7a87148">55</ix:nonFraction> of these lawsuits, covering about <ix:nonFraction unitRef="plaintiff" contextRef="i57962c6f806042039b9a5e06a4c746f8_D20090301-20210930" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfOTY5OQ_e57a5551-47e6-43d4-aec4-a76fd7a152fb">285</ix:nonFraction> plaintiffs, are filed in California state court and coordinated in a Los Angeles Superior Court. Approximately <ix:nonFraction unitRef="lawsuit" contextRef="i5cebe969b12a4a35a83f8a3e3a6c1d34_I20210930" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfOTgxMw_ef37dffc-3110-48a0-a3bc-2f04633e1c50">515</ix:nonFraction> of the lawsuits, covering about <ix:nonFraction unitRef="plaintiff" contextRef="i6a303e3d333446bd9c148cdb72de62b9_D20090301-20210930" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfOTg0OA_1b2409ab-84a8-4514-844d-4513965b062b">515</ix:nonFraction> plaintiffs, are filed in federal court, the majority of which are coordinated in a multi-district litigation (MDL) in the U.S. District Court for the Southern District of California. <ix:nonFraction unitRef="lawsuit" contextRef="ie6b528e1289547a7a6c8125628509fe4_I20210930" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTAwMzQ_9a64edf0-7be5-482f-8dde-30106e7eebf7">Two</ix:nonFraction> lawsuits, representing approximately <ix:nonFraction unitRef="plaintiff" contextRef="i823025d06a794591a0b79f3627915cb6_D20090301-20210930" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTAwNzQ_fa1fd377-470e-414b-9602-9ce7730718ed">two</ix:nonFraction> plaintiffs, have also been filed in various state courts. Approximately <ix:nonFraction unitRef="lawsuit" contextRef="ide3640818e464610a65948e49215fb32_I20210930" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTAxNDk_0770b833-e545-4037-8234-e4653c297124">565</ix:nonFraction> of the lawsuits, involving approximately <ix:nonFraction unitRef="plaintiff" contextRef="iec6231ab796440cea08cae552c4f7aec_D20090301-20210930" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTAxOTM_3439b255-3030-4f26-b499-343128d17337">800</ix:nonFraction> plaintiffs, contain allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer); while <ix:nonFraction unitRef="plaintiff" contextRef="i4e401371e97c43e0b9c5ea15f0b54e42_D20090301-20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTAzNDM_9f5f3a2a-e72a-4eda-bed2-6836fabe8cc1">six</ix:nonFraction> plaintiffs allege Byetta caused or contributed to pancreatitis. In addition, <ix:nonFraction unitRef="plaintiff" contextRef="i7b351247f73c46c28ff4f882e37804b1_D20090301-20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTA0MjM_5934b226-9381-440a-abbe-ead339453207">one</ix:nonFraction> case alleges that Byetta caused or contributed to ampullary cancer. The federal and state trial courts granted summary judgment in favor of us and our co-defendants on the claims alleging pancreatic cancer. The plaintiffs appealed those rulings. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the U.S. Court of Appeals for the Ninth Circuit reversed the U.S. District Court for the Southern District of California's grant of summary judgment in the MDL based on that court's discovery rulings and remanded the cases back to the U.S. District Court for further proceedings. In March 2021, the U.S. District Court granted summary judgment for the defendants. In April 2021, the plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Ninth Circuit, but we have now been dismissed from that appeal. Certain plaintiffs have agreed to dismiss their lawsuits in exchange for a waiver of costs, and individual plaintiffs have begun dismissing their claims based upon this agreement. Approximately 160 of the MDL pancreatic lawsuits have been dismissed as of October 2021. In the state court actions, in November 2018, the California Court of Appeal reversed the Los Angeles County Superior Court of California&#8217;s grant of summary judgment based on that court's discovery rulings and remanded for further proceedings. In April 2021, the Los Angeles County Superior Court of California granted summary judgment for the defendants and the parties await entry of the order of judgment.   </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of approximately <ix:nonFraction unitRef="claimant" contextRef="i02631251065446e8b80c3ef3bde18d1e_I20210930" decimals="0" name="lly:LossContingencyNumberOfClaimants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTE2OTk_fbd3adfb-1d61-46a4-943b-7d2f9b9ccee5">20</ix:nonFraction> additional claimants who have not yet filed suit. These additional claims allege damages for pancreatic cancer or thyroid cancer.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i824dede0ac9b40b38043582aaa252dfc" continuedAt="i344868a2e9014d9dba85a69f5cce5543"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cialis Product Liability</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in approximately <ix:nonFraction unitRef="lawsuit" contextRef="id877b0b6a111490cbd371689fd76bb41_I20210930" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTE5MzQ_f0c188e5-952b-4354-aaff-c46bc0f5debf">350</ix:nonFraction> Cialis product liability lawsuits in the U.S. which were first initiated in August 2015. These cases, many of which were originally filed in various federal courts, contain allegations that Cialis caused or contributed to the plaintiffs' cancer (melanoma). In December 2016, the Judicial Panel on Multidistrict Litigation (JPML) granted the plaintiffs' petition to have filed cases and an unspecified number of future cases coordinated into a federal multidistrict litigation (MDL) in the U.S. District Court for the Northern District of California, alongside an existing coordinated proceeding involving Viagra&#174;. The JPML ordered the transfer of the existing cases to the now-renamed MDL </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In April 2020, the MDL court granted summary judgment to the defendants on all of the claims brought against them by the plaintiffs. In May 2020, plaintiffs filed an appeal in the U.S. Court of Appeals for the Ninth Circuit. The plaintiffs&#8217; appeal was administratively closed until August 2021 pending completion of a procedure to resolve the claims in this litigation. The court has entered an extension until February 2022 to finalize resolution of all claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Jardiance Product Liability </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in January 2019, we and Boehringer Ingelheim Pharmaceuticals, Inc., a subsidiary of BI, have been named as a defendant in approximately <ix:nonFraction unitRef="lawsuit" contextRef="i0974ec7e0d754316996a9ed48591b15f_I20210930" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTMyMzA_90d866dc-68bd-4235-8f87-62bc5e998da3">95</ix:nonFraction> product liability lawsuits in the U.S., mostly in Stamford Superior Court in Connecticut, alleging that Jardiance caused or contributed to plaintiffs&#8217; Fournier&#8217;s gangrene.  Our agreement with BI calls for BI to defend and indemnify us against any damages, costs, expenses, and certain other losses with respect to product liability claims in accordance with the terms of the agreement. All pending cases have been paused to allow for settlement negotiations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Proceedings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than <ix:nonFraction unitRef="site" contextRef="ic2caaa0461b646bfa03a4e4b72b0fd0c_I20210930" decimals="0" name="lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTM4NzQ_427293de-a345-42b3-96c1-b71f2439c166">10</ix:nonFraction> sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">340B Litigation and Investigations</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges the HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies. We seek a declaratory judgment that the defendants violated the Administrative Procedures Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. In March 2021, the court entered an order preliminarily enjoining the government&#8217;s enforcement of the administrative dispute resolution process against us. In May 2021, HRSA notified us that it determined that our  policy was contrary to the 340B statute. In response, in May 2021, we filed a motion for preliminary injunction and temporary restraining order requesting that the U.S. District Court for the Southern District of Indiana enjoin defendants from taking any action against us relating to the 340B drug pricing program until after the court issues a final judgment on the aforementioned litigation. In May 2021, the court denied our motion for a temporary restraining order but deferred resolution of our motion for preliminary injunction. In June 2021, the defendants withdrew the HHS December 30, 2020 advisory opinion. In July 2021, the court held oral argument on the parties&#8217; cross motions for summary judgment, the defendants&#8217; motion to dismiss, and our motion for preliminary injunction related to HRSA&#8217;s May 2021 enforcement letter. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administrative Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program. As described above, the U.S. District Court for the Southern District of Indiana has entered a preliminary injunction enjoining the government&#8217;s enforcement of this administrative dispute resolution process against us.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we, along with Sanofi-Aventis U.S., LLC (Sanofi), Novo Nordisk Inc. (Novo Nordisk), and AstraZeneca Pharmaceuticals LP, were named as a defendant in a purported class action lawsuit filed in the U.S. District Court for the Western District of New York by Mosaic Health, Inc. alleging antitrust and unjust enrichment claims related to the defendants' 340B distribution programs. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i344868a2e9014d9dba85a69f5cce5543" continuedAt="i7f87dd8d232f4717b6665bfba32679e4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a civil investigative subpoena in February 2021 from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program. We are cooperating with this subpoena. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Branchburg Manufacturing Facility </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received a subpoena from the United States Department of Justice requesting the production of certain documents relating to our manufacturing site in Branchburg, New Jersey. We are cooperating with the subpoena.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Brazil Litigation &#8211; Cosmopolis Facility </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Labor Attorney Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a lawsuit brought by the Labor Attorney for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the labor court judge ruled against Lilly Brasil, ordering it to undertake several actions of unspecified financial impact, including paying lifetime health coverage for the employees and contractors who worked at the Cosmopolis facility more than six months during the affected years and their children born during and after this period. We appealed this decision. In July 2018, the appeals court affirmed the labor court's ruling with a liquidated award of&#160;<ix:nonFraction unitRef="brl" contextRef="i4c05f03242a6456dbd827f3bfc73638e_D20180701-20180731" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTgyOTY_64850384-66d0-48ad-a837-0a69a3b3f7f5">300</ix:nonFraction>&#160;million&#160;Brazilian real (for moral damages, donation of equipment, and creation of a foundation) which, adjusted for inflation and interest using the current Central Bank of Brazil's special system of clearance and custody rate (SELIC), is approximately <ix:nonFraction unitRef="brl" contextRef="ib5389c2f3f2b4fecaa12712374100b27_D20210930-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTg1NDQ_4262cb8c-9fc8-426d-b604-8dbd7a67c7c0">950</ix:nonFraction>&#160;million Brazilian real (approximately $<ix:nonFraction unitRef="usd" contextRef="ib5389c2f3f2b4fecaa12712374100b27_D20210930-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfODc5NjA5MzA1MTY5Mg_e0fc94ae-255f-41c8-abdd-43a9269a8bad">175</ix:nonFraction>&#160;million as of September 30, 2021). The appeals court restricted the broad health coverage awarded by the labor court to health problems that claimants could show arose from exposure to the alleged contamination. In August 2019, Lilly Brasil filed an appeal to the superior labor court. In September 2019, the appeals court stayed a number of elements of its prior decision, including the obligation to provide health coverage for contractors, their children, and children of employees who worked at the Cosmopolis facility, pending the determination of Lilly Brasil&#8217;s appeal to the superior labor court. The cost of any such health coverage has not been determined. In June 2021, the appeals court published its decision on the admissibility of Lilly Brasil&#8217;s appeal, admitting the majority of the elements of the appeal to proceed; elements not proceeding are subject to an interlocutory appeal to the appeals court filed in June 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Labor Attorney filed an application in the labor court for enforcement of the healthcare coverage granted by the appeals court in its July 2018 ruling and requested restrictions on Lilly Brasil&#8217;s assets in Brazil. In July 2019, the labor court issued a ruling requiring either a freeze of Lilly Brasil&#8217;s immovable property or, alternatively, a security deposit or lien of <ix:nonFraction unitRef="brl" contextRef="ic5db0916c42c432ab0d7c4f60ea69486_D20190701-20190731" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTk4OTQ_7d83f542-f817-4251-939d-a34b982f09c5">500</ix:nonFraction> million Brazilian real. Lilly Brasil filed a writ of mandamus challenging this ruling</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> but the court has stayed its decision on this writ and instead directed the parties to attend conciliation hearings, a process that concluded unsuccessfully in September 2020. Consequently, the partial stay of the proceedings relating to Lilly Brasil's application to appeal in the main proceedings has been lifted and in June 2021, the court reduced the security deposit or lien to <ix:nonFraction unitRef="brl" contextRef="i0b7f344f3e4a4d4489bf483eb893bcbc_D20210601-20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMjAzNTk_6b0efc85-7a20-4ff2-bce4-83188c2e33e8">100</ix:nonFraction>&#160;million Brazilian real from the <ix:nonFraction unitRef="brl" contextRef="ic5db0916c42c432ab0d7c4f60ea69486_D20190701-20190731" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMjAzODY_356d98c5-41d5-418b-850a-38ecf0088cd6">500</ix:nonFraction>&#160;million Brazilian real referred to above</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Labor Attorney's application for preliminary enforcement of the July 2018 healthcare coverage ruling was granted. As the conciliation hearings have been unsuccessful, we have filed a brief to strike the Labor Attorney&#8217;s application to enforce the previous healthcare coverage. Lilly Brasil is currently awaiting a determination as to whether its application seeking leave to appeal to the superior labor court has been successful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Individual Former Employee Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also named in approximately <ix:nonFraction unitRef="lawsuit" contextRef="i3fa1d97abf9842288bcab6b2233d933e_I20210930" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMjA5NDQ_49456823-c18c-404a-a3b9-2621e4046b3f">30</ix:nonFraction>&#160;lawsuits filed in the same labor court by individual former employees making similar claims. These lawsuits are each at various stages in the litigation process, with judgments being handed down in approximately half of the lawsuits, nearly all of which are on appeal in the labor courts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">China NDRC Antitrust Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The competition authority in China has investigated our distributor pricing practices in China in connection with a broader inquiry into pharmaceutical industry pricing. We have cooperated with this investigation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Eastern District of Pennsylvania Pricing (Average Manufacturer Price) Inquiry</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2014, we, along with another pharmaceutical manufacturer, were named as co-defendants in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. Trial is scheduled for April 2022.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7f87dd8d232f4717b6665bfba32679e4" continuedAt="i7b013d058196456796e09c857eb11d8d"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Health Choice Alliance </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in a lawsuit filed in June 2017 in the U.S. District Court for the Eastern District of Texas seeking damages under the federal anti-kickback statute and state and federal false claims acts for certain patient support programs related to our products Humalog, Humulin, and Forteo. In September 2019, the U.S. District Court granted the U.S. Department of Justice&#8217;s motion to dismiss the relator&#8217;s second amended complaint. In January 2020, the relator appealed the District Court&#8217;s dismissal to the U.S. Court of Appeals for the Fifth Circuit. In July 2021, the U.S. Court of Appeals for the Fifth Circuit affirmed the dismissal of the lawsuit.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also named as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="i67de38ae9b6847fc8362e05564887711_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMjI4MTE_64ee885e-8fba-4f20-add9-deecd9a1669c">two</ix:nonFraction> similar lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively. In November 2020, the Texas state court action was stayed pending a final determination with respect to the aforementioned federal lawsuit. In April 2021, the New Jersey state court action was dismissed with prejudice and in June 2021, the relator filed a notice of appeal to the Appellate Division of the New Jersey Superior Court, appealing the state court&#8217;s decision.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pricing Litigation, Investigations, and Inquiries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we, along with Sanofi and Novo Nordisk were named as defendants in a consolidated purported class action lawsuit,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re. Insulin Pricing Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the U.S. District Court for the District of New Jersey relating to insulin pricing seeking damages under various state consumer protection laws and the Federal Racketeer Influenced and Corrupt Organization Act (federal RICO Act). Separately, in February 2018, we, along with Sanofi and Novo Nordisk, were named as defendants in&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the same court, seeking damages under various state consumer protection laws, common law fraud, unjust enrichment, and the federal RICO Act. In both</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re. Insulin Pricing Litigation </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> MSP Recovery Claims</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> litigation, the court dismissed claims under the federal RICO Act and certain state laws. In April 2021, the plaintiffs in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re. Insulin Pricing Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> amended their complaint to allege additional state law claims for civil conspiracy and violations of state RICO statutes.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, we, along with Sanofi, Novo Nordisk, CVS, Express Scripts, and Optum, have been sued in a purported class action, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al., </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filed in the same court in November 2020, for alleged violations of the federal RICO Act as well as the New Jersey RICO Act and antitrust law. That same group of defendants, along with Medco Health and United Health Group, also have been sued in other purported class actions in the same court, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Value Drug Co. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">both initiated in March 2020, for alleged violations of the federal RICO Act. In September 2020, the U.S. District Court for the District of New Jersey granted plaintiffs&#8217; motion to consolidate </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Value Drug Co. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the U.S. District Court for the District of New Jersey dismissed the <ix:nonFraction unitRef="claim" contextRef="i2330339854444106911984ac8d431494_D20210701-20210731" decimals="INF" format="ixt-sec:numwordsen" name="lly:LitigationClaimsDismissedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMjU1NTM_67db22f0-917a-46e9-970c-fd8f1dd32233">three</ix:nonFraction> antitrust claims alleged by plaintiffs in the consolidated litigation and denied dismissal of the RICO claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Minnesota Attorney General&#8217;s Office initiated litigation against us, Sanofi, and Novo Nordisk,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of Minnesota v. Sanofi-Aventis U.S. LLC et al.,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the U.S. District Court for the District of New Jersey, alleging unjust enrichment, violations of various Minnesota state consumer protection laws, and the federal RICO Act. In March 2021, the U.S. District Court for the District of New Jersey dismissed with prejudice the Minnesota Attorney General&#8217;s federal RICO claims and false advertising claims under state law; the consumer fraud and other related state law claims remain ongoing. Additionally, in May 2019, the Kentucky Attorney General&#8217;s Office filed a complaint against us, Sanofi, and Novo Nordisk,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commonwealth of Kentucky v. Novo Nordisk, Inc. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Kentucky state court, alleging violations of the Kentucky consumer protection law, false advertising, and unjust enrichment. In November 2019, Harris County in Texas initiated litigation against us, Sanofi, Novo Nordisk, Express Scripts, CVS, Optum, and Aetna, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">County of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Harris Texas v. Eli Lilly &amp; Co., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in federal court in the Southern District of Texas alleging violations of the federal RICO Act, the state deceptive trade practices-consumer protection act, and common law claims such as fraud, unjust enrichment, and civil conspiracy. Harris County also alleged violations of federal and state antitrust law, but voluntarily dismissed them. This lawsuit relates to our insulin products as well as Trulicity. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the City of Miami, Florida initiated litigation against us, Sanofi, Novo Nordisk, ESI, CVS/Caremark/Aetna, and Optum, asserting state law antitrust, common law fraud, money had and received, unjust enrichment, and civil conspiracy claims. In June 2021, the Mississippi Attorney General&#8217;s Office initiated litigation against us, Sanofi, Novo Nordisk, Evernorth/ESI, CVS/Caremark, and United/Optum in the Hinds County, Mississippi Chancery Court, alleging state law consumer protection, unjust enrichment, and civil conspiracy claims.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7b013d058196456796e09c857eb11d8d" continuedAt="id50b2001774649868bb16f50fe9e7ab4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigations, Subpoenas, and Inquiries</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a subpoena from the New York a</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd Vermont Attorney General Offices and civil investigative demands from the Washington, New Mexico, and Colorado Attorney General Offices relating to the pricing and sale of our insulin products. The Offices of the Attorney General in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada have requested information relating to the pricing and sale of our insulin products. We also received interrogatories and a subpoena from the California Attorney General's Office regarding our competition in the long-acting insulin market, which was subsequently withdrawn in June 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a&#8239;request in January 2019 from the House of Representatives&#8217; Committee on Oversight and Reform seeking commercial information and business records related to the pricing of insulin products, among other issues. We also received requests from the Senate Finance Committee and the Senate Committee on Health, Education, Labor, and Pensions, and separate requests from the House Committee on Energy and Commerce majority and minority members.&#8239; Those requests sought pricing and other commercial information regarding Lilly&#8217;s insulin products. In January 2021, the Senate Finance Committee released a report summarizing the findings of its investigation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are cooperating with all of these aforementioned investigations, subpoenas, and inquiries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Research Corporation Technologies, Inc. </span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id50b2001774649868bb16f50fe9e7ab4">In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin.</ix:continuation> Both parties moved for summary judgment and a hearing on the motions took place in August 2021. In October 2021, the Court issued a summary judgment decision finding in favor of RCT on certain issues, including with respect to a disputed royalty. Potential damages payable under the litigation, if finally awarded after an appeal, could be material but are not currently reasonably estimable. We intend to appeal the summary judgment decision and related findings. A trial date has not been set.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i48af34e12713400c858f7a29183e5680_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10: <ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RleHRyZWdpb246ZTZhYmQyYzIxYjVhNDE0YWExYTA4MGI1NTAzN2ExYjNfMTI0MQ_5cb13fb3-3598-477f-8b16-70984c0fab06" continuedAt="ic456ada54c2340ff8010143378d4c313" escape="true">Other Comprehensive Income (Loss)</ix:nonNumeric></span></div><ix:continuation id="ic456ada54c2340ff8010143378d4c313" continuedAt="id498c179aa994531a39949ab28d56302"><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RleHRyZWdpb246ZTZhYmQyYzIxYjVhNDE0YWExYTA4MGI1NTAzN2ExYjNfMTI1OQ_e5cd7595-aced-4c82-ad3c-9a5226a985d8" continuedAt="i0f07fb31223946b78a6117381a898d90" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended September&#160;30, 2021 and 2020:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at July 1, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibeb5ba7c9ba14c15ba0052fa193204e3_I20210630" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfMi0xLTEtMS0x_bc82db66-ddf0-4f1d-b2c5-49a808a51551">1,516.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55fb2a4e7d5a40df8b249f3933bb08b6_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfMi0zLTEtMS0x_16dff8d1-7270-4307-ad51-9f4b898e38bf">9.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dd2692507f4266b4a6a0fbf0fee907_I20210630" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfMi01LTEtMS0x_56d79f14-543e-454e-860f-85c1a08b0e1d">4,569.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic193e7bc5e094826be326aee4fe41f2e_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfMi03LTEtMS0x_bdebd0f0-a793-43d1-a952-c21aadd58432">210.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc4a62ea3c3045fcb1975315d8b1874c_I20210630" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfMi0xMS0xLTEtMQ_57f72c12-8533-4296-b7bf-e4eb5c13cddb">6,287.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdb47e6e63294d44a8f97f9e50e54a83_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNC0xLTEtMS0x_c3c342cc-f7fa-494b-a99b-9eedf3ed9fdc">8.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75e7048b106947fda1b1b5e4eabdc0fc_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNC0zLTEtMS0x_e2986626-e4cb-42c7-89c1-8253486aa1e3">2.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b8f930c8cb4479ac83208582a7d734_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNC01LTEtMS0x_d5bbe636-ec5a-408c-b2bd-4e0d3de45517">18.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcde9e91e224331bee5a8adc7892978_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNC03LTEtMS0x_bff91be6-b66d-4b2c-a1cc-3a264c61fd81">16.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNC0xMS0xLTEtMQ_8d1d1e22-7d33-4062-91bf-a5e0c8e6ca47">25.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb47e6e63294d44a8f97f9e50e54a83_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNS0xLTEtMS0x_1dedbe8b-70f1-4fed-9cb4-ac1a2333a377">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e7048b106947fda1b1b5e4eabdc0fc_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNS0zLTEtMS0x_c84d0f3d-832a-46a2-a87d-4f69bcdaa200">0.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b8f930c8cb4479ac83208582a7d734_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNS01LTEtMS0x_4a51c01a-2541-4544-b18b-856782924751">86.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcde9e91e224331bee5a8adc7892978_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNS03LTEtMS0x_4418e64e-66e7-4983-8302-22a03e527d04">3.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNS0xMS0xLTEtMQ_97841230-9183-4522-bc0d-9eb83b4d91dc">89.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdb47e6e63294d44a8f97f9e50e54a83_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNi0xLTEtMS0x_87eecd91-982c-4a82-9a7c-4be38637430d">8.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75e7048b106947fda1b1b5e4eabdc0fc_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNi0zLTEtMS0x_c10d91cd-570d-43ca-b293-e24986c038b0">2.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b8f930c8cb4479ac83208582a7d734_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNi01LTEtMS0x_a8cd0474-2469-4865-936a-3b87cf55db02">104.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcde9e91e224331bee5a8adc7892978_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNi03LTEtMS0x_adec5957-b47f-4ef2-80c5-43905274c7ff">20.1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNi0xMS0xLTEtMQ_cbb6ea19-21e6-4d35-853b-7bb5851dc2c0">114.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6bf89817cf74679b6916eddd60558c9_I20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfOC0xLTEtMS0x_424b82ce-edb4-4ade-a36e-9a20cca3b490">1,524.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2e85aa71f446bdbb141da8010fbe3d_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfOC0zLTEtMS0x_96528146-5dfa-4bed-b134-ab9616293625">6.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic375cded995a4df69d3eae9edc6766c7_I20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfOC01LTEtMS0x_a5e9a54b-7210-49f5-afef-43bce483f8b1">4,465.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d2760fb44974a73a735787c71ae8f1a_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfOC03LTEtMS0x_87532302-1214-4879-aae3-00c72ba1e0a0">190.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b11f523dfe64ce792a038f20fbc68b5_I20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfOC0xMS0xLTEtMQ_01600922-26f9-4d08-8bcc-6bee5083d41c">6,172.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at July 1, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a35afc361544badb9c16d04e8aad497_I20200630" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfMi0xLTEtMS0x_3a334729-0907-4c53-bbb4-585e6da67b47">1,722.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i717939ea3d4e4bb3b1b65e0a974da3c2_I20200630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfMi0zLTEtMS0x_d98b659d-4a61-4408-be3c-9487ae930beb">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37fc3dd032964801aa1348f510cb122b_I20200630" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfMi01LTEtMS0x_4f3a428c-1306-4143-a64d-bfc4d67c9cfc">4,454.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bee3c9d23994e78baa2eba95869bd9b_I20200630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfMi03LTEtMS0x_db656229-47c2-4d1d-acb8-5955cb04e124">520.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1106ce810ad4da5852f6b633b316eee_I20200630" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfMi0xMS0xLTEtMQ_3771fb33-6336-45af-9da7-e2850b7fcfe4">6,682.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dc5691b17b74c35ad24aafdbf59f3fe_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNC0xLTEtMS0x_af343cd7-56fb-4a7f-bf70-9472e2e95ce0">30.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3759b3a7e2f43dcb3def496f0e66523_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNC0zLTEtMS0x_d9af46f3-4b3b-4b77-8f17-b1a41ae1e0a6">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b09b2d2f1f840c7ae5d5461b2c17a11_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNC01LTEtMS0x_ae122a7a-4ac3-4ebc-ab06-034904ab001f">19.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbffb928c8ef4db9847f4474b9b3c4f7_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNC03LTEtMS0x_8ab64a08-841d-4ea5-b2ad-aa0473244596">82.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNC0xMS0xLTEtMQ_556f6614-6171-4841-81ee-7785658a30db">94.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dc5691b17b74c35ad24aafdbf59f3fe_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNS0xLTEtMS0x_1fbd7b32-2744-4134-98d4-285698521e0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3759b3a7e2f43dcb3def496f0e66523_D20200701-20200930" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNS0zLTEtMS0x_e7e577a7-b3a2-4cec-b0aa-a8dd46f32444">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b09b2d2f1f840c7ae5d5461b2c17a11_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNS01LTEtMS0x_478b17d7-8a70-4e20-953f-6e24d4366af0">30.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbffb928c8ef4db9847f4474b9b3c4f7_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNS03LTEtMS0x_eeb1e19d-fbbf-430a-8332-4d4d6812f231">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNS0xMS0xLTEtMQ_ffc4c76b-2c1d-4387-a913-52af2eb06c62">33.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dc5691b17b74c35ad24aafdbf59f3fe_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNi0xLTEtMS0x_526540b0-ca9d-4206-8971-c131009d4b45">30.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3759b3a7e2f43dcb3def496f0e66523_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNi0zLTEtMS0x_a628088b-4168-4394-917c-9d4d70001a48">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b09b2d2f1f840c7ae5d5461b2c17a11_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNi01LTEtMS0x_9076d29e-7ea2-4631-b626-b540769fdf27">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbffb928c8ef4db9847f4474b9b3c4f7_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNi03LTEtMS0x_b0409580-ff2e-41dd-a6b3-1bd626b8e96a">86.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNi0xMS0xLTEtMQ_ab8e7a4b-db27-4192-b8f4-23728e192df0">127.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i749e85ac79ee42a29981a1a54fe12f89_I20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfOC0xLTEtMS0x_c47ae6da-0c66-44d7-b5b1-3e60bdc9ac2b">1,692.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e49dd86e464c6b8eb00c81c2ba5106_I20200930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfOC0zLTEtMS0x_209bfee5-184b-42f5-903d-429144364cd8">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28164fe940424f16b215cb55adf86237_I20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfOC01LTEtMS0x_90776d92-56fe-4183-8216-966c45bf95e7">4,444.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95f3c6593b4b487dae8900c3ac61ac05_I20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfOC03LTEtMS0x_181ac25d-ea79-4ec4-9cdf-332132d07138">434.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92bb29baa2584750986eee75a3d6e4ce_I20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfOC0xMS0xLTEtMQ_87b883de-d858-497c-a39d-63c2831d769a">6,555.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the activity related to each component of other comprehensive income (loss) during the nine months ended September&#160;30, 2021 and 2020: </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:37.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.610%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id65902a544ed43ceb02d93ffc0a552e7_I20201231" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfMS0xLTEtMS0x_9b735024-ed27-416f-b212-ee6d676421ad">1,427.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a29af9f964348b0945d6e3a688d0920_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfMS0zLTEtMS0x_52c493e6-a0a2-4b62-9869-277d91a0d597">14.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id528bf4c135048229335007002573a24_I20201231" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfMS01LTEtMS0x_9d94d35e-94a9-4bf5-8330-142c11107b71">4,751.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1814bfd7e734e99af54e8b90a4f5ba1_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfMS03LTEtMS0x_ca0837b8-266d-4535-bd64-6cbccd83619b">332.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic30630769098404a82485baedba6de39_I20201231" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfMS05LTEtMS0x_e1fd0f79-fd77-4e40-b363-631ee8355a0a">6,496.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343f9384f69a4fbea834e4b74393c357_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfMy0xLTEtMS0x_d0f72129-c031-446d-a569-dbb2c8abaa0f">96.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55f74de7b4534040af7ed40631285711_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfMy0zLTEtMS0x_f97de92f-0724-4621-9c45-04dd1fd3a633">8.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42d644c1be1b47929fd7f33b4aa7934f_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfMy01LTEtMS0x_516c9c2b-8ae9-4e99-ac37-91fc95cb53c4">27.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7a26b32e694ddf89ed67424b0f6153_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfMy03LTEtMS0x_05cad9f1-1d16-41e0-8d79-487287a234ed">132.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfMy05LTEtMS0x_029f2d11-a516-456c-906d-ef407e41392b">54.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343f9384f69a4fbea834e4b74393c357_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNC0xLTEtMS0x_c362c8f9-12fb-41f4-a01f-28373fcbd00f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55f74de7b4534040af7ed40631285711_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNC0zLTEtMS0x_ae7f02dd-2f2b-4dea-b6a8-6bd28fc64c1a">0.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42d644c1be1b47929fd7f33b4aa7934f_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNC01LTEtMS0x_e7e9bc60-d018-4f10-b6d3-89e953f721b9">258.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7a26b32e694ddf89ed67424b0f6153_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNC03LTEtMS0x_4560a933-70f8-4c28-9bf8-0f77c49a209e">9.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNC05LTEtMS0x_71ea9410-0220-45c5-85d2-a10e9432c2cc">269.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343f9384f69a4fbea834e4b74393c357_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNS0xLTEtMS0x_472c6449-aa0a-440d-9237-3f80da4385fa">96.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55f74de7b4534040af7ed40631285711_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNS0zLTEtMS0x_d029409f-f751-44a2-bc06-5535026e333f">8.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42d644c1be1b47929fd7f33b4aa7934f_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNS01LTEtMS0x_35a3730c-1835-46df-b425-2ffe5db41e3d">285.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7a26b32e694ddf89ed67424b0f6153_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNS03LTEtMS0x_4583179b-e41f-43c8-a65c-3a79f7157f2e">142.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNS05LTEtMS0x_b7226736-911a-4f66-9cc8-1284b33dfe01">323.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6bf89817cf74679b6916eddd60558c9_I20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNy0xLTEtMS0x_80696c50-6683-435c-b281-9a04beb8372b">1,524.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2e85aa71f446bdbb141da8010fbe3d_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNy0zLTEtMS0x_aadb9bea-da60-4739-97aa-56e400145022">6.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic375cded995a4df69d3eae9edc6766c7_I20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNy01LTEtMS0x_1ba3dc94-1128-4b82-9866-b35ef8661ef3">4,465.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d2760fb44974a73a735787c71ae8f1a_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNy03LTEtMS0x_83e25b2e-59c9-4dd4-9e72-03b372bee538">190.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b11f523dfe64ce792a038f20fbc68b5_I20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNy05LTEtMS0x_076b82dc-8f16-4705-bef9-5e65574147d1">6,172.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"><tr><td style="width:1.0%"></td><td style="width:38.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.457%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d711cf47db44ea8a7769cdcc03215c2_I20191231" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfMS0xLTEtMS0x_979e7d64-79bd-4532-86cd-557b1fbfdf77">1,678.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1398a4cb6b3b4f82aaf46f5f2990e359_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfMS0zLTEtMS0x_776ad6fe-d440-409e-8444-11d041dcebfa">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b2773f7cce247f2b474587bc25ee417_I20191231" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfMS01LTEtMS0x_a7b518dc-0189-4dbe-8e1b-1d2f64a124d7">4,638.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11592af1b8584d8e941ac285b2b9ff5f_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfMS03LTEtMS0x_849377d2-1ca2-471d-8ba0-c4eb62fcb928">211.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if60b5c4e32da4c9aaf3a96926acf3f56_I20191231" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfMS05LTEtMS0x_70caa9c0-2837-4af1-8712-80ed19480c15">6,523.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f358682845c429a9e682d2659872229_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfMy0xLTEtMS0x_2474e5bb-28ef-4a7f-b8d3-64a148f64c06">14.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8c50c7162047369d212f2103eba93f_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfMy0zLTEtMS0x_723675e8-3189-4bd7-bcb3-8d5f870490a0">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia57652e4c70f423c8b2fd6f637a90a05_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfMy01LTEtMS0x_75d07e2f-a7c8-4f17-9b9b-877fb3122efb">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib297cf9f9edb4c749f2a81b2e539ced2_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfMy03LTEtMS0x_5d879d3a-827a-4f35-afc5-0f4a8e1b491a">232.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfMy05LTEtMS0x_1916fbb9-8a59-407b-8733-f4dcca4afa76">234.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f358682845c429a9e682d2659872229_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNC0xLTEtMS0x_02d94fee-b549-4887-aa42-18d4dfc6250d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8c50c7162047369d212f2103eba93f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNC0zLTEtMS0x_2b08f677-1200-4c3a-8bff-15e2594ff7cf">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia57652e4c70f423c8b2fd6f637a90a05_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNC01LTEtMS0x_fb02626f-7e14-4066-94fb-ab0c52fbedb9">189.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib297cf9f9edb4c749f2a81b2e539ced2_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNC03LTEtMS0x_f2afb616-21ef-4453-b591-16b10aba64c8">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNC05LTEtMS0x_d7f66a9a-8511-40c6-b853-1b4ac4a5ce02">202.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f358682845c429a9e682d2659872229_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNS0xLTEtMS0x_4f80a304-1055-4dbb-bf35-0ac3b9b59e61">14.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8c50c7162047369d212f2103eba93f_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNS0zLTEtMS0x_f74afc4c-a609-4029-aef4-cb9d08be8d36">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia57652e4c70f423c8b2fd6f637a90a05_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNS01LTEtMS0x_5f949dd6-75e7-4dbc-a558-4695f0f3dcae">194.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib297cf9f9edb4c749f2a81b2e539ced2_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNS03LTEtMS0x_125fcf60-dc3c-4408-908d-c58cc02a5523">222.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNS05LTEtMS0x_63eb3c32-c51e-4ed2-b807-bc1635508dda">31.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i749e85ac79ee42a29981a1a54fe12f89_I20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNy0xLTEtMS0x_33f7f16b-926a-4986-b8c8-34493f599c7f">1,692.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e49dd86e464c6b8eb00c81c2ba5106_I20200930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNy0zLTEtMS0x_ab208e75-ded4-4b7e-abc1-4112b1304735">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28164fe940424f16b215cb55adf86237_I20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNy01LTEtMS0x_64327bf8-3879-4cc4-86e1-f6c1a38234a6">4,444.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95f3c6593b4b487dae8900c3ac61ac05_I20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNy03LTEtMS0x_3889d7a1-8e48-4097-b080-461356e86dab">434.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92bb29baa2584750986eee75a3d6e4ce_I20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNy05LTEtMS0x_771d334b-3928-4aa2-8e4d-aca68698d4ae">6,555.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt"><span><br/></span></div><ix:continuation id="id498c179aa994531a39949ab28d56302"><ix:continuation id="i0f07fb31223946b78a6117381a898d90"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense) </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdb47e6e63294d44a8f97f9e50e54a83_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfMi0xLTEtMS0x_232db922-502a-4573-b111-e325a95fd032">39.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dc5691b17b74c35ad24aafdbf59f3fe_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfMi0zLTEtMS0x_bc7c4185-2620-4934-af09-8e3f06c661b6">46.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i343f9384f69a4fbea834e4b74393c357_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfMi01LTEtMS0x_95a71e86-c7e4-428f-acf2-354dec50106e">92.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f358682845c429a9e682d2659872229_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfMi03LTEtMS0x_db4b2ac6-962c-47df-a15d-aacfdc9f2f53">34.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized net gains/losses on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e7048b106947fda1b1b5e4eabdc0fc_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfMy0xLTEtMS0x_2dda60f3-7312-45b1-bd6d-d7754a2cfeaf">0.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3759b3a7e2f43dcb3def496f0e66523_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfMy0zLTEtMS0x_cbab30d5-e4a2-4516-8cd8-a022e49dcfc7">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55f74de7b4534040af7ed40631285711_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfMy01LTEtMS0x_af62592b-7872-46c0-9a65-73c8f59e02c1">3.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd8c50c7162047369d212f2103eba93f_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfMy03LTEtMS0x_121e090b-aa11-491b-bf5c-4cca6f9e7791">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4b8f930c8cb4479ac83208582a7d734_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNC0xLTEtMS0x_d4cf792b-0047-4a9f-9211-56361103e845">28.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b09b2d2f1f840c7ae5d5461b2c17a11_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNC0zLTEtMS0x_036b5f89-f89e-4fc1-bdbf-f0bc35811532">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42d644c1be1b47929fd7f33b4aa7934f_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNC01LTEtMS0x_bd73ceb2-0c6c-4ac0-a978-0599ef8fb87c">79.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia57652e4c70f423c8b2fd6f637a90a05_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNC03LTEtMS0x_8bc262b6-91df-4507-b17e-2041cc1d159e">32.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22630c35f56443229b86ee022e4155d1_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNS0xLTEtMS0x_7ed68ed3-b1aa-40b4-a78c-3422fc1a8174">5.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b485bf17c5749a699e26a1df2e648da_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNS0zLTEtMS0x_5c45e8b1-dd0b-402e-b44d-a53beec8af32">22.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ff88e97ce21499da1d1b1bdb8a2824f_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNS01LTEtMS0x_ae7cf025-c511-44c1-a253-67c574363b90">37.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57b47926a4847e78d8dcd2326b16c65_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNS03LTEtMS0x_c853b8af-7509-4733-b673-2e2432fe3772">59.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNi0xLTEtMS0x_142a2e0b-be00-44b3-b771-a1dc37e2f55e">71.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNi0zLTEtMS0x_9f3fd565-9860-4ccb-b0b9-33d64a8ed781">34.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNi01LTEtMS0x_3651aa0b-540f-4b03-bd80-2b69cfbb63d6">206.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNi03LTEtMS0x_9a4c9e3e-9460-4c77-8bd8-53bcd86529ae">58.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 6), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated condensed statements of operations.</span></div><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RleHRyZWdpb246ZTZhYmQyYzIxYjVhNDE0YWExYTA4MGI1NTAzN2ExYjNfMTI1NQ_98266f8d-d636-45c6-b9cf-868d90bfdf1f" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-bottom:1pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.532%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other Comprehensive Loss Components</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Condensed Statements of Operations</span></td></tr><tr style="height:11pt"><td colspan="30" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dbc75b54c4a4c39a56bbd8e3006acba_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNC0yLTEtMS0x_c1169f81-4864-4629-a39d-0c2f639894c6">13.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i412a43d01f8c4978b95b1d9b22b6028e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNC00LTEtMS0x_e5b4f9e2-9017-49f5-9a3f-dc717f645309">20.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ed2c03cd8446b992f8ed65b4226a3e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNC02LTEtMS0x_55de871f-9dd4-486d-8d7c-1a4d33030751">41.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia29720c84e08498b8a3c6e661a3fe7bd_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNC04LTEtMS0x_bdf8e188-4288-433f-8277-bfe0bda72e8f">48.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15dc1b0ac6eb41bab90c9964ded2067d_D20210701-20210930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNS0yLTEtMS0x_81739f40-ada2-4bce-9917-718e31f083ae">122.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ecbb90470a94e7780adb982e83ad4eb_D20200701-20200930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNS00LTEtMS0x_3d00776d-cb2c-4283-9611-612148fdf713">59.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c3769918b9d406e90beab010e76b7de_D20210101-20210930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNS02LTEtMS0x_bfdccb59-7481-472f-a569-13febb08ca3b">368.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3be6ddfb286c465fa67388157f156b71_D20200101-20200930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNS04LTEtMS0x_8f13bfc7-b788-4b5f-9390-ea16e1442680">288.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b999b38b45f48d6b4eacb839d5ae8ef_D20210701-20210930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNi0yLTEtMS0x_1e10b9e2-ab6b-48c6-9701-4cf7162a0f6d">108.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e909ad38be242f4935ee1c7e0dfc3c7_D20200701-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNi00LTEtMS0x_bb5cb8ea-c940-4008-8164-7eb485cbb784">38.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf900552e5704e3b83f6dd3f56cfb8b1_D20210101-20210930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNi02LTEtMS0x_64e9d6de-1443-4a80-8789-0286ad05d77f">327.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc20efde344e4966b2390b23bdfad980_D20200101-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNi04LTEtMS0x_5e231d70-b933-41ea-b9a2-a36baf4ed6d6">240.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b999b38b45f48d6b4eacb839d5ae8ef_D20210701-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNy0yLTEtMS0x_7c99322d-55d1-4c42-a11c-971027677235">22.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e909ad38be242f4935ee1c7e0dfc3c7_D20200701-20200930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNy00LTEtMS0x_2a6d8ee2-2685-4c14-90a3-7cce1b5a8b86">8.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf900552e5704e3b83f6dd3f56cfb8b1_D20210101-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNy02LTEtMS0x_70016eba-1893-421e-a5da-b9b39d4d354b">68.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc20efde344e4966b2390b23bdfad980_D20200101-20200930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNy04LTEtMS0x_d9f24fc9-a347-4d0f-ac01-58cc46785772">50.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b999b38b45f48d6b4eacb839d5ae8ef_D20210701-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfOC0yLTEtMS0x_4922d58d-33c9-4d44-9e95-5bc8cecdde7b">86.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e909ad38be242f4935ee1c7e0dfc3c7_D20200701-20200930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfOC00LTEtMS0x_a288d8fe-af2f-4006-a6e3-bd04329fb297">30.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf900552e5704e3b83f6dd3f56cfb8b1_D20210101-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfOC02LTEtMS0x_0ca74d28-6e8b-4153-84d1-8f820bdf3ced">258.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc20efde344e4966b2390b23bdfad980_D20200101-20200930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfOC04LTEtMS0x_03c85923-6d6a-4c58-b962-fa260bd3ea30">189.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i846634e73e214b8b9dde808125858a45_D20210701-20210930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfMTAtMi0xLTEtMQ_994eedaf-2ae8-43fe-8013-6df851af3980">3.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed88205905a4275ba8c331b5dbd8547_D20200701-20200930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfMTAtNC0xLTEtMQ_69183b46-5510-4f21-a06b-5aacc92a8613">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaec30f04bf644fea6c5f2229258f4b8_D20210101-20210930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfMTAtNi0xLTEtMQ_5452179a-71e4-44cf-8397-23ea1153a25f">10.7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129d769168bb4388b55fa2891a6051bc_D20200101-20200930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfMTAtOC0xLTEtMQ_31887db6-ecef-4c63-bb7b-972cd4129d3f">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9611b430044e49a384caf7309cee05ff_D20210701-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfMTItMi0xLTEtMQ_2e13cce3-b65d-4b35-b59e-0dcf6f813a8e">89.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d84b8a802d54abdb0af6d412798b456_D20200701-20200930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfMTItNC0xLTEtMQ_1db15d88-c5c3-4c8f-b441-77dc6217c361">33.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e9e954fc084405785c8bdfb174f2726_D20210101-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfMTItNi0xLTEtMQ_455b6925-0f60-4fd0-a225-48bb8b12a2d0">269.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99b24dcf85424c689a8236968bfe8b4d_D20200101-20200930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfMTItOC0xLTEtMQ_c7470ca3-4d67-4e1f-a7e4-7f75bbfe6b7a">202.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i48af34e12713400c858f7a29183e5680_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11: <ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RleHRyZWdpb246YTkxYmY0ZTA5NjM5NDdiYzk0NDU4ZTZhODVmYmM0ZmZfMTAx_8cfecba8-6799-403d-87c9-52dd3b58d769" continuedAt="ibfc8b33017cd4e14978ef913168ad725" escape="true">Other&#8211;Net, (Income) Expense</ix:nonNumeric></span></div><ix:continuation id="ibfc8b33017cd4e14978ef913168ad725"><ix:nonNumeric contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RleHRyZWdpb246YTkxYmY0ZTA5NjM5NDdiYzk0NDU4ZTZhODVmYmM0ZmZfMTE1_88ecc9db-23da-4963-b77a-ff7b7b77a4c0" escape="true"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense consisted of the following:</span></div><div style="margin-bottom:7pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.116%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfMi0xLTEtMS0x_a4516220-3b3e-49c2-8226-fb935850581d">83.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfMi0zLTEtMS0x_4f421098-df74-49fb-8cd2-5aa9d50b42c7">89.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfMi01LTEtMS0x_9e611f64-6a83-458d-ae29-67f1b003d1e3">258.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfMi03LTEtMS0x_1764fb86-f729-4101-b07c-ceb608f6c624">270.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfMy0xLTEtMS0x_278fdc92-3b2b-45da-b9ec-76355df9a9a3">7.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfMy0zLTEtMS0x_ffea9cc5-5e57-4c84-aef4-5832097e6258">5.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfMy01LTEtMS0x_d9951f22-324f-4333-8235-9e2eb10036cf">18.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfMy03LTEtMS0x_a864eb38-faa2-48d6-968c-20e128832c13">27.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment (gains) losses on equity securities (Note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNC0xLTEtMS0x_cff2340f-0dd7-4a76-9122-5e2d2a2538fc">246.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNC0zLTEtMS0x_082b5797-ad24-4e75-b16f-5313b81365b9">141.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNC01LTEtMS0x_b24efc0a-8c64-4d51-b59d-bbe1e4f7b058">270.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNC03LTEtMS0x_048d4178-26e8-47ca-9719-22a8cedce2c7">905.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNS0xLTEtMS0x_05e3ff50-718c-4db5-9490-4f879ba2da66">72.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNS0zLTEtMS0x_09fc8de2-29c1-4597-8741-b94fad82a7e6">114.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNS01LTEtMS0x_5d0e229d-1fa1-4c5d-b0ef-90bedf761cc0">217.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNS03LTEtMS0x_6ea7a29b-14de-4572-bc54-bbbc1647edff">194.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment loss (Note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNi0xLTEtMS0zMDY3NA_07ad1f5c-2459-4b8d-b562-0d5deff063d2">405.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNi0zLTEtMS0zMDY4MQ_7fea2162-cfda-4900-834f-c8815a049832">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNi01LTEtMS0zMDY4OQ_22373340-21bb-4a86-993d-6a305920aa70">405.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNi03LTEtMS0zMDY5Ng_637eb5b8-09db-4795-ade5-b49888574fed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNi0xLTEtMS0x_79f3f5b3-5e92-49e3-b05e-0348c4e1e4cf">20.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNi0zLTEtMS0x_16a2949f-fde2-4fdf-851a-0d109cf9fa4d">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNi01LTEtMS0x_213b587b-fdaf-4150-9851-5d3b7b2d2319">34.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNi03LTEtMS0x_a7554cf8-1171-4ca7-ae50-a55278b0e659">161.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNy0xLTEtMS0x_046e082c-e351-40c8-9a3f-1d9c3ee046a9">635.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNy0zLTEtMS0x_71500839-3f67-4d7e-b14c-e1fa16e405bc">158.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNy01LTEtMS0x_6babaacd-4739-4451-ba0e-593ac3e5d9d7">124.3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNy03LTEtMS0x_6768ab30-c670-4893-9576-0327eddc9dcd">694.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;margin-top:1pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i48af34e12713400c858f7a29183e5680_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition</span></div><div id="i48af34e12713400c858f7a29183e5680_91"></div><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Results of Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Tables present dollars in millions, except per-share data)</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of results of operations and financial condition is intended to assist the reader in understanding and assessing significant changes and trends related to the results of operations and financial position of our consolidated company. This discussion and analysis should be read in conjunction with the consolidated condensed financial statements and accompanying footnotes in Part I, Item 1 of this Quarterly Report on Form 10-Q. Certain statements in this Part I, Item 2 of this Quarterly Report on Form 10-Q constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" in this Quarterly Report on Form 10-Q and &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2020, may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This section provides an overview of our financial results, recent product and late-stage pipeline developments, and other matters affecting our company and the pharmaceutical industry. Earnings per share (EPS) data are presented on a diluted basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, we have focused on maintaining a reliable supply of our medicines; reducing the strain on the medical system; developing treatments for COVID-19; protecting the health, safety, and well-being of our employees; supporting our communities; and ensuring affordability of and access to our medicines, particularly insulin.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced negative impacts to our underlying business due to the COVID-19 pandemic, including decreases in new prescriptions, changes in payer segment mix, and the increased use of patient affordability programs in the United States (U.S.). Additionally, we have experienced, and may continue to experience if the COVID-19 pandemic undergoes resurgent or more severe waves, decreased demand as a result of lack of normal access and fewer in-person interactions by patients and our employees with the healthcare system. Prescriptions in most of our therapeutic areas have returned to pre-COVID-19 pandemic levels in the U.S., and healthcare systems in most of our major markets have largely resumed normal operations as of September 30, 2021. While a majority of in-person interactions by our employees with the healthcare system have resumed, we may decide to halt such activity in the future and, in those cases, expect to resume such interactions as it is safe to do so and in compliance with applicable guidance and requirements. We may experience additional pricing pressures resulting from the financial strain of the COVID-19 pandemic on government-funded healthcare systems around the world. In addition, if the COVID-19 pandemic experiences resurgent or more severe waves, our ability to commercialize some assets in our product pipeline could be delayed or otherwise adversely affected. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the start of the pandemic we have worked with a variety of organizations, including governmental agencies, to facilitate access to our COVID-19 therapies in various countries. The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorizations (EUA) for bamlanivimab and bamlanivimab and etesevimab administered together for higher-risk patients who have been recently diagnosed with mild-to-moderate COVID-19 and for baricitinib for treatment with or without remdesivir in hospitalized COVID-19 patients. In April 2021, the FDA subsequently revoked the EUA for bamlanivimab alone. In the third quarter of 2021, the FDA expanded the EUA for  bamlanivimab and etesevimab administered together to include post-exposure prophylaxis in certain individuals for the prevention of SARS-CoV-2 infection.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have, and will continue to, face unique risks and uncertainties in our development, manufacture, and uptake of potential treatments for COVID-19, including vulnerability to supply chain disruptions, higher manufacturing costs, difficulties in manufacturing appropriate quantities of our therapies, heightened regulatory scrutiny of our manufacturing practices, restrictions on administration that limit widespread and timely access to our therapies, and risks related to handling, return, and/or refund of product after delivery by us. Expedited authorization processes, including our EUA for bamlanivimab and etesevimab administered together, have allowed restricted distribution of products with less than typical safety and efficacy data, and additional data that become available have and may further call into question the safety or effectiveness of our COVID-19 therapies. Additionally, the availability of superior or competitive therapies, including therapies that can be administered more easily, or preventative measures, such as vaccines, coupled with the transient nature of pandemics, have and could further negatively impact or eliminate demand for our COVID-19 therapies. Mutations or the spread of other variants of the coronavirus have in some cases impacted the effectiveness of our COVID-19 therapies, and may further render our therapies more or less effective or ineffective. In addition, evolving regulatory priorities have intensified governmental scrutiny of our operations, including our compliance with Good Manufacturing Practices (cGMP), quality assurance, and similar regulations relating to our manufacture of COVID-19 therapies and other medicines. Any of these risks could prevent us from recouping our substantial investments in the research, development, and manufacture of our COVID-19 therapies. These risks could also affect other aspects of our business, including potentially resulting in delays or denials in the approval or launch of other products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue to operate without significant negative impacts will in part depend on our ability to protect our employees and our supply chain. We have taken steps to protect our employees worldwide, with particular measures in place for those working in our manufacturing sites and distribution facilities. Effective November 2021, we are requiring COVID-19 vaccinations as a condition of employment in the U.S. and Puerto Rico. We have been able to largely maintain our normal operations. However, uncertainty resulting from the COVID-19 pandemic and its effects, including as may relate to our COVID-19 vaccination policy, could have an adverse impact on our manufacturing operations, global supply chain, and distribution systems, which could impact our ability to produce and distribute our products and the ability of third parties on which we rely to fulfill their obligations to us, and could increase our expenses if the COVID-19 pandemic experiences resurgent or more severe waves. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the COVID-19 pandemic has affected our operations and demand for our products, it has not negatively impacted our liquidity position. We expect to continue to generate cash flows to meet our short-term liquidity needs and to have access to liquidity via the short-term and long-term debt markets. As part of our response to the COVID-19 pandemic, and at the request of the U.S. and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic has continued to evolve during 2021,</span><span style="color:#212121;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> w</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e have incurred a net inventory impairment charge related to our COVID-19 antibodies during the nine months ended September 30, 2021, primarily due to the combination of changes to current and forecasted demand from the U.S. and international governments, including c</span><span style="color:#212121;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hanges to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We could experience additional impairments of our assets, including inventory related to our COVID-19 antibodies, or significant changes in the fair value of our assets due to the COVID-19 pandemic, including as a result of the factors discussed above.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2020 for additional information on risk factors that could impact our results.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Results</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our key operating results:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,772.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,740.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,318.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,099.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,342.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,414.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,055.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,336.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin as a percent of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">78.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,286.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,034.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,906.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,815.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development (IPR&amp;D)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">174.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">498.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring, and other special charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">211.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,110.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,208.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,855.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,076.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.23</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - not meaningful</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased for the three and nine months ended September&#160;30, 2021, primarily driven by increased volume. Operating expenses, defined as the sum of research and development and marketing, selling, and administrative expenses, increased for the three months ended September&#160;30, 2021, primarily driven by higher development expenses for late-stage assets. Operating expenses increased for the nine months ended September&#160;30, 2021, primarily driven by higher development expenses for late-stage assets and higher research and development expenses for COVID-19 therapies, as well as higher marketing expenses. The decrease in net income and EPS for the three and nine months ended September&#160;30, 2021 was primarily driven by higher operating expenses and a reduction in other-net, (income) expense, partially offset by higher gross margin.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following highlighted items also affect comparisons of our financial results for the three and nine months ended September&#160;30, 2021 and 2020:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Sales (See Note 5 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized a net inventory impairment charge related to our COVID-19 antibodies of $435.1 million for the nine months ended September 30, 2021. As part of our response to the COVID-19 pandemic, and at the request of the U.S. and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic has continued to evolve during 2021, we incurred a net inventory impairment charge primarily due to the combination of changes to current and forecasted demand from U.S. and international governments, including changes to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D (See Note 3 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized acquired IPR&amp;D charges of $174.0 million and $498.3 million for the three and nine months ended September 30, 2021, respectively. The charges for the three months ended September 30, 2021 were related to business development transactions with Protomer Technologies Inc. (Protomer), Kumquat Biosciences Inc. (Kumquat), Lycia Therapeutics, Inc. (Lycia), and ProQR Therapeutics N.V. (ProQR). The charges for the nine months ended September 30, 2021 also included charges related to business development transactions with Rigel Pharmaceuticals, Inc. (Rigel), Precision BioSciences, Inc. (Precision), Merus N.V. (Merus), MiNA Therapeutics Limited (MiNA), and Asahi Kasei Pharma Corporation (Asahi). </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset Impairment, Restructuring, and Other Special Charges (See Note 5 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized charges of $211.6 million for the nine months ended September 30, 2021, primarily related to an intangible asset impairment resulting from the sale of the rights to Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as acquisition and integration costs associated with the acquisition of Prevail Therapeutics Inc. (Prevail). </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other-Net, (Income) Expense (See Note 6 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized a debt extinguishment loss of $405.2 million related to the repurchase of debt for the three and nine months ended September 30, 2021. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized net investment (losses) gains on equity securities of ($246.8 million) and $270.1 million for the three and nine months ended September 30, 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020 </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D (See Note 3 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized acquired IPR&amp;D charges of $294.1 million for the nine months ended September 30, 2020, related to the acquisition of Petra Pharma Corporation (Petra), as well as business development transactions with Sitryx Therapeutics Limited (Sitryx), AbCellera Biologics Inc. (AbCellera), Evox Therapeutics Limited (Evox), and Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences).</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset Impairment, Restructuring, and Other Special Charges (See Note 5 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized charges of $101.4 million and $161.3 million for the three and nine months ended September 30, 2020, respectively, primarily related to severance costs incurred as a result of actions taken worldwide to reduce our cost structure. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other-Net, (Income) Expense (See Note 6 to the consolidated condensed financial statements)</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized net investment gains on equity securities of $141.7 million and $905.1 million for the three and nine months ended September 30, 2020, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Late-Stage Pipeline</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. We currently have approximately 45 candidates in clinical development or under regulatory review, and a larger number of projects in the discovery phase.</span></div><div style="margin-bottom:8pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following new molecular entities (NMEs) are currently in Phase III clinical trials or have been submitted for regulatory review or have received first regulatory approval in the U.S., Europe, or Japan in 2021. In addition, the following table includes certain NMEs currently in Phase I or Phase II clinical trials. The following table reflects the status of these NMEs, including certain other developments since January&#160;1, 2021.  </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COVID-19 Therapies</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bamlanivimab administered alone</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emergency Use Authorization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the first quarter of 2021 that a Phase III trial met the primary and all key secondary endpoints. The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive scientific opinion in the first quarter of 2021. In the second quarter of 2021 the FDA revoked the EUA for bamlanivimab alone in the U.S.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bamlanivimab and etesevimab administered together</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emergency Use Authorization</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the first quarter of 2021 that Phase III trials met the primary and all key secondary endpoints. Additional Phase III trial is ongoing. The FDA granted EUA for higher-risk patients recently diagnosed with mild-to-moderate COVID-19 in the first quarter of 2021. In the third quarter of 2021 the FDA expanded the EUA to include post-exposure prophylaxis in certain individuals for the prevention of SARS-CoV-2 infection. The EMA's CHMP issued a positive scientific opinion in the first quarter of 2021. Submitted in Europe in the first quarter of 2021. Announced a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses in the third quarter of 2021.</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bamlanivimab, etesevimab and bebtelovimab (LY-CoV1404) administered together</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in the second quarter of 2021.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VIR-7831 and  bamlanivimab administered together</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in the first quarter of 2021.</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Endocrinology</span></td></tr><tr style="height:54pt"><td colspan="3" rowspan="4" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tirzepatide</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 2 diabetes</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the first and second quarters of 2021 that Phase III trials met the primary and key secondary endpoints.  Submitted in the U.S. using a priority review voucher and in Europe in October 2021. Additional Phase III trials are ongoing.</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heart failure with preserved ejection fraction</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial initiated in the second quarter of 2021. </span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesity</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing. </span></td></tr><tr style="height:27pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonalcoholic steatohepatitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing. </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basal Insulin-Fc</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 1 and 2 diabetes</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing. </span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GGG Tri-Agonist</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesity</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials initiated in the second quarter of 2021.</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 2 diabetes</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GLP-1R NPA</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obesity</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials initiated in the third quarter of 2021. </span></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type 2 diabetes</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lebrikizumab</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Announced in the third quarter of 2021 that Phase III trials met primary and all key secondary endpoints. Additional Phase III trials are ongoing. </span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mirikizumab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crohn's disease</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing. </span></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ulcerative colitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the first quarter of 2021 that a Phase III trial met the primary and key secondary endpoints. Additional Phase III trials are ongoing.</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Psoriasis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not pursuing submission</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the second quarter of 2021 that we do not plan to pursue submission.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CXCR1/2 Ligands Monoclonal Antibody</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hidradenitis suppurativa</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing. </span></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IL-2 Conjugate</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic lupus erythematosus</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing. </span></td></tr><tr style="height:17pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ulcerative colitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in the second quarter of 2021. </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PD-1 MAB Agonist</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rheumatoid arthritis</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in the first quarter of 2021.</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Donanemab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early Alzheimer&#8217;s disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submission initiated </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the first quarter of 2021 that a Phase II trial met the primary endpoint and that we expanded a Phase II trial to become a Phase III trial. Granted FDA Breakthrough Therapy designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in the second quarter of 2021. Initiated a rolling submission in the U.S. for accelerated approval in the third quarter of 2021. Additional Phase III trials are ongoing. </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solanezumab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical Alzheimer's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial is ongoing.</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Epiregulin/TGF&#945; MAB</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic pain</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GBA1 Gene Therapy (PR001)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parkinson's disease</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in the Prevail acquisition in the first quarter of 2021. Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Phase II trials are ongoing. </span></div></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GRN Gene Therapy (PR006)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frontotemporal dementia</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PACAP38 Antibody</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial is ongoing.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SSTR4 Agonist</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials are ongoing.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRPA1 Antagonist</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pain</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trials initiated in October 2021.</span></td></tr><tr style="height:30pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tanezumab</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Osteoarthritis pain</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In October 2021, in collaboration with Pfizer, we discontinued the global clinical development program following receipt of a Complete Response Letter from the FDA and a negative opinion from the EMA's CHMP.  </span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer pain</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zagotenemab</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alzheimer&#8217;s disease</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in October 2021 that a Phase II trial did not meet the primary endpoint and we will discontinue development. </span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td></tr><tr style="height:18pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selpercatinib (Retevmo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thyroid cancer</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Launched</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Launched in Europe in the first quarter of 2021. Approved in Japan in the third quarter of 2021. Phase III trials are ongoing. </span></div></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lung cancer </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sintilimab injection</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lung cancer</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In collaboration with Innovent, submitted in the U.S. in the second quarter of 2021.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imlunestrant </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ER+HER2-metastic breast cancer</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial initiated in October 2021. </span></td></tr><tr style="height:35pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pirtobrutinib (LOXO-305)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic lymphocytic leukemia</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials initiated in the first and third quarters of 2021.</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mantle cell lymphoma</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial initiated in the second quarter of 2021.</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B-cell malignancies</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase II trial initiated in the second quarter of 2021.</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">EUAs remain active for certain countries outside of the U.S.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In collaboration with Vir Biotechnology, Inc. and GlaxoSmithKline plc. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In collaboration with Almirall, S.A. (Almirall) in Europe.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fast Track designation is designed to expedite the development and review of new therapies to treat serious conditions and address unmet medical needs.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Breakthrough Therapy designation is designed to expedite the development and review of potential medicines that are intended to treat a serious condition where preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on a clinically significant endpoint.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In collaboration with Pfizer, Inc (Pfizer). </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Continued approval may be contingent on verification and description of clinical benefit in confirmatory Phase III trials.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(8) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In collaboration with Innovent Biologics, Inc. (Innovent).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pipeline also contains several new indication line extension (NILEX) products. The following certain NILEX products are currently in Phase II or Phase III clinical testing, have been submitted for regulatory review, or have received first regulatory approval in the U.S., Europe, or Japan for use in the indication described in 2021. The following table reflects the status of certain NILEX products, including certain other developments since January 1, 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:18.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d8d8d8;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compound</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="background-color:#d8d8d8;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Developments</span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Endocrinology</span></td></tr><tr style="height:35pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Empagliflozin (Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heart failure with reduced ejection fraction</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Launched</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Launched in the U.S. and Europe in the third quarter of 2021. </span></div></td></tr><tr style="height:74pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heart failure with preserved ejection fraction</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. In the third quarter of 2021 the FDA granted Breakthrough Therapy designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Announced in the third quarter of 2021 that a Phase III trial met the primary endpoint. Submitted in the U.S. and Europe in October 2021. </span></div></td></tr><tr style="height:24pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic kidney disease</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Fast Track designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Phase III trials are ongoing.</span></div></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td></tr><tr style="height:45pt"><td colspan="3" rowspan="4" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baricitinib (Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Launched</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Launched in Europe and Japan. Announced in the third quarter of 2021 that the FDA will not meet the Prescription Drug User Fee Act action date for the submission in the U.S.  </span></div></td></tr><tr style="height:83pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emergency Use Authorization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the second quarter of 2021 that a Phase III trial evaluating baricitinib 4 mg once daily plus standard of care did not meet the primary endpoint, but did result in a significant reduction in death. In the third quarter of 2021, the FDA broadened the EUA for baricitinib to allow for treatment with or without remdesivir. </span></div></td></tr><tr style="height:75pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alopecia areata</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted FDA Breakthrough Therapy designation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Announced in the first, second and third quarters of 2021 that Phase III trials met the primary and all key secondary endpoints. Submitted in Europe and Japan in the third quarter of 2021. We intend to submit to the FDA by the end of 2021. </span></div></td></tr><tr style="height:24pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic lupus erythematosus</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trials are ongoing. </span></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td></tr><tr style="height:65pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Abemaciclib (Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HR+, HER2- Adjuvant breast cancer</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Launched</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Announced in the first quarter of 2021 patient-reported outcomes in combination with standard adjuvant endocrine therapy. Submitted in Japan in the first quarter of 2021. Launched in the U.S. in October 2021. </span></div></td></tr><tr style="height:26pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HR+, HER2+ Adjuvant breast cancer</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase III trial initiated in the second quarter of 2021.</span></td></tr><tr style="height:23pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prostate cancer</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase III</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Phase III trial initiated in the third quarter of 2021.</span></td></tr></table></div><div style="margin-top:9pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In collaboration with Boehringer Ingelheim. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fast Track designation is designed to expedite the development and review of new therapies to treat serious conditions and address unmet medical needs.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Breakthrough Therapy designation is designed to expedite the development and review of potential medicines that are intended to treat a serious condition where preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on a clinically significant endpoint. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The FDA granted EUA for treatment with or without remdesivir in hospitalized COVID-19 patients.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Patent Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on patents or other forms of intellectual property protection for most of our revenue, cash flows, and earnings. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vitamin regimen patents for Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expired in major European countries and Japan in June 2021. We have faced, and remain exposed to, generic competition following the loss of exclusivity in major European countries and Japan, which has eroded revenue and is likely to continue to rapidly and severely erode revenue from current levels. In the U.S., we expect the vitamin regimen patent for Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to provide us with patent protection through May 2022. However, we and Eagle Pharmaceuticals, Inc. (Eagle) reached an agreement in December 2019 to settle all pending U.S. patent litigation, allowing Eagle a limited initial entry into the market with its product starting February 2022 (up to an approximate three-week supply) and subsequent unlimited entry starting April 2022. We expect that the entry of generic competition in the U.S. following the loss of patent exclusivity will cause a rapid and severe decline in revenue and will have a material adverse effect on our consolidated results of operations and cash flows. See Note 9 to the consolidated condensed financial statements for a more detailed account of the legal proceedings currently pending regarding, among others, our Alimta patents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compound patent for Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (insulin lispro) has expired in major markets. Global regulators have different legal pathways to approve similar versions of insulin lispro. A competitor launched a similar version of insulin lispro in certain European markets in 2017 and in the U.S. in the second quarter of 2018. While it is difficult to estimate the severity of the impact of insulin lispro products entering the market, we do not expect and have not experienced a rapid and severe decline in revenue; however, we expect additional pricing pressure and some loss of market share that would continue over time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our formulation and use patents for Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have expired in major markets. We expect further decline in revenue as a result of the entry of generic and biosimilar competition due to the loss of patent exclusivity in major markets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compound patent for Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expired in Japan in January 2020. We have faced, and remain exposed to, generic competition following the loss of exclusivity, which has eroded revenue and is likely to continue to rapidly and severely erode revenue from current levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Foreign Currency Exchange Rates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global company with substantial operations outside the U.S., we face foreign currency risk exposure from fluctuating currency exchange rates, primarily the U.S. dollar against the euro, Japanese yen, and Chinese yuan. While we manage a portion of these exposures through hedging and other risk management techniques, significant fluctuations in currency rates can have a substantial impact, either positive or negative, on our revenue, cost of sales, and operating expenses. While there is uncertainty in the future movements in foreign exchange rates, fluctuations in these rates could adversely impact our future consolidated results of operations and cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Trends Affecting Pharmaceutical Pricing, Reimbursement, Access, and Other Regulatory Matters </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global concern over access to and affordability of pharmaceutical products continues to drive regulatory and legislative debate, as well as worldwide cost containment efforts by governmental authorities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such measures may include the use of mandated discounts, price reporting requirements, mandated reference prices, restrictive formularies, changes to available intellectual property protections, as well as other efforts. In addition, consolidation of private payors in the U.S. has significantly impacted the market for pharmaceuticals by increasing payor leverage in negotiating manufacturer price concessions and pharmacy reimbursement rates. We expect that these actions may intensify and could particularly affect certain products, such as insulin, as governments manage and emerge from the pandemic, which could adversely affect our business. It is not possible to predict the potential adverse impact to us or the general pharmaceutical industry of continued cost containment efforts. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, evolving regulatory priorities have intensified governmental scrutiny of our operations and our industry, including with respect to cGMP, quality assurance, and similar regulations, and increased focus on business combinations in our industry. Any regulatory issues concerning these matters could lead to regulatory and legal actions, product recalls and seizures, fines and penalties, interruption of production leading to product shortages, import bans or denials of import certifications, delays or denials in the approvals of new products pending resolution of the issues, impediments to the completion of business combinations, and reputational harm, any of which would adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2020. See also Note 9 to the consolidated condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Tax Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes and various other taxes in the U.S. and in many foreign jurisdictions; therefore, changes in both domestic and international tax laws or regulations could affect our effective tax rate, results of operations, and cash flows. Countries around the world, including the U.S., are actively considering and enacting tax law changes. Tax proposals introduced by Congress and the Biden administration contain significant changes, including increases to the tax rates at which both domestic and foreign income of U.S. companies would be taxed. Further, actions taken with respect to tax-related matters by associations such as the Organisation for Economic Co-operation and Development and the European Commission could influence tax policy in countries in which we operate. In addition, global tax authorities routinely examine our tax returns and are expected to become more aggressive in their examinations of profit allocations among jurisdictions, which could adversely impact our future consolidated results of operations and cash flows.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strategically invest in external research and technologies that we believe to complement and strengthen our own efforts. These investments can take many forms, including acquisitions, strategic alliances, collaborations, investments, and licensing arrangements. We view our business development activity as an important way to achieve our strategies, as we seek to bolster our pipeline and enhance shareholder value. We continuously evaluate business development transactions that have the potential to strengthen our business. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we acquired all shares of Dermira, Inc. for a purchase price of $849.3 million, net of cash acquired. Under the terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the FDA. We also acquired Qbrexza cloth, a medicated cloth for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the nine months ended September&#160;30, 2021, we sold the rights to Qbrexza. See Note 5 to the consolidated condensed financial statements for additional information. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy, or Spain. Under the terms of the agreement, we acquired a gene therapy program for patients with neurodegenerative diseases.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3 to the consolidated condensed financial statements for further discussion regarding our recent acquisitions.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i48af34e12713400c858f7a29183e5680_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue activity by region:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.655%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,989.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,161.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,635.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,631.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,783.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,579.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,683.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,468.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,772.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,740.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,318.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,099.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are components of the change in revenue compared with the prior year:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volume</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Price</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent change</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. for the three and nine months ended September&#160;30, 2021, the increase in volume was primarily driven by COVID-19 therapies, Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the U.S. for the three months ended September 30, 2021, the increase in realized prices was driven by lower utilization in the 340B program, unfavorable changes to estimates for rebates and discounts for Trulicity in the three months ended September 30, 2020, and modest list prices increases, partially offset by increased rebates to maintain access for products across the business. U.S. price performance was not a major driver during the nine months ended September 30, 2021, as increased utilization in more highly-rebated segments was largely offset by lower utilization in the 340B program, primarily for the diabetes portfolio. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S. for the three and nine months ended September&#160;30, 2021, the increase in volume was primarily driven by COVID-19 therapies, Trulicity, Verzenio, and Taltz. Outside the U.S. for the nine months ended September&#160;30, 2021, the increase in volume was also driven by the sale of our rights to Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in China.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue activity by product for the three months ended September&#160;30, 2021 and 2020: </span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" rowspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trulicity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,201.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">398.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,600.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humalog </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">347.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">279.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">626.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taltz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">422.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">170.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">593.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alimta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">297.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">457.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">194.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">212.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">406.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">221.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">169.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">390.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verzenio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">135.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">335.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">193.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">84.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">168.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">253.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 antibodies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">215.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">217.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forteo</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">91.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">200.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">114.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">78.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">192.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">99.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">140.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">114.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cymbalta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">132.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cialis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">137.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">130.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">161.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">447.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,989.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,783.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,772.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,740.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - not meaningful</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to EUA.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">   </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue activity by product for the nine months ended September&#160;30, 2021 and 2020:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:37.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.685%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trulicity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,465.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,122.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,588.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,565.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humalog </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,009.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">842.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,851.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,907.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alimta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">911.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">714.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,626.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taltz</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,071.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">493.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,565.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 antibodies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">949.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">226.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,176.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">566.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,058.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verzenio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">582.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">363.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">945.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humulin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">633.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">290.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">923.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">236.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">572.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">809.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cyramza</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">266.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">496.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">762.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">423.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">226.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">650.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forteo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">330.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">287.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">617.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cialis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">541.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">538.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cymbalta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">454.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">484.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emgality</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">313.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">415.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Erbitux</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">357.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">403.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyvyt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">340.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">340.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zyprexa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">264.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">292.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">462.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">805.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,267.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,635.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,683.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,318.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,099.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - not meaningful</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy, and Trijardy XR. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to EUA.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">   </span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Trulicity, a treatment for type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adult patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors, increased 52 percent and 30 percent in the U.S. during the three and nine months ended September&#160;30, 2021, respectively, driven by increased demand and, to a lesser extent, higher realized prices due to segment mix, including lower utilization in the 340B program, and modest list price increases, partially offset by increased rebates to maintain access. Trulicity's higher realized prices in the U.S. during the three months ended September 30, 2021 were also due to unfavorable changes to estimates for rebates and discounts in the three months ended September 30, 2020. Revenue outside the U.S. increased 26 percent during the three and nine months ended September&#160;30, 2021, driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates, partially offset by lower realized prices.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Humalog, an injectable human insulin analog for the treatment of diabetes, decreased 11 percent and 6 percent in the U.S. during the three and nine months ended September&#160;30, 2021, respectively, driven by lower realized prices, partially offset by increased demand. Revenue outside the U.S. increased 5 percent during the three months ended September&#160;30, 2021, driven by the favorable impact of foreign exchange rates and increased volume, partially offset by lower realized prices. Revenue outside the U.S. increased 1 percent during the nine months ended September&#160;30, 2021, primarily driven by the favorable impact of foreign exchange rates, largely offset by decreased volume. While it is difficult to estimate the severity of the impact of insulin lispro products entering the market, we do not expect and have not experienced a rapid and severe decline in revenue. However, due to the impact of competition and due to pricing pressure in the U.S. and some international markets, we expect some price decline and loss of market share to continue over time. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Alimta, a treatment for various cancers, increased 2 percent in the U.S. during the three months ended September&#160;30, 2021, primarily driven by higher realized prices, partially offset by decreased demand and customer buying patterns. Revenue decreased 2 percent in the U.S. during the nine months ended September&#160;30, 2021, primarily driven by decreased demand, partially offset by higher realized prices. Revenue outside the U.S. decreased 44 percent during the three months ended September&#160;30, 2021, primarily driven by decreased volume due to entry of generic competition and, to a lesser extent, lower realized prices. Revenue outside the U.S. decreased 4 percent during the nine months ended September&#160;30, 2021, driven by lower realized prices and decreased volume, partially offset by the favorable impact of foreign exchange rates. We have faced and remain exposed to generic competition following the loss of exclusivity in major European countries and Japan in June 2021, which has eroded revenue and is likely to continue to rapidly and severely erode revenue from current levels. We expect the limited entry of generic competition in the U.S. starting February 2022 and subsequent unlimited entry starting April 2022. We expect that the entry of generic competition following the loss of exclusivity in the U.S. will cause a rapid and severe decline in revenue. See "Executive Overview - Other Matters- Patent Matters" for more information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Taltz, a treatment for moderate-to-severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and active non-radiographic axial spondyloarthritis, increased 29 percent and 14 percent in the U.S. during the three and nine months ended September&#160;30, 2021, respectively, primarily driven by increased demand, partially offset by lower realized prices due to increased rebates to gain commercial access. Taltz's lower realized prices in the U.S. during the three months ended September&#160;30, 2021 were also driven by unfavorable segment mix, partially offset by changes to estimates for rebates and discounts. Revenue outside the U.S. increased 33 percent and 41 percent during the three and nine months ended September&#160;30, 2021, respectively, driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates, partially offset by lower realized prices.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of COVID-19 antibodies, treatments that were authorized pursuant to EUAs for mild to moderate COVID-19 for higher-risk patients and for post-exposure prophylaxis in certain individuals for the prevention of SARS-CoV-2 infection, was $215.5&#160;million and $949.5&#160;million in the U.S. during the three and nine months ended September&#160;30, 2021, respectively. Revenue outside the U.S. was $1.6&#160;million and $226.7&#160;million during the three and nine months ended September&#160;30, 2021, respectively. The availability of superior or competitive therapies, including therapies that can be administered more easily, or preventative measures, such as vaccines, coupled with the transient nature of pandemics, have and could further negatively impact or eliminate demand for these COVID-19 antibodies. In addition, mutations or the spread of other variants of the coronavirus have in some cases impacted the effectiveness of our COVID-19 antibodies, and may further render our antibodies more or less effective or ineffective.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Jardiance, a treatment for type 2 diabetes, to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and established cardiovascular disease, and to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with reduced ejection fraction, increased 35 percent and 25 percent in the U.S. during the three and nine months ended September&#160;30, 2021, respectively, primarily driven by increased demand. Revenue outside the U.S. increased 15 percent during the three months ended September&#160;30, 2021, driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates. Revenue outside the U.S. increased 27 percent during the nine months ended September&#160;30, 2021, driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates. See Note 4 to the consolidated condensed financial statements for information regarding our collaboration with Boehringer Ingelheim involving Jardiance.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Verzenio, a treatment for HR+, HER2- metastatic breast cancer and high risk early breast cancer, increased 26 percent in the U.S. during the three months ended September&#160;30, 2021, driven by increased demand, partially offset by lower realized prices. Revenue of Verzenio increased 35 percent in the U.S. during the nine months ended September&#160;30, 2021, primarily driven by increased demand. Revenue outside the U.S. increased 80 percent and 81 percent during the three and nine months ended September&#160;30, 2021, respectively, primarily driven by increased volume.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Humulin, an injectable human insulin for the treatment of diabetes, decreased 10 percent and 1 percent in the U.S. during the three and nine months ended September&#160;30, 2021, respectively, driven by lower realized prices and decreased demand. Revenue outside the U.S. increased 2 percent during the three months ended September&#160;30, 2021, driven by higher realized prices and, to a lesser extent, the favorable impact of foreign exchange rates, largely offset by decreased volume. Revenue outside the U.S. decreased 1 percent during the nine months ended September&#160;30, 2021, driven by decreased volume, largely offset by the favorable impact of foreign exchange rates and higher realized prices.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Olumiant, a treatment for adults with moderately-to-severely active rheumatoid arthritis, and of baricitinib, a treatment authorized pursuant to EUA, with or without remdesivir, of hospitalized patients with COVID-19, increased $179.5 million and $197.5 million in the U.S. during the three and nine months ended September&#160;30, 2021, respectively, driven by utilization for the treatment of hospitalized patients with COVID-19 during the third quarter of 2021. Revenue outside the U.S. increased 44 percent and 40 percent during the three and nine months ended September&#160;30, 2021, respectively, driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates, partially offset by lower realized prices. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of Cyramza, a treatment for various cancers, decreased 10 percent and 4 percent in the U.S. during the three and nine months ended September&#160;30, 2021, respectively, primarily driven by decreased demand, partially offset by higher realized prices. Revenue outside the U.S. increased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 percent and 5 percent for the three and nine months ended September&#160;30, 2021, respectively, driven by increased volume. In addition, the increase in revenue outside the U.S. for the three months ended September 30, 2021 was partially offset by lower realized prices and the unfavorable impact of foreign exchange rates. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i48af34e12713400c858f7a29183e5680_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Margin, Costs, and Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin as a percent of revenue increased 2.0 percentage points to 78.9 percent and decreased 3.9 percentage points to 74.1 percent for the three and nine months ended September 30 2021, respectively. The increase in gross margin percent for the three months ended September 30, 2021 was primarily due to favorable product mix and favorable effect of foreign exchange rates on international inventories sold. The decrease in gross margin percent for the nine months ended September 30, 2021 was primarily driven by lower gross margin on COVID-19 therapies, including the impact of $435.1 million of a net inventory impairment charge related to our COVID-19 antibodies. As part of our response to the COVID-19 pandemic, and at the request of the U.S. and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic has continued to evolve during 2021, we incurred a net inventory impairment charge primarily due to the combination of changes to current and forecasted demand from U.S. and international governments</span><span style="color:#212121;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including changes to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 percent</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.71 billion and 19 percent to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.07 billion for the three and nine months ended September&#160;30, 2021, respectively. The increase in research and development expenses for the three and nine months ended September&#160;30, 2021 was primarily driven by higher development expenses for late-stage assets. The increase in research and development expenses for the nine months ended September 30, 2021 was also driven by higher research and development expenses for COVID-19 therapies. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing, selling, and administrative expenses increased 1 percent</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to $1.58 billion and 6 percent to $4.84 billion for the three and nine months ended September&#160;30, 2021, respectively. The increase in marketing, selling, and administrative expenses for the nine months ended September&#160;30, 2021 was primarily driven by lower marketing expenses for the nine months ended September 30, 2020 due to pandemic-related spending reductions.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $174.0 million and $498.3 million of acquired IPR&amp;D charges for the three and nine months ended September&#160;30, 2021, respectively. The charges for the three months ended September 30, 2021 were </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to business development transactions with Protomer, Kumquat, Lycia, and ProQR. The charges for the nine months ended September 30, 2021 also included charges related to business development transactions with Rigel, Precision, Merus, MiNA, and Asahi. We recognized $294.1 million of acquired IPR&amp;D charges for the nine months ended September 30, 2020, related to the acquisition of Petra, as well as business development transactions with Sitryx, AbCellera, Evox, and Junshi Biosciences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized asset impairment, restructuring, and other special charges of $211.6 million for the nine months ended September&#160;30, 2021, primarily related to an intangible asset impairment resulting from the sale of the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail. We recognized asset impairment, restructuring, and other special charges of $101.4 million and $161.3 million for the three and nine months ended September&#160;30, 2020, respectively, primarily related to severance costs incurred as a result of actions taken worldwide to reduce our cost structure. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense was expense of $635.9 million and $124.3 million for the three and nine months ended September&#160;30, 2021, respectively, compared with income of $158.9 million and $694.9 million for the three and nine months ended September&#160;30, 2020, respectively. The decrease in other-net, (income) expense for the three months ended September&#160;30, 2021 was driven primarily by a debt extinguishment loss of $405.2 million related to the repurchase of debt and unfavorable mark-to-market adjustments on investments in equity securities during the three months ended September 30, 2021 compared to favorable mark-to-market adjustments on investments in equity securities during the three months ended September 30, 2020. The decrease in other-net, (income) expense for the nine months ended September 30, 2021 was driven by lower favorable mark-to-market adjustments on investments in equity securities and a debt extinguishment loss of $405.2 million related to the repurchase of debt, partially offset by income from patent settlements in Europe for Alimta. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was 10.9 percent for the three months ended September&#160;30, 2021, compared with 15.9 percent for the three months ended September 30, 2020. The effective tax rate was 10.7 percent for the nine months ended September&#160;30, 2021, compared with 14.4 percent for the nine months ended September 30, 2020. The lower effective tax rate for the three months ended September 30, 2021 was primarily due to the income tax impact of a debt extinguishment loss and unfavorable mark-to-market adjustments on investments in equity securities, partially offset by a lower net discrete tax benefit compared to the three months ended September 30, 2020. The lower effective tax rate for the nine months ended September 30, 2021 was primarily due to the income tax impacts of a net inventory impairment charge related to our COVID-19 antibodies and a debt extinguishment loss, as well as higher acquired IPR&amp;D charges and lower favorable mark-to-market adjustments on investments in equity securities compared to the nine months ended September 30, 2020, partially offset by a lower net discrete tax benefit compared to the nine months ended September 30, 2020. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i48af34e12713400c858f7a29183e5680_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Condition and Liquidity&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our available cash and cash equivalents, together with our ability to generate operating cash flow and our access to short-term and long-term borrowings, are sufficient to fund our existing and planned capital requirements. For a discussion of our capital requirements, see &#8220;Management's Discussion and Analysis of Results of Operations and Financial Condition&#8221; in Part II, Item 7 of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents increased to $3.79 billion as of September&#160;30, 2021, compared with $3.66 billion as of December&#160;31, 2020. Refer to the consolidated condensed statements of cash flows for additional information on the significant sources and uses of cash for the nine months ended September&#160;30, 2021 and 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our cash and cash equivalents, we held total investments of $3.39 billion and $2.99 billion as of September&#160;30, 2021 and December&#160;31, 2020, respectively. See Note 6 to the consolidated condensed financial statements for additional information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable CVR per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable, subject to certain terms and conditions. The acquisition was funded primarily through cash on hand. See Note 3 to the consolidated condensed financial statements for additional information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, total debt was $17.09 billion, an increase of $490.1&#160;million compared with $16.60&#160;billion as of December&#160;31, 2020. In September 2021, we issued euro-denominated notes consisting of &#8364;500.0 million of 1.125 percent fixed-rate notes due in September 2051 and &#8364;700.0 million of 1.375 percent fixed-rate notes due in September 2061, with interest to be paid annually, and British pound-denominated notes consisting of &#163;250.0 million of 1.625 percent fixed-rate notes due in September 2043, with interest to be paid annually. We paid $1.91 billion of the net cash proceeds from the offering to purchase and redeem certain higher interest rate U.S. dollar-denominated notes with an aggregate principal amount of $1.50 billion. We used the remaining net proceeds from the offering to prefund certain 2022 debt maturities and for general corporate purposes In addition, in September 2021, we issued euro-denominated notes consisting of &#8364;600.0 million of 0.50 percent fixed-rate notes due in September 2033, with interest to be paid annually. The net proceeds from the offering will be used to fund, in whole or in part, eligible projects designed to advance one or more of our environmental, social, and governance objectives. See Note 6 to the consolidated condensed financial statements for additional information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, we had a total of $5.24 billion of unused committed bank credit facilities, $5.00 billion of which is available to support our commercial paper program. We believe that amounts accessible through existing commercial paper markets should be adequate to fund short-term borrowing needs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, we repurchased $500.0 million of shares under our $8.00 billion share repurchase program authorized in June 2018. As of September&#160;30, 2021, we had $500.0 million remaining under this program. In May 2021 we authorized an additional $5.00 billion share repurchase program. There were no shares repurchased under the $5.00 billion share repurchase program during the nine months ended September&#160;30, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, we paid dividends of approximately $2.31 billion, or $2.55 per share, to our shareholders. In October 2021, we declared a dividend for the fourth quarter of 2021 of $0.85 per share on outstanding common stock. The dividend of approximately $770 million is payable on December 10, 2021 to shareholders of record at the close of business on November 15, 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Executive Overview - Other Matters - Patent Matters" for information regarding recent and upcoming losses of patent protection.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both domestically and abroad, we continue to monitor the potential impacts of the economic environment; the creditworthiness of our wholesalers and other customers, including foreign government-backed agencies and suppliers; the uncertain impact of health care legislation; various international government funding levels; and fluctuations in interest rates, foreign currency exchange rates (see "Executive Overview - Other Matters - Foreign Currency Exchange Rates"), and fair values of equity securities.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i48af34e12713400c858f7a29183e5680_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Financial Expectations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have updated certain elements of our 2021 financial guidance on a reported basis. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share for 2021 are now expected to be in the range of $6.38 to $6.48. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We now anticipate 2021 revenue to be between $27.2 billion and $27.6 billion. This increase reflects additional revenue from COVID-19 antibodies and the underlying core business. Estimated revenue from COVID-19 antibodies is now expected to be $1.3 billion. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin as a percent of revenue for 2021 is unchanged and expected to be approximately 75 percent. Research and development expenses for 2021 are unchanged and remain in the range of $6.9 billion to $7.1 billion. Marketing, selling, and administrative expenses for 2021 are unchanged and remain in the range of $6.2 billion to $6.4 billion. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D is now expected to be $498.3 million reflecting charges related to business development transactions with Lycia Therapeutics, Inc. and ProQR Therapeutics N.V. recognized during the three months ended September 30, 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8212;net, (income) expense for 2021 is now expected to be expense in the range of $150 million to $250 million, reflecting the impact of a debt extinguishment loss related to the repurchase of debt and unfavorable mark-to-market adjustments on investments in equity securities during the three months ended September 30, 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate for 2021 is now expected to be approximately 11 percent, reflecting primarily the tax impact of the charges associated with a debt extinguishment loss related to the repurchase of debt and acquired IPR&amp;D, as well as unfavorable mark-to-market adjustments on investments in equity securities during the three months ended September 30, 2021.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span><br/></span></div><div id="i48af34e12713400c858f7a29183e5680_112"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Available Information on our Website</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available through our company website, free of charge, our company filings with the Securities and Exchange Commission (SEC) as soon as reasonably practicable after we electronically file them with, or furnish them to, the SEC. The reports we make available include annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, registration statements, and any amendments to those documents.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The website link to our SEC filings is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">investor.lilly.com/financial-information/sec-filings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The information contained in, or that can be accessed through, our website is not a part of, or incorporated by reference in, this Quarterly Report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i48af34e12713400c858f7a29183e5680_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.78pt">Evaluation of Disclosure Controls and Procedures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under applicable SEC regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the company&#8217;s &#8220;disclosure controls and procedures,&#8221; which are defined generally as controls and other procedures of a reporting company designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Quarterly Report on Form&#160;10-Q) is recorded, processed, summarized, and reported on a timely basis.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of David A. Ricks, president and chief executive officer, and Anat Ashkenazi, senior vice president and chief financial officer, evaluated our disclosure controls and procedures (as such terms are defined in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2020) as of September&#160;30, 2021, and concluded that they were effective.</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.78pt">Changes in Internal Controls</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the third quarter of 2021, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i48af34e12713400c858f7a29183e5680_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:120%;text-decoration:underline">PART II. Other Information</span></div><div id="i48af34e12713400c858f7a29183e5680_121"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various currently pending legal actions, government investigations, and environmental proceedings. See Note 9 to the consolidated condensed financial statements for information on various legal proceedings. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Item should be read in conjunction with "Legal Proceedings" in Part I, Item 3 of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2020.</span></div><div id="i48af34e12713400c858f7a29183e5680_124"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our material risk factors are disclosed in "Risk Factors" in Part I, Item 1A of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2020. There have been no material changes from the risk factors previously disclosed in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2020. </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span><br/></span></div><div id="i48af34e12713400c858f7a29183e5680_127"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div id="i48af34e12713400c858f7a29183e5680_130"></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to the principal market for our common stock and related shareholder matters is described in "Management's Discussion and Analysis of Results of Operations and Financial Condition" in Part II, Item 7 and in "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" in Part III, Item 12 of our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to repurchases of our equity securities during the three months ended September&#160;30, 2021:</span></div><div style="margin-bottom:6pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:23.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of<br/>Shares Purchased<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Price Paid&#160;<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number of Shares<br/>Purchased&#160;as Part of<br/>Publicly Announced<br/>Plans or Programs<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs <br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021, we did not repurchase any shares under our $8.00 billion or $5.00 billion share repurchase programs authorized in June 2018 and May 2021, respectively. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="i48af34e12713400c858f7a29183e5680_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;6. Exhibits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed as a part of this Quarterly Report:</span></div><div style="margin-bottom:12pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:16.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/59478/000005947814000078/lly-20131231x10kexhibit31.htm">Amended Articles of Incorporation are incorporated by reference to Exhibit 3.1 to the Company's Annual Report on Form 10-K for the year ended December 31, 2013</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000059478/000119312521033302/d111779dex31.htm">Bylaws, as amended, are incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on February 9, 2021</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT&#160;31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-9302021x10qxexhibit311.htm">Rule&#160;13a-14(a) Certification of David A. Ricks, Chairman, President, and Chief Executive Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-9302021x10qxexhibit312.htm">Rule&#160;13a-14(a) Certification of Anat Ashkenazi, Senior Vice President and Chief Financial Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 32.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="lly-9302021x10qxexhibit32.htm">Section 1350 Certification</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 101.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive Data Files (embedded within the Inline XBRL document)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXHIBIT 104.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i) Long-term debt instruments under which the total amount of securities authorized does not exceed 10% of our consolidated assets are not filed as exhibits to this Quarterly Report. We will furnish a copy of these agreements to the SEC upon request.</span></div><div id="i48af34e12713400c858f7a29183e5680_139"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.646%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">ELI LILLY AND COMPANY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 27, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/Anat Ashkenazi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 27, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Finance, and Chief Accounting Officer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>lly-9302021x10qxexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i540f06c0a08d4b3d8c57b096ce9e2748_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:14pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.1 Rule 13a-14(a) Certification of David A. Ricks, Chairman, President, and Chief Executive Officer</font></div><div style="margin-top:14pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David A. Ricks, Chairman, President, and Chief Executive Officer, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I have reviewed this report on Form 10-Q of Eli Lilly and Company&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s Board of Directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.456%"><tr><td style="width:1.0%"></td><td style="width:9.078%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 27, 2021</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;David A. Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David A. Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman, President, and Chief Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>lly-9302021x10qxexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ibe74b10aafa74d6588a22ce7bcdc9db8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:14pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.2 Rule 13a-14(a) Certification of Anat Ashkenazi, Senior Vice President and Chief Financial Officer</font></div><div style="margin-top:14pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Anat Ashkenazi, Senior Vice President and Chief Financial Officer, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I have reviewed this report on Form 10-Q of Eli Lilly and Company&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s Board of Directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.456%"><tr><td style="width:1.0%"></td><td style="width:9.078%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 27, 2021</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>lly-9302021x10qxexhibit32.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if566317e4527490da58e83a262987b7a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32. Section 1350 Certification</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Eli Lilly and Company, an Indiana corporation (the &#8220;Company&#8221;), does hereby certify that, to the best of their knowledge&#58;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2021 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 27, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;David A. Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David A. Ricks</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman, President, and Chief Executive Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 27, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anat Ashkenazi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>lly-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:83f390d0-6781-4e7e-a1f5-5192701136a4,g:3039e280-7bbd-437e-b91e-6280679dfdce-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lly="http://www.lilly.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lilly.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.lilly.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofOperations" roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations">
        <link:definition>1001002 - Statement - Consolidated Condensed Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofComprehensiveIncomeLoss" roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss">
        <link:definition>1002003 - Statement - Consolidated Condensed Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedBalanceSheets" roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets">
        <link:definition>1003004 - Statement - Consolidated Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedBalanceSheetsParenthetical" roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical">
        <link:definition>1004005 - Statement - Consolidated Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofEquity" roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity">
        <link:definition>1005006 - Statement - Consolidated Condensed Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofEquityParenthetical" roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical">
        <link:definition>1006007 - Statement - Consolidated Condensed Statements of Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedCondensedStatementsofCashFlows" roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows">
        <link:definition>1007008 - Statement - Consolidated Condensed Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.lilly.com/role/BasisofPresentation">
        <link:definition>2101101 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationPolicies" roleURI="http://www.lilly.com/role/BasisofPresentationPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.lilly.com/role/Revenue">
        <link:definition>2103102 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.lilly.com/role/RevenueTables">
        <link:definition>2304301 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueSummaryofRevenueRecognizedDetails" roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails">
        <link:definition>2405401 - Disclosure - Revenue (Summary of Revenue Recognized) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAdjustmentstoRevenueDetails" roleURI="http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails">
        <link:definition>2406402 - Disclosure - Revenue (Adjustments to Revenue) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueContractLiabilitiesDetails" roleURI="http://www.lilly.com/role/RevenueContractLiabilitiesDetails">
        <link:definition>2407403 - Disclosure - Revenue (Contract Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofRevenuebyProductDetails" roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails">
        <link:definition>2408404 - Disclosure - Revenue (Disaggregation of Revenue by Product) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofRevenuebyGeographicalAreaDetails" roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails">
        <link:definition>2409405 - Disclosure - Revenue (Disaggregation of Revenue by Geographical Area) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.lilly.com/role/Acquisitions">
        <link:definition>2110103 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.lilly.com/role/AcquisitionsTables">
        <link:definition>2311302 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.lilly.com/role/AcquisitionsNarrativeDetails">
        <link:definition>2412406 - Disclosure - Acquisitions (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2413407 - Disclosure - Acquisitions (Assets Acquired and Liabilities Assumed) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAssetAcquisitionsDetails" roleURI="http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails">
        <link:definition>2414408 - Disclosure - Acquisitions (Asset Acquisitions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangements" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangements">
        <link:definition>2115104 - Disclosure - Collaborations and Other Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsTables" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables">
        <link:definition>2316303 - Disclosure - Collaborations and Other Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsDetails" roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails">
        <link:definition>2417409 - Disclosure - Collaborations and Other Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetImpairmentRestructuringandOtherSpecialCharges" roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges">
        <link:definition>2118105 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetImpairmentRestructuringandOtherSpecialChargesTables" roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables">
        <link:definition>2319304 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetImpairmentRestructuringandOtherSpecialChargesDetails" roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails">
        <link:definition>2420410 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.lilly.com/role/FinancialInstruments">
        <link:definition>2121106 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.lilly.com/role/FinancialInstrumentsTables">
        <link:definition>2322305 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>2423411 - Disclosure - Financial Instruments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsEffectofRiskManagementInstrumentsDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails">
        <link:definition>2424412 - Disclosure - Financial Instruments (Effect of Risk-Management Instruments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFairValueofFinancialInstrumentsDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails">
        <link:definition>2425413 - Disclosure - Financial Instruments (Fair Value of Financial Instruments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsRiskManagementInstrumentsDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails">
        <link:definition>2426414 - Disclosure - Financial Instruments (Risk Management Instruments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsContractualMaturitiesDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails">
        <link:definition>2427415 - Disclosure - Financial Instruments (Contractual Maturities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsUnrealizedGainsandLossesDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails">
        <link:definition>2428416 - Disclosure - Financial Instruments (Unrealized Gains and Losses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsRealizedGainsandLossesDetails" roleURI="http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails">
        <link:definition>2429417 - Disclosure - Financial Instruments (Realized Gains and Losses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.lilly.com/role/IncomeTaxes">
        <link:definition>2130107 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.lilly.com/role/IncomeTaxesDetails">
        <link:definition>2431418 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefits" roleURI="http://www.lilly.com/role/RetirementBenefits">
        <link:definition>2132108 - Disclosure - Retirement Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsTables" roleURI="http://www.lilly.com/role/RetirementBenefitsTables">
        <link:definition>2333306 - Disclosure - Retirement Benefits (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>2434419 - Disclosure - Retirement Benefits (Components of Net Periodic Benefit Cost) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.lilly.com/role/Contingencies">
        <link:definition>2135109 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://www.lilly.com/role/ContingenciesDetails">
        <link:definition>2436420 - Disclosure - Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLoss" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLoss">
        <link:definition>2137110 - Disclosure - Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossTables" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables">
        <link:definition>2338307 - Disclosure - Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossAOCIDetails" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails">
        <link:definition>2439421 - Disclosure - Other Comprehensive Income (Loss) (AOCI) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossTaxEffectDetails" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails">
        <link:definition>2440422 - Disclosure - Other Comprehensive Income (Loss) (Tax Effect) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossReclassificationDetails" roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails">
        <link:definition>2441423 - Disclosure - Other Comprehensive Income (Loss) (Reclassification) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNetIncomeExpense" roleURI="http://www.lilly.com/role/OtherNetIncomeExpense">
        <link:definition>2142111 - Disclosure - Other&#8211;Net, (Income) Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNetIncomeExpenseTables" roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseTables">
        <link:definition>2343308 - Disclosure - Other&#8211;Net, (Income) Expense (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNetIncomeExpenseDetails" roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails">
        <link:definition>2444424 - Disclosure - Other&#8211;Net, (Income) Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lly_ByettaMember" abstract="true" name="ByettaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" abstract="false" name="AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" abstract="false" name="BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lly_AlimtaMember" abstract="true" name="AlimtaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_TaltzMember" abstract="true" name="TaltzMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AsahiKaseiPharmaCorporationMember" abstract="true" name="AsahiKaseiPharmaCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A2.125NotesDueJune32030Member" abstract="true" name="A2.125NotesDueJune32030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CashFlowHedgeAbstract" abstract="true" name="CashFlowHedgeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lly_BasaglarMember" abstract="true" name="BasaglarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_EmgalityMember" abstract="true" name="EmgalityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LyciaTherapeuticsIncMember" abstract="true" name="LyciaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_PancreatitisMember" abstract="true" name="PancreatitisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_RocheMember" abstract="true" name="RocheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_PurchasedInProcessResearchAndDevelopment" abstract="false" name="PurchasedInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_MilestonePaymentsDevelopmentAndRegulatoryMember" abstract="true" name="MilestonePaymentsDevelopmentAndRegulatoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OncologyMember" abstract="true" name="OncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BuyUSdollarSellJapaneseYenMember" abstract="true" name="BuyUSdollarSellJapaneseYenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_InnoventBiologicsIncMember" abstract="true" name="InnoventBiologicsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LosAngelesMember" abstract="true" name="LosAngelesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BuyEuroSellUsDollarMember" abstract="true" name="BuyEuroSellUsDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DescriptionOfDerivativeActivityVolumePercent" abstract="false" name="DescriptionOfDerivativeActivityVolumePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" abstract="false" name="LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_FairValueHedgeAbstract" abstract="true" name="FairValueHedgeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember" abstract="true" name="MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CymbaltaMember" abstract="true" name="CymbaltaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BuyBritishPoundandSellUSDollarsMember" abstract="true" name="BuyBritishPoundandSellUSDollarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" abstract="true" name="CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_WeilerVTakedaCanadaIncEtAlMember" abstract="true" name="WeilerVTakedaCanadaIncEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DomicileOfLitigationDomain" abstract="true" name="DomicileOfLitigationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A625Notesdue2031Member" abstract="true" name="A625Notesdue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CollaborativeArrangementRightsAndObligationsPercent" abstract="false" name="CollaborativeArrangementRightsAndObligationsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lly_RigelPharmaceuticalsIncMember" abstract="true" name="RigelPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_SouthernDistrictOfCaliforniaMember" abstract="true" name="SouthernDistrictOfCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CollaborationandOtherRevenueMember" abstract="true" name="CollaborationandOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LitigationClaimsDismissedNumber" abstract="false" name="LitigationClaimsDismissedNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" abstract="true" name="AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" abstract="true" name="MilestonePaymentsCapitalizedAsIntangibleAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ProtomerTechnologiesIncMember" abstract="true" name="ProtomerTechnologiesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LebrikizumabMember" abstract="true" name="LebrikizumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" abstract="false" name="BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_DomicileOfLitigationAxis" abstract="true" name="DomicileOfLitigationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="lly_OtherNeuroscienceMember" abstract="true" name="OtherNeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_NonCHINAMember" abstract="true" name="NonCHINAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_NeuroscienceMember" abstract="true" name="NeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsSalesBasedMember" abstract="true" name="MilestonePaymentsSalesBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1125NotesDue2051Member" abstract="true" name="A1125NotesDue2051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LossContingencyNumberOfPatentsRuledUnpatentable" abstract="false" name="LossContingencyNumberOfPatentsRuledUnpatentable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_TrulicityMemberMember" abstract="true" name="TrulicityMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ProductLiabilityMember" abstract="true" name="ProductLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_SwapSwissFrancsToU.S.DollarsMember" abstract="true" name="SwapSwissFrancsToU.S.DollarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AbCelleraBiologicsInc.Member" abstract="true" name="AbCelleraBiologicsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AmpullaryCancerMember" abstract="true" name="AmpullaryCancerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_KumquatBiosciencesIncMember" abstract="true" name="KumquatBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AcquiredInProcessResearchAndDevelopment" abstract="false" name="AcquiredInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_ErbituxMember" abstract="true" name="ErbituxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ImmunologyMember" abstract="true" name="ImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MerusNVMember" abstract="true" name="MerusNVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A718NotesDueJune12025Member" abstract="true" name="A718NotesDueJune12025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1.625NotesDueJune22026Member" abstract="true" name="A1.625NotesDueJune22026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_VariousStateDomicilesMember" abstract="true" name="VariousStateDomicilesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_VerzenioMember" abstract="true" name="VerzenioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_PlaintiffAllegationsAxis" abstract="true" name="PlaintiffAllegationsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="lly_SwapU.S.DollarsToEuroMember" abstract="true" name="SwapU.S.DollarsToEuroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" abstract="false" name="RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lly_PrecisionBiosciencesIncMember" abstract="true" name="PrecisionBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ForeignCurrencyDenominatedDebtMember" abstract="true" name="ForeignCurrencyDenominatedDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_TrajentaBIMember" abstract="true" name="TrajentaBIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherDiabetesMember" abstract="true" name="OtherDiabetesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LossContingencyNumberOfPatents" abstract="false" name="LossContingencyNumberOfPatents" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_A5000NotesDue2033Member" abstract="true" name="A5000NotesDue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CostOfSalesOperatingExpensesAndOtherNet" abstract="false" name="CostOfSalesOperatingExpensesAndOtherNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_A1375NotesDue2061Member" abstract="true" name="A1375NotesDue2061Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LossContingencyNumberOfClaimants" abstract="false" name="LossContingencyNumberOfClaimants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_A395NotesDue2049Member" abstract="true" name="A395NotesDue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" abstract="false" name="LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_ActosMember" abstract="true" name="ActosMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_InsulinMember" abstract="true" name="InsulinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_SitryxTherapeuticsLimitedMember" abstract="true" name="SitryxTherapeuticsLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_PetraPharmaCorporationMember" abstract="true" name="PetraPharmaCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_EvoxTherapeuticsMember" abstract="true" name="EvoxTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_EppVTakedaCanadaIncEtAlMember" abstract="true" name="EppVTakedaCanadaIncEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_TYVYTMember" abstract="true" name="TYVYTMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherImmunologyMember" abstract="true" name="OtherImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_COVID19AntibodiesMember" abstract="true" name="COVID19AntibodiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DiabetesMember" abstract="true" name="DiabetesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" abstract="true" name="MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OlumiantMember" abstract="true" name="OlumiantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" abstract="true" name="MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_A1625NotesDue2043Member" abstract="true" name="A1625NotesDue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" abstract="false" name="DebtSecuritiesAvailableforsaleUnrealizedGainPosition" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_A6.77NotesDueJanuary12036Member" abstract="true" name="A6.77NotesDueJanuary12036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" abstract="false" name="ProceedsfromSaleofEquityandAvailableforSaleSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_DrReddysLabMember" abstract="true" name="DrReddysLabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ProQRTherapeuticsNVMember" abstract="true" name="ProQRTherapeuticsNVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BuyUsDollarSellEuroMember" abstract="true" name="BuyUsDollarSellEuroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MarketableSecuritiesMember" abstract="true" name="MarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_JunshiBiosciencesMember" abstract="true" name="JunshiBiosciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherOncologyMember" abstract="true" name="OtherOncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_EmployeeLitigationMember" abstract="true" name="EmployeeLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CialisMember" abstract="true" name="CialisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_HumalogHumulinAndForteoMember" abstract="true" name="HumalogHumulinAndForteoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" abstract="false" name="FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lly_LossContingencyNumberOfPatentsClaimsDismissed" abstract="false" name="LossContingencyNumberOfPatentsClaimsDismissed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember" abstract="true" name="MilestonePaymentsContingentUponInitiationOfPhaseITrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_EquityMethodAndOtherInvestmentsMember" abstract="true" name="EquityMethodAndOtherInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A3375NotesDue2029Member" abstract="true" name="A3375NotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_MiNATherapeuticsLimitedMember" abstract="true" name="MiNATherapeuticsLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" abstract="false" name="BusinessAcquisitionContingentValueRightAdditionalPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" abstract="false" name="AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_HedgedFixedRateDebtMember" abstract="true" name="HedgedFixedRateDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_BuyUSDollarSellChineseYuanMember" abstract="true" name="BuyUSDollarSellChineseYuanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_PancreaticCancerOrThyroidCancerMember" abstract="true" name="PancreaticCancerOrThyroidCancerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" abstract="false" name="AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_PrevailTherapeuticsIncMember" abstract="true" name="PrevailTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_ZyprexaMember" abstract="true" name="ZyprexaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_PlaintiffAllegationsDomain" abstract="true" name="PlaintiffAllegationsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DerivativeInstrumentsGainLossRecognized" abstract="false" name="DerivativeInstrumentsGainLossRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_OtherForeignCountriesMember" abstract="true" name="OtherForeignCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_HumalogMember" abstract="true" name="HumalogMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_LossContingencyNumberOfDecisionsAffirmed" abstract="false" name="LossContingencyNumberOfDecisionsAffirmed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lly_OtherProductTotalMember" abstract="true" name="OtherProductTotalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_JardianceMember" abstract="true" name="JardianceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherEquitySecuritiesMember" abstract="true" name="OtherEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_SalesRebatesAndDiscounts" abstract="false" name="SalesRebatesAndDiscounts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_ForteoMember" abstract="true" name="ForteoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_OtherProductMember" abstract="true" name="OtherProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_DermiraInc.Member" abstract="true" name="DermiraInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_EmgalityPatentLitigationMember" abstract="true" name="EmgalityPatentLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CollaborativeArrangementRightsAndObligationsRightsObligations" abstract="false" name="CollaborativeArrangementRightsAndObligationsRightsObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lly_HumulinMember" abstract="true" name="HumulinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_CyramzaMember" abstract="true" name="CyramzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A415NotesDue2059Member" abstract="true" name="A415NotesDue2059Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_WhyteEtAlVEliLillyEtAlMember" abstract="true" name="WhyteEtAlVEliLillyEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1.700Notesdue2049Member" abstract="true" name="A1.700Notesdue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1.000NotesDueJune22022Member" abstract="true" name="A1.000NotesDueJune22022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>lly-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:83f390d0-6781-4e7e-a1f5-5192701136a4,g:3039e280-7bbd-437e-b91e-6280679dfdce-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations" xlink:type="simple" xlink:href="lly-20210930.xsd#ConsolidatedCondensedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_01ac8b55-ef25-486c-bdd1-448c6e9bebea" xlink:href="lly-20210930.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e22942a8-68ac-4b59-86a0-408ae7e6e77a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_01ac8b55-ef25-486c-bdd1-448c6e9bebea" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e22942a8-68ac-4b59-86a0-408ae7e6e77a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b3cf4398-ff53-4280-8024-0cad2c42453c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_01ac8b55-ef25-486c-bdd1-448c6e9bebea" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b3cf4398-ff53-4280-8024-0cad2c42453c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a6667375-9943-46cf-8a0a-95d463eee089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_01ac8b55-ef25-486c-bdd1-448c6e9bebea" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a6667375-9943-46cf-8a0a-95d463eee089" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_98bcf335-a23a-48f6-a629-0bd417c63235" xlink:href="lly-20210930.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_01ac8b55-ef25-486c-bdd1-448c6e9bebea" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_98bcf335-a23a-48f6-a629-0bd417c63235" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_eda75cc2-b3b1-49ee-abc8-c993eb9f96ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_01ac8b55-ef25-486c-bdd1-448c6e9bebea" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_eda75cc2-b3b1-49ee-abc8-c993eb9f96ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_13da9152-e357-4a74-8993-c4d07a82b65a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_01ac8b55-ef25-486c-bdd1-448c6e9bebea" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_13da9152-e357-4a74-8993-c4d07a82b65a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_64bd7074-62cc-4cb7-a620-83128c884cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b07f83b5-1e7f-43b2-9fba-5d75e62fb0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_64bd7074-62cc-4cb7-a620-83128c884cf2" xlink:to="loc_us-gaap_Revenues_b07f83b5-1e7f-43b2-9fba-5d75e62fb0a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_250f0324-df80-4d3c-9bb9-32d0e6f9b5d4" xlink:href="lly-20210930.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_64bd7074-62cc-4cb7-a620-83128c884cf2" xlink:to="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_250f0324-df80-4d3c-9bb9-32d0e6f9b5d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d8faaee1-9f48-4c18-8c06-ec256bbe1682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f933b8e9-2931-4cc2-a669-5138e3c9c8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d8faaee1-9f48-4c18-8c06-ec256bbe1682" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f933b8e9-2931-4cc2-a669-5138e3c9c8ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8b99369a-da3d-4e6a-81dc-5774b691124e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d8faaee1-9f48-4c18-8c06-ec256bbe1682" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8b99369a-da3d-4e6a-81dc-5774b691124e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20210930.xsd#ConsolidatedCondensedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_893ce876-d0b0-47a6-bca7-5de621ac9d27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_db4ffe5c-1e2f-4e73-af34-352d389882c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_893ce876-d0b0-47a6-bca7-5de621ac9d27" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_db4ffe5c-1e2f-4e73-af34-352d389882c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3c169d26-da2b-4572-a976-8e75b300cae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_893ce876-d0b0-47a6-bca7-5de621ac9d27" xlink:to="loc_us-gaap_NetIncomeLoss_3c169d26-da2b-4572-a976-8e75b300cae2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="simple" xlink:href="lly-20210930.xsd#ConsolidatedCondensedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8c8cfcc8-88e9-4bad-9b6e-e689b5ffd4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0d507038-cf2a-4fdc-9e11-9d37b65e405d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8c8cfcc8-88e9-4bad-9b6e-e689b5ffd4b4" xlink:to="loc_us-gaap_CommonStockValue_0d507038-cf2a-4fdc-9e11-9d37b65e405d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d69f530c-52b8-40cb-bdb8-e32e16957f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8c8cfcc8-88e9-4bad-9b6e-e689b5ffd4b4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d69f530c-52b8-40cb-bdb8-e32e16957f33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_86f177b4-5dd2-4bb6-8912-29dd97b65aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8c8cfcc8-88e9-4bad-9b6e-e689b5ffd4b4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_86f177b4-5dd2-4bb6-8912-29dd97b65aa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_885315b7-6bc0-4a5d-9882-1fc8d7655411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8c8cfcc8-88e9-4bad-9b6e-e689b5ffd4b4" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_885315b7-6bc0-4a5d-9882-1fc8d7655411" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ae044e31-6f4f-4564-bd61-24a6f540aee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8c8cfcc8-88e9-4bad-9b6e-e689b5ffd4b4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ae044e31-6f4f-4564-bd61-24a6f540aee7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_f92c4149-e5e5-4bfe-a946-3a7606df702d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8c8cfcc8-88e9-4bad-9b6e-e689b5ffd4b4" xlink:to="loc_us-gaap_TreasuryStockValue_f92c4149-e5e5-4bfe-a946-3a7606df702d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ee6ca597-90e1-49ca-a106-855defed04b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7c590636-9f84-4af2-92c3-092ba0e1f91a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ee6ca597-90e1-49ca-a106-855defed04b9" xlink:to="loc_us-gaap_AccountsPayableCurrent_7c590636-9f84-4af2-92c3-092ba0e1f91a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a0bce2bd-9ff6-43e2-9993-df3280f9cd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ee6ca597-90e1-49ca-a106-855defed04b9" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a0bce2bd-9ff6-43e2-9993-df3280f9cd4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SalesRebatesAndDiscounts_4c05ea56-e06b-40d1-8f5e-5be8cc34718e" xlink:href="lly-20210930.xsd#lly_SalesRebatesAndDiscounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ee6ca597-90e1-49ca-a106-855defed04b9" xlink:to="loc_lly_SalesRebatesAndDiscounts_4c05ea56-e06b-40d1-8f5e-5be8cc34718e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_9bacc4b8-d032-4581-9cf8-a2a43affa710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ee6ca597-90e1-49ca-a106-855defed04b9" xlink:to="loc_us-gaap_DividendsPayableCurrent_9bacc4b8-d032-4581-9cf8-a2a43affa710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_32a41448-0a90-4cc2-85ea-155cadc2926d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ee6ca597-90e1-49ca-a106-855defed04b9" xlink:to="loc_us-gaap_TaxesPayableCurrent_32a41448-0a90-4cc2-85ea-155cadc2926d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_d75911a9-195f-4d83-a954-bf3adbffc80d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ee6ca597-90e1-49ca-a106-855defed04b9" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_d75911a9-195f-4d83-a954-bf3adbffc80d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_cab54634-6ee9-49ea-8372-a4996406cb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ee6ca597-90e1-49ca-a106-855defed04b9" xlink:to="loc_us-gaap_DebtCurrent_cab54634-6ee9-49ea-8372-a4996406cb7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5071cde6-5ef1-43da-a79c-ec7c732234b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d8efd829-df53-422d-b411-e136994437a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5071cde6-5ef1-43da-a79c-ec7c732234b7" xlink:to="loc_us-gaap_StockholdersEquity_d8efd829-df53-422d-b411-e136994437a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_cbcdc21f-d2be-461a-82e1-91a2334e72d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5071cde6-5ef1-43da-a79c-ec7c732234b7" xlink:to="loc_us-gaap_MinorityInterest_cbcdc21f-d2be-461a-82e1-91a2334e72d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_630835ed-e491-4ba6-8a5a-9ada77758365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_61316d14-87b2-4ea4-a8bd-4a4e577ecff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_630835ed-e491-4ba6-8a5a-9ada77758365" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_61316d14-87b2-4ea4-a8bd-4a4e577ecff1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_87b70e60-708d-45a6-989e-1067efce0de5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_630835ed-e491-4ba6-8a5a-9ada77758365" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_87b70e60-708d-45a6-989e-1067efce0de5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_ed613f39-86e8-4960-8882-cc902b9ab8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_630835ed-e491-4ba6-8a5a-9ada77758365" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_ed613f39-86e8-4960-8882-cc902b9ab8f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9dbecf56-1c9f-459c-8664-f7576aadf22f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_630835ed-e491-4ba6-8a5a-9ada77758365" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9dbecf56-1c9f-459c-8664-f7576aadf22f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c866a419-121a-4a08-b197-ad777b49bf60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_630835ed-e491-4ba6-8a5a-9ada77758365" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c866a419-121a-4a08-b197-ad777b49bf60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8a42713c-6ba3-411c-a73e-e02ce9502a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_83d07d7d-b206-461d-99f2-e07e2975b467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8a42713c-6ba3-411c-a73e-e02ce9502a4b" xlink:to="loc_us-gaap_AssetsCurrent_83d07d7d-b206-461d-99f2-e07e2975b467" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_82a312dd-1fd3-4dd6-9e65-844ac239b38b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8a42713c-6ba3-411c-a73e-e02ce9502a4b" xlink:to="loc_us-gaap_LongTermInvestments_82a312dd-1fd3-4dd6-9e65-844ac239b38b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e50323cc-dc2e-47d2-ac65-4b8d21e30c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8a42713c-6ba3-411c-a73e-e02ce9502a4b" xlink:to="loc_us-gaap_Goodwill_e50323cc-dc2e-47d2-ac65-4b8d21e30c2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9a9ab57b-5b63-460c-a5f3-6da16d3a69f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8a42713c-6ba3-411c-a73e-e02ce9502a4b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9a9ab57b-5b63-460c-a5f3-6da16d3a69f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_94e67225-e0fb-4e4f-9d50-13cd78a05a31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8a42713c-6ba3-411c-a73e-e02ce9502a4b" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_94e67225-e0fb-4e4f-9d50-13cd78a05a31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_85793de7-533e-4f7e-a45a-943c5d83af3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8a42713c-6ba3-411c-a73e-e02ce9502a4b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_85793de7-533e-4f7e-a45a-943c5d83af3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_06f440fa-55b6-4a83-a083-d2296011659a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8a42713c-6ba3-411c-a73e-e02ce9502a4b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_06f440fa-55b6-4a83-a083-d2296011659a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_158e6205-cff5-4dff-b439-860c4a8e2ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_25040106-82b2-40ba-ac72-0dc583ec2c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_158e6205-cff5-4dff-b439-860c4a8e2ff5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_25040106-82b2-40ba-ac72-0dc583ec2c75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_c325df76-8405-41af-a6d7-e2191120e8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_158e6205-cff5-4dff-b439-860c4a8e2ff5" xlink:to="loc_us-gaap_ShortTermInvestments_c325df76-8405-41af-a6d7-e2191120e8c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_26b4edb2-29a9-4ac1-9c70-aab931ff5289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_158e6205-cff5-4dff-b439-860c4a8e2ff5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_26b4edb2-29a9-4ac1-9c70-aab931ff5289" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_1133ebcc-ee2f-4d85-9312-ff3d642aa026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_158e6205-cff5-4dff-b439-860c4a8e2ff5" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_1133ebcc-ee2f-4d85-9312-ff3d642aa026" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0a496fa0-29d4-4fb9-8b6d-0ff475706b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_158e6205-cff5-4dff-b439-860c4a8e2ff5" xlink:to="loc_us-gaap_InventoryNet_0a496fa0-29d4-4fb9-8b6d-0ff475706b10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_40320075-675c-4ee3-8262-379b19e6d1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_158e6205-cff5-4dff-b439-860c4a8e2ff5" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_40320075-675c-4ee3-8262-379b19e6d1d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1e072181-429d-422d-965c-7e2d650c2a68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a7aa8cb6-5832-407a-9016-83e6adad2c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1e072181-429d-422d-965c-7e2d650c2a68" xlink:to="loc_us-gaap_LiabilitiesCurrent_a7aa8cb6-5832-407a-9016-83e6adad2c56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_59cb306f-682b-4ae5-a494-b65193f34e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1e072181-429d-422d-965c-7e2d650c2a68" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_59cb306f-682b-4ae5-a494-b65193f34e2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3a60c484-112f-4848-9b87-0685435bdc32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1e072181-429d-422d-965c-7e2d650c2a68" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3a60c484-112f-4848-9b87-0685435bdc32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_13ab3bc4-0d25-4877-87e8-b3076b04d1be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1e072181-429d-422d-965c-7e2d650c2a68" xlink:to="loc_us-gaap_CommitmentsAndContingencies_13ab3bc4-0d25-4877-87e8-b3076b04d1be" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows" xlink:type="simple" xlink:href="lly-20210930.xsd#ConsolidatedCondensedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_da94c164-e5b2-4a6f-9901-f613a39666d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_2ce4366a-f07d-46e7-b87a-7404a61430e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_da94c164-e5b2-4a6f-9901-f613a39666d4" xlink:to="loc_us-gaap_PaymentsOfDividends_2ce4366a-f07d-46e7-b87a-7404a61430e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_0b119386-046c-44f9-8e93-66fb5173da5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_da94c164-e5b2-4a6f-9901-f613a39666d4" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_0b119386-046c-44f9-8e93-66fb5173da5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b20d96cf-cf46-4483-a49d-ae2142d982b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_da94c164-e5b2-4a6f-9901-f613a39666d4" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b20d96cf-cf46-4483-a49d-ae2142d982b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3da19973-9f1f-4611-b1ff-1c04193c8c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_da94c164-e5b2-4a6f-9901-f613a39666d4" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3da19973-9f1f-4611-b1ff-1c04193c8c1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_83f9ab8e-9c33-4896-a52d-2fc9249a7053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_da94c164-e5b2-4a6f-9901-f613a39666d4" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_83f9ab8e-9c33-4896-a52d-2fc9249a7053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_fac32026-2984-4d93-9435-69b2e8b9e1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_da94c164-e5b2-4a6f-9901-f613a39666d4" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_fac32026-2984-4d93-9435-69b2e8b9e1f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9f51c2b3-b22a-4f13-9a4f-5d1bf1d53149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_da94c164-e5b2-4a6f-9901-f613a39666d4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9f51c2b3-b22a-4f13-9a4f-5d1bf1d53149" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b4547898-ae58-4f36-9c9f-3f8917071c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_78b89a6d-0f68-48bb-9be3-2f0f4153443e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b4547898-ae58-4f36-9c9f-3f8917071c42" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_78b89a6d-0f68-48bb-9be3-2f0f4153443e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9ba95c19-5484-4d96-802a-5a5b53b3ffec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b4547898-ae58-4f36-9c9f-3f8917071c42" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9ba95c19-5484-4d96-802a-5a5b53b3ffec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6798f809-ce92-4a86-b228-83c0fcbc09d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b4547898-ae58-4f36-9c9f-3f8917071c42" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6798f809-ce92-4a86-b228-83c0fcbc09d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed8b595f-6b5b-421e-9350-efef6e8bda03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b4547898-ae58-4f36-9c9f-3f8917071c42" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed8b595f-6b5b-421e-9350-efef6e8bda03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_99334b70-fcf0-4032-b47b-b5813668cd55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_1ba62d41-9a68-4047-8650-48fab283182d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_99334b70-fcf0-4032-b47b-b5813668cd55" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_1ba62d41-9a68-4047-8650-48fab283182d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_718eb417-9d7d-49b0-9a5b-7cf2050fcde3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_99334b70-fcf0-4032-b47b-b5813668cd55" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_718eb417-9d7d-49b0-9a5b-7cf2050fcde3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments_d0ec6acb-7c78-4f5e-a3eb-6de648d948f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfLongtermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_99334b70-fcf0-4032-b47b-b5813668cd55" xlink:to="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments_d0ec6acb-7c78-4f5e-a3eb-6de648d948f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_958c3c53-e7cf-4f85-8427-b2d3d4cf5963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_99334b70-fcf0-4032-b47b-b5813668cd55" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_958c3c53-e7cf-4f85-8427-b2d3d4cf5963" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_bd4dba94-087d-4354-8d48-7e57cd24be57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_99334b70-fcf0-4032-b47b-b5813668cd55" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_bd4dba94-087d-4354-8d48-7e57cd24be57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PurchasedInProcessResearchAndDevelopment_da1d5a06-8a5d-454f-9609-d9a78b314c7c" xlink:href="lly-20210930.xsd#lly_PurchasedInProcessResearchAndDevelopment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_99334b70-fcf0-4032-b47b-b5813668cd55" xlink:to="loc_lly_PurchasedInProcessResearchAndDevelopment_da1d5a06-8a5d-454f-9609-d9a78b314c7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2a852a0e-e628-49fa-a031-e33a9b21a8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_99334b70-fcf0-4032-b47b-b5813668cd55" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2a852a0e-e628-49fa-a031-e33a9b21a8c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_dd6bf211-99e6-4324-b3d7-a748b94df142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_99334b70-fcf0-4032-b47b-b5813668cd55" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_dd6bf211-99e6-4324-b3d7-a748b94df142" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01c24c46-39d4-49fe-8c71-8bf55e6db2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_21c4ebf3-520e-48e4-8ce4-5bb4e50e18b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01c24c46-39d4-49fe-8c71-8bf55e6db2a6" xlink:to="loc_us-gaap_NetIncomeLoss_21c4ebf3-520e-48e4-8ce4-5bb4e50e18b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ff0c08b2-bbe4-4d12-8560-b9b744e12665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01c24c46-39d4-49fe-8c71-8bf55e6db2a6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ff0c08b2-bbe4-4d12-8560-b9b744e12665" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_7d7491d8-3f6d-415f-8201-05f85c20d65b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01c24c46-39d4-49fe-8c71-8bf55e6db2a6" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_7d7491d8-3f6d-415f-8201-05f85c20d65b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1ceae26c-fde3-42cb-8ae6-05fed26f8243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01c24c46-39d4-49fe-8c71-8bf55e6db2a6" xlink:to="loc_us-gaap_ShareBasedCompensation_1ceae26c-fde3-42cb-8ae6-05fed26f8243" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_38e9d631-ad4d-461c-9a24-989e921840c9" xlink:href="lly-20210930.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01c24c46-39d4-49fe-8c71-8bf55e6db2a6" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_38e9d631-ad4d-461c-9a24-989e921840c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_28e3b537-6e1a-43f0-b7e9-b787fb1e8c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01c24c46-39d4-49fe-8c71-8bf55e6db2a6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_28e3b537-6e1a-43f0-b7e9-b787fb1e8c6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_dca37174-36c4-4a0f-a1ec-a98cddcae8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01c24c46-39d4-49fe-8c71-8bf55e6db2a6" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_dca37174-36c4-4a0f-a1ec-a98cddcae8e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_3fe803da-06ba-49e1-b0ef-d69e346a74fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01c24c46-39d4-49fe-8c71-8bf55e6db2a6" xlink:to="loc_us-gaap_GainLossOnInvestments_3fe803da-06ba-49e1-b0ef-d69e346a74fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3a432ff3-4784-4d6d-a532-f9ede565bc94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01c24c46-39d4-49fe-8c71-8bf55e6db2a6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3a432ff3-4784-4d6d-a532-f9ede565bc94" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1177f6e0-5303-449d-9700-7f51d4d77c24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9fd3c637-b8de-402c-ad86-a9844c0fafcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1177f6e0-5303-449d-9700-7f51d4d77c24" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9fd3c637-b8de-402c-ad86-a9844c0fafcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7c46198a-8f5a-45cb-a70f-c3c697cd7c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1177f6e0-5303-449d-9700-7f51d4d77c24" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_7c46198a-8f5a-45cb-a70f-c3c697cd7c9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e094b71a-8f75-4f19-a63f-43cf56791524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1177f6e0-5303-449d-9700-7f51d4d77c24" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e094b71a-8f75-4f19-a63f-43cf56791524" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_fa4e1eb8-8bf8-4801-9360-71e3c69e4cf0" xlink:href="lly-20210930.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1177f6e0-5303-449d-9700-7f51d4d77c24" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_fa4e1eb8-8bf8-4801-9360-71e3c69e4cf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_767edc59-3d9c-4fb4-bc1b-b5e5d825e40e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1177f6e0-5303-449d-9700-7f51d4d77c24" xlink:to="loc_us-gaap_Goodwill_767edc59-3d9c-4fb4-bc1b-b5e5d825e40e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#AssetImpairmentRestructuringandOtherSpecialChargesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_c2fb85bc-493a-41c5-9b20-196b63d2faf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_1c1bc9ec-0d05-4cdc-8109-6ae66d767d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_c2fb85bc-493a-41c5-9b20-196b63d2faf3" xlink:to="loc_us-gaap_SeveranceCosts1_1c1bc9ec-0d05-4cdc-8109-6ae66d767d90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_cbf58ccb-3ff3-4093-85fd-abf52b2939b0" xlink:href="lly-20210930.xsd#lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_c2fb85bc-493a-41c5-9b20-196b63d2faf3" xlink:to="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_cbf58ccb-3ff3-4093-85fd-abf52b2939b0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized_f9585824-0e40-45d6-8978-e18b2024d208" xlink:href="lly-20210930.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_51bac3a4-f3b4-4b36-a5f7-d8eb5a991382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_f9585824-0e40-45d6-8978-e18b2024d208" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_51bac3a4-f3b4-4b36-a5f7-d8eb5a991382" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_865f7d0e-c171-4b9e-b48c-7bc868dcca9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_f9585824-0e40-45d6-8978-e18b2024d208" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_865f7d0e-c171-4b9e-b48c-7bc868dcca9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_df1b0108-141c-4a8d-8dcc-76c7f792a92f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_f9585824-0e40-45d6-8978-e18b2024d208" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_df1b0108-141c-4a8d-8dcc-76c7f792a92f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_1233e077-ed65-482e-84bd-a6f10a81ed23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized_f9585824-0e40-45d6-8978-e18b2024d208" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_1233e077-ed65-482e-84bd-a6f10a81ed23" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#FinancialInstrumentsFairValueofFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_9503b46a-9d2c-463a-80ba-157ea93e4ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_b1cf7fd5-c631-4e38-abba-a0c2da01cd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_9503b46a-9d2c-463a-80ba-157ea93e4ee2" xlink:to="loc_us-gaap_OtherLongTermInvestments_b1cf7fd5-c631-4e38-abba-a0c2da01cd0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_ce3fb16d-ef96-46ec-ba46-990ad2ea0c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_9503b46a-9d2c-463a-80ba-157ea93e4ee2" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_ce3fb16d-ef96-46ec-ba46-990ad2ea0c1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0a4abce0-abbf-4827-9a05-f340b988aacd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_9503b46a-9d2c-463a-80ba-157ea93e4ee2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0a4abce0-abbf-4827-9a05-f340b988aacd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_669beec5-18ba-4cf0-aae4-6acc0c8ce086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_9503b46a-9d2c-463a-80ba-157ea93e4ee2" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_669beec5-18ba-4cf0-aae4-6acc0c8ce086" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#FinancialInstrumentsContractualMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4e6d5070-7a09-4592-8549-1c072da22c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0d544c4d-2404-44d7-a95e-f256ec6296e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4e6d5070-7a09-4592-8549-1c072da22c4c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0d544c4d-2404-44d7-a95e-f256ec6296e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_957f8f42-39b3-4047-b4d0-d684c205f314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4e6d5070-7a09-4592-8549-1c072da22c4c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_957f8f42-39b3-4047-b4d0-d684c205f314" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_eb7e6e24-d2f0-4f7c-8c9b-5971d1dda072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4e6d5070-7a09-4592-8549-1c072da22c4c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_eb7e6e24-d2f0-4f7c-8c9b-5971d1dda072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_c9c3c304-faf4-46be-85de-1baa9ffa6613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4e6d5070-7a09-4592-8549-1c072da22c4c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_c9c3c304-faf4-46be-85de-1baa9ffa6613" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7261eec1-8745-499f-85db-92d409b10b07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_38f8389b-1487-47f3-b6ad-2050adc1c0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7261eec1-8745-499f-85db-92d409b10b07" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_38f8389b-1487-47f3-b6ad-2050adc1c0c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_0bfba553-5b9b-4260-babc-f05d27f8acd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7261eec1-8745-499f-85db-92d409b10b07" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_0bfba553-5b9b-4260-babc-f05d27f8acd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1364e86b-0eef-4144-bd5e-92e7791c7fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7261eec1-8745-499f-85db-92d409b10b07" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1364e86b-0eef-4144-bd5e-92e7791c7fe4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_8e9c6bd9-1b4d-42fa-85cd-d2ad41c35f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7261eec1-8745-499f-85db-92d409b10b07" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_8e9c6bd9-1b4d-42fa-85cd-d2ad41c35f5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_9bbff73c-cf56-4b72-ac2a-01354e0f0f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7261eec1-8745-499f-85db-92d409b10b07" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_9bbff73c-cf56-4b72-ac2a-01354e0f0f78" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#OtherComprehensiveIncomeLossAOCIDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_92590188-68ba-4d7c-9bee-c4d14d840a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_f3112beb-95e6-42e6-abdc-c379d3cb7138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_92590188-68ba-4d7c-9bee-c4d14d840a32" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_f3112beb-95e6-42e6-abdc-c379d3cb7138" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_e18fc64d-cfe3-4533-a66d-b0fb3134dd0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_92590188-68ba-4d7c-9bee-c4d14d840a32" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_e18fc64d-cfe3-4533-a66d-b0fb3134dd0c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#OtherNetIncomeExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_414f5215-1eb7-4426-87ef-b367a8d8a335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_90262cdf-3299-4552-ad54-42992da21c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_414f5215-1eb7-4426-87ef-b367a8d8a335" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_90262cdf-3299-4552-ad54-42992da21c9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a889f686-fb2a-42c1-ae87-81346886005a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_414f5215-1eb7-4426-87ef-b367a8d8a335" xlink:to="loc_us-gaap_InterestExpense_a889f686-fb2a-42c1-ae87-81346886005a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_035cf58e-d575-46aa-b8b1-4bd18df0a2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_414f5215-1eb7-4426-87ef-b367a8d8a335" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_035cf58e-d575-46aa-b8b1-4bd18df0a2f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_adc421e1-b3e2-4e6e-ad22-6130c8b03503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_414f5215-1eb7-4426-87ef-b367a8d8a335" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_adc421e1-b3e2-4e6e-ad22-6130c8b03503" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_fbac0a49-ad4b-4708-9034-683a563c1097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_414f5215-1eb7-4426-87ef-b367a8d8a335" xlink:to="loc_us-gaap_InvestmentIncomeInterest_fbac0a49-ad4b-4708-9034-683a563c1097" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_bc5efc73-2448-43cb-9898-c26606214037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_414f5215-1eb7-4426-87ef-b367a8d8a335" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_bc5efc73-2448-43cb-9898-c26606214037" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>lly-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:83f390d0-6781-4e7e-a1f5-5192701136a4,g:3039e280-7bbd-437e-b91e-6280679dfdce-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20210930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended" id="if2221fde23954ab8a26bc87630808ea8_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d8ac3641-2a34-4ee5-bd53-0a0ad46ac318" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_DocumentType_d8ac3641-2a34-4ee5-bd53-0a0ad46ac318" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_953c5654-baae-433d-bd69-b85fe407f502" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_DocumentQuarterlyReport_953c5654-baae-433d-bd69-b85fe407f502" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_44234af1-cf0f-4546-9f18-f5a491f99649" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_DocumentTransitionReport_44234af1-cf0f-4546-9f18-f5a491f99649" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_52b76c0f-8ec0-4196-ae54-ad1561876123" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_DocumentPeriodEndDate_52b76c0f-8ec0-4196-ae54-ad1561876123" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1b0cb4bb-3022-42b2-ad11-35a39ad48ea4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityFileNumber_1b0cb4bb-3022-42b2-ad11-35a39ad48ea4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e78cdd33-c36b-4b99-9f5c-2fda8c2bae16" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityRegistrantName_e78cdd33-c36b-4b99-9f5c-2fda8c2bae16" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9a0b05ac-4d45-4117-a5fd-18a0d71dd350" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9a0b05ac-4d45-4117-a5fd-18a0d71dd350" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1fa56348-986b-425d-a703-19050d07f2fd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityTaxIdentificationNumber_1fa56348-986b-425d-a703-19050d07f2fd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d8e9193c-7fb0-4f07-9e0b-a91fe9e661d9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityAddressAddressLine1_d8e9193c-7fb0-4f07-9e0b-a91fe9e661d9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7b02e455-79a2-475f-b094-32c055d4cb5d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityAddressCityOrTown_7b02e455-79a2-475f-b094-32c055d4cb5d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a36d35f5-19d5-4782-9ce7-f82632fceb62" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityAddressStateOrProvince_a36d35f5-19d5-4782-9ce7-f82632fceb62" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_26767187-c7fe-4150-938d-c9ee03f25a09" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityAddressPostalZipCode_26767187-c7fe-4150-938d-c9ee03f25a09" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b3fc5b13-7d8c-4f7e-88bd-6698929125ff" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_CityAreaCode_b3fc5b13-7d8c-4f7e-88bd-6698929125ff" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_60664da3-ca7b-4d68-910c-cd9d4d145519" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_LocalPhoneNumber_60664da3-ca7b-4d68-910c-cd9d4d145519" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_05978ce8-f367-4a2f-a03d-be6843902959" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_Security12bTitle_05978ce8-f367-4a2f-a03d-be6843902959" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b14c079d-c40b-4cd5-bfe4-d78001996b5d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_TradingSymbol_b14c079d-c40b-4cd5-bfe4-d78001996b5d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6a3be7d9-f498-465a-ac3d-07b59e06bb7b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_SecurityExchangeName_6a3be7d9-f498-465a-ac3d-07b59e06bb7b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d513e1cd-86a4-441b-b326-67052f913ad9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityCurrentReportingStatus_d513e1cd-86a4-441b-b326-67052f913ad9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ea9e5f1d-157e-4205-8dd0-0d9404eea1f4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityInteractiveDataCurrent_ea9e5f1d-157e-4205-8dd0-0d9404eea1f4" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_57900e87-de40-4232-ac87-df57e6e9db03" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityFilerCategory_57900e87-de40-4232-ac87-df57e6e9db03" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_6097048e-3bd9-460b-a5e8-797a8e4e1065" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntitySmallBusiness_6097048e-3bd9-460b-a5e8-797a8e4e1065" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_68e2a54b-072a-414e-a8a1-ecbe236b9952" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityEmergingGrowthCompany_68e2a54b-072a-414e-a8a1-ecbe236b9952" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e70d3cdd-c1e4-4845-a995-411334038e9c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityShellCompany_e70d3cdd-c1e4-4845-a995-411334038e9c" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e2368975-87db-413b-9863-4aa74e1870fb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e2368975-87db-413b-9863-4aa74e1870fb" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0b917da1-233c-46d3-840f-54515936e333" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_AmendmentFlag_0b917da1-233c-46d3-840f-54515936e333" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_263604f3-692f-4466-ba19-28e860e0981f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_DocumentFiscalYearFocus_263604f3-692f-4466-ba19-28e860e0981f" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d3d26e29-6dc6-4e61-8b54-631c424ea136" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d3d26e29-6dc6-4e61-8b54-631c424ea136" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_372abf23-6a18-4775-889b-f932b102319e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityCentralIndexKey_372abf23-6a18-4775-889b-f932b102319e" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_186d712e-0d50-4e41-8474-adb5c3bb62c1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_CurrentFiscalYearEndDate_186d712e-0d50-4e41-8474-adb5c3bb62c1" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_831077f7-5d96-4d72-b3d0-e9ab74879336" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_DocumentInformationTable_831077f7-5d96-4d72-b3d0-e9ab74879336" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1dea2afa-26c9-4a7c-8dec-26871925c682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_831077f7-5d96-4d72-b3d0-e9ab74879336" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1dea2afa-26c9-4a7c-8dec-26871925c682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1dea2afa-26c9-4a7c-8dec-26871925c682_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1dea2afa-26c9-4a7c-8dec-26871925c682" xlink:to="loc_us-gaap_ClassOfStockDomain_1dea2afa-26c9-4a7c-8dec-26871925c682_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1dea2afa-26c9-4a7c-8dec-26871925c682" xlink:to="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_f1142436-f587-4460-b724-2951b4df0b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_us-gaap_CommonClassAMember_f1142436-f587-4460-b724-2951b4df0b2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.000NotesDueJune22022Member_09a076b9-5f7d-4858-a55f-806d2524b1b7" xlink:href="lly-20210930.xsd#lly_A1.000NotesDueJune22022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_lly_A1.000NotesDueJune22022Member_09a076b9-5f7d-4858-a55f-806d2524b1b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_dcb5d9c3-8f7c-43e5-b486-056d3c1a13f1" xlink:href="lly-20210930.xsd#lly_A718NotesDueJune12025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_lly_A718NotesDueJune12025Member_dcb5d9c3-8f7c-43e5-b486-056d3c1a13f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_ff8411ca-996e-4fb5-8ce3-103766b4d75f" xlink:href="lly-20210930.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_lly_A1.625NotesDueJune22026Member_ff8411ca-996e-4fb5-8ce3-103766b4d75f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_7c2125b0-acb0-4bba-b7e1-c81ccbf39072" xlink:href="lly-20210930.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_lly_A2.125NotesDueJune32030Member_7c2125b0-acb0-4bba-b7e1-c81ccbf39072" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_d4e99d46-96a6-4955-8935-89d2988c563c" xlink:href="lly-20210930.xsd#lly_A625Notesdue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_lly_A625Notesdue2031Member_d4e99d46-96a6-4955-8935-89d2988c563c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A5000NotesDue2033Member_3c5d99b9-5b86-4c7b-a73b-f55f5e661314" xlink:href="lly-20210930.xsd#lly_A5000NotesDue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_lly_A5000NotesDue2033Member_3c5d99b9-5b86-4c7b-a73b-f55f5e661314" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_3ca47e0b-8982-4174-9b6e-9f8003724561" xlink:href="lly-20210930.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_3ca47e0b-8982-4174-9b6e-9f8003724561" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_4071fab0-c142-4402-ade1-4719309c1517" xlink:href="lly-20210930.xsd#lly_A1625NotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_lly_A1625NotesDue2043Member_4071fab0-c142-4402-ade1-4719309c1517" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_aa12998d-f1ef-4ce3-89cc-54afc5cdcc47" xlink:href="lly-20210930.xsd#lly_A1.700Notesdue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_lly_A1.700Notesdue2049Member_aa12998d-f1ef-4ce3-89cc-54afc5cdcc47" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_1f54d1b5-58aa-429d-8cf5-ef9f2a4cc842" xlink:href="lly-20210930.xsd#lly_A1125NotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_lly_A1125NotesDue2051Member_1f54d1b5-58aa-429d-8cf5-ef9f2a4cc842" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_8a4ea535-f243-40cb-98b7-bb0d7c2c1687" xlink:href="lly-20210930.xsd#lly_A1375NotesDue2061Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_lly_A1375NotesDue2061Member_8a4ea535-f243-40cb-98b7-bb0d7c2c1687" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity" xlink:type="simple" xlink:href="lly-20210930.xsd#ConsolidatedCondensedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity" xlink:type="extended" id="ia3599518ea174a86ace9f5e6fa29b360_ConsolidatedCondensedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5bd598ab-4a9a-4feb-8b1b-e663c8d7e094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5bd598ab-4a9a-4feb-8b1b-e663c8d7e094" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_84c5b8fe-5153-4bdd-932e-39c4fdfbd01b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_SharesIssued_84c5b8fe-5153-4bdd-932e-39c4fdfbd01b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_44500a30-160d-457b-8dff-e652a28baf26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_44500a30-160d-457b-8dff-e652a28baf26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7bdfd4c8-500f-485d-b458-8f4d2ee644e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_ProfitLoss_7bdfd4c8-500f-485d-b458-8f4d2ee644e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8020eabd-8092-47bd-bd35-eff8dd7c20a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8020eabd-8092-47bd-bd35-eff8dd7c20a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_d4d947f3-8209-4c30-b6a0-ffd42a9359a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_Dividends_d4d947f3-8209-4c30-b6a0-ffd42a9359a6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_3b03feee-9102-40b5-95ed-b5d408614681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_3b03feee-9102-40b5-95ed-b5d408614681" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_e95d9ca5-6dc4-4a57-ae31-ffe05c13ccf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_e95d9ca5-6dc4-4a57-ae31-ffe05c13ccf2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_0713cc09-72c8-4da5-aa41-d09cb1ba90b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_0713cc09-72c8-4da5-aa41-d09cb1ba90b7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_06ddc31f-4fd6-4e47-a6b8-5c4f3f8cfe0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_06ddc31f-4fd6-4e47-a6b8-5c4f3f8cfe0e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7a933b0c-1d55-4ceb-b014-3442101b28d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7a933b0c-1d55-4ceb-b014-3442101b28d3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ea76c679-1b97-4ee2-b0ac-d35c20e7d3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ea76c679-1b97-4ee2-b0ac-d35c20e7d3f0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6310c436-960b-4738-9362-197f1998003c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6310c436-960b-4738-9362-197f1998003c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_b15aee82-9e5e-43aa-94af-f69921bc30a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_StockholdersEquityOther_b15aee82-9e5e-43aa-94af-f69921bc30a3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_459edfe2-0d1a-4842-97a3-03e26ff926db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c5b2dee6-41f2-4464-80fd-edc8feddf712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e593532f-6808-4244-a242-44732fc84604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5bd598ab-4a9a-4feb-8b1b-e663c8d7e094" xlink:to="loc_us-gaap_StatementTable_e593532f-6808-4244-a242-44732fc84604" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3bf08dab-eda6-4254-b129-3d3192344b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e593532f-6808-4244-a242-44732fc84604" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3bf08dab-eda6-4254-b129-3d3192344b3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3bf08dab-eda6-4254-b129-3d3192344b3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3bf08dab-eda6-4254-b129-3d3192344b3c" xlink:to="loc_us-gaap_EquityComponentDomain_3bf08dab-eda6-4254-b129-3d3192344b3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_47f6fbcf-a40f-4f18-bd2b-8a9ea7017e23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3bf08dab-eda6-4254-b129-3d3192344b3c" xlink:to="loc_us-gaap_EquityComponentDomain_47f6fbcf-a40f-4f18-bd2b-8a9ea7017e23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9b872143-4753-4448-982c-29d6f5160ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_47f6fbcf-a40f-4f18-bd2b-8a9ea7017e23" xlink:to="loc_us-gaap_CommonStockMember_9b872143-4753-4448-982c-29d6f5160ea5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_78215162-e281-4ee8-9de8-97bfa04bcefa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_47f6fbcf-a40f-4f18-bd2b-8a9ea7017e23" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_78215162-e281-4ee8-9de8-97bfa04bcefa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_149b58ad-2f83-4b1b-a2ea-abcf5e6cff9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_47f6fbcf-a40f-4f18-bd2b-8a9ea7017e23" xlink:to="loc_us-gaap_RetainedEarningsMember_149b58ad-2f83-4b1b-a2ea-abcf5e6cff9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrustForBenefitOfEmployeesMember_30a38348-647b-496b-917b-121fc3106f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrustForBenefitOfEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_47f6fbcf-a40f-4f18-bd2b-8a9ea7017e23" xlink:to="loc_us-gaap_TrustForBenefitOfEmployeesMember_30a38348-647b-496b-917b-121fc3106f7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_81ad3c28-be96-45ae-8e50-f4968d6dc8de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_47f6fbcf-a40f-4f18-bd2b-8a9ea7017e23" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_81ad3c28-be96-45ae-8e50-f4968d6dc8de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_3e29e93a-2f62-4dea-bad0-bd67884505c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_47f6fbcf-a40f-4f18-bd2b-8a9ea7017e23" xlink:to="loc_us-gaap_TreasuryStockMember_3e29e93a-2f62-4dea-bad0-bd67884505c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_3580bd75-e7f6-4a75-81e5-559588893800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_47f6fbcf-a40f-4f18-bd2b-8a9ea7017e23" xlink:to="loc_us-gaap_NoncontrollingInterestMember_3580bd75-e7f6-4a75-81e5-559588893800" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#RevenueSummaryofRevenueRecognizedDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="extended" id="i482ef47a90cd44d096deabbab0c5ec52_RevenueSummaryofRevenueRecognizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_de3e8d11-ac42-448e-a6f8-9e4f1aa05eef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bbd798e2-38cf-4138-be29-942553b7ee88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_de3e8d11-ac42-448e-a6f8-9e4f1aa05eef" xlink:to="loc_us-gaap_Revenues_bbd798e2-38cf-4138-be29-942553b7ee88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5b76bae5-7dfd-4eea-a44d-5985116156de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_de3e8d11-ac42-448e-a6f8-9e4f1aa05eef" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5b76bae5-7dfd-4eea-a44d-5985116156de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_690e337e-818e-4770-8cc8-6ada95343c90" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5b76bae5-7dfd-4eea-a44d-5985116156de" xlink:to="loc_srt_ProductOrServiceAxis_690e337e-818e-4770-8cc8-6ada95343c90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_690e337e-818e-4770-8cc8-6ada95343c90_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_690e337e-818e-4770-8cc8-6ada95343c90" xlink:to="loc_srt_ProductsAndServicesDomain_690e337e-818e-4770-8cc8-6ada95343c90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_511743f7-1233-449b-9712-b10d60870338" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_690e337e-818e-4770-8cc8-6ada95343c90" xlink:to="loc_srt_ProductsAndServicesDomain_511743f7-1233-449b-9712-b10d60870338" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_04edd7ff-9287-44c8-9558-ad955bba02e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_511743f7-1233-449b-9712-b10d60870338" xlink:to="loc_us-gaap_ProductMember_04edd7ff-9287-44c8-9558-ad955bba02e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborationandOtherRevenueMember_ff53dce9-9d5e-4339-9fff-d2403b6c61a4" xlink:href="lly-20210930.xsd#lly_CollaborationandOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_511743f7-1233-449b-9712-b10d60870338" xlink:to="loc_lly_CollaborationandOtherRevenueMember_ff53dce9-9d5e-4339-9fff-d2403b6c61a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_b5b10153-b6ea-4f60-937c-e9367685692d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_511743f7-1233-449b-9712-b10d60870338" xlink:to="loc_us-gaap_RoyaltyMember_b5b10153-b6ea-4f60-937c-e9367685692d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#RevenueAdjustmentstoRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails" xlink:type="extended" id="i0facda762774446588c3663e0e53ae3f_RevenueAdjustmentstoRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems_dc5606eb-f9b8-4cc1-a857-da3a139bd709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_1cc21519-fe9b-4049-91ff-ce11039f5206" xlink:href="lly-20210930.xsd#lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_dc5606eb-f9b8-4cc1-a857-da3a139bd709" xlink:to="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_1cc21519-fe9b-4049-91ff-ce11039f5206" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_fa4d0bc2-e3e5-4492-902b-37c063f454b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_dc5606eb-f9b8-4cc1-a857-da3a139bd709" xlink:to="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_fa4d0bc2-e3e5-4492-902b-37c063f454b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_08ef3c5f-b602-4eb2-a067-03d72cfc6ecd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_fa4d0bc2-e3e5-4492-902b-37c063f454b2" xlink:to="loc_srt_StatementGeographicalAxis_08ef3c5f-b602-4eb2-a067-03d72cfc6ecd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_08ef3c5f-b602-4eb2-a067-03d72cfc6ecd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_08ef3c5f-b602-4eb2-a067-03d72cfc6ecd" xlink:to="loc_srt_SegmentGeographicalDomain_08ef3c5f-b602-4eb2-a067-03d72cfc6ecd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2085dd6c-c124-4fc9-ae16-a533dd3cb7be" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_08ef3c5f-b602-4eb2-a067-03d72cfc6ecd" xlink:to="loc_srt_SegmentGeographicalDomain_2085dd6c-c124-4fc9-ae16-a533dd3cb7be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_22601b8c-63bd-41a1-a319-6fa94709002d" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2085dd6c-c124-4fc9-ae16-a533dd3cb7be" xlink:to="loc_country_US_22601b8c-63bd-41a1-a319-6fa94709002d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_6fbe76ed-68e5-41ee-9137-9ab688addeb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_fa4d0bc2-e3e5-4492-902b-37c063f454b2" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_6fbe76ed-68e5-41ee-9137-9ab688addeb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_6fbe76ed-68e5-41ee-9137-9ab688addeb1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_6fbe76ed-68e5-41ee-9137-9ab688addeb1" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_6fbe76ed-68e5-41ee-9137-9ab688addeb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_145e9dc9-b9d5-47c3-ab07-14c1864c2349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_6fbe76ed-68e5-41ee-9137-9ab688addeb1" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_145e9dc9-b9d5-47c3-ab07-14c1864c2349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_7c846cae-8716-485f-993b-f3b4310a9e53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_145e9dc9-b9d5-47c3-ab07-14c1864c2349" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_7c846cae-8716-485f-993b-f3b4310a9e53" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#RevenueDisaggregationofRevenuebyProductDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="extended" id="ia11fbc008d2d4db5b750826bf3552877_RevenueDisaggregationofRevenuebyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3f7110e8-132f-49d7-ab93-7e919a6cc2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f0e7b6bf-b8fd-47da-85ea-ccea8fe97179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3f7110e8-132f-49d7-ab93-7e919a6cc2a1" xlink:to="loc_us-gaap_Revenues_f0e7b6bf-b8fd-47da-85ea-ccea8fe97179" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6e8b782c-b0d3-46a7-ac0d-def0c52825a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3f7110e8-132f-49d7-ab93-7e919a6cc2a1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6e8b782c-b0d3-46a7-ac0d-def0c52825a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ccd40812-6758-4567-88cb-1b47604e5aae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6e8b782c-b0d3-46a7-ac0d-def0c52825a6" xlink:to="loc_srt_ProductOrServiceAxis_ccd40812-6758-4567-88cb-1b47604e5aae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ccd40812-6758-4567-88cb-1b47604e5aae_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ccd40812-6758-4567-88cb-1b47604e5aae" xlink:to="loc_srt_ProductsAndServicesDomain_ccd40812-6758-4567-88cb-1b47604e5aae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_33a3e01f-d3c6-434c-8446-fcb2d8d2d27d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ccd40812-6758-4567-88cb-1b47604e5aae" xlink:to="loc_srt_ProductsAndServicesDomain_33a3e01f-d3c6-434c-8446-fcb2d8d2d27d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DiabetesMember_7dc57d92-fedf-49a5-9c76-3a0741e7d31f" xlink:href="lly-20210930.xsd#lly_DiabetesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_33a3e01f-d3c6-434c-8446-fcb2d8d2d27d" xlink:to="loc_lly_DiabetesMember_7dc57d92-fedf-49a5-9c76-3a0741e7d31f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrulicityMemberMember_77b8323e-5c70-43a7-bd7a-7a5009651af0" xlink:href="lly-20210930.xsd#lly_TrulicityMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_7dc57d92-fedf-49a5-9c76-3a0741e7d31f" xlink:to="loc_lly_TrulicityMemberMember_77b8323e-5c70-43a7-bd7a-7a5009651af0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogMember_34757186-8c8a-4b8a-84dd-ee25b3f1fea0" xlink:href="lly-20210930.xsd#lly_HumalogMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_7dc57d92-fedf-49a5-9c76-3a0741e7d31f" xlink:to="loc_lly_HumalogMember_34757186-8c8a-4b8a-84dd-ee25b3f1fea0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_8308c2b7-d6dd-4e86-9c68-a07fadb5496c" xlink:href="lly-20210930.xsd#lly_JardianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_7dc57d92-fedf-49a5-9c76-3a0741e7d31f" xlink:to="loc_lly_JardianceMember_8308c2b7-d6dd-4e86-9c68-a07fadb5496c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumulinMember_feb20046-ad7f-42d0-b717-b6b76f722015" xlink:href="lly-20210930.xsd#lly_HumulinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_7dc57d92-fedf-49a5-9c76-3a0741e7d31f" xlink:to="loc_lly_HumulinMember_feb20046-ad7f-42d0-b717-b6b76f722015" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_13d4ebfe-b31c-49e7-8570-39fcfc6c0683" xlink:href="lly-20210930.xsd#lly_BasaglarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_7dc57d92-fedf-49a5-9c76-3a0741e7d31f" xlink:to="loc_lly_BasaglarMember_13d4ebfe-b31c-49e7-8570-39fcfc6c0683" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherDiabetesMember_2717a86d-49f0-497f-a4f0-4dd180e952ce" xlink:href="lly-20210930.xsd#lly_OtherDiabetesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DiabetesMember_7dc57d92-fedf-49a5-9c76-3a0741e7d31f" xlink:to="loc_lly_OtherDiabetesMember_2717a86d-49f0-497f-a4f0-4dd180e952ce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OncologyMember_07ad7466-50a3-49ca-9bc7-c3e91d1d50c6" xlink:href="lly-20210930.xsd#lly_OncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_33a3e01f-d3c6-434c-8446-fcb2d8d2d27d" xlink:to="loc_lly_OncologyMember_07ad7466-50a3-49ca-9bc7-c3e91d1d50c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaMember_a827aa90-4c90-4c1d-850d-9860df3a995e" xlink:href="lly-20210930.xsd#lly_AlimtaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_07ad7466-50a3-49ca-9bc7-c3e91d1d50c6" xlink:to="loc_lly_AlimtaMember_a827aa90-4c90-4c1d-850d-9860df3a995e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VerzenioMember_f5707758-1eab-4dfd-88da-33bba16c50f8" xlink:href="lly-20210930.xsd#lly_VerzenioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_07ad7466-50a3-49ca-9bc7-c3e91d1d50c6" xlink:to="loc_lly_VerzenioMember_f5707758-1eab-4dfd-88da-33bba16c50f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CyramzaMember_8b652d86-3a59-4541-a87a-c26330bcbeda" xlink:href="lly-20210930.xsd#lly_CyramzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_07ad7466-50a3-49ca-9bc7-c3e91d1d50c6" xlink:to="loc_lly_CyramzaMember_8b652d86-3a59-4541-a87a-c26330bcbeda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ErbituxMember_72a4bca5-ef7a-4787-b21c-1dfd4b2cdbba" xlink:href="lly-20210930.xsd#lly_ErbituxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_07ad7466-50a3-49ca-9bc7-c3e91d1d50c6" xlink:to="loc_lly_ErbituxMember_72a4bca5-ef7a-4787-b21c-1dfd4b2cdbba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember_609e4a92-640c-49a5-979c-4d1f0365ac6c" xlink:href="lly-20210930.xsd#lly_TYVYTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_07ad7466-50a3-49ca-9bc7-c3e91d1d50c6" xlink:to="loc_lly_TYVYTMember_609e4a92-640c-49a5-979c-4d1f0365ac6c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherOncologyMember_56cc8ac0-38b7-4a2b-9277-12ac27bb91fb" xlink:href="lly-20210930.xsd#lly_OtherOncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OncologyMember_07ad7466-50a3-49ca-9bc7-c3e91d1d50c6" xlink:to="loc_lly_OtherOncologyMember_56cc8ac0-38b7-4a2b-9277-12ac27bb91fb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmunologyMember_6e5e72ac-8b57-4ca0-a6f4-4393364b9b7b" xlink:href="lly-20210930.xsd#lly_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_33a3e01f-d3c6-434c-8446-fcb2d8d2d27d" xlink:to="loc_lly_ImmunologyMember_6e5e72ac-8b57-4ca0-a6f4-4393364b9b7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaltzMember_4087d63e-f378-4837-936c-c324346e02ce" xlink:href="lly-20210930.xsd#lly_TaltzMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_ImmunologyMember_6e5e72ac-8b57-4ca0-a6f4-4393364b9b7b" xlink:to="loc_lly_TaltzMember_4087d63e-f378-4837-936c-c324346e02ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_e4f57fcb-a663-456d-890b-b5b52868d620" xlink:href="lly-20210930.xsd#lly_OlumiantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_ImmunologyMember_6e5e72ac-8b57-4ca0-a6f4-4393364b9b7b" xlink:to="loc_lly_OlumiantMember_e4f57fcb-a663-456d-890b-b5b52868d620" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherImmunologyMember_b5009049-39b1-4923-8888-399194ddf35b" xlink:href="lly-20210930.xsd#lly_OtherImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_ImmunologyMember_6e5e72ac-8b57-4ca0-a6f4-4393364b9b7b" xlink:to="loc_lly_OtherImmunologyMember_b5009049-39b1-4923-8888-399194ddf35b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NeuroscienceMember_06bbe130-317c-492d-be76-f1ebd1716859" xlink:href="lly-20210930.xsd#lly_NeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_33a3e01f-d3c6-434c-8446-fcb2d8d2d27d" xlink:to="loc_lly_NeuroscienceMember_06bbe130-317c-492d-be76-f1ebd1716859" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityMember_dcfe5cc7-9ae0-4779-9c04-126bbd73e571" xlink:href="lly-20210930.xsd#lly_EmgalityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_06bbe130-317c-492d-be76-f1ebd1716859" xlink:to="loc_lly_EmgalityMember_dcfe5cc7-9ae0-4779-9c04-126bbd73e571" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CymbaltaMember_2cca9aee-bc40-432d-9d65-13d6df06d22f" xlink:href="lly-20210930.xsd#lly_CymbaltaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_06bbe130-317c-492d-be76-f1ebd1716859" xlink:to="loc_lly_CymbaltaMember_2cca9aee-bc40-432d-9d65-13d6df06d22f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ZyprexaMember_64ac31ab-70b3-475c-bea6-6ff1dc93b78a" xlink:href="lly-20210930.xsd#lly_ZyprexaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_06bbe130-317c-492d-be76-f1ebd1716859" xlink:to="loc_lly_ZyprexaMember_64ac31ab-70b3-475c-bea6-6ff1dc93b78a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherNeuroscienceMember_82ea510e-d613-4fa8-9601-537999beda0a" xlink:href="lly-20210930.xsd#lly_OtherNeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_NeuroscienceMember_06bbe130-317c-492d-be76-f1ebd1716859" xlink:to="loc_lly_OtherNeuroscienceMember_82ea510e-d613-4fa8-9601-537999beda0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductTotalMember_95173e97-9113-4192-a25f-bd34b84e4478" xlink:href="lly-20210930.xsd#lly_OtherProductTotalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_33a3e01f-d3c6-434c-8446-fcb2d8d2d27d" xlink:to="loc_lly_OtherProductTotalMember_95173e97-9113-4192-a25f-bd34b84e4478" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_03c68271-6154-45c6-a4b5-95fdde97c059" xlink:href="lly-20210930.xsd#lly_COVID19AntibodiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_95173e97-9113-4192-a25f-bd34b84e4478" xlink:to="loc_lly_COVID19AntibodiesMember_03c68271-6154-45c6-a4b5-95fdde97c059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForteoMember_87a4ca76-3ae4-497f-93f9-fc3676fa79e3" xlink:href="lly-20210930.xsd#lly_ForteoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_95173e97-9113-4192-a25f-bd34b84e4478" xlink:to="loc_lly_ForteoMember_87a4ca76-3ae4-497f-93f9-fc3676fa79e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember_81f0dd48-438c-48e4-9a78-093458e998e6" xlink:href="lly-20210930.xsd#lly_CialisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_95173e97-9113-4192-a25f-bd34b84e4478" xlink:to="loc_lly_CialisMember_81f0dd48-438c-48e4-9a78-093458e998e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductMember_5e04bc56-0259-4ff0-8099-74ce274c8507" xlink:href="lly-20210930.xsd#lly_OtherProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_OtherProductTotalMember_95173e97-9113-4192-a25f-bd34b84e4478" xlink:to="loc_lly_OtherProductMember_5e04bc56-0259-4ff0-8099-74ce274c8507" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_642d60f3-e4e0-4745-ad38-1edb89b39191" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6e8b782c-b0d3-46a7-ac0d-def0c52825a6" xlink:to="loc_srt_StatementGeographicalAxis_642d60f3-e4e0-4745-ad38-1edb89b39191" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_642d60f3-e4e0-4745-ad38-1edb89b39191_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_642d60f3-e4e0-4745-ad38-1edb89b39191" xlink:to="loc_srt_SegmentGeographicalDomain_642d60f3-e4e0-4745-ad38-1edb89b39191_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3b29aa87-3c00-4ccf-8689-1aa050226079" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_642d60f3-e4e0-4745-ad38-1edb89b39191" xlink:to="loc_srt_SegmentGeographicalDomain_3b29aa87-3c00-4ccf-8689-1aa050226079" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_347a936d-35f5-44f7-8b09-eefe9ba6bd93" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3b29aa87-3c00-4ccf-8689-1aa050226079" xlink:to="loc_country_US_347a936d-35f5-44f7-8b09-eefe9ba6bd93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_a5d6e2ad-07c0-47b4-8a07-d4ecd9773efb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3b29aa87-3c00-4ccf-8689-1aa050226079" xlink:to="loc_us-gaap_NonUsMember_a5d6e2ad-07c0-47b4-8a07-d4ecd9773efb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#RevenueDisaggregationofRevenuebyGeographicalAreaDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="extended" id="i43596fe5ee8b4f498e758b93326e13f8_RevenueDisaggregationofRevenuebyGeographicalAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5f05a582-65dc-43e5-9404-092524d9ecc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c68deb26-a6f2-49df-a399-9342531b4549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5f05a582-65dc-43e5-9404-092524d9ecc8" xlink:to="loc_us-gaap_Revenues_c68deb26-a6f2-49df-a399-9342531b4549" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a2b8b636-5db6-4a41-8b0c-5047794fba0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5f05a582-65dc-43e5-9404-092524d9ecc8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a2b8b636-5db6-4a41-8b0c-5047794fba0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3154f6e0-d965-4fc1-ae74-30e9c0b848a5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a2b8b636-5db6-4a41-8b0c-5047794fba0a" xlink:to="loc_srt_StatementGeographicalAxis_3154f6e0-d965-4fc1-ae74-30e9c0b848a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3154f6e0-d965-4fc1-ae74-30e9c0b848a5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_3154f6e0-d965-4fc1-ae74-30e9c0b848a5" xlink:to="loc_srt_SegmentGeographicalDomain_3154f6e0-d965-4fc1-ae74-30e9c0b848a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f00a0c26-ea38-4517-9047-98849729dbf9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_3154f6e0-d965-4fc1-ae74-30e9c0b848a5" xlink:to="loc_srt_SegmentGeographicalDomain_f00a0c26-ea38-4517-9047-98849729dbf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_bc0970b7-1435-4b7a-ac65-d1d5b080cdf1" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f00a0c26-ea38-4517-9047-98849729dbf9" xlink:to="loc_country_US_bc0970b7-1435-4b7a-ac65-d1d5b080cdf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_8423fb42-b136-4887-95e3-2b3e407bd2c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f00a0c26-ea38-4517-9047-98849729dbf9" xlink:to="loc_srt_EuropeMember_8423fb42-b136-4887-95e3-2b3e407bd2c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_5f3bee4d-ce8f-4668-a7af-5b26c91b946a" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f00a0c26-ea38-4517-9047-98849729dbf9" xlink:to="loc_country_JP_5f3bee4d-ce8f-4668-a7af-5b26c91b946a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_38da8a0b-de30-4681-a2b6-fd57bdbc86b0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f00a0c26-ea38-4517-9047-98849729dbf9" xlink:to="loc_country_CN_38da8a0b-de30-4681-a2b6-fd57bdbc86b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember_22818ad0-d272-4e44-99cd-b71b3f430bb5" xlink:href="lly-20210930.xsd#lly_OtherForeignCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f00a0c26-ea38-4517-9047-98849729dbf9" xlink:to="loc_lly_OtherForeignCountriesMember_22818ad0-d272-4e44-99cd-b71b3f430bb5" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsNarrativeDetails" xlink:type="extended" id="i3fea2a1dcc2247cb868deeece03d3c73_AcquisitionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_76620f75-1239-4cdf-b8ee-80e84a46818a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_76620f75-1239-4cdf-b8ee-80e84a46818a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_d8bef0d2-0911-477e-859d-84e3982fae2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_d8bef0d2-0911-477e-859d-84e3982fae2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6b73cdb9-207c-4c32-83e5-e6a00c4b7ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6b73cdb9-207c-4c32-83e5-e6a00c4b7ca8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_48c58242-0a58-49f7-ab5e-9936233a0110" xlink:href="lly-20210930.xsd#lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_48c58242-0a58-49f7-ab5e-9936233a0110" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_c8a39c8f-c6dd-4a7f-8340-64d211d0db0b" xlink:href="lly-20210930.xsd#lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_c8a39c8f-c6dd-4a7f-8340-64d211d0db0b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_9da1a7c0-c60e-4c51-a28a-109d960be22d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_9da1a7c0-c60e-4c51-a28a-109d960be22d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_3d102a13-015f-4512-a01e-c61d11ab1f03" xlink:href="lly-20210930.xsd#lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_3d102a13-015f-4512-a01e-c61d11ab1f03" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_c4fb3f46-d788-4867-8c53-0d23b767473d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_c4fb3f46-d788-4867-8c53-0d23b767473d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_03e5b333-1140-42dd-b1d2-63cb85d19e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_us-gaap_Goodwill_03e5b333-1140-42dd-b1d2-63cb85d19e01" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e8d8aa54-db8f-4c93-90f0-9e7a8a9395b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e8d8aa54-db8f-4c93-90f0-9e7a8a9395b7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_6e8ea531-00a1-408b-b788-87e83fff28af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_6e8ea531-00a1-408b-b788-87e83fff28af" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_dfad0dc2-b49c-41e0-b6aa-81a1419efd21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_dfad0dc2-b49c-41e0-b6aa-81a1419efd21" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_009c9ffa-2761-4f51-befb-699ec6ef7c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_009c9ffa-2761-4f51-befb-699ec6ef7c5b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b377d11b-04ea-499d-8738-e928b95134c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b377d11b-04ea-499d-8738-e928b95134c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_098b68c7-3590-4e49-890e-1640b208a734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b377d11b-04ea-499d-8738-e928b95134c6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_098b68c7-3590-4e49-890e-1640b208a734" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_098b68c7-3590-4e49-890e-1640b208a734_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_098b68c7-3590-4e49-890e-1640b208a734" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_098b68c7-3590-4e49-890e-1640b208a734_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eb644b52-4128-4567-b7a4-42ca979b5d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_098b68c7-3590-4e49-890e-1640b208a734" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eb644b52-4128-4567-b7a4-42ca979b5d21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember_42ef9b2f-5e81-467e-a36a-7c11cad3c8ae" xlink:href="lly-20210930.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eb644b52-4128-4567-b7a4-42ca979b5d21" xlink:to="loc_lly_PrevailTherapeuticsIncMember_42ef9b2f-5e81-467e-a36a-7c11cad3c8ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DermiraInc.Member_a5ed8f86-f3eb-46c7-a268-7edea3e5c93c" xlink:href="lly-20210930.xsd#lly_DermiraInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eb644b52-4128-4567-b7a4-42ca979b5d21" xlink:to="loc_lly_DermiraInc.Member_a5ed8f86-f3eb-46c7-a268-7edea3e5c93c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="if3b09fd72bd544a19af399c883544fa9_AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_26659dfe-4072-42b1-aa2e-f66493691fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e520aeb5-1ba2-462f-ae90-27c2cba34494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_26659dfe-4072-42b1-aa2e-f66493691fd9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e520aeb5-1ba2-462f-ae90-27c2cba34494" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_50e73ad0-3726-4659-8cb3-38bc7833d8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_26659dfe-4072-42b1-aa2e-f66493691fd9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_50e73ad0-3726-4659-8cb3-38bc7833d8a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_39230a06-5572-44c0-a052-237b30c96335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_26659dfe-4072-42b1-aa2e-f66493691fd9" xlink:to="loc_us-gaap_Goodwill_39230a06-5572-44c0-a052-237b30c96335" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a032f281-aa5b-4bb9-8276-bda1bb339b06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_26659dfe-4072-42b1-aa2e-f66493691fd9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a032f281-aa5b-4bb9-8276-bda1bb339b06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_135607b8-2fd8-487a-866e-db235107c8cc" xlink:href="lly-20210930.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_26659dfe-4072-42b1-aa2e-f66493691fd9" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_135607b8-2fd8-487a-866e-db235107c8cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2ffd9634-6d36-4400-8ee5-6aadc0da1e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_26659dfe-4072-42b1-aa2e-f66493691fd9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2ffd9634-6d36-4400-8ee5-6aadc0da1e58" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_7d6fce3d-4ffe-40e5-a708-0bc2502356c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_26659dfe-4072-42b1-aa2e-f66493691fd9" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_7d6fce3d-4ffe-40e5-a708-0bc2502356c2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_0ca57a98-75d1-4f94-9771-e32159656738" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_26659dfe-4072-42b1-aa2e-f66493691fd9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_0ca57a98-75d1-4f94-9771-e32159656738" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5a3600ba-f3a5-4f4e-8291-8e1127dc4366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_26659dfe-4072-42b1-aa2e-f66493691fd9" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5a3600ba-f3a5-4f4e-8291-8e1127dc4366" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_93d2c1f3-0172-4c60-9308-05656f56a41e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_26659dfe-4072-42b1-aa2e-f66493691fd9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_93d2c1f3-0172-4c60-9308-05656f56a41e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9837497f-a6d5-49d3-97c8-4968d9d44f74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_93d2c1f3-0172-4c60-9308-05656f56a41e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9837497f-a6d5-49d3-97c8-4968d9d44f74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9837497f-a6d5-49d3-97c8-4968d9d44f74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9837497f-a6d5-49d3-97c8-4968d9d44f74" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9837497f-a6d5-49d3-97c8-4968d9d44f74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a86f0955-353d-4234-bf92-0bf4cf19786d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9837497f-a6d5-49d3-97c8-4968d9d44f74" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a86f0955-353d-4234-bf92-0bf4cf19786d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember_7362fa42-1b97-43b9-8963-a4137fdb11d8" xlink:href="lly-20210930.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a86f0955-353d-4234-bf92-0bf4cf19786d" xlink:to="loc_lly_PrevailTherapeuticsIncMember_7362fa42-1b97-43b9-8963-a4137fdb11d8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#AcquisitionsAssetAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails" xlink:type="extended" id="i1b3a4a11da504384a9b31a8ce3a9c415_AcquisitionsAssetAcquisitionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_61b49838-c2fb-4568-b584-64d5a65c92b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7fb607e4-ba96-498c-a921-290995693547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_61b49838-c2fb-4568-b584-64d5a65c92b1" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7fb607e4-ba96-498c-a921-290995693547" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_a33af3e5-b066-4191-bb4d-0395c16e74b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_61b49838-c2fb-4568-b584-64d5a65c92b1" xlink:to="loc_us-gaap_AssetAcquisitionTable_a33af3e5-b066-4191-bb4d-0395c16e74b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_a324b36d-016a-427c-8889-90d4f63c48e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_a33af3e5-b066-4191-bb4d-0395c16e74b2" xlink:to="loc_us-gaap_AssetAcquisitionAxis_a324b36d-016a-427c-8889-90d4f63c48e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_a324b36d-016a-427c-8889-90d4f63c48e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_a324b36d-016a-427c-8889-90d4f63c48e1" xlink:to="loc_us-gaap_AssetAcquisitionDomain_a324b36d-016a-427c-8889-90d4f63c48e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_a324b36d-016a-427c-8889-90d4f63c48e1" xlink:to="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrecisionBiosciencesIncMember_0408b1cb-2231-4371-bec0-c4461cd452f8" xlink:href="lly-20210930.xsd#lly_PrecisionBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_PrecisionBiosciencesIncMember_0408b1cb-2231-4371-bec0-c4461cd452f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MerusNVMember_34e2dd76-6797-4dc4-88df-5a86c6f7fd19" xlink:href="lly-20210930.xsd#lly_MerusNVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_MerusNVMember_34e2dd76-6797-4dc4-88df-5a86c6f7fd19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AsahiKaseiPharmaCorporationMember_1ca7037d-fc82-4253-8b1c-2118e6ab7b36" xlink:href="lly-20210930.xsd#lly_AsahiKaseiPharmaCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_AsahiKaseiPharmaCorporationMember_1ca7037d-fc82-4253-8b1c-2118e6ab7b36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RigelPharmaceuticalsIncMember_4030985d-85c9-4b00-ae0a-adc95ee1a22d" xlink:href="lly-20210930.xsd#lly_RigelPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_RigelPharmaceuticalsIncMember_4030985d-85c9-4b00-ae0a-adc95ee1a22d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MiNATherapeuticsLimitedMember_9daa56c8-3120-48df-9d5d-12defb11c06c" xlink:href="lly-20210930.xsd#lly_MiNATherapeuticsLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_MiNATherapeuticsLimitedMember_9daa56c8-3120-48df-9d5d-12defb11c06c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProtomerTechnologiesIncMember_90821605-2a4a-4a6b-920f-1ee2d50a2c42" xlink:href="lly-20210930.xsd#lly_ProtomerTechnologiesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_ProtomerTechnologiesIncMember_90821605-2a4a-4a6b-920f-1ee2d50a2c42" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_KumquatBiosciencesIncMember_13f888d4-5f5f-4cef-93d2-a953b4016bcb" xlink:href="lly-20210930.xsd#lly_KumquatBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_KumquatBiosciencesIncMember_13f888d4-5f5f-4cef-93d2-a953b4016bcb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LyciaTherapeuticsIncMember_3a8f8c6c-9205-480c-a488-cd126b7683a4" xlink:href="lly-20210930.xsd#lly_LyciaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_LyciaTherapeuticsIncMember_3a8f8c6c-9205-480c-a488-cd126b7683a4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProQRTherapeuticsNVMember_65d32318-a7f0-4f84-9006-b194fc5b4db6" xlink:href="lly-20210930.xsd#lly_ProQRTherapeuticsNVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_ProQRTherapeuticsNVMember_65d32318-a7f0-4f84-9006-b194fc5b4db6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SitryxTherapeuticsLimitedMember_160a75be-ccb7-4e8c-834b-c4ab82aa171d" xlink:href="lly-20210930.xsd#lly_SitryxTherapeuticsLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_SitryxTherapeuticsLimitedMember_160a75be-ccb7-4e8c-834b-c4ab82aa171d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AbCelleraBiologicsInc.Member_285f9972-887a-4dd9-9dcb-9c32ac97bb15" xlink:href="lly-20210930.xsd#lly_AbCelleraBiologicsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_AbCelleraBiologicsInc.Member_285f9972-887a-4dd9-9dcb-9c32ac97bb15" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JunshiBiosciencesMember_6506a389-736d-4ea9-9f2f-19c8d93a1f3b" xlink:href="lly-20210930.xsd#lly_JunshiBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_JunshiBiosciencesMember_6506a389-736d-4ea9-9f2f-19c8d93a1f3b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PetraPharmaCorporationMember_67a0102e-0853-46d1-b38c-03ece2ccdf33" xlink:href="lly-20210930.xsd#lly_PetraPharmaCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_PetraPharmaCorporationMember_67a0102e-0853-46d1-b38c-03ece2ccdf33" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EvoxTherapeuticsMember_662d2a44-aa61-4c93-990a-2fbbcfbaf2d3" xlink:href="lly-20210930.xsd#lly_EvoxTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_EvoxTherapeuticsMember_662d2a44-aa61-4c93-990a-2fbbcfbaf2d3" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#CollaborationsandOtherArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="extended" id="ifcf90ce3cd154ff7b3f8040e1edfc92d_CollaborationsandOtherArrangementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a5986bdc-16e7-4549-b672-200873100b58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_40be09e0-a557-42f7-bd32-333ef7562082" xlink:href="lly-20210930.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a5986bdc-16e7-4549-b672-200873100b58" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_40be09e0-a557-42f7-bd32-333ef7562082" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c12bad89-f56a-4c93-a3aa-9b57154cca75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a5986bdc-16e7-4549-b672-200873100b58" xlink:to="loc_us-gaap_Revenues_c12bad89-f56a-4c93-a3aa-9b57154cca75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_44fafc4e-f253-4ae5-8083-cd870eb79345" xlink:href="lly-20210930.xsd#lly_CollaborativeArrangementRightsAndObligationsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a5986bdc-16e7-4549-b672-200873100b58" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_44fafc4e-f253-4ae5-8083-cd870eb79345" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_44103a81-90e4-460a-806b-1a696176c215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a5986bdc-16e7-4549-b672-200873100b58" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_44103a81-90e4-460a-806b-1a696176c215" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_21f06597-0a27-492a-a14b-2f2d54740dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a5986bdc-16e7-4549-b672-200873100b58" xlink:to="loc_us-gaap_ContractWithCustomerLiability_21f06597-0a27-492a-a14b-2f2d54740dc0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d559456b-dc05-4219-a6ad-95b820265853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a5986bdc-16e7-4549-b672-200873100b58" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d559456b-dc05-4219-a6ad-95b820265853" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_427bfdd6-3df5-47fa-bc3d-ecede5fa799f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d559456b-dc05-4219-a6ad-95b820265853" xlink:to="loc_dei_LegalEntityAxis_427bfdd6-3df5-47fa-bc3d-ecede5fa799f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_427bfdd6-3df5-47fa-bc3d-ecede5fa799f_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_427bfdd6-3df5-47fa-bc3d-ecede5fa799f" xlink:to="loc_dei_EntityDomain_427bfdd6-3df5-47fa-bc3d-ecede5fa799f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_81638033-a0a3-471d-9924-02865b42c700" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_427bfdd6-3df5-47fa-bc3d-ecede5fa799f" xlink:to="loc_dei_EntityDomain_81638033-a0a3-471d-9924-02865b42c700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InnoventBiologicsIncMember_f1f4b3d3-ddff-4714-883d-dbe673ea0860" xlink:href="lly-20210930.xsd#lly_InnoventBiologicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_81638033-a0a3-471d-9924-02865b42c700" xlink:to="loc_lly_InnoventBiologicsIncMember_f1f4b3d3-ddff-4714-883d-dbe673ea0860" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RocheMember_e38545e2-ce3e-4e5e-b84d-292bf2978323" xlink:href="lly-20210930.xsd#lly_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_81638033-a0a3-471d-9924-02865b42c700" xlink:to="loc_lly_RocheMember_e38545e2-ce3e-4e5e-b84d-292bf2978323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_54c26dfa-c627-4f42-8cd9-242cd7111fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d559456b-dc05-4219-a6ad-95b820265853" xlink:to="loc_us-gaap_TypeOfArrangementAxis_54c26dfa-c627-4f42-8cd9-242cd7111fcd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54c26dfa-c627-4f42-8cd9-242cd7111fcd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_54c26dfa-c627-4f42-8cd9-242cd7111fcd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54c26dfa-c627-4f42-8cd9-242cd7111fcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce05c9b6-94a6-45fb-a730-250f9659f88f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_54c26dfa-c627-4f42-8cd9-242cd7111fcd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce05c9b6-94a6-45fb-a730-250f9659f88f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_69eb1664-70d1-4056-8503-2ec30eb8a0bc" xlink:href="lly-20210930.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce05c9b6-94a6-45fb-a730-250f9659f88f" xlink:to="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_69eb1664-70d1-4056-8503-2ec30eb8a0bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember_f2fe775d-7b9e-458c-8f7e-8f6a48e997e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce05c9b6-94a6-45fb-a730-250f9659f88f" xlink:to="loc_us-gaap_RoyaltyAgreementTermsMember_f2fe775d-7b9e-458c-8f7e-8f6a48e997e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_2af76e68-1a8f-4fa7-a836-2f5fa7e400c5" xlink:href="lly-20210930.xsd#lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce05c9b6-94a6-45fb-a730-250f9659f88f" xlink:to="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_2af76e68-1a8f-4fa7-a836-2f5fa7e400c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_851cbdfd-af7f-4765-9818-28f9fd49d4ab" xlink:href="lly-20210930.xsd#lly_MilestonePaymentsDevelopmentAndRegulatoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce05c9b6-94a6-45fb-a730-250f9659f88f" xlink:to="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_851cbdfd-af7f-4765-9818-28f9fd49d4ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSalesBasedMember_786d4d32-bd8b-401e-9ed9-e0f49b232fb1" xlink:href="lly-20210930.xsd#lly_MilestonePaymentsSalesBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce05c9b6-94a6-45fb-a730-250f9659f88f" xlink:to="loc_lly_MilestonePaymentsSalesBasedMember_786d4d32-bd8b-401e-9ed9-e0f49b232fb1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_e51b280c-ae81-4096-b7bc-107923964dcc" xlink:href="lly-20210930.xsd#lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce05c9b6-94a6-45fb-a730-250f9659f88f" xlink:to="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_e51b280c-ae81-4096-b7bc-107923964dcc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember_d79d04c9-d38a-4ff4-a93c-f09e89918da2" xlink:href="lly-20210930.xsd#lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce05c9b6-94a6-45fb-a730-250f9659f88f" xlink:to="loc_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember_d79d04c9-d38a-4ff4-a93c-f09e89918da2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember_81d49de2-8bde-4885-943b-974962d92488" xlink:href="lly-20210930.xsd#lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce05c9b6-94a6-45fb-a730-250f9659f88f" xlink:to="loc_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember_81d49de2-8bde-4885-943b-974962d92488" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_042aedd6-32c8-4211-a52b-38ba7d5623d0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d559456b-dc05-4219-a6ad-95b820265853" xlink:to="loc_srt_ProductOrServiceAxis_042aedd6-32c8-4211-a52b-38ba7d5623d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_042aedd6-32c8-4211-a52b-38ba7d5623d0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_042aedd6-32c8-4211-a52b-38ba7d5623d0" xlink:to="loc_srt_ProductsAndServicesDomain_042aedd6-32c8-4211-a52b-38ba7d5623d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3cb30cff-b706-4bac-b842-c1807408e0f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_042aedd6-32c8-4211-a52b-38ba7d5623d0" xlink:to="loc_srt_ProductsAndServicesDomain_3cb30cff-b706-4bac-b842-c1807408e0f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_bec39de6-2ffe-48b6-ad53-4964c5a55efc" xlink:href="lly-20210930.xsd#lly_JardianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3cb30cff-b706-4bac-b842-c1807408e0f2" xlink:to="loc_lly_JardianceMember_bec39de6-2ffe-48b6-ad53-4964c5a55efc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_886ab80b-cd17-4fed-86a9-4912259e1894" xlink:href="lly-20210930.xsd#lly_TrajentaBIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3cb30cff-b706-4bac-b842-c1807408e0f2" xlink:to="loc_lly_TrajentaBIMember_886ab80b-cd17-4fed-86a9-4912259e1894" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_c030103e-4294-4489-bc8b-b045b485bf2d" xlink:href="lly-20210930.xsd#lly_BasaglarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3cb30cff-b706-4bac-b842-c1807408e0f2" xlink:to="loc_lly_BasaglarMember_c030103e-4294-4489-bc8b-b045b485bf2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_6ade9755-0125-49c4-9c73-0bbeefd5c621" xlink:href="lly-20210930.xsd#lly_OlumiantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3cb30cff-b706-4bac-b842-c1807408e0f2" xlink:to="loc_lly_OlumiantMember_6ade9755-0125-49c4-9c73-0bbeefd5c621" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_019df287-6771-4602-9cc3-d380305fc4a7" xlink:href="lly-20210930.xsd#lly_COVID19AntibodiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3cb30cff-b706-4bac-b842-c1807408e0f2" xlink:to="loc_lly_COVID19AntibodiesMember_019df287-6771-4602-9cc3-d380305fc4a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember_538ba058-b0ce-4dd8-99b2-89b6c9dde62d" xlink:href="lly-20210930.xsd#lly_TYVYTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3cb30cff-b706-4bac-b842-c1807408e0f2" xlink:to="loc_lly_TYVYTMember_538ba058-b0ce-4dd8-99b2-89b6c9dde62d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LebrikizumabMember_8cf49795-111a-4635-b561-fdaefcc8bfd2" xlink:href="lly-20210930.xsd#lly_LebrikizumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3cb30cff-b706-4bac-b842-c1807408e0f2" xlink:to="loc_lly_LebrikizumabMember_8cf49795-111a-4635-b561-fdaefcc8bfd2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_79aef9b7-b979-4c93-ba17-c59ee739199c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d559456b-dc05-4219-a6ad-95b820265853" xlink:to="loc_srt_StatementGeographicalAxis_79aef9b7-b979-4c93-ba17-c59ee739199c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_79aef9b7-b979-4c93-ba17-c59ee739199c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_79aef9b7-b979-4c93-ba17-c59ee739199c" xlink:to="loc_srt_SegmentGeographicalDomain_79aef9b7-b979-4c93-ba17-c59ee739199c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f416abd1-cd89-485a-915d-f8b8500120c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_79aef9b7-b979-4c93-ba17-c59ee739199c" xlink:to="loc_srt_SegmentGeographicalDomain_f416abd1-cd89-485a-915d-f8b8500120c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NonCHINAMember_cc9d1469-b945-4515-a7ee-66341d64db67" xlink:href="lly-20210930.xsd#lly_NonCHINAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f416abd1-cd89-485a-915d-f8b8500120c8" xlink:to="loc_lly_NonCHINAMember_cc9d1469-b945-4515-a7ee-66341d64db67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_0ef39a41-9b34-49f9-9e1d-04dd195222d5" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f416abd1-cd89-485a-915d-f8b8500120c8" xlink:to="loc_country_CN_0ef39a41-9b34-49f9-9e1d-04dd195222d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_9d76a938-23d2-4fe1-927d-2a450fba7a54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d559456b-dc05-4219-a6ad-95b820265853" xlink:to="loc_us-gaap_AssetAcquisitionAxis_9d76a938-23d2-4fe1-927d-2a450fba7a54" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_9d76a938-23d2-4fe1-927d-2a450fba7a54_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_9d76a938-23d2-4fe1-927d-2a450fba7a54" xlink:to="loc_us-gaap_AssetAcquisitionDomain_9d76a938-23d2-4fe1-927d-2a450fba7a54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_00422f8b-da9f-44fd-9aee-bf6e117f99b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_9d76a938-23d2-4fe1-927d-2a450fba7a54" xlink:to="loc_us-gaap_AssetAcquisitionDomain_00422f8b-da9f-44fd-9aee-bf6e117f99b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JunshiBiosciencesMember_7751b9f9-dd43-48ef-a94b-b868b4c47b11" xlink:href="lly-20210930.xsd#lly_JunshiBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_00422f8b-da9f-44fd-9aee-bf6e117f99b9" xlink:to="loc_lly_JunshiBiosciencesMember_7751b9f9-dd43-48ef-a94b-b868b4c47b11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PetraPharmaCorporationMember_a9b7b930-3782-4561-9604-d9f038c2006a" xlink:href="lly-20210930.xsd#lly_PetraPharmaCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_00422f8b-da9f-44fd-9aee-bf6e117f99b9" xlink:to="loc_lly_PetraPharmaCorporationMember_a9b7b930-3782-4561-9604-d9f038c2006a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="i12f4dcb1769f414da790e5b882b2c228_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_36023eef-b5f6-438c-b3b4-b3d0e82801be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_36023eef-b5f6-438c-b3b4-b3d0e82801be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_6545f912-a619-4b7f-bab2-6ed593a4a402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_6545f912-a619-4b7f-bab2-6ed593a4a402" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_82a40ff0-bfa5-49bd-9f5a-6233a0c52edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_82a40ff0-bfa5-49bd-9f5a-6233a0c52edd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1fbea623-3e4a-492f-85f7-f84a073265ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_LongTermDebt_1fbea623-3e4a-492f-85f7-f84a073265ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_d9e6b739-3f63-40d8-8eda-be5777c14041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_d9e6b739-3f63-40d8-8eda-be5777c14041" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_0609af37-cd65-48f2-bbb7-dafef5b16941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_DerivativeNotionalAmount_0609af37-cd65-48f2-bbb7-dafef5b16941" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DescriptionOfDerivativeActivityVolumePercent_a4e40c41-3320-4860-ae6a-a620d0fee777" xlink:href="lly-20210930.xsd#lly_DescriptionOfDerivativeActivityVolumePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_lly_DescriptionOfDerivativeActivityVolumePercent_a4e40c41-3320-4860-ae6a-a620d0fee777" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ad6f94c3-148c-426a-809d-1db958b690a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ad6f94c3-148c-426a-809d-1db958b690a1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c83993ed-a5e6-4388-bffe-b4d90457811a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c83993ed-a5e6-4388-bffe-b4d90457811a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_2faf7d18-435f-48ab-95f1-7b6c25782d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_2faf7d18-435f-48ab-95f1-7b6c25782d1e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_8a098af4-4a80-4f6d-aab0-17c062dae8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_8a098af4-4a80-4f6d-aab0-17c062dae8b3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a338f0f0-47ee-4020-9ff8-fb29ddf46327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a338f0f0-47ee-4020-9ff8-fb29ddf46327" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_e23bf3fe-eb34-402c-bd93-3b514d39d326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_e23bf3fe-eb34-402c-bd93-3b514d39d326" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_026ab7a6-4115-4012-bc55-dff9523d6368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_026ab7a6-4115-4012-bc55-dff9523d6368" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_fdc67288-dbd0-4f7a-b306-3eab779624c7" xlink:href="lly-20210930.xsd#lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_fdc67288-dbd0-4f7a-b306-3eab779624c7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_b44ca19d-7794-4bc8-866b-639fa5b49d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_b44ca19d-7794-4bc8-866b-639fa5b49d84" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_1f101e2d-0c2f-4ae0-8f8b-74c526ce6bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_1f101e2d-0c2f-4ae0-8f8b-74c526ce6bd3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_d3f16f16-ef1c-49a6-bb96-d7b3f45d89c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_d3f16f16-ef1c-49a6-bb96-d7b3f45d89c0" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_debd2ac0-eac8-4514-8c8b-9d912da2abc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_debd2ac0-eac8-4514-8c8b-9d912da2abc8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_0534a61b-46cb-4c4c-8a1c-3eedfff5cd04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_debd2ac0-eac8-4514-8c8b-9d912da2abc8" xlink:to="loc_us-gaap_HedgingDesignationAxis_0534a61b-46cb-4c4c-8a1c-3eedfff5cd04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_0534a61b-46cb-4c4c-8a1c-3eedfff5cd04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_0534a61b-46cb-4c4c-8a1c-3eedfff5cd04" xlink:to="loc_us-gaap_HedgingDesignationDomain_0534a61b-46cb-4c4c-8a1c-3eedfff5cd04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_8319220a-c7b2-464e-ba29-d421a107fe32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_0534a61b-46cb-4c4c-8a1c-3eedfff5cd04" xlink:to="loc_us-gaap_HedgingDesignationDomain_8319220a-c7b2-464e-ba29-d421a107fe32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a9315192-0fe6-474d-839f-cd1a2d6c13ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_8319220a-c7b2-464e-ba29-d421a107fe32" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a9315192-0fe6-474d-839f-cd1a2d6c13ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f532bdc0-1400-4d2b-9210-ccc1c678b3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_debd2ac0-eac8-4514-8c8b-9d912da2abc8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f532bdc0-1400-4d2b-9210-ccc1c678b3dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_f532bdc0-1400-4d2b-9210-ccc1c678b3dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f532bdc0-1400-4d2b-9210-ccc1c678b3dd" xlink:to="loc_us-gaap_HedgingRelationshipDomain_f532bdc0-1400-4d2b-9210-ccc1c678b3dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_68dff6c8-aa88-4ca7-9737-0a925ea0bd13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f532bdc0-1400-4d2b-9210-ccc1c678b3dd" xlink:to="loc_us-gaap_HedgingRelationshipDomain_68dff6c8-aa88-4ca7-9737-0a925ea0bd13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_0a27af77-7985-4e78-8209-c46a60155939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_68dff6c8-aa88-4ca7-9737-0a925ea0bd13" xlink:to="loc_us-gaap_CashFlowHedgingMember_0a27af77-7985-4e78-8209-c46a60155939" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_15f96834-d11d-4199-a17d-f7fbcaf625c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_debd2ac0-eac8-4514-8c8b-9d912da2abc8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_15f96834-d11d-4199-a17d-f7fbcaf625c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_15f96834-d11d-4199-a17d-f7fbcaf625c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_15f96834-d11d-4199-a17d-f7fbcaf625c8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_15f96834-d11d-4199-a17d-f7fbcaf625c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f7c52267-1244-4602-88f9-a513b56c1f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_15f96834-d11d-4199-a17d-f7fbcaf625c8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f7c52267-1244-4602-88f9-a513b56c1f7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember_167b213d-7231-41a7-b789-7ca80968100a" xlink:href="lly-20210930.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f7c52267-1244-4602-88f9-a513b56c1f7b" xlink:to="loc_lly_ForeignCurrencyDenominatedDebtMember_167b213d-7231-41a7-b789-7ca80968100a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b48aba87-a539-40eb-8012-e88da26c0e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_debd2ac0-eac8-4514-8c8b-9d912da2abc8" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b48aba87-a539-40eb-8012-e88da26c0e97" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b48aba87-a539-40eb-8012-e88da26c0e97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b48aba87-a539-40eb-8012-e88da26c0e97" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b48aba87-a539-40eb-8012-e88da26c0e97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_728690cf-2332-4556-9f25-b046007b1533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b48aba87-a539-40eb-8012-e88da26c0e97" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_728690cf-2332-4556-9f25-b046007b1533" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUsDollarSellEuroMember_7a9052e8-1aa2-4d1c-8194-d923b0a51871" xlink:href="lly-20210930.xsd#lly_BuyUsDollarSellEuroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_728690cf-2332-4556-9f25-b046007b1533" xlink:to="loc_lly_BuyUsDollarSellEuroMember_7a9052e8-1aa2-4d1c-8194-d923b0a51871" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyEuroSellUsDollarMember_161551ba-0453-4df0-8ace-e5fa97d2122c" xlink:href="lly-20210930.xsd#lly_BuyEuroSellUsDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_728690cf-2332-4556-9f25-b046007b1533" xlink:to="loc_lly_BuyEuroSellUsDollarMember_161551ba-0453-4df0-8ace-e5fa97d2122c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSDollarSellChineseYuanMember_680624f9-2a31-4492-a349-0284f2a5a179" xlink:href="lly-20210930.xsd#lly_BuyUSDollarSellChineseYuanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_728690cf-2332-4556-9f25-b046007b1533" xlink:to="loc_lly_BuyUSDollarSellChineseYuanMember_680624f9-2a31-4492-a349-0284f2a5a179" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSdollarSellJapaneseYenMember_fe7eab15-ea40-4b7e-bce4-2ece97466c44" xlink:href="lly-20210930.xsd#lly_BuyUSdollarSellJapaneseYenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_728690cf-2332-4556-9f25-b046007b1533" xlink:to="loc_lly_BuyUSdollarSellJapaneseYenMember_fe7eab15-ea40-4b7e-bce4-2ece97466c44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyBritishPoundandSellUSDollarsMember_3090a616-3227-4f41-a326-2194ceaa40d9" xlink:href="lly-20210930.xsd#lly_BuyBritishPoundandSellUSDollarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_728690cf-2332-4556-9f25-b046007b1533" xlink:to="loc_lly_BuyBritishPoundandSellUSDollarsMember_3090a616-3227-4f41-a326-2194ceaa40d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapU.S.DollarsToEuroMember_5345e13a-adf8-4d33-993f-def6c5a4d381" xlink:href="lly-20210930.xsd#lly_SwapU.S.DollarsToEuroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_728690cf-2332-4556-9f25-b046007b1533" xlink:to="loc_lly_SwapU.S.DollarsToEuroMember_5345e13a-adf8-4d33-993f-def6c5a4d381" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapSwissFrancsToU.S.DollarsMember_f304dab5-df07-49d9-a8f0-cf0180913105" xlink:href="lly-20210930.xsd#lly_SwapSwissFrancsToU.S.DollarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_728690cf-2332-4556-9f25-b046007b1533" xlink:to="loc_lly_SwapSwissFrancsToU.S.DollarsMember_f304dab5-df07-49d9-a8f0-cf0180913105" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_17ceb914-6b3a-495d-987c-4114f84320ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_728690cf-2332-4556-9f25-b046007b1533" xlink:to="loc_us-gaap_InterestRateSwapMember_17ceb914-6b3a-495d-987c-4114f84320ea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9ae358b2-5903-4281-88c8-3b564c60793b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_debd2ac0-eac8-4514-8c8b-9d912da2abc8" xlink:to="loc_us-gaap_DebtInstrumentAxis_9ae358b2-5903-4281-88c8-3b564c60793b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9ae358b2-5903-4281-88c8-3b564c60793b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9ae358b2-5903-4281-88c8-3b564c60793b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9ae358b2-5903-4281-88c8-3b564c60793b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fccdb485-c854-42cb-98ef-1cf172a5988e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9ae358b2-5903-4281-88c8-3b564c60793b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fccdb485-c854-42cb-98ef-1cf172a5988e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A5000NotesDue2033Member_0f49872d-4f68-4147-b69c-24f7ae5d46c4" xlink:href="lly-20210930.xsd#lly_A5000NotesDue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fccdb485-c854-42cb-98ef-1cf172a5988e" xlink:to="loc_lly_A5000NotesDue2033Member_0f49872d-4f68-4147-b69c-24f7ae5d46c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_69ed9555-1c1c-499a-ba91-797559fb4235" xlink:href="lly-20210930.xsd#lly_A1125NotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fccdb485-c854-42cb-98ef-1cf172a5988e" xlink:to="loc_lly_A1125NotesDue2051Member_69ed9555-1c1c-499a-ba91-797559fb4235" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_a5092064-2c3f-46d3-9664-e23151e68fff" xlink:href="lly-20210930.xsd#lly_A1375NotesDue2061Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fccdb485-c854-42cb-98ef-1cf172a5988e" xlink:to="loc_lly_A1375NotesDue2061Member_a5092064-2c3f-46d3-9664-e23151e68fff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_b9735dfb-5e6b-4f3f-8642-dcf9b207cacf" xlink:href="lly-20210930.xsd#lly_A1625NotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fccdb485-c854-42cb-98ef-1cf172a5988e" xlink:to="loc_lly_A1625NotesDue2043Member_b9735dfb-5e6b-4f3f-8642-dcf9b207cacf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2049Member_95acefd8-60ce-411f-9d62-4f3dffd6f45a" xlink:href="lly-20210930.xsd#lly_A395NotesDue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fccdb485-c854-42cb-98ef-1cf172a5988e" xlink:to="loc_lly_A395NotesDue2049Member_95acefd8-60ce-411f-9d62-4f3dffd6f45a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A415NotesDue2059Member_005cfd39-0dae-4127-ae84-1108dfebadcc" xlink:href="lly-20210930.xsd#lly_A415NotesDue2059Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fccdb485-c854-42cb-98ef-1cf172a5988e" xlink:to="loc_lly_A415NotesDue2059Member_005cfd39-0dae-4127-ae84-1108dfebadcc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3375NotesDue2029Member_2b044fb2-7b2e-4859-98cf-35bdf23b8c8b" xlink:href="lly-20210930.xsd#lly_A3375NotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fccdb485-c854-42cb-98ef-1cf172a5988e" xlink:to="loc_lly_A3375NotesDue2029Member_2b044fb2-7b2e-4859-98cf-35bdf23b8c8b" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails" xlink:type="extended" id="i2e530163b33b4e0ebe30762e0a34091e_FinancialInstrumentsEffectofRiskManagementInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dece77ee-8a53-4eb8-adc2-f3c8736012cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueHedgeAbstract_60ca2d7b-ac3c-4821-880c-3fdd7f7e48b5" xlink:href="lly-20210930.xsd#lly_FairValueHedgeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dece77ee-8a53-4eb8-adc2-f3c8736012cf" xlink:to="loc_lly_FairValueHedgeAbstract_60ca2d7b-ac3c-4821-880c-3fdd7f7e48b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_f86da406-3c77-4aa3-9a03-5fe997b7da96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_FairValueHedgeAbstract_60ca2d7b-ac3c-4821-880c-3fdd7f7e48b5" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_f86da406-3c77-4aa3-9a03-5fe997b7da96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_7fc769b5-a768-4cb4-a7d1-1dfcf2a57146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_FairValueHedgeAbstract_60ca2d7b-ac3c-4821-880c-3fdd7f7e48b5" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_7fc769b5-a768-4cb4-a7d1-1dfcf2a57146" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CashFlowHedgeAbstract_5f3da74b-7c47-4ad8-aba5-47f7dcd2cfe9" xlink:href="lly-20210930.xsd#lly_CashFlowHedgeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dece77ee-8a53-4eb8-adc2-f3c8736012cf" xlink:to="loc_lly_CashFlowHedgeAbstract_5f3da74b-7c47-4ad8-aba5-47f7dcd2cfe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_c5eebcad-d96d-4a50-8761-7a1f9092e3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_CashFlowHedgeAbstract_5f3da74b-7c47-4ad8-aba5-47f7dcd2cfe9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_c5eebcad-d96d-4a50-8761-7a1f9092e3c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_35062063-0841-453a-9a2a-51aeffc30840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dece77ee-8a53-4eb8-adc2-f3c8736012cf" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_35062063-0841-453a-9a2a-51aeffc30840" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized_554009dd-830e-4abb-b3e4-51c7058ea3a2" xlink:href="lly-20210930.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dece77ee-8a53-4eb8-adc2-f3c8736012cf" xlink:to="loc_lly_DerivativeInstrumentsGainLossRecognized_554009dd-830e-4abb-b3e4-51c7058ea3a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_d3a8cd5a-018e-4a10-93a2-205010cce1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dece77ee-8a53-4eb8-adc2-f3c8736012cf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_d3a8cd5a-018e-4a10-93a2-205010cce1a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_dd5ce868-6a63-40c5-a3c4-477f3d45c495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dece77ee-8a53-4eb8-adc2-f3c8736012cf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_dd5ce868-6a63-40c5-a3c4-477f3d45c495" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_98d9b892-3530-4d9e-af5a-a0dc82a99516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dece77ee-8a53-4eb8-adc2-f3c8736012cf" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_98d9b892-3530-4d9e-af5a-a0dc82a99516" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_a519f30d-e638-4587-b582-abbb7bb4d258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_98d9b892-3530-4d9e-af5a-a0dc82a99516" xlink:to="loc_us-gaap_HedgingDesignationAxis_a519f30d-e638-4587-b582-abbb7bb4d258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a519f30d-e638-4587-b582-abbb7bb4d258_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_a519f30d-e638-4587-b582-abbb7bb4d258" xlink:to="loc_us-gaap_HedgingDesignationDomain_a519f30d-e638-4587-b582-abbb7bb4d258_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_02bb265a-07f3-4195-87ec-315be050c5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_a519f30d-e638-4587-b582-abbb7bb4d258" xlink:to="loc_us-gaap_HedgingDesignationDomain_02bb265a-07f3-4195-87ec-315be050c5f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3fd5c1be-976d-41dc-a362-15c8e0785b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_02bb265a-07f3-4195-87ec-315be050c5f1" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3fd5c1be-976d-41dc-a362-15c8e0785b47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_6d5dd8c4-bebe-415e-a6a3-5eb3f2b537f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_02bb265a-07f3-4195-87ec-315be050c5f1" xlink:to="loc_us-gaap_NondesignatedMember_6d5dd8c4-bebe-415e-a6a3-5eb3f2b537f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e1ad01b2-bee0-4379-932e-d35ccf0fe4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_98d9b892-3530-4d9e-af5a-a0dc82a99516" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e1ad01b2-bee0-4379-932e-d35ccf0fe4f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e1ad01b2-bee0-4379-932e-d35ccf0fe4f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e1ad01b2-bee0-4379-932e-d35ccf0fe4f1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e1ad01b2-bee0-4379-932e-d35ccf0fe4f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_bf00ca2a-8507-490c-97f6-6f037bc9518a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e1ad01b2-bee0-4379-932e-d35ccf0fe4f1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_bf00ca2a-8507-490c-97f6-6f037bc9518a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HedgedFixedRateDebtMember_eee2b7d3-223e-4b90-9f60-9246a63bf7e8" xlink:href="lly-20210930.xsd#lly_HedgedFixedRateDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf00ca2a-8507-490c-97f6-6f037bc9518a" xlink:to="loc_lly_HedgedFixedRateDebtMember_eee2b7d3-223e-4b90-9f60-9246a63bf7e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_259786b5-fe06-4845-b7b0-a24e11fc77b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf00ca2a-8507-490c-97f6-6f037bc9518a" xlink:to="loc_us-gaap_InterestRateContractMember_259786b5-fe06-4845-b7b0-a24e11fc77b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_c81bbf4f-e3f1-45b8-92d7-e4ec692d9478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf00ca2a-8507-490c-97f6-6f037bc9518a" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_c81bbf4f-e3f1-45b8-92d7-e4ec692d9478" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_6e71907c-151f-4d30-b212-1c84c41d8541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf00ca2a-8507-490c-97f6-6f037bc9518a" xlink:to="loc_us-gaap_ForeignExchangeContractMember_6e71907c-151f-4d30-b212-1c84c41d8541" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_2d05e6fe-73a0-4138-854a-cd090d02fe97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf00ca2a-8507-490c-97f6-6f037bc9518a" xlink:to="loc_us-gaap_InterestRateSwapMember_2d05e6fe-73a0-4138-854a-cd090d02fe97" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#FinancialInstrumentsFairValueofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="extended" id="icde4742a3bd441e59b67acbe2f22a966_FinancialInstrumentsFairValueofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cce11e6a-0e17-4f6e-8436-a7504d1c10d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0f826475-f37f-425f-87f2-f9dbfb002389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cce11e6a-0e17-4f6e-8436-a7504d1c10d1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0f826475-f37f-425f-87f2-f9dbfb002389" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_bc86cb77-677f-4595-b6f0-a226e765dfe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cce11e6a-0e17-4f6e-8436-a7504d1c10d1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_bc86cb77-677f-4595-b6f0-a226e765dfe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4167ff90-4392-445b-a9c7-c04d3c74683f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cce11e6a-0e17-4f6e-8436-a7504d1c10d1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4167ff90-4392-445b-a9c7-c04d3c74683f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_399d8c06-3962-4998-8461-baebabf7aa0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cce11e6a-0e17-4f6e-8436-a7504d1c10d1" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_399d8c06-3962-4998-8461-baebabf7aa0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_46f7d3eb-fbc7-46d7-a34d-71e45881ecd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cce11e6a-0e17-4f6e-8436-a7504d1c10d1" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_46f7d3eb-fbc7-46d7-a34d-71e45881ecd1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_7b9e6b85-c0bc-42d2-b48b-b8259cc6c95d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cce11e6a-0e17-4f6e-8436-a7504d1c10d1" xlink:to="loc_us-gaap_OtherLongTermInvestments_7b9e6b85-c0bc-42d2-b48b-b8259cc6c95d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_bb2accc5-06d6-4d14-95ee-aa7d9c98b951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cce11e6a-0e17-4f6e-8436-a7504d1c10d1" xlink:to="loc_us-gaap_LongTermInvestments_bb2accc5-06d6-4d14-95ee-aa7d9c98b951" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_455ac1d1-56b1-4805-a630-5fd62454675d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cce11e6a-0e17-4f6e-8436-a7504d1c10d1" xlink:to="loc_us-gaap_LongTermDebt_455ac1d1-56b1-4805-a630-5fd62454675d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2ab79f7-3cb7-43f7-8a84-555ad2b0fae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cce11e6a-0e17-4f6e-8436-a7504d1c10d1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2ab79f7-3cb7-43f7-8a84-555ad2b0fae0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_5d28fd10-3088-4066-ac4a-cfe02f4ae048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2ab79f7-3cb7-43f7-8a84-555ad2b0fae0" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_5d28fd10-3088-4066-ac4a-cfe02f4ae048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5d28fd10-3088-4066-ac4a-cfe02f4ae048_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_5d28fd10-3088-4066-ac4a-cfe02f4ae048" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5d28fd10-3088-4066-ac4a-cfe02f4ae048_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1fcf42f0-da44-45a5-bfa0-218f666155f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_5d28fd10-3088-4066-ac4a-cfe02f4ae048" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1fcf42f0-da44-45a5-bfa0-218f666155f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_54705746-7193-4e1b-88b6-9c91538b1d78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1fcf42f0-da44-45a5-bfa0-218f666155f5" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_54705746-7193-4e1b-88b6-9c91538b1d78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b6d16efb-f781-41c0-94de-972f15efb83b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1fcf42f0-da44-45a5-bfa0-218f666155f5" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b6d16efb-f781-41c0-94de-972f15efb83b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_2bb47092-c232-45e8-adca-4c4ed0c45f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1fcf42f0-da44-45a5-bfa0-218f666155f5" xlink:to="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_2bb47092-c232-45e8-adca-4c4ed0c45f12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_bc3887f5-db7b-45ec-adcf-2fc7abc4aea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1fcf42f0-da44-45a5-bfa0-218f666155f5" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_bc3887f5-db7b-45ec-adcf-2fc7abc4aea0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_441d2176-2791-467c-b5c8-690bed094591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2ab79f7-3cb7-43f7-8a84-555ad2b0fae0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_441d2176-2791-467c-b5c8-690bed094591" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_441d2176-2791-467c-b5c8-690bed094591_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_441d2176-2791-467c-b5c8-690bed094591" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_441d2176-2791-467c-b5c8-690bed094591_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04ef12a5-d41c-4bab-aeae-9d71e6fa94c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_441d2176-2791-467c-b5c8-690bed094591" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04ef12a5-d41c-4bab-aeae-9d71e6fa94c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_fd43c57c-572b-4133-84be-df5037782995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04ef12a5-d41c-4bab-aeae-9d71e6fa94c7" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_fd43c57c-572b-4133-84be-df5037782995" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b1d82271-6033-4692-9616-1aaf417baf43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04ef12a5-d41c-4bab-aeae-9d71e6fa94c7" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b1d82271-6033-4692-9616-1aaf417baf43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_8ccc17a0-c364-48e1-899f-5b68c1b9188a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04ef12a5-d41c-4bab-aeae-9d71e6fa94c7" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_8ccc17a0-c364-48e1-899f-5b68c1b9188a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_d41d22cb-5a49-404e-8785-a362d33140ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04ef12a5-d41c-4bab-aeae-9d71e6fa94c7" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_d41d22cb-5a49-404e-8785-a362d33140ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_5ff520e9-4805-4daa-950e-6099c9eadd89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04ef12a5-d41c-4bab-aeae-9d71e6fa94c7" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_5ff520e9-4805-4daa-950e-6099c9eadd89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherEquitySecuritiesMember_133faf6a-5f65-4e89-b1a8-c297259eef62" xlink:href="lly-20210930.xsd#lly_OtherEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04ef12a5-d41c-4bab-aeae-9d71e6fa94c7" xlink:to="loc_lly_OtherEquitySecuritiesMember_133faf6a-5f65-4e89-b1a8-c297259eef62" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MarketableSecuritiesMember_d9dc6ef2-2c0d-4ce5-ad22-5dd241835b27" xlink:href="lly-20210930.xsd#lly_MarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04ef12a5-d41c-4bab-aeae-9d71e6fa94c7" xlink:to="loc_lly_MarketableSecuritiesMember_d9dc6ef2-2c0d-4ce5-ad22-5dd241835b27" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EquityMethodAndOtherInvestmentsMember_546d107f-702b-486d-958e-83d0364a06f1" xlink:href="lly-20210930.xsd#lly_EquityMethodAndOtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04ef12a5-d41c-4bab-aeae-9d71e6fa94c7" xlink:to="loc_lly_EquityMethodAndOtherInvestmentsMember_546d107f-702b-486d-958e-83d0364a06f1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_62882d70-4910-4b8a-b1fe-247329148cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2ab79f7-3cb7-43f7-8a84-555ad2b0fae0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_62882d70-4910-4b8a-b1fe-247329148cbb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_62882d70-4910-4b8a-b1fe-247329148cbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_62882d70-4910-4b8a-b1fe-247329148cbb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_62882d70-4910-4b8a-b1fe-247329148cbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_26db6ad3-faee-419c-ba65-ebf1be86d887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_62882d70-4910-4b8a-b1fe-247329148cbb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_26db6ad3-faee-419c-ba65-ebf1be86d887" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d5816fed-0d24-4f25-b642-f79709e4ba5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_26db6ad3-faee-419c-ba65-ebf1be86d887" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d5816fed-0d24-4f25-b642-f79709e4ba5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9e6afcdd-9999-4709-901a-234ffaec09b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_26db6ad3-faee-419c-ba65-ebf1be86d887" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9e6afcdd-9999-4709-901a-234ffaec09b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_15e22116-6770-4348-961f-7105b6b45271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_26db6ad3-faee-419c-ba65-ebf1be86d887" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_15e22116-6770-4348-961f-7105b6b45271" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#FinancialInstrumentsRiskManagementInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails" xlink:type="extended" id="iad2ea34872c94e3ba0914025920d2902_FinancialInstrumentsRiskManagementInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e48e751-71f5-4e62-a3a0-36c5446ba6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_b770355c-6a87-41ce-9377-7dfa4659a6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e48e751-71f5-4e62-a3a0-36c5446ba6c0" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_b770355c-6a87-41ce-9377-7dfa4659a6b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_2098af1e-8222-45f3-83b6-4ca6ddb26f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e48e751-71f5-4e62-a3a0-36c5446ba6c0" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_2098af1e-8222-45f3-83b6-4ca6ddb26f32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_46bc07f5-2060-44d1-989d-ef0a7266703a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e48e751-71f5-4e62-a3a0-36c5446ba6c0" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_46bc07f5-2060-44d1-989d-ef0a7266703a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_c045d03a-0963-482c-85ad-11770c292363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e48e751-71f5-4e62-a3a0-36c5446ba6c0" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_c045d03a-0963-482c-85ad-11770c292363" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1c544e30-fd58-4252-997b-95a636f99862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e48e751-71f5-4e62-a3a0-36c5446ba6c0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1c544e30-fd58-4252-997b-95a636f99862" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49f08018-75da-4a66-adf6-d426db3f9e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e48e751-71f5-4e62-a3a0-36c5446ba6c0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49f08018-75da-4a66-adf6-d426db3f9e4a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e9ab24bd-d3f4-4e78-a76d-3dec73eb2bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49f08018-75da-4a66-adf6-d426db3f9e4a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e9ab24bd-d3f4-4e78-a76d-3dec73eb2bc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e9ab24bd-d3f4-4e78-a76d-3dec73eb2bc8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e9ab24bd-d3f4-4e78-a76d-3dec73eb2bc8" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e9ab24bd-d3f4-4e78-a76d-3dec73eb2bc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_7debbce3-a454-4ee3-8a1f-4e4c6e307c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e9ab24bd-d3f4-4e78-a76d-3dec73eb2bc8" xlink:to="loc_us-gaap_HedgingRelationshipDomain_7debbce3-a454-4ee3-8a1f-4e4c6e307c75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_0ba480e5-9344-407c-b238-1a4dcf475f48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7debbce3-a454-4ee3-8a1f-4e4c6e307c75" xlink:to="loc_us-gaap_FairValueHedgingMember_0ba480e5-9344-407c-b238-1a4dcf475f48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_bed25534-cb91-4509-9e1c-a87c34648afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7debbce3-a454-4ee3-8a1f-4e4c6e307c75" xlink:to="loc_us-gaap_CashFlowHedgingMember_bed25534-cb91-4509-9e1c-a87c34648afb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_5a40647e-edac-41ed-b21f-70211d9fbbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7debbce3-a454-4ee3-8a1f-4e4c6e307c75" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_5a40647e-edac-41ed-b21f-70211d9fbbc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_618a2be7-2464-4144-b852-2197156eeb88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49f08018-75da-4a66-adf6-d426db3f9e4a" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_618a2be7-2464-4144-b852-2197156eeb88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_618a2be7-2464-4144-b852-2197156eeb88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_618a2be7-2464-4144-b852-2197156eeb88" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_618a2be7-2464-4144-b852-2197156eeb88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_07ff918b-d709-4a81-90d5-694a811b10c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_618a2be7-2464-4144-b852-2197156eeb88" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_07ff918b-d709-4a81-90d5-694a811b10c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fbfee032-5da5-43be-b222-6992db931b91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_07ff918b-d709-4a81-90d5-694a811b10c6" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fbfee032-5da5-43be-b222-6992db931b91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_31d44525-c092-4251-b75d-5cf7604f98fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_07ff918b-d709-4a81-90d5-694a811b10c6" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_31d44525-c092-4251-b75d-5cf7604f98fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_971bf40f-62fc-4fc2-854f-7d00e85d7a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_07ff918b-d709-4a81-90d5-694a811b10c6" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_971bf40f-62fc-4fc2-854f-7d00e85d7a8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e8d91dc3-a4ff-43bd-8a09-d913ad181c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49f08018-75da-4a66-adf6-d426db3f9e4a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e8d91dc3-a4ff-43bd-8a09-d913ad181c42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e8d91dc3-a4ff-43bd-8a09-d913ad181c42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e8d91dc3-a4ff-43bd-8a09-d913ad181c42" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e8d91dc3-a4ff-43bd-8a09-d913ad181c42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_37acd568-143e-4dcf-a523-bd8034d45ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e8d91dc3-a4ff-43bd-8a09-d913ad181c42" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_37acd568-143e-4dcf-a523-bd8034d45ca3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_66831d0e-5421-46b3-b4cc-e45b1ee17303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_37acd568-143e-4dcf-a523-bd8034d45ca3" xlink:to="loc_us-gaap_InterestRateContractMember_66831d0e-5421-46b3-b4cc-e45b1ee17303" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_8459f559-9139-4a1c-8b63-b1de00511d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_37acd568-143e-4dcf-a523-bd8034d45ca3" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_8459f559-9139-4a1c-8b63-b1de00511d8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_12ca76d7-3b77-44e8-ae14-c5526d8d8ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_37acd568-143e-4dcf-a523-bd8034d45ca3" xlink:to="loc_us-gaap_ForeignExchangeContractMember_12ca76d7-3b77-44e8-ae14-c5526d8d8ca5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_79adc9cd-5c64-4148-bbc9-812e54698959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49f08018-75da-4a66-adf6-d426db3f9e4a" xlink:to="loc_us-gaap_HedgingDesignationAxis_79adc9cd-5c64-4148-bbc9-812e54698959" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_79adc9cd-5c64-4148-bbc9-812e54698959_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_79adc9cd-5c64-4148-bbc9-812e54698959" xlink:to="loc_us-gaap_HedgingDesignationDomain_79adc9cd-5c64-4148-bbc9-812e54698959_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d79d4ec7-a9dd-4103-afab-f1fa4fc273f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_79adc9cd-5c64-4148-bbc9-812e54698959" xlink:to="loc_us-gaap_HedgingDesignationDomain_d79d4ec7-a9dd-4103-afab-f1fa4fc273f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_53ead6d0-5fcb-4f4c-a26d-bb13a009859a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_d79d4ec7-a9dd-4103-afab-f1fa4fc273f1" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_53ead6d0-5fcb-4f4c-a26d-bb13a009859a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_7da3cb8f-61b7-4431-b332-62504078fa52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_d79d4ec7-a9dd-4103-afab-f1fa4fc273f1" xlink:to="loc_us-gaap_NondesignatedMember_7da3cb8f-61b7-4431-b332-62504078fa52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c93a9e1-66ff-4b2f-8421-fcae9685d058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49f08018-75da-4a66-adf6-d426db3f9e4a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c93a9e1-66ff-4b2f-8421-fcae9685d058" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c93a9e1-66ff-4b2f-8421-fcae9685d058_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c93a9e1-66ff-4b2f-8421-fcae9685d058" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c93a9e1-66ff-4b2f-8421-fcae9685d058_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d213eaf8-4cbc-4e71-a65c-73125bcff5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c93a9e1-66ff-4b2f-8421-fcae9685d058" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d213eaf8-4cbc-4e71-a65c-73125bcff5f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_590a633a-feb1-4ae4-9b6b-7ab5a2f8a451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d213eaf8-4cbc-4e71-a65c-73125bcff5f3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_590a633a-feb1-4ae4-9b6b-7ab5a2f8a451" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8078e61e-6aa4-4759-9d63-2201f01cbabc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d213eaf8-4cbc-4e71-a65c-73125bcff5f3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8078e61e-6aa4-4759-9d63-2201f01cbabc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_271f2af3-e83f-44cd-bcf8-aae6b19356d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d213eaf8-4cbc-4e71-a65c-73125bcff5f3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_271f2af3-e83f-44cd-bcf8-aae6b19356d9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="i251f952c4596401e91c2c146cbd33fdc_RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bd963281-4fed-464a-b01e-e4333b663ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_86794c80-93c2-435e-9804-c1204ac61cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bd963281-4fed-464a-b01e-e4333b663ce6" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_86794c80-93c2-435e-9804-c1204ac61cf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_2392a5db-a12d-49a1-98bb-5c5824cd3e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bd963281-4fed-464a-b01e-e4333b663ce6" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_2392a5db-a12d-49a1-98bb-5c5824cd3e0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_ae409171-eb5c-4eb5-ad6e-f6fca94bb3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bd963281-4fed-464a-b01e-e4333b663ce6" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_ae409171-eb5c-4eb5-ad6e-f6fca94bb3f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_41f2a21b-1db0-42fa-895c-ca4dc1fb94f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bd963281-4fed-464a-b01e-e4333b663ce6" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_41f2a21b-1db0-42fa-895c-ca4dc1fb94f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_15c0738d-6b9e-4945-9588-0587b641bce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bd963281-4fed-464a-b01e-e4333b663ce6" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_15c0738d-6b9e-4945-9588-0587b641bce7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_fea6a574-dd64-42c9-8888-1bafd72cad9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bd963281-4fed-464a-b01e-e4333b663ce6" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_fea6a574-dd64-42c9-8888-1bafd72cad9b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fa93bee3-6b8d-4abf-8662-fa206d5d7285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bd963281-4fed-464a-b01e-e4333b663ce6" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fa93bee3-6b8d-4abf-8662-fa206d5d7285" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_05163f9b-a3dc-4dfa-a5b7-82921529222c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fa93bee3-6b8d-4abf-8662-fa206d5d7285" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_05163f9b-a3dc-4dfa-a5b7-82921529222c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_05163f9b-a3dc-4dfa-a5b7-82921529222c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_05163f9b-a3dc-4dfa-a5b7-82921529222c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_05163f9b-a3dc-4dfa-a5b7-82921529222c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_58087575-15db-4443-9cd2-8dde0e255582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_05163f9b-a3dc-4dfa-a5b7-82921529222c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_58087575-15db-4443-9cd2-8dde0e255582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_fb649435-2be6-4366-a37f-f9c072e8ea58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_58087575-15db-4443-9cd2-8dde0e255582" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_fb649435-2be6-4366-a37f-f9c072e8ea58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_8d4cc047-48d2-4a5b-9379-4b2f42701b91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_58087575-15db-4443-9cd2-8dde0e255582" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_8d4cc047-48d2-4a5b-9379-4b2f42701b91" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#ContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/ContingenciesDetails" xlink:type="extended" id="i79ec245094ac4b419fc62e66a68ade03_ContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_1cd12470-75cd-4e44-8693-efa86e39033b" xlink:href="lly-20210930.xsd#lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_1cd12470-75cd-4e44-8693-efa86e39033b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatents_a8eb4ae9-17a7-4887-a1c6-b929c8419d78" xlink:href="lly-20210930.xsd#lly_LossContingencyNumberOfPatents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_lly_LossContingencyNumberOfPatents_a8eb4ae9-17a7-4887-a1c6-b929c8419d78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatentsClaimsDismissed_beaf26b8-bce9-4e29-9697-68a7d53fb302" xlink:href="lly-20210930.xsd#lly_LossContingencyNumberOfPatentsClaimsDismissed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_lly_LossContingencyNumberOfPatentsClaimsDismissed_beaf26b8-bce9-4e29-9697-68a7d53fb302" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatentsRuledUnpatentable_bffb987d-2dfa-44c4-b65c-475a288c9927" xlink:href="lly-20210930.xsd#lly_LossContingencyNumberOfPatentsRuledUnpatentable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_lly_LossContingencyNumberOfPatentsRuledUnpatentable_bffb987d-2dfa-44c4-b65c-475a288c9927" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfDecisionsAffirmed_0a15867a-a5cd-4c60-96c6-8b501460f656" xlink:href="lly-20210930.xsd#lly_LossContingencyNumberOfDecisionsAffirmed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_lly_LossContingencyNumberOfDecisionsAffirmed_0a15867a-a5cd-4c60-96c6-8b501460f656" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_d0011dd1-4e8d-4ac4-a803-2266ce943af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_d0011dd1-4e8d-4ac4-a803-2266ce943af9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_26072ab3-f3c0-456e-95a3-8e73ff358bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_26072ab3-f3c0-456e-95a3-8e73ff358bdd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfClaimants_54f338cb-38cb-409f-af08-804a2c8f2414" xlink:href="lly-20210930.xsd#lly_LossContingencyNumberOfClaimants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_lly_LossContingencyNumberOfClaimants_54f338cb-38cb-409f-af08-804a2c8f2414" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_fdff4b2d-bb48-4bdc-99d8-75fd238b91da" xlink:href="lly-20210930.xsd#lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_fdff4b2d-bb48-4bdc-99d8-75fd238b91da" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_6c58fae6-4969-420c-a932-c7e56f62d132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_6c58fae6-4969-420c-a932-c7e56f62d132" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LitigationClaimsDismissedNumber_8a3f8c83-53db-46e9-8bea-803ae622dffe" xlink:href="lly-20210930.xsd#lly_LitigationClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_lly_LitigationClaimsDismissedNumber_8a3f8c83-53db-46e9-8bea-803ae622dffe" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_944b162d-3fa7-4852-a74c-4dfc691ec547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_us-gaap_LossContingenciesTable_944b162d-3fa7-4852-a74c-4dfc691ec547" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6c68ca90-7d16-4c18-91cd-a83b93ae23ca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_944b162d-3fa7-4852-a74c-4dfc691ec547" xlink:to="loc_srt_StatementGeographicalAxis_6c68ca90-7d16-4c18-91cd-a83b93ae23ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6c68ca90-7d16-4c18-91cd-a83b93ae23ca_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6c68ca90-7d16-4c18-91cd-a83b93ae23ca" xlink:to="loc_srt_SegmentGeographicalDomain_6c68ca90-7d16-4c18-91cd-a83b93ae23ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_41bf7bf2-6467-4cd3-9b5b-b7ffde94fa9d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6c68ca90-7d16-4c18-91cd-a83b93ae23ca" xlink:to="loc_srt_SegmentGeographicalDomain_41bf7bf2-6467-4cd3-9b5b-b7ffde94fa9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR_5de8bab3-7a2d-4758-a835-01ad9750a3ab" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_41bf7bf2-6467-4cd3-9b5b-b7ffde94fa9d" xlink:to="loc_country_BR_5de8bab3-7a2d-4758-a835-01ad9750a3ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_ef017819-497f-4ae8-bec2-a21a14c01b8e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_944b162d-3fa7-4852-a74c-4dfc691ec547" xlink:to="loc_srt_LitigationCaseAxis_ef017819-497f-4ae8-bec2-a21a14c01b8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ef017819-497f-4ae8-bec2-a21a14c01b8e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_ef017819-497f-4ae8-bec2-a21a14c01b8e" xlink:to="loc_srt_LitigationCaseTypeDomain_ef017819-497f-4ae8-bec2-a21a14c01b8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_dbba6098-973d-4d20-bda3-ba201af3a0c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_ef017819-497f-4ae8-bec2-a21a14c01b8e" xlink:to="loc_srt_LitigationCaseTypeDomain_dbba6098-973d-4d20-bda3-ba201af3a0c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DrReddysLabMember_75b60dde-859a-4b81-98b9-5067b3e8aa2a" xlink:href="lly-20210930.xsd#lly_DrReddysLabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dbba6098-973d-4d20-bda3-ba201af3a0c3" xlink:to="loc_lly_DrReddysLabMember_75b60dde-859a-4b81-98b9-5067b3e8aa2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityPatentLitigationMember_28b19340-f869-41dd-af36-7f10cfb962ab" xlink:href="lly-20210930.xsd#lly_EmgalityPatentLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dbba6098-973d-4d20-bda3-ba201af3a0c3" xlink:to="loc_lly_EmgalityPatentLitigationMember_28b19340-f869-41dd-af36-7f10cfb962ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_183b58b2-1d33-4b2a-9333-31835cc171f6" xlink:href="lly-20210930.xsd#lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dbba6098-973d-4d20-bda3-ba201af3a0c3" xlink:to="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_183b58b2-1d33-4b2a-9333-31835cc171f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WhyteEtAlVEliLillyEtAlMember_1d8db733-5aae-44bf-8368-4f535da8bc8b" xlink:href="lly-20210930.xsd#lly_WhyteEtAlVEliLillyEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dbba6098-973d-4d20-bda3-ba201af3a0c3" xlink:to="loc_lly_WhyteEtAlVEliLillyEtAlMember_1d8db733-5aae-44bf-8368-4f535da8bc8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WeilerVTakedaCanadaIncEtAlMember_1954b28a-c8e4-4d67-b1a3-8b259dd91f20" xlink:href="lly-20210930.xsd#lly_WeilerVTakedaCanadaIncEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dbba6098-973d-4d20-bda3-ba201af3a0c3" xlink:to="loc_lly_WeilerVTakedaCanadaIncEtAlMember_1954b28a-c8e4-4d67-b1a3-8b259dd91f20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EppVTakedaCanadaIncEtAlMember_bb4bce46-c925-4284-9c85-4af1b8fac7f6" xlink:href="lly-20210930.xsd#lly_EppVTakedaCanadaIncEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dbba6098-973d-4d20-bda3-ba201af3a0c3" xlink:to="loc_lly_EppVTakedaCanadaIncEtAlMember_bb4bce46-c925-4284-9c85-4af1b8fac7f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationMember_6c34db4f-a8df-4dee-92f9-06c4dd12f5bb" xlink:href="lly-20210930.xsd#lly_EmployeeLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dbba6098-973d-4d20-bda3-ba201af3a0c3" xlink:to="loc_lly_EmployeeLitigationMember_6c34db4f-a8df-4dee-92f9-06c4dd12f5bb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2da8c37a-2404-45c7-b925-05d760e76a9f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_944b162d-3fa7-4852-a74c-4dfc691ec547" xlink:to="loc_srt_ProductOrServiceAxis_2da8c37a-2404-45c7-b925-05d760e76a9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2da8c37a-2404-45c7-b925-05d760e76a9f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2da8c37a-2404-45c7-b925-05d760e76a9f" xlink:to="loc_srt_ProductsAndServicesDomain_2da8c37a-2404-45c7-b925-05d760e76a9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_180727eb-f455-44c1-aa7f-4dbfb7a732d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2da8c37a-2404-45c7-b925-05d760e76a9f" xlink:to="loc_srt_ProductsAndServicesDomain_180727eb-f455-44c1-aa7f-4dbfb7a732d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ActosMember_5841530a-6598-4706-9b12-bed2edd438b7" xlink:href="lly-20210930.xsd#lly_ActosMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_180727eb-f455-44c1-aa7f-4dbfb7a732d4" xlink:to="loc_lly_ActosMember_5841530a-6598-4706-9b12-bed2edd438b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ByettaMember_6b46078b-0979-4eb0-95c3-ccb76647580f" xlink:href="lly-20210930.xsd#lly_ByettaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_180727eb-f455-44c1-aa7f-4dbfb7a732d4" xlink:to="loc_lly_ByettaMember_6b46078b-0979-4eb0-95c3-ccb76647580f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember_accecc3d-83fc-4a52-b932-d51d9a46b0ae" xlink:href="lly-20210930.xsd#lly_CialisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_180727eb-f455-44c1-aa7f-4dbfb7a732d4" xlink:to="loc_lly_CialisMember_accecc3d-83fc-4a52-b932-d51d9a46b0ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_0eb171d6-23cc-4eb2-b99e-1bb1e88642d5" xlink:href="lly-20210930.xsd#lly_JardianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_180727eb-f455-44c1-aa7f-4dbfb7a732d4" xlink:to="loc_lly_JardianceMember_0eb171d6-23cc-4eb2-b99e-1bb1e88642d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogHumulinAndForteoMember_ecbad253-b97b-4ad0-baf9-84b17a6eebde" xlink:href="lly-20210930.xsd#lly_HumalogHumulinAndForteoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_180727eb-f455-44c1-aa7f-4dbfb7a732d4" xlink:to="loc_lly_HumalogHumulinAndForteoMember_ecbad253-b97b-4ad0-baf9-84b17a6eebde" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InsulinMember_6240064c-ef65-4669-a203-3364aabae391" xlink:href="lly-20210930.xsd#lly_InsulinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_180727eb-f455-44c1-aa7f-4dbfb7a732d4" xlink:to="loc_lly_InsulinMember_6240064c-ef65-4669-a203-3364aabae391" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationAxis_8064fa7b-36fb-4587-b9b9-0281239a0ae4" xlink:href="lly-20210930.xsd#lly_DomicileOfLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_944b162d-3fa7-4852-a74c-4dfc691ec547" xlink:to="loc_lly_DomicileOfLitigationAxis_8064fa7b-36fb-4587-b9b9-0281239a0ae4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationDomain_8064fa7b-36fb-4587-b9b9-0281239a0ae4_default" xlink:href="lly-20210930.xsd#lly_DomicileOfLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lly_DomicileOfLitigationAxis_8064fa7b-36fb-4587-b9b9-0281239a0ae4" xlink:to="loc_lly_DomicileOfLitigationDomain_8064fa7b-36fb-4587-b9b9-0281239a0ae4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationDomain_510b2c4d-1ad2-4a44-a47d-a08559768a75" xlink:href="lly-20210930.xsd#lly_DomicileOfLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lly_DomicileOfLitigationAxis_8064fa7b-36fb-4587-b9b9-0281239a0ae4" xlink:to="loc_lly_DomicileOfLitigationDomain_510b2c4d-1ad2-4a44-a47d-a08559768a75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LosAngelesMember_500784bf-9798-45f2-b3a6-9d1ce4dbf2dc" xlink:href="lly-20210930.xsd#lly_LosAngelesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DomicileOfLitigationDomain_510b2c4d-1ad2-4a44-a47d-a08559768a75" xlink:to="loc_lly_LosAngelesMember_500784bf-9798-45f2-b3a6-9d1ce4dbf2dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SouthernDistrictOfCaliforniaMember_2c083f14-cc2c-4ad6-a0a0-b75d367834b5" xlink:href="lly-20210930.xsd#lly_SouthernDistrictOfCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DomicileOfLitigationDomain_510b2c4d-1ad2-4a44-a47d-a08559768a75" xlink:to="loc_lly_SouthernDistrictOfCaliforniaMember_2c083f14-cc2c-4ad6-a0a0-b75d367834b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VariousStateDomicilesMember_34db22ac-1fda-4e0d-9efc-c7dfa81618c5" xlink:href="lly-20210930.xsd#lly_VariousStateDomicilesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_DomicileOfLitigationDomain_510b2c4d-1ad2-4a44-a47d-a08559768a75" xlink:to="loc_lly_VariousStateDomicilesMember_34db22ac-1fda-4e0d-9efc-c7dfa81618c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsAxis_413523b8-6433-4a64-979a-a056fb02a3ca" xlink:href="lly-20210930.xsd#lly_PlaintiffAllegationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_944b162d-3fa7-4852-a74c-4dfc691ec547" xlink:to="loc_lly_PlaintiffAllegationsAxis_413523b8-6433-4a64-979a-a056fb02a3ca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsDomain_413523b8-6433-4a64-979a-a056fb02a3ca_default" xlink:href="lly-20210930.xsd#lly_PlaintiffAllegationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lly_PlaintiffAllegationsAxis_413523b8-6433-4a64-979a-a056fb02a3ca" xlink:to="loc_lly_PlaintiffAllegationsDomain_413523b8-6433-4a64-979a-a056fb02a3ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsDomain_7bb4ce78-980e-4a0f-b694-4dea47e0bbed" xlink:href="lly-20210930.xsd#lly_PlaintiffAllegationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lly_PlaintiffAllegationsAxis_413523b8-6433-4a64-979a-a056fb02a3ca" xlink:to="loc_lly_PlaintiffAllegationsDomain_7bb4ce78-980e-4a0f-b694-4dea47e0bbed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreaticCancerOrThyroidCancerMember_b174c05d-d492-4266-8487-be0b0890fad8" xlink:href="lly-20210930.xsd#lly_PancreaticCancerOrThyroidCancerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_PlaintiffAllegationsDomain_7bb4ce78-980e-4a0f-b694-4dea47e0bbed" xlink:to="loc_lly_PancreaticCancerOrThyroidCancerMember_b174c05d-d492-4266-8487-be0b0890fad8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreatitisMember_139278db-5d0b-4885-91c5-a21d5c37995e" xlink:href="lly-20210930.xsd#lly_PancreatitisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_PlaintiffAllegationsDomain_7bb4ce78-980e-4a0f-b694-4dea47e0bbed" xlink:to="loc_lly_PancreatitisMember_139278db-5d0b-4885-91c5-a21d5c37995e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AmpullaryCancerMember_87ad807a-b80e-447a-aa1d-019ce0e1f8fb" xlink:href="lly-20210930.xsd#lly_AmpullaryCancerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lly_PlaintiffAllegationsDomain_7bb4ce78-980e-4a0f-b694-4dea47e0bbed" xlink:to="loc_lly_AmpullaryCancerMember_87ad807a-b80e-447a-aa1d-019ce0e1f8fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_2b4b267c-d105-4425-ac45-f1fc44b7edbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_944b162d-3fa7-4852-a74c-4dfc691ec547" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_2b4b267c-d105-4425-ac45-f1fc44b7edbc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_2b4b267c-d105-4425-ac45-f1fc44b7edbc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_2b4b267c-d105-4425-ac45-f1fc44b7edbc" xlink:to="loc_us-gaap_LossContingencyNatureDomain_2b4b267c-d105-4425-ac45-f1fc44b7edbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_8a3441a4-06b7-4409-a483-06ebedbb787c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_2b4b267c-d105-4425-ac45-f1fc44b7edbc" xlink:to="loc_us-gaap_LossContingencyNatureDomain_8a3441a4-06b7-4409-a483-06ebedbb787c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProductLiabilityMember_c821f466-bdc7-4c03-be4e-cacd3731d5a6" xlink:href="lly-20210930.xsd#lly_ProductLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8a3441a4-06b7-4409-a483-06ebedbb787c" xlink:to="loc_lly_ProductLiabilityMember_c821f466-bdc7-4c03-be4e-cacd3731d5a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_c5028f35-6207-488e-828f-c7ab34be61ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8a3441a4-06b7-4409-a483-06ebedbb787c" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_c5028f35-6207-488e-828f-c7ab34be61ad" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#OtherComprehensiveIncomeLossAOCIDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="extended" id="i3b188647e48d46ee9c817b71dd4955a2_OtherComprehensiveIncomeLossAOCIDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_466cdcdb-22b5-4e04-9cd3-3e2ba6f11344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d78c5686-675d-4456-aea1-d4db7bf82866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_466cdcdb-22b5-4e04-9cd3-3e2ba6f11344" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d78c5686-675d-4456-aea1-d4db7bf82866" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ae984ac-731a-4c6c-b5de-8cb6efd5914d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d78c5686-675d-4456-aea1-d4db7bf82866" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ae984ac-731a-4c6c-b5de-8cb6efd5914d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_fd0d78d0-f39b-4047-8694-8206db64631f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d78c5686-675d-4456-aea1-d4db7bf82866" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_fd0d78d0-f39b-4047-8694-8206db64631f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7651129e-dbd4-4c2d-b66b-8b560a1dbed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d78c5686-675d-4456-aea1-d4db7bf82866" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7651129e-dbd4-4c2d-b66b-8b560a1dbed2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f517fdd7-f146-4567-ac4a-1cd6d019cdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d78c5686-675d-4456-aea1-d4db7bf82866" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f517fdd7-f146-4567-ac4a-1cd6d019cdf9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_066c8de7-cd77-4fd8-82d7-5fc743c2da60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_2840e17a-6f58-47bd-8eee-26678a15e155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_466cdcdb-22b5-4e04-9cd3-3e2ba6f11344" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_2840e17a-6f58-47bd-8eee-26678a15e155" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e859e2bb-79ed-406c-8664-0866e84ad777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_2840e17a-6f58-47bd-8eee-26678a15e155" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e859e2bb-79ed-406c-8664-0866e84ad777" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e859e2bb-79ed-406c-8664-0866e84ad777_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e859e2bb-79ed-406c-8664-0866e84ad777" xlink:to="loc_us-gaap_EquityComponentDomain_e859e2bb-79ed-406c-8664-0866e84ad777_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ad34808d-6519-4e0f-8d2c-bfe564884203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e859e2bb-79ed-406c-8664-0866e84ad777" xlink:to="loc_us-gaap_EquityComponentDomain_ad34808d-6519-4e0f-8d2c-bfe564884203" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_a3cd1b29-bc44-4117-b6e4-6116711598f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ad34808d-6519-4e0f-8d2c-bfe564884203" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_a3cd1b29-bc44-4117-b6e4-6116711598f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_c2669ce3-096e-4ad5-97a9-4be55ee780bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_a3cd1b29-bc44-4117-b6e4-6116711598f5" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_c2669ce3-096e-4ad5-97a9-4be55ee780bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8a35f135-4b37-4666-b21c-d6c176133bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_a3cd1b29-bc44-4117-b6e4-6116711598f5" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8a35f135-4b37-4666-b21c-d6c176133bf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_4646be11-74f9-4a53-b25a-93b3076d7943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_a3cd1b29-bc44-4117-b6e4-6116711598f5" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_4646be11-74f9-4a53-b25a-93b3076d7943" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_3d57cbd2-95e8-4ea6-b726-219e5feab90f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_a3cd1b29-bc44-4117-b6e4-6116711598f5" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_3d57cbd2-95e8-4ea6-b726-219e5feab90f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#OtherComprehensiveIncomeLossTaxEffectDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" xlink:type="extended" id="ia08e6f508b4641ab8c511695b0544379_OtherComprehensiveIncomeLossTaxEffectDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c40ef1db-b77a-48d3-8bb4-89e3ec6a9645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_18193634-4673-4bac-91b2-d6dd6067e66f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c40ef1db-b77a-48d3-8bb4-89e3ec6a9645" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_18193634-4673-4bac-91b2-d6dd6067e66f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_805bca1b-ec04-4c1f-9e62-ea6f7987e0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c40ef1db-b77a-48d3-8bb4-89e3ec6a9645" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_805bca1b-ec04-4c1f-9e62-ea6f7987e0ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_045bf62d-f90e-41a9-ba2e-96a38cfba02e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_805bca1b-ec04-4c1f-9e62-ea6f7987e0ce" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_045bf62d-f90e-41a9-ba2e-96a38cfba02e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_045bf62d-f90e-41a9-ba2e-96a38cfba02e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_045bf62d-f90e-41a9-ba2e-96a38cfba02e" xlink:to="loc_us-gaap_EquityComponentDomain_045bf62d-f90e-41a9-ba2e-96a38cfba02e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_21fecff1-025b-4aaf-b390-d1ac2c7f5aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_045bf62d-f90e-41a9-ba2e-96a38cfba02e" xlink:to="loc_us-gaap_EquityComponentDomain_21fecff1-025b-4aaf-b390-d1ac2c7f5aa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_23c02dc6-e4ba-4e9d-9030-8bf532b76ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_21fecff1-025b-4aaf-b390-d1ac2c7f5aa5" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_23c02dc6-e4ba-4e9d-9030-8bf532b76ca1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_649f3d50-0ef1-4ed0-889c-6907630e068d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_21fecff1-025b-4aaf-b390-d1ac2c7f5aa5" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_649f3d50-0ef1-4ed0-889c-6907630e068d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_7e8048ca-1f43-4d4e-a926-f1a7884c10cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_21fecff1-025b-4aaf-b390-d1ac2c7f5aa5" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_7e8048ca-1f43-4d4e-a926-f1a7884c10cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_1fb972b5-f4d3-4d46-b0c1-342994a4e65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_21fecff1-025b-4aaf-b390-d1ac2c7f5aa5" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_1fb972b5-f4d3-4d46-b0c1-342994a4e65e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#OtherComprehensiveIncomeLossReclassificationDetails"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" xlink:type="extended" id="i4ccc28299f5c4c6cb66e1c86a52821a1_OtherComprehensiveIncomeLossReclassificationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_b8ad0abd-e41b-40a9-8d88-383d696d9fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fa990034-741c-4875-87d9-8f5a2c96f08f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_b8ad0abd-e41b-40a9-8d88-383d696d9fb7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fa990034-741c-4875-87d9-8f5a2c96f08f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_674ae9f2-4dbe-4d42-8918-720245bfe655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_b8ad0abd-e41b-40a9-8d88-383d696d9fb7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_674ae9f2-4dbe-4d42-8918-720245bfe655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dac0404c-6171-41b8-8251-f67fc6908411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_b8ad0abd-e41b-40a9-8d88-383d696d9fb7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dac0404c-6171-41b8-8251-f67fc6908411" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1c935553-0b90-4ff6-93ec-8e6232ecf3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_b8ad0abd-e41b-40a9-8d88-383d696d9fb7" xlink:to="loc_us-gaap_ProfitLoss_1c935553-0b90-4ff6-93ec-8e6232ecf3f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a1d037c5-17b0-4bff-865f-cb392f6d037c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_b8ad0abd-e41b-40a9-8d88-383d696d9fb7" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a1d037c5-17b0-4bff-865f-cb392f6d037c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_07ea4ccd-060a-4e63-ad13-8fb7349fd4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a1d037c5-17b0-4bff-865f-cb392f6d037c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_07ea4ccd-060a-4e63-ad13-8fb7349fd4f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_07ea4ccd-060a-4e63-ad13-8fb7349fd4f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_07ea4ccd-060a-4e63-ad13-8fb7349fd4f5" xlink:to="loc_us-gaap_EquityComponentDomain_07ea4ccd-060a-4e63-ad13-8fb7349fd4f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eb460a12-79fa-4b94-babb-9d223aaf77d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_07ea4ccd-060a-4e63-ad13-8fb7349fd4f5" xlink:to="loc_us-gaap_EquityComponentDomain_eb460a12-79fa-4b94-babb-9d223aaf77d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_0896d0b9-e8b9-40fb-8c00-748bff641b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eb460a12-79fa-4b94-babb-9d223aaf77d0" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_0896d0b9-e8b9-40fb-8c00-748bff641b9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_a41496b0-2216-4e5e-bf75-fbad2aa895db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_0896d0b9-e8b9-40fb-8c00-748bff641b9f" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_a41496b0-2216-4e5e-bf75-fbad2aa895db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_7dcdba1c-fa4a-4599-a6ec-dd4a31953442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_0896d0b9-e8b9-40fb-8c00-748bff641b9f" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_7dcdba1c-fa4a-4599-a6ec-dd4a31953442" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_e0f55aa6-eb24-40a7-adf8-4aeaa31cce21" xlink:href="lly-20210930.xsd#lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eb460a12-79fa-4b94-babb-9d223aaf77d0" xlink:to="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_e0f55aa6-eb24-40a7-adf8-4aeaa31cce21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_be7aa907-05a3-4da2-bdae-5c9b62c9ed84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a1d037c5-17b0-4bff-865f-cb392f6d037c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_be7aa907-05a3-4da2-bdae-5c9b62c9ed84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_be7aa907-05a3-4da2-bdae-5c9b62c9ed84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_be7aa907-05a3-4da2-bdae-5c9b62c9ed84" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_be7aa907-05a3-4da2-bdae-5c9b62c9ed84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_b90afdde-1fca-4104-8df4-21c2c1f9716e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_be7aa907-05a3-4da2-bdae-5c9b62c9ed84" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_b90afdde-1fca-4104-8df4-21c2c1f9716e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_8eac5881-8dee-4b41-8e75-3cb5b525852a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_b90afdde-1fca-4104-8df4-21c2c1f9716e" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_8eac5881-8dee-4b41-8e75-3cb5b525852a" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>lly-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:83f390d0-6781-4e7e-a1f5-5192701136a4,g:3039e280-7bbd-437e-b91e-6280679dfdce-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_lly_AmpullaryCancerMember_e09e4aec-a030-4ffe-87c7-20c58d37cea8_terseLabel_en-US" xlink:label="lab_lly_AmpullaryCancerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ampullary Cancer</link:label>
    <link:label id="lab_lly_AmpullaryCancerMember_label_en-US" xlink:label="lab_lly_AmpullaryCancerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ampullary Cancer [Member]</link:label>
    <link:label id="lab_lly_AmpullaryCancerMember_documentation_en-US" xlink:label="lab_lly_AmpullaryCancerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ampullary Cancer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AmpullaryCancerMember" xlink:href="lly-20210930.xsd#lly_AmpullaryCancerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AmpullaryCancerMember" xlink:to="lab_lly_AmpullaryCancerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OlumiantMember_fda00be7-01d7-4577-a7f6-b74df2b5eb46_terseLabel_en-US" xlink:label="lab_lly_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olumiant&#174;</link:label>
    <link:label id="lab_lly_OlumiantMember_label_en-US" xlink:label="lab_lly_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olumiant [Member]</link:label>
    <link:label id="lab_lly_OlumiantMember_documentation_en-US" xlink:label="lab_lly_OlumiantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olumiant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember" xlink:href="lly-20210930.xsd#lly_OlumiantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OlumiantMember" xlink:to="lab_lly_OlumiantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_73fede6b-42c8-449b-b347-e96a0fb48fbf_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_eea9dfa6-977e-4bb5-95e9-07283fac29fd_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_a35ad0e9-0603-4339-b146-2608817d30d2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5895fb52-d904-4e8b-a3ba-6b535bc4e253_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_b4b1b1c9-a715-4904-bd30-c7750904f104_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f4436a26-9b47-43d5-8e92-a515aadc7474_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0f38bab7-b86d-488b-abe7-3f9e1fc96631_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_046d53f5-6477-473f-9146-3a74b4be687c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_8a6f5d1a-4ecf-4c54-bc66-594e2c0e50af_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of CVR liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.000NotesDueJune22022Member_7d3146bf-dac9-4acf-bd92-c0b5edfea84d_terseLabel_en-US" xlink:label="lab_lly_A1.000NotesDueJune22022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.000% Notes due 2022</link:label>
    <link:label id="lab_lly_A1.000NotesDueJune22022Member_label_en-US" xlink:label="lab_lly_A1.000NotesDueJune22022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.000% Notes Due June 2, 2022 [Member]</link:label>
    <link:label id="lab_lly_A1.000NotesDueJune22022Member_documentation_en-US" xlink:label="lab_lly_A1.000NotesDueJune22022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.000% Notes Due June 2, 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.000NotesDueJune22022Member" xlink:href="lly-20210930.xsd#lly_A1.000NotesDueJune22022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.000NotesDueJune22022Member" xlink:to="lab_lly_A1.000NotesDueJune22022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LebrikizumabMember_e4599a76-8ab4-4ac2-bc90-f2071a359a02_terseLabel_en-US" xlink:label="lab_lly_LebrikizumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lebrikizumab</link:label>
    <link:label id="lab_lly_LebrikizumabMember_label_en-US" xlink:label="lab_lly_LebrikizumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lebrikizumab [Member]</link:label>
    <link:label id="lab_lly_LebrikizumabMember_documentation_en-US" xlink:label="lab_lly_LebrikizumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lebrikizumab [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LebrikizumabMember" xlink:href="lly-20210930.xsd#lly_LebrikizumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LebrikizumabMember" xlink:to="lab_lly_LebrikizumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_61fcc72e-9f58-45b6-9556-3d097507dabb_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_NeuroscienceMember_2fa50455-5254-4ae2-86d6-7e309fb7a371_terseLabel_en-US" xlink:label="lab_lly_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_lly_NeuroscienceMember_label_en-US" xlink:label="lab_lly_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:label id="lab_lly_NeuroscienceMember_documentation_en-US" xlink:label="lab_lly_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue to unaffiliated customers, Neuroscience</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NeuroscienceMember" xlink:href="lly-20210930.xsd#lly_NeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_NeuroscienceMember" xlink:to="lab_lly_NeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_c1b032a9-2120-43c2-9a75-6039ec0c5856_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_860e6b37-badb-43c8-9aa0-d734d809a994_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_73350554-fd88-4a9c-94e0-c3ea0ff4a1c6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrentAbstract_fa167352-a16e-4269-a4fa-d1bc9cb53e8b_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrentAbstract" xlink:to="lab_us-gaap_ReceivablesNetCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_eb42459e-1f13-483a-86a8-c1050ed855ef_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LyciaTherapeuticsIncMember_508470e7-486a-41b7-99b4-3a6f16298bc6_terseLabel_en-US" xlink:label="lab_lly_LyciaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lycia Therapeutics, Inc.</link:label>
    <link:label id="lab_lly_LyciaTherapeuticsIncMember_label_en-US" xlink:label="lab_lly_LyciaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lycia Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_lly_LyciaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_lly_LyciaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lycia Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LyciaTherapeuticsIncMember" xlink:href="lly-20210930.xsd#lly_LyciaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LyciaTherapeuticsIncMember" xlink:to="lab_lly_LyciaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherDiabetesMember_656bf07f-e674-427a-a0ee-aa6d4f6eac29_terseLabel_en-US" xlink:label="lab_lly_OtherDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Diabetes</link:label>
    <link:label id="lab_lly_OtherDiabetesMember_label_en-US" xlink:label="lab_lly_OtherDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Diabetes [Member]</link:label>
    <link:label id="lab_lly_OtherDiabetesMember_documentation_en-US" xlink:label="lab_lly_OtherDiabetesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Diabetes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherDiabetesMember" xlink:href="lly-20210930.xsd#lly_OtherDiabetesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherDiabetesMember" xlink:to="lab_lly_OtherDiabetesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DermiraInc.Member_f47c5478-b20c-4778-b572-3a08e591510a_terseLabel_en-US" xlink:label="lab_lly_DermiraInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermira</link:label>
    <link:label id="lab_lly_DermiraInc.Member_label_en-US" xlink:label="lab_lly_DermiraInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermira, Inc. [Member]</link:label>
    <link:label id="lab_lly_DermiraInc.Member_documentation_en-US" xlink:label="lab_lly_DermiraInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermira, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DermiraInc.Member" xlink:href="lly-20210930.xsd#lly_DermiraInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DermiraInc.Member" xlink:to="lab_lly_DermiraInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_ff156730-808e-4882-bba5-c80d066d1655_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_1c92557c-0a55-4f97-8333-1297f999fc44_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_acfe28c3-757f-4643-aae3-746987df2b6a_terseLabel_en-US" xlink:label="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, information used to determine revenue recognized, change in accounting estimate, percent (less than - 2021)</link:label>
    <link:label id="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_label_en-US" xlink:label="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent</link:label>
    <link:label id="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_documentation_en-US" xlink:label="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:href="lly-20210930.xsd#lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:to="lab_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_a359700e-9d98-47f6-870b-cb21ce0db09e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of amounts recorded for contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_d7951f25-ecb2-4ecf-80da-2cbf47d4dc4b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_57ee79e8-d6a4-42a2-84ad-cf94686ea24c_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_8a22d6de-507e-4e09-97d5-41a5670b5fcd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service benefits, net</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust_f3df45e9-1497-4ca6-b7df-1e57409a4f1d_negatedLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit trust</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Held in Employee Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:to="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_4956fa0c-7100-4a0a-b3fe-0202b5b74fa0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_a7f4792d-d771-487a-9d41-da6d16bf0506_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_170678b0-65cb-434d-9985-723ca17adf32_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Derivative Risk Management</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_20cae5c0-507d-4c04-a13e-cb6ad224d841_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_af298ee6-2c22-4511-92d3-bafac563402d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CashFlowHedgeAbstract_d1389194-60e3-48e0-b33b-73ee83fac344_terseLabel_en-US" xlink:label="lab_lly_CashFlowHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_lly_CashFlowHedgeAbstract_label_en-US" xlink:label="lab_lly_CashFlowHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedge [Abstract]</link:label>
    <link:label id="lab_lly_CashFlowHedgeAbstract_documentation_en-US" xlink:label="lab_lly_CashFlowHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedge [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CashFlowHedgeAbstract" xlink:href="lly-20210930.xsd#lly_CashFlowHedgeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CashFlowHedgeAbstract" xlink:to="lab_lly_CashFlowHedgeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_658ce491-11ea-457a-bbd3-c21851bb5c2c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other&#8211;net, (income) expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RigelPharmaceuticalsIncMember_909828b7-3320-4ed4-ba09-89b7d1fa81a8_terseLabel_en-US" xlink:label="lab_lly_RigelPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rigel Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_lly_RigelPharmaceuticalsIncMember_label_en-US" xlink:label="lab_lly_RigelPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rigel Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_lly_RigelPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_lly_RigelPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rigel Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RigelPharmaceuticalsIncMember" xlink:href="lly-20210930.xsd#lly_RigelPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RigelPharmaceuticalsIncMember" xlink:to="lab_lly_RigelPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MarketableSecuritiesMember_0c2401c3-440f-48cf-b36f-bd84339a2796_terseLabel_en-US" xlink:label="lab_lly_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_lly_MarketableSecuritiesMember_label_en-US" xlink:label="lab_lly_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:label id="lab_lly_MarketableSecuritiesMember_documentation_en-US" xlink:label="lab_lly_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MarketableSecuritiesMember" xlink:href="lly-20210930.xsd#lly_MarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MarketableSecuritiesMember" xlink:to="lab_lly_MarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_15e7400b-de33-4da3-840f-72666acae5e5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary the contractual maturities of our investments in debt securities measured at fair value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_9cb62489-8a33-492f-afa8-c0d5282db7fd_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reclassifications out of accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_2f0ecdec-3169-48e6-955d-7dea36465b15_terseLabel_en-US" xlink:label="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited initial market entry, supply term</link:label>
    <link:label id="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_label_en-US" xlink:label="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term</link:label>
    <link:label id="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_documentation_en-US" xlink:label="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:href="lly-20210930.xsd#lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:to="lab_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_f1d5a49f-cbf3-4500-9881-b06572010b80_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a740f1c4-9e45-4c5d-8c3b-8168da5fedfe_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_1651f9cc-4c02-49b8-bd5d-127f7fe6f2b3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Gains&#160;(Losses)</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyAgreementTermsMember_a1b52ad7-7b35-4b00-9952-6458bb9503e3_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement Terms</link:label>
    <link:label id="lab_us-gaap_RoyaltyAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyAgreementTermsMember" xlink:to="lab_us-gaap_RoyaltyAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_2030f987-ac76-49c9-a71d-850e2dfacc19_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_022e19c9-325b-478a-8272-b939c15b0dba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_11876d3d-6705-4c8b-ae9a-bea5fb2bba0d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_a2d7a4a6-7c2e-4b6e-9083-17293eeda60a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_26889ba9-7ba9-4494-9962-6b7b09b25201_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, remaining authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_acc63534-41a2-45af-902e-0c6258d1b021_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_6e056af9-a99e-4f18-931a-9577d4e7b5b3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_451376a5-4f9a-4169-9db1-91c0d7f6f3b8_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_b69fcba8-af62-4895-a734-c652da1bfdb7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary certain fair value information, liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_8feaa898-ef0a-4f99-9feb-3f0627b7412e_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued retirement benefits (Note 8)</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_94902005-6584-4e61-a80c-951d74708e4b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MerusNVMember_5ac3616c-dc07-4f18-bcef-88be2e1b69d3_terseLabel_en-US" xlink:label="lab_lly_MerusNVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merus N.V.</link:label>
    <link:label id="lab_lly_MerusNVMember_label_en-US" xlink:label="lab_lly_MerusNVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merus N.V. [Member]</link:label>
    <link:label id="lab_lly_MerusNVMember_documentation_en-US" xlink:label="lab_lly_MerusNVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merus N.V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MerusNVMember" xlink:href="lly-20210930.xsd#lly_MerusNVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MerusNVMember" xlink:to="lab_lly_MerusNVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_9252bae9-634b-4288-a96b-d12bbbed986b_terseLabel_en-US" xlink:label="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment (recovery) and other special charges</link:label>
    <link:label id="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_label_en-US" xlink:label="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges (Recoveries) And Other Special Charges</link:label>
    <link:label id="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_documentation_en-US" xlink:label="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges (Recoveries) And Other Special Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:href="lly-20210930.xsd#lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:to="lab_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SouthernDistrictOfCaliforniaMember_8005d551-5ce1-459f-b108-335ab73bfe2a_terseLabel_en-US" xlink:label="lab_lly_SouthernDistrictOfCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Southern District of California</link:label>
    <link:label id="lab_lly_SouthernDistrictOfCaliforniaMember_label_en-US" xlink:label="lab_lly_SouthernDistrictOfCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Southern District Of California [Member]</link:label>
    <link:label id="lab_lly_SouthernDistrictOfCaliforniaMember_documentation_en-US" xlink:label="lab_lly_SouthernDistrictOfCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Southern District Of California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SouthernDistrictOfCaliforniaMember" xlink:href="lly-20210930.xsd#lly_SouthernDistrictOfCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SouthernDistrictOfCaliforniaMember" xlink:to="lab_lly_SouthernDistrictOfCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_a7df02d1-ad80-4932-ad96-88fb81f362ff_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in net investment hedge, net of tax</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in Net Investment Hedge, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_JunshiBiosciencesMember_21c6a5ea-5eb1-4f10-b69f-6991d347f30b_terseLabel_en-US" xlink:label="lab_lly_JunshiBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Junshi Biosciences</link:label>
    <link:label id="lab_lly_JunshiBiosciencesMember_label_en-US" xlink:label="lab_lly_JunshiBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Junshi Biosciences [Member]</link:label>
    <link:label id="lab_lly_JunshiBiosciencesMember_documentation_en-US" xlink:label="lab_lly_JunshiBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Junshi Biosciences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JunshiBiosciencesMember" xlink:href="lly-20210930.xsd#lly_JunshiBiosciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_JunshiBiosciencesMember" xlink:to="lab_lly_JunshiBiosciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_7c52ca12-de07-45f6-bf71-b3f6ce0cb19e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of asset acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EvoxTherapeuticsMember_b4f50474-be5f-43a3-bd9e-72f15b73ba64_terseLabel_en-US" xlink:label="lab_lly_EvoxTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evox Therapeutics Limited</link:label>
    <link:label id="lab_lly_EvoxTherapeuticsMember_label_en-US" xlink:label="lab_lly_EvoxTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evox Therapeutics [Member]</link:label>
    <link:label id="lab_lly_EvoxTherapeuticsMember_documentation_en-US" xlink:label="lab_lly_EvoxTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evox Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EvoxTherapeuticsMember" xlink:href="lly-20210930.xsd#lly_EvoxTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EvoxTherapeuticsMember" xlink:to="lab_lly_EvoxTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EmployeeLitigationMember_6d67696f-b324-41c8-bb16-c6e9de1612ca_terseLabel_en-US" xlink:label="lab_lly_EmployeeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation</link:label>
    <link:label id="lab_lly_EmployeeLitigationMember_label_en-US" xlink:label="lab_lly_EmployeeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation [Member]</link:label>
    <link:label id="lab_lly_EmployeeLitigationMember_documentation_en-US" xlink:label="lab_lly_EmployeeLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationMember" xlink:href="lly-20210930.xsd#lly_EmployeeLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EmployeeLitigationMember" xlink:to="lab_lly_EmployeeLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_638c9360-6f0e-4937-adee-82d867615314_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_a15dfd93-ea3b-4386-9065-84433c45679c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded, value</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_b03c55fb-fa09-4e3c-bff2-f0c22db6aa8f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_32d5dc15-466e-4403-bef2-0a84e4b6885c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfDecisionsAffirmed_65e37d77-1b35-47a2-9a21-36445c5671f2_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfDecisionsAffirmed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of decisions affirmed</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfDecisionsAffirmed_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfDecisionsAffirmed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Decisions Affirmed</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfDecisionsAffirmed_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfDecisionsAffirmed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Decisions Affirmed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfDecisionsAffirmed" xlink:href="lly-20210930.xsd#lly_LossContingencyNumberOfDecisionsAffirmed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfDecisionsAffirmed" xlink:to="lab_lly_LossContingencyNumberOfDecisionsAffirmed" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_72365aa6-4651-429f-ae40-2233956bbdaf_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_29ba8816-af89-4f0a-b72d-bda21495d220_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_79630f68-1472-4b76-9c1e-e975b4661f62_terseLabel_en-US" xlink:label="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative investments, unfunded commitments, payment period</link:label>
    <link:label id="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_label_en-US" xlink:label="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period</link:label>
    <link:label id="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_documentation_en-US" xlink:label="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:href="lly-20210930.xsd#lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:to="lab_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fb802a7e-a793-4dd9-8549-15a2e713823b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_6d9d95e5-e3b6-4c06-98cd-291d9519a28d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PlaintiffAllegationsAxis_a97da67c-af9b-4c20-bd13-290c16be981b_terseLabel_en-US" xlink:label="lab_lly_PlaintiffAllegationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations [Axis]</link:label>
    <link:label id="lab_lly_PlaintiffAllegationsAxis_label_en-US" xlink:label="lab_lly_PlaintiffAllegationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations [Axis]</link:label>
    <link:label id="lab_lly_PlaintiffAllegationsAxis_documentation_en-US" xlink:label="lab_lly_PlaintiffAllegationsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsAxis" xlink:href="lly-20210930.xsd#lly_PlaintiffAllegationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PlaintiffAllegationsAxis" xlink:to="lab_lly_PlaintiffAllegationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_InnoventBiologicsIncMember_50a6a9c6-47ba-4bbf-9604-9ab0a302c298_terseLabel_en-US" xlink:label="lab_lly_InnoventBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent Biologics, Inc.</link:label>
    <link:label id="lab_lly_InnoventBiologicsIncMember_label_en-US" xlink:label="lab_lly_InnoventBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent Biologics, Inc. [Member]</link:label>
    <link:label id="lab_lly_InnoventBiologicsIncMember_documentation_en-US" xlink:label="lab_lly_InnoventBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovent Biologics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InnoventBiologicsIncMember" xlink:href="lly-20210930.xsd#lly_InnoventBiologicsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_InnoventBiologicsIncMember" xlink:to="lab_lly_InnoventBiologicsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherNeuroscienceMember_62f47ef7-286e-49cf-993a-0094a2f05a21_terseLabel_en-US" xlink:label="lab_lly_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Neuroscience</link:label>
    <link:label id="lab_lly_OtherNeuroscienceMember_label_en-US" xlink:label="lab_lly_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Neuroscience [Member]</link:label>
    <link:label id="lab_lly_OtherNeuroscienceMember_documentation_en-US" xlink:label="lab_lly_OtherNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Neuroscience [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherNeuroscienceMember" xlink:href="lly-20210930.xsd#lly_OtherNeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherNeuroscienceMember" xlink:to="lab_lly_OtherNeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_62794ac0-ce5b-41d5-a2ab-d4feefab1b09_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_15cf75a6-dba2-4d82-9de8-ba28ee0a69de_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5d1d44c4-4d81-467d-b1b0-1fa0b522ae81_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfClaimants_38874c42-cc40-44a2-ab61-19c38f2f5b12_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfClaimants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claimants</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfClaimants_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfClaimants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Claimants</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfClaimants_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfClaimants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Claimants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfClaimants" xlink:href="lly-20210930.xsd#lly_LossContingencyNumberOfClaimants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfClaimants" xlink:to="lab_lly_LossContingencyNumberOfClaimants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_1c38a5bd-32ad-4ebe-b953-9c5a91ab8e3a_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax net losses on cash flow hedges expected to be reclassified during the next 12 months</link:label>
    <link:label id="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_label_en-US" xlink:label="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:to="lab_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_720fb795-a860-4ea7-b753-0bcc052dfabf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in short-term borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_country_BR_42140942-7306-4f47-b31a-3c3810bfc9d6_terseLabel_en-US" xlink:label="lab_country_BR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brazil</link:label>
    <link:label id="lab_country_BR_label_en-US" xlink:label="lab_country_BR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRAZIL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BR" xlink:to="lab_country_BR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_2c7d9332-125f-4883-85f5-6a566bde3c43_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ByettaMember_5c83ece9-ed40-4b32-98c1-c3d43d743b86_terseLabel_en-US" xlink:label="lab_lly_ByettaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Byetta</link:label>
    <link:label id="lab_lly_ByettaMember_label_en-US" xlink:label="lab_lly_ByettaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Byetta [Member]</link:label>
    <link:label id="lab_lly_ByettaMember_documentation_en-US" xlink:label="lab_lly_ByettaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Byetta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ByettaMember" xlink:href="lly-20210930.xsd#lly_ByettaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ByettaMember" xlink:to="lab_lly_ByettaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_cc7df53e-dcc5-4214-9800-4dd39ed41982_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of pending lawsuits</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherForeignCountriesMember_d0a8a62e-dc1e-4c1d-b424-e3fe21904513_terseLabel_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other foreign countries</link:label>
    <link:label id="lab_lly_OtherForeignCountriesMember_label_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Foreign Countries [Member]</link:label>
    <link:label id="lab_lly_OtherForeignCountriesMember_documentation_en-US" xlink:label="lab_lly_OtherForeignCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Foreign Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember" xlink:href="lly-20210930.xsd#lly_OtherForeignCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherForeignCountriesMember" xlink:to="lab_lly_OtherForeignCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_10035bea-2056-474e-a02a-5d5681edb5da_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_17795136-a6c2-46f4-936c-a56f434fa1bd_terseLabel_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential achievements</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_label_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Rights (Obligations)</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_documentation_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terms or rights and obligations under collaborative arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:href="lly-20210930.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:to="lab_lly_CollaborativeArrangementRightsAndObligationsRightsObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_cccc4a61-dcfc-4452-b929-ee6295e32c1c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash acquired</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6753dfb4-6aab-4d4d-9e6c-814eac9390e7_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BasaglarMember_7f657739-868f-41ac-af2f-23ee17a67013_terseLabel_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar&#174;</link:label>
    <link:label id="lab_lly_BasaglarMember_144a0a63-6bee-4f08-a670-3ba71d985479_verboseLabel_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar</link:label>
    <link:label id="lab_lly_BasaglarMember_label_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar [Member]</link:label>
    <link:label id="lab_lly_BasaglarMember_documentation_en-US" xlink:label="lab_lly_BasaglarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basaglar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember" xlink:href="lly-20210930.xsd#lly_BasaglarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BasaglarMember" xlink:to="lab_lly_BasaglarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_be98efae-2e01-4f80-bc34-ec0c60906c50_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_91ed09dd-bacb-450e-87c0-e2bc2745d62b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of disaggregation of revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_KumquatBiosciencesIncMember_83da67b5-a5fd-4dd8-bb86-8904d5b58751_terseLabel_en-US" xlink:label="lab_lly_KumquatBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kumquat Biosciences Inc.</link:label>
    <link:label id="lab_lly_KumquatBiosciencesIncMember_label_en-US" xlink:label="lab_lly_KumquatBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kumquat Biosciences Inc. [Member]</link:label>
    <link:label id="lab_lly_KumquatBiosciencesIncMember_documentation_en-US" xlink:label="lab_lly_KumquatBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kumquat Biosciences Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_KumquatBiosciencesIncMember" xlink:href="lly-20210930.xsd#lly_KumquatBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_KumquatBiosciencesIncMember" xlink:to="lab_lly_KumquatBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_efb6b8c8-7b71-486e-9df9-6e96073c6741_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_b9fc7f43-5cbb-462b-9710-101211d5ef9e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_c450bb30-76b1-4907-8f6d-d8f2195afb5a_terseLabel_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right, monthly reduction (in cents per share)</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_label_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Regulatory Approval Delay, Monthly Reduction</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_documentation_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:href="lly-20210930.xsd#lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:to="lab_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_5bcbdccd-cbaf-429f-9f61-fac653ce2e9f_terseLabel_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and liabilities, net</link:label>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_label_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net</link:label>
    <link:label id="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_documentation_en-US" xlink:label="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:href="lly-20210930.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:to="lab_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_4fbdaf01-3d06-402b-bee2-9ec4898e9b01_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum remaining maturity of foreign currency derivatives</link:label>
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_label_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Remaining Maturity of Foreign Currency Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:to="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_d2f97095-d0f4-4cee-bd64-446a175fecb9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_dd7467d4-0321-4248-b6ab-bdacf68e1ab1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_32bcf88c-2a7f-41d2-ab9d-0e2b2cdb9c8d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_33a5fa13-6c30-48b2-9e6c-9347d90188b3_terseLabel_en-US" xlink:label="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net of tax</link:label>
    <link:label id="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest [Member]</link:label>
    <link:label id="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_documentation_en-US" xlink:label="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="lly-20210930.xsd#lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_ee7af34d-407f-4236-8d60-2ecbe7ad390b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfPatents_a7d39c0e-4c68-4ac4-89cb-95a342b3807e_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatents_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatents_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatents" xlink:href="lly-20210930.xsd#lly_LossContingencyNumberOfPatents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfPatents" xlink:to="lab_lly_LossContingencyNumberOfPatents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_15812e0b-d0f2-41cc-8a88-cf4fde90b496_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity related to our available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_2394c856-a9d5-4d89-a975-ffa48f2a953d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, including current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_ee173d5d-cde0-4aef-8279-80b0a8bd8631_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, including current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_48594784-952a-4415-a38e-13e681848694_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a88e717-7e4b-4274-b850-f9ba94e569f5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PrecisionBiosciencesIncMember_4f3e632d-6477-436a-b754-8897d060eeef_terseLabel_en-US" xlink:label="lab_lly_PrecisionBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision Biosciences, Inc.</link:label>
    <link:label id="lab_lly_PrecisionBiosciencesIncMember_label_en-US" xlink:label="lab_lly_PrecisionBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_lly_PrecisionBiosciencesIncMember_documentation_en-US" xlink:label="lab_lly_PrecisionBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precision Biosciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrecisionBiosciencesIncMember" xlink:href="lly-20210930.xsd#lly_PrecisionBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PrecisionBiosciencesIncMember" xlink:to="lab_lly_PrecisionBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_23e3907e-6373-4887-b8dc-15af6716fc79_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash operating activities, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_851ee43f-cf7b-43a9-99f8-f6340616b638_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_ce73bbd0-0762-48c0-8712-777809edf8e4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_4ed6296c-dd5c-4f60-a20c-f323c5ef331c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_c52bbf66-8b86-40e5-9992-bf7c3561173f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, percentage of nonperforming assets</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_5adbef6f-ff86-4aa4-8076-18bd730bad09_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TaltzMember_fd73a4b9-0e1d-4c61-9f17-674044d7f986_terseLabel_en-US" xlink:label="lab_lly_TaltzMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taltz&#174;</link:label>
    <link:label id="lab_lly_TaltzMember_label_en-US" xlink:label="lab_lly_TaltzMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taltz [Member]</link:label>
    <link:label id="lab_lly_TaltzMember_documentation_en-US" xlink:label="lab_lly_TaltzMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taltz [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaltzMember" xlink:href="lly-20210930.xsd#lly_TaltzMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TaltzMember" xlink:to="lab_lly_TaltzMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_572fcff2-245c-4df6-8ad7-1eba61cb0d0e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b31c8c93-5e9e-463a-8c7c-cefcd30f8327_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_31daa848-3448-4441-85a0-0560acd24cdd_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward-starting interest rate swaps</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_9ba0de5d-70bb-4e88-8f36-0587e11c482c_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A395NotesDue2049Member_063a749c-a3ee-4974-b4a3-5612ddaa2440_terseLabel_en-US" xlink:label="lab_lly_A395NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% Notes Due 2049</link:label>
    <link:label id="lab_lly_A395NotesDue2049Member_label_en-US" xlink:label="lab_lly_A395NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% Notes Due 2049 [Member]</link:label>
    <link:label id="lab_lly_A395NotesDue2049Member_documentation_en-US" xlink:label="lab_lly_A395NotesDue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% Notes Due 2049</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2049Member" xlink:href="lly-20210930.xsd#lly_A395NotesDue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A395NotesDue2049Member" xlink:to="lab_lly_A395NotesDue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_VerzenioMember_06cac8c5-a19e-4a48-94f5-501e1030fefa_terseLabel_en-US" xlink:label="lab_lly_VerzenioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verzenio&#174;</link:label>
    <link:label id="lab_lly_VerzenioMember_label_en-US" xlink:label="lab_lly_VerzenioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verzenio [Member]</link:label>
    <link:label id="lab_lly_VerzenioMember_documentation_en-US" xlink:label="lab_lly_VerzenioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verzenio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VerzenioMember" xlink:href="lly-20210930.xsd#lly_VerzenioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_VerzenioMember" xlink:to="lab_lly_VerzenioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_9284f42a-b823-458d-af7a-467c95ce9ed5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_cf323254-5ea9-40a4-9e46-9f6586198649_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_667dc1a6-497a-4a23-aa02-ded8489349b8_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateralized Mortgage Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_6f54782f-5607-473b-8fe4-60ce9474db75_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities, net unrealized gains (losses)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_d2641d8e-dd77-4abb-89a2-d1be02e94aec_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment gains</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A415NotesDue2059Member_85ddda30-6755-4d76-98f1-5df5901fb0b1_terseLabel_en-US" xlink:label="lab_lly_A415NotesDue2059Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Notes Due 2059</link:label>
    <link:label id="lab_lly_A415NotesDue2059Member_label_en-US" xlink:label="lab_lly_A415NotesDue2059Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Notes Due 2059 [Member]</link:label>
    <link:label id="lab_lly_A415NotesDue2059Member_documentation_en-US" xlink:label="lab_lly_A415NotesDue2059Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Notes Due 2059</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A415NotesDue2059Member" xlink:href="lly-20210930.xsd#lly_A415NotesDue2059Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A415NotesDue2059Member" xlink:to="lab_lly_A415NotesDue2059Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_5d1fc7d2-8954-4624-a681-8fa3bfd3936d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_3d3a27a9-e2bb-4d76-b864-279493f41091_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Other than Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_98be8fff-c02e-4d13-ae51-9f75a1088966_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_71018130-4567-4caf-8551-a6078bf5a23b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes in operating assets and liabilities, net of acquisitions and divestitures</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0f5409a2-4b12-434a-a931-40dc2a301b69_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_1c179ce5-1804-4c99-bbd0-92249c385395_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing, selling, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_942f0afb-ef2f-4e8b-bb2f-f4564c1efe09_terseLabel_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement benefit plans</link:label>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_label_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:to="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ffe43e9c-420f-47a8-aaaa-edc573fbd1c3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gross gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PancreatitisMember_6b2b7fa1-de53-42a5-81fb-7fe85d317433_terseLabel_en-US" xlink:label="lab_lly_PancreatitisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatitis</link:label>
    <link:label id="lab_lly_PancreatitisMember_label_en-US" xlink:label="lab_lly_PancreatitisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatitis [Member]</link:label>
    <link:label id="lab_lly_PancreatitisMember_documentation_en-US" xlink:label="lab_lly_PancreatitisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatitis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreatitisMember" xlink:href="lly-20210930.xsd#lly_PancreatitisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PancreatitisMember" xlink:to="lab_lly_PancreatitisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_81d6e10b-fcc0-4242-9da2-2e666206fbcb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_4df8e804-0ba0-442d-ba30-0e4cdf532a47_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More&#160;Than 10 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EquityMethodAndOtherInvestmentsMember_ea7a6b01-e595-4b52-82a2-658120f1b7ae_verboseLabel_en-US" xlink:label="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_lly_EquityMethodAndOtherInvestmentsMember_label_en-US" xlink:label="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method And Other Investments [Member]</link:label>
    <link:label id="lab_lly_EquityMethodAndOtherInvestmentsMember_documentation_en-US" xlink:label="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method and Other Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EquityMethodAndOtherInvestmentsMember" xlink:href="lly-20210930.xsd#lly_EquityMethodAndOtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EquityMethodAndOtherInvestmentsMember" xlink:to="lab_lly_EquityMethodAndOtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_6c025c38-34c1-4cea-83cc-d97ecafbadbb_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_ace19c8f-22ed-4b51-89a6-5eb2355ccecc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_WhyteEtAlVEliLillyEtAlMember_0084e98d-e4ae-4fd7-a61b-3f0b3e44cb12_terseLabel_en-US" xlink:label="lab_lly_WhyteEtAlVEliLillyEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weiler v. Takeda Canada Inc. et al.</link:label>
    <link:label id="lab_lly_WhyteEtAlVEliLillyEtAlMember_label_en-US" xlink:label="lab_lly_WhyteEtAlVEliLillyEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Whyte Et Al. V. Eli Lilly Et Al. [Member]</link:label>
    <link:label id="lab_lly_WhyteEtAlVEliLillyEtAlMember_documentation_en-US" xlink:label="lab_lly_WhyteEtAlVEliLillyEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Whyte Et Al. V. Eli Lilly Et Al.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WhyteEtAlVEliLillyEtAlMember" xlink:href="lly-20210930.xsd#lly_WhyteEtAlVEliLillyEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_WhyteEtAlVEliLillyEtAlMember" xlink:to="lab_lly_WhyteEtAlVEliLillyEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_2d0708e0-ed78-4aee-891b-ac5bf7f889e1_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_18bb2983-ab89-47e4-9e68-a1eb4dfcd669_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_27b75d7c-4d9f-4381-8f41-a9b7e2ca03af_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisitions, net of cash acquired (Note 3)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4dbaab8c-3364-49c6-bbea-9bdce71a2215_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherOncologyMember_b4b44072-1a97-4922-b85a-31ceae53c8ba_terseLabel_en-US" xlink:label="lab_lly_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology</link:label>
    <link:label id="lab_lly_OtherOncologyMember_label_en-US" xlink:label="lab_lly_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:label id="lab_lly_OtherOncologyMember_documentation_en-US" xlink:label="lab_lly_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherOncologyMember" xlink:href="lly-20210930.xsd#lly_OtherOncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherOncologyMember" xlink:to="lab_lly_OtherOncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_e3ddbf46-b2c8-47b4-b055-0f1a180e8fe6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrustForBenefitOfEmployeesMember_2640594d-a490-4523-88bc-fcb17f61fe90_terseLabel_en-US" xlink:label="lab_us-gaap_TrustForBenefitOfEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Trust</link:label>
    <link:label id="lab_us-gaap_TrustForBenefitOfEmployeesMember_label_en-US" xlink:label="lab_us-gaap_TrustForBenefitOfEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trust for Benefit of Employees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrustForBenefitOfEmployeesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrustForBenefitOfEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrustForBenefitOfEmployeesMember" xlink:to="lab_us-gaap_TrustForBenefitOfEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_bc483eee-5872-4cc6-9ab2-dee6a8cd74e0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HedgedFixedRateDebtMember_b16ef6f1-690a-4aae-84a3-0272e4bd9883_terseLabel_en-US" xlink:label="lab_lly_HedgedFixedRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency-denominated notes</link:label>
    <link:label id="lab_lly_HedgedFixedRateDebtMember_label_en-US" xlink:label="lab_lly_HedgedFixedRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Fixed Rate Debt [Member]</link:label>
    <link:label id="lab_lly_HedgedFixedRateDebtMember_documentation_en-US" xlink:label="lab_lly_HedgedFixedRateDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Fixed-Rate Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HedgedFixedRateDebtMember" xlink:href="lly-20210930.xsd#lly_HedgedFixedRateDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HedgedFixedRateDebtMember" xlink:to="lab_lly_HedgedFixedRateDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AsahiKaseiPharmaCorporationMember_96934cff-34e8-4242-a029-2e67e83e66b9_terseLabel_en-US" xlink:label="lab_lly_AsahiKaseiPharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asahi Kasei Pharma Corporation</link:label>
    <link:label id="lab_lly_AsahiKaseiPharmaCorporationMember_label_en-US" xlink:label="lab_lly_AsahiKaseiPharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asahi Kasei Pharma Corporation [Member]</link:label>
    <link:label id="lab_lly_AsahiKaseiPharmaCorporationMember_documentation_en-US" xlink:label="lab_lly_AsahiKaseiPharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asahi Kasei Pharma Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AsahiKaseiPharmaCorporationMember" xlink:href="lly-20210930.xsd#lly_AsahiKaseiPharmaCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AsahiKaseiPharmaCorporationMember" xlink:to="lab_lly_AsahiKaseiPharmaCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_5d8cec13-a772-4c6c-8dec-e5a9dfb76904_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_b5810822-947c-4908-b52e-10b21ccf7937_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_e6f7f09c-4046-42a0-89d4-8b6dab5761d0_negatedLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#8211;net, (income) expense (Note 11)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_510a290a-2874-4077-aa6d-eb4e1ddab147_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#8211;net, (income) expense</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopment_e7b5a193-e725-4d36-9a20-a19d16745bd8_terseLabel_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development (Note 3)</link:label>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_lly_AcquiredInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment" xlink:href="lly-20210930.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AcquiredInProcessResearchAndDevelopment" xlink:to="lab_lly_AcquiredInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_b410d1ce-d85b-415b-81b6-d9a577f688b3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retiree Health Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_9278f34a-b29c-4d23-ae23-d86ae4e6fe22_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 9)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5b20ae58-1dc8-48c3-a502-61b5d6b06331_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss (Note 10)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_bfb2183d-e2c3-4020-968c-e2cf9671d1c6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, by balance sheet grouping</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_7ef11fd7-61ea-4ce6-b3b2-eb70074f153c_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_04199d02-ae18-4e95-a38c-58307e5bf05e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_8222a2ad-334a-4827-aed1-cbec0c4310cd_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_fb2927ee-08ac-4d52-a1c9-40e50809fc22_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_25ffd7d8-9967-43bb-9e4d-59ccbf3bcafa_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_FairValueHedgeAbstract_28773fc9-91a5-4e60-a190-043381adbc61_terseLabel_en-US" xlink:label="lab_lly_FairValueHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value hedges:</link:label>
    <link:label id="lab_lly_FairValueHedgeAbstract_label_en-US" xlink:label="lab_lly_FairValueHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedge [Abstract]</link:label>
    <link:label id="lab_lly_FairValueHedgeAbstract_documentation_en-US" xlink:label="lab_lly_FairValueHedgeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedge [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueHedgeAbstract" xlink:href="lly-20210930.xsd#lly_FairValueHedgeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_FairValueHedgeAbstract" xlink:to="lab_lly_FairValueHedgeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8ef14a0a-0a42-45fd-b7b7-0a0156bf200d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_2edc002d-24d7-4556-9707-87da87211006_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:href="lly-20210930.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:to="lab_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3675a9fd-1e7a-40d0-8989-eba0ed8f4530_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_d264ab1c-a2f0-4c79-bf36-54c577b20680_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AlimtaMember_3f79ec52-ede3-484c-8944-9f83006ae922_terseLabel_en-US" xlink:label="lab_lly_AlimtaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta&#174;</link:label>
    <link:label id="lab_lly_AlimtaMember_label_en-US" xlink:label="lab_lly_AlimtaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta [Member]</link:label>
    <link:label id="lab_lly_AlimtaMember_documentation_en-US" xlink:label="lab_lly_AlimtaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alimta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaMember" xlink:href="lly-20210930.xsd#lly_AlimtaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AlimtaMember" xlink:to="lab_lly_AlimtaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6225c701-3c76-4a2e-ae14-659e0f3353ff_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_fa8268ff-9d8f-4c11-bd4f-962f1ffc2e71_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SwapSwissFrancsToU.S.DollarsMember_e18a70d7-fb39-4081-b9d1-b890c98a2847_terseLabel_en-US" xlink:label="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap Swiss Francs to U.S. Dollars</link:label>
    <link:label id="lab_lly_SwapSwissFrancsToU.S.DollarsMember_label_en-US" xlink:label="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap Swiss Francs To U.S. Dollars [Member]</link:label>
    <link:label id="lab_lly_SwapSwissFrancsToU.S.DollarsMember_documentation_en-US" xlink:label="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap Swiss Francs To U.S. Dollars [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:href="lly-20210930.xsd#lly_SwapSwissFrancsToU.S.DollarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:to="lab_lly_SwapSwissFrancsToU.S.DollarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_cdadb655-135c-433a-b093-60adcbd8a0e0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_0d56ae1e-7bbd-46ba-9dfd-d42609d153b2_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_4676c291-eb6e-4062-b878-4dcab3f10904_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividend declared per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3e564c34-bd76-4f1e-8298-b4fd13915469_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ErbituxMember_558954db-d4c3-45a7-9391-d24d8c40a3dc_terseLabel_en-US" xlink:label="lab_lly_ErbituxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erbitux&#174;</link:label>
    <link:label id="lab_lly_ErbituxMember_label_en-US" xlink:label="lab_lly_ErbituxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erbitux [Member]</link:label>
    <link:label id="lab_lly_ErbituxMember_documentation_en-US" xlink:label="lab_lly_ErbituxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erbitux [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ErbituxMember" xlink:href="lly-20210930.xsd#lly_ErbituxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ErbituxMember" xlink:to="lab_lly_ErbituxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_1883c9a1-a25e-4f0c-bc75-4327c3beef7e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A718NotesDueJune12025Member_72e309bf-0433-4b34-a734-5d85b40decd7_terseLabel_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes due 2025</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_label_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_documentation_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member" xlink:href="lly-20210930.xsd#lly_A718NotesDueJune12025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A718NotesDueJune12025Member" xlink:to="lab_lly_A718NotesDueJune12025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MiNATherapeuticsLimitedMember_d791069c-e414-48ac-a054-11a932c7eaa4_terseLabel_en-US" xlink:label="lab_lly_MiNATherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MiNA Therapeutics Limited</link:label>
    <link:label id="lab_lly_MiNATherapeuticsLimitedMember_label_en-US" xlink:label="lab_lly_MiNATherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MiNA Therapeutics Limited [Member]</link:label>
    <link:label id="lab_lly_MiNATherapeuticsLimitedMember_documentation_en-US" xlink:label="lab_lly_MiNATherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MiNA Therapeutics Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MiNATherapeuticsLimitedMember" xlink:href="lly-20210930.xsd#lly_MiNATherapeuticsLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MiNATherapeuticsLimitedMember" xlink:to="lab_lly_MiNATherapeuticsLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_802b7077-ae4b-40f4-ae05-b26bfcbbda47_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ce567a2-2a9f-4f1a-a0d3-c40f05595507_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_3ce3b962-14da-473e-a1a3-357cbb9d5527_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ProQRTherapeuticsNVMember_e5f53ee8-9bf0-4982-a013-d7b78c1ee0a6_terseLabel_en-US" xlink:label="lab_lly_ProQRTherapeuticsNVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQR Therapeutics N.V.</link:label>
    <link:label id="lab_lly_ProQRTherapeuticsNVMember_label_en-US" xlink:label="lab_lly_ProQRTherapeuticsNVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQR Therapeutics N.V. [Member]</link:label>
    <link:label id="lab_lly_ProQRTherapeuticsNVMember_documentation_en-US" xlink:label="lab_lly_ProQRTherapeuticsNVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQR Therapeutics N.V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProQRTherapeuticsNVMember" xlink:href="lly-20210930.xsd#lly_ProQRTherapeuticsNVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ProQRTherapeuticsNVMember" xlink:to="lab_lly_ProQRTherapeuticsNVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_c8c93583-ac3e-49d2-b639-cbeb23b8b9db_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_683ff5bb-ceac-4451-9553-0249c23c6b48_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_add033f2-086f-4d82-8675-e43675a99b9e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_b93a4d14-7bcd-4707-9257-a1738e7f46dd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_ce5ce1ed-6b88-47b8-997a-c3428c6e0c99_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of noncurrent investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CostOfSalesOperatingExpensesAndOtherNet_267c35a8-2ae8-4eec-b000-fcfae3086a8b_totalLabel_en-US" xlink:label="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, expenses, and other</link:label>
    <link:label id="lab_lly_CostOfSalesOperatingExpensesAndOtherNet_label_en-US" xlink:label="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales, operating expenses, and other-net</link:label>
    <link:label id="lab_lly_CostOfSalesOperatingExpensesAndOtherNet_documentation_en-US" xlink:label="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales, operating expenses, and other-net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:href="lly-20210930.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:to="lab_lly_CostOfSalesOperatingExpensesAndOtherNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5b42214b-a752-4350-85c2-0a9194191774_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gross losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_825a1ab2-e9c5-4ba2-ade4-956edd930cab_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1-5 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyUSDollarSellChineseYuanMember_b076eab4-1ea1-4692-87af-52606d21a180_terseLabel_en-US" xlink:label="lab_lly_BuyUSDollarSellChineseYuanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US Dollar Sell Chinese Yuan</link:label>
    <link:label id="lab_lly_BuyUSDollarSellChineseYuanMember_label_en-US" xlink:label="lab_lly_BuyUSDollarSellChineseYuanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US Dollar Sell Chinese Yuan [Member]</link:label>
    <link:label id="lab_lly_BuyUSDollarSellChineseYuanMember_documentation_en-US" xlink:label="lab_lly_BuyUSDollarSellChineseYuanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US Dollar Sell Chinese Yuan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSDollarSellChineseYuanMember" xlink:href="lly-20210930.xsd#lly_BuyUSDollarSellChineseYuanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyUSDollarSellChineseYuanMember" xlink:to="lab_lly_BuyUSDollarSellChineseYuanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_d4c3a0b5-8390-476b-9da9-77c4bf5578c2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations and Other Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ImmunologyMember_04b069db-2d31-40d4-962c-097d9dd628ad_terseLabel_en-US" xlink:label="lab_lly_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology</link:label>
    <link:label id="lab_lly_ImmunologyMember_label_en-US" xlink:label="lab_lly_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:label id="lab_lly_ImmunologyMember_documentation_en-US" xlink:label="lab_lly_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmunologyMember" xlink:href="lly-20210930.xsd#lly_ImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ImmunologyMember" xlink:to="lab_lly_ImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_d15691ef-6d23-46fd-b7f3-33d896b90ad1_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b1986245-4bdf-4d15-9018-490581ff0aed_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_727d10ba-094b-4e92-808f-b90b4a3d5406_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_db23aea7-eba0-4ad3-97aa-195915f949fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ProductLiabilityMember_379be066-1b61-4802-bede-c606ffa125c7_terseLabel_en-US" xlink:label="lab_lly_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:label id="lab_lly_ProductLiabilityMember_label_en-US" xlink:label="lab_lly_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability [Member]</link:label>
    <link:label id="lab_lly_ProductLiabilityMember_documentation_en-US" xlink:label="lab_lly_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProductLiabilityMember" xlink:href="lly-20210930.xsd#lly_ProductLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ProductLiabilityMember" xlink:to="lab_lly_ProductLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_830287bc-2206-47c9-9971-3fd850c0c5ef_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ca7252e4-1af0-4506-ad2a-df66cbfd6d1c_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents (Note 6)</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DomicileOfLitigationAxis_bf589d08-b0bf-47b8-8fa7-fbe4f30740ee_terseLabel_en-US" xlink:label="lab_lly_DomicileOfLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile of Litigation [Axis]</link:label>
    <link:label id="lab_lly_DomicileOfLitigationAxis_label_en-US" xlink:label="lab_lly_DomicileOfLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile Of Litigation [Axis]</link:label>
    <link:label id="lab_lly_DomicileOfLitigationAxis_documentation_en-US" xlink:label="lab_lly_DomicileOfLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile Of Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationAxis" xlink:href="lly-20210930.xsd#lly_DomicileOfLitigationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DomicileOfLitigationAxis" xlink:to="lab_lly_DomicileOfLitigationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_05101d57-5e39-42fc-8b3c-089d3660f26c_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_63802a26-55a3-4758-a56b-c5f31dc0d58e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember_9dfb5465-2fe0-4087-83a4-f4d147c1d1a3_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Upon Initiation of Phase I Trial</link:label>
    <link:label id="lab_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Upon Initiation Of Phase I Trial [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Upon Initiation Of Phase I Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember" xlink:href="lly-20210930.xsd#lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember" xlink:to="lab_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_cf2a38e5-0723-433a-998d-6e2a282dea05_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock in Treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ff69448-c8b4-44e4-8fe6-b628f75b0cdb_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_bedc5677-c8f0-4721-9ac8-0282fae37979_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e96b69ee-05d0-4d71-870e-d6e13a24a3a8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#8211;net, (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_c7216335-98ab-4090-a189-cee258fd43e8_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6fc0bba3-8ba8-4727-af8e-ed2ba339a778_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investing activities, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_5c129472-4cb4-4896-8061-bda096dec212_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_d3d1588a-efd4-471d-bf9a-656944b7ab3f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LitigationClaimsDismissedNumber_69b4fefe-efa5-4d05-a435-1b129bb1ac2f_terseLabel_en-US" xlink:label="lab_lly_LitigationClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims dismissed</link:label>
    <link:label id="lab_lly_LitigationClaimsDismissedNumber_label_en-US" xlink:label="lab_lly_LitigationClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation, Claims Dismissed, Number</link:label>
    <link:label id="lab_lly_LitigationClaimsDismissedNumber_documentation_en-US" xlink:label="lab_lly_LitigationClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LitigationClaimsDismissedNumber" xlink:href="lly-20210930.xsd#lly_LitigationClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LitigationClaimsDismissedNumber" xlink:to="lab_lly_LitigationClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_4429c8b7-0180-496c-843b-1071164253d3_terseLabel_en-US" xlink:label="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gross gains on sales</link:label>
    <link:label id="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_label_en-US" xlink:label="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for Sale Securities and Equity Securities, FV-NI, Realized Gain</link:label>
    <link:label id="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_documentation_en-US" xlink:label="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for Sale Securities and Equity Securities, FV-NI, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:href="lly-20210930.xsd#lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:to="lab_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_addfbdc0-cb48-434e-aabf-d30b4f6890aa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of significant milestones and revenue recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_d6d75d91-06be-4465-9436-085bc1d2688e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Portion of Cash&#160;Flow Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_5ed8077a-4052-4bb3-a324-e0a87d479a16_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_9c0fd467-83c7-4672-af74-85f2fd611ba8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for debt extinguishment</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_b34b3e7c-cd89-4562-b792-5ec28b6175d7_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_98916d20-440f-4b89-84bc-e05565fcb82a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_4f41ec8e-6d9c-4a12-83ae-8368934af1db_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Eli Lilly and Company shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherProductTotalMember_285cee6e-bb26-429b-bde0-bc00c1b4df45_terseLabel_en-US" xlink:label="lab_lly_OtherProductTotalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lly_OtherProductTotalMember_label_en-US" xlink:label="lab_lly_OtherProductTotalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product, Total [Member]</link:label>
    <link:label id="lab_lly_OtherProductTotalMember_documentation_en-US" xlink:label="lab_lly_OtherProductTotalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product, Total [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductTotalMember" xlink:href="lly-20210930.xsd#lly_OtherProductTotalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherProductTotalMember" xlink:to="lab_lly_OtherProductTotalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_c91ac0b0-efd1-4dee-bfb0-900925fbc598_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_c0e66671-17a9-4f24-b8b0-35182323d989_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt extinguishment loss (Note 6)</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_70259450-5494-4a8e-bbe1-3fa07ba0b257_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt extinguishment loss</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_f21c85cc-1b70-4e82-bdd1-9d299a12e51e_terseLabel_en-US" xlink:label="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al.</link:label>
    <link:label id="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_label_en-US" xlink:label="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Casseres Et Al. V. Takeda Pharmaceutical North America, Inc., Et Al. [Member]</link:label>
    <link:label id="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_documentation_en-US" xlink:label="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Casseres Et Al. V. Takeda Pharmaceutical North America, Inc., Et Al.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:href="lly-20210930.xsd#lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:to="lab_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_8ef45fe3-b22a-47ec-8f22-4863dfa050e8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_5e72d362-25cc-40e1-a2cf-83c5931ea0e7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_821cc1ac-4fc7-4698-9ee0-9dcef70f7a1b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_bfde9210-c302-4292-be75-866c57094ca0_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_b84dbffb-a41e-431f-9dff-b087fd937719_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_cf76811c-c973-44c7-834b-63964f1f8e0b_terseLabel_en-US" xlink:label="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales</link:label>
    <link:label id="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_label_en-US" xlink:label="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity and Available for Sale Securities</link:label>
    <link:label id="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_documentation_en-US" xlink:label="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity and Available for Sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:href="lly-20210930.xsd#lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:to="lab_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_b5725835-8c3d-462e-93c4-6e2d55369d71_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_WeilerVTakedaCanadaIncEtAlMember_98e4543b-3b9a-4078-ba39-5752f6963039_terseLabel_en-US" xlink:label="lab_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weiler v. Takeda Canada Inc. et al.</link:label>
    <link:label id="lab_lly_WeilerVTakedaCanadaIncEtAlMember_label_en-US" xlink:label="lab_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weiler V. Takeda Canada Inc. Et Al. [Member]</link:label>
    <link:label id="lab_lly_WeilerVTakedaCanadaIncEtAlMember_documentation_en-US" xlink:label="lab_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weiler V. Takeda Canada Inc. Et Al.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:href="lly-20210930.xsd#lly_WeilerVTakedaCanadaIncEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:to="lab_lly_WeilerVTakedaCanadaIncEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_93088ba9-e771-4d84-89be-fe892c4fb9cd_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsPercent_1f49a0b0-7d66-4db4-b9fd-8ff2f059af06_terseLabel_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, rights and obligations, percentage (up to)</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsPercent_label_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations Percent</link:label>
    <link:label id="lab_lly_CollaborativeArrangementRightsAndObligationsPercent_documentation_en-US" xlink:label="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:href="lly-20210930.xsd#lly_CollaborativeArrangementRightsAndObligationsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:to="lab_lly_CollaborativeArrangementRightsAndObligationsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_582a5b97-eeca-4b1c-878a-2c843389103f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_a17a81fb-ca91-41c7-8809-d8903671677c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_45385a07-1b29-4afa-8230-1961cfb5f04a_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_57bae162-33f2-4fad-bf0a-554795825ac3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TrulicityMemberMember_7abeef5f-6be1-45ae-a33a-03b515553a46_terseLabel_en-US" xlink:label="lab_lly_TrulicityMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trulicity&#174;</link:label>
    <link:label id="lab_lly_TrulicityMemberMember_label_en-US" xlink:label="lab_lly_TrulicityMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trulicity [Member] [Member]</link:label>
    <link:label id="lab_lly_TrulicityMemberMember_documentation_en-US" xlink:label="lab_lly_TrulicityMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trulicity [Member] [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrulicityMemberMember" xlink:href="lly-20210930.xsd#lly_TrulicityMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TrulicityMemberMember" xlink:to="lab_lly_TrulicityMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_daf5aa02-5009-4616-9658-05eeb45c9b46_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0036765c-573f-40c0-90b1-2fb317b194c1_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition date fair value of consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HumalogHumulinAndForteoMember_18755f65-4584-43a5-81f8-42c1cd55eb77_terseLabel_en-US" xlink:label="lab_lly_HumalogHumulinAndForteoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog, Humulin and Forteo</link:label>
    <link:label id="lab_lly_HumalogHumulinAndForteoMember_label_en-US" xlink:label="lab_lly_HumalogHumulinAndForteoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog, Humulin, And Forteo [Member]</link:label>
    <link:label id="lab_lly_HumalogHumulinAndForteoMember_documentation_en-US" xlink:label="lab_lly_HumalogHumulinAndForteoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog, Humulin, And Forteo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogHumulinAndForteoMember" xlink:href="lly-20210930.xsd#lly_HumalogHumulinAndForteoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HumalogHumulinAndForteoMember" xlink:to="lab_lly_HumalogHumulinAndForteoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1dfd0739-7584-4b98-ae8c-eee4ba099416_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4ec4bbba-0d0c-49c7-a28b-21ec65a5afc6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PurchasedInProcessResearchAndDevelopment_29376933-7d1e-4e30-834b-a7473edc100d_negatedTerseLabel_en-US" xlink:label="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of in-process research and development</link:label>
    <link:label id="lab_lly_PurchasedInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased in-process research and development</link:label>
    <link:label id="lab_lly_PurchasedInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PurchasedInProcessResearchAndDevelopment" xlink:href="lly-20210930.xsd#lly_PurchasedInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PurchasedInProcessResearchAndDevelopment" xlink:to="lab_lly_PurchasedInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4fde4d65-aed3-4f4c-92ef-026ae49288c9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CyramzaMember_4340ae77-6636-4454-9542-774509f1b95e_terseLabel_en-US" xlink:label="lab_lly_CyramzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyramza&#174;</link:label>
    <link:label id="lab_lly_CyramzaMember_label_en-US" xlink:label="lab_lly_CyramzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyramza [Member]</link:label>
    <link:label id="lab_lly_CyramzaMember_documentation_en-US" xlink:label="lab_lly_CyramzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyramza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CyramzaMember" xlink:href="lly-20210930.xsd#lly_CyramzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CyramzaMember" xlink:to="lab_lly_CyramzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_6de5d9d6-edab-437c-8cc8-de998f819dd1_terseLabel_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes due 2030</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_label_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_documentation_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member" xlink:href="lly-20210930.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A2.125NotesDueJune32030Member" xlink:to="lab_lly_A2.125NotesDueJune32030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_0a77d3a8-0bb4-480d-89ff-237b5096d28a_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsSalesBasedMember_641260fc-aedf-4282-a818-5e88fae71ab8_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Sales-based</link:label>
    <link:label id="lab_lly_MilestonePaymentsSalesBasedMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Sales-based [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsSalesBasedMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Sales-based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSalesBasedMember" xlink:href="lly-20210930.xsd#lly_MilestonePaymentsSalesBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsSalesBasedMember" xlink:to="lab_lly_MilestonePaymentsSalesBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DiabetesMember_3c9dd9da-b5b9-4a3c-a752-28c4155d9718_terseLabel_en-US" xlink:label="lab_lly_DiabetesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes</link:label>
    <link:label id="lab_lly_DiabetesMember_label_en-US" xlink:label="lab_lly_DiabetesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes [Member]</link:label>
    <link:label id="lab_lly_DiabetesMember_documentation_en-US" xlink:label="lab_lly_DiabetesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DiabetesMember" xlink:href="lly-20210930.xsd#lly_DiabetesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DiabetesMember" xlink:to="lab_lly_DiabetesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_3f983331-df07-41a7-86f8-b432203ccd1f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_d511d763-6da4-4a78-b460-643bd37f0750_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the amounts recognized for assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9a47fae8-0424-48d8-b39e-0de88a082ae1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under employee stock plans, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_b8b345a1-e0db-429c-8c9a-950db466f1ba_terseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency interest rate swaps</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:to="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_918019dc-c31b-4d5c-a6a7-bb08be2befc7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_5676534d-9f2d-4c36-9b36-8e160b3905f9_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment gains</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_c8e479da-15eb-47dd-9f16-6a7bb3e21a25_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e1bbc140-dc1e-4a0b-a3ca-d0d9cddbce33_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_VariousStateDomicilesMember_56ef0690-c772-4bea-8f25-75a1039d4029_terseLabel_en-US" xlink:label="lab_lly_VariousStateDomicilesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various State Domiciles</link:label>
    <link:label id="lab_lly_VariousStateDomicilesMember_label_en-US" xlink:label="lab_lly_VariousStateDomicilesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various State Domiciles [Member]</link:label>
    <link:label id="lab_lly_VariousStateDomicilesMember_documentation_en-US" xlink:label="lab_lly_VariousStateDomicilesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various State Domiciles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VariousStateDomicilesMember" xlink:href="lly-20210930.xsd#lly_VariousStateDomicilesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_VariousStateDomicilesMember" xlink:to="lab_lly_VariousStateDomicilesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_b29eb12e-ccab-4384-8463-338687193667_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherProductMember_9064ded5-16fa-49d9-bb7d-0209da65a3d1_terseLabel_en-US" xlink:label="lab_lly_OtherProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lly_OtherProductMember_label_en-US" xlink:label="lab_lly_OtherProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product [Member]</link:label>
    <link:label id="lab_lly_OtherProductMember_documentation_en-US" xlink:label="lab_lly_OtherProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductMember" xlink:href="lly-20210930.xsd#lly_OtherProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherProductMember" xlink:to="lab_lly_OtherProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable_f7a63ba2-d7b5-4813-8afc-5539de371955_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Accounting Estimate [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Accounting Estimate [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyBritishPoundandSellUSDollarsMember_1850d367-edb4-41e8-b550-937a9a96e7c9_terseLabel_en-US" xlink:label="lab_lly_BuyBritishPoundandSellUSDollarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy British Pounds and Sell U.S. Dollars</link:label>
    <link:label id="lab_lly_BuyBritishPoundandSellUSDollarsMember_label_en-US" xlink:label="lab_lly_BuyBritishPoundandSellUSDollarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy British Pound and Sell US Dollars [Member]</link:label>
    <link:label id="lab_lly_BuyBritishPoundandSellUSDollarsMember_documentation_en-US" xlink:label="lab_lly_BuyBritishPoundandSellUSDollarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy British Pound and Sell US Dollars [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyBritishPoundandSellUSDollarsMember" xlink:href="lly-20210930.xsd#lly_BuyBritishPoundandSellUSDollarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyBritishPoundandSellUSDollarsMember" xlink:to="lab_lly_BuyBritishPoundandSellUSDollarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateLineItems_8f41d6fa-b866-4976-be3d-0353a569fe1b_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate [Line Items]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateLineItems_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_0c431c7e-179a-4602-ac08-bf9333bbb4ce_terseLabel_en-US" xlink:label="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gross losses on sales</link:label>
    <link:label id="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_label_en-US" xlink:label="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale Securities and Equity Securities, FV-NI, Realized Loss</link:label>
    <link:label id="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_documentation_en-US" xlink:label="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale Securities and Equity Securities, FV-NI, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:href="lly-20210930.xsd#lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:to="lab_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ProtomerTechnologiesIncMember_d473899b-9d3a-423e-8561-3c3f7b50cd26_terseLabel_en-US" xlink:label="lab_lly_ProtomerTechnologiesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Protomer Technologies Inc.</link:label>
    <link:label id="lab_lly_ProtomerTechnologiesIncMember_label_en-US" xlink:label="lab_lly_ProtomerTechnologiesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Protomer Technologies Inc. [Member]</link:label>
    <link:label id="lab_lly_ProtomerTechnologiesIncMember_documentation_en-US" xlink:label="lab_lly_ProtomerTechnologiesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Protomer Technologies Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProtomerTechnologiesIncMember" xlink:href="lly-20210930.xsd#lly_ProtomerTechnologiesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ProtomerTechnologiesIncMember" xlink:to="lab_lly_ProtomerTechnologiesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_62554d62-f818-45f0-b67d-e98fb73c54aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments (Note 6)</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_81d3b768-b6f4-4264-a1de-a917f326c20c_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_36ab5535-84ee-47f1-8ea3-ffb196b8f219_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8c7b23d5-c0eb-45da-9939-c8b2b757136b_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_de8907a2-dc78-40f6-b330-47503477a9f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes (Note 7)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2efa0e10-143b-40f3-8974-a88d32a4a0c8_negatedNetLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PetraPharmaCorporationMember_7348c102-8619-4c2d-9eb7-bbd61adc0f72_terseLabel_en-US" xlink:label="lab_lly_PetraPharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Petra</link:label>
    <link:label id="lab_lly_PetraPharmaCorporationMember_label_en-US" xlink:label="lab_lly_PetraPharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Petra Pharma Corporation [Member]</link:label>
    <link:label id="lab_lly_PetraPharmaCorporationMember_documentation_en-US" xlink:label="lab_lly_PetraPharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Petra Pharma Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PetraPharmaCorporationMember" xlink:href="lly-20210930.xsd#lly_PetraPharmaCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PetraPharmaCorporationMember" xlink:to="lab_lly_PetraPharmaCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_3fb1974c-b0f2-44ba-8bde-b637934a44a8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowances of $24.1 (2021) and $25.9 (2020)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e7d95999-6342-4abd-a57e-2f4dd4be9b9a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_33390968-dac8-4907-b4ca-55c5c2567f0e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6a2eb823-541c-402e-b127-a252263313de_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_8352d8ec-c825-4608-b9fc-61c8e384a71c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_59f592bf-e4ec-4b2a-abb0-f6ac7ab108cd_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_e1f00b6e-e1aa-4574-8faa-e39c1bc05117_negatedLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect from interest rate contracts</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_950068dc-2194-42c1-b3e4-3a9d3d2889bc_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_493e4f03-685e-40e8-9007-e00e668011ca_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTable" xlink:to="lab_us-gaap_AssetAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_203c1c1a-36f1-42ea-b765-980c66885bcb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EppVTakedaCanadaIncEtAlMember_1e3f38be-1451-40b1-b19c-76f1f349dd63_terseLabel_en-US" xlink:label="lab_lly_EppVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epp v. Takeda Canada Inc. et al.</link:label>
    <link:label id="lab_lly_EppVTakedaCanadaIncEtAlMember_label_en-US" xlink:label="lab_lly_EppVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epp V. Takeda Canada Inc. Et Al. [Member]</link:label>
    <link:label id="lab_lly_EppVTakedaCanadaIncEtAlMember_documentation_en-US" xlink:label="lab_lly_EppVTakedaCanadaIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epp V. Takeda Canada Inc. Et Al.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EppVTakedaCanadaIncEtAlMember" xlink:href="lly-20210930.xsd#lly_EppVTakedaCanadaIncEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EppVTakedaCanadaIncEtAlMember" xlink:to="lab_lly_EppVTakedaCanadaIncEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTextBlock_20a07d2d-ef69-463a-b112-f01722d613fb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4b333134-342e-48f7-b42c-847bf356bcbc_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3f546c79-cf22-4399-84d3-b36c0c251ef3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_eb09639e-31f3-4520-b0f7-cea46b79cafe_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_a51c7c68-5001-4670-b875-a6180ad0bae9_terseLabel_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right, additional price per share (up to) (in dollars per share)</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_label_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Additional Price Per Share</link:label>
    <link:label id="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_documentation_en-US" xlink:label="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Value Right, Additional Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:href="lly-20210930.xsd#lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:to="lab_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_0514907e-23ed-4514-b4f3-8079a54da406_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b11d73ab-a458-46d5-a12f-81dd82e0e4f4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_5d2e6e0f-0bda-45ff-b1f7-e99b30163911_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_8452ce1f-adc1-488f-9def-5aec7558e0ff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#8211;Net, (Income) Expense</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e2b604b2-b12b-4a9b-afa6-6c3347f9c3c9_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_f3b85d5a-0298-451f-8f69-f12fcfdc702a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_6a878dff-87e9-4159-b811-2fea270a0148_negatedLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CymbaltaMember_cecdd64c-42ec-479e-a51d-2453e09028c3_terseLabel_en-US" xlink:label="lab_lly_CymbaltaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cymbalta&#174;</link:label>
    <link:label id="lab_lly_CymbaltaMember_label_en-US" xlink:label="lab_lly_CymbaltaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cymbalta [Member]</link:label>
    <link:label id="lab_lly_CymbaltaMember_documentation_en-US" xlink:label="lab_lly_CymbaltaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cymbalta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CymbaltaMember" xlink:href="lly-20210930.xsd#lly_CymbaltaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CymbaltaMember" xlink:to="lab_lly_CymbaltaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f1f5d566-30ae-4c9a-8e5d-1a1e862fb898_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_1bb39cc5-a8e2-4700-97a2-cbe7d1970298_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_dad42cee-27fc-4094-8360-9e8fe47b50b1_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Capitalized as Intangible Assets</link:label>
    <link:label id="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Capitalized As Intangible Assets [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Capitalized As Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:href="lly-20210930.xsd#lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:to="lab_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_83942ff4-4560-4f7f-be34-1c934f49aa4a_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent investments, debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_f8d3a4fb-e02e-4a93-8310-0ed77f5e1047_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effects of risk-management instruments were recognized in other&#8211;net, (income) expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6fe0184f-c378-4798-ad8c-ac346194b3e5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A625Notesdue2031Member_577b1731-b765-4e50-964e-1697c87be30a_terseLabel_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.625% Notes due 2031</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_label_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_documentation_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member" xlink:href="lly-20210930.xsd#lly_A625Notesdue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A625Notesdue2031Member" xlink:to="lab_lly_A625Notesdue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_ff54ad5d-6914-4f01-a22f-a4d6117b573a_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_38806592-95bc-4e02-bd64-d03fbe27e483_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_a2952cc5-db84-45c2-9190-5ca9ff2e16fa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right, additional price per share, aggregate amount</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_cfb19a7d-49be-47c0-aece-1e0594a4b988_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c9eb7400-4967-403c-be96-e428f9fcecda_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_66732c5a-26d8-47e1-8018-7bb74e94fb12_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4a40aae1-0b9d-4672-96db-a938f94e5af6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total before tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_466e58c2-2261-4fa4-8648-061192fc8247_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_c00b0804-4899-473e-b60b-9c0af3157e0b_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_42012b08-ff42-486e-938b-2ea003fea5db_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of securities in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_bc4fb59d-4a5d-455d-a755-3ff6a84d6a75_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_ae31cf09-775c-4ee7-9485-f5104f297b93_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_ce518016-c60c-4872-b186-dbb8a3951c27_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_c9ec3da7-cdbb-40b1-b2ce-3c94bc265365_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_02ce596b-5069-42f5-bbb1-9ba9e271a34a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_892ef399-175d-4dd5-909f-3b3149b29db0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions_9e7a3cfe-f315-49fc-8aa5-d7a7f9b8a42f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment, restructuring, and other special charges (Note 5)</link:label>
    <link:label id="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions_e26ba78b-947f-4842-a311-8de72c36f742_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total asset impairment, restructuring, and other special charges</link:label>
    <link:label id="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions_label_en-US" xlink:label="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Settlement and Impairment Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:to="lab_us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_43a8681f-2e78-4109-8147-085328914432_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Net Gains (Losses) on&#160;Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_1e170582-2b7c-4774-8db0-a562074358c9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized net gains/losses on securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SitryxTherapeuticsLimitedMember_675b1c73-e6f3-4781-86b4-1e3bedc87338_terseLabel_en-US" xlink:label="lab_lly_SitryxTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sitryx Therapeutics Limited</link:label>
    <link:label id="lab_lly_SitryxTherapeuticsLimitedMember_label_en-US" xlink:label="lab_lly_SitryxTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sitryx Therapeutics Limited [Member]</link:label>
    <link:label id="lab_lly_SitryxTherapeuticsLimitedMember_documentation_en-US" xlink:label="lab_lly_SitryxTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sitryx Therapeutics Limited [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SitryxTherapeuticsLimitedMember" xlink:href="lly-20210930.xsd#lly_SitryxTherapeuticsLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SitryxTherapeuticsLimitedMember" xlink:to="lab_lly_SitryxTherapeuticsLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_17feacbf-1a1c-474a-81b9-6370f0b3e3a8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit (provision) for income taxes allocated to other comprehensive income (loss) items</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_95e7e058-70f2-40ea-b0aa-3ed217eb0fd8_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_f222ccf6-c76d-436a-bdf5-f610eed2b5f7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments" xlink:to="lab_us-gaap_OtherLongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_846871b3-c24c-4df1-ab55-c491de6d7d83_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_5d497ee7-f160-4f8e-a42d-bd7ee9d3e42a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_NonCHINAMember_4d2918d4-94a5-489f-b68d-2d48cfbf12a9_terseLabel_en-US" xlink:label="lab_lly_NonCHINAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-CHINA</link:label>
    <link:label id="lab_lly_NonCHINAMember_label_en-US" xlink:label="lab_lly_NonCHINAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-CHINA [Member]</link:label>
    <link:label id="lab_lly_NonCHINAMember_documentation_en-US" xlink:label="lab_lly_NonCHINAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NonCHINAMember" xlink:href="lly-20210930.xsd#lly_NonCHINAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_NonCHINAMember" xlink:to="lab_lly_NonCHINAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_801bc6d3-03dc-4b0f-a8e6-cff51071f0c0_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_c47a5376-5d14-4343-bb67-3d2c6739e6e5_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_9c0a7f4c-25c6-477d-8e98-cbf3ba9248db_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3da451e2-3475-481e-b2f5-ad9501f297f4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_083b3f71-c71f-49cc-85e3-cdc2c2147e0e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7200458b-850e-4aac-b22d-e615b94609de_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability, other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_88cdb62e-896d-4129-9671-427673cc939b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherImmunologyMember_edd8bda4-3d07-4874-8ee8-ba5e16b7cbd5_terseLabel_en-US" xlink:label="lab_lly_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology</link:label>
    <link:label id="lab_lly_OtherImmunologyMember_label_en-US" xlink:label="lab_lly_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:label id="lab_lly_OtherImmunologyMember_documentation_en-US" xlink:label="lab_lly_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherImmunologyMember" xlink:href="lly-20210930.xsd#lly_OtherImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherImmunologyMember" xlink:to="lab_lly_OtherImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_d6450300-bb8d-4c4f-9f20-b7274f288e6c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative investments, unfunded commitments</link:label>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_label_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:to="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1ffba0d-c7ba-49a1-9245-87188c6f7866_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_e49a68cf-a932-4421-a14b-0210446f7c72_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_085f0284-8db8-450f-bfdd-c1fb605a6df7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1625NotesDue2043Member_9a238691-f091-42c8-8cec-5aad67fc20d9_terseLabel_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes due 2043</link:label>
    <link:label id="lab_lly_A1625NotesDue2043Member_label_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due 2043 [Member]</link:label>
    <link:label id="lab_lly_A1625NotesDue2043Member_documentation_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due 2043</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member" xlink:href="lly-20210930.xsd#lly_A1625NotesDue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1625NotesDue2043Member" xlink:to="lab_lly_A1625NotesDue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d5a6be8d-8020-47a2-b416-439faddd46d6_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_ece5c825-dea0-461e-8a80-9a3a8fe58d1b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_744d6bde-c331-40fc-8d98-f765d0cd72c0_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_8dd60b0c-1e46-4e96-b737-0a0e090e69ad_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfPatentsClaimsDismissed_cafe45c1-66c6-4225-9475-e5dc89a37874_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatentsClaimsDismissed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents, claims dismissed</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatentsClaimsDismissed_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatentsClaimsDismissed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents, Claims Dismissed</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatentsClaimsDismissed_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatentsClaimsDismissed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents, Claims Dismissed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatentsClaimsDismissed" xlink:href="lly-20210930.xsd#lly_LossContingencyNumberOfPatentsClaimsDismissed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfPatentsClaimsDismissed" xlink:to="lab_lly_LossContingencyNumberOfPatentsClaimsDismissed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e416876c-8352-4985-b4f0-385e6d1eea6a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_60cf364c-08b4-4bc7-9333-0b7ceb54b92f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LosAngelesMember_0e6a27b2-23c6-4ec4-8b8a-eeae74d65b44_terseLabel_en-US" xlink:label="lab_lly_LosAngelesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Los Angeles</link:label>
    <link:label id="lab_lly_LosAngelesMember_label_en-US" xlink:label="lab_lly_LosAngelesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Los Angeles [Member]</link:label>
    <link:label id="lab_lly_LosAngelesMember_documentation_en-US" xlink:label="lab_lly_LosAngelesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Los Angeles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LosAngelesMember" xlink:href="lly-20210930.xsd#lly_LosAngelesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LosAngelesMember" xlink:to="lab_lly_LosAngelesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_3c0fedec-3183-4d57-8bfa-2c21807956a9_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_2527f921-3b6d-4e98-ae1f-d753f2b1ed55_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_88ee4e29-debc-4fc3-9fb2-54dcfec03e60_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment hedges</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3e4aab40-1538-4267-8dd2-6ef66e56b200_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_COVID19AntibodiesMember_406f3e8e-f15e-447a-8f6c-1b611ca38860_terseLabel_en-US" xlink:label="lab_lly_COVID19AntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Antibodies</link:label>
    <link:label id="lab_lly_COVID19AntibodiesMember_label_en-US" xlink:label="lab_lly_COVID19AntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Antibodies [Member]</link:label>
    <link:label id="lab_lly_COVID19AntibodiesMember_documentation_en-US" xlink:label="lab_lly_COVID19AntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Antibodies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember" xlink:href="lly-20210930.xsd#lly_COVID19AntibodiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_COVID19AntibodiesMember" xlink:to="lab_lly_COVID19AntibodiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_937c8be7-de7d-42af-81a8-4166660040df_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized actuarial loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Actuarial Gain (Loss), Immediate Recognition as Component in Net Periodic Benefit (Cost) Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_c7cedc7f-1b2c-4f0b-94da-8d683a7032b8_terseLabel_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of securities in an unrealized gain position</link:label>
    <link:label id="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_label_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain Position</link:label>
    <link:label id="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_documentation_en-US" xlink:label="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:href="lly-20210930.xsd#lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:to="lab_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_cdd70f43-7c1c-4f1e-bac7-6548ab8ad3bd_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside U.S.</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_9ad61555-b933-4ad3-9af4-2f167e65b173_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_e9390aeb-43b4-4290-a9ca-7ffab473b1dd_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_1aca1a06-1937-4ac7-94d5-94a2b7c77f50_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_471fe28c-e97d-40bc-944a-b07bb6398965_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Used for Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_d50fedb5-6509-4858-afff-795c04f8acd3_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of common stock in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a25c368a-c028-4aca-bc6d-3c7f63a37f2f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in calculation of earnings per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_6ac2cd49-9876-417c-bf42-74c8c71e7c71_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial losses, net</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_614a611c-f07c-497f-8d4e-0deaac814fac_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_85198d66-707f-4841-bdc7-e6fb0e30db99_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ForeignCurrencyDenominatedDebtMember_da8fe998-9e8f-4789-bbf2-faaf1777e70a_terseLabel_en-US" xlink:label="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt</link:label>
    <link:label id="lab_lly_ForeignCurrencyDenominatedDebtMember_label_en-US" xlink:label="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt [Member]</link:label>
    <link:label id="lab_lly_ForeignCurrencyDenominatedDebtMember_documentation_en-US" xlink:label="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Denominated Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember" xlink:href="lly-20210930.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ForeignCurrencyDenominatedDebtMember" xlink:to="lab_lly_ForeignCurrencyDenominatedDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_6c012fc8-6b0d-4930-a5eb-cdd9796bc9e2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A5000NotesDue2033Member_09f52c91-38dd-44ab-ad34-5a03def795fc_terseLabel_en-US" xlink:label="lab_lly_A5000NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2033</link:label>
    <link:label id="lab_lly_A5000NotesDue2033Member_label_en-US" xlink:label="lab_lly_A5000NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.5000% Notes Due 2033 [Member]</link:label>
    <link:label id="lab_lly_A5000NotesDue2033Member_documentation_en-US" xlink:label="lab_lly_A5000NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.5000% Notes Due 2033</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A5000NotesDue2033Member" xlink:href="lly-20210930.xsd#lly_A5000NotesDue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A5000NotesDue2033Member" xlink:to="lab_lly_A5000NotesDue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_6ec03fe9-5a55-48bd-a57c-b1990ba4162e_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_9bbc6ed6-0f8b-4c5d-818e-a40407f34110_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_87c4e5c2-9f7c-45a5-8612-375c61d0e9f4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4abbdf28-c190-40e5-979a-ff6e0a745c38_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EmgalityPatentLitigationMember_43b6954d-fad3-49a1-b2b5-af31433bf0c3_terseLabel_en-US" xlink:label="lab_lly_EmgalityPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality Patent Litigation</link:label>
    <link:label id="lab_lly_EmgalityPatentLitigationMember_label_en-US" xlink:label="lab_lly_EmgalityPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality Patent Litigation [Member]</link:label>
    <link:label id="lab_lly_EmgalityPatentLitigationMember_documentation_en-US" xlink:label="lab_lly_EmgalityPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality Patent Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityPatentLitigationMember" xlink:href="lly-20210930.xsd#lly_EmgalityPatentLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EmgalityPatentLitigationMember" xlink:to="lab_lly_EmgalityPatentLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_5b4b8375-5226-4eae-b9a5-2f4b95be8c67_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary certain fair value information, assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_8806fe88-d40e-410d-af54-a597fb1e5c27_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4ff2b4db-67ce-4389-95cf-4fcdbd033edb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_179e71d8-7927-4fec-884c-a717a7a557df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The components of the charges included in asset impairment, restructuring, and other special charges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1125NotesDue2051Member_acfc6ac4-ed2c-42b2-a707-e68547ad73c1_terseLabel_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_label_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes Due 2051 [Member]</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_documentation_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes Due 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member" xlink:href="lly-20210930.xsd#lly_A1125NotesDue2051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1125NotesDue2051Member" xlink:to="lab_lly_A1125NotesDue2051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_d06b23ed-acd7-4b88-8f84-90f2b9533426_terseLabel_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action</link:label>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_label_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:to="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_ead9d5fd-b377-4c0e-8dd1-2996841dddec_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the fair value of available-for-sale securities in an unrealized gain or loss position</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_3e6986b5-ded2-40e8-90c5-893ef5d2228d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments (Note 6)</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_8047794d-f083-48d5-9291-3f65d46b1c5c_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_ed3e59bb-2c1b-41e1-9109-1925ec170aa2_terseLabel_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes due 2026</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_label_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_documentation_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member" xlink:href="lly-20210930.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.625NotesDueJune22026Member" xlink:to="lab_lly_A1.625NotesDueJune22026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_13cd1fe1-109f-4ea4-b0b5-7b1494ee1738_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_ba312c06-1b8a-4240-a1b2-05118d49e38f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6-10 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_8bb28c69-026f-4d1c-96b9-9d67342d7574_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Retired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesRetired" xlink:to="lab_us-gaap_TreasuryStockSharesRetired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfLongtermInvestments_d751e450-ec33-4b84-a7eb-67592d586b93_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of noncurrent investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfLongtermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfLongtermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfLongtermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_dff95817-baa9-491d-9fd1-c8b48c4b4a93_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_InsulinMember_9e14d643-3735-4e11-967b-fdead5945859_terseLabel_en-US" xlink:label="lab_lly_InsulinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insulin</link:label>
    <link:label id="lab_lly_InsulinMember_label_en-US" xlink:label="lab_lly_InsulinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insulin [Member]</link:label>
    <link:label id="lab_lly_InsulinMember_documentation_en-US" xlink:label="lab_lly_InsulinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insulin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InsulinMember" xlink:href="lly-20210930.xsd#lly_InsulinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_InsulinMember" xlink:to="lab_lly_InsulinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_9f179517-25b1-4965-80b0-411e899e9f0e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ActosMember_a63da6ee-274e-4730-b306-32332f72a1e2_terseLabel_en-US" xlink:label="lab_lly_ActosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actos</link:label>
    <link:label id="lab_lly_ActosMember_label_en-US" xlink:label="lab_lly_ActosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actos [Member]</link:label>
    <link:label id="lab_lly_ActosMember_documentation_en-US" xlink:label="lab_lly_ActosMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actos</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ActosMember" xlink:href="lly-20210930.xsd#lly_ActosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ActosMember" xlink:to="lab_lly_ActosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_e6f573d7-c575-4aae-838d-b67fefee2e9a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D Expense</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DomicileOfLitigationDomain_ddf89689-8e36-45d1-9d76-0bf00f8e0e41_terseLabel_en-US" xlink:label="lab_lly_DomicileOfLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile of Litigation [Domain]</link:label>
    <link:label id="lab_lly_DomicileOfLitigationDomain_label_en-US" xlink:label="lab_lly_DomicileOfLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile Of Litigation [Domain]</link:label>
    <link:label id="lab_lly_DomicileOfLitigationDomain_documentation_en-US" xlink:label="lab_lly_DomicileOfLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domicile Of Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationDomain" xlink:href="lly-20210930.xsd#lly_DomicileOfLitigationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DomicileOfLitigationDomain" xlink:to="lab_lly_DomicileOfLitigationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_0538aa8a-7fe0-4718-9362-14b5806a42e1_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales returns, rebates, and discounts</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0beba103-b5e8-4bc0-acee-473e2d858191_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TYVYTMember_5ebb5042-827a-44eb-80fa-1b7bd1723a83_terseLabel_en-US" xlink:label="lab_lly_TYVYTMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tyvyt&#174;</link:label>
    <link:label id="lab_lly_TYVYTMember_label_en-US" xlink:label="lab_lly_TYVYTMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYVYT [Member]</link:label>
    <link:label id="lab_lly_TYVYTMember_documentation_en-US" xlink:label="lab_lly_TYVYTMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYVYT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember" xlink:href="lly-20210930.xsd#lly_TYVYTMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TYVYTMember" xlink:to="lab_lly_TYVYTMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_12dc3fdf-54d3-4e3f-94de-5946332fd82e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b3187b86-779f-4f21-bfbe-42d49648173a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $9,962.8 (2021) and $9,570.7 (2020)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_c354c0a3-aff0-4d01-96f2-05d69465d0b5_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PancreaticCancerOrThyroidCancerMember_da89bf0c-c668-45f3-8e4b-3249352fdcc8_terseLabel_en-US" xlink:label="lab_lly_PancreaticCancerOrThyroidCancerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatic Cancer or Thyroid Cancer</link:label>
    <link:label id="lab_lly_PancreaticCancerOrThyroidCancerMember_label_en-US" xlink:label="lab_lly_PancreaticCancerOrThyroidCancerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatic Cancer Or Thyroid Cancer [Member]</link:label>
    <link:label id="lab_lly_PancreaticCancerOrThyroidCancerMember_documentation_en-US" xlink:label="lab_lly_PancreaticCancerOrThyroidCancerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pancreatic Cancer Or Thyroid Cancer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreaticCancerOrThyroidCancerMember" xlink:href="lly-20210930.xsd#lly_PancreaticCancerOrThyroidCancerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PancreaticCancerOrThyroidCancerMember" xlink:to="lab_lly_PancreaticCancerOrThyroidCancerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_2fb5805c-6de2-4d6c-b4a6-ca56de7ffe45_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_d85ea1d7-cc91-4b4a-b9d0-38f41ea49b97_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_2692cc40-3092-4c3e-9a62-f3db6803a7ca_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_b25e94ec-5699-4c90-b60f-c1ed591c24e7_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_7071450c-da9d-4503-8b94-ebf452a8b522_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_32f609a5-a0f5-4eb9-9591-4465a8696315_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of sites jointly and severally liable for cleanup (fewer than)</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:href="lly-20210930.xsd#lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:to="lab_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_0169c732-8143-4a43-a9ae-41f98ef9be29_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OncologyMember_0141b49b-7646-49dc-bdbd-206badf1362f_terseLabel_en-US" xlink:label="lab_lly_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology</link:label>
    <link:label id="lab_lly_OncologyMember_label_en-US" xlink:label="lab_lly_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_lly_OncologyMember_documentation_en-US" xlink:label="lab_lly_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue to unaffiliated customers, Oncology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OncologyMember" xlink:href="lly-20210930.xsd#lly_OncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OncologyMember" xlink:to="lab_lly_OncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_db81c1bd-a58b-4d3a-941d-e907eae231fb_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Success-based Regulatory and Sales-based</link:label>
    <link:label id="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Success-based Regulatory And Sales-based [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Success-based Regulatory And Sales-based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:href="lly-20210930.xsd#lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:to="lab_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_EmgalityMember_c0bbdfed-2019-476d-b08a-4d07d9deafa4_terseLabel_en-US" xlink:label="lab_lly_EmgalityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality&#174;</link:label>
    <link:label id="lab_lly_EmgalityMember_label_en-US" xlink:label="lab_lly_EmgalityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality [Member]</link:label>
    <link:label id="lab_lly_EmgalityMember_documentation_en-US" xlink:label="lab_lly_EmgalityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emgality [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityMember" xlink:href="lly-20210930.xsd#lly_EmgalityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_EmgalityMember" xlink:to="lab_lly_EmgalityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_944481c3-ff20-4a8d-8d39-34ddd321c5d9_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_cb32ecce-2587-4b6f-956d-2fa44334b7ff_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Development and Regulatory [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:href="lly-20210930.xsd#lly_MilestonePaymentsDevelopmentAndRegulatoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:to="lab_lly_MilestonePaymentsDevelopmentAndRegulatoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_a506660e-484d-4123-a6a3-b4f95cde52eb_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue (Note 2)</link:label>
    <link:label id="lab_us-gaap_Revenues_5a4e192c-7e09-4e8e-a96d-0d55ebb06fc7_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_93ce7f75-7342-4869-a051-19b0fe42e385_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7e1ec4d0-7a9f-44d2-9b7f-e7eb9c3111df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.700Notesdue2049Member_3185a396-faaf-4672-8736-50481c089f05_terseLabel_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_label_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_documentation_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member" xlink:href="lly-20210930.xsd#lly_A1.700Notesdue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.700Notesdue2049Member" xlink:to="lab_lly_A1.700Notesdue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_bcf2730f-4f45-4834-9190-9ab66d2b4d70_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_f0bddf0a-d484-487c-a9fe-1772165c4c0c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ca7d18c2-991b-4d7c-b9ba-6f5ba53bf3a5_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_845fa66b-9b94-4689-a076-c3de4da2fe97_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_25a21e43-8533-4b1b-903b-36577cc57a7c_terseLabel_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes due 2036</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_label_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_documentation_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member" xlink:href="lly-20210930.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A6.77NotesDueJanuary12036Member" xlink:to="lab_lly_A6.77NotesDueJanuary12036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SalesRebatesAndDiscounts_10da3c61-2ab4-42ad-b96e-9f9a27dddf2c_terseLabel_en-US" xlink:label="lab_lly_SalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales rebates and discounts</link:label>
    <link:label id="lab_lly_SalesRebatesAndDiscounts_label_en-US" xlink:label="lab_lly_SalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales rebates and discounts</link:label>
    <link:label id="lab_lly_SalesRebatesAndDiscounts_documentation_en-US" xlink:label="lab_lly_SalesRebatesAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales rebates and discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SalesRebatesAndDiscounts" xlink:href="lly-20210930.xsd#lly_SalesRebatesAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SalesRebatesAndDiscounts" xlink:to="lab_lly_SalesRebatesAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_745839e4-eaf4-425a-b704-6c09bf769c49_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, expenses, and other:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DrReddysLabMember_99767d0a-89f4-4ff6-95cd-969930c77b25_terseLabel_en-US" xlink:label="lab_lly_DrReddysLabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr Reddy's Lab</link:label>
    <link:label id="lab_lly_DrReddysLabMember_label_en-US" xlink:label="lab_lly_DrReddysLabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr Reddy's Lab [Member]</link:label>
    <link:label id="lab_lly_DrReddysLabMember_documentation_en-US" xlink:label="lab_lly_DrReddysLabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr Reddy's Lab [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DrReddysLabMember" xlink:href="lly-20210930.xsd#lly_DrReddysLabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DrReddysLabMember" xlink:to="lab_lly_DrReddysLabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_0d7ba90a-7e2d-4b31-aed2-ac51d3fd5e3d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_15f0b758-fde0-4ed3-9c68-bf44f71a0c04_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DerivativeInstrumentsGainLossRecognized_e34ac099-e0e0-4fa2-acd2-b7862a693246_negatedTotalLabel_en-US" xlink:label="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_lly_DerivativeInstrumentsGainLossRecognized_label_en-US" xlink:label="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized</link:label>
    <link:label id="lab_lly_DerivativeInstrumentsGainLossRecognized_documentation_en-US" xlink:label="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized" xlink:href="lly-20210930.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DerivativeInstrumentsGainLossRecognized" xlink:to="lab_lly_DerivativeInstrumentsGainLossRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_e421ee8a-783a-4b45-b38e-6064a0741724_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CialisMember_5ec87c5f-97b8-454d-b138-a996398d9c41_terseLabel_en-US" xlink:label="lab_lly_CialisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cialis&#174;</link:label>
    <link:label id="lab_lly_CialisMember_label_en-US" xlink:label="lab_lly_CialisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cialis [Member]</link:label>
    <link:label id="lab_lly_CialisMember_documentation_en-US" xlink:label="lab_lly_CialisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cialis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember" xlink:href="lly-20210930.xsd#lly_CialisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CialisMember" xlink:to="lab_lly_CialisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_61432314-79b7-4f28-aa39-a1be18b7d65d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2f97dd51-76fd-46a7-902e-5a6a80e0d791_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate, percentage</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_70c33996-6e8e-4173-bd2d-c36968fc270c_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_OtherEquitySecuritiesMember_20aaa9fe-e535-4672-9317-b8f91fe1b0ac_terseLabel_en-US" xlink:label="lab_lly_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other securities, noncurrent investments</link:label>
    <link:label id="lab_lly_OtherEquitySecuritiesMember_label_en-US" xlink:label="lab_lly_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Equity Securities [Member]</link:label>
    <link:label id="lab_lly_OtherEquitySecuritiesMember_documentation_en-US" xlink:label="lab_lly_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherEquitySecuritiesMember" xlink:href="lly-20210930.xsd#lly_OtherEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_OtherEquitySecuritiesMember" xlink:to="lab_lly_OtherEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_1506428a-11d3-49d4-8861-45d8b9a6b70e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other securities, current investments</link:label>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Debt Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDebtSecuritiesMember" xlink:to="lab_us-gaap_OtherDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_85258b81-d03e-45dd-8900-1633793a7186_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_6699b052-0867-4aab-bdf3-df244a347a3a_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_ec04b738-b2c5-4390-acdf-795d9501db7e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term borrowings and current maturities of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_3fba630e-06ce-408f-91a1-0c97e4afa1f0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock (no par value)</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_7ed640eb-2b8c-4976-9613-edbc4d88698e_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_c58da517-712c-40da-89a6-f4a58984e0c2_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_4d000c82-24dc-4293-8fbd-ab37133331d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividend declared</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_154c8214-760f-45a0-a33d-2154c0474024_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_ba9fbcd8-a41f-4424-86c1-444acfb09168_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_80ad35e3-2567-49e3-912e-6463eabccd15_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_953ddc2a-6011-46b5-92dc-8f5a3f109329_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_275a3128-b443-4d9c-93db-4c8e0ae7e4b4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_CollaborationandOtherRevenueMember_510d6f6c-fad5-4aee-a156-a0f555c85e84_verboseLabel_en-US" xlink:label="lab_lly_CollaborationandOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and other revenue</link:label>
    <link:label id="lab_lly_CollaborationandOtherRevenueMember_label_en-US" xlink:label="lab_lly_CollaborationandOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Revenue [Member]</link:label>
    <link:label id="lab_lly_CollaborationandOtherRevenueMember_documentation_en-US" xlink:label="lab_lly_CollaborationandOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborationandOtherRevenueMember" xlink:href="lly-20210930.xsd#lly_CollaborationandOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_CollaborationandOtherRevenueMember" xlink:to="lab_lly_CollaborationandOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6ebc3af0-5dbb-4769-bdd7-5d5d70f0e8a2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other financing activities, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_06266b8f-dcf2-4bb4-9d1f-0186bc6588bf_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1b353f51-e5a3-45f9-b63b-196ebccdd876_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_34c3a1c2-1426-419c-b757-5aa51903b2d5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e4240ba7-a4f4-43ff-a2a7-702039d598a0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_08c33675-1cde-4066-bfc5-7d31e6aa58fa_terseLabel_en-US" xlink:label="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of receivable derecognized</link:label>
    <link:label id="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_label_en-US" xlink:label="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of Financial Assets Accounted for as Sales, Amount Derecognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:to="lab_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae39266a-85ce-4055-9ffa-9d8ccbdd96f4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_944014f2-9783-4f2d-8c5e-2b1c8972b26a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax (Note 10)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e423cdab-b1bd-4f75-bbf0-b9a900d1ecec_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_2c429c5e-c1cc-4a9a-8f2b-6c66d22e6478_terseLabel_en-US" xlink:label="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred, number of contingent value rights</link:label>
    <link:label id="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_label_en-US" xlink:label="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Number Of Contingent Value Rights</link:label>
    <link:label id="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_documentation_en-US" xlink:label="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Number Of Contingent Value Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:href="lly-20210930.xsd#lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:to="lab_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1375NotesDue2061Member_f81f5ae1-62b0-40cc-8227-4c3975999979_terseLabel_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_label_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes Due 2061 [Member]</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_documentation_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes Due 2061</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member" xlink:href="lly-20210930.xsd#lly_A1375NotesDue2061Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1375NotesDue2061Member" xlink:to="lab_lly_A1375NotesDue2061Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_0a4a7fc8-8e17-4f9c-86ef-d2e1314e55fe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_f89272bf-7c8e-4f26-9896-2f9a14422afb_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_5d37246f-e20c-44a4-a0ca-772e2cee4ba0_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_2edcf6a2-86e6-4411-9121-c298f8bc0dc0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of net pension and retiree health benefit (income) cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A3375NotesDue2029Member_c7a3b164-cf09-4375-8849-bc3d0a8fcd8f_terseLabel_en-US" xlink:label="lab_lly_A3375NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes Due 2029</link:label>
    <link:label id="lab_lly_A3375NotesDue2029Member_label_en-US" xlink:label="lab_lly_A3375NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes Due 2029 [Member]</link:label>
    <link:label id="lab_lly_A3375NotesDue2029Member_documentation_en-US" xlink:label="lab_lly_A3375NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes Due 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3375NotesDue2029Member" xlink:href="lly-20210930.xsd#lly_A3375NotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A3375NotesDue2029Member" xlink:to="lab_lly_A3375NotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_94d4b5d1-dfe0-4daf-9251-f9a9a2df01ed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PrevailTherapeuticsIncMember_0969c229-fdae-498b-a3f4-66da12e56615_terseLabel_en-US" xlink:label="lab_lly_PrevailTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevail Therapeutics Inc.</link:label>
    <link:label id="lab_lly_PrevailTherapeuticsIncMember_label_en-US" xlink:label="lab_lly_PrevailTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevail Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_lly_PrevailTherapeuticsIncMember_documentation_en-US" xlink:label="lab_lly_PrevailTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevail Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember" xlink:href="lly-20210930.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PrevailTherapeuticsIncMember" xlink:to="lab_lly_PrevailTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HumulinMember_e2415e9f-d3f2-403d-b5ec-4ca264d61b48_terseLabel_en-US" xlink:label="lab_lly_HumulinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humulin&#174;</link:label>
    <link:label id="lab_lly_HumulinMember_label_en-US" xlink:label="lab_lly_HumulinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humulin [Member]</link:label>
    <link:label id="lab_lly_HumulinMember_documentation_en-US" xlink:label="lab_lly_HumulinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humulin [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumulinMember" xlink:href="lly-20210930.xsd#lly_HumulinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HumulinMember" xlink:to="lab_lly_HumulinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_b0093821-4379-4ea4-916c-24e0c7692179_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_a5524208-7671-47d8-9b30-3363a9a03a28_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_JardianceMember_9698b2cb-ed9a-4f54-9147-09f6808d20a1_terseLabel_en-US" xlink:label="lab_lly_JardianceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jardiance</link:label>
    <link:label id="lab_lly_JardianceMember_label_en-US" xlink:label="lab_lly_JardianceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jardiance [Member]</link:label>
    <link:label id="lab_lly_JardianceMember_documentation_en-US" xlink:label="lab_lly_JardianceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jardiance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember" xlink:href="lly-20210930.xsd#lly_JardianceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_JardianceMember" xlink:to="lab_lly_JardianceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_HumalogMember_79c926f7-2dca-41a3-9e91-ec85b252df63_terseLabel_en-US" xlink:label="lab_lly_HumalogMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog&#174;</link:label>
    <link:label id="lab_lly_HumalogMember_label_en-US" xlink:label="lab_lly_HumalogMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog [Member]</link:label>
    <link:label id="lab_lly_HumalogMember_documentation_en-US" xlink:label="lab_lly_HumalogMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Humalog [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogMember" xlink:href="lly-20210930.xsd#lly_HumalogMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_HumalogMember" xlink:to="lab_lly_HumalogMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_PlaintiffAllegationsDomain_3455f009-be5f-4e1b-96ba-9d1b4dd12f9a_terseLabel_en-US" xlink:label="lab_lly_PlaintiffAllegationsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations [Domain]</link:label>
    <link:label id="lab_lly_PlaintiffAllegationsDomain_label_en-US" xlink:label="lab_lly_PlaintiffAllegationsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations [Domain]</link:label>
    <link:label id="lab_lly_PlaintiffAllegationsDomain_documentation_en-US" xlink:label="lab_lly_PlaintiffAllegationsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Allegations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsDomain" xlink:href="lly-20210930.xsd#lly_PlaintiffAllegationsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_PlaintiffAllegationsDomain" xlink:to="lab_lly_PlaintiffAllegationsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_LossContingencyNumberOfPatentsRuledUnpatentable_35b4772d-ef56-434d-944e-d550ceb29d12_terseLabel_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatentsRuledUnpatentable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents ruled unpatentable</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatentsRuledUnpatentable_label_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatentsRuledUnpatentable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents Ruled Unpatentable</link:label>
    <link:label id="lab_lly_LossContingencyNumberOfPatentsRuledUnpatentable_documentation_en-US" xlink:label="lab_lly_LossContingencyNumberOfPatentsRuledUnpatentable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents Ruled Unpatentable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatentsRuledUnpatentable" xlink:href="lly-20210930.xsd#lly_LossContingencyNumberOfPatentsRuledUnpatentable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_LossContingencyNumberOfPatentsRuledUnpatentable" xlink:to="lab_lly_LossContingencyNumberOfPatentsRuledUnpatentable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_fefb9674-054d-4beb-b213-7e698d3d70a5_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_473dfdec-a405-402f-96ed-f88bd8311f5c_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and other revenue associated with prior period transfers of intellectual property</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_c8146d3c-74e9-495a-899d-f2e62f34588d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Used for Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_9a3baf7b-d5e6-4334-8cf5-4908ef3ec19f_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_197d4cd4-73a6-430a-9a3a-34ff1cf2532c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under employee stock plans, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_47f26f32-c03c-48a5-a362-795af7c32bea_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_f6d7e496-35aa-451d-890d-5831527aecf8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:to="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3962265a-f358-44cc-a53a-1b7243174fd4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e986b771-9161-407e-a496-8d94522f3cea_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_1bbbfe57-39b0-421e-9872-74e2bf3a3f50_negatedLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect from hedged fixed-rate debt</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ForteoMember_80ec5556-b4fd-4ed4-9974-7937c29cd00a_terseLabel_en-US" xlink:label="lab_lly_ForteoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forteo&#174;</link:label>
    <link:label id="lab_lly_ForteoMember_label_en-US" xlink:label="lab_lly_ForteoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forteo [Member]</link:label>
    <link:label id="lab_lly_ForteoMember_documentation_en-US" xlink:label="lab_lly_ForteoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forteo [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForteoMember" xlink:href="lly-20210930.xsd#lly_ForteoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ForteoMember" xlink:to="lab_lly_ForteoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_73fff89c-eee4-4b50-93ec-20a9019d2bd4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_b9d75baf-74c7-4170-831e-6c29d6716d24_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_TrajentaBIMember_3b4a926f-1b89-4b81-bdde-674434086891_terseLabel_en-US" xlink:label="lab_lly_TrajentaBIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trajenta</link:label>
    <link:label id="lab_lly_TrajentaBIMember_label_en-US" xlink:label="lab_lly_TrajentaBIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trajenta (BI) [Member]</link:label>
    <link:label id="lab_lly_TrajentaBIMember_documentation_en-US" xlink:label="lab_lly_TrajentaBIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trajenta (BI) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember" xlink:href="lly-20210930.xsd#lly_TrajentaBIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_TrajentaBIMember" xlink:to="lab_lly_TrajentaBIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_91fc8e57-922f-481d-936b-8b99c3e60328_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_075a9c4b-03ce-464c-bee5-ae45246454ed_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_f32558b0-07a9-4540-90fc-32b0af9937a3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c93e7787-3a10-4cbf-b1d1-c358552f8271_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_RocheMember_4c8e28ca-9708-4171-b4ca-9fa3ea735795_terseLabel_en-US" xlink:label="lab_lly_RocheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche</link:label>
    <link:label id="lab_lly_RocheMember_label_en-US" xlink:label="lab_lly_RocheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:label id="lab_lly_RocheMember_documentation_en-US" xlink:label="lab_lly_RocheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RocheMember" xlink:href="lly-20210930.xsd#lly_RocheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_RocheMember" xlink:to="lab_lly_RocheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8c577c72-57cf-4f2a-8f33-0b40a9722d72_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_9227b00d-5250-4030-9bb2-e7352c3ee987_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_234a35b6-8104-490e-833e-039ca7f20738_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6db0f644-d2d7-475c-a9d8-4bbbd9d4c09b_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyUSdollarSellJapaneseYenMember_3f0de70c-b938-4427-80d7-37f2ee5cc210_terseLabel_en-US" xlink:label="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy U.S. Dollars Sell Japanese Yen</link:label>
    <link:label id="lab_lly_BuyUSdollarSellJapaneseYenMember_label_en-US" xlink:label="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US dollar Sell Japanese Yen [Member]</link:label>
    <link:label id="lab_lly_BuyUSdollarSellJapaneseYenMember_documentation_en-US" xlink:label="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy US dollar Sell Japanese Yen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSdollarSellJapaneseYenMember" xlink:href="lly-20210930.xsd#lly_BuyUSdollarSellJapaneseYenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyUSdollarSellJapaneseYenMember" xlink:to="lab_lly_BuyUSdollarSellJapaneseYenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyEuroSellUsDollarMember_b83089d1-026b-4ea0-91f9-7a7299af3b63_terseLabel_en-US" xlink:label="lab_lly_BuyEuroSellUsDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Euros Sell U.S. Dollars</link:label>
    <link:label id="lab_lly_BuyEuroSellUsDollarMember_label_en-US" xlink:label="lab_lly_BuyEuroSellUsDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Euro Sell Us Dollar [Member]</link:label>
    <link:label id="lab_lly_BuyEuroSellUsDollarMember_documentation_en-US" xlink:label="lab_lly_BuyEuroSellUsDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Forward Commitment to Buy euro Sell US dollar</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyEuroSellUsDollarMember" xlink:href="lly-20210930.xsd#lly_BuyEuroSellUsDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyEuroSellUsDollarMember" xlink:to="lab_lly_BuyEuroSellUsDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b283a93d-3b77-4914-9665-a378ff69fdb3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_BuyUsDollarSellEuroMember_05ab00e4-1af5-4c89-aeeb-aea8593dd016_terseLabel_en-US" xlink:label="lab_lly_BuyUsDollarSellEuroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy U.S. Dollars Sell Euros</link:label>
    <link:label id="lab_lly_BuyUsDollarSellEuroMember_label_en-US" xlink:label="lab_lly_BuyUsDollarSellEuroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy Us Dollar Sell Euro [Member]</link:label>
    <link:label id="lab_lly_BuyUsDollarSellEuroMember_documentation_en-US" xlink:label="lab_lly_BuyUsDollarSellEuroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Forward commitment to Buy US dollar Sell euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUsDollarSellEuroMember" xlink:href="lly-20210930.xsd#lly_BuyUsDollarSellEuroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_BuyUsDollarSellEuroMember" xlink:to="lab_lly_BuyUsDollarSellEuroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2ab5e42-fec4-4f8c-8877-51c704878e91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_57af66f5-ac98-46e3-b0f7-5fd9a996bbcf_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_SwapU.S.DollarsToEuroMember_281d55ca-36ae-4505-ab4d-d896b226cc5a_terseLabel_en-US" xlink:label="lab_lly_SwapU.S.DollarsToEuroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap U.S. Dollars to Euro</link:label>
    <link:label id="lab_lly_SwapU.S.DollarsToEuroMember_label_en-US" xlink:label="lab_lly_SwapU.S.DollarsToEuroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap U.S. Dollars To Euro [Member]</link:label>
    <link:label id="lab_lly_SwapU.S.DollarsToEuroMember_documentation_en-US" xlink:label="lab_lly_SwapU.S.DollarsToEuroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap U.S. Dollars To Euro [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapU.S.DollarsToEuroMember" xlink:href="lly-20210930.xsd#lly_SwapU.S.DollarsToEuroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_SwapU.S.DollarsToEuroMember" xlink:to="lab_lly_SwapU.S.DollarsToEuroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_d762e524-c83e-4c35-931d-985134bbb83c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment, Restructuring, and Other Special Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment, and Other Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_df014af9-7809-45a6-8821-76e62e8f2998_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at January&#160;1</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_dfd2c92a-2172-4ffc-bcff-e867522ff8da_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents at September 30</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_0d9e3111-e47d-48ca-8693-08b1b566b5df_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_9f9a27e4-ca9f-4180-a76c-1afe34eab55d_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_734937b2-abcf-461b-b698-a0ed6c32ca84_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of debt, amount</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_fdf7b63c-61ac-4254-9ecf-cb671f0337d4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_a57d087a-bec9-4a72-98ec-dd1d389b66d9_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember_31033e15-952b-4759-a561-2770e703108a_terseLabel_en-US" xlink:label="lab_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Upon Achieving Clinical Proof of Concept</link:label>
    <link:label id="lab_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember_label_en-US" xlink:label="lab_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Upon Achieving Clinical Proof Of Concept [Member]</link:label>
    <link:label id="lab_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember_documentation_en-US" xlink:label="lab_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Contingent Upon Achieving Clinical Proof Of Concept</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember" xlink:href="lly-20210930.xsd#lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember" xlink:to="lab_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_065e1beb-2a0b-4434-94ff-fa6ccdbca937_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_6e613d78-599f-416f-ada9-776318227531_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Pension Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c31917bb-b4a9-47d3-90ad-bfa84f56281f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less&#160;Than 1 Year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_DescriptionOfDerivativeActivityVolumePercent_04879a4c-3239-45e8-930b-51ec8709e23b_terseLabel_en-US" xlink:label="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of long-term fixed-rate notes to floating rates through the use of interest rate swaps converted</link:label>
    <link:label id="lab_lly_DescriptionOfDerivativeActivityVolumePercent_label_en-US" xlink:label="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Derivative Activity Volume Percent</link:label>
    <link:label id="lab_lly_DescriptionOfDerivativeActivityVolumePercent_documentation_en-US" xlink:label="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Derivative Activity Volume Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:href="lly-20210930.xsd#lly_DescriptionOfDerivativeActivityVolumePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:to="lab_lly_DescriptionOfDerivativeActivityVolumePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_AbCelleraBiologicsInc.Member_00835cae-42a4-44f2-900e-9f9d2c8d970a_terseLabel_en-US" xlink:label="lab_lly_AbCelleraBiologicsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbCellera</link:label>
    <link:label id="lab_lly_AbCelleraBiologicsInc.Member_label_en-US" xlink:label="lab_lly_AbCelleraBiologicsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbCellera Biologics Inc. [Member]</link:label>
    <link:label id="lab_lly_AbCelleraBiologicsInc.Member_documentation_en-US" xlink:label="lab_lly_AbCelleraBiologicsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbCellera Biologics Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AbCelleraBiologicsInc.Member" xlink:href="lly-20210930.xsd#lly_AbCelleraBiologicsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_AbCelleraBiologicsInc.Member" xlink:to="lab_lly_AbCelleraBiologicsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_ZyprexaMember_3e4c162d-e4f5-4f2c-ab13-2d1c3a99d3a4_terseLabel_en-US" xlink:label="lab_lly_ZyprexaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyprexa&#174;</link:label>
    <link:label id="lab_lly_ZyprexaMember_label_en-US" xlink:label="lab_lly_ZyprexaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyprexa [Member]</link:label>
    <link:label id="lab_lly_ZyprexaMember_documentation_en-US" xlink:label="lab_lly_ZyprexaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyprexa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ZyprexaMember" xlink:href="lly-20210930.xsd#lly_ZyprexaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_ZyprexaMember" xlink:to="lab_lly_ZyprexaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_badde2c2-4c98-4fb8-b0b5-337a0433b3dc_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>lly-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:83f390d0-6781-4e7e-a1f5-5192701136a4,g:3039e280-7bbd-437e-b91e-6280679dfdce-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20210930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d790cefd-17ae-4aae-9326-b6ac1bb8305b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_831077f7-5d96-4d72-b3d0-e9ab74879336" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d790cefd-17ae-4aae-9326-b6ac1bb8305b" xlink:to="loc_dei_DocumentInformationTable_831077f7-5d96-4d72-b3d0-e9ab74879336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1dea2afa-26c9-4a7c-8dec-26871925c682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_831077f7-5d96-4d72-b3d0-e9ab74879336" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1dea2afa-26c9-4a7c-8dec-26871925c682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1dea2afa-26c9-4a7c-8dec-26871925c682" xlink:to="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_f1142436-f587-4460-b724-2951b4df0b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_us-gaap_CommonClassAMember_f1142436-f587-4460-b724-2951b4df0b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.000NotesDueJune22022Member_09a076b9-5f7d-4858-a55f-806d2524b1b7" xlink:href="lly-20210930.xsd#lly_A1.000NotesDueJune22022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_lly_A1.000NotesDueJune22022Member_09a076b9-5f7d-4858-a55f-806d2524b1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_dcb5d9c3-8f7c-43e5-b486-056d3c1a13f1" xlink:href="lly-20210930.xsd#lly_A718NotesDueJune12025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_lly_A718NotesDueJune12025Member_dcb5d9c3-8f7c-43e5-b486-056d3c1a13f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_ff8411ca-996e-4fb5-8ce3-103766b4d75f" xlink:href="lly-20210930.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_lly_A1.625NotesDueJune22026Member_ff8411ca-996e-4fb5-8ce3-103766b4d75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_7c2125b0-acb0-4bba-b7e1-c81ccbf39072" xlink:href="lly-20210930.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_lly_A2.125NotesDueJune32030Member_7c2125b0-acb0-4bba-b7e1-c81ccbf39072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_d4e99d46-96a6-4955-8935-89d2988c563c" xlink:href="lly-20210930.xsd#lly_A625Notesdue2031Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_lly_A625Notesdue2031Member_d4e99d46-96a6-4955-8935-89d2988c563c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A5000NotesDue2033Member_3c5d99b9-5b86-4c7b-a73b-f55f5e661314" xlink:href="lly-20210930.xsd#lly_A5000NotesDue2033Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_lly_A5000NotesDue2033Member_3c5d99b9-5b86-4c7b-a73b-f55f5e661314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_3ca47e0b-8982-4174-9b6e-9f8003724561" xlink:href="lly-20210930.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_3ca47e0b-8982-4174-9b6e-9f8003724561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_4071fab0-c142-4402-ade1-4719309c1517" xlink:href="lly-20210930.xsd#lly_A1625NotesDue2043Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_lly_A1625NotesDue2043Member_4071fab0-c142-4402-ade1-4719309c1517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_aa12998d-f1ef-4ce3-89cc-54afc5cdcc47" xlink:href="lly-20210930.xsd#lly_A1.700Notesdue2049Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_lly_A1.700Notesdue2049Member_aa12998d-f1ef-4ce3-89cc-54afc5cdcc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_1f54d1b5-58aa-429d-8cf5-ef9f2a4cc842" xlink:href="lly-20210930.xsd#lly_A1125NotesDue2051Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_lly_A1125NotesDue2051Member_1f54d1b5-58aa-429d-8cf5-ef9f2a4cc842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_8a4ea535-f243-40cb-98b7-bb0d7c2c1687" xlink:href="lly-20210930.xsd#lly_A1375NotesDue2061Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7ddcc520-e7d9-4651-96de-3b2f1f179733" xlink:to="loc_lly_A1375NotesDue2061Member_8a4ea535-f243-40cb-98b7-bb0d7c2c1687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_831077f7-5d96-4d72-b3d0-e9ab74879336" xlink:to="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d8ac3641-2a34-4ee5-bd53-0a0ad46ac318" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_DocumentType_d8ac3641-2a34-4ee5-bd53-0a0ad46ac318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_953c5654-baae-433d-bd69-b85fe407f502" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_DocumentQuarterlyReport_953c5654-baae-433d-bd69-b85fe407f502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_44234af1-cf0f-4546-9f18-f5a491f99649" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_DocumentTransitionReport_44234af1-cf0f-4546-9f18-f5a491f99649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_52b76c0f-8ec0-4196-ae54-ad1561876123" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_DocumentPeriodEndDate_52b76c0f-8ec0-4196-ae54-ad1561876123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1b0cb4bb-3022-42b2-ad11-35a39ad48ea4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityFileNumber_1b0cb4bb-3022-42b2-ad11-35a39ad48ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e78cdd33-c36b-4b99-9f5c-2fda8c2bae16" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityRegistrantName_e78cdd33-c36b-4b99-9f5c-2fda8c2bae16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9a0b05ac-4d45-4117-a5fd-18a0d71dd350" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9a0b05ac-4d45-4117-a5fd-18a0d71dd350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1fa56348-986b-425d-a703-19050d07f2fd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityTaxIdentificationNumber_1fa56348-986b-425d-a703-19050d07f2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d8e9193c-7fb0-4f07-9e0b-a91fe9e661d9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityAddressAddressLine1_d8e9193c-7fb0-4f07-9e0b-a91fe9e661d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7b02e455-79a2-475f-b094-32c055d4cb5d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityAddressCityOrTown_7b02e455-79a2-475f-b094-32c055d4cb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a36d35f5-19d5-4782-9ce7-f82632fceb62" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityAddressStateOrProvince_a36d35f5-19d5-4782-9ce7-f82632fceb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_26767187-c7fe-4150-938d-c9ee03f25a09" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityAddressPostalZipCode_26767187-c7fe-4150-938d-c9ee03f25a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b3fc5b13-7d8c-4f7e-88bd-6698929125ff" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_CityAreaCode_b3fc5b13-7d8c-4f7e-88bd-6698929125ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_60664da3-ca7b-4d68-910c-cd9d4d145519" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_LocalPhoneNumber_60664da3-ca7b-4d68-910c-cd9d4d145519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_05978ce8-f367-4a2f-a03d-be6843902959" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_Security12bTitle_05978ce8-f367-4a2f-a03d-be6843902959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b14c079d-c40b-4cd5-bfe4-d78001996b5d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_TradingSymbol_b14c079d-c40b-4cd5-bfe4-d78001996b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6a3be7d9-f498-465a-ac3d-07b59e06bb7b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_SecurityExchangeName_6a3be7d9-f498-465a-ac3d-07b59e06bb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d513e1cd-86a4-441b-b326-67052f913ad9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityCurrentReportingStatus_d513e1cd-86a4-441b-b326-67052f913ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ea9e5f1d-157e-4205-8dd0-0d9404eea1f4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityInteractiveDataCurrent_ea9e5f1d-157e-4205-8dd0-0d9404eea1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_57900e87-de40-4232-ac87-df57e6e9db03" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityFilerCategory_57900e87-de40-4232-ac87-df57e6e9db03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_6097048e-3bd9-460b-a5e8-797a8e4e1065" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntitySmallBusiness_6097048e-3bd9-460b-a5e8-797a8e4e1065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_68e2a54b-072a-414e-a8a1-ecbe236b9952" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityEmergingGrowthCompany_68e2a54b-072a-414e-a8a1-ecbe236b9952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e70d3cdd-c1e4-4845-a995-411334038e9c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityShellCompany_e70d3cdd-c1e4-4845-a995-411334038e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e2368975-87db-413b-9863-4aa74e1870fb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e2368975-87db-413b-9863-4aa74e1870fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0b917da1-233c-46d3-840f-54515936e333" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_AmendmentFlag_0b917da1-233c-46d3-840f-54515936e333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_263604f3-692f-4466-ba19-28e860e0981f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_DocumentFiscalYearFocus_263604f3-692f-4466-ba19-28e860e0981f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d3d26e29-6dc6-4e61-8b54-631c424ea136" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d3d26e29-6dc6-4e61-8b54-631c424ea136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_372abf23-6a18-4775-889b-f932b102319e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_EntityCentralIndexKey_372abf23-6a18-4775-889b-f932b102319e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_186d712e-0d50-4e41-8474-adb5c3bb62c1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_7bcbe744-87d4-495a-beb4-da19555ec65c" xlink:to="loc_dei_CurrentFiscalYearEndDate_186d712e-0d50-4e41-8474-adb5c3bb62c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations" xlink:type="simple" xlink:href="lly-20210930.xsd#ConsolidatedCondensedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_bd2e9029-64bd-4d27-929e-8bd3a84b4a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_983d846a-194b-4456-801a-bcf55516c20c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bd2e9029-64bd-4d27-929e-8bd3a84b4a81" xlink:to="loc_us-gaap_Revenues_983d846a-194b-4456-801a-bcf55516c20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_2686ecd4-05c2-44d4-ba42-b340dca67b27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bd2e9029-64bd-4d27-929e-8bd3a84b4a81" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_2686ecd4-05c2-44d4-ba42-b340dca67b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0fe8d410-58fe-493d-a148-2334e86ae477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2686ecd4-05c2-44d4-ba42-b340dca67b27" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0fe8d410-58fe-493d-a148-2334e86ae477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_30e8435b-935e-4b81-9c3b-78edd3cd5f79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2686ecd4-05c2-44d4-ba42-b340dca67b27" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_30e8435b-935e-4b81-9c3b-78edd3cd5f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_945a1a73-d26a-4b9d-ad77-efeebf452dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2686ecd4-05c2-44d4-ba42-b340dca67b27" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_945a1a73-d26a-4b9d-ad77-efeebf452dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_48330c0f-b487-4fb2-81f7-06e757ddd91b" xlink:href="lly-20210930.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2686ecd4-05c2-44d4-ba42-b340dca67b27" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_48330c0f-b487-4fb2-81f7-06e757ddd91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_bf4f3a02-9196-4c32-b7a5-603cb1b87a35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2686ecd4-05c2-44d4-ba42-b340dca67b27" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_bf4f3a02-9196-4c32-b7a5-603cb1b87a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_228d239d-d64f-4eda-bded-04d021eb94b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2686ecd4-05c2-44d4-ba42-b340dca67b27" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_228d239d-d64f-4eda-bded-04d021eb94b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_a955c074-db9e-4c8f-b927-7b05c4b424ab" xlink:href="lly-20210930.xsd#lly_CostOfSalesOperatingExpensesAndOtherNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2686ecd4-05c2-44d4-ba42-b340dca67b27" xlink:to="loc_lly_CostOfSalesOperatingExpensesAndOtherNet_a955c074-db9e-4c8f-b927-7b05c4b424ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_823b87c9-8040-4e2f-bf5d-64d48d5e77f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bd2e9029-64bd-4d27-929e-8bd3a84b4a81" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_823b87c9-8040-4e2f-bf5d-64d48d5e77f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1f42c445-476f-4df9-ba5d-f24a315d1dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bd2e9029-64bd-4d27-929e-8bd3a84b4a81" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1f42c445-476f-4df9-ba5d-f24a315d1dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6236f588-5f5d-4511-8537-abf6dd3662d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bd2e9029-64bd-4d27-929e-8bd3a84b4a81" xlink:to="loc_us-gaap_NetIncomeLoss_6236f588-5f5d-4511-8537-abf6dd3662d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_55dd842a-e7ad-41c6-aab7-bf7672a60680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bd2e9029-64bd-4d27-929e-8bd3a84b4a81" xlink:to="loc_us-gaap_EarningsPerShareAbstract_55dd842a-e7ad-41c6-aab7-bf7672a60680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_daf1d3f5-a72e-4157-a856-159aeaa4e641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_55dd842a-e7ad-41c6-aab7-bf7672a60680" xlink:to="loc_us-gaap_EarningsPerShareBasic_daf1d3f5-a72e-4157-a856-159aeaa4e641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2d4787d3-a264-4a6c-b762-0990a52ed55b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_55dd842a-e7ad-41c6-aab7-bf7672a60680" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2d4787d3-a264-4a6c-b762-0990a52ed55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4307eacb-c523-453c-a2d5-21e540d15c84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bd2e9029-64bd-4d27-929e-8bd3a84b4a81" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4307eacb-c523-453c-a2d5-21e540d15c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a626f8b0-ea4c-43a1-8be4-8312d1b07c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4307eacb-c523-453c-a2d5-21e540d15c84" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a626f8b0-ea4c-43a1-8be4-8312d1b07c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_eb85b7a0-3ddf-44dd-a650-017108ad9d43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4307eacb-c523-453c-a2d5-21e540d15c84" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_eb85b7a0-3ddf-44dd-a650-017108ad9d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20210930.xsd#ConsolidatedCondensedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ce27d60f-9dcd-4c84-98d2-41741a6cf712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_af796bdd-6da0-4d28-a520-d8422f79a448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ce27d60f-9dcd-4c84-98d2-41741a6cf712" xlink:to="loc_us-gaap_NetIncomeLoss_af796bdd-6da0-4d28-a520-d8422f79a448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c43201ca-f8c3-4cfd-8de6-4005c2bbae8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ce27d60f-9dcd-4c84-98d2-41741a6cf712" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c43201ca-f8c3-4cfd-8de6-4005c2bbae8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ab81541c-5684-4d92-aa3e-44d221c3a0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ce27d60f-9dcd-4c84-98d2-41741a6cf712" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_ab81541c-5684-4d92-aa3e-44d221c3a0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="simple" xlink:href="lly-20210930.xsd#ConsolidatedCondensedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_590360c8-9c4f-4f72-af9d-fa60f3bc64d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_f1428363-2b8a-4dcb-b76a-fe373de24b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_590360c8-9c4f-4f72-af9d-fa60f3bc64d4" xlink:to="loc_us-gaap_AssetsAbstract_f1428363-2b8a-4dcb-b76a-fe373de24b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_a3cb8bd5-7a47-4a6f-987a-ee5cb0d9867f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f1428363-2b8a-4dcb-b76a-fe373de24b3a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_a3cb8bd5-7a47-4a6f-987a-ee5cb0d9867f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c78f8b87-7157-413a-a87c-7584efbf7617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a3cb8bd5-7a47-4a6f-987a-ee5cb0d9867f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c78f8b87-7157-413a-a87c-7584efbf7617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_f33eb051-eb83-485c-a0e5-c5b7b655e587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a3cb8bd5-7a47-4a6f-987a-ee5cb0d9867f" xlink:to="loc_us-gaap_ShortTermInvestments_f33eb051-eb83-485c-a0e5-c5b7b655e587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_42d9c527-18fa-4989-a2e6-f4b2603aa080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a3cb8bd5-7a47-4a6f-987a-ee5cb0d9867f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_42d9c527-18fa-4989-a2e6-f4b2603aa080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_6b6ebb0c-e5bc-4395-832a-48077c301b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a3cb8bd5-7a47-4a6f-987a-ee5cb0d9867f" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_6b6ebb0c-e5bc-4395-832a-48077c301b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7072b09d-1232-4b90-8dc8-990244b97a22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a3cb8bd5-7a47-4a6f-987a-ee5cb0d9867f" xlink:to="loc_us-gaap_InventoryNet_7072b09d-1232-4b90-8dc8-990244b97a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1366c657-476f-4638-8088-ceb5f128a6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a3cb8bd5-7a47-4a6f-987a-ee5cb0d9867f" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1366c657-476f-4638-8088-ceb5f128a6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ca3b1843-21c1-46ab-ba24-718df509518b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a3cb8bd5-7a47-4a6f-987a-ee5cb0d9867f" xlink:to="loc_us-gaap_AssetsCurrent_ca3b1843-21c1-46ab-ba24-718df509518b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_ffb82796-b979-4984-b9c2-14f94b990144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f1428363-2b8a-4dcb-b76a-fe373de24b3a" xlink:to="loc_us-gaap_LongTermInvestments_ffb82796-b979-4984-b9c2-14f94b990144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_32c41434-c0ef-41ce-b66a-d246a2a0b821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f1428363-2b8a-4dcb-b76a-fe373de24b3a" xlink:to="loc_us-gaap_Goodwill_32c41434-c0ef-41ce-b66a-d246a2a0b821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_578d16b8-2dc5-4455-88a6-f0c7a3d0bf06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f1428363-2b8a-4dcb-b76a-fe373de24b3a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_578d16b8-2dc5-4455-88a6-f0c7a3d0bf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_95f93e93-a110-4e26-a84a-93bd13e806db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f1428363-2b8a-4dcb-b76a-fe373de24b3a" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_95f93e93-a110-4e26-a84a-93bd13e806db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_745ffd77-24a4-4a53-878b-89bec3b3d540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f1428363-2b8a-4dcb-b76a-fe373de24b3a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_745ffd77-24a4-4a53-878b-89bec3b3d540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9123d82a-b6ce-4dc5-872f-39ed6e27ab90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f1428363-2b8a-4dcb-b76a-fe373de24b3a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9123d82a-b6ce-4dc5-872f-39ed6e27ab90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_626b5583-a3d9-4333-873d-9a512290c4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f1428363-2b8a-4dcb-b76a-fe373de24b3a" xlink:to="loc_us-gaap_Assets_626b5583-a3d9-4333-873d-9a512290c4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67ff2504-796b-4ca2-944c-ca15c0b2ee66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_590360c8-9c4f-4f72-af9d-fa60f3bc64d4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67ff2504-796b-4ca2-944c-ca15c0b2ee66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a32cb083-561d-4b4f-9cb6-b2ff1d85cf4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67ff2504-796b-4ca2-944c-ca15c0b2ee66" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a32cb083-561d-4b4f-9cb6-b2ff1d85cf4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_8da2ad4d-cf97-452b-91e6-97c0fafe0e10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a32cb083-561d-4b4f-9cb6-b2ff1d85cf4a" xlink:to="loc_us-gaap_DebtCurrent_8da2ad4d-cf97-452b-91e6-97c0fafe0e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c8beec72-65b5-4f99-9708-ba577d3e1fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a32cb083-561d-4b4f-9cb6-b2ff1d85cf4a" xlink:to="loc_us-gaap_AccountsPayableCurrent_c8beec72-65b5-4f99-9708-ba577d3e1fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_de14e830-3c3b-4ced-9816-f6bee329c69e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a32cb083-561d-4b4f-9cb6-b2ff1d85cf4a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_de14e830-3c3b-4ced-9816-f6bee329c69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SalesRebatesAndDiscounts_55a8d236-afe2-4174-bca7-d522927d6d3f" xlink:href="lly-20210930.xsd#lly_SalesRebatesAndDiscounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a32cb083-561d-4b4f-9cb6-b2ff1d85cf4a" xlink:to="loc_lly_SalesRebatesAndDiscounts_55a8d236-afe2-4174-bca7-d522927d6d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_07dc7c86-6979-419f-8164-ed3cbabccb1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a32cb083-561d-4b4f-9cb6-b2ff1d85cf4a" xlink:to="loc_us-gaap_DividendsPayableCurrent_07dc7c86-6979-419f-8164-ed3cbabccb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_f06b2e06-200a-4a58-a03f-a6cc62309b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a32cb083-561d-4b4f-9cb6-b2ff1d85cf4a" xlink:to="loc_us-gaap_TaxesPayableCurrent_f06b2e06-200a-4a58-a03f-a6cc62309b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_d1420e6f-9ac5-4c10-bbfd-ae87c7135934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a32cb083-561d-4b4f-9cb6-b2ff1d85cf4a" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_d1420e6f-9ac5-4c10-bbfd-ae87c7135934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_37552281-8f3d-4be3-8116-3dbd57d6e8de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a32cb083-561d-4b4f-9cb6-b2ff1d85cf4a" xlink:to="loc_us-gaap_LiabilitiesCurrent_37552281-8f3d-4be3-8116-3dbd57d6e8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_18802e36-dc19-4dc9-8feb-2728e62dd930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67ff2504-796b-4ca2-944c-ca15c0b2ee66" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_18802e36-dc19-4dc9-8feb-2728e62dd930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_b96b99e7-1eb7-4d8c-b00c-ad86a167b186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_18802e36-dc19-4dc9-8feb-2728e62dd930" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_b96b99e7-1eb7-4d8c-b00c-ad86a167b186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_0c4e5c93-47ef-4984-b91d-c6973e0df8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_18802e36-dc19-4dc9-8feb-2728e62dd930" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_0c4e5c93-47ef-4984-b91d-c6973e0df8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_d106b1a1-b728-459b-9d7b-af963d659049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_18802e36-dc19-4dc9-8feb-2728e62dd930" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_d106b1a1-b728-459b-9d7b-af963d659049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5f6202b7-0d88-4ec0-971d-5d138c5b0f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_18802e36-dc19-4dc9-8feb-2728e62dd930" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5f6202b7-0d88-4ec0-971d-5d138c5b0f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_765549f3-4c5f-4134-8e83-d54313bf48aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_18802e36-dc19-4dc9-8feb-2728e62dd930" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_765549f3-4c5f-4134-8e83-d54313bf48aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_2b8881f1-de39-4a34-b56f-c7582c340fac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_18802e36-dc19-4dc9-8feb-2728e62dd930" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_2b8881f1-de39-4a34-b56f-c7582c340fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_806040fa-a03f-4fe7-aac4-961330f8706f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67ff2504-796b-4ca2-944c-ca15c0b2ee66" xlink:to="loc_us-gaap_CommitmentsAndContingencies_806040fa-a03f-4fe7-aac4-961330f8706f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e3552c99-ab66-4cf1-b4db-827f1a7cee82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67ff2504-796b-4ca2-944c-ca15c0b2ee66" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e3552c99-ab66-4cf1-b4db-827f1a7cee82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6f66c208-53c6-44af-bc1f-d7e07ad98c43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e3552c99-ab66-4cf1-b4db-827f1a7cee82" xlink:to="loc_us-gaap_CommonStockValue_6f66c208-53c6-44af-bc1f-d7e07ad98c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d5457ca8-d254-44ac-aca3-d72879822c66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e3552c99-ab66-4cf1-b4db-827f1a7cee82" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d5457ca8-d254-44ac-aca3-d72879822c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ed7a0dde-76d4-4bee-ad30-4f7bde8ff618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e3552c99-ab66-4cf1-b4db-827f1a7cee82" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ed7a0dde-76d4-4bee-ad30-4f7bde8ff618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_0c2040e0-78b2-4a68-819b-a68f7bd6f1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e3552c99-ab66-4cf1-b4db-827f1a7cee82" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_0c2040e0-78b2-4a68-819b-a68f7bd6f1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9e1e2aca-171d-4709-9749-986cacf95266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e3552c99-ab66-4cf1-b4db-827f1a7cee82" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9e1e2aca-171d-4709-9749-986cacf95266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_24b43d95-d4bc-4e27-8620-1de5405a6d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e3552c99-ab66-4cf1-b4db-827f1a7cee82" xlink:to="loc_us-gaap_TreasuryStockValue_24b43d95-d4bc-4e27-8620-1de5405a6d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d2e2bb3f-73fc-4808-8cac-eed54533f27a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e3552c99-ab66-4cf1-b4db-827f1a7cee82" xlink:to="loc_us-gaap_StockholdersEquity_d2e2bb3f-73fc-4808-8cac-eed54533f27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_df3bda20-4d7b-4882-ac2e-4394fa20a6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67ff2504-796b-4ca2-944c-ca15c0b2ee66" xlink:to="loc_us-gaap_MinorityInterest_df3bda20-4d7b-4882-ac2e-4394fa20a6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ed50eb13-535a-47cc-9455-1838eaa27137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67ff2504-796b-4ca2-944c-ca15c0b2ee66" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ed50eb13-535a-47cc-9455-1838eaa27137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cd997a5b-e9c3-4fbb-91b7-10aa48ca7bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_67ff2504-796b-4ca2-944c-ca15c0b2ee66" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_cd997a5b-e9c3-4fbb-91b7-10aa48ca7bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="lly-20210930.xsd#ConsolidatedCondensedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrentAbstract_92642ed1-056e-4370-bd14-b4198c38d95c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_a2f3bb36-e265-4d40-be0b-d22741e576ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesNetCurrentAbstract_92642ed1-056e-4370-bd14-b4198c38d95c" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_a2f3bb36-e265-4d40-be0b-d22741e576ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c35187d4-4c78-4d10-8b4c-6b2be6a3b99f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesNetCurrentAbstract_92642ed1-056e-4370-bd14-b4198c38d95c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c35187d4-4c78-4d10-8b4c-6b2be6a3b99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity" xlink:type="simple" xlink:href="lly-20210930.xsd#ConsolidatedCondensedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1bec374e-2196-4bfa-ab41-c9b56575edec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e593532f-6808-4244-a242-44732fc84604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1bec374e-2196-4bfa-ab41-c9b56575edec" xlink:to="loc_us-gaap_StatementTable_e593532f-6808-4244-a242-44732fc84604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3bf08dab-eda6-4254-b129-3d3192344b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e593532f-6808-4244-a242-44732fc84604" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3bf08dab-eda6-4254-b129-3d3192344b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_47f6fbcf-a40f-4f18-bd2b-8a9ea7017e23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3bf08dab-eda6-4254-b129-3d3192344b3c" xlink:to="loc_us-gaap_EquityComponentDomain_47f6fbcf-a40f-4f18-bd2b-8a9ea7017e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9b872143-4753-4448-982c-29d6f5160ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_47f6fbcf-a40f-4f18-bd2b-8a9ea7017e23" xlink:to="loc_us-gaap_CommonStockMember_9b872143-4753-4448-982c-29d6f5160ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_78215162-e281-4ee8-9de8-97bfa04bcefa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_47f6fbcf-a40f-4f18-bd2b-8a9ea7017e23" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_78215162-e281-4ee8-9de8-97bfa04bcefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_149b58ad-2f83-4b1b-a2ea-abcf5e6cff9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_47f6fbcf-a40f-4f18-bd2b-8a9ea7017e23" xlink:to="loc_us-gaap_RetainedEarningsMember_149b58ad-2f83-4b1b-a2ea-abcf5e6cff9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrustForBenefitOfEmployeesMember_30a38348-647b-496b-917b-121fc3106f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrustForBenefitOfEmployeesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_47f6fbcf-a40f-4f18-bd2b-8a9ea7017e23" xlink:to="loc_us-gaap_TrustForBenefitOfEmployeesMember_30a38348-647b-496b-917b-121fc3106f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_81ad3c28-be96-45ae-8e50-f4968d6dc8de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_47f6fbcf-a40f-4f18-bd2b-8a9ea7017e23" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_81ad3c28-be96-45ae-8e50-f4968d6dc8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_3e29e93a-2f62-4dea-bad0-bd67884505c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_47f6fbcf-a40f-4f18-bd2b-8a9ea7017e23" xlink:to="loc_us-gaap_TreasuryStockMember_3e29e93a-2f62-4dea-bad0-bd67884505c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_3580bd75-e7f6-4a75-81e5-559588893800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_47f6fbcf-a40f-4f18-bd2b-8a9ea7017e23" xlink:to="loc_us-gaap_NoncontrollingInterestMember_3580bd75-e7f6-4a75-81e5-559588893800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5bd598ab-4a9a-4feb-8b1b-e663c8d7e094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e593532f-6808-4244-a242-44732fc84604" xlink:to="loc_us-gaap_StatementLineItems_5bd598ab-4a9a-4feb-8b1b-e663c8d7e094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5bd598ab-4a9a-4feb-8b1b-e663c8d7e094" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_84c5b8fe-5153-4bdd-932e-39c4fdfbd01b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_SharesIssued_84c5b8fe-5153-4bdd-932e-39c4fdfbd01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_44500a30-160d-457b-8dff-e652a28baf26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_44500a30-160d-457b-8dff-e652a28baf26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7bdfd4c8-500f-485d-b458-8f4d2ee644e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_ProfitLoss_7bdfd4c8-500f-485d-b458-8f4d2ee644e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8020eabd-8092-47bd-bd35-eff8dd7c20a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8020eabd-8092-47bd-bd35-eff8dd7c20a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_d4d947f3-8209-4c30-b6a0-ffd42a9359a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_Dividends_d4d947f3-8209-4c30-b6a0-ffd42a9359a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_3b03feee-9102-40b5-95ed-b5d408614681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_3b03feee-9102-40b5-95ed-b5d408614681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_e95d9ca5-6dc4-4a57-ae31-ffe05c13ccf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_e95d9ca5-6dc4-4a57-ae31-ffe05c13ccf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_0713cc09-72c8-4da5-aa41-d09cb1ba90b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_0713cc09-72c8-4da5-aa41-d09cb1ba90b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_06ddc31f-4fd6-4e47-a6b8-5c4f3f8cfe0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_06ddc31f-4fd6-4e47-a6b8-5c4f3f8cfe0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7a933b0c-1d55-4ceb-b014-3442101b28d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7a933b0c-1d55-4ceb-b014-3442101b28d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ea76c679-1b97-4ee2-b0ac-d35c20e7d3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ea76c679-1b97-4ee2-b0ac-d35c20e7d3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6310c436-960b-4738-9362-197f1998003c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6310c436-960b-4738-9362-197f1998003c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_b15aee82-9e5e-43aa-94af-f69921bc30a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_StockholdersEquityOther_b15aee82-9e5e-43aa-94af-f69921bc30a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_459edfe2-0d1a-4842-97a3-03e26ff926db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_SharesIssued_459edfe2-0d1a-4842-97a3-03e26ff926db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c5b2dee6-41f2-4464-80fd-edc8feddf712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ef032a57-9c9a-4d06-819c-d28391879d35" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c5b2dee6-41f2-4464-80fd-edc8feddf712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="lly-20210930.xsd#ConsolidatedCondensedStatementsofEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6c3151cf-4fc3-42df-b5f8-83b7d6861dae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_a293defa-1a76-4764-9b89-a96526431711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6c3151cf-4fc3-42df-b5f8-83b7d6861dae" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_a293defa-1a76-4764-9b89-a96526431711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_46a311bc-35a3-4d22-8d23-ccf3d37bab2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6c3151cf-4fc3-42df-b5f8-83b7d6861dae" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_46a311bc-35a3-4d22-8d23-ccf3d37bab2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_272f8d74-8ea9-498c-b0d1-8133fb6b6e45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6c3151cf-4fc3-42df-b5f8-83b7d6861dae" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_272f8d74-8ea9-498c-b0d1-8133fb6b6e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows" xlink:type="simple" xlink:href="lly-20210930.xsd#ConsolidatedCondensedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_4a2f9043-da67-4c61-9503-b29ec9ea9e90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dc935339-8fb3-44f3-8201-da57f1331283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a2f9043-da67-4c61-9503-b29ec9ea9e90" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dc935339-8fb3-44f3-8201-da57f1331283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_55806e8f-285a-4341-a935-986878dcc75b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dc935339-8fb3-44f3-8201-da57f1331283" xlink:to="loc_us-gaap_NetIncomeLoss_55806e8f-285a-4341-a935-986878dcc75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1455eea2-7b36-4638-afc6-67c61bfb5ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dc935339-8fb3-44f3-8201-da57f1331283" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1455eea2-7b36-4638-afc6-67c61bfb5ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_67c35a5c-1fa4-4d8b-ba65-9e4f9109c7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1455eea2-7b36-4638-afc6-67c61bfb5ffc" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_67c35a5c-1fa4-4d8b-ba65-9e4f9109c7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_79527189-c5ee-4d8a-a063-71c89aa0533f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1455eea2-7b36-4638-afc6-67c61bfb5ffc" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_79527189-c5ee-4d8a-a063-71c89aa0533f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_20bf4f9f-b6cc-4e93-9658-af19883a622c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1455eea2-7b36-4638-afc6-67c61bfb5ffc" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_20bf4f9f-b6cc-4e93-9658-af19883a622c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_af5d26a5-2a84-4843-8fc3-6252e506c33b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1455eea2-7b36-4638-afc6-67c61bfb5ffc" xlink:to="loc_us-gaap_ShareBasedCompensation_af5d26a5-2a84-4843-8fc3-6252e506c33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_2db3dd7c-acd4-481f-b04b-8dea4a107b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1455eea2-7b36-4638-afc6-67c61bfb5ffc" xlink:to="loc_us-gaap_GainLossOnInvestments_2db3dd7c-acd4-481f-b04b-8dea4a107b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AcquiredInProcessResearchAndDevelopment_4e205676-d58b-4383-b24a-b4f3439f0ab0" xlink:href="lly-20210930.xsd#lly_AcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1455eea2-7b36-4638-afc6-67c61bfb5ffc" xlink:to="loc_lly_AcquiredInProcessResearchAndDevelopment_4e205676-d58b-4383-b24a-b4f3439f0ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_9f561918-faea-47c1-af5e-d72c80f56f60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1455eea2-7b36-4638-afc6-67c61bfb5ffc" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_9f561918-faea-47c1-af5e-d72c80f56f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_b3d41849-db45-44d0-a7d4-8bf8b0416d66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1455eea2-7b36-4638-afc6-67c61bfb5ffc" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_b3d41849-db45-44d0-a7d4-8bf8b0416d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae128838-9719-4b10-b8d3-dfc5c3cc5639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dc935339-8fb3-44f3-8201-da57f1331283" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae128838-9719-4b10-b8d3-dfc5c3cc5639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce0bc6bc-4872-43cb-9b6c-1ab37999c90e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a2f9043-da67-4c61-9503-b29ec9ea9e90" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce0bc6bc-4872-43cb-9b6c-1ab37999c90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_264d5cee-b288-4dae-b800-52c1d5707786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce0bc6bc-4872-43cb-9b6c-1ab37999c90e" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_264d5cee-b288-4dae-b800-52c1d5707786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_954e27c3-4a56-481c-af49-50b58e3c69e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce0bc6bc-4872-43cb-9b6c-1ab37999c90e" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_954e27c3-4a56-481c-af49-50b58e3c69e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_685f06cb-3041-4e0e-9fdd-863dc0530610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce0bc6bc-4872-43cb-9b6c-1ab37999c90e" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_685f06cb-3041-4e0e-9fdd-863dc0530610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments_61d0ec81-2772-4ede-a910-c94254867a38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfLongtermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce0bc6bc-4872-43cb-9b6c-1ab37999c90e" xlink:to="loc_us-gaap_ProceedsFromSaleOfLongtermInvestments_61d0ec81-2772-4ede-a910-c94254867a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_929c4617-3a3c-46ef-9d31-51e0df337d33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce0bc6bc-4872-43cb-9b6c-1ab37999c90e" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_929c4617-3a3c-46ef-9d31-51e0df337d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_cb0390c1-e665-4224-a9a2-58af6089f0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce0bc6bc-4872-43cb-9b6c-1ab37999c90e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_cb0390c1-e665-4224-a9a2-58af6089f0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PurchasedInProcessResearchAndDevelopment_b8bddb0e-406b-4b95-8179-9dd073b1e3c2" xlink:href="lly-20210930.xsd#lly_PurchasedInProcessResearchAndDevelopment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce0bc6bc-4872-43cb-9b6c-1ab37999c90e" xlink:to="loc_lly_PurchasedInProcessResearchAndDevelopment_b8bddb0e-406b-4b95-8179-9dd073b1e3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b0f79ac8-887a-4cc5-a289-0a9427f56379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce0bc6bc-4872-43cb-9b6c-1ab37999c90e" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b0f79ac8-887a-4cc5-a289-0a9427f56379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c76eda04-d272-4e50-93bd-8a30373ae341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce0bc6bc-4872-43cb-9b6c-1ab37999c90e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c76eda04-d272-4e50-93bd-8a30373ae341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d739bd96-d913-4b70-aeef-38685776259d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a2f9043-da67-4c61-9503-b29ec9ea9e90" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d739bd96-d913-4b70-aeef-38685776259d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_077c81c1-0738-4f69-ab60-90b2772906c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d739bd96-d913-4b70-aeef-38685776259d" xlink:to="loc_us-gaap_PaymentsOfDividends_077c81c1-0738-4f69-ab60-90b2772906c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_72aff9d0-1f3e-4f80-bf2a-bbf9bb446ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d739bd96-d913-4b70-aeef-38685776259d" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_72aff9d0-1f3e-4f80-bf2a-bbf9bb446ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_f3024397-9900-4a96-b427-19ec5ae6d746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d739bd96-d913-4b70-aeef-38685776259d" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_f3024397-9900-4a96-b427-19ec5ae6d746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3df1c144-c44d-48e9-9625-2fb260fe33b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d739bd96-d913-4b70-aeef-38685776259d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3df1c144-c44d-48e9-9625-2fb260fe33b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_dc11a26e-0268-437c-9730-44dc781be890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d739bd96-d913-4b70-aeef-38685776259d" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_dc11a26e-0268-437c-9730-44dc781be890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c6674f17-afa6-4442-ac7d-3e54ec9dad84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d739bd96-d913-4b70-aeef-38685776259d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c6674f17-afa6-4442-ac7d-3e54ec9dad84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8b8de2b1-b2ce-4d06-88f3-7aafc4307e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d739bd96-d913-4b70-aeef-38685776259d" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8b8de2b1-b2ce-4d06-88f3-7aafc4307e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e102c49f-2aeb-4286-afe3-059fa44df96f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d739bd96-d913-4b70-aeef-38685776259d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e102c49f-2aeb-4286-afe3-059fa44df96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_83549dd4-5678-4028-9f09-68725df39af6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a2f9043-da67-4c61-9503-b29ec9ea9e90" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_83549dd4-5678-4028-9f09-68725df39af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d17f1e8b-a413-41b8-bfe1-4d5e60ceafcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a2f9043-da67-4c61-9503-b29ec9ea9e90" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d17f1e8b-a413-41b8-bfe1-4d5e60ceafcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c4ba8888-9164-4ed8-bd21-0f9b1e7cf48a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a2f9043-da67-4c61-9503-b29ec9ea9e90" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c4ba8888-9164-4ed8-bd21-0f9b1e7cf48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6b8f011f-acc5-4165-a4af-3d857ac2eeca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a2f9043-da67-4c61-9503-b29ec9ea9e90" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6b8f011f-acc5-4165-a4af-3d857ac2eeca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BasisofPresentation" xlink:type="simple" xlink:href="lly-20210930.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3dc96ec0-fe16-4365-ad38-1e5c9c0b2c28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_03bf01fb-5940-4b6e-87ab-81d443606e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3dc96ec0-fe16-4365-ad38-1e5c9c0b2c28" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_03bf01fb-5940-4b6e-87ab-81d443606e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/BasisofPresentationPolicies" xlink:type="simple" xlink:href="lly-20210930.xsd#BasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/BasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f9d6ee65-e1cf-4354-a3ce-75a64f33b360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_d3dbbcf3-810a-4e0a-9bb8-f8b9a2de7b93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f9d6ee65-e1cf-4354-a3ce-75a64f33b360" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_d3dbbcf3-810a-4e0a-9bb8-f8b9a2de7b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_993b1315-5553-4892-b8da-3c67de72463e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f9d6ee65-e1cf-4354-a3ce-75a64f33b360" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_993b1315-5553-4892-b8da-3c67de72463e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Revenue" xlink:type="simple" xlink:href="lly-20210930.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1ac0abec-9271-492a-b8f1-02f82cefd9db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_bf9ec06c-d97e-47d8-a1a3-d106ab69d966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1ac0abec-9271-492a-b8f1-02f82cefd9db" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_bf9ec06c-d97e-47d8-a1a3-d106ab69d966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueTables" xlink:type="simple" xlink:href="lly-20210930.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c76c397f-215f-47d5-b004-9c54cf18947c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_85b3d10a-d3b1-4b26-8eeb-5675cfeaba57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c76c397f-215f-47d5-b004-9c54cf18947c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_85b3d10a-d3b1-4b26-8eeb-5675cfeaba57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_e88fd30c-5e1c-4b64-9676-eddc26a231f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c76c397f-215f-47d5-b004-9c54cf18947c" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_e88fd30c-5e1c-4b64-9676-eddc26a231f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#RevenueSummaryofRevenueRecognizedDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_82c319ea-dee3-463e-8d58-1e37ec568251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5b76bae5-7dfd-4eea-a44d-5985116156de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_82c319ea-dee3-463e-8d58-1e37ec568251" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5b76bae5-7dfd-4eea-a44d-5985116156de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_690e337e-818e-4770-8cc8-6ada95343c90" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5b76bae5-7dfd-4eea-a44d-5985116156de" xlink:to="loc_srt_ProductOrServiceAxis_690e337e-818e-4770-8cc8-6ada95343c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_511743f7-1233-449b-9712-b10d60870338" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_690e337e-818e-4770-8cc8-6ada95343c90" xlink:to="loc_srt_ProductsAndServicesDomain_511743f7-1233-449b-9712-b10d60870338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_04edd7ff-9287-44c8-9558-ad955bba02e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_511743f7-1233-449b-9712-b10d60870338" xlink:to="loc_us-gaap_ProductMember_04edd7ff-9287-44c8-9558-ad955bba02e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborationandOtherRevenueMember_ff53dce9-9d5e-4339-9fff-d2403b6c61a4" xlink:href="lly-20210930.xsd#lly_CollaborationandOtherRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_511743f7-1233-449b-9712-b10d60870338" xlink:to="loc_lly_CollaborationandOtherRevenueMember_ff53dce9-9d5e-4339-9fff-d2403b6c61a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_b5b10153-b6ea-4f60-937c-e9367685692d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_511743f7-1233-449b-9712-b10d60870338" xlink:to="loc_us-gaap_RoyaltyMember_b5b10153-b6ea-4f60-937c-e9367685692d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_de3e8d11-ac42-448e-a6f8-9e4f1aa05eef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5b76bae5-7dfd-4eea-a44d-5985116156de" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_de3e8d11-ac42-448e-a6f8-9e4f1aa05eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bbd798e2-38cf-4138-be29-942553b7ee88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_de3e8d11-ac42-448e-a6f8-9e4f1aa05eef" xlink:to="loc_us-gaap_Revenues_bbd798e2-38cf-4138-be29-942553b7ee88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#RevenueAdjustmentstoRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6cdfedbc-dbec-43d0-a61b-c1a96e332381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_fa4d0bc2-e3e5-4492-902b-37c063f454b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6cdfedbc-dbec-43d0-a61b-c1a96e332381" xlink:to="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_fa4d0bc2-e3e5-4492-902b-37c063f454b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_08ef3c5f-b602-4eb2-a067-03d72cfc6ecd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_fa4d0bc2-e3e5-4492-902b-37c063f454b2" xlink:to="loc_srt_StatementGeographicalAxis_08ef3c5f-b602-4eb2-a067-03d72cfc6ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2085dd6c-c124-4fc9-ae16-a533dd3cb7be" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_08ef3c5f-b602-4eb2-a067-03d72cfc6ecd" xlink:to="loc_srt_SegmentGeographicalDomain_2085dd6c-c124-4fc9-ae16-a533dd3cb7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_22601b8c-63bd-41a1-a319-6fa94709002d" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2085dd6c-c124-4fc9-ae16-a533dd3cb7be" xlink:to="loc_country_US_22601b8c-63bd-41a1-a319-6fa94709002d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_6fbe76ed-68e5-41ee-9137-9ab688addeb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_fa4d0bc2-e3e5-4492-902b-37c063f454b2" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_6fbe76ed-68e5-41ee-9137-9ab688addeb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_145e9dc9-b9d5-47c3-ab07-14c1864c2349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_6fbe76ed-68e5-41ee-9137-9ab688addeb1" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_145e9dc9-b9d5-47c3-ab07-14c1864c2349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_7c846cae-8716-485f-993b-f3b4310a9e53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_145e9dc9-b9d5-47c3-ab07-14c1864c2349" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_7c846cae-8716-485f-993b-f3b4310a9e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems_dc5606eb-f9b8-4cc1-a857-da3a139bd709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_fa4d0bc2-e3e5-4492-902b-37c063f454b2" xlink:to="loc_us-gaap_ChangeInAccountingEstimateLineItems_dc5606eb-f9b8-4cc1-a857-da3a139bd709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_1cc21519-fe9b-4049-91ff-ce11039f5206" xlink:href="lly-20210930.xsd#lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_dc5606eb-f9b8-4cc1-a857-da3a139bd709" xlink:to="loc_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent_1cc21519-fe9b-4049-91ff-ce11039f5206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueContractLiabilitiesDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#RevenueContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_577f02db-bfb0-4a71-9777-6233ea9fe57a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f5ab9c9c-7789-478e-9468-6e28ef202f42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_577f02db-bfb0-4a71-9777-6233ea9fe57a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_f5ab9c9c-7789-478e-9468-6e28ef202f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#RevenueDisaggregationofRevenuebyProductDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1c88eb88-294f-4fd3-b908-fc1678fdc249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6e8b782c-b0d3-46a7-ac0d-def0c52825a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1c88eb88-294f-4fd3-b908-fc1678fdc249" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6e8b782c-b0d3-46a7-ac0d-def0c52825a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ccd40812-6758-4567-88cb-1b47604e5aae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6e8b782c-b0d3-46a7-ac0d-def0c52825a6" xlink:to="loc_srt_ProductOrServiceAxis_ccd40812-6758-4567-88cb-1b47604e5aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_33a3e01f-d3c6-434c-8446-fcb2d8d2d27d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ccd40812-6758-4567-88cb-1b47604e5aae" xlink:to="loc_srt_ProductsAndServicesDomain_33a3e01f-d3c6-434c-8446-fcb2d8d2d27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DiabetesMember_7dc57d92-fedf-49a5-9c76-3a0741e7d31f" xlink:href="lly-20210930.xsd#lly_DiabetesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_33a3e01f-d3c6-434c-8446-fcb2d8d2d27d" xlink:to="loc_lly_DiabetesMember_7dc57d92-fedf-49a5-9c76-3a0741e7d31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrulicityMemberMember_77b8323e-5c70-43a7-bd7a-7a5009651af0" xlink:href="lly-20210930.xsd#lly_TrulicityMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_7dc57d92-fedf-49a5-9c76-3a0741e7d31f" xlink:to="loc_lly_TrulicityMemberMember_77b8323e-5c70-43a7-bd7a-7a5009651af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogMember_34757186-8c8a-4b8a-84dd-ee25b3f1fea0" xlink:href="lly-20210930.xsd#lly_HumalogMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_7dc57d92-fedf-49a5-9c76-3a0741e7d31f" xlink:to="loc_lly_HumalogMember_34757186-8c8a-4b8a-84dd-ee25b3f1fea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_8308c2b7-d6dd-4e86-9c68-a07fadb5496c" xlink:href="lly-20210930.xsd#lly_JardianceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_7dc57d92-fedf-49a5-9c76-3a0741e7d31f" xlink:to="loc_lly_JardianceMember_8308c2b7-d6dd-4e86-9c68-a07fadb5496c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumulinMember_feb20046-ad7f-42d0-b717-b6b76f722015" xlink:href="lly-20210930.xsd#lly_HumulinMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_7dc57d92-fedf-49a5-9c76-3a0741e7d31f" xlink:to="loc_lly_HumulinMember_feb20046-ad7f-42d0-b717-b6b76f722015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_13d4ebfe-b31c-49e7-8570-39fcfc6c0683" xlink:href="lly-20210930.xsd#lly_BasaglarMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_7dc57d92-fedf-49a5-9c76-3a0741e7d31f" xlink:to="loc_lly_BasaglarMember_13d4ebfe-b31c-49e7-8570-39fcfc6c0683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherDiabetesMember_2717a86d-49f0-497f-a4f0-4dd180e952ce" xlink:href="lly-20210930.xsd#lly_OtherDiabetesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DiabetesMember_7dc57d92-fedf-49a5-9c76-3a0741e7d31f" xlink:to="loc_lly_OtherDiabetesMember_2717a86d-49f0-497f-a4f0-4dd180e952ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OncologyMember_07ad7466-50a3-49ca-9bc7-c3e91d1d50c6" xlink:href="lly-20210930.xsd#lly_OncologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_33a3e01f-d3c6-434c-8446-fcb2d8d2d27d" xlink:to="loc_lly_OncologyMember_07ad7466-50a3-49ca-9bc7-c3e91d1d50c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AlimtaMember_a827aa90-4c90-4c1d-850d-9860df3a995e" xlink:href="lly-20210930.xsd#lly_AlimtaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_07ad7466-50a3-49ca-9bc7-c3e91d1d50c6" xlink:to="loc_lly_AlimtaMember_a827aa90-4c90-4c1d-850d-9860df3a995e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VerzenioMember_f5707758-1eab-4dfd-88da-33bba16c50f8" xlink:href="lly-20210930.xsd#lly_VerzenioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_07ad7466-50a3-49ca-9bc7-c3e91d1d50c6" xlink:to="loc_lly_VerzenioMember_f5707758-1eab-4dfd-88da-33bba16c50f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CyramzaMember_8b652d86-3a59-4541-a87a-c26330bcbeda" xlink:href="lly-20210930.xsd#lly_CyramzaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_07ad7466-50a3-49ca-9bc7-c3e91d1d50c6" xlink:to="loc_lly_CyramzaMember_8b652d86-3a59-4541-a87a-c26330bcbeda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ErbituxMember_72a4bca5-ef7a-4787-b21c-1dfd4b2cdbba" xlink:href="lly-20210930.xsd#lly_ErbituxMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_07ad7466-50a3-49ca-9bc7-c3e91d1d50c6" xlink:to="loc_lly_ErbituxMember_72a4bca5-ef7a-4787-b21c-1dfd4b2cdbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember_609e4a92-640c-49a5-979c-4d1f0365ac6c" xlink:href="lly-20210930.xsd#lly_TYVYTMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_07ad7466-50a3-49ca-9bc7-c3e91d1d50c6" xlink:to="loc_lly_TYVYTMember_609e4a92-640c-49a5-979c-4d1f0365ac6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherOncologyMember_56cc8ac0-38b7-4a2b-9277-12ac27bb91fb" xlink:href="lly-20210930.xsd#lly_OtherOncologyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OncologyMember_07ad7466-50a3-49ca-9bc7-c3e91d1d50c6" xlink:to="loc_lly_OtherOncologyMember_56cc8ac0-38b7-4a2b-9277-12ac27bb91fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ImmunologyMember_6e5e72ac-8b57-4ca0-a6f4-4393364b9b7b" xlink:href="lly-20210930.xsd#lly_ImmunologyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_33a3e01f-d3c6-434c-8446-fcb2d8d2d27d" xlink:to="loc_lly_ImmunologyMember_6e5e72ac-8b57-4ca0-a6f4-4393364b9b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TaltzMember_4087d63e-f378-4837-936c-c324346e02ce" xlink:href="lly-20210930.xsd#lly_TaltzMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_ImmunologyMember_6e5e72ac-8b57-4ca0-a6f4-4393364b9b7b" xlink:to="loc_lly_TaltzMember_4087d63e-f378-4837-936c-c324346e02ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_e4f57fcb-a663-456d-890b-b5b52868d620" xlink:href="lly-20210930.xsd#lly_OlumiantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_ImmunologyMember_6e5e72ac-8b57-4ca0-a6f4-4393364b9b7b" xlink:to="loc_lly_OlumiantMember_e4f57fcb-a663-456d-890b-b5b52868d620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherImmunologyMember_b5009049-39b1-4923-8888-399194ddf35b" xlink:href="lly-20210930.xsd#lly_OtherImmunologyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_ImmunologyMember_6e5e72ac-8b57-4ca0-a6f4-4393364b9b7b" xlink:to="loc_lly_OtherImmunologyMember_b5009049-39b1-4923-8888-399194ddf35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NeuroscienceMember_06bbe130-317c-492d-be76-f1ebd1716859" xlink:href="lly-20210930.xsd#lly_NeuroscienceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_33a3e01f-d3c6-434c-8446-fcb2d8d2d27d" xlink:to="loc_lly_NeuroscienceMember_06bbe130-317c-492d-be76-f1ebd1716859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityMember_dcfe5cc7-9ae0-4779-9c04-126bbd73e571" xlink:href="lly-20210930.xsd#lly_EmgalityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_06bbe130-317c-492d-be76-f1ebd1716859" xlink:to="loc_lly_EmgalityMember_dcfe5cc7-9ae0-4779-9c04-126bbd73e571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CymbaltaMember_2cca9aee-bc40-432d-9d65-13d6df06d22f" xlink:href="lly-20210930.xsd#lly_CymbaltaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_06bbe130-317c-492d-be76-f1ebd1716859" xlink:to="loc_lly_CymbaltaMember_2cca9aee-bc40-432d-9d65-13d6df06d22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ZyprexaMember_64ac31ab-70b3-475c-bea6-6ff1dc93b78a" xlink:href="lly-20210930.xsd#lly_ZyprexaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_06bbe130-317c-492d-be76-f1ebd1716859" xlink:to="loc_lly_ZyprexaMember_64ac31ab-70b3-475c-bea6-6ff1dc93b78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherNeuroscienceMember_82ea510e-d613-4fa8-9601-537999beda0a" xlink:href="lly-20210930.xsd#lly_OtherNeuroscienceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_NeuroscienceMember_06bbe130-317c-492d-be76-f1ebd1716859" xlink:to="loc_lly_OtherNeuroscienceMember_82ea510e-d613-4fa8-9601-537999beda0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductTotalMember_95173e97-9113-4192-a25f-bd34b84e4478" xlink:href="lly-20210930.xsd#lly_OtherProductTotalMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_33a3e01f-d3c6-434c-8446-fcb2d8d2d27d" xlink:to="loc_lly_OtherProductTotalMember_95173e97-9113-4192-a25f-bd34b84e4478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_03c68271-6154-45c6-a4b5-95fdde97c059" xlink:href="lly-20210930.xsd#lly_COVID19AntibodiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_95173e97-9113-4192-a25f-bd34b84e4478" xlink:to="loc_lly_COVID19AntibodiesMember_03c68271-6154-45c6-a4b5-95fdde97c059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForteoMember_87a4ca76-3ae4-497f-93f9-fc3676fa79e3" xlink:href="lly-20210930.xsd#lly_ForteoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_95173e97-9113-4192-a25f-bd34b84e4478" xlink:to="loc_lly_ForteoMember_87a4ca76-3ae4-497f-93f9-fc3676fa79e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember_81f0dd48-438c-48e4-9a78-093458e998e6" xlink:href="lly-20210930.xsd#lly_CialisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_95173e97-9113-4192-a25f-bd34b84e4478" xlink:to="loc_lly_CialisMember_81f0dd48-438c-48e4-9a78-093458e998e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherProductMember_5e04bc56-0259-4ff0-8099-74ce274c8507" xlink:href="lly-20210930.xsd#lly_OtherProductMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_OtherProductTotalMember_95173e97-9113-4192-a25f-bd34b84e4478" xlink:to="loc_lly_OtherProductMember_5e04bc56-0259-4ff0-8099-74ce274c8507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_642d60f3-e4e0-4745-ad38-1edb89b39191" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6e8b782c-b0d3-46a7-ac0d-def0c52825a6" xlink:to="loc_srt_StatementGeographicalAxis_642d60f3-e4e0-4745-ad38-1edb89b39191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3b29aa87-3c00-4ccf-8689-1aa050226079" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_642d60f3-e4e0-4745-ad38-1edb89b39191" xlink:to="loc_srt_SegmentGeographicalDomain_3b29aa87-3c00-4ccf-8689-1aa050226079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_347a936d-35f5-44f7-8b09-eefe9ba6bd93" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3b29aa87-3c00-4ccf-8689-1aa050226079" xlink:to="loc_country_US_347a936d-35f5-44f7-8b09-eefe9ba6bd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_a5d6e2ad-07c0-47b4-8a07-d4ecd9773efb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3b29aa87-3c00-4ccf-8689-1aa050226079" xlink:to="loc_us-gaap_NonUsMember_a5d6e2ad-07c0-47b4-8a07-d4ecd9773efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3f7110e8-132f-49d7-ab93-7e919a6cc2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6e8b782c-b0d3-46a7-ac0d-def0c52825a6" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_3f7110e8-132f-49d7-ab93-7e919a6cc2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f0e7b6bf-b8fd-47da-85ea-ccea8fe97179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3f7110e8-132f-49d7-ab93-7e919a6cc2a1" xlink:to="loc_us-gaap_Revenues_f0e7b6bf-b8fd-47da-85ea-ccea8fe97179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#RevenueDisaggregationofRevenuebyGeographicalAreaDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1b0fd1f6-2d1d-4451-8d83-6c29a50cb961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a2b8b636-5db6-4a41-8b0c-5047794fba0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1b0fd1f6-2d1d-4451-8d83-6c29a50cb961" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a2b8b636-5db6-4a41-8b0c-5047794fba0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3154f6e0-d965-4fc1-ae74-30e9c0b848a5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a2b8b636-5db6-4a41-8b0c-5047794fba0a" xlink:to="loc_srt_StatementGeographicalAxis_3154f6e0-d965-4fc1-ae74-30e9c0b848a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f00a0c26-ea38-4517-9047-98849729dbf9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_3154f6e0-d965-4fc1-ae74-30e9c0b848a5" xlink:to="loc_srt_SegmentGeographicalDomain_f00a0c26-ea38-4517-9047-98849729dbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_bc0970b7-1435-4b7a-ac65-d1d5b080cdf1" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f00a0c26-ea38-4517-9047-98849729dbf9" xlink:to="loc_country_US_bc0970b7-1435-4b7a-ac65-d1d5b080cdf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_8423fb42-b136-4887-95e3-2b3e407bd2c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f00a0c26-ea38-4517-9047-98849729dbf9" xlink:to="loc_srt_EuropeMember_8423fb42-b136-4887-95e3-2b3e407bd2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_5f3bee4d-ce8f-4668-a7af-5b26c91b946a" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f00a0c26-ea38-4517-9047-98849729dbf9" xlink:to="loc_country_JP_5f3bee4d-ce8f-4668-a7af-5b26c91b946a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_38da8a0b-de30-4681-a2b6-fd57bdbc86b0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f00a0c26-ea38-4517-9047-98849729dbf9" xlink:to="loc_country_CN_38da8a0b-de30-4681-a2b6-fd57bdbc86b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherForeignCountriesMember_22818ad0-d272-4e44-99cd-b71b3f430bb5" xlink:href="lly-20210930.xsd#lly_OtherForeignCountriesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f00a0c26-ea38-4517-9047-98849729dbf9" xlink:to="loc_lly_OtherForeignCountriesMember_22818ad0-d272-4e44-99cd-b71b3f430bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5f05a582-65dc-43e5-9404-092524d9ecc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a2b8b636-5db6-4a41-8b0c-5047794fba0a" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_5f05a582-65dc-43e5-9404-092524d9ecc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c68deb26-a6f2-49df-a399-9342531b4549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5f05a582-65dc-43e5-9404-092524d9ecc8" xlink:to="loc_us-gaap_Revenues_c68deb26-a6f2-49df-a399-9342531b4549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Acquisitions" xlink:type="simple" xlink:href="lly-20210930.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_74e0900a-8ca7-413c-af54-8e3b49ff6ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_f2e75e47-c305-4bcf-a120-4d31fa89d9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_74e0900a-8ca7-413c-af54-8e3b49ff6ee7" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_f2e75e47-c305-4bcf-a120-4d31fa89d9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock_e1017cf0-3961-4546-9a19-f420ea0ccf76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_74e0900a-8ca7-413c-af54-8e3b49ff6ee7" xlink:to="loc_us-gaap_AssetAcquisitionTextBlock_e1017cf0-3961-4546-9a19-f420ea0ccf76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="lly-20210930.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4928efe8-8c7e-48cf-b000-5c2f262d65bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_ef638404-8128-4511-996d-d07ff0617a37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4928efe8-8c7e-48cf-b000-5c2f262d65bd" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_ef638404-8128-4511-996d-d07ff0617a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_a7e48262-85db-4899-8e3f-feb0626880be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4928efe8-8c7e-48cf-b000-5c2f262d65bd" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_a7e48262-85db-4899-8e3f-feb0626880be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_601d2fb2-88e5-460b-bfa7-13f620caaa74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b377d11b-04ea-499d-8738-e928b95134c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_601d2fb2-88e5-460b-bfa7-13f620caaa74" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b377d11b-04ea-499d-8738-e928b95134c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_098b68c7-3590-4e49-890e-1640b208a734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b377d11b-04ea-499d-8738-e928b95134c6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_098b68c7-3590-4e49-890e-1640b208a734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eb644b52-4128-4567-b7a4-42ca979b5d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_098b68c7-3590-4e49-890e-1640b208a734" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eb644b52-4128-4567-b7a4-42ca979b5d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember_42ef9b2f-5e81-467e-a36a-7c11cad3c8ae" xlink:href="lly-20210930.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eb644b52-4128-4567-b7a4-42ca979b5d21" xlink:to="loc_lly_PrevailTherapeuticsIncMember_42ef9b2f-5e81-467e-a36a-7c11cad3c8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DermiraInc.Member_a5ed8f86-f3eb-46c7-a268-7edea3e5c93c" xlink:href="lly-20210930.xsd#lly_DermiraInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eb644b52-4128-4567-b7a4-42ca979b5d21" xlink:to="loc_lly_DermiraInc.Member_a5ed8f86-f3eb-46c7-a268-7edea3e5c93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b377d11b-04ea-499d-8738-e928b95134c6" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_76620f75-1239-4cdf-b8ee-80e84a46818a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_76620f75-1239-4cdf-b8ee-80e84a46818a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_d8bef0d2-0911-477e-859d-84e3982fae2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_d8bef0d2-0911-477e-859d-84e3982fae2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6b73cdb9-207c-4c32-83e5-e6a00c4b7ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6b73cdb9-207c-4c32-83e5-e6a00c4b7ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_48c58242-0a58-49f7-ab5e-9936233a0110" xlink:href="lly-20210930.xsd#lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights_48c58242-0a58-49f7-ab5e-9936233a0110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_c8a39c8f-c6dd-4a7f-8340-64d211d0db0b" xlink:href="lly-20210930.xsd#lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare_c8a39c8f-c6dd-4a7f-8340-64d211d0db0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_9da1a7c0-c60e-4c51-a28a-109d960be22d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_9da1a7c0-c60e-4c51-a28a-109d960be22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_3d102a13-015f-4512-a01e-c61d11ab1f03" xlink:href="lly-20210930.xsd#lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction_3d102a13-015f-4512-a01e-c61d11ab1f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_c4fb3f46-d788-4867-8c53-0d23b767473d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_c4fb3f46-d788-4867-8c53-0d23b767473d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_03e5b333-1140-42dd-b1d2-63cb85d19e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_us-gaap_Goodwill_03e5b333-1140-42dd-b1d2-63cb85d19e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e8d8aa54-db8f-4c93-90f0-9e7a8a9395b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_e8d8aa54-db8f-4c93-90f0-9e7a8a9395b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_6e8ea531-00a1-408b-b788-87e83fff28af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_6e8ea531-00a1-408b-b788-87e83fff28af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_dfad0dc2-b49c-41e0-b6aa-81a1419efd21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_dfad0dc2-b49c-41e0-b6aa-81a1419efd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_009c9ffa-2761-4f51-befb-699ec6ef7c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70aea25c-ef7f-42b3-981a-c9d8394e3fc9" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_009c9ffa-2761-4f51-befb-699ec6ef7c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e0443b1b-010e-4034-bcf8-e09fcdba2da8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_93d2c1f3-0172-4c60-9308-05656f56a41e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e0443b1b-010e-4034-bcf8-e09fcdba2da8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_93d2c1f3-0172-4c60-9308-05656f56a41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9837497f-a6d5-49d3-97c8-4968d9d44f74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_93d2c1f3-0172-4c60-9308-05656f56a41e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9837497f-a6d5-49d3-97c8-4968d9d44f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a86f0955-353d-4234-bf92-0bf4cf19786d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9837497f-a6d5-49d3-97c8-4968d9d44f74" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a86f0955-353d-4234-bf92-0bf4cf19786d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrevailTherapeuticsIncMember_7362fa42-1b97-43b9-8963-a4137fdb11d8" xlink:href="lly-20210930.xsd#lly_PrevailTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a86f0955-353d-4234-bf92-0bf4cf19786d" xlink:to="loc_lly_PrevailTherapeuticsIncMember_7362fa42-1b97-43b9-8963-a4137fdb11d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_26659dfe-4072-42b1-aa2e-f66493691fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_93d2c1f3-0172-4c60-9308-05656f56a41e" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_26659dfe-4072-42b1-aa2e-f66493691fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e520aeb5-1ba2-462f-ae90-27c2cba34494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_26659dfe-4072-42b1-aa2e-f66493691fd9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e520aeb5-1ba2-462f-ae90-27c2cba34494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_50e73ad0-3726-4659-8cb3-38bc7833d8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_26659dfe-4072-42b1-aa2e-f66493691fd9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_50e73ad0-3726-4659-8cb3-38bc7833d8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_39230a06-5572-44c0-a052-237b30c96335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_26659dfe-4072-42b1-aa2e-f66493691fd9" xlink:to="loc_us-gaap_Goodwill_39230a06-5572-44c0-a052-237b30c96335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a032f281-aa5b-4bb9-8276-bda1bb339b06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_26659dfe-4072-42b1-aa2e-f66493691fd9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a032f281-aa5b-4bb9-8276-bda1bb339b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_135607b8-2fd8-487a-866e-db235107c8cc" xlink:href="lly-20210930.xsd#lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_26659dfe-4072-42b1-aa2e-f66493691fd9" xlink:to="loc_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet_135607b8-2fd8-487a-866e-db235107c8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2ffd9634-6d36-4400-8ee5-6aadc0da1e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_26659dfe-4072-42b1-aa2e-f66493691fd9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2ffd9634-6d36-4400-8ee5-6aadc0da1e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_7d6fce3d-4ffe-40e5-a708-0bc2502356c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_26659dfe-4072-42b1-aa2e-f66493691fd9" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_7d6fce3d-4ffe-40e5-a708-0bc2502356c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_0ca57a98-75d1-4f94-9771-e32159656738" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_26659dfe-4072-42b1-aa2e-f66493691fd9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_0ca57a98-75d1-4f94-9771-e32159656738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5a3600ba-f3a5-4f4e-8291-8e1127dc4366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_26659dfe-4072-42b1-aa2e-f66493691fd9" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5a3600ba-f3a5-4f4e-8291-8e1127dc4366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#AcquisitionsAssetAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0141c78f-50d3-4969-b8bd-d46c9546e20a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_a33af3e5-b066-4191-bb4d-0395c16e74b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0141c78f-50d3-4969-b8bd-d46c9546e20a" xlink:to="loc_us-gaap_AssetAcquisitionTable_a33af3e5-b066-4191-bb4d-0395c16e74b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_a324b36d-016a-427c-8889-90d4f63c48e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_a33af3e5-b066-4191-bb4d-0395c16e74b2" xlink:to="loc_us-gaap_AssetAcquisitionAxis_a324b36d-016a-427c-8889-90d4f63c48e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_a324b36d-016a-427c-8889-90d4f63c48e1" xlink:to="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PrecisionBiosciencesIncMember_0408b1cb-2231-4371-bec0-c4461cd452f8" xlink:href="lly-20210930.xsd#lly_PrecisionBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_PrecisionBiosciencesIncMember_0408b1cb-2231-4371-bec0-c4461cd452f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MerusNVMember_34e2dd76-6797-4dc4-88df-5a86c6f7fd19" xlink:href="lly-20210930.xsd#lly_MerusNVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_MerusNVMember_34e2dd76-6797-4dc4-88df-5a86c6f7fd19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AsahiKaseiPharmaCorporationMember_1ca7037d-fc82-4253-8b1c-2118e6ab7b36" xlink:href="lly-20210930.xsd#lly_AsahiKaseiPharmaCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_AsahiKaseiPharmaCorporationMember_1ca7037d-fc82-4253-8b1c-2118e6ab7b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RigelPharmaceuticalsIncMember_4030985d-85c9-4b00-ae0a-adc95ee1a22d" xlink:href="lly-20210930.xsd#lly_RigelPharmaceuticalsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_RigelPharmaceuticalsIncMember_4030985d-85c9-4b00-ae0a-adc95ee1a22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MiNATherapeuticsLimitedMember_9daa56c8-3120-48df-9d5d-12defb11c06c" xlink:href="lly-20210930.xsd#lly_MiNATherapeuticsLimitedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_MiNATherapeuticsLimitedMember_9daa56c8-3120-48df-9d5d-12defb11c06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProtomerTechnologiesIncMember_90821605-2a4a-4a6b-920f-1ee2d50a2c42" xlink:href="lly-20210930.xsd#lly_ProtomerTechnologiesIncMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_ProtomerTechnologiesIncMember_90821605-2a4a-4a6b-920f-1ee2d50a2c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_KumquatBiosciencesIncMember_13f888d4-5f5f-4cef-93d2-a953b4016bcb" xlink:href="lly-20210930.xsd#lly_KumquatBiosciencesIncMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_KumquatBiosciencesIncMember_13f888d4-5f5f-4cef-93d2-a953b4016bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LyciaTherapeuticsIncMember_3a8f8c6c-9205-480c-a488-cd126b7683a4" xlink:href="lly-20210930.xsd#lly_LyciaTherapeuticsIncMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_LyciaTherapeuticsIncMember_3a8f8c6c-9205-480c-a488-cd126b7683a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProQRTherapeuticsNVMember_65d32318-a7f0-4f84-9006-b194fc5b4db6" xlink:href="lly-20210930.xsd#lly_ProQRTherapeuticsNVMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_ProQRTherapeuticsNVMember_65d32318-a7f0-4f84-9006-b194fc5b4db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SitryxTherapeuticsLimitedMember_160a75be-ccb7-4e8c-834b-c4ab82aa171d" xlink:href="lly-20210930.xsd#lly_SitryxTherapeuticsLimitedMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_SitryxTherapeuticsLimitedMember_160a75be-ccb7-4e8c-834b-c4ab82aa171d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AbCelleraBiologicsInc.Member_285f9972-887a-4dd9-9dcb-9c32ac97bb15" xlink:href="lly-20210930.xsd#lly_AbCelleraBiologicsInc.Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_AbCelleraBiologicsInc.Member_285f9972-887a-4dd9-9dcb-9c32ac97bb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JunshiBiosciencesMember_6506a389-736d-4ea9-9f2f-19c8d93a1f3b" xlink:href="lly-20210930.xsd#lly_JunshiBiosciencesMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_JunshiBiosciencesMember_6506a389-736d-4ea9-9f2f-19c8d93a1f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PetraPharmaCorporationMember_67a0102e-0853-46d1-b38c-03ece2ccdf33" xlink:href="lly-20210930.xsd#lly_PetraPharmaCorporationMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_PetraPharmaCorporationMember_67a0102e-0853-46d1-b38c-03ece2ccdf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EvoxTherapeuticsMember_662d2a44-aa61-4c93-990a-2fbbcfbaf2d3" xlink:href="lly-20210930.xsd#lly_EvoxTherapeuticsMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b86b46c5-6b6a-4b2a-8edf-2a829d11e8fc" xlink:to="loc_lly_EvoxTherapeuticsMember_662d2a44-aa61-4c93-990a-2fbbcfbaf2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_61b49838-c2fb-4568-b584-64d5a65c92b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_a33af3e5-b066-4191-bb4d-0395c16e74b2" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_61b49838-c2fb-4568-b584-64d5a65c92b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7fb607e4-ba96-498c-a921-290995693547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_61b49838-c2fb-4568-b584-64d5a65c92b1" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7fb607e4-ba96-498c-a921-290995693547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangements" xlink:type="simple" xlink:href="lly-20210930.xsd#CollaborationsandOtherArrangements"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4247875c-dbaa-4a35-bb36-145d7f34be91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_7b47d2d9-d55c-4c90-9f16-9ded053d57d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4247875c-dbaa-4a35-bb36-145d7f34be91" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_7b47d2d9-d55c-4c90-9f16-9ded053d57d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables" xlink:type="simple" xlink:href="lly-20210930.xsd#CollaborationsandOtherArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0adb80bf-f975-4f43-8244-ed0b7eeed2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_cebed40d-f6c8-442f-9309-db0f5249f95d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0adb80bf-f975-4f43-8244-ed0b7eeed2d8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_cebed40d-f6c8-442f-9309-db0f5249f95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#CollaborationsandOtherArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d1fbf45e-2a7b-4261-93f3-af8fc1625dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d559456b-dc05-4219-a6ad-95b820265853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d1fbf45e-2a7b-4261-93f3-af8fc1625dbe" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d559456b-dc05-4219-a6ad-95b820265853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_427bfdd6-3df5-47fa-bc3d-ecede5fa799f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d559456b-dc05-4219-a6ad-95b820265853" xlink:to="loc_dei_LegalEntityAxis_427bfdd6-3df5-47fa-bc3d-ecede5fa799f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_81638033-a0a3-471d-9924-02865b42c700" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_427bfdd6-3df5-47fa-bc3d-ecede5fa799f" xlink:to="loc_dei_EntityDomain_81638033-a0a3-471d-9924-02865b42c700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InnoventBiologicsIncMember_f1f4b3d3-ddff-4714-883d-dbe673ea0860" xlink:href="lly-20210930.xsd#lly_InnoventBiologicsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_81638033-a0a3-471d-9924-02865b42c700" xlink:to="loc_lly_InnoventBiologicsIncMember_f1f4b3d3-ddff-4714-883d-dbe673ea0860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_RocheMember_e38545e2-ce3e-4e5e-b84d-292bf2978323" xlink:href="lly-20210930.xsd#lly_RocheMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_81638033-a0a3-471d-9924-02865b42c700" xlink:to="loc_lly_RocheMember_e38545e2-ce3e-4e5e-b84d-292bf2978323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_54c26dfa-c627-4f42-8cd9-242cd7111fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d559456b-dc05-4219-a6ad-95b820265853" xlink:to="loc_us-gaap_TypeOfArrangementAxis_54c26dfa-c627-4f42-8cd9-242cd7111fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce05c9b6-94a6-45fb-a730-250f9659f88f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_54c26dfa-c627-4f42-8cd9-242cd7111fcd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce05c9b6-94a6-45fb-a730-250f9659f88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_69eb1664-70d1-4056-8503-2ec30eb8a0bc" xlink:href="lly-20210930.xsd#lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce05c9b6-94a6-45fb-a730-250f9659f88f" xlink:to="loc_lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember_69eb1664-70d1-4056-8503-2ec30eb8a0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementTermsMember_f2fe775d-7b9e-458c-8f7e-8f6a48e997e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyAgreementTermsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce05c9b6-94a6-45fb-a730-250f9659f88f" xlink:to="loc_us-gaap_RoyaltyAgreementTermsMember_f2fe775d-7b9e-458c-8f7e-8f6a48e997e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_2af76e68-1a8f-4fa7-a836-2f5fa7e400c5" xlink:href="lly-20210930.xsd#lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce05c9b6-94a6-45fb-a730-250f9659f88f" xlink:to="loc_lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember_2af76e68-1a8f-4fa7-a836-2f5fa7e400c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_851cbdfd-af7f-4765-9818-28f9fd49d4ab" xlink:href="lly-20210930.xsd#lly_MilestonePaymentsDevelopmentAndRegulatoryMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce05c9b6-94a6-45fb-a730-250f9659f88f" xlink:to="loc_lly_MilestonePaymentsDevelopmentAndRegulatoryMember_851cbdfd-af7f-4765-9818-28f9fd49d4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSalesBasedMember_786d4d32-bd8b-401e-9ed9-e0f49b232fb1" xlink:href="lly-20210930.xsd#lly_MilestonePaymentsSalesBasedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce05c9b6-94a6-45fb-a730-250f9659f88f" xlink:to="loc_lly_MilestonePaymentsSalesBasedMember_786d4d32-bd8b-401e-9ed9-e0f49b232fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_e51b280c-ae81-4096-b7bc-107923964dcc" xlink:href="lly-20210930.xsd#lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce05c9b6-94a6-45fb-a730-250f9659f88f" xlink:to="loc_lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember_e51b280c-ae81-4096-b7bc-107923964dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember_d79d04c9-d38a-4ff4-a93c-f09e89918da2" xlink:href="lly-20210930.xsd#lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce05c9b6-94a6-45fb-a730-250f9659f88f" xlink:to="loc_lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember_d79d04c9-d38a-4ff4-a93c-f09e89918da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember_81d49de2-8bde-4885-943b-974962d92488" xlink:href="lly-20210930.xsd#lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce05c9b6-94a6-45fb-a730-250f9659f88f" xlink:to="loc_lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember_81d49de2-8bde-4885-943b-974962d92488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_042aedd6-32c8-4211-a52b-38ba7d5623d0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d559456b-dc05-4219-a6ad-95b820265853" xlink:to="loc_srt_ProductOrServiceAxis_042aedd6-32c8-4211-a52b-38ba7d5623d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3cb30cff-b706-4bac-b842-c1807408e0f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_042aedd6-32c8-4211-a52b-38ba7d5623d0" xlink:to="loc_srt_ProductsAndServicesDomain_3cb30cff-b706-4bac-b842-c1807408e0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_bec39de6-2ffe-48b6-ad53-4964c5a55efc" xlink:href="lly-20210930.xsd#lly_JardianceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3cb30cff-b706-4bac-b842-c1807408e0f2" xlink:to="loc_lly_JardianceMember_bec39de6-2ffe-48b6-ad53-4964c5a55efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TrajentaBIMember_886ab80b-cd17-4fed-86a9-4912259e1894" xlink:href="lly-20210930.xsd#lly_TrajentaBIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3cb30cff-b706-4bac-b842-c1807408e0f2" xlink:to="loc_lly_TrajentaBIMember_886ab80b-cd17-4fed-86a9-4912259e1894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BasaglarMember_c030103e-4294-4489-bc8b-b045b485bf2d" xlink:href="lly-20210930.xsd#lly_BasaglarMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3cb30cff-b706-4bac-b842-c1807408e0f2" xlink:to="loc_lly_BasaglarMember_c030103e-4294-4489-bc8b-b045b485bf2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OlumiantMember_6ade9755-0125-49c4-9c73-0bbeefd5c621" xlink:href="lly-20210930.xsd#lly_OlumiantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3cb30cff-b706-4bac-b842-c1807408e0f2" xlink:to="loc_lly_OlumiantMember_6ade9755-0125-49c4-9c73-0bbeefd5c621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_COVID19AntibodiesMember_019df287-6771-4602-9cc3-d380305fc4a7" xlink:href="lly-20210930.xsd#lly_COVID19AntibodiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3cb30cff-b706-4bac-b842-c1807408e0f2" xlink:to="loc_lly_COVID19AntibodiesMember_019df287-6771-4602-9cc3-d380305fc4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_TYVYTMember_538ba058-b0ce-4dd8-99b2-89b6c9dde62d" xlink:href="lly-20210930.xsd#lly_TYVYTMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3cb30cff-b706-4bac-b842-c1807408e0f2" xlink:to="loc_lly_TYVYTMember_538ba058-b0ce-4dd8-99b2-89b6c9dde62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LebrikizumabMember_8cf49795-111a-4635-b561-fdaefcc8bfd2" xlink:href="lly-20210930.xsd#lly_LebrikizumabMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3cb30cff-b706-4bac-b842-c1807408e0f2" xlink:to="loc_lly_LebrikizumabMember_8cf49795-111a-4635-b561-fdaefcc8bfd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_79aef9b7-b979-4c93-ba17-c59ee739199c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d559456b-dc05-4219-a6ad-95b820265853" xlink:to="loc_srt_StatementGeographicalAxis_79aef9b7-b979-4c93-ba17-c59ee739199c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f416abd1-cd89-485a-915d-f8b8500120c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_79aef9b7-b979-4c93-ba17-c59ee739199c" xlink:to="loc_srt_SegmentGeographicalDomain_f416abd1-cd89-485a-915d-f8b8500120c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_NonCHINAMember_cc9d1469-b945-4515-a7ee-66341d64db67" xlink:href="lly-20210930.xsd#lly_NonCHINAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f416abd1-cd89-485a-915d-f8b8500120c8" xlink:to="loc_lly_NonCHINAMember_cc9d1469-b945-4515-a7ee-66341d64db67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_0ef39a41-9b34-49f9-9e1d-04dd195222d5" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f416abd1-cd89-485a-915d-f8b8500120c8" xlink:to="loc_country_CN_0ef39a41-9b34-49f9-9e1d-04dd195222d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_9d76a938-23d2-4fe1-927d-2a450fba7a54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d559456b-dc05-4219-a6ad-95b820265853" xlink:to="loc_us-gaap_AssetAcquisitionAxis_9d76a938-23d2-4fe1-927d-2a450fba7a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_00422f8b-da9f-44fd-9aee-bf6e117f99b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_9d76a938-23d2-4fe1-927d-2a450fba7a54" xlink:to="loc_us-gaap_AssetAcquisitionDomain_00422f8b-da9f-44fd-9aee-bf6e117f99b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JunshiBiosciencesMember_7751b9f9-dd43-48ef-a94b-b868b4c47b11" xlink:href="lly-20210930.xsd#lly_JunshiBiosciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_00422f8b-da9f-44fd-9aee-bf6e117f99b9" xlink:to="loc_lly_JunshiBiosciencesMember_7751b9f9-dd43-48ef-a94b-b868b4c47b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PetraPharmaCorporationMember_a9b7b930-3782-4561-9604-d9f038c2006a" xlink:href="lly-20210930.xsd#lly_PetraPharmaCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_00422f8b-da9f-44fd-9aee-bf6e117f99b9" xlink:to="loc_lly_PetraPharmaCorporationMember_a9b7b930-3782-4561-9604-d9f038c2006a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a5986bdc-16e7-4549-b672-200873100b58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d559456b-dc05-4219-a6ad-95b820265853" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a5986bdc-16e7-4549-b672-200873100b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_40be09e0-a557-42f7-bd32-333ef7562082" xlink:href="lly-20210930.xsd#lly_CollaborativeArrangementRightsAndObligationsRightsObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a5986bdc-16e7-4549-b672-200873100b58" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsRightsObligations_40be09e0-a557-42f7-bd32-333ef7562082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c12bad89-f56a-4c93-a3aa-9b57154cca75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a5986bdc-16e7-4549-b672-200873100b58" xlink:to="loc_us-gaap_Revenues_c12bad89-f56a-4c93-a3aa-9b57154cca75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_44fafc4e-f253-4ae5-8083-cd870eb79345" xlink:href="lly-20210930.xsd#lly_CollaborativeArrangementRightsAndObligationsPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a5986bdc-16e7-4549-b672-200873100b58" xlink:to="loc_lly_CollaborativeArrangementRightsAndObligationsPercent_44fafc4e-f253-4ae5-8083-cd870eb79345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_44103a81-90e4-460a-806b-1a696176c215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a5986bdc-16e7-4549-b672-200873100b58" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_44103a81-90e4-460a-806b-1a696176c215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_21f06597-0a27-492a-a14b-2f2d54740dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a5986bdc-16e7-4549-b672-200873100b58" xlink:to="loc_us-gaap_ContractWithCustomerLiability_21f06597-0a27-492a-a14b-2f2d54740dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" xlink:type="simple" xlink:href="lly-20210930.xsd#AssetImpairmentRestructuringandOtherSpecialCharges"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_f126f3bd-ef24-444e-ba29-3a50de049e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_54d5346e-7da5-42b4-b1c0-154ba6488ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_f126f3bd-ef24-444e-ba29-3a50de049e8a" xlink:to="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_54d5346e-7da5-42b4-b1c0-154ba6488ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" xlink:type="simple" xlink:href="lly-20210930.xsd#AssetImpairmentRestructuringandOtherSpecialChargesTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_bf46a056-9082-4b1f-81c8-24ec1e048c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_bad9be7b-aebe-479b-bdfd-1082b43205ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_bf46a056-9082-4b1f-81c8-24ec1e048c18" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_bad9be7b-aebe-479b-bdfd-1082b43205ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#AssetImpairmentRestructuringandOtherSpecialChargesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_732bcecb-766c-48ff-868e-64cf5c248240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_12608bef-99b6-485c-a555-3886c62ba6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_732bcecb-766c-48ff-868e-64cf5c248240" xlink:to="loc_us-gaap_SeveranceCosts1_12608bef-99b6-485c-a555-3886c62ba6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_c512498b-6e23-4e7d-8e12-4ee02a159bc6" xlink:href="lly-20210930.xsd#lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_732bcecb-766c-48ff-868e-64cf5c248240" xlink:to="loc_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges_c512498b-6e23-4e7d-8e12-4ee02a159bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_9c9ba8e1-782e-4220-800c-e43cb309cb00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_732bcecb-766c-48ff-868e-64cf5c248240" xlink:to="loc_us-gaap_RestructuringSettlementAndImpairmentProvisions_9c9ba8e1-782e-4220-800c-e43cb309cb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1cef23ff-ce68-4248-8766-11335f159ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_732bcecb-766c-48ff-868e-64cf5c248240" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1cef23ff-ce68-4248-8766-11335f159ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_539b4f5c-a3ce-43a7-ac76-56be28aa691c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_732bcecb-766c-48ff-868e-64cf5c248240" xlink:to="loc_us-gaap_InventoryWriteDown_539b4f5c-a3ce-43a7-ac76-56be28aa691c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstruments" xlink:type="simple" xlink:href="lly-20210930.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_398d4354-2747-4517-b5c0-1b10001ed3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_e07add32-227d-4b55-bbd1-174f0c6ef30d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_398d4354-2747-4517-b5c0-1b10001ed3dc" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_e07add32-227d-4b55-bbd1-174f0c6ef30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="lly-20210930.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1ed5515d-097f-4396-8240-0dce8092abbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_caa87498-5ed3-4090-b52a-e9bec14d6cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1ed5515d-097f-4396-8240-0dce8092abbd" xlink:to="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_caa87498-5ed3-4090-b52a-e9bec14d6cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_c73fae44-4979-4c96-b49f-c814cb1717ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1ed5515d-097f-4396-8240-0dce8092abbd" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_c73fae44-4979-4c96-b49f-c814cb1717ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_13859bd9-5ea9-4e78-8c94-d1a6f2ab5c64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1ed5515d-097f-4396-8240-0dce8092abbd" xlink:to="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_13859bd9-5ea9-4e78-8c94-d1a6f2ab5c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_e42cda39-da2d-4e60-ac64-a973664cacd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1ed5515d-097f-4396-8240-0dce8092abbd" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_e42cda39-da2d-4e60-ac64-a973664cacd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_cbd90d32-9a9c-42d5-93ea-593c3e8510df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1ed5515d-097f-4396-8240-0dce8092abbd" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_cbd90d32-9a9c-42d5-93ea-593c3e8510df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_b909ff2e-0c85-4546-b455-b161d4cc5e73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1ed5515d-097f-4396-8240-0dce8092abbd" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_b909ff2e-0c85-4546-b455-b161d4cc5e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_29a094bc-94dc-4247-a7e5-d82b18a51683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1ed5515d-097f-4396-8240-0dce8092abbd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_29a094bc-94dc-4247-a7e5-d82b18a51683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_ad999fce-584c-41cf-b9d4-07a749ddc523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1ed5515d-097f-4396-8240-0dce8092abbd" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_ad999fce-584c-41cf-b9d4-07a749ddc523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_42354011-e216-4f95-b44f-e6dde94bf271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1ed5515d-097f-4396-8240-0dce8092abbd" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_42354011-e216-4f95-b44f-e6dde94bf271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6ca1479e-c533-4df2-bb4b-cd40928c79fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_debd2ac0-eac8-4514-8c8b-9d912da2abc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6ca1479e-c533-4df2-bb4b-cd40928c79fc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_debd2ac0-eac8-4514-8c8b-9d912da2abc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_0534a61b-46cb-4c4c-8a1c-3eedfff5cd04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_debd2ac0-eac8-4514-8c8b-9d912da2abc8" xlink:to="loc_us-gaap_HedgingDesignationAxis_0534a61b-46cb-4c4c-8a1c-3eedfff5cd04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_8319220a-c7b2-464e-ba29-d421a107fe32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_0534a61b-46cb-4c4c-8a1c-3eedfff5cd04" xlink:to="loc_us-gaap_HedgingDesignationDomain_8319220a-c7b2-464e-ba29-d421a107fe32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a9315192-0fe6-474d-839f-cd1a2d6c13ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_8319220a-c7b2-464e-ba29-d421a107fe32" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a9315192-0fe6-474d-839f-cd1a2d6c13ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f532bdc0-1400-4d2b-9210-ccc1c678b3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_debd2ac0-eac8-4514-8c8b-9d912da2abc8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f532bdc0-1400-4d2b-9210-ccc1c678b3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_68dff6c8-aa88-4ca7-9737-0a925ea0bd13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f532bdc0-1400-4d2b-9210-ccc1c678b3dd" xlink:to="loc_us-gaap_HedgingRelationshipDomain_68dff6c8-aa88-4ca7-9737-0a925ea0bd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_0a27af77-7985-4e78-8209-c46a60155939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_68dff6c8-aa88-4ca7-9737-0a925ea0bd13" xlink:to="loc_us-gaap_CashFlowHedgingMember_0a27af77-7985-4e78-8209-c46a60155939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_15f96834-d11d-4199-a17d-f7fbcaf625c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_debd2ac0-eac8-4514-8c8b-9d912da2abc8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_15f96834-d11d-4199-a17d-f7fbcaf625c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f7c52267-1244-4602-88f9-a513b56c1f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_15f96834-d11d-4199-a17d-f7fbcaf625c8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f7c52267-1244-4602-88f9-a513b56c1f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ForeignCurrencyDenominatedDebtMember_167b213d-7231-41a7-b789-7ca80968100a" xlink:href="lly-20210930.xsd#lly_ForeignCurrencyDenominatedDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f7c52267-1244-4602-88f9-a513b56c1f7b" xlink:to="loc_lly_ForeignCurrencyDenominatedDebtMember_167b213d-7231-41a7-b789-7ca80968100a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b48aba87-a539-40eb-8012-e88da26c0e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_debd2ac0-eac8-4514-8c8b-9d912da2abc8" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b48aba87-a539-40eb-8012-e88da26c0e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_728690cf-2332-4556-9f25-b046007b1533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b48aba87-a539-40eb-8012-e88da26c0e97" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_728690cf-2332-4556-9f25-b046007b1533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUsDollarSellEuroMember_7a9052e8-1aa2-4d1c-8194-d923b0a51871" xlink:href="lly-20210930.xsd#lly_BuyUsDollarSellEuroMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_728690cf-2332-4556-9f25-b046007b1533" xlink:to="loc_lly_BuyUsDollarSellEuroMember_7a9052e8-1aa2-4d1c-8194-d923b0a51871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyEuroSellUsDollarMember_161551ba-0453-4df0-8ace-e5fa97d2122c" xlink:href="lly-20210930.xsd#lly_BuyEuroSellUsDollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_728690cf-2332-4556-9f25-b046007b1533" xlink:to="loc_lly_BuyEuroSellUsDollarMember_161551ba-0453-4df0-8ace-e5fa97d2122c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSDollarSellChineseYuanMember_680624f9-2a31-4492-a349-0284f2a5a179" xlink:href="lly-20210930.xsd#lly_BuyUSDollarSellChineseYuanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_728690cf-2332-4556-9f25-b046007b1533" xlink:to="loc_lly_BuyUSDollarSellChineseYuanMember_680624f9-2a31-4492-a349-0284f2a5a179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyUSdollarSellJapaneseYenMember_fe7eab15-ea40-4b7e-bce4-2ece97466c44" xlink:href="lly-20210930.xsd#lly_BuyUSdollarSellJapaneseYenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_728690cf-2332-4556-9f25-b046007b1533" xlink:to="loc_lly_BuyUSdollarSellJapaneseYenMember_fe7eab15-ea40-4b7e-bce4-2ece97466c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_BuyBritishPoundandSellUSDollarsMember_3090a616-3227-4f41-a326-2194ceaa40d9" xlink:href="lly-20210930.xsd#lly_BuyBritishPoundandSellUSDollarsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_728690cf-2332-4556-9f25-b046007b1533" xlink:to="loc_lly_BuyBritishPoundandSellUSDollarsMember_3090a616-3227-4f41-a326-2194ceaa40d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapU.S.DollarsToEuroMember_5345e13a-adf8-4d33-993f-def6c5a4d381" xlink:href="lly-20210930.xsd#lly_SwapU.S.DollarsToEuroMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_728690cf-2332-4556-9f25-b046007b1533" xlink:to="loc_lly_SwapU.S.DollarsToEuroMember_5345e13a-adf8-4d33-993f-def6c5a4d381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SwapSwissFrancsToU.S.DollarsMember_f304dab5-df07-49d9-a8f0-cf0180913105" xlink:href="lly-20210930.xsd#lly_SwapSwissFrancsToU.S.DollarsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_728690cf-2332-4556-9f25-b046007b1533" xlink:to="loc_lly_SwapSwissFrancsToU.S.DollarsMember_f304dab5-df07-49d9-a8f0-cf0180913105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_17ceb914-6b3a-495d-987c-4114f84320ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_728690cf-2332-4556-9f25-b046007b1533" xlink:to="loc_us-gaap_InterestRateSwapMember_17ceb914-6b3a-495d-987c-4114f84320ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9ae358b2-5903-4281-88c8-3b564c60793b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_debd2ac0-eac8-4514-8c8b-9d912da2abc8" xlink:to="loc_us-gaap_DebtInstrumentAxis_9ae358b2-5903-4281-88c8-3b564c60793b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fccdb485-c854-42cb-98ef-1cf172a5988e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9ae358b2-5903-4281-88c8-3b564c60793b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fccdb485-c854-42cb-98ef-1cf172a5988e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A5000NotesDue2033Member_0f49872d-4f68-4147-b69c-24f7ae5d46c4" xlink:href="lly-20210930.xsd#lly_A5000NotesDue2033Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fccdb485-c854-42cb-98ef-1cf172a5988e" xlink:to="loc_lly_A5000NotesDue2033Member_0f49872d-4f68-4147-b69c-24f7ae5d46c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_69ed9555-1c1c-499a-ba91-797559fb4235" xlink:href="lly-20210930.xsd#lly_A1125NotesDue2051Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fccdb485-c854-42cb-98ef-1cf172a5988e" xlink:to="loc_lly_A1125NotesDue2051Member_69ed9555-1c1c-499a-ba91-797559fb4235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_a5092064-2c3f-46d3-9664-e23151e68fff" xlink:href="lly-20210930.xsd#lly_A1375NotesDue2061Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fccdb485-c854-42cb-98ef-1cf172a5988e" xlink:to="loc_lly_A1375NotesDue2061Member_a5092064-2c3f-46d3-9664-e23151e68fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_b9735dfb-5e6b-4f3f-8642-dcf9b207cacf" xlink:href="lly-20210930.xsd#lly_A1625NotesDue2043Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fccdb485-c854-42cb-98ef-1cf172a5988e" xlink:to="loc_lly_A1625NotesDue2043Member_b9735dfb-5e6b-4f3f-8642-dcf9b207cacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A395NotesDue2049Member_95acefd8-60ce-411f-9d62-4f3dffd6f45a" xlink:href="lly-20210930.xsd#lly_A395NotesDue2049Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fccdb485-c854-42cb-98ef-1cf172a5988e" xlink:to="loc_lly_A395NotesDue2049Member_95acefd8-60ce-411f-9d62-4f3dffd6f45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A415NotesDue2059Member_005cfd39-0dae-4127-ae84-1108dfebadcc" xlink:href="lly-20210930.xsd#lly_A415NotesDue2059Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fccdb485-c854-42cb-98ef-1cf172a5988e" xlink:to="loc_lly_A415NotesDue2059Member_005cfd39-0dae-4127-ae84-1108dfebadcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A3375NotesDue2029Member_2b044fb2-7b2e-4859-98cf-35bdf23b8c8b" xlink:href="lly-20210930.xsd#lly_A3375NotesDue2029Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fccdb485-c854-42cb-98ef-1cf172a5988e" xlink:to="loc_lly_A3375NotesDue2029Member_2b044fb2-7b2e-4859-98cf-35bdf23b8c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_debd2ac0-eac8-4514-8c8b-9d912da2abc8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_36023eef-b5f6-438c-b3b4-b3d0e82801be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_36023eef-b5f6-438c-b3b4-b3d0e82801be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_6545f912-a619-4b7f-bab2-6ed593a4a402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_6545f912-a619-4b7f-bab2-6ed593a4a402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_82a40ff0-bfa5-49bd-9f5a-6233a0c52edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_82a40ff0-bfa5-49bd-9f5a-6233a0c52edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1fbea623-3e4a-492f-85f7-f84a073265ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_LongTermDebt_1fbea623-3e4a-492f-85f7-f84a073265ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_d9e6b739-3f63-40d8-8eda-be5777c14041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax_d9e6b739-3f63-40d8-8eda-be5777c14041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_0609af37-cd65-48f2-bbb7-dafef5b16941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_DerivativeNotionalAmount_0609af37-cd65-48f2-bbb7-dafef5b16941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DescriptionOfDerivativeActivityVolumePercent_a4e40c41-3320-4860-ae6a-a620d0fee777" xlink:href="lly-20210930.xsd#lly_DescriptionOfDerivativeActivityVolumePercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_lly_DescriptionOfDerivativeActivityVolumePercent_a4e40c41-3320-4860-ae6a-a620d0fee777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ad6f94c3-148c-426a-809d-1db958b690a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ad6f94c3-148c-426a-809d-1db958b690a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c83993ed-a5e6-4388-bffe-b4d90457811a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c83993ed-a5e6-4388-bffe-b4d90457811a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_2faf7d18-435f-48ab-95f1-7b6c25782d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_2faf7d18-435f-48ab-95f1-7b6c25782d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_8a098af4-4a80-4f6d-aab0-17c062dae8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_8a098af4-4a80-4f6d-aab0-17c062dae8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a338f0f0-47ee-4020-9ff8-fb29ddf46327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a338f0f0-47ee-4020-9ff8-fb29ddf46327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_e23bf3fe-eb34-402c-bd93-3b514d39d326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet_e23bf3fe-eb34-402c-bd93-3b514d39d326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_026ab7a6-4115-4012-bc55-dff9523d6368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_026ab7a6-4115-4012-bc55-dff9523d6368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_fdc67288-dbd0-4f7a-b306-3eab779624c7" xlink:href="lly-20210930.xsd#lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod_fdc67288-dbd0-4f7a-b306-3eab779624c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_b44ca19d-7794-4bc8-866b-639fa5b49d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_b44ca19d-7794-4bc8-866b-639fa5b49d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_1f101e2d-0c2f-4ae0-8f8b-74c526ce6bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets_1f101e2d-0c2f-4ae0-8f8b-74c526ce6bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_d3f16f16-ef1c-49a6-bb96-d7b3f45d89c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cf56328d-8fa4-4add-aa09-709156bee290" xlink:to="loc_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized_d3f16f16-ef1c-49a6-bb96-d7b3f45d89c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_49383b1e-5028-4e2e-bd37-23acef211e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_98d9b892-3530-4d9e-af5a-a0dc82a99516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_49383b1e-5028-4e2e-bd37-23acef211e8a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_98d9b892-3530-4d9e-af5a-a0dc82a99516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_a519f30d-e638-4587-b582-abbb7bb4d258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_98d9b892-3530-4d9e-af5a-a0dc82a99516" xlink:to="loc_us-gaap_HedgingDesignationAxis_a519f30d-e638-4587-b582-abbb7bb4d258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_02bb265a-07f3-4195-87ec-315be050c5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_a519f30d-e638-4587-b582-abbb7bb4d258" xlink:to="loc_us-gaap_HedgingDesignationDomain_02bb265a-07f3-4195-87ec-315be050c5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3fd5c1be-976d-41dc-a362-15c8e0785b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_02bb265a-07f3-4195-87ec-315be050c5f1" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3fd5c1be-976d-41dc-a362-15c8e0785b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_6d5dd8c4-bebe-415e-a6a3-5eb3f2b537f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_02bb265a-07f3-4195-87ec-315be050c5f1" xlink:to="loc_us-gaap_NondesignatedMember_6d5dd8c4-bebe-415e-a6a3-5eb3f2b537f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e1ad01b2-bee0-4379-932e-d35ccf0fe4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_98d9b892-3530-4d9e-af5a-a0dc82a99516" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e1ad01b2-bee0-4379-932e-d35ccf0fe4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_bf00ca2a-8507-490c-97f6-6f037bc9518a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e1ad01b2-bee0-4379-932e-d35ccf0fe4f1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_bf00ca2a-8507-490c-97f6-6f037bc9518a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HedgedFixedRateDebtMember_eee2b7d3-223e-4b90-9f60-9246a63bf7e8" xlink:href="lly-20210930.xsd#lly_HedgedFixedRateDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf00ca2a-8507-490c-97f6-6f037bc9518a" xlink:to="loc_lly_HedgedFixedRateDebtMember_eee2b7d3-223e-4b90-9f60-9246a63bf7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_259786b5-fe06-4845-b7b0-a24e11fc77b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf00ca2a-8507-490c-97f6-6f037bc9518a" xlink:to="loc_us-gaap_InterestRateContractMember_259786b5-fe06-4845-b7b0-a24e11fc77b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_c81bbf4f-e3f1-45b8-92d7-e4ec692d9478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf00ca2a-8507-490c-97f6-6f037bc9518a" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_c81bbf4f-e3f1-45b8-92d7-e4ec692d9478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_6e71907c-151f-4d30-b212-1c84c41d8541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf00ca2a-8507-490c-97f6-6f037bc9518a" xlink:to="loc_us-gaap_ForeignExchangeContractMember_6e71907c-151f-4d30-b212-1c84c41d8541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_2d05e6fe-73a0-4138-854a-cd090d02fe97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bf00ca2a-8507-490c-97f6-6f037bc9518a" xlink:to="loc_us-gaap_InterestRateSwapMember_2d05e6fe-73a0-4138-854a-cd090d02fe97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dece77ee-8a53-4eb8-adc2-f3c8736012cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_98d9b892-3530-4d9e-af5a-a0dc82a99516" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dece77ee-8a53-4eb8-adc2-f3c8736012cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_FairValueHedgeAbstract_60ca2d7b-ac3c-4821-880c-3fdd7f7e48b5" xlink:href="lly-20210930.xsd#lly_FairValueHedgeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dece77ee-8a53-4eb8-adc2-f3c8736012cf" xlink:to="loc_lly_FairValueHedgeAbstract_60ca2d7b-ac3c-4821-880c-3fdd7f7e48b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_f86da406-3c77-4aa3-9a03-5fe997b7da96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_FairValueHedgeAbstract_60ca2d7b-ac3c-4821-880c-3fdd7f7e48b5" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_f86da406-3c77-4aa3-9a03-5fe997b7da96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_7fc769b5-a768-4cb4-a7d1-1dfcf2a57146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_FairValueHedgeAbstract_60ca2d7b-ac3c-4821-880c-3fdd7f7e48b5" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_7fc769b5-a768-4cb4-a7d1-1dfcf2a57146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CashFlowHedgeAbstract_5f3da74b-7c47-4ad8-aba5-47f7dcd2cfe9" xlink:href="lly-20210930.xsd#lly_CashFlowHedgeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dece77ee-8a53-4eb8-adc2-f3c8736012cf" xlink:to="loc_lly_CashFlowHedgeAbstract_5f3da74b-7c47-4ad8-aba5-47f7dcd2cfe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_c5eebcad-d96d-4a50-8761-7a1f9092e3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_CashFlowHedgeAbstract_5f3da74b-7c47-4ad8-aba5-47f7dcd2cfe9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_c5eebcad-d96d-4a50-8761-7a1f9092e3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_35062063-0841-453a-9a2a-51aeffc30840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dece77ee-8a53-4eb8-adc2-f3c8736012cf" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_35062063-0841-453a-9a2a-51aeffc30840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DerivativeInstrumentsGainLossRecognized_554009dd-830e-4abb-b3e4-51c7058ea3a2" xlink:href="lly-20210930.xsd#lly_DerivativeInstrumentsGainLossRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dece77ee-8a53-4eb8-adc2-f3c8736012cf" xlink:to="loc_lly_DerivativeInstrumentsGainLossRecognized_554009dd-830e-4abb-b3e4-51c7058ea3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_d3a8cd5a-018e-4a10-93a2-205010cce1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dece77ee-8a53-4eb8-adc2-f3c8736012cf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_d3a8cd5a-018e-4a10-93a2-205010cce1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_dd5ce868-6a63-40c5-a3c4-477f3d45c495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dece77ee-8a53-4eb8-adc2-f3c8736012cf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_dd5ce868-6a63-40c5-a3c4-477f3d45c495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#FinancialInstrumentsFairValueofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3d642ecb-401a-4225-b5e1-61825a58e866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2ab79f7-3cb7-43f7-8a84-555ad2b0fae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3d642ecb-401a-4225-b5e1-61825a58e866" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2ab79f7-3cb7-43f7-8a84-555ad2b0fae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_5d28fd10-3088-4066-ac4a-cfe02f4ae048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2ab79f7-3cb7-43f7-8a84-555ad2b0fae0" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_5d28fd10-3088-4066-ac4a-cfe02f4ae048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1fcf42f0-da44-45a5-bfa0-218f666155f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_5d28fd10-3088-4066-ac4a-cfe02f4ae048" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1fcf42f0-da44-45a5-bfa0-218f666155f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_54705746-7193-4e1b-88b6-9c91538b1d78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1fcf42f0-da44-45a5-bfa0-218f666155f5" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_54705746-7193-4e1b-88b6-9c91538b1d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b6d16efb-f781-41c0-94de-972f15efb83b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1fcf42f0-da44-45a5-bfa0-218f666155f5" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b6d16efb-f781-41c0-94de-972f15efb83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_2bb47092-c232-45e8-adca-4c4ed0c45f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1fcf42f0-da44-45a5-bfa0-218f666155f5" xlink:to="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_2bb47092-c232-45e8-adca-4c4ed0c45f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_bc3887f5-db7b-45ec-adcf-2fc7abc4aea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1fcf42f0-da44-45a5-bfa0-218f666155f5" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_bc3887f5-db7b-45ec-adcf-2fc7abc4aea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_441d2176-2791-467c-b5c8-690bed094591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2ab79f7-3cb7-43f7-8a84-555ad2b0fae0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_441d2176-2791-467c-b5c8-690bed094591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04ef12a5-d41c-4bab-aeae-9d71e6fa94c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_441d2176-2791-467c-b5c8-690bed094591" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04ef12a5-d41c-4bab-aeae-9d71e6fa94c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_fd43c57c-572b-4133-84be-df5037782995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04ef12a5-d41c-4bab-aeae-9d71e6fa94c7" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_fd43c57c-572b-4133-84be-df5037782995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b1d82271-6033-4692-9616-1aaf417baf43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04ef12a5-d41c-4bab-aeae-9d71e6fa94c7" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b1d82271-6033-4692-9616-1aaf417baf43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_8ccc17a0-c364-48e1-899f-5b68c1b9188a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04ef12a5-d41c-4bab-aeae-9d71e6fa94c7" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_8ccc17a0-c364-48e1-899f-5b68c1b9188a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_d41d22cb-5a49-404e-8785-a362d33140ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04ef12a5-d41c-4bab-aeae-9d71e6fa94c7" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_d41d22cb-5a49-404e-8785-a362d33140ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_5ff520e9-4805-4daa-950e-6099c9eadd89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04ef12a5-d41c-4bab-aeae-9d71e6fa94c7" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_5ff520e9-4805-4daa-950e-6099c9eadd89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_OtherEquitySecuritiesMember_133faf6a-5f65-4e89-b1a8-c297259eef62" xlink:href="lly-20210930.xsd#lly_OtherEquitySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04ef12a5-d41c-4bab-aeae-9d71e6fa94c7" xlink:to="loc_lly_OtherEquitySecuritiesMember_133faf6a-5f65-4e89-b1a8-c297259eef62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_MarketableSecuritiesMember_d9dc6ef2-2c0d-4ce5-ad22-5dd241835b27" xlink:href="lly-20210930.xsd#lly_MarketableSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04ef12a5-d41c-4bab-aeae-9d71e6fa94c7" xlink:to="loc_lly_MarketableSecuritiesMember_d9dc6ef2-2c0d-4ce5-ad22-5dd241835b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EquityMethodAndOtherInvestmentsMember_546d107f-702b-486d-958e-83d0364a06f1" xlink:href="lly-20210930.xsd#lly_EquityMethodAndOtherInvestmentsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04ef12a5-d41c-4bab-aeae-9d71e6fa94c7" xlink:to="loc_lly_EquityMethodAndOtherInvestmentsMember_546d107f-702b-486d-958e-83d0364a06f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_62882d70-4910-4b8a-b1fe-247329148cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2ab79f7-3cb7-43f7-8a84-555ad2b0fae0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_62882d70-4910-4b8a-b1fe-247329148cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_26db6ad3-faee-419c-ba65-ebf1be86d887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_62882d70-4910-4b8a-b1fe-247329148cbb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_26db6ad3-faee-419c-ba65-ebf1be86d887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d5816fed-0d24-4f25-b642-f79709e4ba5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_26db6ad3-faee-419c-ba65-ebf1be86d887" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d5816fed-0d24-4f25-b642-f79709e4ba5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9e6afcdd-9999-4709-901a-234ffaec09b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_26db6ad3-faee-419c-ba65-ebf1be86d887" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9e6afcdd-9999-4709-901a-234ffaec09b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_15e22116-6770-4348-961f-7105b6b45271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_26db6ad3-faee-419c-ba65-ebf1be86d887" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_15e22116-6770-4348-961f-7105b6b45271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cce11e6a-0e17-4f6e-8436-a7504d1c10d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c2ab79f7-3cb7-43f7-8a84-555ad2b0fae0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cce11e6a-0e17-4f6e-8436-a7504d1c10d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0f826475-f37f-425f-87f2-f9dbfb002389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cce11e6a-0e17-4f6e-8436-a7504d1c10d1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0f826475-f37f-425f-87f2-f9dbfb002389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_bc86cb77-677f-4595-b6f0-a226e765dfe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cce11e6a-0e17-4f6e-8436-a7504d1c10d1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_bc86cb77-677f-4595-b6f0-a226e765dfe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4167ff90-4392-445b-a9c7-c04d3c74683f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cce11e6a-0e17-4f6e-8436-a7504d1c10d1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4167ff90-4392-445b-a9c7-c04d3c74683f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_399d8c06-3962-4998-8461-baebabf7aa0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cce11e6a-0e17-4f6e-8436-a7504d1c10d1" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_399d8c06-3962-4998-8461-baebabf7aa0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_46f7d3eb-fbc7-46d7-a34d-71e45881ecd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cce11e6a-0e17-4f6e-8436-a7504d1c10d1" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_46f7d3eb-fbc7-46d7-a34d-71e45881ecd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_7b9e6b85-c0bc-42d2-b48b-b8259cc6c95d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cce11e6a-0e17-4f6e-8436-a7504d1c10d1" xlink:to="loc_us-gaap_OtherLongTermInvestments_7b9e6b85-c0bc-42d2-b48b-b8259cc6c95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_bb2accc5-06d6-4d14-95ee-aa7d9c98b951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cce11e6a-0e17-4f6e-8436-a7504d1c10d1" xlink:to="loc_us-gaap_LongTermInvestments_bb2accc5-06d6-4d14-95ee-aa7d9c98b951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_455ac1d1-56b1-4805-a630-5fd62454675d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cce11e6a-0e17-4f6e-8436-a7504d1c10d1" xlink:to="loc_us-gaap_LongTermDebt_455ac1d1-56b1-4805-a630-5fd62454675d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#FinancialInstrumentsRiskManagementInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_99ae724c-97d5-4a70-80c9-452b3989a81b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49f08018-75da-4a66-adf6-d426db3f9e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_99ae724c-97d5-4a70-80c9-452b3989a81b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49f08018-75da-4a66-adf6-d426db3f9e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e9ab24bd-d3f4-4e78-a76d-3dec73eb2bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49f08018-75da-4a66-adf6-d426db3f9e4a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e9ab24bd-d3f4-4e78-a76d-3dec73eb2bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_7debbce3-a454-4ee3-8a1f-4e4c6e307c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e9ab24bd-d3f4-4e78-a76d-3dec73eb2bc8" xlink:to="loc_us-gaap_HedgingRelationshipDomain_7debbce3-a454-4ee3-8a1f-4e4c6e307c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_0ba480e5-9344-407c-b238-1a4dcf475f48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7debbce3-a454-4ee3-8a1f-4e4c6e307c75" xlink:to="loc_us-gaap_FairValueHedgingMember_0ba480e5-9344-407c-b238-1a4dcf475f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_bed25534-cb91-4509-9e1c-a87c34648afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7debbce3-a454-4ee3-8a1f-4e4c6e307c75" xlink:to="loc_us-gaap_CashFlowHedgingMember_bed25534-cb91-4509-9e1c-a87c34648afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_5a40647e-edac-41ed-b21f-70211d9fbbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7debbce3-a454-4ee3-8a1f-4e4c6e307c75" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_5a40647e-edac-41ed-b21f-70211d9fbbc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_618a2be7-2464-4144-b852-2197156eeb88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49f08018-75da-4a66-adf6-d426db3f9e4a" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_618a2be7-2464-4144-b852-2197156eeb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_07ff918b-d709-4a81-90d5-694a811b10c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_618a2be7-2464-4144-b852-2197156eeb88" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_07ff918b-d709-4a81-90d5-694a811b10c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fbfee032-5da5-43be-b222-6992db931b91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_07ff918b-d709-4a81-90d5-694a811b10c6" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fbfee032-5da5-43be-b222-6992db931b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_31d44525-c092-4251-b75d-5cf7604f98fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_07ff918b-d709-4a81-90d5-694a811b10c6" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_31d44525-c092-4251-b75d-5cf7604f98fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_971bf40f-62fc-4fc2-854f-7d00e85d7a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_07ff918b-d709-4a81-90d5-694a811b10c6" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_971bf40f-62fc-4fc2-854f-7d00e85d7a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e8d91dc3-a4ff-43bd-8a09-d913ad181c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49f08018-75da-4a66-adf6-d426db3f9e4a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e8d91dc3-a4ff-43bd-8a09-d913ad181c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_37acd568-143e-4dcf-a523-bd8034d45ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e8d91dc3-a4ff-43bd-8a09-d913ad181c42" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_37acd568-143e-4dcf-a523-bd8034d45ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_66831d0e-5421-46b3-b4cc-e45b1ee17303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_37acd568-143e-4dcf-a523-bd8034d45ca3" xlink:to="loc_us-gaap_InterestRateContractMember_66831d0e-5421-46b3-b4cc-e45b1ee17303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_8459f559-9139-4a1c-8b63-b1de00511d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_37acd568-143e-4dcf-a523-bd8034d45ca3" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_8459f559-9139-4a1c-8b63-b1de00511d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_12ca76d7-3b77-44e8-ae14-c5526d8d8ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_37acd568-143e-4dcf-a523-bd8034d45ca3" xlink:to="loc_us-gaap_ForeignExchangeContractMember_12ca76d7-3b77-44e8-ae14-c5526d8d8ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_79adc9cd-5c64-4148-bbc9-812e54698959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49f08018-75da-4a66-adf6-d426db3f9e4a" xlink:to="loc_us-gaap_HedgingDesignationAxis_79adc9cd-5c64-4148-bbc9-812e54698959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d79d4ec7-a9dd-4103-afab-f1fa4fc273f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_79adc9cd-5c64-4148-bbc9-812e54698959" xlink:to="loc_us-gaap_HedgingDesignationDomain_d79d4ec7-a9dd-4103-afab-f1fa4fc273f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_53ead6d0-5fcb-4f4c-a26d-bb13a009859a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_d79d4ec7-a9dd-4103-afab-f1fa4fc273f1" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_53ead6d0-5fcb-4f4c-a26d-bb13a009859a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_7da3cb8f-61b7-4431-b332-62504078fa52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_d79d4ec7-a9dd-4103-afab-f1fa4fc273f1" xlink:to="loc_us-gaap_NondesignatedMember_7da3cb8f-61b7-4431-b332-62504078fa52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c93a9e1-66ff-4b2f-8421-fcae9685d058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49f08018-75da-4a66-adf6-d426db3f9e4a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c93a9e1-66ff-4b2f-8421-fcae9685d058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d213eaf8-4cbc-4e71-a65c-73125bcff5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c93a9e1-66ff-4b2f-8421-fcae9685d058" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d213eaf8-4cbc-4e71-a65c-73125bcff5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_590a633a-feb1-4ae4-9b6b-7ab5a2f8a451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d213eaf8-4cbc-4e71-a65c-73125bcff5f3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_590a633a-feb1-4ae4-9b6b-7ab5a2f8a451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8078e61e-6aa4-4759-9d63-2201f01cbabc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d213eaf8-4cbc-4e71-a65c-73125bcff5f3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8078e61e-6aa4-4759-9d63-2201f01cbabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_271f2af3-e83f-44cd-bcf8-aae6b19356d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d213eaf8-4cbc-4e71-a65c-73125bcff5f3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_271f2af3-e83f-44cd-bcf8-aae6b19356d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e48e751-71f5-4e62-a3a0-36c5446ba6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49f08018-75da-4a66-adf6-d426db3f9e4a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e48e751-71f5-4e62-a3a0-36c5446ba6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_b770355c-6a87-41ce-9377-7dfa4659a6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e48e751-71f5-4e62-a3a0-36c5446ba6c0" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_b770355c-6a87-41ce-9377-7dfa4659a6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_2098af1e-8222-45f3-83b6-4ca6ddb26f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e48e751-71f5-4e62-a3a0-36c5446ba6c0" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_2098af1e-8222-45f3-83b6-4ca6ddb26f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_46bc07f5-2060-44d1-989d-ef0a7266703a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e48e751-71f5-4e62-a3a0-36c5446ba6c0" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_46bc07f5-2060-44d1-989d-ef0a7266703a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_c045d03a-0963-482c-85ad-11770c292363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e48e751-71f5-4e62-a3a0-36c5446ba6c0" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_c045d03a-0963-482c-85ad-11770c292363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1c544e30-fd58-4252-997b-95a636f99862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e48e751-71f5-4e62-a3a0-36c5446ba6c0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1c544e30-fd58-4252-997b-95a636f99862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#FinancialInstrumentsContractualMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8bb55c46-2d55-48a8-96eb-09691b628b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_94418969-be29-4d90-a6a8-f15cd0c21750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8bb55c46-2d55-48a8-96eb-09691b628b50" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_94418969-be29-4d90-a6a8-f15cd0c21750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d68d1990-e03f-4650-b0cf-7631b7416e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8bb55c46-2d55-48a8-96eb-09691b628b50" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d68d1990-e03f-4650-b0cf-7631b7416e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_92afead3-8d41-4c6d-b5cb-66994a5b25d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8bb55c46-2d55-48a8-96eb-09691b628b50" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_92afead3-8d41-4c6d-b5cb-66994a5b25d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_b01a6bf1-5e11-49dd-b5d4-61135564343d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8bb55c46-2d55-48a8-96eb-09691b628b50" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_b01a6bf1-5e11-49dd-b5d4-61135564343d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_74bdc0f1-74d7-4a01-a9f0-ff4a377f4d37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8bb55c46-2d55-48a8-96eb-09691b628b50" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_74bdc0f1-74d7-4a01-a9f0-ff4a377f4d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#FinancialInstrumentsUnrealizedGainsandLossesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9cee1461-02f8-4f2d-bef5-48da85ac1406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c7abb1ba-c800-4eab-9db6-e46da339151f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9cee1461-02f8-4f2d-bef5-48da85ac1406" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c7abb1ba-c800-4eab-9db6-e46da339151f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d971c2cf-87ce-4981-b514-b26f153a0536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9cee1461-02f8-4f2d-bef5-48da85ac1406" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d971c2cf-87ce-4981-b514-b26f153a0536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_1a12b0a5-457f-4d55-8a38-000a7c06933f" xlink:href="lly-20210930.xsd#lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9cee1461-02f8-4f2d-bef5-48da85ac1406" xlink:to="loc_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition_1a12b0a5-457f-4d55-8a38-000a7c06933f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_fb33a967-a99f-474c-a2f7-10468f33c65f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9cee1461-02f8-4f2d-bef5-48da85ac1406" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_fb33a967-a99f-474c-a2f7-10468f33c65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#FinancialInstrumentsRealizedGainsandLossesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_867303dd-f31b-458b-8ac2-80707f184a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_5af0d8f1-c382-4473-b4d8-e2312efff7a5" xlink:href="lly-20210930.xsd#lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_867303dd-f31b-458b-8ac2-80707f184a4e" xlink:to="loc_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities_5af0d8f1-c382-4473-b4d8-e2312efff7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_af6f317e-786c-4552-af58-18e81117929d" xlink:href="lly-20210930.xsd#lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_867303dd-f31b-458b-8ac2-80707f184a4e" xlink:to="loc_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain_af6f317e-786c-4552-af58-18e81117929d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_8783ea85-01df-46f8-933c-5347e6feba33" xlink:href="lly-20210930.xsd#lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_867303dd-f31b-458b-8ac2-80707f184a4e" xlink:to="loc_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss_8783ea85-01df-46f8-933c-5347e6feba33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lly-20210930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_70bb0138-7b80-4c1a-95e6-12a58afe3901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_bb7780fd-2c85-4da4-87ed-30f89869bcfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_70bb0138-7b80-4c1a-95e6-12a58afe3901" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_bb7780fd-2c85-4da4-87ed-30f89869bcfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b5596b78-e2a5-475a-8d3f-7366f4e76466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2e3e1305-5ae4-4036-bc38-97ea6504b5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b5596b78-e2a5-475a-8d3f-7366f4e76466" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2e3e1305-5ae4-4036-bc38-97ea6504b5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefits" xlink:type="simple" xlink:href="lly-20210930.xsd#RetirementBenefits"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefits" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_244494f6-aab9-4b55-8fa3-3a811e5cc187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_a4a78271-d800-443d-bf00-c1a7c8fd3200" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_244494f6-aab9-4b55-8fa3-3a811e5cc187" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_a4a78271-d800-443d-bf00-c1a7c8fd3200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsTables" xlink:type="simple" xlink:href="lly-20210930.xsd#RetirementBenefitsTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_f2f37607-d734-42bf-843f-398c482ccdf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_015dbab3-7db0-4342-a805-283abea0d7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_f2f37607-d734-42bf-843f-398c482ccdf3" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_015dbab3-7db0-4342-a805-283abea0d7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d004c1c2-612a-4049-981e-4c9dc4a21afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fa93bee3-6b8d-4abf-8662-fa206d5d7285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d004c1c2-612a-4049-981e-4c9dc4a21afb" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fa93bee3-6b8d-4abf-8662-fa206d5d7285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_05163f9b-a3dc-4dfa-a5b7-82921529222c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fa93bee3-6b8d-4abf-8662-fa206d5d7285" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_05163f9b-a3dc-4dfa-a5b7-82921529222c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_58087575-15db-4443-9cd2-8dde0e255582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_05163f9b-a3dc-4dfa-a5b7-82921529222c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_58087575-15db-4443-9cd2-8dde0e255582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_fb649435-2be6-4366-a37f-f9c072e8ea58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_58087575-15db-4443-9cd2-8dde0e255582" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_fb649435-2be6-4366-a37f-f9c072e8ea58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_8d4cc047-48d2-4a5b-9379-4b2f42701b91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_58087575-15db-4443-9cd2-8dde0e255582" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_8d4cc047-48d2-4a5b-9379-4b2f42701b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bd963281-4fed-464a-b01e-e4333b663ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_fa93bee3-6b8d-4abf-8662-fa206d5d7285" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bd963281-4fed-464a-b01e-e4333b663ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_86794c80-93c2-435e-9804-c1204ac61cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bd963281-4fed-464a-b01e-e4333b663ce6" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_86794c80-93c2-435e-9804-c1204ac61cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_2392a5db-a12d-49a1-98bb-5c5824cd3e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bd963281-4fed-464a-b01e-e4333b663ce6" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_2392a5db-a12d-49a1-98bb-5c5824cd3e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_ae409171-eb5c-4eb5-ad6e-f6fca94bb3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bd963281-4fed-464a-b01e-e4333b663ce6" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_ae409171-eb5c-4eb5-ad6e-f6fca94bb3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_41f2a21b-1db0-42fa-895c-ca4dc1fb94f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bd963281-4fed-464a-b01e-e4333b663ce6" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_41f2a21b-1db0-42fa-895c-ca4dc1fb94f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_15c0738d-6b9e-4945-9588-0587b641bce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bd963281-4fed-464a-b01e-e4333b663ce6" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_15c0738d-6b9e-4945-9588-0587b641bce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_fea6a574-dd64-42c9-8888-1bafd72cad9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bd963281-4fed-464a-b01e-e4333b663ce6" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_fea6a574-dd64-42c9-8888-1bafd72cad9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/Contingencies" xlink:type="simple" xlink:href="lly-20210930.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b5062710-b3b1-4c04-87ae-f6471cb9cb21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ebb923be-7c88-4ad9-bc8b-4e026f032492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b5062710-b3b1-4c04-87ae-f6471cb9cb21" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ebb923be-7c88-4ad9-bc8b-4e026f032492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#ContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_270b6f1e-d4f7-4596-be7f-6bc74be8bec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_944b162d-3fa7-4852-a74c-4dfc691ec547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_270b6f1e-d4f7-4596-be7f-6bc74be8bec4" xlink:to="loc_us-gaap_LossContingenciesTable_944b162d-3fa7-4852-a74c-4dfc691ec547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6c68ca90-7d16-4c18-91cd-a83b93ae23ca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_944b162d-3fa7-4852-a74c-4dfc691ec547" xlink:to="loc_srt_StatementGeographicalAxis_6c68ca90-7d16-4c18-91cd-a83b93ae23ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_41bf7bf2-6467-4cd3-9b5b-b7ffde94fa9d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6c68ca90-7d16-4c18-91cd-a83b93ae23ca" xlink:to="loc_srt_SegmentGeographicalDomain_41bf7bf2-6467-4cd3-9b5b-b7ffde94fa9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR_5de8bab3-7a2d-4758-a835-01ad9750a3ab" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_41bf7bf2-6467-4cd3-9b5b-b7ffde94fa9d" xlink:to="loc_country_BR_5de8bab3-7a2d-4758-a835-01ad9750a3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_ef017819-497f-4ae8-bec2-a21a14c01b8e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_944b162d-3fa7-4852-a74c-4dfc691ec547" xlink:to="loc_srt_LitigationCaseAxis_ef017819-497f-4ae8-bec2-a21a14c01b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_dbba6098-973d-4d20-bda3-ba201af3a0c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_ef017819-497f-4ae8-bec2-a21a14c01b8e" xlink:to="loc_srt_LitigationCaseTypeDomain_dbba6098-973d-4d20-bda3-ba201af3a0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DrReddysLabMember_75b60dde-859a-4b81-98b9-5067b3e8aa2a" xlink:href="lly-20210930.xsd#lly_DrReddysLabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dbba6098-973d-4d20-bda3-ba201af3a0c3" xlink:to="loc_lly_DrReddysLabMember_75b60dde-859a-4b81-98b9-5067b3e8aa2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmgalityPatentLitigationMember_28b19340-f869-41dd-af36-7f10cfb962ab" xlink:href="lly-20210930.xsd#lly_EmgalityPatentLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dbba6098-973d-4d20-bda3-ba201af3a0c3" xlink:to="loc_lly_EmgalityPatentLitigationMember_28b19340-f869-41dd-af36-7f10cfb962ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_183b58b2-1d33-4b2a-9333-31835cc171f6" xlink:href="lly-20210930.xsd#lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dbba6098-973d-4d20-bda3-ba201af3a0c3" xlink:to="loc_lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember_183b58b2-1d33-4b2a-9333-31835cc171f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WhyteEtAlVEliLillyEtAlMember_1d8db733-5aae-44bf-8368-4f535da8bc8b" xlink:href="lly-20210930.xsd#lly_WhyteEtAlVEliLillyEtAlMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dbba6098-973d-4d20-bda3-ba201af3a0c3" xlink:to="loc_lly_WhyteEtAlVEliLillyEtAlMember_1d8db733-5aae-44bf-8368-4f535da8bc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_WeilerVTakedaCanadaIncEtAlMember_1954b28a-c8e4-4d67-b1a3-8b259dd91f20" xlink:href="lly-20210930.xsd#lly_WeilerVTakedaCanadaIncEtAlMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dbba6098-973d-4d20-bda3-ba201af3a0c3" xlink:to="loc_lly_WeilerVTakedaCanadaIncEtAlMember_1954b28a-c8e4-4d67-b1a3-8b259dd91f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EppVTakedaCanadaIncEtAlMember_bb4bce46-c925-4284-9c85-4af1b8fac7f6" xlink:href="lly-20210930.xsd#lly_EppVTakedaCanadaIncEtAlMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dbba6098-973d-4d20-bda3-ba201af3a0c3" xlink:to="loc_lly_EppVTakedaCanadaIncEtAlMember_bb4bce46-c925-4284-9c85-4af1b8fac7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_EmployeeLitigationMember_6c34db4f-a8df-4dee-92f9-06c4dd12f5bb" xlink:href="lly-20210930.xsd#lly_EmployeeLitigationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dbba6098-973d-4d20-bda3-ba201af3a0c3" xlink:to="loc_lly_EmployeeLitigationMember_6c34db4f-a8df-4dee-92f9-06c4dd12f5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2da8c37a-2404-45c7-b925-05d760e76a9f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_944b162d-3fa7-4852-a74c-4dfc691ec547" xlink:to="loc_srt_ProductOrServiceAxis_2da8c37a-2404-45c7-b925-05d760e76a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_180727eb-f455-44c1-aa7f-4dbfb7a732d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2da8c37a-2404-45c7-b925-05d760e76a9f" xlink:to="loc_srt_ProductsAndServicesDomain_180727eb-f455-44c1-aa7f-4dbfb7a732d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ActosMember_5841530a-6598-4706-9b12-bed2edd438b7" xlink:href="lly-20210930.xsd#lly_ActosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_180727eb-f455-44c1-aa7f-4dbfb7a732d4" xlink:to="loc_lly_ActosMember_5841530a-6598-4706-9b12-bed2edd438b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ByettaMember_6b46078b-0979-4eb0-95c3-ccb76647580f" xlink:href="lly-20210930.xsd#lly_ByettaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_180727eb-f455-44c1-aa7f-4dbfb7a732d4" xlink:to="loc_lly_ByettaMember_6b46078b-0979-4eb0-95c3-ccb76647580f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_CialisMember_accecc3d-83fc-4a52-b932-d51d9a46b0ae" xlink:href="lly-20210930.xsd#lly_CialisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_180727eb-f455-44c1-aa7f-4dbfb7a732d4" xlink:to="loc_lly_CialisMember_accecc3d-83fc-4a52-b932-d51d9a46b0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_JardianceMember_0eb171d6-23cc-4eb2-b99e-1bb1e88642d5" xlink:href="lly-20210930.xsd#lly_JardianceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_180727eb-f455-44c1-aa7f-4dbfb7a732d4" xlink:to="loc_lly_JardianceMember_0eb171d6-23cc-4eb2-b99e-1bb1e88642d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_HumalogHumulinAndForteoMember_ecbad253-b97b-4ad0-baf9-84b17a6eebde" xlink:href="lly-20210930.xsd#lly_HumalogHumulinAndForteoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_180727eb-f455-44c1-aa7f-4dbfb7a732d4" xlink:to="loc_lly_HumalogHumulinAndForteoMember_ecbad253-b97b-4ad0-baf9-84b17a6eebde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_InsulinMember_6240064c-ef65-4669-a203-3364aabae391" xlink:href="lly-20210930.xsd#lly_InsulinMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_180727eb-f455-44c1-aa7f-4dbfb7a732d4" xlink:to="loc_lly_InsulinMember_6240064c-ef65-4669-a203-3364aabae391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationAxis_8064fa7b-36fb-4587-b9b9-0281239a0ae4" xlink:href="lly-20210930.xsd#lly_DomicileOfLitigationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_944b162d-3fa7-4852-a74c-4dfc691ec547" xlink:to="loc_lly_DomicileOfLitigationAxis_8064fa7b-36fb-4587-b9b9-0281239a0ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_DomicileOfLitigationDomain_510b2c4d-1ad2-4a44-a47d-a08559768a75" xlink:href="lly-20210930.xsd#lly_DomicileOfLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DomicileOfLitigationAxis_8064fa7b-36fb-4587-b9b9-0281239a0ae4" xlink:to="loc_lly_DomicileOfLitigationDomain_510b2c4d-1ad2-4a44-a47d-a08559768a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LosAngelesMember_500784bf-9798-45f2-b3a6-9d1ce4dbf2dc" xlink:href="lly-20210930.xsd#lly_LosAngelesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DomicileOfLitigationDomain_510b2c4d-1ad2-4a44-a47d-a08559768a75" xlink:to="loc_lly_LosAngelesMember_500784bf-9798-45f2-b3a6-9d1ce4dbf2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_SouthernDistrictOfCaliforniaMember_2c083f14-cc2c-4ad6-a0a0-b75d367834b5" xlink:href="lly-20210930.xsd#lly_SouthernDistrictOfCaliforniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DomicileOfLitigationDomain_510b2c4d-1ad2-4a44-a47d-a08559768a75" xlink:to="loc_lly_SouthernDistrictOfCaliforniaMember_2c083f14-cc2c-4ad6-a0a0-b75d367834b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_VariousStateDomicilesMember_34db22ac-1fda-4e0d-9efc-c7dfa81618c5" xlink:href="lly-20210930.xsd#lly_VariousStateDomicilesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_DomicileOfLitigationDomain_510b2c4d-1ad2-4a44-a47d-a08559768a75" xlink:to="loc_lly_VariousStateDomicilesMember_34db22ac-1fda-4e0d-9efc-c7dfa81618c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsAxis_413523b8-6433-4a64-979a-a056fb02a3ca" xlink:href="lly-20210930.xsd#lly_PlaintiffAllegationsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_944b162d-3fa7-4852-a74c-4dfc691ec547" xlink:to="loc_lly_PlaintiffAllegationsAxis_413523b8-6433-4a64-979a-a056fb02a3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PlaintiffAllegationsDomain_7bb4ce78-980e-4a0f-b694-4dea47e0bbed" xlink:href="lly-20210930.xsd#lly_PlaintiffAllegationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_PlaintiffAllegationsAxis_413523b8-6433-4a64-979a-a056fb02a3ca" xlink:to="loc_lly_PlaintiffAllegationsDomain_7bb4ce78-980e-4a0f-b694-4dea47e0bbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreaticCancerOrThyroidCancerMember_b174c05d-d492-4266-8487-be0b0890fad8" xlink:href="lly-20210930.xsd#lly_PancreaticCancerOrThyroidCancerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_PlaintiffAllegationsDomain_7bb4ce78-980e-4a0f-b694-4dea47e0bbed" xlink:to="loc_lly_PancreaticCancerOrThyroidCancerMember_b174c05d-d492-4266-8487-be0b0890fad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_PancreatitisMember_139278db-5d0b-4885-91c5-a21d5c37995e" xlink:href="lly-20210930.xsd#lly_PancreatitisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_PlaintiffAllegationsDomain_7bb4ce78-980e-4a0f-b694-4dea47e0bbed" xlink:to="loc_lly_PancreatitisMember_139278db-5d0b-4885-91c5-a21d5c37995e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AmpullaryCancerMember_87ad807a-b80e-447a-aa1d-019ce0e1f8fb" xlink:href="lly-20210930.xsd#lly_AmpullaryCancerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lly_PlaintiffAllegationsDomain_7bb4ce78-980e-4a0f-b694-4dea47e0bbed" xlink:to="loc_lly_AmpullaryCancerMember_87ad807a-b80e-447a-aa1d-019ce0e1f8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_2b4b267c-d105-4425-ac45-f1fc44b7edbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_944b162d-3fa7-4852-a74c-4dfc691ec547" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_2b4b267c-d105-4425-ac45-f1fc44b7edbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_8a3441a4-06b7-4409-a483-06ebedbb787c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_2b4b267c-d105-4425-ac45-f1fc44b7edbc" xlink:to="loc_us-gaap_LossContingencyNatureDomain_8a3441a4-06b7-4409-a483-06ebedbb787c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_ProductLiabilityMember_c821f466-bdc7-4c03-be4e-cacd3731d5a6" xlink:href="lly-20210930.xsd#lly_ProductLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8a3441a4-06b7-4409-a483-06ebedbb787c" xlink:to="loc_lly_ProductLiabilityMember_c821f466-bdc7-4c03-be4e-cacd3731d5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_c5028f35-6207-488e-828f-c7ab34be61ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8a3441a4-06b7-4409-a483-06ebedbb787c" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_c5028f35-6207-488e-828f-c7ab34be61ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_944b162d-3fa7-4852-a74c-4dfc691ec547" xlink:to="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_1cd12470-75cd-4e44-8693-efa86e39033b" xlink:href="lly-20210930.xsd#lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm_1cd12470-75cd-4e44-8693-efa86e39033b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatents_a8eb4ae9-17a7-4887-a1c6-b929c8419d78" xlink:href="lly-20210930.xsd#lly_LossContingencyNumberOfPatents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_lly_LossContingencyNumberOfPatents_a8eb4ae9-17a7-4887-a1c6-b929c8419d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatentsClaimsDismissed_beaf26b8-bce9-4e29-9697-68a7d53fb302" xlink:href="lly-20210930.xsd#lly_LossContingencyNumberOfPatentsClaimsDismissed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_lly_LossContingencyNumberOfPatentsClaimsDismissed_beaf26b8-bce9-4e29-9697-68a7d53fb302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfPatentsRuledUnpatentable_bffb987d-2dfa-44c4-b65c-475a288c9927" xlink:href="lly-20210930.xsd#lly_LossContingencyNumberOfPatentsRuledUnpatentable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_lly_LossContingencyNumberOfPatentsRuledUnpatentable_bffb987d-2dfa-44c4-b65c-475a288c9927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfDecisionsAffirmed_0a15867a-a5cd-4c60-96c6-8b501460f656" xlink:href="lly-20210930.xsd#lly_LossContingencyNumberOfDecisionsAffirmed"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_lly_LossContingencyNumberOfDecisionsAffirmed_0a15867a-a5cd-4c60-96c6-8b501460f656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_d0011dd1-4e8d-4ac4-a803-2266ce943af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_d0011dd1-4e8d-4ac4-a803-2266ce943af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_26072ab3-f3c0-456e-95a3-8e73ff358bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_26072ab3-f3c0-456e-95a3-8e73ff358bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfClaimants_54f338cb-38cb-409f-af08-804a2c8f2414" xlink:href="lly-20210930.xsd#lly_LossContingencyNumberOfClaimants"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_lly_LossContingencyNumberOfClaimants_54f338cb-38cb-409f-af08-804a2c8f2414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_fdff4b2d-bb48-4bdc-99d8-75fd238b91da" xlink:href="lly-20210930.xsd#lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup_fdff4b2d-bb48-4bdc-99d8-75fd238b91da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_6c58fae6-4969-420c-a932-c7e56f62d132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_6c58fae6-4969-420c-a932-c7e56f62d132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_LitigationClaimsDismissedNumber_8a3f8c83-53db-46e9-8bea-803ae622dffe" xlink:href="lly-20210930.xsd#lly_LitigationClaimsDismissedNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_26f41b6b-59e0-476b-b5d3-0cf7a037036f" xlink:to="loc_lly_LitigationClaimsDismissedNumber_8a3f8c83-53db-46e9-8bea-803ae622dffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="lly-20210930.xsd#OtherComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_485db7b9-fe09-4ad8-b0d1-f689e8bb859c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_d714cac2-d470-4bfb-8f74-ffdd28034247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_485db7b9-fe09-4ad8-b0d1-f689e8bb859c" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_d714cac2-d470-4bfb-8f74-ffdd28034247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="lly-20210930.xsd#OtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c8132097-8fbc-4fc8-809b-8721ac3ba527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_bbbf591f-470b-484f-b4b6-69f697c93973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c8132097-8fbc-4fc8-809b-8721ac3ba527" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_bbbf591f-470b-484f-b4b6-69f697c93973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_23172c96-2836-4485-8219-17b5f40ac20e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c8132097-8fbc-4fc8-809b-8721ac3ba527" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_23172c96-2836-4485-8219-17b5f40ac20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#OtherComprehensiveIncomeLossAOCIDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_272569fa-f126-46c4-84da-b05ceb52c92d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_2840e17a-6f58-47bd-8eee-26678a15e155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_272569fa-f126-46c4-84da-b05ceb52c92d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_2840e17a-6f58-47bd-8eee-26678a15e155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e859e2bb-79ed-406c-8664-0866e84ad777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_2840e17a-6f58-47bd-8eee-26678a15e155" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e859e2bb-79ed-406c-8664-0866e84ad777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ad34808d-6519-4e0f-8d2c-bfe564884203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e859e2bb-79ed-406c-8664-0866e84ad777" xlink:to="loc_us-gaap_EquityComponentDomain_ad34808d-6519-4e0f-8d2c-bfe564884203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_a3cd1b29-bc44-4117-b6e4-6116711598f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ad34808d-6519-4e0f-8d2c-bfe564884203" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_a3cd1b29-bc44-4117-b6e4-6116711598f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_c2669ce3-096e-4ad5-97a9-4be55ee780bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_a3cd1b29-bc44-4117-b6e4-6116711598f5" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_c2669ce3-096e-4ad5-97a9-4be55ee780bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8a35f135-4b37-4666-b21c-d6c176133bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_a3cd1b29-bc44-4117-b6e4-6116711598f5" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_8a35f135-4b37-4666-b21c-d6c176133bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_4646be11-74f9-4a53-b25a-93b3076d7943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_a3cd1b29-bc44-4117-b6e4-6116711598f5" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_4646be11-74f9-4a53-b25a-93b3076d7943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_3d57cbd2-95e8-4ea6-b726-219e5feab90f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_a3cd1b29-bc44-4117-b6e4-6116711598f5" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_3d57cbd2-95e8-4ea6-b726-219e5feab90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_466cdcdb-22b5-4e04-9cd3-3e2ba6f11344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_2840e17a-6f58-47bd-8eee-26678a15e155" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_466cdcdb-22b5-4e04-9cd3-3e2ba6f11344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d78c5686-675d-4456-aea1-d4db7bf82866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_466cdcdb-22b5-4e04-9cd3-3e2ba6f11344" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d78c5686-675d-4456-aea1-d4db7bf82866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ae984ac-731a-4c6c-b5de-8cb6efd5914d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d78c5686-675d-4456-aea1-d4db7bf82866" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ae984ac-731a-4c6c-b5de-8cb6efd5914d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_fd0d78d0-f39b-4047-8694-8206db64631f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d78c5686-675d-4456-aea1-d4db7bf82866" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_fd0d78d0-f39b-4047-8694-8206db64631f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7651129e-dbd4-4c2d-b66b-8b560a1dbed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d78c5686-675d-4456-aea1-d4db7bf82866" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7651129e-dbd4-4c2d-b66b-8b560a1dbed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f517fdd7-f146-4567-ac4a-1cd6d019cdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d78c5686-675d-4456-aea1-d4db7bf82866" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f517fdd7-f146-4567-ac4a-1cd6d019cdf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_066c8de7-cd77-4fd8-82d7-5fc743c2da60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d78c5686-675d-4456-aea1-d4db7bf82866" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_066c8de7-cd77-4fd8-82d7-5fc743c2da60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#OtherComprehensiveIncomeLossTaxEffectDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e0ec02ad-df4a-434a-acc2-19de7c24a160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_805bca1b-ec04-4c1f-9e62-ea6f7987e0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e0ec02ad-df4a-434a-acc2-19de7c24a160" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_805bca1b-ec04-4c1f-9e62-ea6f7987e0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_045bf62d-f90e-41a9-ba2e-96a38cfba02e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_805bca1b-ec04-4c1f-9e62-ea6f7987e0ce" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_045bf62d-f90e-41a9-ba2e-96a38cfba02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_21fecff1-025b-4aaf-b390-d1ac2c7f5aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_045bf62d-f90e-41a9-ba2e-96a38cfba02e" xlink:to="loc_us-gaap_EquityComponentDomain_21fecff1-025b-4aaf-b390-d1ac2c7f5aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_23c02dc6-e4ba-4e9d-9030-8bf532b76ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_21fecff1-025b-4aaf-b390-d1ac2c7f5aa5" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_23c02dc6-e4ba-4e9d-9030-8bf532b76ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_649f3d50-0ef1-4ed0-889c-6907630e068d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_21fecff1-025b-4aaf-b390-d1ac2c7f5aa5" xlink:to="loc_us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_649f3d50-0ef1-4ed0-889c-6907630e068d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_7e8048ca-1f43-4d4e-a926-f1a7884c10cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_21fecff1-025b-4aaf-b390-d1ac2c7f5aa5" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_7e8048ca-1f43-4d4e-a926-f1a7884c10cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_1fb972b5-f4d3-4d46-b0c1-342994a4e65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_21fecff1-025b-4aaf-b390-d1ac2c7f5aa5" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_1fb972b5-f4d3-4d46-b0c1-342994a4e65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c40ef1db-b77a-48d3-8bb4-89e3ec6a9645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_805bca1b-ec04-4c1f-9e62-ea6f7987e0ce" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c40ef1db-b77a-48d3-8bb4-89e3ec6a9645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_18193634-4673-4bac-91b2-d6dd6067e66f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c40ef1db-b77a-48d3-8bb4-89e3ec6a9645" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_18193634-4673-4bac-91b2-d6dd6067e66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#OtherComprehensiveIncomeLossReclassificationDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5d990ecd-8276-47e3-8ecc-a6f7e88ce686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a1d037c5-17b0-4bff-865f-cb392f6d037c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5d990ecd-8276-47e3-8ecc-a6f7e88ce686" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a1d037c5-17b0-4bff-865f-cb392f6d037c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_07ea4ccd-060a-4e63-ad13-8fb7349fd4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a1d037c5-17b0-4bff-865f-cb392f6d037c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_07ea4ccd-060a-4e63-ad13-8fb7349fd4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eb460a12-79fa-4b94-babb-9d223aaf77d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_07ea4ccd-060a-4e63-ad13-8fb7349fd4f5" xlink:to="loc_us-gaap_EquityComponentDomain_eb460a12-79fa-4b94-babb-9d223aaf77d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_0896d0b9-e8b9-40fb-8c00-748bff641b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eb460a12-79fa-4b94-babb-9d223aaf77d0" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_0896d0b9-e8b9-40fb-8c00-748bff641b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_a41496b0-2216-4e5e-bf75-fbad2aa895db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_0896d0b9-e8b9-40fb-8c00-748bff641b9f" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember_a41496b0-2216-4e5e-bf75-fbad2aa895db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_7dcdba1c-fa4a-4599-a6ec-dd4a31953442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_0896d0b9-e8b9-40fb-8c00-748bff641b9f" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_7dcdba1c-fa4a-4599-a6ec-dd4a31953442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_e0f55aa6-eb24-40a7-adf8-4aeaa31cce21" xlink:href="lly-20210930.xsd#lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eb460a12-79fa-4b94-babb-9d223aaf77d0" xlink:to="loc_lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_e0f55aa6-eb24-40a7-adf8-4aeaa31cce21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_be7aa907-05a3-4da2-bdae-5c9b62c9ed84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a1d037c5-17b0-4bff-865f-cb392f6d037c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_be7aa907-05a3-4da2-bdae-5c9b62c9ed84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_b90afdde-1fca-4104-8df4-21c2c1f9716e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_be7aa907-05a3-4da2-bdae-5c9b62c9ed84" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_b90afdde-1fca-4104-8df4-21c2c1f9716e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_8eac5881-8dee-4b41-8e75-3cb5b525852a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_b90afdde-1fca-4104-8df4-21c2c1f9716e" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_8eac5881-8dee-4b41-8e75-3cb5b525852a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_b8ad0abd-e41b-40a9-8d88-383d696d9fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_a1d037c5-17b0-4bff-865f-cb392f6d037c" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_b8ad0abd-e41b-40a9-8d88-383d696d9fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fa990034-741c-4875-87d9-8f5a2c96f08f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_b8ad0abd-e41b-40a9-8d88-383d696d9fb7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fa990034-741c-4875-87d9-8f5a2c96f08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_674ae9f2-4dbe-4d42-8918-720245bfe655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_b8ad0abd-e41b-40a9-8d88-383d696d9fb7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_674ae9f2-4dbe-4d42-8918-720245bfe655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dac0404c-6171-41b8-8251-f67fc6908411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_b8ad0abd-e41b-40a9-8d88-383d696d9fb7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dac0404c-6171-41b8-8251-f67fc6908411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1c935553-0b90-4ff6-93ec-8e6232ecf3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_b8ad0abd-e41b-40a9-8d88-383d696d9fb7" xlink:to="loc_us-gaap_ProfitLoss_1c935553-0b90-4ff6-93ec-8e6232ecf3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpense" xlink:type="simple" xlink:href="lly-20210930.xsd#OtherNetIncomeExpense"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpense" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_446690c1-524e-4fc7-a51d-25ab0c55bd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_f72edd06-82f0-4cf3-b3fd-dfb187032d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_446690c1-524e-4fc7-a51d-25ab0c55bd5b" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_f72edd06-82f0-4cf3-b3fd-dfb187032d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseTables" xlink:type="simple" xlink:href="lly-20210930.xsd#OtherNetIncomeExpenseTables"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2b5d986d-625a-472d-a52c-5e8bb7baeed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5466f554-552f-44c9-a660-44c09ea3b632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2b5d986d-625a-472d-a52c-5e8bb7baeed3" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_5466f554-552f-44c9-a660-44c09ea3b632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="simple" xlink:href="lly-20210930.xsd#OtherNetIncomeExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/OtherNetIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_803c928b-f6f5-4009-93a9-268b935ad317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b05fd509-a9af-43ba-bf8c-29100897d1df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_803c928b-f6f5-4009-93a9-268b935ad317" xlink:to="loc_us-gaap_InterestExpense_b05fd509-a9af-43ba-bf8c-29100897d1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_530beef3-4c66-4be4-bf81-1d6bf53a11ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_803c928b-f6f5-4009-93a9-268b935ad317" xlink:to="loc_us-gaap_InvestmentIncomeInterest_530beef3-4c66-4be4-bf81-1d6bf53a11ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_da76c8ef-9e33-422d-86df-4faeb5a77061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_803c928b-f6f5-4009-93a9-268b935ad317" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_da76c8ef-9e33-422d-86df-4faeb5a77061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_4d633840-7111-4730-8534-d174ccd6a404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_803c928b-f6f5-4009-93a9-268b935ad317" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_4d633840-7111-4730-8534-d174ccd6a404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4bf657a4-982c-492c-b381-1e9d0088f812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_803c928b-f6f5-4009-93a9-268b935ad317" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4bf657a4-982c-492c-b381-1e9d0088f812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_31fdf265-7907-4ff6-baa1-4aceaa6ee3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_803c928b-f6f5-4009-93a9-268b935ad317" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_31fdf265-7907-4ff6-baa1-4aceaa6ee3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_637fc837-62db-4ddb-ab93-3f0689d8674a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_803c928b-f6f5-4009-93a9-268b935ad317" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_637fc837-62db-4ddb-ab93-3f0689d8674a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>lly-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lly="http://www.lilly.com/20210930"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lly-20210930.xsd" xlink:type="simple"/>
    <context id="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5f70d4ddb50548fc9ed454e70437d29f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iee28461a11ce40dd892a5d1af3d82bc3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.000NotesDueJune22022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3a43a3f2ce8e49b3b401dcf8182bda5e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icb1af12eeba04c0f906f5e5eb7425b07_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i753e0f88d69d41e891ceddd7541604a2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i66895af514214364a9f5110c5ce8708d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7531f4ca382a43839cf3a3b4014bb13b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A5000NotesDue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i972a26e5571a4689b6a657c98879bc5b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idd06d4fd694d41f1b11ae0159a256cbf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iff4a44c5161c49a984d21cfcdf9ec6cc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iec85e79d1f4b4520aaed094ce2211f85_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i26ec5aeeab074242968c82cb92e236a7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i738a150fa85d48f491f84c759c959068_I20211022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2021-10-22</instant>
        </period>
    </context>
    <context id="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie526750480d147ff852c5266a9af6876_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie146f46cbfc341289d8af574772b4b88_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6269e3039a904047803aaf8c59d2c31e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i277f40e31a78476c8a25e89e3ad7fad7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i480c67fa255d4952aec1ce6fdc96a5cf_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie79822b045d24ca8816e16c558b018d9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9c4de3b4868049e78934ed4495abd9dc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i292925605a554dd98b2bb9c1601dcacd_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5cc02b3f1ff146b89aaf8d18611bff3a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if9b17be62717498291500daeab724167_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i128373a43773438d93068364bbda7364_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i646c747914e84ad991f450bbec883d19_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i527414e868ec4177853d359e75ca6df1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8cd72451146c46faa7d53de5bc28c3ac_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if2dc23546086416285bbd41e25d62584_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i74a77b8d5d984968b3c4578e17bbb5e9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i36d3b669185e44dbbd9e6e8943ab4f6a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie279100c0102406e93bb14b4657500dc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i28b47563db924e53a3b01da85a1c1857_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8b458bdf7deb40b29fead2a4923fcdc0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic401234ddcb24a04b3a48f1e46bb9d26_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9230f02f9af8414aaa820e4637091e33_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i661e35a5d390434383f2e73f7a2a947c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic9b807fcb6dd415889f60755aa586d46_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7557d0c1a88148acb26d4de3f94524bd_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia2f9c0959ab041ef9cd49b71327449cd_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5e006e6aa4cf4c4c8d995f6d7ef007b3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id48ee4fdf79b43f68e80f1116057e733_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4d263bfcfede470e849adc44fbd95b02_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4489a9298a74411cb30a8b6d1d8c0a5a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i408826e558824625a2ca711ba35a4da0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3d29538f03db4d85830f1a00e8cc2a3d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9112ede45bca4fa485446dc88c3c5484_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4b653f1fba914f8dbac7b520ac3265a7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i83143935f8da447d9261cebfc72ce7ff_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5bb41cf2a9504b31b3ee0af14c18f87f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i22679a982313462397a5663f58993f05_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6d120ba2343e410780602579de874a5f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0287914b178a46d4be80deab95a97314_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie425975ac2314fc3bf1853a1bc359060_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic5af76f55c3349ba859b1f9206178021_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="if8b0a3ca285542978d0be33bc0249ffb_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i612deeb868604a2c937e486f25fce6f6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4a83d082225245798aa0f1e672ee7810_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i05ea4e8d0df642af8b6a87953f1f8e23_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i177bd18351114d5c8ae70dbc77c8660c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4622633489fa4632a9800fb6fb1326c9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i831186dd08c8458bb74c88268733509a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2781ee2a1570463cb045238d0fe460f5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id986361421254ab4997b4c92dec009d3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i252777c0f5ec42bb81ec84d8bffeaebc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib0f254d6b3ea463b8d26b218473a23dd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5b73aed77d4d4a3aa3b99395305f0cb5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i252f3fa632ef43be9ad24db3bffe5ad8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i22b957be322b4417a234d68dfb557223_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iead50fa9bd39400bb6f8a9b5d3d03acd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i90982ebb563845899ddc7a66f27f1455_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a74fbbdc9ac408e8912ccf4e1576ae8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice93dc7ac1da463ea4ecca4d2fba8434_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TrustForBenefitOfEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia0aebdc3dbd54d82a80cf1b888beb150_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i76fda2c740f94c7ca2ee9b4ceda0b709_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd1b1734812948e294108968f3a834d3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i218e2fbd7bbc48deba986aa580060342_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i44128d85d4474ad681fc84f6f83f73b7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i741888a65d6744479381fb901e13925c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icdd23d64b8ba4239ab77fe5df21cd6d5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i08ae5e3d75fc49a3b01da53199cc2e26_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i79216bede2b24f049a04d252ea215271_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic89977d02ab1401dbc23753322c8563b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idac57d16ce9f4dcb9b27d234834a1cc0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3751844cca5948b7a2fad81b7407b645_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9740fd412b0b4c8b8920a13188bc08f6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i008aee30db1f4ed2b8bb7a205e2a213a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie6e915f6611043fda08216f49f3b300a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib870f3d12a3f45ffba916dc4a4d8bc56_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8622b2e9dd4842da9e583319c95a3d10_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i82cca299a87747259a76bff17b9d3f03_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4b10af06686e401d9bc0772daa1af568_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CollaborationandOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2afe7200511442b9be37640fe7d2a7f4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i33cd075c62264add8dfcb7b313a654d0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iba7b305393e54b31bccb95fbd0f79f67_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i69d6b9eefe5e435997214a4dc60d7f32_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i61a4e12edfa84ace81f68212f895f984_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6c7c7535680c41bdb5edaa1a9d31b011_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i75ef086b481246719964b43441307bdb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5618c9f0179444b3b10b8ab8e3e9bef3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i619decfb20794db0b459aef3c32bc5e6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2ac5fda408e6497890499865b967861b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0a9cefb7c292416bb0d6ebbb330edbc3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8c1d6f95905448d385eb2e6e6dae543f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i143a18efe3784ef881f53727b5686001_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4197f4f08df34479bd091bfc5c54df55_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3615f0b224ea424280772b92ec8e7d2e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifc03cbb9d199450ea24aed63300c9230_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i636a3552add040f5ad7def2b7dd765bc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic0bcc0407fc64c0286f70bd29d8897e6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if95e2942890f4e65b9ee7a2130447a4a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4e2e117448cb42c2a288857bc438f50f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9f0f99a60bc04551b5ae2d2be7ceceb1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2467cd73fd4349ddbfa9e1baf740e12c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie7a26c27a65f403eb8beb3df6550f89c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5fa2f284977c46d9989820ed12d7553f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia1cd05c961fe4864a7ad4058c5bb2cbe_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifc63f2b4f3ad4a38885421b13733cfbd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic1843d4702b74c9b8adbaf5ab7aae759_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibf7ecd718b194d13826533eda4fbf459_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6dc7e770251b4603b707a2b28a01efc6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6efe748f82424164bff261d4d56704a4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6e1edb9e5a264ddaa2145ab88b861f25_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4e0bd74a50404b86b9780ef0d7574708_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i23405a005d0043188b612fbd2cb9a01c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5f5d4c7e9fc24d87a56948514836e08b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idcd5ed73cc264b21bfcf6eb9c75a76f1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibc683f8f7aec487db1c97534775202e0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i013c2fd777cb4ad78b3588d03b646777_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic4c206cb2e614db381ab7a7d1967bd03_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iad1245294846401dbd994a69555c3b22_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id662cd6af0a1437492d74860015d4dd3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic60d8559880548869550b76fd7e1622c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i81fb83afd9174a4584c76d363f319ed7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6cfded4b3a63477dab06f1ce39f440c2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2b041f3ba59449439e77c6a72a154148_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i71a09b1522b247eb870ad3c04226f894_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if07f1bed036f4a8cab6b04215059a9a0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2a81a76397d14cf3920f2f8dc0aff2ad_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i66fe92bb4b37478283f0fcde0b4655e7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i35a15d4ca7a14c94906cb2cb75408325_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0e81fb756b57423eb9b5630c52df179d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i833d461ea6104a85b39825c841b91425_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3f9102a7fb8049fa9237e84cee584b52_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7fc787ae1bbb4d8cb11f4f23e454b76c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i65bdcc2ecaf44f2393df1548f2ca567b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i91e9f2f10aae452e851237fa01acebad_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0f970f1846c9427d96a62ed28a252336_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i808fde7a4bcc424abe955ca582b6c429_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4cb18d4711ef487292258d52ebcbb56f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i85255af923d2412cadfe050e3f55be5a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i55b77fb4de574805b40a93cc0c77e784_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i610e677c79024836a14be2d01ea5588e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6adc0c0529714689a5664f338caae315_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iac732504ce454cb9af710f8437b31b72_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iad7f4df9b6b44f7b8942015b498f808e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id9596c4e04274bb8b84585df2008c087_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib3cadcc0ccc047aeadd216305626ae7e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9b7407649b1a42b38ee51c3819e286b9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i74f827e23ec74d3592ec62c9d8a24045_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1f64171c60cb40589455a45ddebdb7f0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i87336623af3c4094ae1f02a8981d1c87_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i44aed9a2ff864ffbb9dabb42a9652a4d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2ae25d95b4f8443e97e0378c32d9625a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i34c6cc4dbeb24eeb82e00b1ebe898947_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i99138be47ed847849c3df6c670763516_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iafb2cb4b4ba94633a0d9effd3535a22d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i94a1de0c39bb4d91a6b8220fd88cc995_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i897388675b95435fb4f36e6b1e6cd6f9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia8207dcbe71c47eca3c2f1096df4b7a8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id34b15be682a4e5cafaba09fd90dc0a3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i33b4d90ccdd9479fa1adc0ede684c6b6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9dbd0fc64d85402a8c6614d6d2cc1b34_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i252c837f8bcb4ac0b13f2285fadeb589_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7569cb5db95e4d16ab9bf1906d28a414_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6e344efb8a154f9293c35b2a2071dea2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8bc5a0211b694ef1ad818a7c769134c9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i79cde695c635485fb5969cbeffb8ee65_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i79a992ad9b904ca59f6786e45f7b37de_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id598f2d470ee46d09e2445b9507ad3f2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib8103205049b472f8eae31d6a58e53a8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if532b94bdbac4bce82537f40e4a0cf51_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iafbd8b57ba564ee298f69bd41e7e8601_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2e4c02ed82d7415eb7c1bcf15c6c21b8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8d59e5583c8648d7b78f39b5a5466a11_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id6aab2127a004f0ba2023cc7bf0b485e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia56673e90d78440b919786ca8b4e5230_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if0f342cfe7ed447c972ee626e06d8847_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2f56993e98d5433a8d3954524f86fd8d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i77fbbc9968cf4bb18902690fe1fd8686_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iad10567d7217449bb0a0eacc29b03bb1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i28a2e586d3c54230929df1bb15cecbc0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifb79dda4914c4c118d30138f4db6d0c9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia634a6f32f8d47e087b88320b460594d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibc9c80adfe494319a49b462b4c84e227_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i89bc1277904f44ebb00cc1c346f34407_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibc39388717ab43b39a31ccad3c4b5ae1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i391eae2ff09a4964b6b7b192b55be566_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i252d50dbb8234dcaa62617a57a7f132c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i87081eb668e448cca72a3cfd33b884eb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3510314a6b1348e1ad1a289c769221a5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i69df563139e5499c9977856b5c047b89_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic3eefcda66434dc7bdb28af6eacee5ae_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ide62ca0bafc24f6189c5766c74864a61_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6fc211aaf0c04cde8b946bf6a6c2101c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9ae2f07cc5ec45d7b4df160393ddcfeb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i17c7b300da94407dacde87022ba06fe4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4a964d449ac84c94b6a4e507792eaf2d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2e0ddfd3674c4908827fced5b7901b52_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i65e6b9bae263441f8bb7c2a734d070c0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i603eda46c0be4d8b86ba9ef36bd2af4d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4fbcaa2d029c4c05bafbb0400bfe6df8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1492ec6093ff478e916d7d23f4f020ab_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i60dde10942844b47a3c7d72ca1e89c00_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic9a4c536cd364a3fb26c3f2186868f7d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3881ab6fddaf4d0397d1251b9b335eaf_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5821c8abb9f442939c46c5f2ea55e15a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6f20b6672fbd429cbc47b24cc460ae1b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3bac77c719ed47c6b5e1daba371ea914_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibcff59ffda63475ea32a7379c4669b03_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if2f4b471c7e348ca914c418fd367c183_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idd4429e99d4349deb077d59d1dad17eb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iceae9cbc8e6f428cac0b0351b0034ee5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i92d973cd4a0a4537962a3af58489887b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifebda85ec8dd4ce192a74a6531b9d614_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibe8ab0e4d8fd4cfd9126dfb95a32ada2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3921ded1beba40848d3de915564681a9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia7659a70032347a1a0b90552b4d62ed3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i186444e26ab54d898b6b15b3ec836f25_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i453051ae80004c3eaa95fb204101dd02_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i31a4994fe4e0451d9b0de9fc4cc45241_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib39a29f5f552438ea4ed0f6636e277a8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i052653fc20254249a0de9e128a7c2a7b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i089ee5a884734f048eeee3e2567bf7ce_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i292fa580da6a4de9822a300c2b0366fa_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7a55f0b0a5af4394ad7de980181c592f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8a2b9316931c41cbad3fbe52783bbc71_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6cc53c31079d4498baf5c2908aa20aa4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i71b81d21fbe94b4e98b74b22e329e4fe_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i083918a48bb449d78ad626ecb038546e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id1915b82ef0745bc9e6902e358dcf426_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1382419146344dc79bef45e72e6ff200_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7998ccfffad54f5a9b058726aa6b7326_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i55ecf9bd230b4e6f9a61f2f6dd604b6a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifd86bf7f1e8344b3a7dbfbaf21dd0e6a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i51349dbae1e142efbd09be3fc1d7902d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie18eb8b2caaa4e6bba191b1bd794bac5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i517eba3441bc456fbc2a2c195f1e25bf_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibe5334101eb14c808e2139001ea4c06e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia255d15fc6ff4cff922a9ee2fb0c0e96_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8bb5a4110102404cbfd2c7b4ba607883_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8cf54671a7af41728bdbea955e0f5c5f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8890bd1f5f1a4efaaaca2db702f79703_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i959c1d63793f4187b23a4c1b7682d284_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idbe2a3bad44c450a8397960daacfd707_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i19c6a9959ea140fd9890927f182fe605_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic46899cdc2a5456f9e0611bd0426b4fd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idf2deaf4d18c449490361e41a4ac0cef_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i289d3252ca6a485f820ef1ea3ad85c12_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i784dad6404be43dfb6fc2b79158399e7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icaa3e0c977aa4404a714b3813766c78f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i82485c3a3fba4749bfbbb721e21e7f30_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i58158972e0264a6fa5cee16276b66a34_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia3ec4f79f58b44a296e438bfeb9305c9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iddc5a8ab9f9e49e9b1727ce623456ec5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1fe1bbef48c94f69a1e7eb1738576328_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i41665e7d5323479fa5a85ac7afd7a612_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id54a327ff97d4ef9958f15bb7ed74770_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibd448a0d7d984d978046eded1bdbef98_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if41782491b964242bf0779976ed75cfc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if0fa9309b68448efb27e0f24f9cfa0a4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iecf6d4dabc7f494caae8aa84b2e0e2bc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ida742051726641c1a38ba8085a59818b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8afbe65684454a96aad4f5fcc43bb2f2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6c156843918049c3b017e903d0c8b152_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8c0e23525a404bd980161347b9d48297_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0f487e07da6a4df7beced03386ce2cb2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifda1418c5f224ffabb56a4cd20894bb4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrulicityMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i21f5c26534d04950a2d18f70db623648_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idd90c62ee1c04e2e80e99978c6745eb9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i392ba95f36004b559b3dabf4a7d68df7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i78362cdcc41745bb8bda6133796f6fd2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1b810a3d51924e95aeb4d64791147211_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1d57ac52c7bb44dba43dbba774be4bf2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3f3d83ab14504b6689cc76eec030040f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9a6c69c487df42779007c37685f53e85_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0c5cb50d0a384037b1da389f2a6e0996_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5877d4ccd49f4569b4e2595a05ac782b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iee73ab780a8f46d8b5fd8ade8860c89a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idfc25dba031242f7b3f38ee74a40876d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7646113be96547db8a4bb44230ae23e6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibe4ca92881b34f2d87b3d3d4afee83d4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2f931c0b571a4fe0ba04399bb7cf2882_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic6079c23287c458d90dcf5793335aca1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i45f071d62d774401ae3df21bca257b94_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if6bfac32d58a4b7db6eb70dfb23fd9fd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumulinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic485be951f44461b83f7178570da126d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i399cec6d60df445682e5e26167ab0fa6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib84ab601c2e045f9b4f9ff1a30e0787a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8f09f9b3b0ed4eeaadea6c487497dc7e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia0327ede8f6347659e88e5324c757fc9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie9fdd628b285469fb2e83ec947cf3bb1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i397a56587b474dc5810261bc659887e2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iacfcc3433c15426bac8a79d18149a311_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2fda94809a0f43ca9938efc6f0994e74_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifd07e050427d4b0495759b6f44c3273e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id4d463248ad74b09a08446c68620a3e1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0185d32bea7d4ee0b0b5e34fbac1fa96_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherDiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i03a83d2e4f15480780af7cc663a095e8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iafb64cc18d0c4af79c7b894a05a665e1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7d04d41e5ada46e1a63e592fc6a9b2d2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i652338f7e46b486589e3d75d6a3de4a0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i705897b88c1c4bc9ae28abf5053986a2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i73e2acd9dcfc42759dfd0fcf3b77d702_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:DiabetesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if46b1191ac1c46e9b91d7193b8f302bd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ica3c1e4736274954a8d703df9c2b167a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0a497c7c118f46e98f40fdba8afad80b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifa5c550586744b789a920295b90fe29b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i99d38563475f4c678f23755bdbf34b9e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibc96b44a7e7c4b2d9067f6309c9e0981_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:AlimtaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie4dee8841aff467e8d34d2a66b5ede53_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8aa0f1db9a924a86a4539ed44bb03cf4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i55ad0c64dc4445c8b5360106446e4e0e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i619fc1a06c8e4e23955358634606df7a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2b9c66fd8850463dabe617b7427612b9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i90fe301cd12a458a8609a9e6744b77c2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:VerzenioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icc36beb9b14e4b9783e4927f8ff53209_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6fc16180ac704e6f8cae3536cc15fc44_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1974eeef369549dc94df5ceef4375ee4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4683a7953b994727aa54bdf352b5d02d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7cda66e9d3f64ed7b5ab5be8945ea9dd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0289a925449c4af893800c44334d7179_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CyramzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i760c1d6d41874cbba99a6b0a36e9dbfc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9171d813dd8744aa8ebf6be081733303_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia12001823d9949fbaf94effdadcee1f0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i374b134314ff4f75bf1e218faeb7a140_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5a772071ec7b42b5a35616776c47cc46_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2a60daf847d84c269726d5443505a7f6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ErbituxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iea2febe706a44680bc01a519177d071a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8d5607f6891d49dea32ba497824c5cf6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i47a1977d3def441282bd0a67b40c3f58_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6922b33207dc47c696a18cd215b4fc89_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i99b621e206fb43b2af4e311739f64ce3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i721201b823f24281ab0040324500b66f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i390fccc895414dbc80bc7b21902083d8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id3b5806021254319908670087ba01693_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i12d8057fb6f44881adf62c66da12a47b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4d2c31facfd84348940f0a8c61dbc204_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie5f004ac1b604026a7bc7798d77ef19e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i469dc8fbbc274df3ac3a499298b1aaa1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia11ae3c44d264cff812e96e38e8bcecc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i77eccb6aa9be4aadabe9b433c7c2d2c4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1cd766bc4a6a436d9bc943dc45e61200_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i738ee12d2f674f3d8ecab5b26681f558_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i90f1e252129e42289186cf041bf33a8e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2a6eb6ab1d454923bb5c11298dc3ad33_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i44f8e7433d104910ac58ce5909942f8d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6fda936960b8455e927557e937bd1b99_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5bf37d8e1a9840ff840b07a02b3d5386_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i800cc0342090483daa741525f8744ff3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5551db7f547e415f84b80f7c3b385f9b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1e75cf8e17334bd7905b58023a170fa9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TaltzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iabc3b21ccc994e3890088301e3cfc653_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia4683cd0b47d404d9b3503f7a600a568_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia2e4795f073d468fac40d557656ecda2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id06212a669134804953343ff9b9678f8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie85525da43ff40e380aee019e6218166_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if93d6526b32048608464727fad92c9bb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1d1869f9b9284dfcbe120478faa3f6cc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i184a7a62437441fe889424d1df050960_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib1d8fa886c14458d88747c5a3f5ebeac_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9b1a3020e2314eaaacf0bd2fc78d63c1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7bc589b7bd644e10835ebc480ec4a412_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i18de420a47cf41a793c58b470768a0e8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibb9be07b275a40f8852a6c540fe99af8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie2861a0c3822428d869e6001e7582ec3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id05ffc1309fe428888516a9c3f40e7a7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id34d06576e4145798da69e8840b8ea78_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if71dd64ea4de44d9afaf6d6a512ba1db_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i12b21ce236de4ed8bf7e747d6eea29ff_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1523e93b1ffd4b70acacf4087551c5db_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie2bc530014104c0cb422de56d4d03e82_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if9e84e4ca8de4c4b97234a747132a31e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i38c6380bb9864e3587fe92837bf5d091_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icc35c7271a8a4943a6227055ab125eb0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7a99b6d9c4c747ce99e9e703d54444b3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CymbaltaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i491c10fe08e342f4a4ac07e509c92936_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i816868a48c8b48099f4d274ded2ea7ed_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idc3314eed4cb4b9d8584ffe6c2837839_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i624804e1e29b4c2f970fd6fb40049075_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i76a9135fab1f4504b803607fb262021d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6e0b11e3d0d14a5baf6de15812c649f2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:EmgalityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibd82f3451e814629b0bd328a44af9778_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i399f4d91b8034567938ddf63d2231514_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2b3ace2be01a4932a527ada8b0e95c08_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9cec004919c74d1abb18678fa0d18ec8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie56c114480404e369f4c566552d2726d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i273b596e58b94897a35fd6eaf5a112bb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ZyprexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if68930386e0e490d9cc62c2853246366_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2219da41e098458f8e17480a24f019ae_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icc7fc4722f76404a8a37d85632337dbc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i00900522405a4bb38276038085c324e4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i86b2429251b54a7389aab14092777b48_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iffa2fbcd9aae4080910c4a7ea104fd94_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id60f7f14418c463da58451d606950976_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie16f11aac59c4ca3a1b1d3532c9651a5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6a99b63187cb430c89fd5d3823917b2d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1dd55add52d845c6a51186e6507d9fd1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i610c7613e7d44f308a44a6dc9bbbaaf3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i96c837650d554f56a6200ace6566fe10_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic36dcc53ac3e4228adb3e7a26ca46465_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i133749f5535c426db6fff5b68d432a9a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib066c49389e847e08dd9e47b3dd013ff_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i00cdf12927374e9ea2bd4fd171d087a8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8046f99bbe284c3ba18f324d7e76338d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia784a32e102a4a3c897cd146133b8efa_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:COVID19AntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3f926fe8ad974b88bb900b9493519ef1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie6aab15dd89e4fb29adda466320b7ab7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2214d9b014994300805fe9c16ab74705_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iba10a9ccc98d4a24b8827dac6bfff7da_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9600095f80154ce7888d5d052fbc1c34_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib2d77207bbde4ab49c305e35c7f2a45f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ForteoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i197272b1a6734b7c91e241f32e6dd646_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idd45ae5c53e04751870a061d88a445ce_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i31c1a896fd4244b5a8e15e4ac8abb96b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5f6f899a265e4b63b17af12da3b7c5b8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i847263e5354d4a72a9f742d7dbe5f329_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3c361d809be0426984f9993fb59eccd6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i608a490542db4b6893542e7e7a64f228_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8dc52535a84848d5a963a822901590da_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifcf246e7d1304af48b16a8f5ee00dc49_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5a2c4c9002a344d1bd2cb16fc80b4bf3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i33e9f09317ba4403a2235be6dea1faa9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i39c4874639894af4bbd798a405ef14f9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ide834e2a43444a5cb9b3500607e4ff20_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7b5acdd57ce5404da6a626cbe3b64a5e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if99f841c17e145b28e1c88eceea31bab_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i863ea645f4b549408c451c4882b42085_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic231bc3ee12e4b1285ddceb9e02b4a26_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5ef4e15111c14cd19aa8255c772b5d92_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OtherProductTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia2a183d7003942d49ed5ae4cef5356cb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i428cf713dc7b4901beedaa25a7950476_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5b9750abc82c4253b256ba599ee15596_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic2b62bc7ef73412295dc475eeadec217_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia3c0a13a33a349aa92d5012e4b636a7a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i669cb3004ae84cf6960440516244078b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id268ee0f04df42a4a96c475b5cfcbcc9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib82ffaddfbef4082af244efc218be24a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i14d504c5ac9c4198822bc799884207ec_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idce8121dee4344e18147fc49a8d5a07b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib632c646a6e9448cbae9a56d4a57fbfc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifbc00e7246a6407b8cc8a82ca741b867_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5391e5cb27db47b8ba06894098bd568e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9971c726971d4e269f7742be265aaaa7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9f70dfeee6ed4ead97768caa6e0b0573_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i37a3d265d5664f4fac0555e3347dda9a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id317a865e2e349898f18728c5ca604b3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4d381b3aade5467ea39cf273c6cc47ae_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1dd27416e4d244238ac2cf4eafcbc5e3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i468cf70e06e74d9abb4442d6f2e6ac71_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:OtherForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i34f0affb1412406985b955e8954cdf8e_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i69178206ce654ab9873b9e9c1d36fa34_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:PrevailTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="ibb396fb0bb334dbdb983642373e2383a_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="ib0548c5b9afb4dfb8d20e8ccf806b912_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="ia3663573ba3c48a5bdcf5eb80a22298a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lly:DermiraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6b575113de824b30a1c74f39db88aefd_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:PrecisionBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="ie6e905c8a80b4d38b9c543fb5bf2ef03_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i9500cb4fcb444bd2b15d0629279eaf70_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:AsahiKaseiPharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="iaa35124ffe304988988994e711548e86_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:RigelPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4a14466d4a0e4b20bc65b50a6842b2f5_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:MiNATherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i870c4b4df8a341cc9b9dab7c879317b8_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:ProtomerTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i3dd9b9e634e34e57897aaaf824716990_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:KumquatBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="ide01e64c4e60431ba5c28356bcc7cb42_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:LyciaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="i0ed04cd38d964fc2af21956c88de5379_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:ProQRTherapeuticsNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i531eb44bb094404198d87fc5156c354e_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:SitryxTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9ca3bd941a584b85b1b0b4d72b454dda_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:AbCelleraBiologicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibab640a2f0fa4cf195eec35598754f90_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i2a26ac8fb34d4458b120b7a6bc3235c0_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:PetraPharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i20e4f1b2ae08456c8caf48e2e1fdbe90_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:EvoxTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3cb5bd55318443f49ec7b5fbcc892280_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:AbCelleraBiologicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i2711efdfc53c49bd9e0e8915915d9f02_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia1acc40e06de4a0f94f52199958700b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb083c377a2b4107a6eb8d5b758dee94_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idc5eafc995df4bbc9a45fd9e9b60dd25_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iba9b3f1d338b4eda841d752024c756c7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i46d24272d19741b5a607f6c2f4e46637_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:BasaglarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if5010b2b7e5545ed8348dbdee8d74c25_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iae1bfc71fb534381a72a38855339542f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic26a9205f4884f5fafe309bf577ca246_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if23d24438d434f35937e458ed4abff61_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TrajentaBIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib280a0fecb8d4d45a80cbda714aed6f5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3551bdde470b46ae9c137fe74872a446_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i27a8de99546f46b5b97d0667185d1775_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7ac78500f4494fa597feac64cdfc42b7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i832240d2148c4ade980357dce8b58dcf_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:OlumiantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7ba69dd64a4449d7b5cc355b8cdb4e0c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie1df26c2f1ab404684e40f47a90f31a2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:JunshiBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic1c05dd0b56b403e9e561ab09c6adf97_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsCapitalizedAsIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib67b5243a6ad40ec868a47e512875138_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lly:NonCHINAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3fabc22c5af942a5bb088863f27e3c17_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:TYVYTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:InnoventBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6cdf764053f54a69bddcc58019bd9a9c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6ed81d6975474a5abcbc174337c27bd4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lly:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie35017a9e84c4b85960feecbdacbbfd4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3a58e1d1992e4f0e821edbda0434c22b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsSalesBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i212f03ee260a4a1d8b38aa6b588dc87e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2e7d5f5212014d5fb1eecf77eb35a41b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:LebrikizumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia9d50a42ad904e8cbe293593bfa34095_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:PetraPharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsContingentUponInitiationOfPhaseITrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iea65191ac5fc4dbb8e7121cae60f91a9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">lly:PetraPharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lly:MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib3e68e01c19a4aaa93a9c6e8d4d5ca0f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUsDollarSellEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3c88f68cc2d7438497246b3d6404eead_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyEuroSellUsDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9a4f51f3d44f4d129128571ca91c4045_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSDollarSellChineseYuanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia65189ebfe674bcdaa496351f69f95ed_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyUSdollarSellJapaneseYenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i608ccb2010534f3489d040d1051be217_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:BuyBritishPoundandSellUSDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i51538ef7c00c4b7ca042552f8fcf1b56_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if2282403149944b6a454777d0cbe119e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifec1b340db5a429986bb4f14e4d51236_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapU.S.DollarsToEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id050ee0435604da9889144406e53ddb1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:SwapSwissFrancsToU.S.DollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3a30bd1d6f09458d9b484f6eede92a0b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie0197954b7f246438579f727a96ba302_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A5000NotesDue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4a56fd67eaa446d58b10847878682132_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icf519817e48d4e2aa20f61c0464569ac_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if42acdc6f14644c49737fbdd91a729b4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0007a0646ac4490fab4a90fe8acda870_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic965f0de559d414494ead6ebab58b9b6_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib811247eae3e4f2c950b855814774a4e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A395NotesDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifdef17a4b3924ef18dc393a876d0f969_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i59558243da25489986f3aa7a759e9236_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A415NotesDue2059Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i630bb94f7a0241fc85ecb2d9d7c1705e_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i246b98760440439aa55a1d9c36f1efc2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lly:A3375NotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">lly:ForeignCurrencyDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i83977bd0653b402a9c4271c7b321f9a4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i39101bb15f78410c92851ae13eb04f8f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifc0dc774626d4895bcd260e8b1e00a1c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i49a37f83c03b41ed93d44441b19d8ce5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i864b815909f7410a8ae48163786157ed_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5a61299558154a88a75737f4e52e86db_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2460f130430a483aa8e55f391938b835_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8cc83e8355fd4482bebf96cb53270e2a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8d6ca7bce852474597f1638b0244034b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4372afcae30c4182a4a4b043e87b2b28_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id8b918e825124054b3c412a4eb18978d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i75f82b84a5c44509970d0b0205ee4b7a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8c88bbe6ccfc45ef949dcef76b904617_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i937f1bdb1bc1479a931e868c6d681bbe_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifd44da12be9b4958bc40d1622ff85d3d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic0315d885ffd4214b0351c0717eb4c2d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icaeede8153e14149b4dd378cfd5bb59e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1f55cc8a2fb64fcb9720f4b9b61421d6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if8ef8f194e1446699469424765ff1fa8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if92f732c456441e6ad74d4c284c639fb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lly:HedgedFixedRateDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i67dbdc3d2d474dbabc54a7a74c1ea885_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie121f355ecb34b25b0508086f86f2a6c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3ba09cfe8cfa4f10bc560bc45b9319b5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i864500d9b5b94bfaaa7d9ea71c3b0c26_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i42cf035468e94826ad3cde71dde916af_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id79d99cd800d4ad28394d8150c6332df_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib2a25406ea954c5f8992888e7c738569_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9e8ec6c42f514d1e80c619a050d59507_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iab73c3bd3fe34c699b5cb054ccb42a6b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icf8e31e25410469a84688b7fb5b87b90_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i44ef377c866e48298d0988babb457ef5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4ad610fc9575465b996c10f1fb676d8e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6e0450a0148940568359bd2bb4fd1c7a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie387bef8710440e4832f0dd71a46bba0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i05166d7e427248f89521f9a6bcdaa937_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i519a8c1745264739b16980e97bd28088_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6137cc328cc64a7b8e6dc90a371cff51_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6ac4ef28e5ea4608a5b80501977931f5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia1b8587493d44060ac22b7dfc95bcf5b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i254a65a32a434ab6b7ef57c8e79f3444_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id0eea1fbbff8437281fea8e1a0f1bef3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1a167b8fec544f85a40ec24ff3dca2ae_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8271ad9786914a7b9146b4cac43d9253_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9346e5ce6da0496eb9220c6582e6049a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i68599e7c7d4b45eca411fa801f914c08_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3674d32a89aa4e689ac0f2091ddd444f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i600421af4c80421291f0d5e08ea11d36_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i027d17439d6c44daaa8479672e90cc93_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iec3eb54ea13545388e93581cfd374f6b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0a3380d8d6904862a95b183e88d6721d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9f93a011c64e4f2c94195e681aac557a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ife05bc1f99a24066a3787f493ad65c20_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i667849e28703418487b214fec3474bdf_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i175f9851b84d40c69587dda3c8dc10b9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ida2502dbdf2544cb9724ce9126589989_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1e73b6978a284142bdbfa2193963e239_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7df8c985cdf740f7bae9773aa95472ab_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i59605113a4b745c8bb79328b1a984d9e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2bf8581a0b224377866093121945c682_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i994afc29ec17435a9bee9daefa8e55bb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8242f0bb64934a2f96b9efb3621ba78f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iac3d68dc29d04fa68b9b49b08724abb8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1917512fec5348218ab246fc29ac8b87_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i03ec7add2c2b40edbdc4d76abab59030_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9ee0ce7fbbd74335ae49c786f5ce512f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i52017fe562964955b55493c294addb61_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id52dc374b89b4866b4adf274c2fa1a1e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib5c4cc06a6de46e1aad4f9ff97b84c27_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i225a1a562a4642abb6920b01f2fbb477_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5501586573ce4f1cbc984235a5fde549_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i770397553c8b4514ae29bcfa65ceee7b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5b9c433fde8f4a7b8dc0cbfd63eae7e9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if6bfbe4f40464147acb2b478e7971494_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7edbfa9acbdb4bc6a481ff5ca1ce3c46_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8f2ea2a6d6594fc5a90ebcefa22bf6ed_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iad249b87b2f44e35b139a24f5d4d84db_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i87dfd73c05814b0fbc8871daab747004_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7cb6f993649c432f91ab9ca4b71ffef8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4fe77029755145319472019556e746c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i96ca3e07a01148b094a43c55448e4efb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1e0615e204f473cba443f60b3f7de5f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i05295ce03244400fa6766b9e219b8bf3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8fa9cde6db5c48a49a12b2bf050fed02_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i08e5d8fcb3fd44119480db6dbff280ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ied8184781f424f29a27dadddc6ed8731_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4a9d1a3a1cff4a65a746020df220cf2f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i65469da25ad54c90b48a89c0f3bf3d24_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id88987a437d54b93a06bb21dda0b2e94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic54aa0ee54c84aa7b85f303e4d069d0d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iae50a005012c4da184ec9eab81c511a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id30187a0d3b642f182acd93577234424_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if108dc8c33db49f1b50918a4d21f04b6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie1d6a3638c5d4a708badbca1668d1e74_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iafebeab06586446d912397c6fb09946f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i559d13b3f37b4eb4ab054a4bce781df7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id471726344764ff2b385dbc67cf0ff8c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i579833d7d4e94e06b8586597ea11d6be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i529b971a380a4005bfd7acd5587ded3e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibc82ddb19c4945f884bbc5cd15cb96f4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2f53adcd59224d2687568795466dfc6f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2f2b5896fbb642c0a0b59d18c9b0e845_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i10c6b8bdcad04d0d88e821b45c159a43_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i034058bf069a4dbcaae7e84a4aa255ae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie0365c0c3dd2458dae2cab0433af8f3e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i19165abf56a04452a4c3551fe3755e80_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i289304fc14e749fea082a39de3765686_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i38b1cd4f68cc409893c60409151dc138_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia0246f3af391442d94cfbdb8ee92c330_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i647c8bc2ff894d94933a6d11cfd86f10_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i07aa6c9aa38745159a6c6e80527e089c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic0d94775a2e4434f8f30c1ad2daaa4be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibb3a371deaa94088a0072db110d4390c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5bf5bc5acb2d44fdb267cb99d8658e57_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i61279d09c7f74590ba3c78f533210f01_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i09e35a2009cd4049b44091d2fbad8303_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2e126e3688134c3599ff5a999c9c666e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d5ca9edfa0a4d2e8a076d65f4bf86f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8bfadc646ecc4dc6b43cf57447e0394b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i32ae0f6ced194431824adea4c4770c08_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1bf0bd0fc1154e00a1a1c2c3d2110606_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8fff8d67cdfe4a6694c7c5b6f0cb54c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44c59f63225e4451a3244ff421561da5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i90ec35ef834d4369a726dac716752c0a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if06045f0fcf1478f9c730dddb34ab7ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2da876ea43f4439ebedccb5d73cf5b3b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib359550524f54c8f8a3d1f33d72a5dda_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lly:EquityMethodAndOtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i505924e93d794dcfb0c5b8f9156cc31d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib69916829c7f4e9fbfb75dc86bee47ef_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ide74b136d9db45dc9cd0829ce1591b43_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i66fa7e1e841c4a48bef41810792cf5e1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i95b523dd0c89497e8d0a8474b6749ceb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iffd5ed0fac1144d3bbe9bcce7cd1dcab_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1c09bc5eb3b44d3b988ac6fdb7749025_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i070877701c5a412581e58eb922963dfb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5427871777084be79a6dd7b683f42940_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icdeeaeee0d0d4d56bc48afc50bdbf622_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8f9e2597f06c4231ae5d5e3a773d4991_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i971a91d6ce39447f86a1c28fa9944956_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3aed62f649184956b1971ad38859077d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic36d644f83d345269c981d8628439fe7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id8af5b44af8147c684f333006fbe7f0c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7f931a8eb6e44ca2a36918808b02f5e3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i97d367acc5bc4a7693028a8fc46010a4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i89eb7f65122e4d24b2f6d71a3d2035ca_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i378115cc1767432b9131fab24760be6c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i79a2635cf98d414eb4d6df658c5f7006_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i610fa7df3a574a30bb25b81f30f3394e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i544e08e2a3a1491f9a0fa4048ca7ab95_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie0b124c9b6104c87b8aeb05c89cb6f96_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifd3f4727952e4020b12ae68aacca865d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id907a8104c9441f294b2de3071a1225c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i81adb51d1b8642b89fde93b4d30867a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie853d3ba19364e30b51bd241ce67c53e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if4754a075a4b41139b71c1d8bd51b1d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d66e7dd621e49b19263feb5a5399308_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i70f111854ded42afbf8cf34c68376b8b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic96c9ad703a245439fd588caaf8599df_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3066f646c41949fea57b1468cb30aa61_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3114cab844d04fb094abf5ed273c4e1a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i462ca7b5109d432893cd43002d27ce96_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i143e36fc013841a18710bf40ddbee422_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3ce61f92b7b2406a94a6f87d2dd9623e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i667fa4a2085f406eb99b492e2438f438_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c435b9259f241fbad90a81868ac7e93_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i38d8fd0978ab4d4893660a6cce21b4ac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0716e0eaab47406db717f55a7cbf94ae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12ec379ba231490e890d0b394891be1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i29cc6f270f8e4052ada8d9109a7be71d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i90ded503eb9c4993b67215c3faca3095_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f59e5a852fa4290a1df65e6c201066d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4d085d14349d484c957844f0450fce23_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i646f429e54744f22989e1d0d53220bc3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i350054955cb548ee9fa3d529afd9be07_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1213fc8d77534b999d9ec3dd2556fa3d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id562cb2b7ee2435a966ee63e3c0c3331_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8744c9db8c224530b3a70c3dc9a6e821_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i176730f8aadd46128632c5ba433875c6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i26ed7f2fc0cc4fc2b518e980d510d435_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6f0d0b356cce49a8934e6af36a6e9f3f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9e32aff16cce45f1bbc5d66e0afc2090_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6733dbedc8dc49a5a3099a9d0ba22916_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifbc6413f2deb444f9703aae3ad14ffef_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i07abba9f0ad143a1bd6ac13320789ca2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9c740c841315439ab33499536b4e70a2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3396e46f9d1e40d387eef70e8d15804f_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ifba4f334917d401c815c949e200f615c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i04488b288a30423980051e6f31d6daef_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i9a8ded4399f14dd3a19c466a1b1af3e9_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="ieee62783e4544f66ab4860b55a43cd90_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7c00bf1eb48e4add853803f501de39e3_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="ifa01b284a88a485895b7e8d41c34e4e9_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmgalityPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="ie7da18cbbc67441ea99ca54c41121ad6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if922480499654c8fa72000e69a03bbe5_I20111231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-12-31</instant>
        </period>
    </context>
    <context id="i9ec7a80a2fc74972819c8c8d4ae943cb_I20120731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:WhyteEtAlVEliLillyEtAlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-07-31</instant>
        </period>
    </context>
    <context id="ia2d0b9f9d00c4789a57ac22dffd8de57_I20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:WeilerVTakedaCanadaIncEtAlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="id492c2aa322440ef91df2d2864ae3436_I20130131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EppVTakedaCanadaIncEtAlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ActosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-01-31</instant>
        </period>
    </context>
    <context id="i02631251065446e8b80c3ef3bde18d1e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id08a7fa5ef244fbdb2e5f2a1bf85908a_D20090301-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5a6d539b9e9b4a2e9a56aa47022fef97_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:LosAngelesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i57962c6f806042039b9a5e06a4c746f8_D20090301-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:LosAngelesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5cebe969b12a4a35a83f8a3e3a6c1d34_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:SouthernDistrictOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6a303e3d333446bd9c148cdb72de62b9_D20090301-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:SouthernDistrictOfCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie6b528e1289547a7a6c8125628509fe4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i823025d06a794591a0b79f3627915cb6_D20090301-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:DomicileOfLitigationAxis">lly:VariousStateDomicilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ide3640818e464610a65948e49215fb32_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreaticCancerOrThyroidCancerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iec6231ab796440cea08cae552c4f7aec_D20090301-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreaticCancerOrThyroidCancerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4e401371e97c43e0b9c5ea15f0b54e42_D20090301-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:PancreatitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7b351247f73c46c28ff4f882e37804b1_D20090301-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:ByettaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lly:PlaintiffAllegationsAxis">lly:AmpullaryCancerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id877b0b6a111490cbd371689fd76bb41_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:CialisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0974ec7e0d754316996a9ed48591b15f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:JardianceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">lly:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic2caaa0461b646bfa03a4e4b72b0fd0c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4c05f03242a6456dbd827f3bfc73638e_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="ib5389c2f3f2b4fecaa12712374100b27_D20210930-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-30</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic5db0916c42c432ab0d7c4f60ea69486_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i0b7f344f3e4a4d4489bf483eb893bcbc_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3fa1d97abf9842288bcab6b2233d933e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:EmployeeLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i67de38ae9b6847fc8362e05564887711_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:HumalogHumulinAndForteoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2330339854444106911984ac8d431494_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lly:InsulinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i13bb526970b946c4a88c0fdfe320bd02_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lly:DrReddysLabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibeb5ba7c9ba14c15ba0052fa193204e3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i55fb2a4e7d5a40df8b249f3933bb08b6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i44dd2692507f4266b4a6a0fbf0fee907_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic193e7bc5e094826be326aee4fe41f2e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibc4a62ea3c3045fcb1975315d8b1874c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibdb47e6e63294d44a8f97f9e50e54a83_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i75e7048b106947fda1b1b5e4eabdc0fc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if4b8f930c8cb4479ac83208582a7d734_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6fcde9e91e224331bee5a8adc7892978_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie6bf89817cf74679b6916eddd60558c9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibd2e85aa71f446bdbb141da8010fbe3d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic375cded995a4df69d3eae9edc6766c7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4d2760fb44974a73a735787c71ae8f1a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4b11f523dfe64ce792a038f20fbc68b5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4a35afc361544badb9c16d04e8aad497_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i717939ea3d4e4bb3b1b65e0a974da3c2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i37fc3dd032964801aa1348f510cb122b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8bee3c9d23994e78baa2eba95869bd9b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib1106ce810ad4da5852f6b633b316eee_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8dc5691b17b74c35ad24aafdbf59f3fe_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic3759b3a7e2f43dcb3def496f0e66523_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2b09b2d2f1f840c7ae5d5461b2c17a11_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idbffb928c8ef4db9847f4474b9b3c4f7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i749e85ac79ee42a29981a1a54fe12f89_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if2e49dd86e464c6b8eb00c81c2ba5106_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i28164fe940424f16b215cb55adf86237_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i95f3c6593b4b487dae8900c3ac61ac05_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i92bb29baa2584750986eee75a3d6e4ce_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id65902a544ed43ceb02d93ffc0a552e7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9a29af9f964348b0945d6e3a688d0920_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id528bf4c135048229335007002573a24_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib1814bfd7e734e99af54e8b90a4f5ba1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic30630769098404a82485baedba6de39_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i343f9384f69a4fbea834e4b74393c357_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i55f74de7b4534040af7ed40631285711_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i42d644c1be1b47929fd7f33b4aa7934f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibb7a26b32e694ddf89ed67424b0f6153_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2d711cf47db44ea8a7769cdcc03215c2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1398a4cb6b3b4f82aaf46f5f2990e359_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7b2773f7cce247f2b474587bc25ee417_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i11592af1b8584d8e941ac285b2b9ff5f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if60b5c4e32da4c9aaf3a96926acf3f56_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9f358682845c429a9e682d2659872229_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifd8c50c7162047369d212f2103eba93f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia57652e4c70f423c8b2fd6f637a90a05_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib297cf9f9edb4c749f2a81b2e539ced2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i22630c35f56443229b86ee022e4155d1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5b485bf17c5749a699e26a1df2e648da_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6ff88e97ce21499da1d1b1bdb8a2824f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if57b47926a4847e78d8dcd2326b16c65_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5dbc75b54c4a4c39a56bbd8e3006acba_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i412a43d01f8c4978b95b1d9b22b6028e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic8ed2c03cd8446b992f8ed65b4226a3e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia29720c84e08498b8a3c6e661a3fe7bd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i15dc1b0ac6eb41bab90c9964ded2067d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9ecbb90470a94e7780adb982e83ad4eb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6c3769918b9d406e90beab010e76b7de_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3be6ddfb286c465fa67388157f156b71_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3b999b38b45f48d6b4eacb839d5ae8ef_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4e909ad38be242f4935ee1c7e0dfc3c7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idf900552e5704e3b83f6dd3f56cfb8b1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibc20efde344e4966b2390b23bdfad980_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i846634e73e214b8b9dde808125858a45_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifed88205905a4275ba8c331b5dbd8547_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaaec30f04bf644fea6c5f2229258f4b8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i129d769168bb4388b55fa2891a6051bc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lly:AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9611b430044e49a384caf7309cee05ff_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9d84b8a802d54abdb0af6d412798b456_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3e9e954fc084405785c8bdfb174f2726_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i99b24dcf85424c689a8236968bfe8b4d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="right">
        <measure>lly:right</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="cny">
        <measure>iso4217:CNY</measure>
    </unit>
    <unit id="jpy">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="patent">
        <measure>lly:patent</measure>
    </unit>
    <unit id="decision">
        <measure>lly:decision</measure>
    </unit>
    <unit id="lawsuit">
        <measure>lly:lawsuit</measure>
    </unit>
    <unit id="plaintiff">
        <measure>lly:plaintiff</measure>
    </unit>
    <unit id="claimant">
        <measure>lly:claimant</measure>
    </unit>
    <unit id="site">
        <measure>lly:site</measure>
    </unit>
    <unit id="brl">
        <measure>iso4217:BRL</measure>
    </unit>
    <unit id="claim">
        <measure>lly:claim</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80L2ZyYWc6YzE4M2RjOThlOWViNDM1MjgyYzgyM2I5NWZiNTMzZDEvdGFibGU6NjJkNDVlN2Q0MWNmNDY2Njg0ZGFmN2Q0NWE3YTk1ZWMvdGFibGVyYW5nZTo2MmQ0NWU3ZDQxY2Y0NjY2ODRkYWY3ZDQ1YTdhOTVlY18zLTEtMS0xLTE_2d2a7254-7d9a-4aaa-9102-df902cb79d94">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80L2ZyYWc6YzE4M2RjOThlOWViNDM1MjgyYzgyM2I5NWZiNTMzZDEvdGFibGU6NjJkNDVlN2Q0MWNmNDY2Njg0ZGFmN2Q0NWE3YTk1ZWMvdGFibGVyYW5nZTo2MmQ0NWU3ZDQxY2Y0NjY2ODRkYWY3ZDQ1YTdhOTVlY180LTEtMS0xLTE_7d5d6d3e-b874-4096-9353-4e38adb404e5">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80L2ZyYWc6YzE4M2RjOThlOWViNDM1MjgyYzgyM2I5NWZiNTMzZDEvdGFibGU6NjJkNDVlN2Q0MWNmNDY2Njg0ZGFmN2Q0NWE3YTk1ZWMvdGFibGVyYW5nZTo2MmQ0NWU3ZDQxY2Y0NjY2ODRkYWY3ZDQ1YTdhOTVlY181LTEtMS0xLTE_c815e478-01e0-41a7-96a3-28346cc5ed9b">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80L2ZyYWc6YzE4M2RjOThlOWViNDM1MjgyYzgyM2I5NWZiNTMzZDEvdGFibGU6NjJkNDVlN2Q0MWNmNDY2Njg0ZGFmN2Q0NWE3YTk1ZWMvdGFibGVyYW5nZTo2MmQ0NWU3ZDQxY2Y0NjY2ODRkYWY3ZDQ1YTdhOTVlY182LTEtMS0xLTE_f8d4b19c-ecbc-4209-83a2-a5e84f2d07f9">0000059478</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80L2ZyYWc6YzE4M2RjOThlOWViNDM1MjgyYzgyM2I5NWZiNTMzZDEvdGFibGU6NjJkNDVlN2Q0MWNmNDY2Njg0ZGFmN2Q0NWE3YTk1ZWMvdGFibGVyYW5nZTo2MmQ0NWU3ZDQxY2Y0NjY2ODRkYWY3ZDQ1YTdhOTVlY183LTEtMS0xLTE_c510a59d-5daa-4957-a37e-34563ce60f09">--12-31</dei:CurrentFiscalYearEndDate>
    <lly:LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm
      contextRef="i13bb526970b946c4a88c0fdfe320bd02_D20191201-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83Ni9mcmFnOmQ5YTM1OTUwMDNmOTRjMWY5NGM2NTcxYjIwNGMxNzU0L3RleHRyZWdpb246ZDlhMzU5NTAwM2Y5NGMxZjk0YzY1NzFiMjA0YzE3NTRfNTA3_71b706d2-671a-4cfb-9a07-6a78cd599e24">P21D</lly:LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm>
    <dei:DocumentType
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDM0_adb3021a-e2e4-458e-826b-0e5e73b3b007">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDM2_7b706731-56eb-40a1-aa0c-5985c4520aed">true</dei:DocumentQuarterlyReport>
    <dei:DocumentTransitionReport
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDM2_ca9e0923-21e1-496f-a02d-679b615f644f">false</dei:DocumentTransitionReport>
    <dei:DocumentPeriodEndDate
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMTA_ac0fdd48-7c72-4272-bae2-3540a618976b">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:EntityFileNumber
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDM4_4eb20bdd-67fe-4a08-aa77-5034541c66d8">001-6351</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDM5_77e58531-ec70-4c54-b2e4-74603b597aa7">ELI LILLY AND COMPANY</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6Mzg2NDgzM2VhYTdiNGM0YTk1YzM0M2YzNmE1ZGFjYTgvdGFibGVyYW5nZTozODY0ODMzZWFhN2I0YzRhOTVjMzQzZjM2YTVkYWNhOF8wLTAtMS0xLTE_a2e1e443-4d97-47de-a6c1-d73cb28e6868">IN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6Mzg2NDgzM2VhYTdiNGM0YTk1YzM0M2YzNmE1ZGFjYTgvdGFibGVyYW5nZTozODY0ODMzZWFhN2I0YzRhOTVjMzQzZjM2YTVkYWNhOF8wLTItMS0xLTE_31231fc9-660c-43a4-8fdb-c60a87cd958b">35-0470950</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDQy_be9ca824-c7f6-4e0b-900b-8067e6003502">Lilly Corporate Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDQw_582d1ebb-c06a-4b6b-a3bb-1021c4170cf9">Indianapolis</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDQz_ed3f926e-e5eb-4d04-b906-bc24d5d1a3f8">IN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDQ0_7a254437-8ea5-42a9-bc84-d19f458d55b9">46285</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDQ1_42050a59-75a5-4cf0-b270-3d055e8a27f9">317</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDQ2_80123cfa-6062-437e-8b59-f65bd7ffc96a">276-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i5f70d4ddb50548fc9ed454e70437d29f_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18xLTAtMS0xLTE_c382913e-1a3d-4197-a50f-183877d3b9fe">Common Stock (no par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5f70d4ddb50548fc9ed454e70437d29f_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18xLTEtMS0xLTE_c61557d6-7e69-4c5a-a233-c26f4d0c6ef6">LLY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i5f70d4ddb50548fc9ed454e70437d29f_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18xLTItMS0xLTE_65afef7b-2c80-47f8-abb4-91aced52358e">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="iee28461a11ce40dd892a5d1af3d82bc3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18yLTAtMS0xLTE_1a1bfc7c-064b-4c9b-b958-bbc1c0594a43">1.000% Notes due 2022</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iee28461a11ce40dd892a5d1af3d82bc3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18yLTEtMS0xLTE_30948371-ec84-4cd0-b6a8-3dbd7ac0d9e1">LLY22</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iee28461a11ce40dd892a5d1af3d82bc3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18yLTItMS0xLTE_9fc5dee8-4ffe-43a9-ac78-b0c28ab56677">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i3a43a3f2ce8e49b3b401dcf8182bda5e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18zLTAtMS0xLTE_c5aabe85-9111-4292-9591-2b80015e698f">7 1/8% Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i3a43a3f2ce8e49b3b401dcf8182bda5e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18zLTEtMS0xLTE_f552ca04-13d3-40eb-b7a2-39bf08645348">LLY25</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i3a43a3f2ce8e49b3b401dcf8182bda5e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18zLTItMS0xLTE_26be8a93-7fd0-4e2a-b120-0bb24ca46f3f">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="icb1af12eeba04c0f906f5e5eb7425b07_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN180LTAtMS0xLTE_dd0acf62-bbf3-43e6-80a3-9080a67d6442">1.625% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="icb1af12eeba04c0f906f5e5eb7425b07_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN180LTEtMS0xLTE_5605af12-bedf-4010-a351-a72f1eeaabfb">LLY26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="icb1af12eeba04c0f906f5e5eb7425b07_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN180LTItMS0xLTE_84e53497-ace4-4136-9aa1-4ac271b28856">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i753e0f88d69d41e891ceddd7541604a2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN181LTAtMS0xLTE_2172b1d5-480c-47e5-a41e-44679705dd73">2.125% Notes due 2030</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i753e0f88d69d41e891ceddd7541604a2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN181LTEtMS0xLTE_01e947eb-409c-44a6-9a0c-f2c3f84ac87b">LLY30</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i753e0f88d69d41e891ceddd7541604a2_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN181LTItMS0xLTE_069bf895-a39e-473b-8bc0-b2c031c2d619">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i66895af514214364a9f5110c5ce8708d_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN182LTAtMS0xLTE_74706c88-48fd-44af-a901-42b0870dbe95">0.625% Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i66895af514214364a9f5110c5ce8708d_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN182LTEtMS0xLTE_cd1da11d-1a01-43ef-9393-6fd3f6aaa924">LLY31</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i66895af514214364a9f5110c5ce8708d_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN182LTItMS0xLTE_1d681337-2ca8-4829-8eb6-7372c07afb6b">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i7531f4ca382a43839cf3a3b4014bb13b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN183LTAtMS0xLTMxNzgy_89c591b2-15ea-4891-b871-617c61ff1300">0.500% Notes due 2033</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7531f4ca382a43839cf3a3b4014bb13b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN183LTEtMS0xLTMxNzgy_1042648d-6c35-4a9e-af66-df6aabd176cf">LLY33</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i7531f4ca382a43839cf3a3b4014bb13b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN183LTItMS0xLTMxNzgy_39b77007-b947-4ee8-8d1e-3673d02b9dfd">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i972a26e5571a4689b6a657c98879bc5b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN183LTAtMS0xLTE_5a2dad99-63cf-4a12-b227-c35448074bfd">6.77%&#160;Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i972a26e5571a4689b6a657c98879bc5b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN183LTEtMS0xLTE_a64b01d9-af21-4d2c-b47c-71d03fdb252e">LLY36</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i972a26e5571a4689b6a657c98879bc5b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN183LTItMS0xLTE_76c09442-918c-4d42-b80c-305b0120aba8">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="idd06d4fd694d41f1b11ae0159a256cbf_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN185LTAtMS0xLTMxNzg0_9de8bb6e-6e58-4cea-a7ab-863470ea953a">1.625% Notes due 2043</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="idd06d4fd694d41f1b11ae0159a256cbf_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN185LTEtMS0xLTMxNzg0_c34febc0-46e2-47b3-89fa-16257289c14e">LLY43</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="idd06d4fd694d41f1b11ae0159a256cbf_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN185LTItMS0xLTMxNzg0_eadf7203-ce56-4873-9cf4-4bac758559c5">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="iff4a44c5161c49a984d21cfcdf9ec6cc_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN184LTAtMS0xLTE_e14bf815-0f39-4df3-941e-087d8102fcdd">1.700% Notes due 2049</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iff4a44c5161c49a984d21cfcdf9ec6cc_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN184LTEtMS0xLTE_4333a664-b7fc-4a2e-9784-3a26f65a7634">LLY49A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iff4a44c5161c49a984d21cfcdf9ec6cc_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN184LTItMS0xLTE_81acc779-7e25-443b-aed1-676547b27c3a">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="iec85e79d1f4b4520aaed094ce2211f85_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18xMS0wLTEtMS0zMTc4Ng_4483e6d9-0540-4f12-be29-fbe104694bc5">1.125% Notes due 2051</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iec85e79d1f4b4520aaed094ce2211f85_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18xMS0xLTEtMS0zMTc4Ng_c430338a-1d30-4281-9a40-6b79c2352596">LLY51</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iec85e79d1f4b4520aaed094ce2211f85_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18xMS0yLTEtMS0zMTc4Ng_66c76faf-37a7-4765-8c6b-92462359843d">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i26ec5aeeab074242968c82cb92e236a7_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18xMi0wLTEtMS0zMTc4OA_e2f2ef25-dcae-4bc4-bc45-2b1007cfdfba">1.375% Notes due 2061</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i26ec5aeeab074242968c82cb92e236a7_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18xMi0xLTEtMS0zMTc4OA_4d408d15-9570-483c-b2d6-b5ca557e72fb">LLY61</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i26ec5aeeab074242968c82cb92e236a7_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZjhlMDYyZWQ5Mzc2NDUyMGJiODEzOTc3ZDdjYzMyZDcvdGFibGVyYW5nZTpmOGUwNjJlZDkzNzY0NTIwYmI4MTM5NzdkN2NjMzJkN18xMi0yLTEtMS0zMTc4OA_2ff67aa7-a04c-4633-a417-23ca49e323e7">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDQx_b938ede1-2717-492b-8aef-7b9479ed72bd">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDM1_616f66ad-eb54-4cff-8374-0a483436dce6">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZGZlNDBmNjI2YmJjNDY2Zjg2ZTVmYzhkYTVhYjVjMDIvdGFibGVyYW5nZTpkZmU0MGY2MjZiYmM0NjZmODZlNWZjOGRhNWFiNWMwMl8wLTAtMS0xLTE_d6e242be-699a-4a20-a95f-8a025e4748c6">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZGZlNDBmNjI2YmJjNDY2Zjg2ZTVmYzhkYTVhYjVjMDIvdGFibGVyYW5nZTpkZmU0MGY2MjZiYmM0NjZmODZlNWZjOGRhNWFiNWMwMl8xLTctMS0xLTE_85d39978-42ea-4d33-89d4-9b8a8aa1f72f">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6ZGZlNDBmNjI2YmJjNDY2Zjg2ZTVmYzhkYTVhYjVjMDIvdGFibGVyYW5nZTpkZmU0MGY2MjZiYmM0NjZmODZlNWZjOGRhNWFiNWMwMl8yLTctMS0xLTE_27696ad2-d0bd-4cb7-ab5b-b69c9fb06f20">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGV4dHJlZ2lvbjo2NzY2NTk3YWU5M2M0YzFjYjM5MWMxN2ZiMTFjMmIyY18yMDQ3_5fdba16c-70b5-4e53-bd26-f470c4b99529">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i738a150fa85d48f491f84c759c959068_I20211022"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xL2ZyYWc6Njc2NjU5N2FlOTNjNGMxY2IzOTFjMTdmYjExYzJiMmMvdGFibGU6MzM3NzA5MTlhN2Q3NGNlYThiMmRlNmNlMTZmZmY4YjQvdGFibGVyYW5nZTozMzc3MDkxOWE3ZDc0Y2VhOGIyZGU2Y2UxNmZmZjhiNF8xLTItMS0xLTE_9b8f825c-77c3-473a-84b8-95a974f53f73"
      unitRef="shares">956592393</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMi0xLTEtMS0x_6aeb8430-dd3c-44ab-aa58-9ce5c77bf6a9"
      unitRef="usd">6772800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMi0zLTEtMS0x_acd27e42-404e-4fb3-9253-a5d40b075fe6"
      unitRef="usd">5740600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMi01LTEtMS0x_5bdd77e2-deaa-444f-aa4a-9a210a3243ac"
      unitRef="usd">20318500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMi03LTEtMS0x_35de0b63-a9e5-44e5-a748-93e721083fac"
      unitRef="usd">17099800000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNC0xLTEtMS0x_2450fdf9-f95e-4642-90f4-c4552791a1ab"
      unitRef="usd">1430800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNC0zLTEtMS0x_4e2241e0-f7b7-4a52-a9b9-dd05e13c98be"
      unitRef="usd">1326400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNC01LTEtMS0x_8a9eaf21-35b8-41e4-93e1-36a64e0982ad"
      unitRef="usd">5262600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNC03LTEtMS0x_b3ff789a-dab4-4152-a5db-71566736c235"
      unitRef="usd">3763500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNS0xLTEtMS0x_3ad3de67-5405-42ea-ba44-8fb47d397dc2"
      unitRef="usd">1708900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNS0zLTEtMS0x_ee61019f-b124-4500-b377-1e1890e34587"
      unitRef="usd">1465400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNS01LTEtMS0x_2851d719-8873-448d-aa73-8b7c87827c57"
      unitRef="usd">5066500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNS03LTEtMS0x_4c14624c-0605-4982-9d35-1763400bd254"
      unitRef="usd">4247700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNi0xLTEtMS0x_c4d03752-9cbb-40a8-b380-ad039a587558"
      unitRef="usd">1577900000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNi0zLTEtMS0x_a6a9f990-79af-4d69-836b-7de9489a218a"
      unitRef="usd">1569100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNi01LTEtMS0x_4d6e4b4c-5cf3-42f9-930e-0dea7b11fc2b"
      unitRef="usd">4839600000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNi03LTEtMS0x_b24cc544-35b1-42ee-94a6-4f960dacb812"
      unitRef="usd">4567300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNy0xLTEtMS0x_ca0d0149-f521-4af5-8a2c-09ad60317e17"
      unitRef="usd">174000000.0</lly:AcquiredInProcessResearchAndDevelopment>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNy0zLTEtMS0x_9fa2bb95-129a-4f30-9058-aa4b73f0bcf2"
      unitRef="usd">0</lly:AcquiredInProcessResearchAndDevelopment>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNy01LTEtMS0x_c04be530-a582-47e4-8ba9-68a4bb76dee8"
      unitRef="usd">498300000</lly:AcquiredInProcessResearchAndDevelopment>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfNy03LTEtMS0x_2b31f7cb-e289-44c9-adc9-8dcfc07687fe"
      unitRef="usd">294100000</lly:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfOC0xLTEtMS0x_e8f704f0-82ee-411a-9fac-6ae1951528b0"
      unitRef="usd">0</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfOC0zLTEtMS0x_debab27b-55f7-4ece-8244-ede7484909ef"
      unitRef="usd">101400000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfOC01LTEtMS0x_4b5c5abb-3e3e-482e-bf1d-9d9eb8a13f2d"
      unitRef="usd">211600000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfOC03LTEtMS0x_0994ef60-2e2b-4540-bf15-87f330dc6a87"
      unitRef="usd">161300000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfOS0xLTEtMS0x_ad5733dc-bbb4-4d96-894e-91b7f2df9089"
      unitRef="usd">-635900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfOS0zLTEtMS0x_c36f78f0-b792-4e63-b896-60c712da1b85"
      unitRef="usd">158900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfOS01LTEtMS0x_519470d4-2aae-4079-b8f2-04275653e4f5"
      unitRef="usd">-124300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfOS03LTEtMS0x_80b430be-1e60-45c5-b8d8-943ec8cb8ed1"
      unitRef="usd">694900000</us-gaap:NonoperatingIncomeExpense>
    <lly:CostOfSalesOperatingExpensesAndOtherNet
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTAtMS0xLTEtMQ_1aa77ffa-dee2-48ee-9ba2-3b5197e4211c"
      unitRef="usd">5527500000</lly:CostOfSalesOperatingExpensesAndOtherNet>
    <lly:CostOfSalesOperatingExpensesAndOtherNet
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTAtMy0xLTEtMQ_ac13915e-0efb-45b5-9710-6f721449d048"
      unitRef="usd">4303400000</lly:CostOfSalesOperatingExpensesAndOtherNet>
    <lly:CostOfSalesOperatingExpensesAndOtherNet
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTAtNS0xLTEtMQ_d96d074f-aba2-4677-97e0-685310d463b0"
      unitRef="usd">16002900000</lly:CostOfSalesOperatingExpensesAndOtherNet>
    <lly:CostOfSalesOperatingExpensesAndOtherNet
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTAtNy0xLTEtMQ_167f4a8f-87e2-458f-9d9b-44b8b3beabbc"
      unitRef="usd">12339000000</lly:CostOfSalesOperatingExpensesAndOtherNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTEtMS0xLTEtMQ_5ba62958-7021-4bbd-b583-631e6c5f47e2"
      unitRef="usd">1245300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTEtMy0xLTEtMQ_5b308398-663a-4b4d-a7f1-feb644108d7d"
      unitRef="usd">1437200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTEtNS0xLTEtMQ_b510b444-615d-4832-92db-b5458b47072c"
      unitRef="usd">4315600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTEtNy0xLTEtMQ_64aade7f-4134-4f1b-b190-0462f866cbce"
      unitRef="usd">4760800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTItMS0xLTEtMQ_df685639-aeb9-4ecf-a271-7faf1715983d"
      unitRef="usd">135200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTItMy0xLTEtMQ_e457ab0e-3672-4277-8a32-283f81cd9ae2"
      unitRef="usd">228800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTItNS0xLTEtMQ_48550cd0-49c3-4be8-b938-416fb2af7d8e"
      unitRef="usd">460000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTItNy0xLTEtMQ_97b1a3f0-8c07-42ad-9ebb-0d9222187529"
      unitRef="usd">683900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTMtMS0xLTEtMQ_cfd3584d-b56b-4e13-8892-db2023353fec"
      unitRef="usd">1110100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTMtMy0xLTEtMQ_b2df48c3-3c8e-4e98-a604-230a293e0fda"
      unitRef="usd">1208400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTMtNS0xLTEtMQ_9d9c01e8-30fe-4af4-a5d8-77d110a52905"
      unitRef="usd">3855600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTMtNy0xLTEtMQ_8e0722b4-dd6b-4494-9a41-b76186fad467"
      unitRef="usd">4076900000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTgtMS0xLTEtMQ_0b8f33f8-1334-4126-8acc-5c99751b30f3"
      unitRef="usdPerShare">1.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTgtMy0xLTEtMQ_be253913-3d2d-48d3-99fd-7ad1dfbb7d91"
      unitRef="usdPerShare">1.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTgtNS0xLTEtMQ_449bdca5-fc31-4c6b-8b9a-1ee5c9fa57fd"
      unitRef="usdPerShare">4.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMTgtNy0xLTEtMQ_b2912f51-2185-4dde-b499-588c8c98965c"
      unitRef="usdPerShare">4.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjAtMS0xLTEtMQ_6edd7764-0eac-457d-9093-092e4476bbaf"
      unitRef="usdPerShare">1.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjAtMy0xLTEtMQ_1809cfb1-8234-4674-9321-eb1273eeecd5"
      unitRef="usdPerShare">1.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjAtNS0xLTEtMQ_8cb935fc-24e6-4f66-827b-06037e7bdb2c"
      unitRef="usdPerShare">4.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjAtNy0xLTEtMQ_fd2d9614-1d60-4a77-af9d-2dcbd278f001"
      unitRef="usdPerShare">4.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjQtMS0xLTEtMQ_34fc6d9f-b73b-46b9-bb03-645405a5e299"
      unitRef="shares">906700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjQtMy0xLTEtMQ_03072602-53b1-40e6-b2fb-974f4f8fcf45"
      unitRef="shares">907200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjQtNS0xLTEtMQ_bd017fde-2b27-4f2d-aad0-ba809d1cc720"
      unitRef="shares">907700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjQtNy0xLTEtMQ_d5d6dfab-16d0-4154-9276-5d213a46e2a8"
      unitRef="shares">907500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjUtMS0xLTEtMQ_fd786269-6e83-46fe-8d74-e4c006f453cb"
      unitRef="shares">910800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjUtMy0xLTEtMQ_40383998-5b8e-4d78-9789-86f231802724"
      unitRef="shares">911400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjUtNS0xLTEtMQ_00882621-3a68-4235-9d82-2072b62f7237"
      unitRef="shares">911700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8xOS9mcmFnOjRkMDk5NDhkZjVhMDQxZjI5NmM2YmQxNDVlYWM3YjUwL3RhYmxlOjY5MzQ2NmM1MDg5YjRhYzNiNjkwNjFjNGZiZWI2MWVmL3RhYmxlcmFuZ2U6NjkzNDY2YzUwODliNGFjM2I2OTA2MWM0ZmJlYjYxZWZfMjUtNy0xLTEtMQ_bf5777a3-a4dd-44f8-91bd-5da720f3b425"
      unitRef="shares">911900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfMi0xLTEtMS0x_cfd3584d-b56b-4e13-8892-db2023353fec"
      unitRef="usd">1110100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfMi0zLTEtMS0x_b2df48c3-3c8e-4e98-a604-230a293e0fda"
      unitRef="usd">1208400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfMi01LTEtMS0x_ccb5166e-02ef-4b55-a83a-a814596383f9"
      unitRef="usd">3855600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfMi03LTEtMS0x_1181b960-27ea-45cd-9b6c-1981e62b1388"
      unitRef="usd">4076900000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfMy0xLTEtMS0x_f3d6ad8b-0fac-452f-90bc-f98903c71b32"
      unitRef="usd">114400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfMy0zLTEtMS0x_96417fcf-1898-4487-9014-84f5a5c8f80d"
      unitRef="usd">127800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfMy01LTEtMS0x_20573a15-0396-45ea-944a-b50c2dcb3e58"
      unitRef="usd">323700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfMy03LTEtMS0x_b454d558-6681-45b0-8d00-d44cba898998"
      unitRef="usd">-31500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfNC0xLTEtMS0x_137a9f4b-8805-4541-afc7-56f36d41793d"
      unitRef="usd">1224500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfNC0zLTEtMS0x_4f0141d1-a1e5-45ae-ad99-d8022b943c14"
      unitRef="usd">1336200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfNC01LTEtMS0x_6bfba242-fdce-47cf-a895-705ccafaed59"
      unitRef="usd">4179300000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yMi9mcmFnOjdmZmQ1ZjJhMjkzYTRlMGRiMjUyMDg1ZTU1OTdhYWFlL3RhYmxlOjc5ZjcyMDVhYjM3MzRkYWViZmNjNzMyN2FmYTg2M2VkL3RhYmxlcmFuZ2U6NzlmNzIwNWFiMzczNGRhZWJmY2M3MzI3YWZhODYzZWRfNC03LTEtMS0x_61bc5c84-a765-4576-a8d0-9aeaca1184cb"
      unitRef="usd">4045400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMy0xLTEtMS0x_eb254b0c-5207-473a-adb1-781a6d17562f"
      unitRef="usd">3788200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMy0zLTEtMS0x_64f312ae-4b59-475a-a998-bb7d3fdbdb72"
      unitRef="usd">3657100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNC0xLTEtMS0x_01d00118-b4d2-4fa6-bf36-80c8625ef6d2"
      unitRef="usd">37100000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNC0zLTEtMS0x_834ed4fc-3ccf-4908-ab0c-a84ca1302798"
      unitRef="usd">24200000</us-gaap:ShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNS0wLTEtMS0xL3RleHRyZWdpb246MzM4NmM1ODY4MjBmNDFjYzg5ZjRkZmQ5YjQ2ZTFmZWVfNDY_1a6fb4cd-2286-4de1-99da-27716e318084"
      unitRef="usd">24100000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNS0wLTEtMS0xL3RleHRyZWdpb246MzM4NmM1ODY4MjBmNDFjYzg5ZjRkZmQ5YjQ2ZTFmZWVfNjA_92157756-a1ab-4bd7-9133-e46081625d2c"
      unitRef="usd">25900000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNS0xLTEtMS0x_0870d42b-a566-4c11-bec3-12a45d5a4b2e"
      unitRef="usd">5914300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNS0zLTEtMS0x_3a509a43-9037-4f79-9f91-1b92468b2a33"
      unitRef="usd">5875300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNi0xLTEtMS0x_67040dce-b835-40da-ac87-5c55c22bc3b4"
      unitRef="usd">1110700000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNi0zLTEtMS0x_f044ec56-cd7c-4f76-8106-19ce43767ebe"
      unitRef="usd">1053700000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNy0xLTEtMS0x_1aeab4bb-4ccc-4d09-9946-3965ae57e684"
      unitRef="usd">3907400000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNy0zLTEtMS0x_250b3dae-bf1c-49f0-beed-c7d24997e6f9"
      unitRef="usd">3980300000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfOC0xLTEtMS0x_0099710c-e745-4000-8f8d-a32c75676c9a"
      unitRef="usd">3050600000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfOC0zLTEtMS0x_c52c4f92-8b55-46ce-bbe0-84696cc69df5"
      unitRef="usd">2871500000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfOS0xLTEtMS0x_2bb75d83-0f92-45f4-a6e7-c3bd5936a3db"
      unitRef="usd">17808300000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfOS0zLTEtMS0x_91dab63d-c9c7-47c5-93d5-44bbf065f4e2"
      unitRef="usd">17462100000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTAtMS0xLTEtMQ_24ad9b03-4781-43be-ba4d-dc5310ec4c59"
      unitRef="usd">3350500000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTAtMy0xLTEtMQ_5af00377-d991-4423-80da-ba6590672526"
      unitRef="usd">2966800000</us-gaap:LongTermInvestments>
    <us-gaap:Goodwill
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTEtMS0xLTEtMQ_cc695948-4b67-43db-8ae9-9fb4e1a786b7"
      unitRef="usd">3884100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTEtMy0xLTEtMQ_b7d7803b-fb68-4de8-a740-b8026229f509"
      unitRef="usd">3766500000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTItMS0xLTEtMQ_4df70616-d9de-4bcb-b259-a0b3662cc883"
      unitRef="usd">7887700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTItMy0xLTEtMQ_848feb6e-3920-46a4-ace8-bc842cf77a56"
      unitRef="usd">7450000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTMtMS0xLTEtMQ_a45709e0-17e7-440c-825d-b8d4374db0a8"
      unitRef="usd">2625600000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTMtMy0xLTEtMQ_51904687-b14c-46eb-aad2-6d5fa7620ab3"
      unitRef="usd">2830400000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTQtMC0xLTEtMS90ZXh0cmVnaW9uOjc2NDEzNGFkNGY5ZjQyNGI5NjUwYjIxYmU5NWNkNGFmXzYz_b89867a5-49e5-4b54-852a-cfe23c40a1c7"
      unitRef="usd">9962800000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTQtMC0xLTEtMS90ZXh0cmVnaW9uOjc2NDEzNGFkNGY5ZjQyNGI5NjUwYjIxYmU5NWNkNGFmXzc3_4fd5196a-7988-491e-a8fc-e05c6f841334"
      unitRef="usd">9570700000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTQtMS0xLTEtMQ_26a71930-dbe4-4805-864c-c8d027aa5a4d"
      unitRef="usd">8920400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTQtMy0xLTEtMQ_6f09a6e6-d2cd-4f31-b072-c7b036ee9833"
      unitRef="usd">8681900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTUtMS0xLTEtMQ_7778efdc-1de6-4037-a635-256e1dbe099c"
      unitRef="usd">3710400000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTUtMy0xLTEtMQ_a2020b07-b7e8-4e91-a893-c81ee12ae4fe"
      unitRef="usd">3475400000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTYtMS0xLTEtMQ_fd2898b3-b014-492b-94cd-51c5c78b6c4b"
      unitRef="usd">48187000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTYtMy0xLTEtMQ_11009ad8-7265-467f-be75-f698fbc98648"
      unitRef="usd">46633100000</us-gaap:Assets>
    <us-gaap:DebtCurrent
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTktMS0xLTEtMQ_2521087c-e3eb-4107-b662-eb1627522656"
      unitRef="usd">1563000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMTktMy0xLTEtMQ_10b8920f-d7c9-45f1-89f2-a58bed64f25d"
      unitRef="usd">8700000</us-gaap:DebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjAtMS0xLTEtMQ_b44c2e82-dce8-49ef-a7e9-621fa848c62c"
      unitRef="usd">1566800000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjAtMy0xLTEtMQ_38e694f1-fc2a-43e8-b528-c8e5f055b79f"
      unitRef="usd">1606700000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjEtMS0xLTEtMQ_92607218-efe9-4bcf-b865-24a3b4a148cb"
      unitRef="usd">836600000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjEtMy0xLTEtMQ_7787c8a4-406e-428b-ad4a-92106efdb4f7"
      unitRef="usd">997200000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <lly:SalesRebatesAndDiscounts
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjItMS0xLTEtMQ_291a0eaa-7bef-42de-9b61-6c21d3195e5c"
      unitRef="usd">7185600000</lly:SalesRebatesAndDiscounts>
    <lly:SalesRebatesAndDiscounts
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjItMy0xLTEtMQ_e0960acb-f51d-4da8-a669-99e85a0db439"
      unitRef="usd">5853000000</lly:SalesRebatesAndDiscounts>
    <us-gaap:DividendsPayableCurrent
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjMtMS0xLTEtMQ_5f3c371b-4b69-425b-9b4a-2135bce5afd7"
      unitRef="usd">0</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjMtMy0xLTEtMQ_d46634bf-093b-4407-8fef-ffc6d5382406"
      unitRef="usd">770600000</us-gaap:DividendsPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjQtMS0xLTEtMQ_d085075a-a305-4cd4-bf31-88b784ae0b7d"
      unitRef="usd">203500000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjQtMy0xLTEtMQ_0875ea10-3858-4398-adbb-d4f55bfef975"
      unitRef="usd">495100000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjUtMS0xLTEtMQ_140855e7-c0d8-41f6-99ac-78b996c1841a"
      unitRef="usd">2326500000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjUtMy0xLTEtMQ_25b9579a-1b5c-4c17-9c45-bbd070daac1d"
      unitRef="usd">2750300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjYtMS0xLTEtMQ_28bcea19-8eaa-4438-a7bb-efa8998aa9be"
      unitRef="usd">13682000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjYtMy0xLTEtMQ_35d078ba-6f79-4b36-b77f-54848b3e1bb5"
      unitRef="usd">12481600000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjgtMS0xLTEtMQ_1fb454ff-3489-421b-900b-5886451d184f"
      unitRef="usd">15522400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjgtMy0xLTEtMQ_68b90dfa-d3a5-4e96-b364-b828bfa36c8f"
      unitRef="usd">16586600000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjktMS0xLTEtMQ_674b3e70-50b8-4ad2-a548-9a38616d7e1c"
      unitRef="usd">3878800000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMjktMy0xLTEtMQ_d03af194-4b73-462f-927b-a9de78c610a3"
      unitRef="usd">4094500000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzAtMS0xLTEtMQ_fa617148-d515-4435-8bf5-c25ba260066b"
      unitRef="usd">3768500000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzAtMy0xLTEtMQ_deb8f35a-4b58-4521-86bb-24241d83f276"
      unitRef="usd">3837800000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzEtMS0xLTEtMQ_bb440fb0-d27d-4a33-9447-792a06063a18"
      unitRef="usd">1632500000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzEtMy0xLTEtMQ_452af235-70ec-4103-9cf2-3c3fbcb076bb"
      unitRef="usd">2099900000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzItMS0xLTEtMQ_4813dec0-4510-4547-9db7-97fd092b9f35"
      unitRef="usd">1748700000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzItMy0xLTEtMQ_823f9915-15e6-457c-b866-e03fc6f5ebfb"
      unitRef="usd">1707500000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzMtMS0xLTEtMQ_78625911-05bb-44b0-8c39-fd59b98ea4c0"
      unitRef="usd">26550900000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzMtMy0xLTEtMQ_2d503620-3e60-47eb-ae6d-99d38f1c52c0"
      unitRef="usd">28326300000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzQtMS0xLTEtMQ_f9f3845f-b417-4c76-b300-8e45af121fb2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzQtMy0xLTEtMQ_9c5c0544-cdd9-473b-b275-d419b7f2694d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzYtMS0xLTEtMQ_e39e9ec3-3687-4fcb-9921-5985db63cfed"
      unitRef="usd">598200000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzYtMy0xLTEtMQ_a1120ec7-b077-4b43-9a75-6619819b1597"
      unitRef="usd">598200000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzctMS0xLTEtMQ_ab396775-c581-4324-a8e0-f97da2428d19"
      unitRef="usd">6758000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzctMy0xLTEtMQ_bbbb2691-6681-488a-8509-dd092dd4ee20"
      unitRef="usd">6778500000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzgtMS0xLTEtMQ_0a7fddfe-feb0-4e3f-b30d-46d3608c2057"
      unitRef="usd">9639400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzgtMy0xLTEtMQ_36756b14-86b3-4047-8246-25a7e0fbf8e8"
      unitRef="usd">7830200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CommonStockSharesHeldInEmployeeTrust
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzktMS0xLTEtMQ_4bedf658-fe61-4478-b97d-53a68c16527f"
      unitRef="usd">3013200000</us-gaap:CommonStockSharesHeldInEmployeeTrust>
    <us-gaap:CommonStockSharesHeldInEmployeeTrust
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfMzktMy0xLTEtMQ_53c56fc5-0d3f-45d5-97e8-ca6b62c47994"
      unitRef="usd">3013200000</us-gaap:CommonStockSharesHeldInEmployeeTrust>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDAtMS0xLTEtMQ_969296be-0f8c-422b-8c6e-a9d99899b2bb"
      unitRef="usd">-6172700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDAtMy0xLTEtMQ_320ac504-d73e-440d-990f-c38c82645f2c"
      unitRef="usd">-6496400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockValue
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDEtMS0xLTEtMQ_64f1d5b1-4fe4-4de0-848d-9478d684eeb3"
      unitRef="usd">52700000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDEtMy0xLTEtMQ_b9ad3000-9cad-4ce8-a540-53b595f26fc5"
      unitRef="usd">55700000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDItMS0xLTEtMQ_d66a1c64-8516-4639-a10f-87d050326424"
      unitRef="usd">7757000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDItMy0xLTEtMQ_3cb6db63-b6bb-4759-8f26-5e54b1410f5f"
      unitRef="usd">5641600000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDMtMS0xLTEtMQ_f92caa9d-945c-4282-84a8-814d917b231b"
      unitRef="usd">197100000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDMtMy0xLTEtMQ_cf3df9cc-4fb1-4ccf-9f1b-ebd9726ea907"
      unitRef="usd">183600000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDQtMS0xLTEtMQ_f2dbb74b-441d-4c3f-9fae-330291c55502"
      unitRef="usd">7954100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDQtMy0xLTEtMQ_d5426f64-a79a-467e-a8da-17d621b306f9"
      unitRef="usd">5825200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDUtMS0xLTEtMQ_3bfc63ea-3730-46b9-9f66-6d311025b324"
      unitRef="usd">48187000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8yNS9mcmFnOjZkNWZkN2I3YjU3NDQzNjhiZDRkODEyOTI4OTFlNTE1L3RhYmxlOmZlMGMxZjU0MGQ5YjQ5YzY5MzE5Njk1YjRkZmUyODFiL3RhYmxlcmFuZ2U6ZmUwYzFmNTQwZDliNDljNjkzMTk2OTViNGRmZTI4MWJfNDUtMy0xLTEtMQ_89afda48-8a08-4142-8001-f4a91b8d50c8"
      unitRef="usd">46633100000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i6269e3039a904047803aaf8c59d2c31e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy0xLTEtMS0x_9bf6a804-abdc-4ddb-a962-b88bdb60294a"
      unitRef="shares">956953000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6269e3039a904047803aaf8c59d2c31e_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy0zLTEtMS0x_4460a629-36e4-42ac-b5bc-101f4f53d56b"
      unitRef="usd">598100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i277f40e31a78476c8a25e89e3ad7fad7_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy01LTEtMS0x_fd36ba59-8a5b-45f4-9fd3-96b0a12dcf3f"
      unitRef="usd">6629400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i480c67fa255d4952aec1ce6fdc96a5cf_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy03LTEtMS0x_2ad5213e-ede3-4874-a0d4-23b946f18779"
      unitRef="usd">6617200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie79822b045d24ca8816e16c558b018d9_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy05LTEtMS0x_503efdc8-e8bf-49a5-9680-b9d493fb4419"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9c4de3b4868049e78934ed4495abd9dc_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy0xMS0xLTEtMQ_02ea13bf-2be8-4d34-8041-630729360782"
      unitRef="usd">-6682900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i292925605a554dd98b2bb9c1601dcacd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy0xMy0xLTEtMQ_b2dd5832-acf7-498f-805b-6e6692197d01"
      unitRef="shares">487000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i292925605a554dd98b2bb9c1601dcacd_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy0xNS0xLTEtMQ_11779181-5463-4bed-be4b-1ac758305555"
      unitRef="usd">-55700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5cc02b3f1ff146b89aaf8d18611bff3a_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy0xNy0xLTEtMQ_68b5f7f4-c96d-4142-982e-24552096fc58"
      unitRef="usd">179100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="if9b17be62717498291500daeab724167_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfNC03LTEtMS0x_9ab8b39d-e518-4fbe-b35e-d7d9b089c1e3"
      unitRef="usd">1208400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i128373a43773438d93068364bbda7364_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfNC0xNy0xLTEtMQ_3255a2ce-decb-4c23-9a90-31b60121250b"
      unitRef="usd">-4800000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i646c747914e84ad991f450bbec883d19_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfNS0xMS0xLTEtMQ_074f4485-601f-447f-ae4c-5b264c965169"
      unitRef="usd">127800000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfNy0wLTEtMS0xL3RleHRyZWdpb246MTU5ZjIxMWYzN2NmNDEyZjk3YzFiNDJkNjA4NTVkZWVfMzk_0852a533-cf39-4099-ae46-2e97bdc30154"
      unitRef="usdPerShare">0.74</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="if9b17be62717498291500daeab724167_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfNy03LTEtMS0x_0b16bf5f-b27b-47ef-9ea1-a3ce2315edd3"
      unitRef="usd">671600000</us-gaap:Dividends>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i527414e868ec4177853d359e75ca6df1_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfOS0xLTEtMS0x_74146e4f-89d5-49a7-890d-84585e2ef278"
      unitRef="shares">25000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i8cd72451146c46faa7d53de5bc28c3ac_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfOS01LTEtMS0x_d10706e2-ed1b-4b55-b5b4-973b2dc99b7e"
      unitRef="usd">-2300000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8cd72451146c46faa7d53de5bc28c3ac_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTAtNS0xLTEtMQ_30cf8996-7ea5-4cc2-acf8-67558e819667"
      unitRef="usd">71700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityOther
      contextRef="i128373a43773438d93068364bbda7364_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTMtMTctMS0xLTE_75cb5388-6f61-4387-acdd-d9869f1ecf61"
      unitRef="usd">5200000</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="if2dc23546086416285bbd41e25d62584_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtMS0xLTEtMQ_745d0356-2fc7-42d8-a2d1-f6c3edc7fc5c"
      unitRef="shares">956978000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2dc23546086416285bbd41e25d62584_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtMy0xLTEtMQ_e7d09c11-ca02-4e69-b530-d68a18dfdced"
      unitRef="usd">598100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i74a77b8d5d984968b3c4578e17bbb5e9_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtNS0xLTEtMQ_11dc22c0-de0d-4a87-b600-5fb3e0db1d9f"
      unitRef="usd">6698800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i36d3b669185e44dbbd9e6e8943ab4f6a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtNy0xLTEtMQ_8ff65bbd-e0ad-4b55-b334-9de5c5cdc853"
      unitRef="usd">7154000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie279100c0102406e93bb14b4657500dc_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtOS0xLTEtMQ_e0c710a8-a100-4a9c-aed8-941793ea6e1e"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i28b47563db924e53a3b01da85a1c1857_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtMTEtMS0xLTE_d0171b74-adc6-48b9-8f0a-aa917f38db04"
      unitRef="usd">-6555100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i8b458bdf7deb40b29fead2a4923fcdc0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtMTMtMS0xLTE_7e106991-453e-4af5-b4d7-11292ad1f604"
      unitRef="shares">487000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b458bdf7deb40b29fead2a4923fcdc0_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtMTUtMS0xLTE_2bef079f-6b48-4928-a3b6-b6990292d907"
      unitRef="usd">-55700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic401234ddcb24a04b3a48f1e46bb9d26_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtMTctMS0xLTE_fbd77ed0-a6f5-4cd7-a99b-a574d940a201"
      unitRef="usd">169100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i9230f02f9af8414aaa820e4637091e33_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtMS0xLTEtMQ_0753c190-d743-47f8-aa97-ee1a3507346e"
      unitRef="shares">957038000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9230f02f9af8414aaa820e4637091e33_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtMy0xLTEtMQ_985f9019-3356-49f6-9774-99ef932500df"
      unitRef="usd">598100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i661e35a5d390434383f2e73f7a2a947c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtNS0xLTEtMQ_3b0b9786-3edb-417e-bd32-8ca1264beaf4"
      unitRef="usd">6669200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9b807fcb6dd415889f60755aa586d46_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtNy0xLTEtMQ_a8ee0614-85b2-450c-b205-6e9e2b4b5683"
      unitRef="usd">8530100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7557d0c1a88148acb26d4de3f94524bd_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtOS0xLTEtMQ_f76a1ebb-4efc-425c-9218-8b66bf8db7b5"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2f9c0959ab041ef9cd49b71327449cd_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtMTEtMS0xLTE_a695eb47-8103-4ce7-b515-a149f6b07276"
      unitRef="usd">-6287100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i5e006e6aa4cf4c4c8d995f6d7ef007b3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtMTMtMS0xLTE_46112e1c-12d7-46c8-be5f-d81e03cd4a21"
      unitRef="shares">463000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e006e6aa4cf4c4c8d995f6d7ef007b3_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtMTUtMS0xLTE_bc0dde86-46f2-4741-980a-39ace0aca559"
      unitRef="usd">-52700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id48ee4fdf79b43f68e80f1116057e733_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtMTctMS0xLTE_00cf3841-0137-4df4-acfd-52ef412e4354"
      unitRef="usd">219100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i4d263bfcfede470e849adc44fbd95b02_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTctNy0xLTEtMQ_8ab66daa-f859-49db-921e-ff91bb62b3d6"
      unitRef="usd">1110100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4489a9298a74411cb30a8b6d1d8c0a5a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTctMTctMS0xLTE_3a91288c-2b55-45da-8010-8a4da8369ca4"
      unitRef="usd">-22600000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i408826e558824625a2ca711ba35a4da0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTgtMTEtMS0xLTE_e269fe50-8916-4ae3-b523-7084355771f8"
      unitRef="usd">114400000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i3d29538f03db4d85830f1a00e8cc2a3d_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjItMS0xLTEtMQ_f744bc32-1d7d-457e-8079-6980e67d56c5"
      unitRef="shares">14000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i3d29538f03db4d85830f1a00e8cc2a3d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjItMy0xLTEtMQ_f8252ae7-1927-4ff8-9446-a9d022d3f0c7"
      unitRef="usd">100000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i9112ede45bca4fa485446dc88c3c5484_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjItNS0xLTEtMQ_58a34db2-bc5b-4b37-a53d-0be8e5434f09"
      unitRef="usd">-1300000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9112ede45bca4fa485446dc88c3c5484_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjMtNS0xLTEtMQ_9961e108-94d9-44cd-bcd3-a3c5d2e9c14c"
      unitRef="usd">90100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityOther
      contextRef="i4d263bfcfede470e849adc44fbd95b02_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjQtNy0xLTEtMQ_a6dfc2b0-0bea-466e-9d94-ec3dc04b1547"
      unitRef="usd">800000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i4489a9298a74411cb30a8b6d1d8c0a5a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjQtMTctMS0xLTE_4b4b6c03-e470-44d6-b526-6401042fe769"
      unitRef="usd">-600000</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="i4b653f1fba914f8dbac7b520ac3265a7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtMS0xLTEtMQ_4aede6db-b565-42b2-86d7-8441785ec6f3"
      unitRef="shares">957052000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b653f1fba914f8dbac7b520ac3265a7_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtMy0xLTEtMQ_1707f197-b093-4012-8e5d-70b509beef0b"
      unitRef="usd">598200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i83143935f8da447d9261cebfc72ce7ff_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtNS0xLTEtMQ_83fbb6c3-2052-44d4-b0ca-705fd5743ba3"
      unitRef="usd">6758000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5bb41cf2a9504b31b3ee0af14c18f87f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtNy0xLTEtMQ_f49488fa-c28e-4d58-97be-684c35910b70"
      unitRef="usd">9639400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i22679a982313462397a5663f58993f05_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtOS0xLTEtMQ_9b5ef9be-482a-44a2-a11e-0c386e72237e"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d120ba2343e410780602579de874a5f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtMTEtMS0xLTE_89166a32-b029-4f7b-8559-ded28cf43975"
      unitRef="usd">-6172700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i0287914b178a46d4be80deab95a97314_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtMTMtMS0xLTE_b13827a8-af2d-4a7d-87ea-2fb03492aaf7"
      unitRef="shares">463000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0287914b178a46d4be80deab95a97314_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtMTUtMS0xLTE_2cdb2d62-671e-48fd-a8a2-6a96a76d2aa9"
      unitRef="usd">-52700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie425975ac2314fc3bf1853a1bc359060_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtMTctMS0xLTE_b13f101a-9ac2-40e0-9895-b79a427ed8b6"
      unitRef="usd">197100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfMTMxOTQxMzk1MzQ4MzY_b1620fc8-c38a-4f9d-97fb-c83256c887f8"
      unitRef="usd">500000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ic5af76f55c3349ba859b1f9206178021_I20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfMTMxOTQxMzk1MzQ4NjA_03e20580-3467-49be-87db-4ebc6842bd6c"
      unitRef="usd">8000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="if8b0a3ca285542978d0be33bc0249ffb_I20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfMTMxOTQxMzk1MzQ5MTc_f367f371-ddfb-48f3-9820-91e978519ce1"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="if8b0a3ca285542978d0be33bc0249ffb_I20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfMTMxOTQxMzk1MzQ5NDM_f367f371-ddfb-48f3-9820-91e978519ce1"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:SharesIssued
      contextRef="i612deeb868604a2c937e486f25fce6f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy0xLTEtMS0x_e6c6bbcc-f973-43e0-9464-d0c619076356"
      unitRef="shares">958056000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i612deeb868604a2c937e486f25fce6f6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy0zLTEtMS0x_7a7302e0-9b6d-47f2-b739-3ad306052332"
      unitRef="usd">598800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a83d082225245798aa0f1e672ee7810_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy01LTEtMS0x_fc179345-0aed-4bc9-8ab8-0f8cb01f65ea"
      unitRef="usd">6685300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i05ea4e8d0df642af8b6a87953f1f8e23_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy03LTEtMS0x_82d1dfaf-b2e9-4cbf-8053-aa974848a382"
      unitRef="usd">4920400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i177bd18351114d5c8ae70dbc77c8660c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy05LTEtMS0x_13807d6a-aa75-4adc-afc0-db398fb00b4f"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4622633489fa4632a9800fb6fb1326c9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy0xMS0xLTEtMQ_f38b6f0f-050c-4a9e-8e2b-796fc8a59dc6"
      unitRef="usd">-6523600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i831186dd08c8458bb74c88268733509a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy0xMy0xLTEtMQ_ff7fe7bf-ba9f-4686-897f-21f2098bcd8a"
      unitRef="shares">530000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i831186dd08c8458bb74c88268733509a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy0xNS0xLTEtMQ_cf430d6f-18f9-497d-bc39-23d0fb10324b"
      unitRef="usd">-60800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2781ee2a1570463cb045238d0fe460f5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy0xNy0xLTEtMQ_b013564b-1af2-49fb-baae-5472783800c1"
      unitRef="usd">92200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="id986361421254ab4997b4c92dec009d3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNC03LTEtMS0x_05d4c4c5-a1c4-478c-a41f-e115415b9942"
      unitRef="usd">4076900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i252777c0f5ec42bb81ec84d8bffeaebc_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNC0xNy0xLTEtMQ_2b5a5e89-7f34-4238-80eb-7974bcccfd8f"
      unitRef="usd">95900000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib0f254d6b3ea463b8d26b218473a23dd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNS0xMS0xLTEtMQ_e6f9036f-ede8-4288-ab52-7705d109bf34"
      unitRef="usd">-31500000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNi0wLTEtMS0xL3RleHRyZWdpb246YjcyMjk5YTAwZDk2NDA1N2E3YjI4ZGQ3NTljMGY1M2VfMzk_389f56b8-b791-4f0a-b0d5-a945e04e9189"
      unitRef="usdPerShare">1.48</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="id986361421254ab4997b4c92dec009d3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNi03LTEtMS0x_bc114d0b-e96f-472d-aa7c-d8bda2e9353c"
      unitRef="usd">1345600000</us-gaap:Dividends>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i5b73aed77d4d4a3aa3b99395305f0cb5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNy0xLTEtMS0x_29786c6c-6eda-4cbe-bdef-5a26c8312f0b"
      unitRef="shares">3627000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i5b73aed77d4d4a3aa3b99395305f0cb5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNy0zLTEtMS0x_582274dd-8d67-4dd3-886d-40c66875741d"
      unitRef="usd">2300000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="id986361421254ab4997b4c92dec009d3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNy03LTEtMS0x_c6bf48aa-8c83-4308-a6ae-a1896f94e823"
      unitRef="usd">497700000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i252f3fa632ef43be9ad24db3bffe5ad8_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNy0xMy0xLTEtMQ_1e99a41f-b073-458d-8bf2-86a4fd6bb7f1"
      unitRef="shares">3627000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i252f3fa632ef43be9ad24db3bffe5ad8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNy0xNS0xLTEtMQ_ec16c59e-9d22-4e6d-b90e-d91e2ddf8102"
      unitRef="usd">-500000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i252f3fa632ef43be9ad24db3bffe5ad8_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOC0xMy0xLTEtMQ_4a20c478-f442-4f2e-b927-524ce344d68c"
      unitRef="shares">3627000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i252f3fa632ef43be9ad24db3bffe5ad8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOC0xNS0xLTEtMQ_e5260fcd-2cb4-4b54-bb00-7081c06c9b68"
      unitRef="usd">500000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i5b73aed77d4d4a3aa3b99395305f0cb5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOS0xLTEtMS0x_bde450ac-46e3-4134-b2b1-b15c34c842c6"
      unitRef="shares">2549000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i5b73aed77d4d4a3aa3b99395305f0cb5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOS0zLTEtMS0x_315a66c8-dc5c-445a-94b6-14006e92be0a"
      unitRef="usd">1600000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i22b957be322b4417a234d68dfb557223_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOS01LTEtMS0x_8ada6546-763a-4b05-8898-22ebb182b744"
      unitRef="usd">-206400000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i252f3fa632ef43be9ad24db3bffe5ad8_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOS0xMy0xLTEtMQ_cb23c7b5-c41a-4e13-ae27-b624034d3d92"
      unitRef="shares">-43000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i252f3fa632ef43be9ad24db3bffe5ad8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOS0xNS0xLTEtMQ_0d17fa04-e5b1-4fd4-b3d0-b5a50e67f519"
      unitRef="usd">5100000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i22b957be322b4417a234d68dfb557223_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTAtNS0xLTEtMQ_618b5d71-8f47-4164-b10e-e1ecbc645751"
      unitRef="usd">220300000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityOther
      contextRef="i22b957be322b4417a234d68dfb557223_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTMtNS0xLTEtMQ_58ecc180-110f-4743-92db-8ca04c869551"
      unitRef="usd">400000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i252777c0f5ec42bb81ec84d8bffeaebc_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTMtMTctMS0xLTE_629aa5e0-19c1-4fbd-9449-b59bf78b0356"
      unitRef="usd">19000000.0</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="if2dc23546086416285bbd41e25d62584_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtMS0xLTEtMQ_4a869520-b7e8-4b23-8d17-59800f2ed165"
      unitRef="shares">956978000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2dc23546086416285bbd41e25d62584_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtMy0xLTEtMQ_80621e44-fa9b-461a-aa7e-7ce5f473d50a"
      unitRef="usd">598100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i74a77b8d5d984968b3c4578e17bbb5e9_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtNS0xLTEtMQ_a12890a2-510e-42fd-95f2-5af8dff26a90"
      unitRef="usd">6698800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i36d3b669185e44dbbd9e6e8943ab4f6a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtNy0xLTEtMQ_8ff65bbd-e0ad-4b55-b334-9de5c5cdc853"
      unitRef="usd">7154000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie279100c0102406e93bb14b4657500dc_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtOS0xLTEtMQ_6704c959-1465-4e27-ad0e-562e56f998de"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i28b47563db924e53a3b01da85a1c1857_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtMTEtMS0xLTE_b700a4bc-fe83-4689-a2e7-ad9f0552941b"
      unitRef="usd">-6555100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i8b458bdf7deb40b29fead2a4923fcdc0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtMTMtMS0xLTE_6d009de1-88d9-4000-b2d9-620f045c6496"
      unitRef="shares">487000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b458bdf7deb40b29fead2a4923fcdc0_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtMTUtMS0xLTE_6bfefc11-3f8e-46b8-8bab-7377c0bd95f0"
      unitRef="usd">-55700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic401234ddcb24a04b3a48f1e46bb9d26_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtMTctMS0xLTE_b05aa41e-5cb8-46f6-9c36-d989291f5fd1"
      unitRef="usd">169100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="iead50fa9bd39400bb6f8a9b5d3d03acd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtMS0xLTEtMQ_c65349cd-9818-4a7f-ad01-643066d476d5"
      unitRef="shares">957077000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iead50fa9bd39400bb6f8a9b5d3d03acd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtMy0xLTEtMQ_8c1b8e92-1c92-431a-b046-df2039cb61ba"
      unitRef="usd">598200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i90982ebb563845899ddc7a66f27f1455_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtNS0xLTEtMQ_a0a1ce21-12f7-44d7-b759-4325a7f162af"
      unitRef="usd">6778500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7a74fbbdc9ac408e8912ccf4e1576ae8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtNy0xLTEtMQ_1bae4dfc-0540-4fb4-94e0-4b1e058ca15f"
      unitRef="usd">7830200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice93dc7ac1da463ea4ecca4d2fba8434_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtOS0xLTEtMQ_b60167ab-616b-4452-87c8-b69566baf831"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia0aebdc3dbd54d82a80cf1b888beb150_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtMTEtMS0xLTE_863acd1b-2738-47cc-a8ab-2dab63134f39"
      unitRef="usd">-6496400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i76fda2c740f94c7ca2ee9b4ceda0b709_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtMTMtMS0xLTE_7bfab548-476d-464d-b4f0-7f48f5e144be"
      unitRef="shares">487000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i76fda2c740f94c7ca2ee9b4ceda0b709_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtMTUtMS0xLTE_4439dc84-d22d-4752-923a-26a9bc5cdf2b"
      unitRef="usd">-55700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icd1b1734812948e294108968f3a834d3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtMTctMS0xLTE_2b9a8f35-5867-4372-afd1-949017ec6d47"
      unitRef="usd">183600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i218e2fbd7bbc48deba986aa580060342_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTctNy0xLTEtMQ_e8c56663-5c45-4525-b902-a9856c3ca957"
      unitRef="usd">3855600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i44128d85d4474ad681fc84f6f83f73b7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTctMTctMS0xLTE_f16f615e-2d0e-4e35-b537-cfd98bad6c89"
      unitRef="usd">25200000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i741888a65d6744479381fb901e13925c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTgtMTEtMS0xLTE_99364500-5ee6-4d81-86d7-a6bc99cb1ab7"
      unitRef="usd">323700000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTktMC0xLTEtMS90ZXh0cmVnaW9uOjBlNTQ0NGIzNzhmNjQ0NzZiMzg4NmJkNzY2NjIxNDc4XzM5_42c0428f-57b5-4724-86c1-21f4f65e4b10"
      unitRef="usdPerShare">1.70</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="i218e2fbd7bbc48deba986aa580060342_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTktNy0xLTEtMQ_2a91b842-d616-472b-983f-c500b8e9a9ff"
      unitRef="usd">1542900000</us-gaap:Dividends>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="icdd23d64b8ba4239ab77fe5df21cd6d5_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjAtMS0xLTEtMQ_74469328-cffa-47da-9111-4e7c6b8d3ba4"
      unitRef="shares">2467000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="icdd23d64b8ba4239ab77fe5df21cd6d5_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjAtMy0xLTEtMQ_55531944-a889-447a-8035-bacf149200d6"
      unitRef="usd">1500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i218e2fbd7bbc48deba986aa580060342_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjAtNy0xLTEtMQ_4baa87c1-8a19-4856-89a7-ac5f41293e2e"
      unitRef="usd">498500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i08ae5e3d75fc49a3b01da53199cc2e26_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjAtMTMtMS0xLTE_ae12d3ca-246d-4b32-8d5d-2b62d86d16c2"
      unitRef="shares">2467000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i08ae5e3d75fc49a3b01da53199cc2e26_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjAtMTUtMS0xLTE_42356bcd-102e-4951-908b-9fbe63c054f2"
      unitRef="usd">-500000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i08ae5e3d75fc49a3b01da53199cc2e26_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjEtMTMtMS0xLTE_eed90e6f-7db6-4694-8923-b3ee18dc613a"
      unitRef="shares">2467000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i08ae5e3d75fc49a3b01da53199cc2e26_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjEtMTUtMS0xLTE_4a039bb4-7d57-4cc6-8345-e8a588bc0e9d"
      unitRef="usd">500000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="icdd23d64b8ba4239ab77fe5df21cd6d5_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjItMS0xLTEtMQ_98f02d12-1663-4111-a71e-8e22f7e287f6"
      unitRef="shares">2442000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="icdd23d64b8ba4239ab77fe5df21cd6d5_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjItMy0xLTEtMQ_69d94a7d-01d5-4e07-bcf7-27e11f8911db"
      unitRef="usd">1500000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i79216bede2b24f049a04d252ea215271_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjItNS0xLTEtMQ_e8ede1e4-cd8d-4eb7-aedd-67ad42df7a06"
      unitRef="usd">-287100000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i08ae5e3d75fc49a3b01da53199cc2e26_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjItMTMtMS0xLTE_f6b0cbf1-8ea9-4e3c-8fda-d4606c6d2fea"
      unitRef="shares">-24000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i08ae5e3d75fc49a3b01da53199cc2e26_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjItMTUtMS0xLTE_7abe819a-50fc-4c27-8850-eae51083415c"
      unitRef="usd">3000000.0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i79216bede2b24f049a04d252ea215271_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjMtNS0xLTEtMQ_92764229-f6c3-47c8-8a6c-ce9842d90db3"
      unitRef="usd">267500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityOther
      contextRef="i79216bede2b24f049a04d252ea215271_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjQtNS0xLTEtMQ_444e108c-d08f-4bb2-837f-1d64d73dbf7d"
      unitRef="usd">900000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i218e2fbd7bbc48deba986aa580060342_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjQtNy0xLTEtMQ_039ce9e9-0ca3-4c98-a1cc-f5253de6634c"
      unitRef="usd">5000000.0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i44128d85d4474ad681fc84f6f83f73b7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjQtMTctMS0xLTE_6bbad395-2979-46b0-86c5-9c8cf19bf0c9"
      unitRef="usd">11700000</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="i4b653f1fba914f8dbac7b520ac3265a7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtMS0xLTEtMQ_69d2db7e-143a-4fd8-96b2-89302e6f4c14"
      unitRef="shares">957052000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b653f1fba914f8dbac7b520ac3265a7_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtMy0xLTEtMQ_931daebc-a26e-43db-ba49-bee4e869a799"
      unitRef="usd">598200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i83143935f8da447d9261cebfc72ce7ff_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtNS0xLTEtMQ_ff082a01-21c3-4b95-a0dc-a78d035d1173"
      unitRef="usd">6758000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5bb41cf2a9504b31b3ee0af14c18f87f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtNy0xLTEtMQ_8ae1c49a-0b75-4fe8-96cd-ebd7574132c0"
      unitRef="usd">9639400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i22679a982313462397a5663f58993f05_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtOS0xLTEtMQ_2bbf7361-3d51-4547-b18b-7d4e52e38f25"
      unitRef="usd">-3013200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d120ba2343e410780602579de874a5f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtMTEtMS0xLTE_004f39fb-ecc6-4923-af83-20597f879729"
      unitRef="usd">-6172700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i0287914b178a46d4be80deab95a97314_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtMTMtMS0xLTE_c9e80bc4-8a71-4fb6-87d4-1656f4ee2264"
      unitRef="shares">463000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0287914b178a46d4be80deab95a97314_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtMTUtMS0xLTE_52d0cae5-5189-43c9-a3ba-a9fa5a6931fe"
      unitRef="usd">-52700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie425975ac2314fc3bf1853a1bc359060_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtMTctMS0xLTE_0deba168-6ab7-44a8-a2a2-ccbf4a8a7e8c"
      unitRef="usd">197100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfNDUx_b1620fc8-c38a-4f9d-97fb-c83256c887f8"
      unitRef="usd">500000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ic5af76f55c3349ba859b1f9206178021_I20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfNDc0_03e20580-3467-49be-87db-4ebc6842bd6c"
      unitRef="usd">8000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="if8b0a3ca285542978d0be33bc0249ffb_I20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfNTI5_f367f371-ddfb-48f3-9820-91e978519ce1"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="if8b0a3ca285542978d0be33bc0249ffb_I20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfNjI4_f367f371-ddfb-48f3-9820-91e978519ce1"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:NetIncomeLoss
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMy0xLTEtMS0x_a61fdd3d-6078-4a22-b43e-6ab80af7b66e"
      unitRef="usd">3855600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMy0zLTEtMS0x_d735664a-860f-4b2c-987b-f34b51d92b3d"
      unitRef="usd">4076900000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfNi0xLTEtMS0x_4d98d016-279f-431e-9da3-b36619cc77d0"
      unitRef="usd">1101900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfNi0zLTEtMS0x_9c6310eb-ff02-45dd-a6c9-fccb488ca7bb"
      unitRef="usd">956400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfNy0xLTEtMS0x_5e9ef2ac-d861-418c-9c68-50e875bbcb81"
      unitRef="usd">709800000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfNy0zLTEtMS0x_eb6debc5-85c3-42bc-8d32-55f20d6a211a"
      unitRef="usd">-66200000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfOC0xLTEtMS0x_e08536f0-5805-42d8-8e43-c5b83c26770f"
      unitRef="usd">-405200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfOC0zLTEtMS0x_3875aba8-1ffe-4bee-889a-2f55b30baeb9"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfOS0xLTEtMS0x_9b1c83aa-224e-4efb-b76e-f8b851c4b5e4"
      unitRef="usd">267500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfOS0zLTEtMS0x_a4138cf3-45d0-4841-bbec-5f147f9e8898"
      unitRef="usd">220300000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnInvestments
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTEtMS0xLTEtMQ_625bd6cc-1a54-48bf-973d-43352ec73629"
      unitRef="usd">271100000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTEtMy0xLTEtMQ_29456d63-92f0-4b09-af07-5c8575acb5e8"
      unitRef="usd">909500000</us-gaap:GainLossOnInvestments>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTItMS0xLTEtMQ_c86ace15-bd57-403d-a137-8ef50efc0b3f"
      unitRef="usd">498300000</lly:AcquiredInProcessResearchAndDevelopment>
    <lly:AcquiredInProcessResearchAndDevelopment
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTItMy0xLTEtMQ_f9653e83-918c-42ff-8244-0eef9e004bb3"
      unitRef="usd">294100000</lly:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTMtMS0xLTEtMQ_90c0c61f-1361-4885-bd54-5a5394fb6957"
      unitRef="usd">548100000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTMtMy0xLTEtMQ_5687113c-fe05-420f-bb61-ce040a3a0745"
      unitRef="usd">232200000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTQtMS0xLTEtMQ_d4c3e449-1c86-49d9-8fbb-60a1a8831c82"
      unitRef="usd">504700000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTQtMy0xLTEtMQ_8f5b19ea-7efb-4482-98bb-a6544c6ed872"
      unitRef="usd">212200000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTUtMS0xLTEtMQ_1a6a5c37-b605-49c5-8d6a-0b587b195513"
      unitRef="usd">5104200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTUtMy0xLTEtMQ_07b208be-3192-4a14-bfd4-4e6d00bec174"
      unitRef="usd">4684400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTctMS0xLTEtMQ_4e6b809b-ca86-4ab0-bac7-cf764962bd72"
      unitRef="usd">1018400000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTctMy0xLTEtMQ_54d110d4-5c41-4590-b53d-9ccf105058a6"
      unitRef="usd">933200000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTgtMS0xLTEtMQ_c4307dbd-3981-40f2-90c5-d48c89247bf2"
      unitRef="usd">46600000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTgtMy0xLTEtMQ_cfc03f2c-2b1a-403d-8525-815bab557fbe"
      unitRef="usd">118800000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTktMS0xLTEtMQ_93247dd8-5c02-4d8e-9c39-d313cc0915b9"
      unitRef="usd">27900000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMTktMy0xLTEtMQ_b17bf0fd-02f4-4b78-bdb7-7738f24f9e6f"
      unitRef="usd">11400000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfLongtermInvestments
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjAtMS0xLTEtMQ_aa6f8732-ffc3-43c0-8153-91219d29be58"
      unitRef="usd">537200000</us-gaap:ProceedsFromSaleOfLongtermInvestments>
    <us-gaap:ProceedsFromSaleOfLongtermInvestments
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjAtMy0xLTEtMQ_85c815bf-8b12-4637-9ec2-25a439a53823"
      unitRef="usd">574100000</us-gaap:ProceedsFromSaleOfLongtermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjEtMS0xLTEtMQ_d7db5249-047b-454f-a63f-01017192880e"
      unitRef="usd">710100000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjEtMy0xLTEtMQ_80e8ab32-4b57-4741-abbb-f6a608fc8677"
      unitRef="usd">223700000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjItMS0xLTEtMQ_38fe2d78-0d4f-4cc5-9bf8-2f4b88a9124b"
      unitRef="usd">747400000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjItMy0xLTEtMQ_dfc4508f-c091-4679-aca3-9c418e6e3e9c"
      unitRef="usd">849300000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <lly:PurchasedInProcessResearchAndDevelopment
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjQtMS0xLTEtMQ_d3bb94c7-3b3b-4eaf-94fa-c4a60c8db772"
      unitRef="usd">460600000</lly:PurchasedInProcessResearchAndDevelopment>
    <lly:PurchasedInProcessResearchAndDevelopment
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjQtMy0xLTEtMQ_5930c56a-dd17-4723-927f-776f23666242"
      unitRef="usd">276400000</lly:PurchasedInProcessResearchAndDevelopment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjUtMS0xLTEtMQ_a7eb945c-288d-4b7b-8339-056ba9ff403e"
      unitRef="usd">2700000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjUtMy0xLTEtMQ_88af6585-3f52-43c6-86cd-7e2f9bb9f860"
      unitRef="usd">-16300000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjYtMS0xLTEtMQ_344ac4cf-eb2f-4b54-a542-44430a8489e0"
      unitRef="usd">-2383300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjYtMy0xLTEtMQ_dec20764-d814-4302-9d6a-6d6960487b62"
      unitRef="usd">-1584800000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfDividends
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjgtMS0xLTEtMQ_e0c98ee0-5d62-496b-b88c-d0221731c0ab"
      unitRef="usd">2313500000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjgtMy0xLTEtMQ_439cda2f-a317-4cbc-9ba7-f43b8051ece1"
      unitRef="usd">2017100000</us-gaap:PaymentsOfDividends>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjktMS0xLTEtMQ_f5b46d46-d2bb-4269-9c77-8e6d6eb3b403"
      unitRef="usd">-1500000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMjktMy0xLTEtMQ_d597c373-4ea4-47ad-bf12-2492a18e6f77"
      unitRef="usd">914300000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzAtMS0xLTEtMQ_1fdf7a8c-6c16-469a-af87-f16587dfe24e"
      unitRef="usd">2410800000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzAtMy0xLTEtMQ_b3e16eec-928e-4798-9ed1-1d315625dea4"
      unitRef="usd">2062300000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzEtMS0xLTEtMQ_39ed2f4e-cd0c-4bc7-866b-cff0a3f7fafe"
      unitRef="usd">1905300000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzEtMy0xLTEtMQ_56f4f7b9-1d2b-4ea2-aa8d-af14a4fbeaf7"
      unitRef="usd">276300000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzItMS0xLTEtMQ_87fd0d08-1898-4235-83ea-9f9f7bf63a8b"
      unitRef="usd">500000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzItMy0xLTEtMQ_8bd5fcb3-0cfe-4bad-b081-ae344825d61c"
      unitRef="usd">500000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzQtMS0xLTEtMQ_bd704200-1a77-4b94-ac0f-c14f072fcc7b"
      unitRef="usd">-295300000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzQtMy0xLTEtMQ_138d0004-cf91-4c1f-bf23-549a2e2950e9"
      unitRef="usd">-200200000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzUtMS0xLTEtMQ_5252cb44-2e35-4b1d-b6e0-f9529a8a3156"
      unitRef="usd">-2604800000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzUtMy0xLTEtMQ_99110c56-2207-4388-93b0-818b8f93b29a"
      unitRef="usd">-1845600000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzYtMS0xLTEtMQ_e38e73d9-9805-41b5-b188-9a7fa48d5633"
      unitRef="usd">15000000.0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzYtMy0xLTEtMQ_ea5994dd-cd80-48c9-9aef-bc60df0ad4dc"
      unitRef="usd">3800000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzgtMS0xLTEtMQ_21f47b8d-0688-4af8-93b2-fc108c6a858a"
      unitRef="usd">131100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzgtMy0xLTEtMQ_a686ccef-6092-4e00-9155-8ec9f2380bb0"
      unitRef="usd">1257800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzktMS0xLTEtMQ_1b1d86fb-b393-48bb-aca4-b42a5c145e14"
      unitRef="usd">3657100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ic89977d02ab1401dbc23753322c8563b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfMzktMy0xLTEtMQ_1ba9a186-455a-41bf-999c-99bf4ad03399"
      unitRef="usd">2337500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfNDAtMS0xLTEtMQ_261ca41e-a0da-44f5-943f-565ca3a92467"
      unitRef="usd">3788200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="idac57d16ce9f4dcb9b27d234834a1cc0_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zNC9mcmFnOmZjODZiMjk2YjYyMDQwYzI5YTMzN2E0NzU2NWNkMTVlL3RhYmxlOmViNDczZjFiMmE0ODRkZTQ4MTRkMzczM2Q0YTg5Y2IyL3RhYmxlcmFuZ2U6ZWI0NzNmMWIyYTQ4NGRlNDgxNGQzNzMzZDRhODljYjJfNDAtMy0xLTEtMQ_b0ca7367-3719-4ad5-9c7c-ecc10b2c4fd8"
      unitRef="usd">3595300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80MC9mcmFnOmRmZGRmOTllMDZiYzQ4MjlhNTRjYjJiMDg0ZWRlNTU4L3RleHRyZWdpb246ZGZkZGY5OWUwNmJjNDgyOWE1NGNiMmIwODRlZGU1NThfMjQzNw_a1fb07d7-5c21-4c94-b68c-11414a6db880">Basis of Presentation &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the consolidated condensed financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Form 10-K&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the year ended December&#160;31, 2020. We issue our financial statements by filing them with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing of this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis; that is, based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RleHRyZWdpb246ZjQ4NTU3MjI0MjQ2NGE2YTg5MmUwYmNiYzA0YTMyODNfMzUxMA_022d6599-e2b2-4396-b788-580ad4cdfa17">Revenue&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our revenue recognized in our consolidated condensed statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,189.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,281.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,579.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,762.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration and other revenue &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;583.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,739.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,772.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,740.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20,318.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,099.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Collaboration and other revenue associated with prior period transfers of intellectual property was $62.1 million and $136.1 million during the three and nine months ended September&#160;30, 2021, respectively, and $31.5 million and $101.5 million during the three and nine months ended September 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to certain of our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trajenta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Adjustments to Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjustments to increase (decrease) revenue recognized as a result of changes in estimates for our most significant United States (U.S.) sales returns, rebates, and discounts liability balances for products shipped in previous periods were less than 1 percent of U.S. revenue during each of the three and nine months ended September&#160;30, 2021, and approximately (1) percent and 1 percent of U.S. revenue for the three and nine months ended September 30, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract liability balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.276%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;278.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2021 and 2020, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by product for the three months ended September 30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trulicity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,201.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;398.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,600.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,106.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humalog&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;347.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;279.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;626.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;656.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Jardiance &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;221.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;169.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;390.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humulin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;193.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;93.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;286.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;114.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;78.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;192.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;65.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;112.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;177.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,143.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,131.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,274.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,798.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,783.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oncology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Alimta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;297.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;159.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;457.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Verzenio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;199.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;135.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;335.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cyramza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;84.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;168.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;253.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Erbitux&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;114.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;134.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tyvyt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;125.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;125.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;65.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;730.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;675.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,406.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,333.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immunology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Taltz&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;422.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;170.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;593.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;194.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;212.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;406.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;616.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;388.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,004.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Emgality&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;99.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;140.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cymbalta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;125.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;132.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zyprexa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;88.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;101.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;51.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;76.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;144.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;305.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;450.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;COVID-19 Antibodies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;215.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;217.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Forteo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;109.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;91.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;200.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cialis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;137.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;130.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;36.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;52.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;88.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;354.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;282.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;637.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,989.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,783.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,772.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,161.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,579.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,740.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Humalog revenue includes insulin lispro.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Jardiance revenue includes Glyxambi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Synjardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and Trijardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; XR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to Emergency Use Authorization (EUA).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by product for the nine months ended September 30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trulicity&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,465.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,122.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,588.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,673.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;892.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,565.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humalog&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,009.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;842.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,851.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,907.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Jardiance &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;566.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;492.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,058.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humulin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;633.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;290.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;923.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;935.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;423.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;226.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;650.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;185.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;302.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;488.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,284.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,276.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,560.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,663.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,868.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,530.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oncology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Alimta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;911.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;714.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,626.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,677.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Verzenio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;582.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;363.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;945.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cyramza&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;266.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;496.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;762.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Erbitux&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;357.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;45.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;403.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tyvyt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;340.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;340.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;83.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;169.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;253.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,201.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,130.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,332.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,023.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,780.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,803.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immunology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Taltz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,071.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;493.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,565.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,293.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Olumiant &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;236.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;572.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;809.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,323.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,080.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,404.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;995.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,761.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cymbalta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;454.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;484.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Emgality&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;313.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;102.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;415.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zyprexa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;28.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;264.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;292.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;81.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;154.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;235.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;453.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;974.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,427.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,356.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;COVID-19 Antibodies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;949.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;226.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,176.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Forteo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;330.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;287.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;617.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cialis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;541.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;538.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;96.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;164.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;260.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,373.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,220.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,593.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,052.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,647.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,635.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,683.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20,318.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,631.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,468.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,099.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Humalog revenue includes insulin lispro.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Jardiance revenue includes Glyxambi,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Synjardy, and Trijardy XR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to EUA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by geographical area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,989.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,161.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,635.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,631.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,098.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,629.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,984.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;595.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,832.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,919.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;400.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,285.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other foreign countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;689.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,936.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,768.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,772.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,740.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20,318.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,099.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Revenue is attributed to the countries based on the location of the customer.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RleHRyZWdpb246ZjQ4NTU3MjI0MjQ2NGE2YTg5MmUwYmNiYzA0YTMyODNfMzUyNg_82f83a83-1a65-4067-8c20-badf64689066">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our revenue recognized in our consolidated condensed statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,189.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,281.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,579.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,762.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration and other revenue &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;583.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,739.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,772.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,740.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20,318.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,099.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Collaboration and other revenue associated with prior period transfers of intellectual property was $62.1 million and $136.1 million during the three and nine months ended September&#160;30, 2021, respectively, and $31.5 million and $101.5 million during the three and nine months ended September 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by product for the three months ended September 30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trulicity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,201.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;398.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,600.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,106.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humalog&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;347.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;279.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;626.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;656.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Jardiance &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;221.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;169.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;390.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humulin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;193.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;93.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;286.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;114.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;78.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;192.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;65.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;112.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;177.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,143.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,131.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,274.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,798.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,783.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oncology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Alimta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;297.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;159.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;457.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Verzenio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;199.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;135.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;335.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cyramza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;84.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;168.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;253.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Erbitux&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;114.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;134.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tyvyt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;125.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;125.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;65.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;730.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;675.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,406.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,333.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immunology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Taltz&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;422.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;170.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;593.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;194.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;212.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;406.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;616.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;388.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,004.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Emgality&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;99.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;140.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cymbalta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;125.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;132.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zyprexa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;88.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;101.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;51.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;76.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;144.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;305.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;450.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;COVID-19 Antibodies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;215.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;217.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Forteo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;109.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;91.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;200.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cialis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;137.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;130.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;36.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;52.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;88.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;354.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;282.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;637.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,989.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,783.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,772.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,161.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,579.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,740.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Humalog revenue includes insulin lispro.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Jardiance revenue includes Glyxambi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Synjardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and Trijardy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; XR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to Emergency Use Authorization (EUA).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by product for the nine months ended September 30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outside U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diabetes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Trulicity&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,465.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,122.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,588.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,673.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;892.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,565.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humalog&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,009.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;842.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,851.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,907.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Jardiance &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;566.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;492.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,058.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Humulin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;633.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;290.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;923.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;935.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;423.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;226.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;650.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;185.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;302.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;488.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,284.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,276.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,560.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,663.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,868.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,530.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oncology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Alimta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;911.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;714.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,626.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,677.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Verzenio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;582.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;363.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;945.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cyramza&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;266.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;496.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;762.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Erbitux&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;357.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;45.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;403.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tyvyt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;340.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;340.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;83.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;169.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;253.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,201.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,130.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,332.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,023.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,780.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,803.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immunology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Taltz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,071.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;493.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,565.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,293.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Olumiant &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;236.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;572.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;809.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,323.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,080.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,404.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;995.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,761.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neuroscience:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cymbalta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;454.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;484.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Emgality&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;313.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;102.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;415.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zyprexa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;28.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;264.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;292.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;81.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;154.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;235.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;453.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;974.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,427.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,356.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;COVID-19 Antibodies &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;949.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;226.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,176.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Forteo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;330.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;287.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;617.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cialis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;541.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;538.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;96.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;164.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;260.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,373.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,220.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,593.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,052.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,647.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,635.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,683.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20,318.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,631.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,468.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,099.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Humalog revenue includes insulin lispro.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Jardiance revenue includes Glyxambi,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Synjardy, and Trijardy XR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to EUA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenue by geographical area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&#x2014;to unaffiliated customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,989.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,161.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,635.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,631.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,098.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,629.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,984.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;595.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,832.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,919.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;400.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,285.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other foreign countries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;689.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,936.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,768.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,772.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,740.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20,318.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,099.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numbers may not add due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Revenue is attributed to the countries based on the location of the customer.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="i3751844cca5948b7a2fad81b7407b645_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfMi0xLTEtMS0x_0bebfc4b-4c23-4bb9-b2ff-4d70f71b686d"
      unitRef="usd">6189000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9740fd412b0b4c8b8920a13188bc08f6_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfMi0zLTEtMS0x_41a493d9-5f08-469b-9412-bbc0f4bb4dd0"
      unitRef="usd">5281100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i008aee30db1f4ed2b8bb7a205e2a213a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfMi01LTEtMS0x_ca966531-d949-4e87-868d-efe9e36b3cb6"
      unitRef="usd">18579500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie6e915f6611043fda08216f49f3b300a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfMi03LTEtMS0x_05b4d1ca-b48a-4c41-b91e-52ff3676d93c"
      unitRef="usd">15762300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib870f3d12a3f45ffba916dc4a4d8bc56_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfMy0xLTEtMS0x_e91b5415-dee5-48b6-bbb8-001f627488c5"
      unitRef="usd">583800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8622b2e9dd4842da9e583319c95a3d10_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfMy0zLTEtMS0x_69745157-f0ea-445e-aa79-d6316cbcae19"
      unitRef="usd">459500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i82cca299a87747259a76bff17b9d3f03_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfMy01LTEtMS0x_be2d6dde-05e1-4827-a3ec-75147d8de70b"
      unitRef="usd">1739000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b10af06686e401d9bc0772daa1af568_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfMy03LTEtMS0x_3b5b9db7-5096-41c5-8fc8-0472f55a0297"
      unitRef="usd">1337500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfNC0xLTEtMS0x_139b6588-f55a-4d1c-a4b8-8fa8816896ac"
      unitRef="usd">6772800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfNC0zLTEtMS0x_59337a68-552e-477d-bf03-1e7ff266959f"
      unitRef="usd">5740600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfNC01LTEtMS0x_4f71a1a2-f950-40ac-99a3-90eaa65b3a92"
      unitRef="usd">20318500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjkwYWRjZjVhMmZiMTQ4YzRhMWZlYmY0NDU1ODQ5MjgyL3RhYmxlcmFuZ2U6OTBhZGNmNWEyZmIxNDhjNGExZmViZjQ0NTU4NDkyODJfNC03LTEtMS0x_33917439-7ffe-40c6-9fa0-01fd8f68fde4"
      unitRef="usd">17099800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2afe7200511442b9be37640fe7d2a7f4_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RleHRyZWdpb246ZjQ4NTU3MjI0MjQ2NGE2YTg5MmUwYmNiYzA0YTMyODNfMjM4_180e556d-11d3-42f2-bbc5-ca162b9e59c3"
      unitRef="usd">62100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i33cd075c62264add8dfcb7b313a654d0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RleHRyZWdpb246ZjQ4NTU3MjI0MjQ2NGE2YTg5MmUwYmNiYzA0YTMyODNfMjQ1_a17e9349-6c64-4584-ab9d-2a3c4057fd29"
      unitRef="usd">136100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iba7b305393e54b31bccb95fbd0f79f67_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RleHRyZWdpb246ZjQ4NTU3MjI0MjQ2NGE2YTg5MmUwYmNiYzA0YTMyODNfMzA3_a4345444-e0ea-4b70-94c2-d3ca11680d84"
      unitRef="usd">31500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i69d6b9eefe5e435997214a4dc60d7f32_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RleHRyZWdpb246ZjQ4NTU3MjI0MjQ2NGE2YTg5MmUwYmNiYzA0YTMyODNfMzE0_1e3279fc-fdd0-4784-a036-61b4b157bb11"
      unitRef="usd">101500000</us-gaap:Revenues>
    <lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent
      contextRef="i61a4e12edfa84ace81f68212f895f984_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RleHRyZWdpb246ZjQ4NTU3MjI0MjQ2NGE2YTg5MmUwYmNiYzA0YTMyODNfODc5NjA5MzAyNjUwMQ_7b1c303d-1129-467f-8c48-0d90d3d74523"
      unitRef="number">0.01</lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent>
    <lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent
      contextRef="i6c7c7535680c41bdb5edaa1a9d31b011_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RleHRyZWdpb246ZjQ4NTU3MjI0MjQ2NGE2YTg5MmUwYmNiYzA0YTMyODNfODc5NjA5MzAyNjUwMQ_c80214d9-4629-46a6-b84b-1efe69fada68"
      unitRef="number">0.01</lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent>
    <lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent
      contextRef="i75ef086b481246719964b43441307bdb_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RleHRyZWdpb246ZjQ4NTU3MjI0MjQ2NGE2YTg5MmUwYmNiYzA0YTMyODNfMTU2MA_6a397baa-2016-4281-8103-300ab76039c4"
      unitRef="number">-0.01</lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent>
    <lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent
      contextRef="i5618c9f0179444b3b10b8ab8e3e9bef3_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RleHRyZWdpb246ZjQ4NTU3MjI0MjQ2NGE2YTg5MmUwYmNiYzA0YTMyODNfMTU2Nw_b22092d7-9960-4fad-8892-3e30b3389c26"
      unitRef="number">0.01</lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RleHRyZWdpb246ZjQ4NTU3MjI0MjQ2NGE2YTg5MmUwYmNiYzA0YTMyODNfMzUwNg_c7cd3b8c-c483-4230-b9bf-b3d668e44b4b">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract liability balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.276%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;278.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1ZWVkOWJmYzU1ODQxZWViOTBhMjljMzQzMDAzYzRlL3RhYmxlcmFuZ2U6NzVlZWQ5YmZjNTU4NDFlZWI5MGEyOWMzNDMwMDNjNGVfMS0xLTEtMS0x_3de6dab0-0080-4307-9fe2-f71a0452c1f8"
      unitRef="usd">278400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1ZWVkOWJmYzU1ODQxZWViOTBhMjljMzQzMDAzYzRlL3RhYmxlcmFuZ2U6NzVlZWQ5YmZjNTU4NDFlZWI5MGEyOWMzNDMwMDNjNGVfMS0zLTEtMS0x_bd2fa686-e22b-4282-8fa5-b1524ee6804b"
      unitRef="usd">276800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:Revenues
      contextRef="i619decfb20794db0b459aef3c32bc5e6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNS0xLTEtMS0x_d59e78b6-2212-43a6-beb6-a7b33237c2d5"
      unitRef="usd">1201400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2ac5fda408e6497890499865b967861b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNS0yLTEtMS0x_465e60e1-e082-4a5f-806a-60de75b76ee3"
      unitRef="usd">398800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0a9cefb7c292416bb0d6ebbb330edbc3_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNS0zLTEtMS0x_edc084dc-e191-410f-b0b0-f04a6bd6e4ce"
      unitRef="usd">1600100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8c1d6f95905448d385eb2e6e6dae543f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNS01LTEtMS0x_03f67b95-c383-42af-8d87-160fa1cef097"
      unitRef="usd">791200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i143a18efe3784ef881f53727b5686001_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNS02LTEtMS0x_b4ecd5d9-46e2-4659-932e-40d8b16fae4f"
      unitRef="usd">315400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4197f4f08df34479bd091bfc5c54df55_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNS03LTEtMS0x_fca2c5d6-4f05-4044-86ba-9b2629d133e7"
      unitRef="usd">1106600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3615f0b224ea424280772b92ec8e7d2e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNi0xLTEtMS0x_1e7abe53-bd3f-49a3-a96d-8e5cebb2030e"
      unitRef="usd">347300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc03cbb9d199450ea24aed63300c9230_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNi0yLTEtMS0x_f5ed7522-8677-4d53-8996-958bcee6d2b7"
      unitRef="usd">279400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i636a3552add040f5ad7def2b7dd765bc_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNi0zLTEtMS0x_952f3ee6-f5f6-47b7-9985-539b5da98bcd"
      unitRef="usd">626700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic0bcc0407fc64c0286f70bd29d8897e6_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNi01LTEtMS0x_fc4e26e0-8003-4558-abdf-10f17c8de3ed"
      unitRef="usd">390100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if95e2942890f4e65b9ee7a2130447a4a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNi02LTEtMS0x_caad2d3d-63b4-46c1-a965-81e6870634d0"
      unitRef="usd">266900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4e2e117448cb42c2a288857bc438f50f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNi03LTEtMS0x_1de8228b-08fd-467f-8bd0-a11bc60d23d8"
      unitRef="usd">656900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f0f99a60bc04551b5ae2d2be7ceceb1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy0xLTEtMS0zMDIzNA_72ea39d6-78d9-4cf8-8f19-c5340e3dd9b4"
      unitRef="usd">221200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2467cd73fd4349ddbfa9e1baf740e12c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy0yLTEtMS0zMDIzNA_097dd879-e794-4783-b09c-eddd7d691988"
      unitRef="usd">169200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie7a26c27a65f403eb8beb3df6550f89c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy0zLTEtMS0zMDIzNA_04c477ea-eaef-468e-bd0a-1e4307125c36"
      unitRef="usd">390400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5fa2f284977c46d9989820ed12d7553f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy01LTEtMS0zMDIzNA_d4157852-4c91-4742-81a4-4a5bf33479af"
      unitRef="usd">163300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia1cd05c961fe4864a7ad4058c5bb2cbe_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy02LTEtMS0zMDIzNA_acd59dc9-0a3f-4a1b-8c2f-8817c1dff27c"
      unitRef="usd">147500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc63f2b4f3ad4a38885421b13733cfbd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy03LTEtMS0zMDIzNA_9f8a6083-9cea-4827-bac7-176607621836"
      unitRef="usd">310800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic1843d4702b74c9b8adbaf5ab7aae759_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy0xLTEtMS0x_c591220a-4f49-42d0-879c-3ddf6fbce04c"
      unitRef="usd">193400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibf7ecd718b194d13826533eda4fbf459_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy0yLTEtMS0x_7d7c171e-f926-4cec-8196-fbf7bf8fcaa3"
      unitRef="usd">93400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6dc7e770251b4603b707a2b28a01efc6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy0zLTEtMS0x_8e82f5a7-dcf8-4247-8182-a90f94930f33"
      unitRef="usd">286700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6efe748f82424164bff261d4d56704a4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy01LTEtMS0x_7db2a0bd-3449-474c-9405-d490b400575f"
      unitRef="usd">214000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e1edb9e5a264ddaa2145ab88b861f25_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy02LTEtMS0x_59f3d1dc-951f-4b6d-86c3-c5371dc54197"
      unitRef="usd">91900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4e0bd74a50404b86b9780ef0d7574708_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNy03LTEtMS0x_2507d52b-1f55-49bc-b10a-2c5d14a0f1b5"
      unitRef="usd">305900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i23405a005d0043188b612fbd2cb9a01c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfOS0xLTEtMS0x_9f173bbb-3f0c-4b33-9b31-7aacd43eb2cd"
      unitRef="usd">114700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5f5d4c7e9fc24d87a56948514836e08b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfOS0yLTEtMS0x_65d3f4dc-6e79-419b-89a7-55d446a7572c"
      unitRef="usd">78100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idcd5ed73cc264b21bfcf6eb9c75a76f1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfOS0zLTEtMS0x_08954fd5-21c2-43c9-a017-6383ee01c53a"
      unitRef="usd">192800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibc683f8f7aec487db1c97534775202e0_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfOS01LTEtMS0x_e77599b2-37e4-44df-bbfc-d56d857a5328"
      unitRef="usd">178500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i013c2fd777cb4ad78b3588d03b646777_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfOS02LTEtMS0x_c0feb8a0-30cc-4a3b-9f2c-ac1b96209e94"
      unitRef="usd">69700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic4c206cb2e614db381ab7a7d1967bd03_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfOS03LTEtMS0x_0bd9260f-d6a2-4422-97f0-67a0f7762c19"
      unitRef="usd">248200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iad1245294846401dbd994a69555c3b22_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTAtMS0xLTEtMQ_dde0f8f4-8942-40e1-9a88-8ba97505d5b7"
      unitRef="usd">65000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id662cd6af0a1437492d74860015d4dd3_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTAtMi0xLTEtMQ_296e3256-6643-4b96-938f-14ecc961bff8"
      unitRef="usd">112200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic60d8559880548869550b76fd7e1622c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTAtMy0xLTEtMQ_a2c269f7-640b-48d9-99de-f91a2eb85f7f"
      unitRef="usd">177400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i81fb83afd9174a4584c76d363f319ed7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTAtNS0xLTEtMQ_45683a48-0bfe-4780-8cc9-6ae37eb3e26f"
      unitRef="usd">61400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6cfded4b3a63477dab06f1ce39f440c2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTAtNi0xLTEtMQ_10136077-00af-4266-b4b4-2e7be2eeaead"
      unitRef="usd">93100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2b041f3ba59449439e77c6a72a154148_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTAtNy0xLTEtMQ_b27f08a0-bc74-4eb0-bc5a-dfafc75ae20a"
      unitRef="usd">154600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i71a09b1522b247eb870ad3c04226f894_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTEtMS0xLTEtMQ_9cc4beaa-8e82-4865-9857-d969f10b96f0"
      unitRef="usd">2143000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if07f1bed036f4a8cab6b04215059a9a0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTEtMi0xLTEtMQ_9cdf0a13-90f1-4a6a-b37a-606779fe3034"
      unitRef="usd">1131100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2a81a76397d14cf3920f2f8dc0aff2ad_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTEtMy0xLTEtMQ_39b04d96-8007-43a1-b2c1-c77d8b788618"
      unitRef="usd">3274100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i66fe92bb4b37478283f0fcde0b4655e7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTEtNS0xLTEtMQ_355f2db2-7267-4b69-97e8-906fe33cbe06"
      unitRef="usd">1798500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i35a15d4ca7a14c94906cb2cb75408325_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTEtNi0xLTEtMQ_c12811cd-3c36-4894-a3f2-a7f2e3f4cbc9"
      unitRef="usd">984500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0e81fb756b57423eb9b5630c52df179d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTEtNy0xLTEtMQ_5c913652-c231-4b4a-8119-e686ddda411f"
      unitRef="usd">2783000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i833d461ea6104a85b39825c841b91425_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTQtMS0xLTEtMQ_2b0c6094-9152-4d7e-8af0-93a474e946e1"
      unitRef="usd">297200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f9102a7fb8049fa9237e84cee584b52_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTQtMi0xLTEtMQ_78972bf2-5702-43a1-8a80-286120813453"
      unitRef="usd">159800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7fc787ae1bbb4d8cb11f4f23e454b76c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTQtMy0xLTEtMQ_69d5ae31-aac0-44a4-86fa-5dafdec18fc5"
      unitRef="usd">457000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i65bdcc2ecaf44f2393df1548f2ca567b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTQtNS0xLTEtMQ_e58a5614-1349-4f78-b559-ff978b54cdf5"
      unitRef="usd">291900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i91e9f2f10aae452e851237fa01acebad_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTQtNi0xLTEtMQ_ce855260-5d02-4acd-9c5c-defc80425698"
      unitRef="usd">286100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f970f1846c9427d96a62ed28a252336_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTQtNy0xLTEtMQ_f2eca35e-809d-4592-a2c6-d652fcb467a4"
      unitRef="usd">578000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i808fde7a4bcc424abe955ca582b6c429_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTUtMS0xLTEtMQ_6798ec32-2e55-4aad-9c78-3731f89c9a6b"
      unitRef="usd">199600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4cb18d4711ef487292258d52ebcbb56f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTUtMi0xLTEtMQ_09b4d604-901b-4c2c-b951-0979d15b9891"
      unitRef="usd">135900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i85255af923d2412cadfe050e3f55be5a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTUtMy0xLTEtMQ_3fcfd93b-7610-41d4-a847-9eeba60a8797"
      unitRef="usd">335500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i55b77fb4de574805b40a93cc0c77e784_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTUtNS0xLTEtMQ_cd44d13f-4a36-4bba-9f13-5f7beddc94ee"
      unitRef="usd">158900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i610e677c79024836a14be2d01ea5588e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTUtNi0xLTEtMQ_474bf45e-2bc7-46ac-a2ba-666f19dfb7c3"
      unitRef="usd">75500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6adc0c0529714689a5664f338caae315_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTUtNy0xLTEtMQ_9055d34c-16f5-4f37-81f4-552cabb37319"
      unitRef="usd">234400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iac732504ce454cb9af710f8437b31b72_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTYtMS0xLTEtMQ_2cc7cce4-752b-4688-b6c0-743703529e75"
      unitRef="usd">84800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iad7f4df9b6b44f7b8942015b498f808e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTYtMi0xLTEtMQ_bad36f12-0775-46bf-85e8-336b49cbcf94"
      unitRef="usd">168600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id9596c4e04274bb8b84585df2008c087_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTYtMy0xLTEtMQ_1f86c386-3ee4-4368-9837-f380a82e45e2"
      unitRef="usd">253400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib3cadcc0ccc047aeadd216305626ae7e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTYtNS0xLTEtMQ_07b7b0e1-d16f-4ffd-8521-5bcbb091565b"
      unitRef="usd">94500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9b7407649b1a42b38ee51c3819e286b9_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTYtNi0xLTEtMQ_0517fe89-e236-422b-99ef-b8fa579293e5"
      unitRef="usd">158200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i74f827e23ec74d3592ec62c9d8a24045_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTYtNy0xLTEtMQ_255c6448-7883-4229-bfb7-3d7851d88f6f"
      unitRef="usd">252700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1f64171c60cb40589455a45ddebdb7f0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTctMS0xLTEtMQ_dbc7a650-e747-49a1-b18e-584822fed171"
      unitRef="usd">114000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i87336623af3c4094ae1f02a8981d1c87_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTctMi0xLTEtMQ_1357c7d0-9a30-4a71-9d9e-c21ccd91b907"
      unitRef="usd">20300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i44aed9a2ff864ffbb9dabb42a9652a4d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTctMy0xLTEtMQ_207bccec-9349-4fbb-b328-0f662719c871"
      unitRef="usd">134300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2ae25d95b4f8443e97e0378c32d9625a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTctNS0xLTEtMQ_dcbe035a-c9f8-46bc-9505-42786393b005"
      unitRef="usd">122500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i34c6cc4dbeb24eeb82e00b1ebe898947_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTctNi0xLTEtMQ_35d0f556-455a-484c-b893-70a4e81145de"
      unitRef="usd">14000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i99138be47ed847849c3df6c670763516_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTctNy0xLTEtMQ_afc9d3a3-91bc-4c79-bcd1-5be707e251c3"
      unitRef="usd">136400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iafb2cb4b4ba94633a0d9effd3535a22d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTgtMS0xLTEtMQ_afccdbc0-cb9e-450d-ae08-aafa732349be"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i94a1de0c39bb4d91a6b8220fd88cc995_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTgtMi0xLTEtMQ_e889874a-3b4d-43b4-85af-abe821cc0439"
      unitRef="usd">125600000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i897388675b95435fb4f36e6b1e6cd6f9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTgtMy0xLTEtMQ_39d3e977-4a04-4ba9-81e2-587ec283cc4b"
      unitRef="usd">125600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="ia8207dcbe71c47eca3c2f1096df4b7a8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTgtNS0xLTEtMQ_212de80d-d46a-46f7-95b4-0ab0d455a982"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id34b15be682a4e5cafaba09fd90dc0a3_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTgtNi0xLTEtMQ_e66e90c8-79a7-4a5c-a7c4-e3be41d15076"
      unitRef="usd">84400000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33b4d90ccdd9479fa1adc0ede684c6b6_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTgtNy0xLTEtMQ_54ee13a5-40a6-4053-a4a5-53eee5f277c2"
      unitRef="usd">84400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i9dbd0fc64d85402a8c6614d6d2cc1b34_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTktMS0xLTEtMQ_ed079269-9c1b-4ed6-9a1e-cb3a887f7dc9"
      unitRef="usd">35300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i252c837f8bcb4ac0b13f2285fadeb589_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTktMi0xLTEtMQ_20ca714c-a959-4915-995c-ab667b245811"
      unitRef="usd">65100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7569cb5db95e4d16ab9bf1906d28a414_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTktMy0xLTEtMQ_050ea72d-15ad-46d9-9f24-75716f0b07f8"
      unitRef="usd">100300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e344efb8a154f9293c35b2a2071dea2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTktNS0xLTEtMQ_e67c8c99-31dc-4476-8291-735a516c64e5"
      unitRef="usd">14700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8bc5a0211b694ef1ad818a7c769134c9_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTktNi0xLTEtMQ_f39ce5ce-e1c5-41f1-a5e5-dad9450c367d"
      unitRef="usd">32700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i79cde695c635485fb5969cbeffb8ee65_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMTktNy0xLTEtMQ_759e1e2a-7ac1-4dbd-a0b9-81e0e54af977"
      unitRef="usd">47500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i79a992ad9b904ca59f6786e45f7b37de_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjAtMS0xLTEtMQ_609d4f29-c70b-4db0-8c94-6aca7ef8d6ef"
      unitRef="usd">730900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id598f2d470ee46d09e2445b9507ad3f2_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjAtMi0xLTEtMQ_8744d27f-3782-43e5-b043-3ee2bdbde78b"
      unitRef="usd">675300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib8103205049b472f8eae31d6a58e53a8_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjAtMy0xLTEtMQ_27700197-1972-4b12-ac86-9b5fe303c638"
      unitRef="usd">1406100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if532b94bdbac4bce82537f40e4a0cf51_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjAtNS0xLTEtMQ_eca1ae2c-3111-452c-a61c-ff14493f0a35"
      unitRef="usd">682500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iafbd8b57ba564ee298f69bd41e7e8601_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjAtNi0xLTEtMQ_503ed0c6-ecee-437a-bf30-80bfc06fee56"
      unitRef="usd">650900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2e4c02ed82d7415eb7c1bcf15c6c21b8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjAtNy0xLTEtMQ_dd155eac-1731-42d2-90e2-e5645520587c"
      unitRef="usd">1333400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8d59e5583c8648d7b78f39b5a5466a11_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjMtMS0xLTEtMQ_20158550-7403-4999-8c0e-ba884d7a76ee"
      unitRef="usd">422200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id6aab2127a004f0ba2023cc7bf0b485e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjMtMi0xLTEtMQ_a42332f5-281b-44ef-b1c1-38a52c3dd4ce"
      unitRef="usd">170900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia56673e90d78440b919786ca8b4e5230_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjMtMy0xLTEtMQ_0f071850-945c-48a0-a795-2dd2a6627e54"
      unitRef="usd">593100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0f342cfe7ed447c972ee626e06d8847_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjMtNS0xLTEtMQ_40660ae6-0c59-4fdd-91b2-5989b2702686"
      unitRef="usd">326200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2f56993e98d5433a8d3954524f86fd8d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjMtNi0xLTEtMQ_1b5cf3e7-f24d-40f8-aebf-90920f376790"
      unitRef="usd">128300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i77fbbc9968cf4bb18902690fe1fd8686_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjMtNy0xLTEtMQ_4698ffc1-2d20-4fb6-882a-268256cac90f"
      unitRef="usd">454500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iad10567d7217449bb0a0eacc29b03bb1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjQtMS0xLTEtMQ_321e7864-67d9-4b6f-9d90-08d246a427d1"
      unitRef="usd">194000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i28a2e586d3c54230929df1bb15cecbc0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjQtMi0xLTEtMQ_159f018e-e75a-4d04-b20e-69ebacf382ed"
      unitRef="usd">212900000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb79dda4914c4c118d30138f4db6d0c9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjQtMy0xLTEtMQ_58a3f336-9243-4044-9159-317fb0607fdd"
      unitRef="usd">406900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="ia634a6f32f8d47e087b88320b460594d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjQtNS0xLTEtMQ_134463ea-ea4f-47f9-8b5f-735bdff2d039"
      unitRef="usd">14500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibc9c80adfe494319a49b462b4c84e227_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjQtNi0xLTEtMQ_a12a5c38-42d0-493e-9ef1-23bc31379d9d"
      unitRef="usd">147500000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89bc1277904f44ebb00cc1c346f34407_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjQtNy0xLTEtMQ_1bf30166-cd31-47d3-81ad-f9d8858e6723"
      unitRef="usd">162000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="ibc39388717ab43b39a31ccad3c4b5ae1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjUtMS0xLTEtMQ_486ce1be-dddc-4d7b-b194-3427b21d73ec"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i391eae2ff09a4964b6b7b192b55be566_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjUtMi0xLTEtMQ_1983c21a-2943-4911-828a-dfbeee300b44"
      unitRef="usd">4900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i252d50dbb8234dcaa62617a57a7f132c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjUtMy0xLTEtMQ_15389c95-ab2b-47d9-88ef-edb0c2ac74bc"
      unitRef="usd">4900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i87081eb668e448cca72a3cfd33b884eb_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjUtNS0xLTEtMQ_9b59f405-bc62-4230-852d-a385d40241bf"
      unitRef="usd">6100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3510314a6b1348e1ad1a289c769221a5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjUtNi0xLTEtMQ_1bfe96cc-f878-4b39-95e0-b67bdba8e7f9"
      unitRef="usd">4500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i69df563139e5499c9977856b5c047b89_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjUtNy0xLTEtMQ_b7b8c522-5189-4074-8b61-d94ee3a3ae28"
      unitRef="usd">10600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3eefcda66434dc7bdb28af6eacee5ae_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjYtMS0xLTEtMQ_f86bc3ba-c150-4528-9c7c-41182d0bd320"
      unitRef="usd">616200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide62ca0bafc24f6189c5766c74864a61_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjYtMi0xLTEtMQ_14b31436-b06c-4108-aaed-483bd85e13ef"
      unitRef="usd">388700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6fc211aaf0c04cde8b946bf6a6c2101c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjYtMy0xLTEtMQ_4f7c7e4a-c4e4-4b6f-bff1-3c041ced1f08"
      unitRef="usd">1004900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ae2f07cc5ec45d7b4df160393ddcfeb_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjYtNS0xLTEtMQ_3f1df87d-69a4-42bb-8f66-95a7b121ae4e"
      unitRef="usd">346800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i17c7b300da94407dacde87022ba06fe4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjYtNi0xLTEtMQ_48e39929-0c68-4031-b81d-2106b6369544"
      unitRef="usd">280300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4a964d449ac84c94b6a4e507792eaf2d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMjYtNy0xLTEtMQ_61378411-086a-4bfe-a8e1-6e550c8dda1f"
      unitRef="usd">627100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2e0ddfd3674c4908827fced5b7901b52_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtMS0xLTEtMzAyNDI_c67dab2c-f924-41e0-9672-5f4de2d68c71"
      unitRef="usd">99900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i65e6b9bae263441f8bb7c2a734d070c0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtMi0xLTEtMzAyNDI_8539d989-b50c-4864-ade9-a6f48c2c636c"
      unitRef="usd">40100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i603eda46c0be4d8b86ba9ef36bd2af4d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtMy0xLTEtMzAyNDI_99b2375b-8ae0-4c4a-ba6d-c08972ad9239"
      unitRef="usd">140000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4fbcaa2d029c4c05bafbb0400bfe6df8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtNS0xLTEtMzAyNDI_349740f2-e6f7-471a-b1df-67caaa79fa3c"
      unitRef="usd">81400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4fbcaa2d029c4c05bafbb0400bfe6df8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtNS0xLTEtMzAyNDI_6091d61a-51b8-430c-861a-b412afc2b445"
      unitRef="usd">81400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1492ec6093ff478e916d7d23f4f020ab_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtNi0xLTEtMzAyNDI_8a5273a3-2af5-4eac-a092-45c5e31de5dc"
      unitRef="usd">10100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1492ec6093ff478e916d7d23f4f020ab_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtNi0xLTEtMzAyNDI_dd55312e-517c-4205-af6e-7db820c3950a"
      unitRef="usd">10100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i60dde10942844b47a3c7d72ca1e89c00_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtNy0xLTEtMzAyNDI_39d9f907-ad06-4633-a6f6-0ecf4718cef1"
      unitRef="usd">91500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic9a4c536cd364a3fb26c3f2186868f7d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtMS0xLTEtMQ_42d1dc3f-30b4-431b-b3b9-4e8edf21e3d2"
      unitRef="usd">7000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3881ab6fddaf4d0397d1251b9b335eaf_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtMi0xLTEtMQ_272ac533-d017-476e-9809-19843c857679"
      unitRef="usd">125100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5821c8abb9f442939c46c5f2ea55e15a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtMy0xLTEtMQ_b4a4db5f-3858-4aa9-9845-802943067f62"
      unitRef="usd">132000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6f20b6672fbd429cbc47b24cc460ae1b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtNS0xLTEtMQ_ba9f3be3-ba6c-48f8-98ab-e8bfb2b39f3a"
      unitRef="usd">11100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3bac77c719ed47c6b5e1daba371ea914_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtNi0xLTEtMQ_c6b99f78-753a-48b7-a3e5-551e4979ac50"
      unitRef="usd">175500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibcff59ffda63475ea32a7379c4669b03_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzAtNy0xLTEtMQ_bee46743-dfae-405f-9786-4b9a164a9186"
      unitRef="usd">186600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if2f4b471c7e348ca914c418fd367c183_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzEtMS0xLTEtMQ_9dc074c5-d907-4c53-88e5-d85a4f119c0c"
      unitRef="usd">13000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd4429e99d4349deb077d59d1dad17eb_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzEtMi0xLTEtMQ_78436f1d-4079-4114-bfe7-0505adfdabe0"
      unitRef="usd">88700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iceae9cbc8e6f428cac0b0351b0034ee5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzEtMy0xLTEtMQ_53631442-93e6-444f-9bc5-f8c2adb6f2a7"
      unitRef="usd">101700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i92d973cd4a0a4537962a3af58489887b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzEtNS0xLTEtMQ_8f9a28e6-1751-4acd-9d6d-5db135ab3527"
      unitRef="usd">21200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifebda85ec8dd4ce192a74a6531b9d614_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzEtNi0xLTEtMQ_d0d8b7a1-796f-41ee-89fe-f185a75c161c"
      unitRef="usd">91500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe8ab0e4d8fd4cfd9126dfb95a32ada2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzEtNy0xLTEtMQ_64151707-2980-406e-886a-bf0f02486d53"
      unitRef="usd">112700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3921ded1beba40848d3de915564681a9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzMtMS0xLTEtMQ_8ec30cb3-871f-458f-b6e2-3c0510c0b997"
      unitRef="usd">24700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia7659a70032347a1a0b90552b4d62ed3_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzMtMi0xLTEtMQ_449430ae-5a8e-4bc7-9551-1a5089636309"
      unitRef="usd">51600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i186444e26ab54d898b6b15b3ec836f25_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzMtMy0xLTEtMQ_f17090db-b164-4cec-b57f-b91d48a10fd2"
      unitRef="usd">76500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i453051ae80004c3eaa95fb204101dd02_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzMtNS0xLTEtMQ_ffe2fd1a-22c4-4f3e-87c5-79c384363aa2"
      unitRef="usd">26700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i31a4994fe4e0451d9b0de9fc4cc45241_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzMtNi0xLTEtMQ_4d250ba0-46d1-4cac-bd57-37413988adf2"
      unitRef="usd">53200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib39a29f5f552438ea4ed0f6636e277a8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzMtNy0xLTEtMQ_d8ffb844-705d-444d-af42-b672a1ec43b4"
      unitRef="usd">79900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i052653fc20254249a0de9e128a7c2a7b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzQtMS0xLTEtMQ_c3aacfda-9566-43c8-8f47-88529f5780f1"
      unitRef="usd">144600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i089ee5a884734f048eeee3e2567bf7ce_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzQtMi0xLTEtMQ_d2b22e32-1014-409e-bd0a-e893ced779ca"
      unitRef="usd">305500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i292fa580da6a4de9822a300c2b0366fa_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzQtMy0xLTEtMQ_d7075acf-7ae5-4ca2-9682-a4ecf16a0ef2"
      unitRef="usd">450200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7a55f0b0a5af4394ad7de980181c592f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzQtNS0xLTEtMQ_62f89521-7a21-420e-8495-5b5d41a19c6d"
      unitRef="usd">140400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8a2b9316931c41cbad3fbe52783bbc71_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzQtNi0xLTEtMQ_520cebcd-f45f-4993-a367-2cdabd1b163f"
      unitRef="usd">330300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6cc53c31079d4498baf5c2908aa20aa4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzQtNy0xLTEtMQ_8e59a9fd-8236-496d-8c46-85517fcfb9d1"
      unitRef="usd">470700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i71b81d21fbe94b4e98b74b22e329e4fe_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzgtMS0xLTEtMQ_719e4dcf-db3f-4327-b74b-e8a13e0ff261"
      unitRef="usd">215500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i083918a48bb449d78ad626ecb038546e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzgtMi0xLTEtMQ_1cda5468-9c90-4840-a158-01c22c25e6a9"
      unitRef="usd">1600000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1915b82ef0745bc9e6902e358dcf426_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzgtMy0xLTEtMQ_6dc441b1-235f-4a1f-bcdc-e193e5d2b244"
      unitRef="usd">217100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i1382419146344dc79bef45e72e6ff200_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzgtNS0xLTEtMQ_28eac30f-7154-4066-9d49-7c58f3ad1981"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7998ccfffad54f5a9b058726aa6b7326_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzgtNi0xLTEtMQ_f16f27da-8314-4541-8d2b-8a336255448a"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i55ecf9bd230b4e6f9a61f2f6dd604b6a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzgtNy0xLTEtMQ_378eada0-977f-4253-a5ef-e8a2731a3218"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifd86bf7f1e8344b3a7dbfbaf21dd0e6a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzktMS0xLTEtMQ_754d7448-e56b-4b11-8b6a-b22fa87da68f"
      unitRef="usd">109600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i51349dbae1e142efbd09be3fc1d7902d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzktMi0xLTEtMQ_cb147a87-d4f0-47af-9a52-aaf5b6157910"
      unitRef="usd">91300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie18eb8b2caaa4e6bba191b1bd794bac5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzktMy0xLTEtMQ_7808cba8-fe2e-45f4-ae3e-a221eff92e2b"
      unitRef="usd">200900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i517eba3441bc456fbc2a2c195f1e25bf_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzktNS0xLTEtMQ_58899e93-4d7b-4504-a387-423e445fc45d"
      unitRef="usd">144600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe5334101eb14c808e2139001ea4c06e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzktNi0xLTEtMQ_0a319970-ca3c-4e8c-b100-30929b41106d"
      unitRef="usd">122300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia255d15fc6ff4cff922a9ee2fb0c0e96_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfMzktNy0xLTEtMQ_17c261cb-801a-44bc-a2e5-3bd78dc95eed"
      unitRef="usd">266900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8bb5a4110102404cbfd2c7b4ba607883_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDAtMS0xLTEtMQ_6c818eb2-883a-4208-8119-ed690237dc16"
      unitRef="usd">-6500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8cf54671a7af41728bdbea955e0f5c5f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDAtMi0xLTEtMQ_4f1a3d05-7601-427c-989e-5aead6fda2e4"
      unitRef="usd">137400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8890bd1f5f1a4efaaaca2db702f79703_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDAtMy0xLTEtMQ_7889c926-be9a-40e8-a1b8-50de91ce2d02"
      unitRef="usd">130900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i959c1d63793f4187b23a4c1b7682d284_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDAtNS0xLTEtMQ_cbd0dddf-db00-4378-876b-3e257f5611b0"
      unitRef="usd">15100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idbe2a3bad44c450a8397960daacfd707_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDAtNi0xLTEtMQ_72889837-ec62-481b-b32e-0ba50bfda2e1"
      unitRef="usd">147300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i19c6a9959ea140fd9890927f182fe605_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDAtNy0xLTEtMQ_4745ec45-04bf-4b3d-98f4-64bd8805fdae"
      unitRef="usd">162500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic46899cdc2a5456f9e0611bd0426b4fd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDEtMS0xLTEtMQ_71529216-f3ef-40f6-8584-e164a553a5a2"
      unitRef="usd">36300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf2deaf4d18c449490361e41a4ac0cef_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDEtMi0xLTEtMQ_fd30446a-2dc3-4700-a20e-64ec2349aaa6"
      unitRef="usd">52400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i289d3252ca6a485f820ef1ea3ad85c12_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDEtMy0xLTEtMQ_0630543a-b0f6-4566-bbb1-cb8ee33e08d2"
      unitRef="usd">88800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i784dad6404be43dfb6fc2b79158399e7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDEtNS0xLTEtMQ_ab2ecb1a-13ba-401f-9690-d53b6471c0d5"
      unitRef="usd">33500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icaa3e0c977aa4404a714b3813766c78f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDEtNi0xLTEtMQ_460636c4-6443-4704-91df-68a980db8d90"
      unitRef="usd">63600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i82485c3a3fba4749bfbbb721e21e7f30_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDEtNy0xLTEtMQ_96efc2ba-e5bc-4391-beb5-05bcddf270ba"
      unitRef="usd">97000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i58158972e0264a6fa5cee16276b66a34_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDItMS0xLTEtMQ_8e528a55-bdfe-489d-9bfb-c51f348f7110"
      unitRef="usd">354900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia3ec4f79f58b44a296e438bfeb9305c9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDItMi0xLTEtMQ_fab602ef-ff21-4698-abd8-b57a782c939f"
      unitRef="usd">282700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iddc5a8ab9f9e49e9b1727ce623456ec5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDItMy0xLTEtMQ_4c657260-75ff-4605-9afb-c5443e18faee"
      unitRef="usd">637700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1fe1bbef48c94f69a1e7eb1738576328_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDItNS0xLTEtMQ_a3e3e369-c7c9-49f6-87b3-160b7b5dec7a"
      unitRef="usd">193200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i41665e7d5323479fa5a85ac7afd7a612_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDItNi0xLTEtMQ_c5c17eb1-a678-42b1-bd95-5f168e74cf6f"
      unitRef="usd">333200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id54a327ff97d4ef9958f15bb7ed74770_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDItNy0xLTEtMQ_b12a47c4-ff44-4323-9e21-4f9ba5c6e8d5"
      unitRef="usd">526400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibd448a0d7d984d978046eded1bdbef98_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDMtMS0xLTEtMQ_a14094ca-d373-4d11-9f3e-b14de5c68431"
      unitRef="usd">3989600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if41782491b964242bf0779976ed75cfc_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDMtMi0xLTEtMQ_ba2ed9fe-9624-4ddc-b5a2-409e7d7e18ac"
      unitRef="usd">2783300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDMtMy0xLTEtMQ_686ead47-4daf-4162-93ce-47b333b3b580"
      unitRef="usd">6772800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0fa9309b68448efb27e0f24f9cfa0a4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDMtNS0xLTEtMQ_e9fdcf8f-a448-4faa-b719-f1db7fc197f1"
      unitRef="usd">3161400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iecf6d4dabc7f494caae8aa84b2e0e2bc_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDMtNi0xLTEtMQ_9da00898-6dd5-45c3-b1aa-ecd87b55992f"
      unitRef="usd">2579300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjE0NmRjN2MwNmRhMTQwMzRhY2QzMGNiMjViYTI1YzI4L3RhYmxlcmFuZ2U6MTQ2ZGM3YzA2ZGExNDAzNGFjZDMwY2IyNWJhMjVjMjhfNDMtNy0xLTEtMQ_54cf53b5-f5e5-41f6-b1ba-e2ae37c0b222"
      unitRef="usd">5740600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ida742051726641c1a38ba8085a59818b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNS0xLTEtMS0x_8aad5ef2-0b8c-44a0-8e6e-8630589c2ea7"
      unitRef="usd">3465700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8afbe65684454a96aad4f5fcc43bb2f2_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNS0yLTEtMS0x_ded1ddf9-99df-4d11-95fa-96de5fce663e"
      unitRef="usd">1122500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c156843918049c3b017e903d0c8b152_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNS0zLTEtMS0x_76ce43ab-0513-4887-893d-5442a0a8f52e"
      unitRef="usd">4588200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8c0e23525a404bd980161347b9d48297_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNS01LTEtMS0x_e04b6e2a-6b7d-4a82-bbfe-fc6d934993f9"
      unitRef="usd">2673200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f487e07da6a4df7beced03386ce2cb2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNS02LTEtMS0x_cda15270-0560-4341-b7d4-548eb232b098"
      unitRef="usd">892500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifda1418c5f224ffabb56a4cd20894bb4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNS03LTEtMS0x_ed5b4f10-e2c8-4e67-a59a-cbfc18262958"
      unitRef="usd">3565700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i21f5c26534d04950a2d18f70db623648_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNi0xLTEtMS0x_c2c55b82-46ce-4f46-bca2-748e731fd7e3"
      unitRef="usd">1009000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd90c62ee1c04e2e80e99978c6745eb9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNi0yLTEtMS0x_cb375e2a-c88d-4aaf-840c-a5d568a74360"
      unitRef="usd">842300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i392ba95f36004b559b3dabf4a7d68df7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNi0zLTEtMS0x_1e662a27-8d5b-40fc-9f4f-a104046206ea"
      unitRef="usd">1851300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i78362cdcc41745bb8bda6133796f6fd2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNi01LTEtMS0x_a2c3c5f9-578b-47fc-8ee0-a0de0c4dac89"
      unitRef="usd">1070400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1b810a3d51924e95aeb4d64791147211_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNi02LTEtMS0x_06cbd221-3c92-4237-a79b-3d9c47f66577"
      unitRef="usd">837400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1d57ac52c7bb44dba43dbba774be4bf2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNi03LTEtMS0x_7f734537-3de3-489b-9ae8-a08f636c0442"
      unitRef="usd">1907800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f3d83ab14504b6689cc76eec030040f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy0xLTEtMS0zMDI1OA_7b89ebe0-faf4-4c0a-8726-9305cda30758"
      unitRef="usd">566800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9a6c69c487df42779007c37685f53e85_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy0yLTEtMS0zMDI1OA_3539b872-6c40-47fd-97f8-5ad7cf7b134c"
      unitRef="usd">492100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0c5cb50d0a384037b1da389f2a6e0996_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy0zLTEtMS0zMDI1OA_2fe7df2b-2d70-415d-b85d-21a4ed6a2917"
      unitRef="usd">1058900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0c5cb50d0a384037b1da389f2a6e0996_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy0zLTEtMS0zMDI1OA_90845ff0-de10-47e8-800d-e192fb7b3100"
      unitRef="usd">1058900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5877d4ccd49f4569b4e2595a05ac782b_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy01LTEtMS0zMDI1OA_727c0cb3-01a7-40a7-94c0-e0876048ff59"
      unitRef="usd">453000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iee73ab780a8f46d8b5fd8ade8860c89a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy02LTEtMS0zMDI1OA_51d26a21-0335-45c4-bded-dbe430b728b7"
      unitRef="usd">387300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idfc25dba031242f7b3f38ee74a40876d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy03LTEtMS0zMDI1OA_9ee139b7-1f1d-4453-9546-e4cd3f70f1d0"
      unitRef="usd">840300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7646113be96547db8a4bb44230ae23e6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy0xLTEtMS0x_d7ad04ec-8185-43e9-a9c4-c79866b6f5d3"
      unitRef="usd">633500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe4ca92881b34f2d87b3d3d4afee83d4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy0yLTEtMS0x_12795a2a-0e15-47e6-bd19-62b7adf3b772"
      unitRef="usd">290300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2f931c0b571a4fe0ba04399bb7cf2882_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy0zLTEtMS0x_fabb4110-1559-4d92-8e32-920e13cc04fd"
      unitRef="usd">923800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic6079c23287c458d90dcf5793335aca1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy01LTEtMS0x_aef9b0ae-2f7f-445a-8119-d322db16546f"
      unitRef="usd">642500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i45f071d62d774401ae3df21bca257b94_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy02LTEtMS0x_85284325-790b-49b3-91ee-666d28bc402a"
      unitRef="usd">292700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if6bfac32d58a4b7db6eb70dfb23fd9fd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNy03LTEtMS0x_d7b5575c-0c49-4cdb-9f75-1d92e5e3b55f"
      unitRef="usd">935200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic485be951f44461b83f7178570da126d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfOS0xLTEtMS0x_8ed96778-9181-445b-b7e5-900679f61661"
      unitRef="usd">423300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i399cec6d60df445682e5e26167ab0fa6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfOS0yLTEtMS0x_513b64cb-6be0-440c-805c-d821704a95ad"
      unitRef="usd">226800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib84ab601c2e045f9b4f9ff1a30e0787a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfOS0zLTEtMS0x_fb9d9946-288e-4fd4-b533-a14533f1ea7a"
      unitRef="usd">650100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8f09f9b3b0ed4eeaadea6c487497dc7e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfOS01LTEtMS0x_dbc6c011-711c-45b7-9650-fe0cbe6ea97e"
      unitRef="usd">638700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia0327ede8f6347659e88e5324c757fc9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfOS02LTEtMS0x_1ce795bc-e7af-41af-b63d-c5a186863906"
      unitRef="usd">203700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie9fdd628b285469fb2e83ec947cf3bb1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfOS03LTEtMS0x_d0d78fdd-45bd-4c66-8e65-823515fdc548"
      unitRef="usd">842300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i397a56587b474dc5810261bc659887e2_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTAtMS0xLTEtMQ_ed4accfc-cc2e-4e11-bfba-007ed8793610"
      unitRef="usd">185700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iacfcc3433c15426bac8a79d18149a311_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTAtMi0xLTEtMQ_53516c02-49c8-48cd-b927-2343d61a079d"
      unitRef="usd">302600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2fda94809a0f43ca9938efc6f0994e74_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTAtMy0xLTEtMQ_4b463fd5-d756-4b6a-ab42-14e66107b85e"
      unitRef="usd">488300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifd07e050427d4b0495759b6f44c3273e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTAtNS0xLTEtMQ_d13daaa9-bade-4711-816c-262ef333e024"
      unitRef="usd">185200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id4d463248ad74b09a08446c68620a3e1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTAtNi0xLTEtMQ_b3732117-35cd-47a1-98cf-02ee69a6d648"
      unitRef="usd">254400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0185d32bea7d4ee0b0b5e34fbac1fa96_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTAtNy0xLTEtMQ_6272786a-bf87-45f6-ad76-c05177c37f61"
      unitRef="usd">439600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03a83d2e4f15480780af7cc663a095e8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTEtMS0xLTEtMQ_1aef078b-19f1-412a-9ba8-42d76113f31e"
      unitRef="usd">6284000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iafb64cc18d0c4af79c7b894a05a665e1_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTEtMi0xLTEtMQ_384e64d7-d868-4b89-8a03-8e309157833f"
      unitRef="usd">3276600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d04d41e5ada46e1a63e592fc6a9b2d2_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTEtMy0xLTEtMQ_08cf7b84-32ed-457f-a476-3efbf1a9efa2"
      unitRef="usd">9560600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i652338f7e46b486589e3d75d6a3de4a0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTEtNS0xLTEtMQ_0f796504-77b3-42ce-8dde-a740f7de07d1"
      unitRef="usd">5663000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i705897b88c1c4bc9ae28abf5053986a2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTEtNi0xLTEtMQ_ea3798af-83ad-4ef4-9fee-d9e2b0c9e094"
      unitRef="usd">2868000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i73e2acd9dcfc42759dfd0fcf3b77d702_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTEtNy0xLTEtMQ_257dd121-faf8-49e2-ae31-e5bbf596031a"
      unitRef="usd">8530900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if46b1191ac1c46e9b91d7193b8f302bd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTQtMS0xLTEtMQ_f8158f3d-24bd-47a2-97fe-c19b3dfcedea"
      unitRef="usd">911900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ica3c1e4736274954a8d703df9c2b167a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTQtMi0xLTEtMQ_401620f9-b55a-4461-bfa9-2c97ec1fdf0c"
      unitRef="usd">714700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0a497c7c118f46e98f40fdba8afad80b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTQtMy0xLTEtMQ_088434a9-726e-4c9f-a42f-6477dc490f2b"
      unitRef="usd">1626600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifa5c550586744b789a920295b90fe29b_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTQtNS0xLTEtMQ_7910288c-1fb8-4363-ac8a-46b97170adfd"
      unitRef="usd">933400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i99d38563475f4c678f23755bdbf34b9e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTQtNi0xLTEtMQ_8304fc29-390f-42f1-a8c7-e5f29bf26a11"
      unitRef="usd">743800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibc96b44a7e7c4b2d9067f6309c9e0981_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTQtNy0xLTEtMQ_33278e34-06d2-4b98-8ccb-c8b498d0ff3b"
      unitRef="usd">1677200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie4dee8841aff467e8d34d2a66b5ede53_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTUtMS0xLTEtMQ_69f95715-cb83-46fd-ae14-8603597059a1"
      unitRef="usd">582100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8aa0f1db9a924a86a4539ed44bb03cf4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTUtMi0xLTEtMQ_a6f8a1e4-6e7c-434c-b17f-0f98cbff1b01"
      unitRef="usd">363700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i55ad0c64dc4445c8b5360106446e4e0e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTUtMy0xLTEtMQ_e7e3464a-f866-4ed2-914a-cbb221916f7c"
      unitRef="usd">945800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i619fc1a06c8e4e23955358634606df7a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTUtNS0xLTEtMQ_28ee84cc-fa79-4425-a3ee-80f9ab577981"
      unitRef="usd">430000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2b9c66fd8850463dabe617b7427612b9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTUtNi0xLTEtMQ_b41e5855-0495-4018-bb5b-96274b251306"
      unitRef="usd">201100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i90fe301cd12a458a8609a9e6744b77c2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTUtNy0xLTEtMQ_693e4402-d4ee-4ef0-b3e3-49d7c1053741"
      unitRef="usd">631100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc36beb9b14e4b9783e4927f8ff53209_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTYtMS0xLTEtMQ_787b6cb5-6ed1-43ed-9b78-141ece7b5545"
      unitRef="usd">266300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6fc16180ac704e6f8cae3536cc15fc44_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTYtMi0xLTEtMQ_962932c1-ba21-403b-a5dd-6c12798987b5"
      unitRef="usd">496300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1974eeef369549dc94df5ceef4375ee4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTYtMy0xLTEtMQ_27834960-6aba-4ee0-9f4b-3613d5f3253a"
      unitRef="usd">762500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4683a7953b994727aa54bdf352b5d02d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTYtNS0xLTEtMQ_74d2211f-14f2-4fca-9b26-5d9287f2bec3"
      unitRef="usd">277600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7cda66e9d3f64ed7b5ab5be8945ea9dd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTYtNi0xLTEtMQ_696dd423-a903-44e0-bdb2-670da71284ed"
      unitRef="usd">470800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0289a925449c4af893800c44334d7179_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTYtNy0xLTEtMQ_4a37b3f4-546f-475f-88d8-dcd827d2ef1d"
      unitRef="usd">748400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i760c1d6d41874cbba99a6b0a36e9dbfc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTctMS0xLTEtMQ_51f12bde-9720-4a87-a011-a7ffce3769ad"
      unitRef="usd">357700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9171d813dd8744aa8ebf6be081733303_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTctMi0xLTEtMQ_365f403f-aba2-4941-b9a6-f6f9d2151026"
      unitRef="usd">45900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia12001823d9949fbaf94effdadcee1f0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTctMy0xLTEtMQ_620f0e68-9b23-4e9d-961e-bfb2a07b7b84"
      unitRef="usd">403700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i374b134314ff4f75bf1e218faeb7a140_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTctNS0xLTEtMQ_afbe7492-ccd2-4c45-89e4-ef70ee3e920a"
      unitRef="usd">356100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a772071ec7b42b5a35616776c47cc46_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTctNi0xLTEtMQ_9a107846-dafa-4900-b6b7-c9a50aa8b913"
      unitRef="usd">40600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2a60daf847d84c269726d5443505a7f6_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTctNy0xLTEtMQ_edd95175-dc7d-45b6-808f-10aab9de3b69"
      unitRef="usd">396700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea2febe706a44680bc01a519177d071a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTgtMS0xLTEtMQ_5ac0d262-c2c6-4f8c-83d9-969687cda761"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8d5607f6891d49dea32ba497824c5cf6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTgtMi0xLTEtMQ_35bade17-f1f3-43f5-85cf-08a1e6c414ab"
      unitRef="usd">340200000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47a1977d3def441282bd0a67b40c3f58_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTgtMy0xLTEtMQ_35b87a5c-eeef-4e28-a91e-bf8e3d692b4c"
      unitRef="usd">340200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i6922b33207dc47c696a18cd215b4fc89_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTgtNS0xLTEtMQ_ab4e609c-98d3-4268-ab25-0384885bd22c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i99b621e206fb43b2af4e311739f64ce3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTgtNi0xLTEtMQ_773e73cd-497d-44a6-8372-ba9883d32370"
      unitRef="usd">205900000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i721201b823f24281ab0040324500b66f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTgtNy0xLTEtMQ_d4462724-0964-4cfa-9bff-2c477e651b55"
      unitRef="usd">205900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i390fccc895414dbc80bc7b21902083d8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTktMS0xLTEtMQ_2e2eadd1-caf1-445e-b598-e50d8255f92c"
      unitRef="usd">83700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id3b5806021254319908670087ba01693_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTktMi0xLTEtMQ_3599b1ff-e552-4967-9972-658a704cac0f"
      unitRef="usd">169900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i12d8057fb6f44881adf62c66da12a47b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTktMy0xLTEtMQ_efb5bd2e-2ddd-4899-8b05-5eb32d7ffc98"
      unitRef="usd">253600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4d2c31facfd84348940f0a8c61dbc204_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTktNS0xLTEtMQ_313489a3-e86f-44c5-bccc-727141b4cce3"
      unitRef="usd">26000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie5f004ac1b604026a7bc7798d77ef19e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTktNi0xLTEtMQ_caf195c4-8a9d-4bb5-b78b-4b8e7a30872a"
      unitRef="usd">118200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i469dc8fbbc274df3ac3a499298b1aaa1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMTktNy0xLTEtMQ_d21214c5-7906-4d81-bc7a-4b85adc310c0"
      unitRef="usd">144200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia11ae3c44d264cff812e96e38e8bcecc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjAtMS0xLTEtMQ_1648af9b-961f-4868-8d32-28377d92cb09"
      unitRef="usd">2201700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i77eccb6aa9be4aadabe9b433c7c2d2c4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjAtMi0xLTEtMQ_ce362396-a850-41b0-a344-6d9d348fe729"
      unitRef="usd">2130700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1cd766bc4a6a436d9bc943dc45e61200_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjAtMy0xLTEtMQ_012afa4a-b361-47a6-be89-f93a972f174d"
      unitRef="usd">4332400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i738ee12d2f674f3d8ecab5b26681f558_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjAtNS0xLTEtMQ_7e5e2d46-6b7f-47c8-a79e-e823a4512fdc"
      unitRef="usd">2023100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i90f1e252129e42289186cf041bf33a8e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjAtNi0xLTEtMQ_0a4ff36d-1d0a-4a43-8ff5-a2deb04e3937"
      unitRef="usd">1780400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2a6eb6ab1d454923bb5c11298dc3ad33_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjAtNy0xLTEtMQ_cf2afdb8-86e4-4913-b174-cd653a16def3"
      unitRef="usd">3803500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i44f8e7433d104910ac58ce5909942f8d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjMtMS0xLTEtMQ_a63f3b37-3c2b-46b4-b662-663a8ccecac1"
      unitRef="usd">1071600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6fda936960b8455e927557e937bd1b99_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjMtMi0xLTEtMQ_23ce7a1a-21b8-472b-aae3-c16312efebf5"
      unitRef="usd">493800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5bf37d8e1a9840ff840b07a02b3d5386_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjMtMy0xLTEtMQ_f4d14a6f-2d49-4f35-9fd4-35fc08bc4771"
      unitRef="usd">1565400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i800cc0342090483daa741525f8744ff3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjMtNS0xLTEtMQ_c5d1d5bf-38bc-477e-ac79-24f31e21e013"
      unitRef="usd">942900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5551db7f547e415f84b80f7c3b385f9b_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjMtNi0xLTEtMQ_fd643c21-8abe-4b86-b5e4-b0af46ccfe62"
      unitRef="usd">350300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1e75cf8e17334bd7905b58023a170fa9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjMtNy0xLTEtMQ_3eafd05b-55cd-4ba5-bbea-62c127841f34"
      unitRef="usd">1293200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iabc3b21ccc994e3890088301e3cfc653_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjQtMS0xLTEtMQ_9aaef09f-7edf-4aa5-a428-420e5f6b4925"
      unitRef="usd">236500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia4683cd0b47d404d9b3503f7a600a568_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjQtMi0xLTEtMQ_1ab71337-3957-4149-8e2d-ba283203ea44"
      unitRef="usd">572600000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2e4795f073d468fac40d557656ecda2_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjQtMy0xLTEtMQ_a36d1910-0a3c-40aa-8a71-bb7cc4534aac"
      unitRef="usd">809100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="id06212a669134804953343ff9b9678f8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjQtNS0xLTEtMQ_f0b1e825-3044-4a3c-b53e-f8b95e5a67e0"
      unitRef="usd">39000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie85525da43ff40e380aee019e6218166_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjQtNi0xLTEtMQ_fa50c9b8-49e7-4eb1-abe6-826f5693de13"
      unitRef="usd">407700000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if93d6526b32048608464727fad92c9bb_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjQtNy0xLTEtMQ_b84ef628-f2c3-4afe-b03a-8d64c12a5284"
      unitRef="usd">446700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i1d1869f9b9284dfcbe120478faa3f6cc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjUtMS0xLTEtMQ_32b18b94-aa1c-489c-a221-0b7b3141153d"
      unitRef="usd">15200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i184a7a62437441fe889424d1df050960_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjUtMi0xLTEtMQ_4b72f47c-69ff-4eb1-9057-89d9bc57fc9e"
      unitRef="usd">14500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib1d8fa886c14458d88747c5a3f5ebeac_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjUtMy0xLTEtMQ_8339d9d6-e57a-4015-906e-12ae92e1226a"
      unitRef="usd">29700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9b1a3020e2314eaaacf0bd2fc78d63c1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjUtNS0xLTEtMQ_8838b3bb-e494-4711-bdf3-de6961969223"
      unitRef="usd">13200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7bc589b7bd644e10835ebc480ec4a412_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjUtNi0xLTEtMQ_7c395a20-399b-49b8-9529-29a36a09275e"
      unitRef="usd">8100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i18de420a47cf41a793c58b470768a0e8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjUtNy0xLTEtMQ_c88544eb-7a07-4897-acfa-dbe19a4ea5d1"
      unitRef="usd">21300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibb9be07b275a40f8852a6c540fe99af8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjYtMS0xLTEtMQ_9f226424-53f4-4103-8e4b-2c00263d17c6"
      unitRef="usd">1323300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie2861a0c3822428d869e6001e7582ec3_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjYtMi0xLTEtMQ_10fae536-ff59-4fcd-89e1-5645477fa97b"
      unitRef="usd">1080900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id05ffc1309fe428888516a9c3f40e7a7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjYtMy0xLTEtMQ_8dac8ecb-82ca-499f-ba8a-1347f1533147"
      unitRef="usd">2404200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id34d06576e4145798da69e8840b8ea78_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjYtNS0xLTEtMQ_84b57652-d993-496e-9e82-0e00533eb79c"
      unitRef="usd">995100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if71dd64ea4de44d9afaf6d6a512ba1db_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjYtNi0xLTEtMQ_2ce47fc5-5b52-4ec3-88ba-eb1ffa761a06"
      unitRef="usd">766100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i12b21ce236de4ed8bf7e747d6eea29ff_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjYtNy0xLTEtMQ_a1b3085c-e82d-4922-8570-214d9bf75b9b"
      unitRef="usd">1761200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1523e93b1ffd4b70acacf4087551c5db_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjktMS0xLTEtMQ_23233f43-ca2a-4119-a7f6-e94458d80643"
      unitRef="usd">30300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie2bc530014104c0cb422de56d4d03e82_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjktMi0xLTEtMQ_b0f72fd8-b682-4d0a-8c7a-baa0946f58cf"
      unitRef="usd">454000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if9e84e4ca8de4c4b97234a747132a31e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjktMy0xLTEtMQ_2204760b-8fdb-49b1-8893-c35c5431cf30"
      unitRef="usd">484300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i38c6380bb9864e3587fe92837bf5d091_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjktNS0xLTEtMQ_1d406bfe-951c-426b-887d-c88030cc599d"
      unitRef="usd">30500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc35c7271a8a4943a6227055ab125eb0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjktNi0xLTEtMQ_4305871e-946c-4c3c-8281-3eaff70f2806"
      unitRef="usd">546500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7a99b6d9c4c747ce99e9e703d54444b3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMjktNy0xLTEtMQ_ff4cf130-2110-47ee-ba4d-b32b26ffbea3"
      unitRef="usd">576900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i491c10fe08e342f4a4ac07e509c92936_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzAtMS0xLTEtMQ_cd487a77-5859-48ab-aeea-db03cf40b356"
      unitRef="usd">313500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i816868a48c8b48099f4d274ded2ea7ed_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzAtMi0xLTEtMQ_6f46a4d5-9f83-44bb-be69-eae4cb4c5c0b"
      unitRef="usd">102200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idc3314eed4cb4b9d8584ffe6c2837839_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzAtMy0xLTEtMQ_64772018-cc59-4d94-a6ed-5a3e435cfdb9"
      unitRef="usd">415700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i624804e1e29b4c2f970fd6fb40049075_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzAtNS0xLTEtMQ_7a76500b-a890-4e5f-8540-36cd6ec53b36"
      unitRef="usd">229300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i76a9135fab1f4504b803607fb262021d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzAtNi0xLTEtMQ_e3a1f27a-7a82-4d02-a281-19f2bafea4ba"
      unitRef="usd">23600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e0b11e3d0d14a5baf6de15812c649f2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzAtNy0xLTEtMQ_b82dd3ec-9719-4e96-953e-97cb9358e20d"
      unitRef="usd">252900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibd82f3451e814629b0bd328a44af9778_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzEtMS0xLTEtMQ_76c23481-d653-4a06-ba39-479e481f1d32"
      unitRef="usd">28300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i399f4d91b8034567938ddf63d2231514_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzEtMi0xLTEtMQ_ddbf4e1a-51bd-4d0d-8b4d-71fd94793a10"
      unitRef="usd">264500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2b3ace2be01a4932a527ada8b0e95c08_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzEtMy0xLTEtMQ_c927db52-38ef-4f6d-bf86-36ed31ba8e70"
      unitRef="usd">292800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9cec004919c74d1abb18678fa0d18ec8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzEtNS0xLTEtMQ_f2c3c71a-79a0-48e3-b59e-88504fd3c0cc"
      unitRef="usd">41500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie56c114480404e369f4c566552d2726d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzEtNi0xLTEtMQ_f4616900-1e60-46a5-97be-64cc734166c0"
      unitRef="usd">266200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i273b596e58b94897a35fd6eaf5a112bb_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzEtNy0xLTEtMQ_6963d16f-431e-43a3-b5d9-14168f6694cf"
      unitRef="usd">307700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if68930386e0e490d9cc62c2853246366_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzMtMS0xLTEtMQ_1a71cd4f-484a-42ef-abb0-22f7caab7e5a"
      unitRef="usd">81000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2219da41e098458f8e17480a24f019ae_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzMtMi0xLTEtMQ_7f8a7049-dff9-48b7-8174-aa5af1306c06"
      unitRef="usd">154000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc7fc4722f76404a8a37d85632337dbc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzMtMy0xLTEtMQ_8f141480-ddf2-41cd-8b41-50ad532a94c8"
      unitRef="usd">235000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i00900522405a4bb38276038085c324e4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzMtNS0xLTEtMQ_6d7ea537-e9ee-4726-b023-831248e1aa3d"
      unitRef="usd">53400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i86b2429251b54a7389aab14092777b48_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzMtNi0xLTEtMQ_60f09845-fc91-48f5-892c-c85c7d03e129"
      unitRef="usd">165700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iffa2fbcd9aae4080910c4a7ea104fd94_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzMtNy0xLTEtMQ_5f3558b8-9f6a-4a31-bfda-872bf4a87a2c"
      unitRef="usd">219200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id60f7f14418c463da58451d606950976_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzQtMS0xLTEtMQ_8375e427-7998-4b5b-914e-5e735d6dc9fb"
      unitRef="usd">453100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie16f11aac59c4ca3a1b1d3532c9651a5_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzQtMi0xLTEtMQ_7f4231fb-25cb-4c67-992a-21adad845690"
      unitRef="usd">974700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6a99b63187cb430c89fd5d3823917b2d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzQtMy0xLTEtMQ_56704494-d3ac-43c5-9f2a-3fc2f2924af0"
      unitRef="usd">1427800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1dd55add52d845c6a51186e6507d9fd1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzQtNS0xLTEtMQ_67ab4009-fc4d-4aa5-a78b-9fc9ed97d3b2"
      unitRef="usd">354700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i610c7613e7d44f308a44a6dc9bbbaaf3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzQtNi0xLTEtMQ_90dc66c9-e598-4e76-a22e-fc9db1124ed6"
      unitRef="usd">1002000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i96c837650d554f56a6200ace6566fe10_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzQtNy0xLTEtMQ_c4fe0aab-9dab-44f7-8dc6-fadde87ce026"
      unitRef="usd">1356700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic36dcc53ac3e4228adb3e7a26ca46465_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzctMS0xLTEtMQ_b42d3734-dddc-4686-8ecd-0f821c8ae66e"
      unitRef="usd">949500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i133749f5535c426db6fff5b68d432a9a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzctMi0xLTEtMQ_ded315eb-e280-42a8-b023-9d71666e15d3"
      unitRef="usd">226700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib066c49389e847e08dd9e47b3dd013ff_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzctMy0xLTEtMQ_7ca45fe7-aa06-44e6-a905-cad8a1994487"
      unitRef="usd">1176200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i00cdf12927374e9ea2bd4fd171d087a8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzctNS0xLTEtMQ_38a53cdb-9414-49fc-9aa6-ce58d232690f"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8046f99bbe284c3ba18f324d7e76338d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzctNi0xLTEtMQ_c92f275f-6e98-4ee6-a84f-5d103eb34b96"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia784a32e102a4a3c897cd146133b8efa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzctNy0xLTEtMQ_0e92b41a-8950-499f-8c2d-b1d0b6235faa"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f926fe8ad974b88bb900b9493519ef1_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzgtMS0xLTEtMQ_64c2b720-015d-4ec1-9583-36334bbf7697"
      unitRef="usd">330100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie6aab15dd89e4fb29adda466320b7ab7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzgtMi0xLTEtMQ_82eb2d9c-a87a-4673-b993-5e9e805e5878"
      unitRef="usd">287700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2214d9b014994300805fe9c16ab74705_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzgtMy0xLTEtMQ_cca31554-fd45-4108-a09f-10957d95ea65"
      unitRef="usd">617800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iba10a9ccc98d4a24b8827dac6bfff7da_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzgtNS0xLTEtMQ_c2c4169e-8867-4328-a17b-d53284816220"
      unitRef="usd">386700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9600095f80154ce7888d5d052fbc1c34_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzgtNi0xLTEtMQ_7247739e-d6fa-4991-ac11-b26c8b60f71c"
      unitRef="usd">405200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib2d77207bbde4ab49c305e35c7f2a45f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzgtNy0xLTEtMQ_cf7407ac-e6c3-48e8-95d8-7a043b959c99"
      unitRef="usd">791900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i197272b1a6734b7c91e241f32e6dd646_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzktMS0xLTEtMQ_fc6642a7-c537-41cd-a50b-db600e0782b6"
      unitRef="usd">-3100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd45ae5c53e04751870a061d88a445ce_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzktMi0xLTEtMQ_96175141-babf-4e8d-bee1-293f1f2ac9f2"
      unitRef="usd">541800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i31c1a896fd4244b5a8e15e4ac8abb96b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzktMy0xLTEtMQ_89ed1b9a-a773-4b86-96f9-daa4b9fb2f0e"
      unitRef="usd">538700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5f6f899a265e4b63b17af12da3b7c5b8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzktNS0xLTEtMQ_a2683b5c-d239-4da2-821c-68592e5e9aa6"
      unitRef="usd">64600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i847263e5354d4a72a9f742d7dbe5f329_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzktNi0xLTEtMQ_de0c9493-15c8-4188-9e00-a5906f41105a"
      unitRef="usd">421600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3c361d809be0426984f9993fb59eccd6_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfMzktNy0xLTEtMQ_147fffe2-c048-4941-87a8-ef970d164167"
      unitRef="usd">486200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i608a490542db4b6893542e7e7a64f228_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDAtMS0xLTEtMQ_fbae7da6-fe49-4608-8c80-49edc25c9a92"
      unitRef="usd">96500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8dc52535a84848d5a963a822901590da_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDAtMi0xLTEtMQ_0e14a9f8-d2cf-473d-9624-a1449d02332a"
      unitRef="usd">164300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifcf246e7d1304af48b16a8f5ee00dc49_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDAtMy0xLTEtMQ_50ba2c21-b365-4fef-bd43-9638a5ee6176"
      unitRef="usd">260800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a2c4c9002a344d1bd2cb16fc80b4bf3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDAtNS0xLTEtMQ_e3f22b9a-0026-4350-82fa-2a85f40425e7"
      unitRef="usd">144200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i33e9f09317ba4403a2235be6dea1faa9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDAtNi0xLTEtMQ_7bf99392-08e4-49b4-86d9-659256ef20af"
      unitRef="usd">225200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i39c4874639894af4bbd798a405ef14f9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDAtNy0xLTEtMQ_3622f10d-87fc-4ca4-a2c2-03e0ba195c66"
      unitRef="usd">369400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide834e2a43444a5cb9b3500607e4ff20_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDEtMS0xLTEtMQ_dfc897f4-f881-4983-821e-e2b96c9363ef"
      unitRef="usd">1373000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7b5acdd57ce5404da6a626cbe3b64a5e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDEtMi0xLTEtMQ_6f851df5-544f-472a-81e1-89ba1b6bb787"
      unitRef="usd">1220500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if99f841c17e145b28e1c88eceea31bab_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDEtMy0xLTEtMQ_22b955ee-a40e-4177-bde4-9ccd1ee84e7a"
      unitRef="usd">2593500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i863ea645f4b549408c451c4882b42085_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDEtNS0xLTEtMQ_e9e618dc-40e9-493c-a3c6-15f0896e81b2"
      unitRef="usd">595500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic231bc3ee12e4b1285ddceb9e02b4a26_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDEtNi0xLTEtMQ_6f10985c-abe6-4dad-99c7-fdb88bcdf2a8"
      unitRef="usd">1052000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5ef4e15111c14cd19aa8255c772b5d92_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDEtNy0xLTEtMQ_ee377515-7b93-4214-ae73-eab13cc0349a"
      unitRef="usd">1647500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia2a183d7003942d49ed5ae4cef5356cb_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDItMS0xLTEtMQ_c60a9997-535a-48ff-a6a1-fbb8c907e340"
      unitRef="usd">11635100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i428cf713dc7b4901beedaa25a7950476_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDItMi0xLTEtMQ_77a9283f-3274-49a4-b88e-050cfb3a59b6"
      unitRef="usd">8683400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDItMy0xLTEtMQ_f80ed7e4-c037-4c63-ad22-a4e0e26f712f"
      unitRef="usd">20318500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5b9750abc82c4253b256ba599ee15596_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDItNS0xLTEtMQ_21e2a9ba-164e-4e89-8476-ee3baaa26f75"
      unitRef="usd">9631400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic2b62bc7ef73412295dc475eeadec217_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDItNi0xLTEtMQ_7f031149-2486-4b9c-86c5-145d88775c82"
      unitRef="usd">7468500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOmE3M2RhMzQwMWQ0ZDQ4MzRiMTcyYTMyNTljZGI1NDhmL3RhYmxlcmFuZ2U6YTczZGEzNDAxZDRkNDgzNGIxNzJhMzI1OWNkYjU0OGZfNDItNy0xLTEtMQ_2210ee6b-aa03-48b7-a8ba-062d362ad625"
      unitRef="usd">17099800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibd448a0d7d984d978046eded1bdbef98_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfMy0xLTEtMS0x_1c6c1fd8-e703-4e88-b805-c758b4399da0"
      unitRef="usd">3989600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0fa9309b68448efb27e0f24f9cfa0a4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfMy0zLTEtMS0x_1a2c1c4e-8010-4644-a59e-391df1a84c06"
      unitRef="usd">3161400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia2a183d7003942d49ed5ae4cef5356cb_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfMy01LTEtMS0x_c079cfcb-c22f-4895-b4f6-715e41b76e3c"
      unitRef="usd">11635100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5b9750abc82c4253b256ba599ee15596_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfMy03LTEtMS0x_43e27256-d941-46be-a35a-1a835f2de20e"
      unitRef="usd">9631400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia3c0a13a33a349aa92d5012e4b636a7a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNC0xLTEtMS0x_6bb1e6d0-c8d3-4e48-8274-361b4b0a18e0"
      unitRef="usd">1098600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i669cb3004ae84cf6960440516244078b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNC0zLTEtMS0x_4def9408-a1be-4d9b-9d75-86afdbf040bc"
      unitRef="usd">1046700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id268ee0f04df42a4a96c475b5cfcbcc9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNC01LTEtMS0x_176838e1-12d1-4091-a3ed-bff282160006"
      unitRef="usd">3629600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib82ffaddfbef4082af244efc218be24a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNC03LTEtMS0x_b546e18c-cec1-4d60-a08d-9ad1032daf55"
      unitRef="usd">2984400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i14d504c5ac9c4198822bc799884207ec_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNS0xLTEtMS0x_e218e7d1-9025-4e68-85e2-e416557d4671"
      unitRef="usd">595000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idce8121dee4344e18147fc49a8d5a07b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNS0zLTEtMS0x_d89e3af6-e1be-4f20-8e42-d9524af0debe"
      unitRef="usd">660100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib632c646a6e9448cbae9a56d4a57fbfc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNS01LTEtMS0x_a71498cf-18b3-4bc2-9056-14c738c40107"
      unitRef="usd">1832200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifbc00e7246a6407b8cc8a82ca741b867_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNS03LTEtMS0x_b13f3a25-37e5-437c-937b-3a15d9b321a2"
      unitRef="usd">1919100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5391e5cb27db47b8ba06894098bd568e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNi0xLTEtMS0x_9a4ceeab-5b14-4bff-8964-a0214ca9375e"
      unitRef="usd">400300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9971c726971d4e269f7742be265aaaa7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNi0zLTEtMS0x_0558a0fa-9465-45ca-ae4e-cc43db8800a9"
      unitRef="usd">289100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f70dfeee6ed4ead97768caa6e0b0573_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNi01LTEtMS0x_0c5e7239-d1fa-4e33-99a7-8e39da1cad62"
      unitRef="usd">1285000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i37a3d265d5664f4fac0555e3347dda9a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNi03LTEtMS0x_a7d9ddd9-f7c9-46b9-8321-8c3d30aac593"
      unitRef="usd">796200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id317a865e2e349898f18728c5ca604b3_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNy0xLTEtMS0x_ceaeb1ad-68f5-4c45-b9b5-d53f539e5180"
      unitRef="usd">689400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4d381b3aade5467ea39cf273c6cc47ae_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNy0zLTEtMS0x_0a276c39-ba7d-4b5d-a585-d8bffc83d1d3"
      unitRef="usd">583200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1dd27416e4d244238ac2cf4eafcbc5e3_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNy01LTEtMS0x_2a551a8e-e413-414e-83e7-09777d41a662"
      unitRef="usd">1936700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i468cf70e06e74d9abb4442d6f2e6ac71_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfNy03LTEtMS0x_271afaca-f429-4ddd-90b2-3f68a653429d"
      unitRef="usd">1768700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfOC0xLTEtMS0x_be49abdb-fa01-49cd-ae96-b7783a4b2cb8"
      unitRef="usd">6772800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfOC0zLTEtMS0x_4da3d3d7-0177-43af-8875-33f91bcea104"
      unitRef="usd">5740600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfOC01LTEtMS0x_19298224-bd8c-42a4-ac68-0f0f4bbc3a3a"
      unitRef="usd">20318500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80My9mcmFnOmY0ODU1NzIyNDI0NjRhNmE4OTJlMGJjYmMwNGEzMjgzL3RhYmxlOjc1OGI4NzBiZTcxMTRjYzM4MTI0NzM5ZDNmZDI4NDUwL3RhYmxlcmFuZ2U6NzU4Yjg3MGJlNzExNGNjMzgxMjQ3MzlkM2ZkMjg0NTBfOC03LTEtMS0x_9e772ce6-bc85-499a-88f1-aae0afab800a"
      unitRef="usd">17099800000</us-gaap:Revenues>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNjg1Nw_5ff41fcb-206d-465f-90f9-ec9f74a6be80">Acquisitions&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021 and February 2020, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail) and Dermira, Inc. (Dermira), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated condensed financial statements from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also acquired assets in development which are further discussed in this note below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired in-process research and development (IPR&amp;amp;D) was immediately expensed because the compound had no alternative future use. We recognized acquired IPR&amp;amp;D charges of $174.0 million and $498.3 million for the three and nine months ended September&#160;30, 2021, respectively, and $294.1 million for the nine months ended September 30, 2020. There were no acquired IPR&amp;amp;D charges recognized in the three months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisitions of Businesses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Prevail Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail&#x2019;s portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson&#x2019;s disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our access to Prevail information was limited prior to the acquisition. As a consequence, we are in the process of determining fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at January 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition date fair value of consideration transferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Fair value of CVR liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D intangibles primarily relate to PR001.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The goodwill recognized from this acquisition is not deductible for tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;See Note 6 for a discussion on the estimation of the CVR liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma information has not been included as this acquisition did not have a material impact on our consolidated condensed statements of operations for the three and nine months ended September 30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Dermira Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, we acquired all shares of Dermira for a purchase price of approximately $849.3 million, net of cash acquired. Under the terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the FDA. We also acquired Qbrexza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the nine months ended September&#160;30, 2021, we sold the rights to Qbrexza. See Note 5 for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $86.8 million, other intangibles of $1.20 billion primarily related to lebrikizumab, deferred income tax liabilities of $49.5 million, and long-term debt of $375.5 million. After the acquisition, we repaid $276.2 million of long-term debt assumed as part of our acquisition of Dermira.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asset Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our asset acquisitions during the nine months ended September&#160;30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compound(s) or Therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Phase of Development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired IPR&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Precision Biosciences, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential in vivo therapies for genetic disorders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;107.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merus N.V. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CD3-engaging T-cell re-directing bispecific antibodies for the potential treatment of cancer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asahi Kasei Pharma Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AK1780, an orally bioavailable P2X7 receptor antagonist for the potential treatment of chronic pain conditions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rigel Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;125.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MiNA Therapeutics Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Protomer Technologies Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Glucose-sensing insulin program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kumquat Biosciences Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical small molecules that stimulate tumor-specific immune responses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;55.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lycia Therapeutics, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Several potential modalities across a spectrum of therapeutic areas and diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ProQR Therapeutics N.V.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines for genetic disorders in the liver and nervous system&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sitryx Therapeutics Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines for autoimmune diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AbCellera Biologics Inc. (AbCellera)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neutralizing antibodies for the treatment and prevention of COVID-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neutralizing antibodies for the treatment and prevention of COVID-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Petra Pharma Corporation (Petra)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutant-selective PI3K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x3b1;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; inhibitor that could lead to potential new medicine &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Evox Therapeutics Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets for the potential treatment of neurological disorders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; We recognized an acquired IPR&amp;amp;D expense of $25.0 million in May 2020 upon closing of the transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:AssetAcquisitionTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNjg1Nw_60f716e0-209d-4fee-80e2-fcb110b6815b">Acquisitions&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021 and February 2020, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail) and Dermira, Inc. (Dermira), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated condensed financial statements from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also acquired assets in development which are further discussed in this note below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired in-process research and development (IPR&amp;amp;D) was immediately expensed because the compound had no alternative future use. We recognized acquired IPR&amp;amp;D charges of $174.0 million and $498.3 million for the three and nine months ended September&#160;30, 2021, respectively, and $294.1 million for the nine months ended September 30, 2020. There were no acquired IPR&amp;amp;D charges recognized in the three months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisitions of Businesses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Prevail Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail&#x2019;s portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson&#x2019;s disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our access to Prevail information was limited prior to the acquisition. As a consequence, we are in the process of determining fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at January 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition date fair value of consideration transferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Fair value of CVR liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D intangibles primarily relate to PR001.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The goodwill recognized from this acquisition is not deductible for tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;See Note 6 for a discussion on the estimation of the CVR liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma information has not been included as this acquisition did not have a material impact on our consolidated condensed statements of operations for the three and nine months ended September 30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Dermira Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Overview of Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, we acquired all shares of Dermira for a purchase price of approximately $849.3 million, net of cash acquired. Under the terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the FDA. We also acquired Qbrexza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the nine months ended September&#160;30, 2021, we sold the rights to Qbrexza. See Note 5 for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $86.8 million, other intangibles of $1.20 billion primarily related to lebrikizumab, deferred income tax liabilities of $49.5 million, and long-term debt of $375.5 million. After the acquisition, we repaid $276.2 million of long-term debt assumed as part of our acquisition of Dermira.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asset Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our asset acquisitions during the nine months ended September&#160;30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compound(s) or Therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Phase of Development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired IPR&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Precision Biosciences, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential in vivo therapies for genetic disorders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;107.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merus N.V. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CD3-engaging T-cell re-directing bispecific antibodies for the potential treatment of cancer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asahi Kasei Pharma Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AK1780, an orally bioavailable P2X7 receptor antagonist for the potential treatment of chronic pain conditions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rigel Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;125.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MiNA Therapeutics Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Protomer Technologies Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Glucose-sensing insulin program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kumquat Biosciences Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical small molecules that stimulate tumor-specific immune responses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;55.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lycia Therapeutics, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Several potential modalities across a spectrum of therapeutic areas and diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ProQR Therapeutics N.V.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines for genetic disorders in the liver and nervous system&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sitryx Therapeutics Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines for autoimmune diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AbCellera Biologics Inc. (AbCellera)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neutralizing antibodies for the treatment and prevention of COVID-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neutralizing antibodies for the treatment and prevention of COVID-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Petra Pharma Corporation (Petra)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutant-selective PI3K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x3b1;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; inhibitor that could lead to potential new medicine &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Evox Therapeutics Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets for the potential treatment of neurological disorders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; We recognized an acquired IPR&amp;amp;D expense of $25.0 million in May 2020 upon closing of the transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.&lt;/span&gt;&lt;/div&gt;</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNjg0MQ_f020c5fc-4f86-4cf2-8c95-9d4b3bba0484">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated condensed financial statements from the date of acquisition.Upon each acquisition, the cost allocated to acquired in-process research and development (IPR&amp;amp;D) was immediately expensed because the compound had no alternative future use.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfMTI0NQ_75b06413-023f-4751-9e49-db532a25d9ec"
      unitRef="usd">174000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfMTI1Mg_43af69eb-73ce-43cb-9e99-4737b87a0399"
      unitRef="usd">498300000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfMTMxOA_8c856173-e5f4-4ecc-be06-5c3163ba2007"
      unitRef="usd">294100000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfODc5NjA5MzAzMDEwMA_7b832bf9-a4b7-4c7a-8703-9c2e37a6e9f9"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i34f0affb1412406985b955e8954cdf8e_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfMTU0MQ_6e9bff1a-4ae7-4fca-aecb-a80868a8652f"
      unitRef="usdPerShare">22.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i69178206ce654ab9873b9e9c1d36fa34_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfMTU4Mg_37a34817-e5b8-4543-8360-760a11bfaf58"
      unitRef="usd">747400000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights
      contextRef="i69178206ce654ab9873b9e9c1d36fa34_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfMTYyMQ_816fe77e-4a25-4236-8823-bf1844317a77"
      unitRef="right">1</lly:BusinessCombinationConsiderationTransferredNumberOfContingentValueRights>
    <lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare
      contextRef="i34f0affb1412406985b955e8954cdf8e_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfMTczOA_dfdef7ed-d963-44cc-8ada-63d417dd9a8f"
      unitRef="usdPerShare">4.00</lly:BusinessAcquisitionContingentValueRightAdditionalPricePerShare>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i34f0affb1412406985b955e8954cdf8e_I20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfMTc5Mw_5762f5ab-c9fc-4f79-ac0c-be0f4b15dbe5"
      unitRef="usd">160000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <lly:BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction
      contextRef="i34f0affb1412406985b955e8954cdf8e_I20210131"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfMjIxMA_b121ca4c-4112-4019-8930-857232cea2bc"
      unitRef="usdPerShare">0.083</lly:BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNjg2OA_ff65be0a-86f6-4b2f-b172-f9d8912a576f">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value at January 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition date fair value of consideration transferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Fair value of CVR liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D intangibles primarily relate to PR001.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The goodwill recognized from this acquisition is not deductible for tax purposes. &lt;/span&gt;&lt;/div&gt;(3) See Note 6 for a discussion on the estimation of the CVR liability.</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i34f0affb1412406985b955e8954cdf8e_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOmRkYzg1Y2ViMTg4ZDQ5MjY5OGZkYTlmMTMwZDBkOWNlL3RhYmxlcmFuZ2U6ZGRjODVjZWIxODhkNDkyNjk4ZmRhOWYxMzBkMGQ5Y2VfMS0xLTEtMS0x_fb89b3d9-b060-4a6b-9692-262087b0bc1d"
      unitRef="usd">90500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i34f0affb1412406985b955e8954cdf8e_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOmRkYzg1Y2ViMTg4ZDQ5MjY5OGZkYTlmMTMwZDBkOWNlL3RhYmxlcmFuZ2U6ZGRjODVjZWIxODhkNDkyNjk4ZmRhOWYxMzBkMGQ5Y2VfMi0xLTEtMS0x_54f59bd8-0557-4204-965b-0b00f57dcb0e"
      unitRef="usd">824000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="i34f0affb1412406985b955e8954cdf8e_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOmRkYzg1Y2ViMTg4ZDQ5MjY5OGZkYTlmMTMwZDBkOWNlL3RhYmxlcmFuZ2U6ZGRjODVjZWIxODhkNDkyNjk4ZmRhOWYxMzBkMGQ5Y2VfMy0xLTEtMS0x_e03993e2-acbd-4384-bf9a-0aefcd224bae"
      unitRef="usd">118800000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i34f0affb1412406985b955e8954cdf8e_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOmRkYzg1Y2ViMTg4ZDQ5MjY5OGZkYTlmMTMwZDBkOWNlL3RhYmxlcmFuZ2U6ZGRjODVjZWIxODhkNDkyNjk4ZmRhOWYxMzBkMGQ5Y2VfNC0xLTEtMS0x_0d115117-1438-4dd9-a838-7ea6c0ef3b97"
      unitRef="usd">98000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet
      contextRef="i34f0affb1412406985b955e8954cdf8e_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOmRkYzg1Y2ViMTg4ZDQ5MjY5OGZkYTlmMTMwZDBkOWNlL3RhYmxlcmFuZ2U6ZGRjODVjZWIxODhkNDkyNjk4ZmRhOWYxMzBkMGQ5Y2VfNS0xLTEtMS0x_06cd71ec-329d-4666-a5cf-e2b601b7362e"
      unitRef="usd">-31500000</lly:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i34f0affb1412406985b955e8954cdf8e_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOmRkYzg1Y2ViMTg4ZDQ5MjY5OGZkYTlmMTMwZDBkOWNlL3RhYmxlcmFuZ2U6ZGRjODVjZWIxODhkNDkyNjk4ZmRhOWYxMzBkMGQ5Y2VfNi0xLTEtMS0x_efcf26ab-4c96-46f2-a050-b2fce79ba05a"
      unitRef="usd">903800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="i69178206ce654ab9873b9e9c1d36fa34_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOmRkYzg1Y2ViMTg4ZDQ5MjY5OGZkYTlmMTMwZDBkOWNlL3RhYmxlcmFuZ2U6ZGRjODVjZWIxODhkNDkyNjk4ZmRhOWYxMzBkMGQ5Y2VfOC0xLTEtMS0x_7d039795-f143-4713-9789-66e743978f4e"
      unitRef="usd">90500000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
      contextRef="i34f0affb1412406985b955e8954cdf8e_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOmRkYzg1Y2ViMTg4ZDQ5MjY5OGZkYTlmMTMwZDBkOWNlL3RhYmxlcmFuZ2U6ZGRjODVjZWIxODhkNDkyNjk4ZmRhOWYxMzBkMGQ5Y2VfOS0xLTEtMS0x_942d00eb-fe68-4b25-8102-09c65f0eb857"
      unitRef="usd">65900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i69178206ce654ab9873b9e9c1d36fa34_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOmRkYzg1Y2ViMTg4ZDQ5MjY5OGZkYTlmMTMwZDBkOWNlL3RhYmxlcmFuZ2U6ZGRjODVjZWIxODhkNDkyNjk4ZmRhOWYxMzBkMGQ5Y2VfMTAtMS0xLTEtMQ_65f66b5a-7e87-46b1-bcc7-efe2843c5c6c"
      unitRef="usd">747400000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ibb396fb0bb334dbdb983642373e2383a_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNDM2OA_f4c9757d-18bc-4bb9-abeb-606dc4c00a37"
      unitRef="usd">849300000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:Goodwill
      contextRef="ib0548c5b9afb4dfb8d20e8ccf806b912_I20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNTA5NQ_8babb782-6f46-413a-8d24-091b2a1b7dd9"
      unitRef="usd">86800000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ib0548c5b9afb4dfb8d20e8ccf806b912_I20200229"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNTEyMA_3c117bd2-246b-4869-b5e8-f58757724780"
      unitRef="usd">1200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="ib0548c5b9afb4dfb8d20e8ccf806b912_I20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNTE5Mw_cea203c3-c4d2-49f6-a67d-38383601da0e"
      unitRef="usd">49500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt
      contextRef="ib0548c5b9afb4dfb8d20e8ccf806b912_I20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNTIxOQ_5d4d031b-9430-4add-bc08-d3794ac29b13"
      unitRef="usd">375500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ia3663573ba3c48a5bdcf5eb80a22298a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNTI1Ng_371d0a9e-3783-4b0c-b53a-13c82bad34b7"
      unitRef="usd">276200000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNjg1NQ_02848d64-1945-431d-b6aa-0f6a8d85a805">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our asset acquisitions during the nine months ended September&#160;30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Counterparty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Compound(s) or Therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition Month&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Phase of Development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired IPR&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Precision Biosciences, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential in vivo therapies for genetic disorders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;107.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merus N.V. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CD3-engaging T-cell re-directing bispecific antibodies for the potential treatment of cancer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asahi Kasei Pharma Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AK1780, an orally bioavailable P2X7 receptor antagonist for the potential treatment of chronic pain conditions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rigel Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Phase I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;125.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MiNA Therapeutics Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Protomer Technologies Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Glucose-sensing insulin program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kumquat Biosciences Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical small molecules that stimulate tumor-specific immune responses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;55.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lycia Therapeutics, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Several potential modalities across a spectrum of therapeutic areas and diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ProQR Therapeutics N.V.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines for genetic disorders in the liver and nervous system&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sitryx Therapeutics Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets that could lead to potential new medicines for autoimmune diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AbCellera Biologics Inc. (AbCellera)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neutralizing antibodies for the treatment and prevention of COVID-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neutralizing antibodies for the treatment and prevention of COVID-19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Petra Pharma Corporation (Petra)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutant-selective PI3K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x3b1;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; inhibitor that could lead to potential new medicine &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Evox Therapeutics Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical targets for the potential treatment of neurological disorders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. &lt;/span&gt;&lt;/div&gt;(2) We recognized an acquired IPR&amp;amp;D expense of $25.0 million in May 2020 upon closing of the transaction.</us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i6b575113de824b30a1c74f39db88aefd_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfMS02LTEtMS0x_4540b202-5b19-4515-b504-116a206ef6b8"
      unitRef="usd">107800000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ie6e905c8a80b4d38b9c543fb5bf2ef03_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfMi02LTEtMS0x_51985457-d6be-4730-a271-bd6c534e5db2"
      unitRef="usd">46500000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i9500cb4fcb444bd2b15d0629279eaf70_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfMy02LTEtMS0x_e8273ed0-6abe-4580-b4a3-2344364696b5"
      unitRef="usd">20000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="iaa35124ffe304988988994e711548e86_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfNC02LTEtMS0x_1b4564b4-b604-4962-8db0-c261e8b3d7da"
      unitRef="usd">125000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i4a14466d4a0e4b20bc65b50a6842b2f5_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfNS02LTEtMS0x_7841ccc7-0f50-4a77-83fa-f389371013a2"
      unitRef="usd">25000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i870c4b4df8a341cc9b9dab7c879317b8_D20210701-20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfNi02LTEtMS03ODk_99598d96-da9f-4587-8235-a8110f2123e2"
      unitRef="usd">57300000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i3dd9b9e634e34e57897aaaf824716990_D20210701-20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfNy02LTEtMS04MjU_558ef509-5f74-46af-a83f-30c9d9287114"
      unitRef="usd">55000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ide01e64c4e60431ba5c28356bcc7cb42_D20210801-20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfOC02LTEtMS0xMDU5_30573df8-1cea-41f7-868e-58fdf09aaa58"
      unitRef="usd">35000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i0ed04cd38d964fc2af21956c88de5379_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfOS02LTEtMS05NTI_8e789121-02ef-47eb-a2e3-2183977e0ad0"
      unitRef="usd">26700000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i531eb44bb094404198d87fc5156c354e_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfNy02LTEtMS0x_5d3c545b-2f89-472a-85ca-435db8d4a1e5"
      unitRef="usd">52300000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i9ca3bd941a584b85b1b0b4d72b454dda_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfOC02LTEtMS0x_7bd29c66-c51c-4da2-a8b1-e53e47f54274"
      unitRef="usd">25000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ibab640a2f0fa4cf195eec35598754f90_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfOS02LTEtMS0x_7a2ec042-74f3-437a-88d6-f9953fcd587e"
      unitRef="usd">20000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i2a26ac8fb34d4458b120b7a6bc3235c0_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfMTAtNi0xLTEtMQ_4298c956-f21d-42e2-a2ec-b968ca7f84d7"
      unitRef="usd">174800000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i20e4f1b2ae08456c8caf48e2e1fdbe90_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RhYmxlOjA1MmYyMTFjYjU3ZjQ5YzdiMTNmOGY5MTk5NWVkN2VlL3RhYmxlcmFuZ2U6MDUyZjIxMWNiNTdmNDljN2IxM2Y4ZjkxOTk1ZWQ3ZWVfMTEtNi0xLTEtMQ_90b6e7a6-643c-4346-9d12-fc75c3188679"
      unitRef="usd">22000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i3cb5bd55318443f49ec7b5fbcc892280_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF80OS9mcmFnOjA0MWY4M2EyNzdlNzRlZTNhNzhmYjNkOWJmYzZhNTZiL3RleHRyZWdpb246MDQxZjgzYTI3N2U3NGVlM2E3OGZiM2Q5YmZjNmE1NmJfNTY1OA_c8b6e030-a78e-4d69-9e8f-d82ccaf5d70c"
      unitRef="usd">25000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfMTIyODg_9e45c00f-6b24-4407-b715-b90f8bba46dd">Collaborations and Other Arrangements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Boehringer Ingelheim Diabetes Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim&#x2019;s oral diabetes products: Jardiance,  Glyxambi, Synjardy, Trijardy XR, Trajenta, and Jentadueto&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as well as our basal insulin, Basaglar. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. Jentadueto is included in the Trajenta product family. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the net amount of significant milestones capitalized (deferred) at September 30, 2021 and December 31, 2020 for the compounds included in this collaboration: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Milestones Capitalized (Deferred) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;as of:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product Family&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;141.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;95.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(154.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In  connection with the regulatory approvals of Jardiance and Trajenta, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. In connection with the regulatory approvals of Basaglar, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the Jardiance product family, we and Boehringer Ingelheim share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue. Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family. Beginning January 1, 2021, the royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds. We pay to Boehringer Ingelheim a royalty on net sales for Basaglar in the U.S. We record our sales of Basaglar to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and our net product revenue recognized with respect to Basaglar:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product Family&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;390.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,058.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;192.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;650.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;96.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;279.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Olumiant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to its Janus tyrosine kinase (JAK) inhibitor compound, now known as Olumiant (baricitinib), and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double digit royalty payments on global net sales with rates ranging up to 20 percent. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. In 2020, the agreement was amended to include the treatment of COVID-19, with Incyte obtaining the right to receive an additional royalty ranging up to the low teens on global net sales for the treatment of COVID-19 that exceed a specified aggregate global net sales threshold. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, milestone payments of $210.0 million were capitalized as intangible assets as of September 30, 2021 and December 31, 2020 and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, Incyte is eligible to receive up to $100.0 million of additional payments from us contingent upon certain success-based regulatory milestones. Incyte is also eligible to receive up to $150.0 million of potential sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record our sales of Olumiant, including sales of baricitinib that were made pursuant to EUA, to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. The following table summarizes our net product revenue recognized with respect to Olumiant:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;406.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;809.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;COVID-19 antibodies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we entered into a worldwide license and collaboration agreement with AbCellera to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab, for which we hold development and commercialization rights. AbCellera has the right to receive tiered royalty payments on global net sales of bamlanivimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera are recorded as cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we entered into a license and collaboration agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including etesevimab, for which we hold development and commercialization rights outside of mainland China and the Special Administrative Regions of Hong Kong and Macau, and for which Junshi Biosciences currently maintains all rights in mainland China and the Special Administrative Regions of Hong Kong and Macau. Junshi Biosciences has the right to receive royalty payments in the mid-teens on our net sales of etesevimab. Junshi Biosciences also has the right to receive certain development, success-based regulatory and sales-based milestones. In connection with the regulatory authorizations of etesevimab (for administration with bamlanivimab) as well as achievement of a sales-based milestone, milestone payments of $95.0 million were capitalized as intangible assets as of September&#160;30, 2021 and are being amortized to cost of sales over the estimated useful life of etesevimab. As of September&#160;30, 2021, Junshi Biosciences is eligible to receive up to $100.0 million of potential sales-based milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to EUAs, we recognized $217.1 million and $1.18 billion of net product revenue associated with our sales of our COVID-19 antibodies during the three and nine months ended September&#160;30, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Sintilimab Injection&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with Innovent Biologics, Inc. (Innovent) to jointly develop and commercialize sintilimab injection in China, where it is branded and trademarked as Tyvyt. In 2019, we and Innovent began co-commercializing Tyvyt in China. In 2020, we obtained an exclusive license for sintilimab injection from Innovent for geographies outside of China. Innovent, with collaboration from us, has filed the initial registration of sintilimab injection in the U.S., and we will pursue initial registration of sintilimab injection in other markets and all other subsequent registrations of sintilimab injection. We have exclusive commercialization rights outside of China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with a regulatory approval for Tyvyt in China in the second quarter of 2021, we capitalized a milestone payment of $40.0 million as an intangible asset which is being amortized to cost of sales through the term of the collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, Innovent is eligible to receive up to $825.0 million for geographies outside of China and up to $195.0 million in China in success-based regulatory and sales-based milestones. Innovent is also eligible to receive tiered double digit royalties on net sales for geographies outside of China. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record our sales of Tyvyt to third parties as net product revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. We report as collaboration and other revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties. The following table summarizes our revenue recognized in China with respect to Tyvyt:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tyvyt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;125.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;340.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tanezumab&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain and cancer pain. In October 2021, we and Pfizer discontinued the global clinical development program of tanezumab for the treatment of osteoarthritis pain and cancer pain following the receipt of a Complete Response Letter from the FDA and a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lebrikizumab&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of Dermira, we have a worldwide licensing agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively Roche), which provides us the global development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future global net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of September&#160;30, 2021, Roche is eligible to receive up to $180.0 million of payments from us contingent upon the achievement of success-based regulatory milestones and up to $1.03 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of Dermira, we have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of September&#160;30, 2021, we are eligible to receive additional payments of $85.0 million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $1.25 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021 and December 31, 2020, $15.3 million and $29.7 million, respectively, were recorded as contract liabilities on the consolidated condensed balance sheets and are expected to be recognized as collaboration and other revenue over the remaining Phase III development period. During the three and nine months ended September&#160;30, 2021 and 2020, milestones received and collaboration and other revenue recognized were not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Petra&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of Petra, we are required to make milestone payments to Petra shareholders contingent upon the occurrence of certain future events linked to the success of the mutant-selective PI3K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x3b1;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; inhibitor. Our more significant, near term milestones include a development milestone of approximately $205&#160;million in 2022 contingent upon initiation of its Phase I trial and a further development milestone of approximately $164&#160;million in 2023 contingent upon achieving clinical proof of concept.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfMTIyOTg_4882a120-8afa-4430-a71c-94f021e45419">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the net amount of significant milestones capitalized (deferred) at September 30, 2021 and December 31, 2020 for the compounds included in this collaboration: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Milestones Capitalized (Deferred) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;as of:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product Family&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;141.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;95.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(154.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In  connection with the regulatory approvals of Jardiance and Trajenta, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. In connection with the regulatory approvals of Basaglar, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and our net product revenue recognized with respect to Basaglar:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product Family&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jardiance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;390.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,058.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basaglar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;192.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;650.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trajenta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;96.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;279.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following table summarizes our net product revenue recognized with respect to Olumiant:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Olumiant&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;406.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;809.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;The following table summarizes our revenue recognized in China with respect to Tyvyt:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tyvyt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;125.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;340.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i2711efdfc53c49bd9e0e8915915d9f02_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOmM0Zjg4MzgxMjVkNDQyNThhYjBiMzIxNTRjYTk2ZjE5L3RhYmxlcmFuZ2U6YzRmODgzODEyNWQ0NDI1OGFiMGIzMjE1NGNhOTZmMTlfMi0xLTEtMS0x_0153cb53-0bdc-4133-823c-be62ed38488a"
      unitRef="usd">141100000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ia1acc40e06de4a0f94f52199958700b4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOmM0Zjg4MzgxMjVkNDQyNThhYjBiMzIxNTRjYTk2ZjE5L3RhYmxlcmFuZ2U6YzRmODgzODEyNWQ0NDI1OGFiMGIzMjE1NGNhOTZmMTlfMi0yLTEtMS0x_fd2c5995-c612-4cf0-8b15-48e9a92e594a"
      unitRef="usd">156200000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="idb083c377a2b4107a6eb8d5b758dee94_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOmM0Zjg4MzgxMjVkNDQyNThhYjBiMzIxNTRjYTk2ZjE5L3RhYmxlcmFuZ2U6YzRmODgzODEyNWQ0NDI1OGFiMGIzMjE1NGNhOTZmMTlfMy0xLTEtMS0x_bd98ad74-7dc9-4d09-ad8d-d8cb0f10ea10"
      unitRef="usd">95100000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="idc5eafc995df4bbc9a45fd9e9b60dd25_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOmM0Zjg4MzgxMjVkNDQyNThhYjBiMzIxNTRjYTk2ZjE5L3RhYmxlcmFuZ2U6YzRmODgzODEyNWQ0NDI1OGFiMGIzMjE1NGNhOTZmMTlfMy0yLTEtMS0x_272e16f6-830d-4c5c-9d5c-3b2b5bad2e31"
      unitRef="usd">114600000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="iba9b3f1d338b4eda841d752024c756c7_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOmM0Zjg4MzgxMjVkNDQyNThhYjBiMzIxNTRjYTk2ZjE5L3RhYmxlcmFuZ2U6YzRmODgzODEyNWQ0NDI1OGFiMGIzMjE1NGNhOTZmMTlfNC0xLTEtMS0x_4b72bbe4-ca30-43d3-b205-1b6ab166373e"
      unitRef="usd">-154000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i46d24272d19741b5a607f6c2f4e46637_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOmM0Zjg4MzgxMjVkNDQyNThhYjBiMzIxNTRjYTk2ZjE5L3RhYmxlcmFuZ2U6YzRmODgzODEyNWQ0NDI1OGFiMGIzMjE1NGNhOTZmMTlfNC0yLTEtMS0x_877bbaaa-fcc7-40d5-8533-c55d7e2322ea"
      unitRef="usd">-168000000.0</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:Revenues
      contextRef="ie7a26c27a65f403eb8beb3df6550f89c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfMi0xLTEtMS0x_04c477ea-eaef-468e-bd0a-1e4307125c36"
      unitRef="usd">390400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc63f2b4f3ad4a38885421b13733cfbd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfMi0zLTEtMS0x_9f8a6083-9cea-4827-bac7-176607621836"
      unitRef="usd">310800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0c5cb50d0a384037b1da389f2a6e0996_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfMi01LTEtMS0x_2fe7df2b-2d70-415d-b85d-21a4ed6a2917"
      unitRef="usd">1058900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0c5cb50d0a384037b1da389f2a6e0996_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfMi01LTEtMS0x_90845ff0-de10-47e8-800d-e192fb7b3100"
      unitRef="usd">1058900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idfc25dba031242f7b3f38ee74a40876d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfMi03LTEtMS0x_9ee139b7-1f1d-4453-9546-e4cd3f70f1d0"
      unitRef="usd">840300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idcd5ed73cc264b21bfcf6eb9c75a76f1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfMy0xLTEtMS0x_08954fd5-21c2-43c9-a017-6383ee01c53a"
      unitRef="usd">192800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic4c206cb2e614db381ab7a7d1967bd03_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfMy0zLTEtMS0x_0bd9260f-d6a2-4422-97f0-67a0f7762c19"
      unitRef="usd">248200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib84ab601c2e045f9b4f9ff1a30e0787a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfMy01LTEtMS0x_fb9d9946-288e-4fd4-b533-a14533f1ea7a"
      unitRef="usd">650100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie9fdd628b285469fb2e83ec947cf3bb1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfMy03LTEtMS0x_d0d78fdd-45bd-4c66-8e65-823515fdc548"
      unitRef="usd">842300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if5010b2b7e5545ed8348dbdee8d74c25_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfNC0xLTEtMS0x_a6a533a7-798e-4a59-bb9f-abd130fd9ef1"
      unitRef="usd">96100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iae1bfc71fb534381a72a38855339542f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfNC0zLTEtMS0x_39d29c23-6988-4775-883d-1f62eba842c4"
      unitRef="usd">91700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic26a9205f4884f5fafe309bf577ca246_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfNC01LTEtMS0x_e0da7e08-80cc-4dcb-9b72-7893f48c9f1f"
      unitRef="usd">279900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if23d24438d434f35937e458ed4abff61_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjhmNjIyOWY0MDRjODRjYzM5NTg1NjcwYTIxNjFjMTQ3L3RhYmxlcmFuZ2U6OGY2MjI5ZjQwNGM4NGNjMzk1ODU2NzBhMjE2MWMxNDdfNC03LTEtMS0x_28cb9d23-c1bb-44bc-b209-8805e9f51135"
      unitRef="usd">261700000</us-gaap:Revenues>
    <lly:CollaborativeArrangementRightsAndObligationsPercent
      contextRef="ib280a0fecb8d4d45a80cbda714aed6f5_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfNDY4NQ_007a5b43-709e-4ff2-b5ff-2a7a78e3764f"
      unitRef="number">0.20</lly:CollaborativeArrangementRightsAndObligationsPercent>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i3551bdde470b46ae9c137fe74872a446_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfNTIxOA_4361265b-fc22-4084-bd3f-788573004717"
      unitRef="usd">210000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i27a8de99546f46b5b97d0667185d1775_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfNTIxOA_bfbb2bde-b1f5-4bc2-8ac5-6c202afbfa33"
      unitRef="usd">210000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i7ac78500f4494fa597feac64cdfc42b7_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfNTU3Mg_970a736c-7f73-4c96-b2ff-4f2471abe605"
      unitRef="usd">100000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i832240d2148c4ade980357dce8b58dcf_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfNTcwOA_ab4cc65a-024e-4ba4-a261-a4c08261efe7"
      unitRef="usd">150000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb79dda4914c4c118d30138f4db6d0c9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjJiYWFiYjMzOTUxMTRlOTM4ZjIyYzk1ZTkyM2IxYmU3L3RhYmxlcmFuZ2U6MmJhYWJiMzM5NTExNGU5MzhmMjJjOTVlOTIzYjFiZTdfMi0xLTEtMS0x_58a3f336-9243-4044-9159-317fb0607fdd"
      unitRef="usd">406900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89bc1277904f44ebb00cc1c346f34407_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjJiYWFiYjMzOTUxMTRlOTM4ZjIyYzk1ZTkyM2IxYmU3L3RhYmxlcmFuZ2U6MmJhYWJiMzM5NTExNGU5MzhmMjJjOTVlOTIzYjFiZTdfMi0zLTEtMS0x_1bf30166-cd31-47d3-81ad-f9d8858e6723"
      unitRef="usd">162000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2e4795f073d468fac40d557656ecda2_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjJiYWFiYjMzOTUxMTRlOTM4ZjIyYzk1ZTkyM2IxYmU3L3RhYmxlcmFuZ2U6MmJhYWJiMzM5NTExNGU5MzhmMjJjOTVlOTIzYjFiZTdfMi01LTEtMS0x_a36d1910-0a3c-40aa-8a71-bb7cc4534aac"
      unitRef="usd">809100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if93d6526b32048608464727fad92c9bb_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjJiYWFiYjMzOTUxMTRlOTM4ZjIyYzk1ZTkyM2IxYmU3L3RhYmxlcmFuZ2U6MmJhYWJiMzM5NTExNGU5MzhmMjJjOTVlOTIzYjFiZTdfMi03LTEtMS0x_b84ef628-f2c3-4afe-b03a-8d64c12a5284"
      unitRef="usd">446700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i7ba69dd64a4449d7b5cc355b8cdb4e0c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfNzMyMQ_27b8ecbf-591f-4ec9-a891-9f52ed4b8a2b"
      unitRef="usd">95000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ie1df26c2f1ab404684e40f47a90f31a2_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfNzYxMg_58adc924-de86-4562-81f4-58e8e7ad764b"
      unitRef="usd">100000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1915b82ef0745bc9e6902e358dcf426_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfNzY4NQ_6dc441b1-235f-4a1f-bcdc-e193e5d2b244"
      unitRef="usd">217100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib066c49389e847e08dd9e47b3dd013ff_D20210101-20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfNzY5Mg_23f02272-3971-4551-8d3d-f198b808c301"
      unitRef="usd">1180000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ic1c05dd0b56b403e9e561ab09c6adf97_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfODY0OQ_c63a38b4-b02f-48e5-8a0b-0c9b442c2b64"
      unitRef="usd">40000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ib67b5243a6ad40ec868a47e512875138_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfODgyNw_cd0c830a-eb98-4dac-bb69-3c3d19e5a0f9"
      unitRef="usd">825000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i3fabc22c5af942a5bb088863f27e3c17_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfODg3Mw_23fb8db9-97a9-4e62-bddf-1fb6e92f74f3"
      unitRef="usd">195000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i897388675b95435fb4f36e6b1e6cd6f9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjM4YjQzYzdmNWFlYjQzODM5YTcxMTAyZjc3NTQ5YzlkL3RhYmxlcmFuZ2U6MzhiNDNjN2Y1YWViNDM4MzlhNzExMDJmNzc1NDljOWRfMi0xLTEtMS0x_39d3e977-4a04-4ba9-81e2-587ec283cc4b"
      unitRef="usd">125600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33b4d90ccdd9479fa1adc0ede684c6b6_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjM4YjQzYzdmNWFlYjQzODM5YTcxMTAyZjc3NTQ5YzlkL3RhYmxlcmFuZ2U6MzhiNDNjN2Y1YWViNDM4MzlhNzExMDJmNzc1NDljOWRfMi0zLTEtMS0x_54ee13a5-40a6-4053-a4a5-53eee5f277c2"
      unitRef="usd">84400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47a1977d3def441282bd0a67b40c3f58_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjM4YjQzYzdmNWFlYjQzODM5YTcxMTAyZjc3NTQ5YzlkL3RhYmxlcmFuZ2U6MzhiNDNjN2Y1YWViNDM4MzlhNzExMDJmNzc1NDljOWRfMi01LTEtMS0x_35b87a5c-eeef-4e28-a91e-bf8e3d692b4c"
      unitRef="usd">340200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i721201b823f24281ab0040324500b66f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RhYmxlOjM4YjQzYzdmNWFlYjQzODM5YTcxMTAyZjc3NTQ5YzlkL3RhYmxlcmFuZ2U6MzhiNDNjN2Y1YWViNDM4MzlhNzExMDJmNzc1NDljOWRfMi03LTEtMS0x_d4462724-0964-4cfa-9bff-2c477e651b55"
      unitRef="usd">205900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i6cdf764053f54a69bddcc58019bd9a9c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfMTA5MjA_125190d1-64cf-452d-9a23-75dcdb24dd09"
      unitRef="usd">180000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i6ed81d6975474a5abcbc174337c27bd4_I20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfMTEwMjQ_5a4f7333-f988-4458-9a00-b4b432c5b568"
      unitRef="usd">1030000000.00</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ie35017a9e84c4b85960feecbdacbbfd4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfMTE2ODA_731d4895-c447-42c8-b014-1a33f2611a8a"
      unitRef="usd">85000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="i3a58e1d1992e4f0e821edbda0434c22b_I20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfMTE3Nzg_4da35d6a-088b-4449-a702-e8ba65b2af95"
      unitRef="usd">1250000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i212f03ee260a4a1d8b38aa6b588dc87e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfMTE5MDg_3f9efa4e-2019-498f-9369-672822c59664"
      unitRef="usd">15300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i2e7d5f5212014d5fb1eecf77eb35a41b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfMTE5MTU_ab44b1af-2144-4c29-8ecb-b5b3ae3fe540"
      unitRef="usd">29700000</us-gaap:ContractWithCustomerLiability>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="ia9d50a42ad904e8cbe293593bfa34095_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfODc5NjA5MzA0MTQ5NQ_f05b3369-78c2-4854-b661-48527a36eed6"
      unitRef="usd">205000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <lly:CollaborativeArrangementRightsAndObligationsRightsObligations
      contextRef="iea65191ac5fc4dbb8e7121cae60f91a9_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF81Mi9mcmFnOmUxYTViY2ExNWUzMDQ0ZDRiNWY1OGZmN2ZiYzI2NmUxL3RleHRyZWdpb246ZTFhNWJjYTE1ZTMwNDRkNGI1ZjU4ZmY3ZmJjMjY2ZTFfODc5NjA5MzA0MTUxMQ_232db588-8a56-456a-9351-18adac89539c"
      unitRef="usd">164000000</lly:CollaborativeArrangementRightsAndObligationsRightsObligations>
    <us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RleHRyZWdpb246MDU4YzIzYTFmMTc2NDliZDk0MjE0ZThkYjEwYjI0M2NfMjA4NA_72c35c86-4438-46ec-ac86-b939b32c9eed">Asset Impairment, Restructuring, and Other Special Charges&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairment (recovery) and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;200.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total asset impairment, restructuring, and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;211.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairment, restructuring, and other special charges recognized during the nine months ended September&#160;30, 2021 were primarily related to an intangible asset impairment of $108.1&#160;million resulting from the sale of the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Severance costs recognized during the three and nine months ended September&#160;30, 2020 were incurred as a result of actions taken worldwide to reduce our cost structure. Substantially all of the severance costs incurred during the three and nine months ended September&#160;30, 2020 have been paid. &lt;/span&gt;&lt;/div&gt;We recognized a net inventory impairment charge related to our COVID-19 antibodies of $435.1&#160;million during the nine months ended September 30, 2021 in cost of sales in our consolidated condensed statements of operations. As part of our response to the COVID-19 pandemic, and at the request of the U.S. and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic has continued to evolve during 2021, we incurred a net inventory impairment charge primarily due to the combination of changes to current and forecasted demand from U.S. and international governments, including changes to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies.</us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RleHRyZWdpb246MDU4YzIzYTFmMTc2NDliZDk0MjE0ZThkYjEwYjI0M2NfMjA3NQ_7bb77a05-cdf7-471c-8cfd-f0f9150488ea">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairment (recovery) and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;200.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total asset impairment, restructuring, and other special charges&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;211.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfMi0xLTEtMS0x_6bade988-0068-4a6c-b48e-da92511095ed"
      unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfMi0zLTEtMS0x_213c965f-4235-438e-82fb-1848c49b9b05"
      unitRef="usd">144400000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfMi01LTEtMS0x_d7cde435-10b9-4f53-8a16-f9ab3782b8c4"
      unitRef="usd">11500000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfMi03LTEtMS0x_b4a2c792-926d-4bf0-a50c-c1326573d977"
      unitRef="usd">154200000</us-gaap:SeveranceCosts1>
    <lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfMy0xLTEtMS0x_6a3037fe-06f1-474c-8af7-c7fe4b261441"
      unitRef="usd">0</lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges>
    <lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfMy0zLTEtMS0x_ed30cd26-d7ac-403f-8beb-f41ed04375ba"
      unitRef="usd">-43000000.0</lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges>
    <lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfMy01LTEtMS0x_b0f0d5d0-41bb-4907-b4ae-17b72558ec6b"
      unitRef="usd">200100000</lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges>
    <lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfMy03LTEtMS0x_0b819744-ef8f-4244-8cac-c8d582994d5c"
      unitRef="usd">7100000</lly:AssetImpairmentChargesRecoveriesAndOtherSpecialCharges>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfNC0xLTEtMS0x_e8f704f0-82ee-411a-9fac-6ae1951528b0"
      unitRef="usd">0</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfNC0zLTEtMS0x_debab27b-55f7-4ece-8244-ede7484909ef"
      unitRef="usd">101400000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfNC01LTEtMS0x_4b5c5abb-3e3e-482e-bf1d-9d9eb8a13f2d"
      unitRef="usd">211600000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RhYmxlOjJlMTNjYmVjODJmMTQ4MjA4NTlkOTg0YWExZTRiYmZjL3RhYmxlcmFuZ2U6MmUxM2NiZWM4MmYxNDgyMDg1OWQ5ODRhYTFlNGJiZmNfNC03LTEtMS0x_0994ef60-2e2b-4540-bf15-87f330dc6a87"
      unitRef="usd">161300000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RleHRyZWdpb246MDU4YzIzYTFmMTc2NDliZDk0MjE0ZThkYjEwYjI0M2NfNTUz_f5338a35-35da-46fe-b0c6-b9de6d1b0d68"
      unitRef="usd">108100000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:InventoryWriteDown
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82MS9mcmFnOjA1OGMyM2ExZjE3NjQ5YmQ5NDIxNGU4ZGIxMGIyNDNjL3RleHRyZWdpb246MDU4YzIzYTFmMTc2NDliZDk0MjE0ZThkYjEwYjI0M2NfODc5NjA5MzAyODc1Mg_da7e9c4e-b137-44d0-a319-81f46e61279c"
      unitRef="usd">435100000</us-gaap:InventoryWriteDown>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ4MTU_08dde6ca-240c-421f-b6ed-1858529fb45d">Financial Instruments&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our equity investments are accounted for using three different methods depending on the type of equity investment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review equity investments other than public equity investments for indications of impairment and observable price changes on a regular basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#x2013;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At September&#160;30, 2021, we had outstanding foreign currency forward commitments to purchase 707.3 million U.S. dollars and sell 604.5 million euro, commitments to purchase 2.54 billion euro and sell 2.98 billion U.S. dollars, commitments to purchase 151.6 million U.S. dollars and sell 980.0 million Chinese yuan, commitments to purchase 144.7 million U.S. dollars and sell 16.13 billion Japanese yen, and commitments to purchase 155.5 million British pounds and sell 212.6 million U.S. dollars, which all have settlement dates within 180 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes had carrying amounts of $8.08 billion and $6.02 billion as of September&#160;30, 2021 and December&#160;31, 2020, respectively, of which $5.95 billion and $4.50 billion have been designated as, and are effective as, economic hedges of net investments in certain of our foreign operations as of September&#160;30, 2021 and December&#160;31, 2020, respectively. At September&#160;30, 2021, we had outstanding cross-currency swaps with notional amounts of $2.69 billion swapping U.S. dollars to euro and $1.00 billion swapping Swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed-rate debt to foreign-denominated fixed-rate debt, have also been designated as, and are effective as, economic hedges of net investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated condensed statements of cash flows. At September&#160;30, 2021, substantially all of our total long-term debt is at a fixed rate. We have converted approximately 12 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss), and upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt. As of September&#160;30, 2021, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $1.75 billion, which have settlement dates ranging between 2023 and 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, we issued euro-denominated notes consisting of &#x20ac;600.0&#160;million of 0.50 percent fixed-rate notes due in September 2033, with interest to be paid annually. The net proceeds from the offering will be used to fund, in whole or in part, eligible projects designed to advance one or more of our environmental, social, and governance objectives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, we issued euro-denominated notes consisting of &#x20ac;500.0&#160;million of 1.125 percent fixed-rate notes due in September 2051 and &#x20ac;700.0&#160;million of 1.375 percent fixed-rate notes due in September 2061, with interest to be paid annually, and British pound-denominated notes consisting of &#xa3;250.0&#160;million of 1.625 percent fixed-rate notes due in September 2043, with interest to be paid annually. We paid $1.91&#160;billion of the net cash proceeds from the offering to purchase and redeem certain higher interest rate U.S. dollar-denominated notes with an aggregate principal amount of $1.50&#160;billion, resulting in a debt extinguishment loss of $405.2&#160;million. This loss was included in other-net, (income) expense in our consolidated statement of operations during the three and nine months ended September 30, 2021. The $1.50&#160;billion principal amount of higher interest rate U.S. dollar-denominated notes that were redeemed primarily included $541.8&#160;million of 3.95 percent notes due 2049, $408.7&#160;million of 4.15 percent notes due 2059, and $219.4&#160;million of 3.375 percent notes due 2029. We used the remaining net proceeds from the offering to prefund certain 2022 debt maturities and for general corporate purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Effect of Risk-Management Instruments on the Consolidated Condensed Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following effects of risk-management instruments were recognized in other&#x2013;net, (income) expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from hedged fixed-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(10.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(60.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;60.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;58.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;50.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;110.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;65.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;181.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2021 and 2020, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.231%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.231%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.235%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Foreign currency-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;119.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;268.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(186.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;66.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;170.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Forward-starting interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;149.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the next 12&#160;months, we expect to reclassify $16.4&#160;million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other&#x2013;net, (income) expense. During the three and nine months ended September&#160;30, 2021 and 2020, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize certain fair value information at September&#160;30, 2021 and December&#160;31, 2020 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other&lt;br/&gt;Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,373.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,373.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,373.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,373.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;15.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;15.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;15.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;37.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;129.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;129.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;129.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;129.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;219.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;215.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;219.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;219.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;110.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;107.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;110.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;110.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;19.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;19.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;19.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;19.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;105.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;21.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;105.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;105.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,482.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;420.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,482.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,482.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;556.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;725.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,350.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;373.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;471.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,966.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term debt, including current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(17,085.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(18,354.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(18,354.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,595.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,038.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,038.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-management instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;87.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;87.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;87.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;77.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;77.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;77.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(17.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(17.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(17.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(23.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(23.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(23.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(25.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(25.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(25.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration liability:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(70.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(70.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(70.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-management instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. Fair values are not readily available for certain equity investments measured under the measurement alternative. As of September 30, 2021, we had approximately $781 million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to 10 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration liability relates to our liability arising in connection with the CVR issued as a result of the Prevail acquisition. The fair value of the CVR liability was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant's view of the expected cash payment associated with the first potential regulatory approval of a Prevail compound in the applicable countries based on probabilities of technical success, timing of the potential approval events for the compounds, and an estimated discount rate. See Note 3 for additional information related to the CVR arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturities by Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less&#160;Than&lt;br/&gt;1 Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1-5&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6-10&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More&#160;Than&lt;br/&gt;10 Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net gains (losses) recognized in our consolidated condensed statements of operations for equity securities were $(246.8)&#160;million and $270.1 million for the three and nine months ended September&#160;30, 2021, respectively, and $141.7 million and $905.1 million for the three and nine months ended September 30, 2020, respectively. The net gains/losses recognized during the three and nine months ended September&#160;30, 2021 and 2020 on equity securities sold during the respective periods were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded during the three and nine months ended September&#160;30, 2021 and 2020 were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross gains&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized gain position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;293.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized loss position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;208.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the three and nine months ended September&#160;30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately 97 percent&#160;of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of September&#160;30, 2021, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity related to our available-for-sale securities was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;49.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;137.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross gains on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross losses on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable Factoring Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and, risk related to, the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $617.4 million and $754.9 million&#160;of accounts receivable as of September&#160;30, 2021 and December 31, 2020, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated condensed results of operations for the three and nine months ended September&#160;30, 2021 and 2020&#160;were&#160;not material.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ4NDE_3cad7bdc-9bec-4377-91ed-6a4bd23d9a96">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.&lt;/span&gt;&lt;/div&gt;We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#x2013;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ib3e68e01c19a4aaa93a9c6e8d4d5ca0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDMwNw_e47ff949-03f3-4765-bd45-5343c185c10d"
      unitRef="usd">707300000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="ib3e68e01c19a4aaa93a9c6e8d4d5ca0f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDMzMg_4b3745e7-175e-40a7-ae28-28918c4ddde2"
      unitRef="eur">604500000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i3c88f68cc2d7438497246b3d6404eead_I20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDM2NQ_0f09828d-8fdb-48ce-8543-7f96263debef"
      unitRef="eur">2540000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i3c88f68cc2d7438497246b3d6404eead_I20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDM4Mg_9553632a-9fd4-4a39-bfc0-bb8ae92f1086"
      unitRef="usd">2980000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i9a4f51f3d44f4d129128571ca91c4045_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMjQxODkyNTU4MzQwMTM_41ce16c3-c1d3-4a96-a7a5-9c760a52f476"
      unitRef="usd">151600000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i9a4f51f3d44f4d129128571ca91c4045_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMjQxODkyNTU4MzQwNDM_caabe4e2-4bff-47a8-9110-2411b6d35436"
      unitRef="cny">980000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ia65189ebfe674bcdaa496351f69f95ed_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDQyMw_35479ae1-20c4-4ccd-bf8b-cd75f518194f"
      unitRef="usd">144700000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="ia65189ebfe674bcdaa496351f69f95ed_I20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDQ0OA_b77c4f52-9bf7-4c59-b896-60bbccfeb8ad"
      unitRef="jpy">16130000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i608ccb2010534f3489d040d1051be217_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDQ5Mw_64043cac-ebbe-46ac-bdcc-4bdefe3d4a0e"
      unitRef="gbp">155500000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i608ccb2010534f3489d040d1051be217_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDUyMA_877d3e63-b1fd-4e6a-8771-9f69f9091167"
      unitRef="usd">212600000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDU2Mg_2a3e3b6f-2a92-43e0-87aa-a87ed7a48be8">P180D</us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1>
    <us-gaap:LongTermDebt
      contextRef="i51538ef7c00c4b7ca042552f8fcf1b56_I20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDc1Nw_a774b920-5f28-4a8c-a111-f13ff3a32a64"
      unitRef="usd">8080000000.00</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if2282403149944b6a454777d0cbe119e_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDc2NA_1dd7a349-db3f-428a-88d2-7cc4913d264a"
      unitRef="usd">6020000000.00</us-gaap:LongTermDebt>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDgwNw_4d174bfa-26cf-46f0-838f-4a30fb57561d"
      unitRef="usd">5950000000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNDgxNA_36312693-0f16-4132-a6e9-59c07b1cc5a7"
      unitRef="usd">4500000000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTax>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ifec1b340db5a429986bb4f14e4d51236_I20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNTA1Nw_785eaf60-37aa-4cd5-8f47-ef485ce60178"
      unitRef="usd">2690000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id050ee0435604da9889144406e53ddb1_I20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNTA5NA_893f6bb0-3bcc-4900-80ab-fa444a93a409"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <lly:DescriptionOfDerivativeActivityVolumePercent
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNjg3Ng_611f0811-419b-4620-891a-ebed997c68b4"
      unitRef="number">0.12</lly:DescriptionOfDerivativeActivityVolumePercent>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i3a30bd1d6f09458d9b484f6eede92a0b_I20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfNzU4NQ_47df96c9-aae0-488b-b0e9-4fd7868f2968"
      unitRef="usd">1750000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie0197954b7f246438579f727a96ba302_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODc5NjA5MzA0NTIxNQ_a6836399-a938-4866-86b9-7a67f62abd56"
      unitRef="eur">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie0197954b7f246438579f727a96ba302_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODc5NjA5MzA0NTI1OA_008a36f8-b646-4a0e-8a27-73f96727d89b"
      unitRef="number">0.005</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4a56fd67eaa446d58b10847878682132_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODc5NjA5MzA0NTIzNw_b3e01b85-c655-4be0-91cc-204abd02b8c0"
      unitRef="eur">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4a56fd67eaa446d58b10847878682132_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODc5NjA5MzA0NTI1Mg_434cd5d2-e95e-4194-b9aa-8a60e48dd55c"
      unitRef="number">0.01125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="icf519817e48d4e2aa20f61c0464569ac_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODc5NjA5MzA0NTI5OQ_8edbd230-8ba1-471f-9520-ea59d93b6a6d"
      unitRef="eur">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icf519817e48d4e2aa20f61c0464569ac_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODc5NjA5MzA0NTMxNA_642b6c1d-8f7b-4b59-aa21-8ffc50eef769"
      unitRef="number">0.01375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if42acdc6f14644c49737fbdd91a729b4_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODc5NjA5MzA0NTMzNg_d54ec132-82f1-40cc-9a72-59fc9ba4ec3e"
      unitRef="gbp">250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if42acdc6f14644c49737fbdd91a729b4_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODc5NjA5MzA0NTM1MQ_b4e41c02-b84c-475c-9df6-0de5a7db9d2e"
      unitRef="number">0.01625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i0007a0646ac4490fab4a90fe8acda870_D20210901-20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODc5NjA5MzA0NTM3Mw_7b7213fc-c5a6-496c-9aab-ee33e93f3df7"
      unitRef="usd">1910000000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i0007a0646ac4490fab4a90fe8acda870_D20210901-20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODc5NjA5MzA0NTM4OA_2190392a-db4e-4199-ad29-8bd1718753b3"
      unitRef="usd">1500000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0007a0646ac4490fab4a90fe8acda870_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODc5NjA5MzA0NTQwMw_a759ec46-80a7-4434-9d54-af07914e6b90"
      unitRef="usd">-405200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i0007a0646ac4490fab4a90fe8acda870_D20210901-20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTIwOTQ2Mjc5MzA3MjU_2190392a-db4e-4199-ad29-8bd1718753b3"
      unitRef="usd">1500000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="ic965f0de559d414494ead6ebab58b9b6_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfOTM0NTg0ODg2MTQwNw_f15b1402-6965-4666-99a9-bb5a40960f37"
      unitRef="usd">541800000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib811247eae3e4f2c950b855814774a4e_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfOTM0NTg0ODg2MTQ1NQ_6aa82544-7ead-4286-8210-3b6521a9dc6a"
      unitRef="number">0.0395</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="ifdef17a4b3924ef18dc393a876d0f969_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfOTM0NTg0ODg2MTQyMw_bdca5a18-512a-4aad-a887-8c5c645ed1eb"
      unitRef="usd">408700000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i59558243da25489986f3aa7a759e9236_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfOTM0NTg0ODg2MTQ2Mg_06e54607-214f-4e4e-97ed-0e1555eaf26a"
      unitRef="number">0.0415</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i630bb94f7a0241fc85ecb2d9d7c1705e_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfOTM0NTg0ODg2MTQzOQ_c03913d9-cd5e-4fc3-bad6-d854a7e2b731"
      unitRef="usd">219400000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i246b98760440439aa55a1d9c36f1efc2_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfOTM0NTg0ODg2MTQ2OQ_0b994f5a-6bcb-4ff7-9381-7405207c04d7"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ4MDg_f813520e-21c1-4bee-8021-d9071b6a83d3">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following effects of risk-management instruments were recognized in other&#x2013;net, (income) expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from hedged fixed-rate debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(10.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(60.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect from interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;60.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;58.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;50.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;110.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;65.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;181.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i83977bd0653b402a9c4271c7b321f9a4_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfMy0xLTEtMS0x_b10530bd-783c-4d7c-8d13-70b1d5d320b8"
      unitRef="usd">10100000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i39101bb15f78410c92851ae13eb04f8f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfMy0zLTEtMS0x_417c5a2f-02d3-4bcd-80db-b8d74581dfa9"
      unitRef="usd">14000000.0</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="ifc0dc774626d4895bcd260e8b1e00a1c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfMy01LTEtMS0x_0f03f7f2-cbad-4724-b25b-8507a36431f7"
      unitRef="usd">60500000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i49a37f83c03b41ed93d44441b19d8ce5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfMy03LTEtMS0x_32ddfa7d-23f0-434c-a76f-e56f1abe4135"
      unitRef="usd">-110400000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i864b815909f7410a8ae48163786157ed_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNC0xLTEtMS0x_851d62c7-a278-426a-ae5a-32310cd7d910"
      unitRef="usd">-10100000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i5a61299558154a88a75737f4e52e86db_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNC0zLTEtMS0x_50396fa3-055c-4c1a-99a7-e9b7f7e2036e"
      unitRef="usd">-14000000.0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i2460f130430a483aa8e55f391938b835_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNC01LTEtMS0x_65732ad2-787d-43a4-be16-c9c6f9d32b6b"
      unitRef="usd">-60500000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i8cc83e8355fd4482bebf96cb53270e2a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNC03LTEtMS0x_db3bc860-5234-4c42-ba74-07eb025f49bb"
      unitRef="usd">110400000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i864b815909f7410a8ae48163786157ed_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNi0xLTEtMS0x_28d76808-7664-470d-8150-6022d5e518fa"
      unitRef="usd">4200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i5a61299558154a88a75737f4e52e86db_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNi0zLTEtMS0x_f5eece09-d1c3-46c1-ba4a-d3debfb7c106"
      unitRef="usd">4100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i2460f130430a483aa8e55f391938b835_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNi01LTEtMS0x_13164f51-207c-4d68-b75b-38c1f718d2fd"
      unitRef="usd">12500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i8cc83e8355fd4482bebf96cb53270e2a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNi03LTEtMS0x_44ba6bd1-7308-4209-a06e-81b37377a8eb"
      unitRef="usd">12300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i8d6ca7bce852474597f1638b0244034b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNy0xLTEtMS0x_a91eae9e-a73a-4617-9ce0-ffbeddae511e"
      unitRef="usd">10000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i4372afcae30c4182a4a4b043e87b2b28_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNy0zLTEtMS0x_42a48ffc-de1c-4570-84c3-f78657b8bb7e"
      unitRef="usd">-30200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="id8b918e825124054b3c412a4eb18978d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNy01LTEtMS0x_f3ce665e-2eab-4b0f-bfa9-bad07ae8783f"
      unitRef="usd">58100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i75f82b84a5c44509970d0b0205ee4b7a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfNy03LTEtMS0x_a9ce3769-ac6c-4908-9203-36834be75e7d"
      unitRef="usd">-54600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i8c88bbe6ccfc45ef949dcef76b904617_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfOC0xLTEtMS0x_431cb638-16fd-4e75-a37a-dcf2ec2fb699"
      unitRef="usd">-50800000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i937f1bdb1bc1479a931e868c6d681bbe_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfOC0zLTEtMS0x_98f347bb-595a-4dc0-aa12-da0b0a5e4bca"
      unitRef="usd">54200000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="ifd44da12be9b4958bc40d1622ff85d3d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfOC01LTEtMS0x_3e7e6830-43ab-4f42-b79c-b663933c4c7c"
      unitRef="usd">-110600000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="ic0315d885ffd4214b0351c0717eb4c2d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfOC03LTEtMS0x_a5f87b6d-9913-4cfd-b7b8-f7c145a20401"
      unitRef="usd">82800000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <lly:DerivativeInstrumentsGainLossRecognized
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfOS0xLTEtMS0x_6dae6a37-b682-4233-9da2-b3ccccfe3a4e"
      unitRef="usd">-65000000.0</lly:DerivativeInstrumentsGainLossRecognized>
    <lly:DerivativeInstrumentsGainLossRecognized
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfOS0zLTEtMS0x_ea266c0e-b2c8-4cac-8493-e31d87f6c5c3"
      unitRef="usd">80300000</lly:DerivativeInstrumentsGainLossRecognized>
    <lly:DerivativeInstrumentsGainLossRecognized
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfOS01LTEtMS0x_98967c3b-e149-45f4-9f09-e3190dc2028e"
      unitRef="usd">-181200000</lly:DerivativeInstrumentsGainLossRecognized>
    <lly:DerivativeInstrumentsGainLossRecognized
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjgzY2Q4ZGZlOTI4MDQ4ZjE5MzJiMjQxYWMzMTQxYzBhL3RhYmxlcmFuZ2U6ODNjZDhkZmU5MjgwNDhmMTkzMmIyNDFhYzMxNDFjMGFfOS03LTEtMS0x_a447d0e9-eeb7-4a67-b977-3725757baddc"
      unitRef="usd">125100000</lly:DerivativeInstrumentsGainLossRecognized>
    <us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ4MjM_edb4428e-e3c9-4947-92b1-7a62f9aec61a">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.231%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.231%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.235%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Foreign currency-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;119.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;268.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(186.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;66.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;170.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Forward-starting interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;149.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ4NjI_1a88ba55-0089-4ff0-85b4-4489506e5c82">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.231%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.231%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.235%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Foreign currency-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;119.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;268.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(186.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;66.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;170.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Forward-starting interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;149.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Cross-currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="icaeede8153e14149b4dd378cfd5bb59e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfMy0xLTEtMS0x_2fc85ca3-9e6d-439b-966e-b7ebe4ef1d44"
      unitRef="usd">119000000.0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i1f55cc8a2fb64fcb9720f4b9b61421d6_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfMy0zLTEtMS0x_0eee6e25-ac35-4800-be30-c5d242440c0d"
      unitRef="usd">-181100000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="if8ef8f194e1446699469424765ff1fa8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfMy01LTEtMS0x_7c9b950b-b313-4839-8dba-0ca2be7c5080"
      unitRef="usd">268800000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="if92f732c456441e6ad74d4c284c639fb_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfMy03LTEtMS0x_6476cb7a-b1ea-49d2-a596-da1bfcc9a92c"
      unitRef="usd">-186000000.0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i67dbdc3d2d474dbabc54a7a74c1ea885_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfNC0xLTEtMS0x_7f7af1ba-20b3-4dfc-84af-24c06a059159"
      unitRef="usd">66700000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie121f355ecb34b25b0508086f86f2a6c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfNC0zLTEtMS0x_af50af7a-12ff-4a42-a9a8-fdf43d1bb58e"
      unitRef="usd">-110400000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i3ba09cfe8cfa4f10bc560bc45b9319b5_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfNC01LTEtMS0x_a0f45580-1b4e-4684-a7c9-c944afb28922"
      unitRef="usd">170800000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i864500d9b5b94bfaaa7d9ea71c3b0c26_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfNC03LTEtMS0x_9b889061-798f-4fa3-b7e3-9c51d908fad3"
      unitRef="usd">-55400000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i42cf035468e94826ad3cde71dde916af_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfNy0xLTEtMS0x_6e39fbb5-ec66-4a50-becd-f1be3e7717d2"
      unitRef="usd">19400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="id79d99cd800d4ad28394d8150c6332df_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfNy0zLTEtMS0x_f3a46a42-85ae-4ec0-a2c2-7c0bd58a856d"
      unitRef="usd">99600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ib2a25406ea954c5f8992888e7c738569_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfNy01LTEtMS0x_4dd827ce-57d4-4702-bad6-4dc60149cf8a"
      unitRef="usd">149300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i9e8ec6c42f514d1e80c619a050d59507_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfNy03LTEtMS0x_e24699ee-0b05-41f1-8636-23b8232e8a3f"
      unitRef="usd">-231900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i67dbdc3d2d474dbabc54a7a74c1ea885_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfOC0xLTEtMS0x_6f3ce22f-f547-4ac1-aaeb-20536309c5d4"
      unitRef="usd">3100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie121f355ecb34b25b0508086f86f2a6c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfOC0zLTEtMS0x_08df76dd-2aa0-46df-b96a-9cb534f87d17"
      unitRef="usd">6600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i3ba09cfe8cfa4f10bc560bc45b9319b5_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfOC01LTEtMS0x_83bc563f-a63a-473c-b8d9-65ab1beecb8b"
      unitRef="usd">22500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i864500d9b5b94bfaaa7d9ea71c3b0c26_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmFiMzJhZDEzNjBmMjRmMTViNDRlOGI5ZmU1NGViM2VjL3RhYmxlcmFuZ2U6YWIzMmFkMTM2MGYyNGYxNWI0NGU4YjlmZTU0ZWIzZWNfOC03LTEtMS0x_1b3cd0de-8d04-4906-b5b8-bb8c290f2d55"
      unitRef="usd">-58300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfODM1Mg_79472be9-1b19-4a0a-bd1f-f3c9067bece6"
      unitRef="usd">-16400000</us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ4MjQ_3d3ed61d-d71c-4984-9770-e4204d6848b5">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize certain fair value information at September&#160;30, 2021 and December&#160;31, 2020 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other&lt;br/&gt;Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,373.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,373.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,373.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2,373.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;11.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;15.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;15.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;15.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;37.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;129.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;129.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;129.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;129.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;219.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;215.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;219.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;219.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;110.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;107.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;110.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;110.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;19.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;19.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;19.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;19.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;105.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;21.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;105.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;105.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,482.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;420.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,482.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,482.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;556.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;725.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,350.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,097.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity investments without readily determinable fair values &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;373.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;471.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,966.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iab73c3bd3fe34c699b5cb054ccb42a6b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMy0xLTEtMS0x_bd11384a-eff4-4e3c-af73-c1b089ecdfaf"
      unitRef="usd">2373800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icf8e31e25410469a84688b7fb5b87b90_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMy0zLTEtMS0x_7b92a418-4fdb-43af-975a-cf42f4f1d270"
      unitRef="usd">2373800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i44ef377c866e48298d0988babb457ef5_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMy01LTEtMS0x_90d237d9-5825-4135-b952-1142fb675fd5"
      unitRef="usd">2373800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4ad610fc9575465b996c10f1fb676d8e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMy03LTEtMS0x_274ab38a-4b4a-42e9-be72-37da0e110b94"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6e0450a0148940568359bd2bb4fd1c7a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMy05LTEtMS0x_f06edd41-c540-4b90-a2f6-7876899bc970"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie387bef8710440e4832f0dd71a46bba0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMy0xMS0xLTEtMQ_6098ce4a-add7-4294-8284-35c76bfe92a6"
      unitRef="usd">2373800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i05166d7e427248f89521f9a6bcdaa937_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNi0xLTEtMS0x_345e0282-2ecb-4ad5-aac7-b6a8140b59b0"
      unitRef="usd">11300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i519a8c1745264739b16980e97bd28088_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNi0zLTEtMS0x_d2aecea0-fe11-4ff1-b8bb-d32c639d1a13"
      unitRef="usd">11100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6137cc328cc64a7b8e6dc90a371cff51_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNi01LTEtMS0x_c24f751d-3055-4c29-9f74-31fc671ce9a1"
      unitRef="usd">11300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6ac4ef28e5ea4608a5b80501977931f5_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNi03LTEtMS0x_c7ff46a1-49ce-4fa2-8039-df385fd68169"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia1b8587493d44060ac22b7dfc95bcf5b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNi05LTEtMS0x_f79078b9-a734-4c8b-add1-feddcfd0f7d0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i254a65a32a434ab6b7ef57c8e79f3444_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNi0xMS0xLTEtMQ_e2b9cc22-4f6e-4eaa-b06a-be5b2b54c36b"
      unitRef="usd">11300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id0eea1fbbff8437281fea8e1a0f1bef3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNy0xLTEtMS0x_72bdbfb3-c1bb-4caa-b675-da77de5113f4"
      unitRef="usd">6800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i1a167b8fec544f85a40ec24ff3dca2ae_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNy0zLTEtMS0x_46cade2e-33fb-4514-920d-ff3ff08f43b0"
      unitRef="usd">6700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8271ad9786914a7b9146b4cac43d9253_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNy01LTEtMS0zMDQwNg_863371ed-1924-4ca2-85d1-57863f3050d3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9346e5ce6da0496eb9220c6582e6049a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNy03LTEtMS0x_d74d4f87-784f-40f5-a9f0-87ce773d059e"
      unitRef="usd">6800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i68599e7c7d4b45eca411fa801f914c08_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNy05LTEtMS0zMTc2NQ_2c648535-c119-4923-91ec-67391191654e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3674d32a89aa4e689ac0f2091ddd444f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNy0xMS0xLTEtMQ_49aa75ad-bf4d-4aff-97e6-e7b671149772"
      unitRef="usd">6800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i600421af4c80421291f0d5e08ea11d36_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOC0xLTEtMS0x_22a7e579-2de0-4bec-9f19-9615b440f2c7"
      unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i027d17439d6c44daaa8479672e90cc93_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOC0zLTEtMS0x_bde194ac-3c9f-4ad8-a17f-cea68911e39f"
      unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iec3eb54ea13545388e93581cfd374f6b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOC01LTEtMS0x_1f0325c2-a721-4577-9441-9ede384ebe95"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0a3380d8d6904862a95b183e88d6721d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOC03LTEtMS0x_c660f6af-e2a4-4e69-9982-f4b64250ac4c"
      unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9f93a011c64e4f2c94195e681aac557a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOC05LTEtMS0x_c3e40e5a-e033-4880-89a7-61fcc07239b5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ife05bc1f99a24066a3787f493ad65c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOC0xMS0xLTEtMQ_f0662b14-f548-4fcb-ba9a-7c05e267f5a9"
      unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i667849e28703418487b214fec3474bdf_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOS0xLTEtMS0x_0d98fce7-7171-4df1-b3d1-7e08eadedf79"
      unitRef="usd">3300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i175f9851b84d40c69587dda3c8dc10b9_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOS0zLTEtMS0x_a23863eb-fe69-4e5b-9344-165a34ceecd9"
      unitRef="usd">3200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ida2502dbdf2544cb9724ce9126589989_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOS01LTEtMS0x_94bfc1b4-c807-40f9-b352-5559c270e94c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i1e73b6978a284142bdbfa2193963e239_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOS03LTEtMS0x_5768357b-843c-4a7c-b232-26472801c88e"
      unitRef="usd">3300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i7df8c985cdf740f7bae9773aa95472ab_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOS05LTEtMS0x_96068ad9-fe56-4c4d-9171-7e36b539a697"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i59605113a4b745c8bb79328b1a984d9e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfOS0xMS0xLTEtMQ_d958215b-85c7-433b-9443-b7c1ee667800"
      unitRef="usd">3300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2bf8581a0b224377866093121945c682_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTAtMS0xLTEtMQ_cd80f676-11b2-47ae-90ef-2cffd86cf63b"
      unitRef="usd">15500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i994afc29ec17435a9bee9daefa8e55bb_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTAtMy0xLTEtMQ_3f839b46-0276-406a-8869-689a82ccd638"
      unitRef="usd">15500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8242f0bb64934a2f96b9efb3621ba78f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTAtNS0xLTEtMQ_0396bd62-2ccd-4808-b4f3-374d4328d11e"
      unitRef="usd">6600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iac3d68dc29d04fa68b9b49b08724abb8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTAtNy0xLTEtMQ_c0926dbd-f1cd-42cb-a71b-526625a2ec85"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i1917512fec5348218ab246fc29ac8b87_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTAtOS0xLTEtMQ_1f7cf6dc-36dd-4e13-a3ba-ad6cbc145d4d"
      unitRef="usd">8900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i03ec7add2c2b40edbdc4d76abab59030_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTAtMTEtMS0xLTE_ecbf3bf8-d55a-4c78-b9e1-86d542641f12"
      unitRef="usd">15500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iab73c3bd3fe34c699b5cb054ccb42a6b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTItMS0xLTEtMQ_29abac4c-6a50-49ca-b886-c964d7781ec6"
      unitRef="usd">37100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i05166d7e427248f89521f9a6bcdaa937_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTUtMS0xLTEtMQ_2e736d90-6123-4ad8-8604-6ce61ffd7a01"
      unitRef="usd">129900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i519a8c1745264739b16980e97bd28088_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTUtMy0xLTEtMQ_a84457b8-db14-4f58-968a-82d873c5544b"
      unitRef="usd">129000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i6137cc328cc64a7b8e6dc90a371cff51_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTUtNS0xLTEtMQ_abd375ad-4c7f-4d82-9e39-d58b1cf74776"
      unitRef="usd">129900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i6ac4ef28e5ea4608a5b80501977931f5_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTUtNy0xLTEtMQ_801ead89-5011-42b2-947f-ff8c6185d818"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia1b8587493d44060ac22b7dfc95bcf5b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTUtOS0xLTEtMQ_e48f5994-14ae-4e54-b7a3-a6b7508b9cee"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i254a65a32a434ab6b7ef57c8e79f3444_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTUtMTEtMS0xLTE_128bb1ef-633e-41d1-8aef-815be56a5829"
      unitRef="usd">129900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id0eea1fbbff8437281fea8e1a0f1bef3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTctMS0xLTEtMQ_8885cb74-5dc2-467e-9231-52064eefef75"
      unitRef="usd">219700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i1a167b8fec544f85a40ec24ff3dca2ae_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTctMy0xLTEtMQ_5de15221-a63f-4f07-9177-9d9e485aabfc"
      unitRef="usd">215000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i8271ad9786914a7b9146b4cac43d9253_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTctNS0xLTEtMQ_7e57ab2b-167b-407d-8cfd-0e070a5c5f73"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9346e5ce6da0496eb9220c6582e6049a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTctNy0xLTEtMQ_b943cc0b-09a3-41bc-bdb2-8e0d3eb3000c"
      unitRef="usd">219700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i68599e7c7d4b45eca411fa801f914c08_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTctOS0xLTEtMQ_d6fe598e-7527-4a65-b3bf-4399d9ba359c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i3674d32a89aa4e689ac0f2091ddd444f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTctMTEtMS0xLTE_d7ead940-2f50-4ba5-9f84-b3f5101851ea"
      unitRef="usd">219700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i600421af4c80421291f0d5e08ea11d36_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTgtMS0xLTEtMQ_297940fc-fa09-4083-ac99-99846c411c06"
      unitRef="usd">110700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i027d17439d6c44daaa8479672e90cc93_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTgtMy0xLTEtMQ_3c18c740-a314-4cd3-87ac-7ce8f26237bc"
      unitRef="usd">107900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iec3eb54ea13545388e93581cfd374f6b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTgtNS0xLTEtMQ_5153fa82-3eec-48dc-963a-821b0dcacc48"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0a3380d8d6904862a95b183e88d6721d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTgtNy0xLTEtMQ_ad9432d3-c207-4140-aa8e-9a4d70992d76"
      unitRef="usd">110700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9f93a011c64e4f2c94195e681aac557a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTgtOS0xLTEtMQ_fe83aac7-d835-44cd-af65-fe4ed29e70b2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ife05bc1f99a24066a3787f493ad65c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTgtMTEtMS0xLTE_c768fc4f-b3f6-4d19-83a2-54c7b71991a1"
      unitRef="usd">110700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i667849e28703418487b214fec3474bdf_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTktMS0xLTEtMQ_00a78140-05c2-452e-bac8-9433c47daf41"
      unitRef="usd">19700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i175f9851b84d40c69587dda3c8dc10b9_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTktMy0xLTEtMQ_4268b94c-71ba-4cec-b17f-b7ee93cbceff"
      unitRef="usd">19600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ida2502dbdf2544cb9724ce9126589989_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTktNS0xLTEtMQ_db97b18b-f08e-4ae3-8235-a5280d0b92df"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i1e73b6978a284142bdbfa2193963e239_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTktNy0xLTEtMQ_a9cbf156-f004-41be-bc97-56458e0bbf8e"
      unitRef="usd">19700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i7df8c985cdf740f7bae9773aa95472ab_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTktOS0xLTEtMQ_7fa13799-0098-420a-94a7-c6c71be0d610"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i59605113a4b745c8bb79328b1a984d9e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMTktMTEtMS0xLTE_c52f07ef-a295-4cf8-82b0-53b1598cb9d7"
      unitRef="usd">19700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9ee0ce7fbbd74335ae49c786f5ce512f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjAtMS0xLTEtMQ_3e1718db-6e88-4e25-b0d0-c0fe6fd02c60"
      unitRef="usd">105600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i52017fe562964955b55493c294addb61_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjAtMy0xLTEtMQ_eb608ed0-20d8-4fff-91aa-56a729a35622"
      unitRef="usd">21600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id52dc374b89b4866b4adf274c2fa1a1e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjAtNS0xLTEtMQ_1fe4a1f0-15b3-4003-a099-ed20912b76f7"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib5c4cc06a6de46e1aad4f9ff97b84c27_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjAtNy0xLTEtMQ_aacdd2c0-8e0b-4f08-8f72-81f8f558cc14"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i225a1a562a4642abb6920b01f2fbb477_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjAtOS0xLTEtMQ_8d167f41-4b68-469a-884a-573ef17ddfe6"
      unitRef="usd">105600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5501586573ce4f1cbc984235a5fde549_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjAtMTEtMS0xLTE_6ea812df-ad15-4a34-88d1-433dfbc2d061"
      unitRef="usd">105600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i770397553c8b4514ae29bcfa65ceee7b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjEtMS0xLTEtMQ_4892055f-848c-4124-98be-c648a9a2d8d8"
      unitRef="usd">1482800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5b9c433fde8f4a7b8dc0cbfd63eae7e9_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjEtMy0xLTEtMQ_0c48f03a-11bc-45d9-9bae-a7ed8c8e3030"
      unitRef="usd">420500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if6bfbe4f40464147acb2b478e7971494_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjEtNS0xLTEtMQ_2b7f5f10-fdac-432f-923d-1048e1456de7"
      unitRef="usd">1482800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7edbfa9acbdb4bc6a481ff5ca1ce3c46_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjEtNy0xLTEtMQ_497f69ba-d2ae-4049-8a92-a44073146f78"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8f2ea2a6d6594fc5a90ebcefa22bf6ed_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjEtOS0xLTEtMQ_4f970d2d-44a5-47ca-a42b-599e5e059838"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iad249b87b2f44e35b139a24f5d4d84db_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjEtMTEtMS0xLTE_5a9184f4-085b-4e67-8608-7fceb86fb060"
      unitRef="usd">1482800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="iab73c3bd3fe34c699b5cb054ccb42a6b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjItMS0xLTEtMQ_3f95a4d3-c1c2-4756-9b21-361f46d9c936"
      unitRef="usd">556300000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherLongTermInvestments
      contextRef="i87dfd73c05814b0fbc8871daab747004_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjMtMS0xLTEtMQ_9ed3bc51-cc02-40a3-85f4-5ecb7a7ff5d8"
      unitRef="usd">725800000</us-gaap:OtherLongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="iab73c3bd3fe34c699b5cb054ccb42a6b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjQtMS0xLTEtMQ_ff921f6f-11c3-40da-8688-7fd3b4b4e5f1"
      unitRef="usd">3350500000</us-gaap:LongTermInvestments>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7cb6f993649c432f91ab9ca4b71ffef8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjctMS0xLTEtMQ_7ffc9201-c649-434b-bd23-40367b48863d"
      unitRef="usd">2097900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4fe77029755145319472019556e746c7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjctMy0xLTEtMQ_baa3ac97-1435-4859-b3a0-de5092cfd8c6"
      unitRef="usd">2097900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i96ca3e07a01148b094a43c55448e4efb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjctNS0xLTEtMQ_21543e09-312d-4b2f-a9f7-246c9357ccaa"
      unitRef="usd">2097900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia1e0615e204f473cba443f60b3f7de5f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjctNy0xLTEtMQ_92d587c4-5752-4116-b954-7555ce87bc9f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i05295ce03244400fa6766b9e219b8bf3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjctOS0xLTEtMQ_95e4f2dd-b375-4934-9203-9fdba245b3e9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8fa9cde6db5c48a49a12b2bf050fed02_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMjctMTEtMS0xLTE_bf57940b-d57b-4660-ba7a-a06d15725065"
      unitRef="usd">2097900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i08e5d8fcb3fd44119480db6dbff280ce_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzAtMS0xLTEtMQ_5f5fe95c-f24f-40ec-8620-8ecc98996ba8"
      unitRef="usd">9900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ied8184781f424f29a27dadddc6ed8731_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzAtMy0xLTEtMQ_351197c0-ae73-449b-ab48-4cf440ba636a"
      unitRef="usd">9900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i4a9d1a3a1cff4a65a746020df220cf2f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzAtNS0xLTEtMQ_56a9eefa-cfca-4bf4-8ec5-c5d64621f6e0"
      unitRef="usd">9900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i65469da25ad54c90b48a89c0f3bf3d24_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzAtNy0xLTEtMQ_221fd8d0-a30b-40db-9cd9-110dd88840ab"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id88987a437d54b93a06bb21dda0b2e94_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzAtOS0xLTEtMQ_95c1c6cd-8f0d-495c-b36d-6f5a7415800d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic54aa0ee54c84aa7b85f303e4d069d0d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzAtMTEtMS0xLTE_1cfa14e9-9722-42fa-95ee-232a35419ec9"
      unitRef="usd">9900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iae50a005012c4da184ec9eab81c511a8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzEtMS0xLTEtMQ_ff73ec80-6fac-4fc2-9d4e-66272020af71"
      unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id30187a0d3b642f182acd93577234424_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzEtMy0xLTEtMQ_c76ad34a-46a5-4eb7-940b-0c8f2a5496fe"
      unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if108dc8c33db49f1b50918a4d21f04b6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzEtNS0xLTEtMQ_2e4f7eb9-8aa8-400b-bf88-cca6836e209b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie1d6a3638c5d4a708badbca1668d1e74_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzEtNy0xLTEtMQ_d4a986d5-c7f7-4b36-a775-729e47e813ef"
      unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iafebeab06586446d912397c6fb09946f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzEtOS0xLTEtMQ_04f7706c-5311-48c0-8119-f41703e5359c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i559d13b3f37b4eb4ab054a4bce781df7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzEtMTEtMS0xLTE_8a6ff988-7954-41ed-b9d7-4de3056d2684"
      unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id471726344764ff2b385dbc67cf0ff8c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzItMS0xLTEtMQ_02acb382-76fa-47a2-82f3-cb0368b1d728"
      unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i579833d7d4e94e06b8586597ea11d6be_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzItMy0xLTEtMQ_df3cc659-0bb7-45b8-991f-a9328e6a2728"
      unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i529b971a380a4005bfd7acd5587ded3e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzItNS0xLTEtMQ_6b668a60-c635-4937-8b22-35745822b13b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibc82ddb19c4945f884bbc5cd15cb96f4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzItNy0xLTEtMQ_929ab758-6193-43ec-9c29-b0c21de1ef91"
      unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2f53adcd59224d2687568795466dfc6f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzItOS0xLTEtMQ_9914f7c5-885f-43ef-b26a-bcf506f7812e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2f2b5896fbb642c0a0b59d18c9b0e845_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzItMTEtMS0xLTE_91fee13c-0c93-4359-a2bc-e2b8d20bef4a"
      unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i10c6b8bdcad04d0d88e821b45c159a43_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzMtMS0xLTEtMQ_f84baa54-cc53-4001-9244-981259f39dd6"
      unitRef="usd">10300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i034058bf069a4dbcaae7e84a4aa255ae_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzMtMy0xLTEtMQ_df352e52-b081-4115-aac5-1b45c278d866"
      unitRef="usd">10300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie0365c0c3dd2458dae2cab0433af8f3e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzMtNS0xLTEtMQ_7b200eff-0d5e-4cae-a429-40a0330fbcc3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i19165abf56a04452a4c3551fe3755e80_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzMtNy0xLTEtMQ_32418277-399d-493e-9558-bd492593c9dd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i289304fc14e749fea082a39de3765686_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzMtOS0xLTEtMQ_e82927f7-7bd4-4507-a922-89c8234e4ed3"
      unitRef="usd">10300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i38b1cd4f68cc409893c60409151dc138_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzMtMTEtMS0xLTE_e54449bf-2127-4638-9029-ace0f080e03d"
      unitRef="usd">10300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i7cb6f993649c432f91ab9ca4b71ffef8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzUtMS0xLTEtMQ_f06afd6e-4f8c-45e0-9f21-4023a5b0a057"
      unitRef="usd">24200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i08e5d8fcb3fd44119480db6dbff280ce_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzgtMS0xLTEtMQ_db5c1142-0225-425f-bac5-2f75f3dbe327"
      unitRef="usd">78700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ied8184781f424f29a27dadddc6ed8731_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzgtMy0xLTEtMQ_da910a6b-a034-4bf2-a021-34da31ff4430"
      unitRef="usd">74300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i4a9d1a3a1cff4a65a746020df220cf2f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzgtNS0xLTEtMQ_a4c0b59e-361e-46e4-92a7-9acf2c65e277"
      unitRef="usd">78700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i65469da25ad54c90b48a89c0f3bf3d24_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzgtNy0xLTEtMQ_ddbad957-10c1-48cf-adac-1044d7031c7e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id88987a437d54b93a06bb21dda0b2e94_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzgtOS0xLTEtMQ_5dec742f-d381-4188-a2c5-2bcb204d192c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ic54aa0ee54c84aa7b85f303e4d069d0d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzgtMTEtMS0xLTE_7e204cdd-9495-489f-8463-8210956a8e5c"
      unitRef="usd">78700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iae50a005012c4da184ec9eab81c511a8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzktMS0xLTEtMQ_235c5f36-65f7-40a4-84d4-c749ab338e3e"
      unitRef="usd">137000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id30187a0d3b642f182acd93577234424_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzktMy0xLTEtMQ_8befb4eb-3d53-45db-ae43-2566362c642f"
      unitRef="usd">126800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if108dc8c33db49f1b50918a4d21f04b6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzktNS0xLTEtMQ_2937eb20-f85b-4454-823c-8d1fc72c1a46"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ie1d6a3638c5d4a708badbca1668d1e74_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzktNy0xLTEtMQ_1d60fa53-d6eb-4832-b45a-8a5cef44e965"
      unitRef="usd">137000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="iafebeab06586446d912397c6fb09946f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzktOS0xLTEtMQ_962761fc-e85e-4b74-adfe-d95b71b6a2b3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i559d13b3f37b4eb4ab054a4bce781df7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfMzktMTEtMS0xLTE_5242c572-16d1-4aac-b007-ca988b6f2259"
      unitRef="usd">137000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia0246f3af391442d94cfbdb8ee92c330_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDAtMS0xLTEtMQ_84efd655-bf09-4ed8-b623-4a7f85e7641e"
      unitRef="usd">106400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i647c8bc2ff894d94933a6d11cfd86f10_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDAtMy0xLTEtMQ_af501f7f-41d0-4c5d-b245-bbb419cee4f9"
      unitRef="usd">101400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i07aa6c9aa38745159a6c6e80527e089c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDAtNS0xLTEtMQ_54b99fb8-1c22-4ee2-8b21-eda526e7999f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ic0d94775a2e4434f8f30c1ad2daaa4be_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDAtNy0xLTEtMQ_5defc809-176c-4571-8694-138acbc79512"
      unitRef="usd">106400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ibb3a371deaa94088a0072db110d4390c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDAtOS0xLTEtMQ_fa66b6d0-e930-442d-bd9a-01dec0df81cf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5bf5bc5acb2d44fdb267cb99d8658e57_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDAtMTEtMS0xLTE_e086806e-5692-401d-924a-c0fcebe8cb5b"
      unitRef="usd">106400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id471726344764ff2b385dbc67cf0ff8c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDEtMS0xLTEtMQ_c1446edb-3ecf-48a6-a95b-e019e87a651d"
      unitRef="usd">24300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i579833d7d4e94e06b8586597ea11d6be_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDEtMy0xLTEtMQ_860dea17-95c3-4760-a6b4-362441334f6a"
      unitRef="usd">23700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i529b971a380a4005bfd7acd5587ded3e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDEtNS0xLTEtMQ_088e2f24-90f3-49b8-98aa-f8d67b9f0222"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ibc82ddb19c4945f884bbc5cd15cb96f4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDEtNy0xLTEtMQ_07870655-aabc-4090-80df-f94a525a8b29"
      unitRef="usd">24300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2f53adcd59224d2687568795466dfc6f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDEtOS0xLTEtMQ_c8ded427-3729-469b-b719-0f38ef54f402"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2f2b5896fbb642c0a0b59d18c9b0e845_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDEtMTEtMS0xLTE_1e5ebcbc-af02-4849-8e8a-849f69e3c68e"
      unitRef="usd">24300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i61279d09c7f74590ba3c78f533210f01_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDItMS0xLTEtMQ_f6121407-1532-44bd-ab06-b80575a5c1db"
      unitRef="usd">110500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i09e35a2009cd4049b44091d2fbad8303_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDItMy0xLTEtMQ_1a6e28f4-7ad5-4608-8536-f6fdc488bf6f"
      unitRef="usd">31800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2e126e3688134c3599ff5a999c9c666e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDItNS0xLTEtMQ_1786a3e0-001d-400b-8ec6-e930d5516a6f"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6d5ca9edfa0a4d2e8a076d65f4bf86f7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDItNy0xLTEtMQ_112660a2-d39e-42e2-b32b-a0e933d60e29"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8bfadc646ecc4dc6b43cf57447e0394b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDItOS0xLTEtMQ_36b51613-b918-4dfd-b338-28bff72a1fd7"
      unitRef="usd">110500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i32ae0f6ced194431824adea4c4770c08_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDItMTEtMS0xLTE_e3dc63c1-03ce-49a6-bbbe-9d4d9bb7b950"
      unitRef="usd">110500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1bf0bd0fc1154e00a1a1c2c3d2110606_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDMtMS0xLTEtMQ_3b8de3f7-f7d7-45ff-af70-6be43f4e9dff"
      unitRef="usd">1664200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8fff8d67cdfe4a6694c7c5b6f0cb54c7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDMtMy0xLTEtMQ_03cfd17e-1b98-44f8-8ad8-0818c75d4a7f"
      unitRef="usd">311600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i44c59f63225e4451a3244ff421561da5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDMtNS0xLTEtMQ_aa5fa329-760e-47a7-b9ca-cd9f0096b810"
      unitRef="usd">1664200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i90ec35ef834d4369a726dac716752c0a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDMtNy0xLTEtMQ_a0cd427b-2a3e-411a-86f8-416f7fb52a90"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if06045f0fcf1478f9c730dddb34ab7ef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDMtOS0xLTEtMQ_e50ee9e1-47a6-45fc-8fa5-9ace36999149"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2da876ea43f4439ebedccb5d73cf5b3b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDMtMTEtMS0xLTE_bf289067-a3dc-4ef7-92ff-2c68ee933736"
      unitRef="usd">1664200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i7cb6f993649c432f91ab9ca4b71ffef8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDQtMS0xLTEtMQ_52fa221d-c547-4c2d-a217-972dd81d1917"
      unitRef="usd">373900000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherLongTermInvestments
      contextRef="ib359550524f54c8f8a3d1f33d72a5dda_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDUtMS0xLTEtMQ_308dd6f2-906e-477e-872a-338016d8c564"
      unitRef="usd">471800000</us-gaap:OtherLongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i7cb6f993649c432f91ab9ca4b71ffef8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhYmVjNjE5MTVmZjQ4ZGFiN2E5OGQ4YmYxODM0Y2ZhL3RhYmxlcmFuZ2U6NWFiZWM2MTkxNWZmNDhkYWI3YTk4ZDhiZjE4MzRjZmFfNDYtMS0xLTEtMQ_5481cc60-2e84-4e68-97e4-8fa4c7e28162"
      unitRef="usd">2966800000</us-gaap:LongTermInvestments>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ4Mjk_a9d6fc9d-caa0-46da-906a-74b73a0ad1eb">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term debt, including current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(17,085.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(18,354.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(18,354.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,595.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,038.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,038.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:LongTermDebt
      contextRef="iab73c3bd3fe34c699b5cb054ccb42a6b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjY5ZDk1ZjQ4Njg5NTQ0YjBhNWU3MTM3NzY0NjhjMTk0L3RhYmxlcmFuZ2U6NjlkOTVmNDg2ODk1NDRiMGE1ZTcxMzc3NjQ2OGMxOTRfNi0xLTEtMS0x_ba8a4079-b25f-4304-a22f-404db10405df"
      unitRef="usd">17085400000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i44ef377c866e48298d0988babb457ef5_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjY5ZDk1ZjQ4Njg5NTQ0YjBhNWU3MTM3NzY0NjhjMTk0L3RhYmxlcmFuZ2U6NjlkOTVmNDg2ODk1NDRiMGE1ZTcxMzc3NjQ2OGMxOTRfNi0zLTEtMS0x_d10a8181-4e06-45a2-9ae4-16016b808448"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i4ad610fc9575465b996c10f1fb676d8e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjY5ZDk1ZjQ4Njg5NTQ0YjBhNWU3MTM3NzY0NjhjMTk0L3RhYmxlcmFuZ2U6NjlkOTVmNDg2ODk1NDRiMGE1ZTcxMzc3NjQ2OGMxOTRfNi01LTEtMS0x_7b34dd29-8295-431a-87a1-cb81bef0a7e4"
      unitRef="usd">18354900000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i6e0450a0148940568359bd2bb4fd1c7a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjY5ZDk1ZjQ4Njg5NTQ0YjBhNWU3MTM3NzY0NjhjMTk0L3RhYmxlcmFuZ2U6NjlkOTVmNDg2ODk1NDRiMGE1ZTcxMzc3NjQ2OGMxOTRfNi03LTEtMS0x_5986a2ca-e309-4c98-b9c0-1f7a7ec6d34e"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie387bef8710440e4832f0dd71a46bba0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjY5ZDk1ZjQ4Njg5NTQ0YjBhNWU3MTM3NzY0NjhjMTk0L3RhYmxlcmFuZ2U6NjlkOTVmNDg2ODk1NDRiMGE1ZTcxMzc3NjQ2OGMxOTRfNi05LTEtMS0x_822dbe6b-b683-4b89-ac52-49e4c5f204ef"
      unitRef="usd">18354900000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i7cb6f993649c432f91ab9ca4b71ffef8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjY5ZDk1ZjQ4Njg5NTQ0YjBhNWU3MTM3NzY0NjhjMTk0L3RhYmxlcmFuZ2U6NjlkOTVmNDg2ODk1NDRiMGE1ZTcxMzc3NjQ2OGMxOTRfNy0xLTEtMS0x_23c01535-0cf1-45cb-87d9-f7767f66333c"
      unitRef="usd">16595300000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i96ca3e07a01148b094a43c55448e4efb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjY5ZDk1ZjQ4Njg5NTQ0YjBhNWU3MTM3NzY0NjhjMTk0L3RhYmxlcmFuZ2U6NjlkOTVmNDg2ODk1NDRiMGE1ZTcxMzc3NjQ2OGMxOTRfNy0zLTEtMS0x_5b4f1eee-fc34-4f4f-ba2c-352fc252870e"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ia1e0615e204f473cba443f60b3f7de5f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjY5ZDk1ZjQ4Njg5NTQ0YjBhNWU3MTM3NzY0NjhjMTk0L3RhYmxlcmFuZ2U6NjlkOTVmNDg2ODk1NDRiMGE1ZTcxMzc3NjQ2OGMxOTRfNy01LTEtMS0x_85bb53df-ba84-4ca0-bd59-52865bab3be9"
      unitRef="usd">19038900000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i05295ce03244400fa6766b9e219b8bf3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjY5ZDk1ZjQ4Njg5NTQ0YjBhNWU3MTM3NzY0NjhjMTk0L3RhYmxlcmFuZ2U6NjlkOTVmNDg2ODk1NDRiMGE1ZTcxMzc3NjQ2OGMxOTRfNy03LTEtMS0x_a5827d87-8d28-493f-9fe4-6bb203ca956a"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i8fa9cde6db5c48a49a12b2bf050fed02_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjY5ZDk1ZjQ4Njg5NTQ0YjBhNWU3MTM3NzY0NjhjMTk0L3RhYmxlcmFuZ2U6NjlkOTVmNDg2ODk1NDRiMGE1ZTcxMzc3NjQ2OGMxOTRfNy05LTEtMS0x_ffaea9df-cc0d-4193-b39b-4b0bdf07096d"
      unitRef="usd">19038900000</us-gaap:LongTermDebt>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ4NjU_d293b8a1-f9b7-4a50-91ad-c1ca119bf348">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-management instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;87.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;87.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;87.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;77.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;77.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;77.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(17.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(17.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(17.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(23.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(23.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(23.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(25.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(25.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(25.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration liability:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(70.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(70.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(70.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-management instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency interest rate contracts designated as cash flow hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i505924e93d794dcfb0c5b8f9156cc31d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNS0xLTEtMS0x_950594e0-225c-4649-bcd3-f765de28663e"
      unitRef="usd">8500000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ib69916829c7f4e9fbfb75dc86bee47ef_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNS0zLTEtMS0x_f7eec9bb-4627-4df5-a4f0-95da365416f8"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ide74b136d9db45dc9cd0829ce1591b43_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNS01LTEtMS0x_59289fcc-53f5-49d0-a9ba-b9b91192f83c"
      unitRef="usd">8500000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i66fa7e1e841c4a48bef41810792cf5e1_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNS03LTEtMS0x_30fcdec2-d71f-49a9-872b-c3c2704ef449"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i95b523dd0c89497e8d0a8474b6749ceb_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNS05LTEtMS0x_6c17c171-488b-46c8-8f40-c54b34745b19"
      unitRef="usd">8500000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i505924e93d794dcfb0c5b8f9156cc31d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNi0xLTEtMS0x_af304bea-1572-4ec6-acf3-87b73e25ba47"
      unitRef="usd">87200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ib69916829c7f4e9fbfb75dc86bee47ef_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNi0zLTEtMS0x_cb935489-8cfc-489e-8ef3-19f29bc208a3"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ide74b136d9db45dc9cd0829ce1591b43_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNi01LTEtMS0x_169637bd-1591-4a43-8dbb-bb372fc13f54"
      unitRef="usd">87200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i66fa7e1e841c4a48bef41810792cf5e1_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNi03LTEtMS0x_8d2aa148-7e30-40c2-9b3a-5f2c94e452a3"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i95b523dd0c89497e8d0a8474b6749ceb_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNi05LTEtMS0x_66913aaf-c65a-47be-9fec-1b3d4b2cc87b"
      unitRef="usd">87200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i505924e93d794dcfb0c5b8f9156cc31d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfOC0xLTEtMS0x_8a9833e2-d8d3-463a-8dfc-44807c7d8a0f"
      unitRef="usd">2200000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ib69916829c7f4e9fbfb75dc86bee47ef_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfOC0zLTEtMS0x_bf1dc077-4f21-4c61-aca7-c09fd0bb2c3f"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ide74b136d9db45dc9cd0829ce1591b43_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfOC01LTEtMS0x_23e0c649-9346-4dcc-ac0e-68cfbced4ede"
      unitRef="usd">2200000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i66fa7e1e841c4a48bef41810792cf5e1_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfOC03LTEtMS0x_59575745-174e-4116-8f3a-dbd0d75cca7d"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i95b523dd0c89497e8d0a8474b6749ceb_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfOC05LTEtMS0x_7dcbb21a-8bff-412c-85f1-0c63769d9772"
      unitRef="usd">2200000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="iffd5ed0fac1144d3bbe9bcce7cd1dcab_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTItMS0xLTEtMQ_007df8ee-2114-4dc2-b697-f573c7463ed4"
      unitRef="usd">77300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i1c09bc5eb3b44d3b988ac6fdb7749025_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTItMy0xLTEtMQ_e999e37d-a4ba-4be9-9667-6832a78fa62e"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i070877701c5a412581e58eb922963dfb_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTItNS0xLTEtMQ_3572e437-5549-494f-93f2-504acf1037d2"
      unitRef="usd">77300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i5427871777084be79a6dd7b683f42940_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTItNy0xLTEtMQ_7776ab5f-64c6-46d6-b963-b672bebe68a4"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="icdeeaeee0d0d4d56bc48afc50bdbf622_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTItOS0xLTEtMQ_69c23d69-ae37-4568-8940-d2ddb9f0c152"
      unitRef="usd">77300000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i8f9e2597f06c4231ae5d5e3a773d4991_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTUtMS0xLTEtMQ_a5321c2e-2f3b-4536-a4b4-9c26d60db3e4"
      unitRef="usd">18700000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i971a91d6ce39447f86a1c28fa9944956_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTUtMy0xLTEtMQ_13edb567-083e-42f2-89dd-f5f064be7f9a"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i3aed62f649184956b1971ad38859077d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTUtNS0xLTEtMQ_1c95f434-8e50-4f54-bb4b-5f85d0ac0fdd"
      unitRef="usd">18700000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ic36d644f83d345269c981d8628439fe7_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTUtNy0xLTEtMQ_b58d0a7e-6b74-4e87-8fd2-18b975602a6d"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="id8af5b44af8147c684f333006fbe7f0c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTUtOS0xLTEtMQ_4cc69e8b-5bfb-4c11-9feb-92b8bd7eeb56"
      unitRef="usd">18700000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i8f9e2597f06c4231ae5d5e3a773d4991_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTYtMS0xLTEtMQ_46cd8efd-fb5f-435c-a5ce-cfa8f2fdedd0"
      unitRef="usd">38700000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i971a91d6ce39447f86a1c28fa9944956_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTYtMy0xLTEtMQ_c7f29217-5a8c-424b-8951-4bbe21847dd5"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i3aed62f649184956b1971ad38859077d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTYtNS0xLTEtMQ_08d2f569-47a5-41f3-a72e-a1b4098628b7"
      unitRef="usd">38700000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ic36d644f83d345269c981d8628439fe7_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTYtNy0xLTEtMQ_ed624983-e0f4-4325-9477-8580bf149239"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="id8af5b44af8147c684f333006fbe7f0c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTYtOS0xLTEtMQ_9cfb5fcc-fa0a-469b-9ece-716bb8f42199"
      unitRef="usd">38700000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i8f9e2597f06c4231ae5d5e3a773d4991_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTctMS0xLTEtMQ_b114a70e-4c81-42fd-853f-effcd07824d0"
      unitRef="usd">17000000.0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i971a91d6ce39447f86a1c28fa9944956_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTctMy0xLTEtMQ_c8937584-479f-443e-b629-4349e4e7ca4a"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i3aed62f649184956b1971ad38859077d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTctNS0xLTEtMQ_e22da6f2-66d1-4152-b70b-cbbfe811914d"
      unitRef="usd">17000000.0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ic36d644f83d345269c981d8628439fe7_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTctNy0xLTEtMQ_eb141ded-09ec-4b98-8b63-c8078534a96f"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="id8af5b44af8147c684f333006fbe7f0c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTctOS0xLTEtMQ_2b8ae683-7ba5-44ef-aae1-ba35de8b850e"
      unitRef="usd">17000000.0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i8f9e2597f06c4231ae5d5e3a773d4991_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTgtMS0xLTEtMQ_5ef55294-7dd1-47d2-99e6-6f4521c5605b"
      unitRef="usd">9500000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i971a91d6ce39447f86a1c28fa9944956_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTgtMy0xLTEtMQ_d25efbda-9631-4854-907c-8cf1cda564cd"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i3aed62f649184956b1971ad38859077d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTgtNS0xLTEtMQ_f1ab80d2-08d2-4804-aaaa-eec52ed90089"
      unitRef="usd">9500000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ic36d644f83d345269c981d8628439fe7_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTgtNy0xLTEtMQ_cc70a4cd-9b6c-4899-a1fb-f4f3db764c8e"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="id8af5b44af8147c684f333006fbe7f0c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMTgtOS0xLTEtMQ_7fcddd43-db4e-49f5-8754-98a7a7988177"
      unitRef="usd">9500000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i7f931a8eb6e44ca2a36918808b02f5e3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjAtMS0xLTEtMQ_4f33e7d6-ef05-4a69-9d5f-2f3a6db644ee"
      unitRef="usd">10800000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i97d367acc5bc4a7693028a8fc46010a4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjAtMy0xLTEtMQ_a821aa44-6488-4cd9-82b3-0eb464eafafd"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i89eb7f65122e4d24b2f6d71a3d2035ca_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjAtNS0xLTEtMQ_048e68d2-73bb-47e8-ae2a-a691e890a50f"
      unitRef="usd">10800000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i378115cc1767432b9131fab24760be6c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjAtNy0xLTEtMQ_6b92b405-5773-475c-ad31-23bcb8aba69b"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i79a2635cf98d414eb4d6df658c5f7006_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjAtOS0xLTEtMQ_46734113-e4ae-4424-9f94-83c0f701d5c7"
      unitRef="usd">10800000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i7f931a8eb6e44ca2a36918808b02f5e3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjEtMS0xLTEtMQ_2e2c0c58-6b2d-43cd-bd12-7cfa158d899f"
      unitRef="usd">23000000.0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i97d367acc5bc4a7693028a8fc46010a4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjEtMy0xLTEtMQ_c4b56589-276d-4616-b39d-d13ae99ee8f2"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i89eb7f65122e4d24b2f6d71a3d2035ca_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjEtNS0xLTEtMQ_c0678df0-a78e-4324-bfa7-8ffb94f09bf6"
      unitRef="usd">23000000.0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i378115cc1767432b9131fab24760be6c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjEtNy0xLTEtMQ_21886843-4525-463a-8c9c-108c141f8ec6"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i79a2635cf98d414eb4d6df658c5f7006_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjEtOS0xLTEtMQ_625df700-577b-4034-85d8-5ccf9890e85c"
      unitRef="usd">23000000.0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i610fa7df3a574a30bb25b81f30f3394e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjMtMS0xLTEtMQ_aaf89376-2159-4b21-ab3d-0af4c1dbcbad"
      unitRef="usd">5500000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i544e08e2a3a1491f9a0fa4048ca7ab95_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjMtMy0xLTEtMQ_ad8fa7fe-c741-46f2-ba81-f5222d4d12a1"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ie0b124c9b6104c87b8aeb05c89cb6f96_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjMtNS0xLTEtMQ_84d435b2-28ac-4b44-a8da-0ca1fef45ff9"
      unitRef="usd">5500000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ifd3f4727952e4020b12ae68aacca865d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjMtNy0xLTEtMQ_73ba7e05-b99f-4035-9bff-ad859236d1c4"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="id907a8104c9441f294b2de3071a1225c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjMtOS0xLTEtMQ_8a89e176-a233-48fd-90bf-c658af101519"
      unitRef="usd">5500000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i610fa7df3a574a30bb25b81f30f3394e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjQtMS0xLTEtMQ_87c95159-a42a-4231-a30c-c215840a4c09"
      unitRef="usd">25700000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i544e08e2a3a1491f9a0fa4048ca7ab95_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjQtMy0xLTEtMQ_ebfa0b97-64cf-427a-a080-d103983220f7"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ie0b124c9b6104c87b8aeb05c89cb6f96_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjQtNS0xLTEtMQ_e445a71c-7837-407f-bf59-4a978098c9e8"
      unitRef="usd">25700000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ifd3f4727952e4020b12ae68aacca865d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjQtNy0xLTEtMQ_ad3ca60a-63f0-4e70-a835-3bfc85c2ef1d"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="id907a8104c9441f294b2de3071a1225c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjQtOS0xLTEtMQ_7e365f81-6ae8-4a3e-a3af-ce72d91250d4"
      unitRef="usd">25700000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iab73c3bd3fe34c699b5cb054ccb42a6b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjktMS0xLTEtMQ_82f306c1-45c1-4320-9859-ab461044b2dc"
      unitRef="usd">70700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i44ef377c866e48298d0988babb457ef5_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjktMy0xLTEtMQ_ae0cb087-a092-425e-a5dc-bddc363160e1"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4ad610fc9575465b996c10f1fb676d8e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjktNS0xLTEtMQ_6bb8f014-b44f-4a72-ad11-80c5c2058b0e"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6e0450a0148940568359bd2bb4fd1c7a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjktNy0xLTEtMQ_c156b692-d4cb-4729-99de-1b9a1bf44444"
      unitRef="usd">70700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie387bef8710440e4832f0dd71a46bba0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMjktOS0xLTEtMQ_4139a395-fa39-466a-9ccf-207363ce0859"
      unitRef="usd">70700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i81adb51d1b8642b89fde93b4d30867a1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMzUtMS0xLTEtMQ_0c191769-a03d-41a1-bde6-044a66032b51"
      unitRef="usd">158900000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ie853d3ba19364e30b51bd241ce67c53e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMzUtMy0xLTEtMQ_7ceb754b-031f-4200-b26c-a50ad0b3afe3"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="if4754a075a4b41139b71c1d8bd51b1d1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMzUtNS0xLTEtMQ_fc1a556d-d0fd-4b4c-afba-1a3f2076afe3"
      unitRef="usd">158900000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i6d66e7dd621e49b19263feb5a5399308_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMzUtNy0xLTEtMQ_69867c8b-56c0-438a-9925-af889f54f474"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i70f111854ded42afbf8cf34c68376b8b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMzUtOS0xLTEtMQ_0baf0bd3-e030-4c0b-a655-c5202a2d1475"
      unitRef="usd">158900000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ic96c9ad703a245439fd588caaf8599df_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMzktMS0xLTEtMQ_fb02fd92-b281-4df5-b615-35f01df1d7fd"
      unitRef="usd">38100000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i3066f646c41949fea57b1468cb30aa61_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMzktMy0xLTEtMQ_480ed097-bb00-40d6-aab0-18cf66ce7f7f"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i3114cab844d04fb094abf5ed273c4e1a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMzktNS0xLTEtMQ_47e3e20d-0f7b-4f96-9c72-4dd5b406e9a0"
      unitRef="usd">38100000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i462ca7b5109d432893cd43002d27ce96_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMzktNy0xLTEtMQ_4000dfc7-950e-4b6c-8bef-975a453dfd9a"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i143e36fc013841a18710bf40ddbee422_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfMzktOS0xLTEtMQ_5d42fd63-d6df-4894-9353-203dd964376c"
      unitRef="usd">38100000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ic96c9ad703a245439fd588caaf8599df_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDAtMS0xLTEtMQ_20da0f9d-265c-495d-8be1-4fe3eb1cdb67"
      unitRef="usd">97800000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i3066f646c41949fea57b1468cb30aa61_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDAtMy0xLTEtMQ_9fd59462-2f30-4eed-b9d3-70e275968933"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i3114cab844d04fb094abf5ed273c4e1a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDAtNS0xLTEtMQ_3f0386a0-beae-4d0f-abfe-6a2879f72b73"
      unitRef="usd">97800000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i462ca7b5109d432893cd43002d27ce96_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDAtNy0xLTEtMQ_1ffa9acc-4538-475d-9494-82caa602d197"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i143e36fc013841a18710bf40ddbee422_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDAtOS0xLTEtMQ_2216c89f-dca5-49e3-81bd-dc67b8a75408"
      unitRef="usd">97800000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i3ce61f92b7b2406a94a6f87d2dd9623e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDMtMS0xLTEtMQ_2c963f87-2e2f-482e-a430-9cc1c3cc3185"
      unitRef="usd">92600000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i667fa4a2085f406eb99b492e2438f438_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDMtMy0xLTEtMQ_50778011-1f00-4064-8297-291e73a1b932"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i2c435b9259f241fbad90a81868ac7e93_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDMtNS0xLTEtMQ_38d6d3f0-a5e1-4733-9fb9-1dcd9723737f"
      unitRef="usd">92600000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i38d8fd0978ab4d4893660a6cce21b4ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDMtNy0xLTEtMQ_e9ec1758-5b56-4bc1-8d9c-5a341f442f01"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i0716e0eaab47406db717f55a7cbf94ae_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDMtOS0xLTEtMQ_1ae52815-15d4-4f26-96ec-8b8ab89405a2"
      unitRef="usd">92600000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i3ce61f92b7b2406a94a6f87d2dd9623e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDQtMS0xLTEtMQ_dc8c574d-8cb3-40aa-8d65-d9681663c10a"
      unitRef="usd">97200000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i667fa4a2085f406eb99b492e2438f438_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDQtMy0xLTEtMQ_6ce30aab-cba3-45df-8767-2a8b3659eff0"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i2c435b9259f241fbad90a81868ac7e93_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDQtNS0xLTEtMQ_1227abe3-bce7-40b8-818d-3b042dc62eb1"
      unitRef="usd">97200000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i38d8fd0978ab4d4893660a6cce21b4ac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDQtNy0xLTEtMQ_96d6807e-c55d-4b46-8c7a-56f8342b9d2f"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i0716e0eaab47406db717f55a7cbf94ae_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDQtOS0xLTEtMQ_f1a94ed6-31cf-44e8-b458-79ec29c934b3"
      unitRef="usd">97200000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i12ec379ba231490e890d0b394891be1b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDYtMS0xLTEtMQ_b68a02a8-c477-4238-b759-a0c577e09284"
      unitRef="usd">34400000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i29cc6f270f8e4052ada8d9109a7be71d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDYtMy0xLTEtMQ_4079d3bf-cf06-4f89-9551-76e7987dcbc7"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i90ded503eb9c4993b67215c3faca3095_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDYtNS0xLTEtMQ_8cf37fbe-a655-467e-87ec-a00b565508dd"
      unitRef="usd">34400000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i9f59e5a852fa4290a1df65e6c201066d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDYtNy0xLTEtMQ_92c2c48c-51b2-4bd2-aeaf-899a90b4efbc"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i4d085d14349d484c957844f0450fce23_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDYtOS0xLTEtMQ_73d90ae2-5f17-4e12-bd04-a9e35fbb2a2e"
      unitRef="usd">34400000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i12ec379ba231490e890d0b394891be1b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDctMS0xLTEtMQ_a30f4197-944d-408b-93cc-2fee3bf28293"
      unitRef="usd">2900000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i29cc6f270f8e4052ada8d9109a7be71d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDctMy0xLTEtMQ_7301795a-c109-48ef-b4df-cbfd82a10fa1"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i90ded503eb9c4993b67215c3faca3095_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDctNS0xLTEtMQ_b528b910-4831-4836-81b1-2aefb2a15407"
      unitRef="usd">2900000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i9f59e5a852fa4290a1df65e6c201066d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDctNy0xLTEtMQ_8cec31fe-9368-45e2-b2e2-ca83ffe9bbe1"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i4d085d14349d484c957844f0450fce23_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDctOS0xLTEtMQ_78a553f9-e8a4-4f7f-877a-0775e4105f4a"
      unitRef="usd">2900000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i646f429e54744f22989e1d0d53220bc3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDktMS0xLTEtMQ_0b2f2ea5-b376-4137-a8fc-2cf623f943dd"
      unitRef="usd">41100000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i350054955cb548ee9fa3d529afd9be07_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDktMy0xLTEtMQ_0f5ab5e1-6e4c-454c-8234-c1a891928179"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i1213fc8d77534b999d9ec3dd2556fa3d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDktNS0xLTEtMQ_769f2666-6c4e-4c4b-8b2c-ae246252b81c"
      unitRef="usd">41100000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="id562cb2b7ee2435a966ee63e3c0c3331_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDktNy0xLTEtMQ_794ac8c0-7dc1-4993-9917-1bd0b07a0c77"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i8744c9db8c224530b3a70c3dc9a6e821_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNDktOS0xLTEtMQ_9f3ef571-e8bb-4453-bb06-1e4233043903"
      unitRef="usd">41100000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i646f429e54744f22989e1d0d53220bc3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNTAtMS0xLTEtMQ_319efccd-153e-492d-8dc1-1fc09406feab"
      unitRef="usd">15200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i350054955cb548ee9fa3d529afd9be07_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNTAtMy0xLTEtMQ_9a4f095b-ffef-4670-96dd-80851d55c558"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i1213fc8d77534b999d9ec3dd2556fa3d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNTAtNS0xLTEtMQ_695107dd-daf9-4263-a5df-78a9063a3ae5"
      unitRef="usd">15200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="id562cb2b7ee2435a966ee63e3c0c3331_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNTAtNy0xLTEtMQ_f530dbda-9d86-4796-85fe-cfc9d35e187a"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i8744c9db8c224530b3a70c3dc9a6e821_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOmQyZDJhZTI5MjEyODQxYzA4MWZkN2Q4YTFiMTJlY2IzL3RhYmxlcmFuZ2U6ZDJkMmFlMjkyMTI4NDFjMDgxZmQ3ZDhhMWIxMmVjYjNfNTAtOS0xLTEtMQ_29bb8871-e6ae-4052-bb24-e5013f756312"
      unitRef="usd">15200000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTAyNzQ_7881f4df-c584-4950-bdb8-4d8f0e1488d1"
      unitRef="usd">781000000</us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments>
    <lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTAzOTM_46781d2d-34a0-4cf9-80e0-b18264b03dab">P10Y</lly:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ4NTA_ce7a1e98-0a3c-427e-b59b-29dd3d3618eb">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturities by Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less&#160;Than&lt;br/&gt;1 Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1-5&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6-10&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More&#160;Than&lt;br/&gt;10 Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjZjZDIwMDYyNWRhMTQ0NDI4OTFiYjE3ZTU3MWMxMmZiL3RhYmxlcmFuZ2U6NmNkMjAwNjI1ZGExNDQ0Mjg5MWJiMTdlNTcxYzEyZmJfMi0xLTEtMS0x_7ea86a0a-0719-4afd-8069-bf8f19bbac8a"
      unitRef="usd">501600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjZjZDIwMDYyNWRhMTQ0NDI4OTFiYjE3ZTU3MWMxMmZiL3RhYmxlcmFuZ2U6NmNkMjAwNjI1ZGExNDQ0Mjg5MWJiMTdlNTcxYzEyZmJfMi0zLTEtMS0x_409b27ab-7760-4edb-aadc-3ed5d6b49313"
      unitRef="usd">21600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjZjZDIwMDYyNWRhMTQ0NDI4OTFiYjE3ZTU3MWMxMmZiL3RhYmxlcmFuZ2U6NmNkMjAwNjI1ZGExNDQ0Mjg5MWJiMTdlNTcxYzEyZmJfMi01LTEtMS0x_1ad4f1ee-cef6-4f75-9467-be7ce17b0de8"
      unitRef="usd">157800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjZjZDIwMDYyNWRhMTQ0NDI4OTFiYjE3ZTU3MWMxMmZiL3RhYmxlcmFuZ2U6NmNkMjAwNjI1ZGExNDQ0Mjg5MWJiMTdlNTcxYzEyZmJfMi03LTEtMS0x_5582218c-dcfa-429a-abd5-ebb959545f3d"
      unitRef="usd">153400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjZjZDIwMDYyNWRhMTQ0NDI4OTFiYjE3ZTU3MWMxMmZiL3RhYmxlcmFuZ2U6NmNkMjAwNjI1ZGExNDQ0Mjg5MWJiMTdlNTcxYzEyZmJfMi05LTEtMS0x_54699860-c3cc-4a3f-a4e1-b6ea9b67dbdc"
      unitRef="usd">168800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTEyOTI_24325b8f-1a14-4019-b214-3654e29213fb"
      unitRef="usd">-246800000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTEyOTk_9bb989c5-5748-406b-94b6-84153fbf64f9"
      unitRef="usd">270100000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTEzNTk_baa8b4f0-0203-4af5-a6b9-d11df3a016fb"
      unitRef="usd">141700000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTEzNjY_c284ce25-ba65-439c-9916-43c9c9cc69ed"
      unitRef="usd">905100000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ4NTE_1ae438c3-88e4-4811-a6c0-f64222d52972">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross gains&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gross losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized gain position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;293.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of securities in an unrealized loss position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;208.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhMDc2OTc1NDkxMDRmNzU4ODZlNmZjYTJjZDg5NTBlL3RhYmxlcmFuZ2U6NWEwNzY5NzU0OTEwNGY3NTg4NmU2ZmNhMmNkODk1MGVfMS0xLTEtMS0x_97ecbd3d-2986-4c0f-9e10-5dcee2f8299b"
      unitRef="usd">12500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhMDc2OTc1NDkxMDRmNzU4ODZlNmZjYTJjZDg5NTBlL3RhYmxlcmFuZ2U6NWEwNzY5NzU0OTEwNGY3NTg4NmU2ZmNhMmNkODk1MGVfMS0zLTEtMS0x_1ba8175a-a546-49e6-91cf-f07ed228475c"
      unitRef="usd">20900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhMDc2OTc1NDkxMDRmNzU4ODZlNmZjYTJjZDg5NTBlL3RhYmxlcmFuZ2U6NWEwNzY5NzU0OTEwNGY3NTg4NmU2ZmNhMmNkODk1MGVfMi0xLTEtMS0x_9d82ab89-6c93-4ff2-bda4-e9802244dd2a"
      unitRef="usd">4000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhMDc2OTc1NDkxMDRmNzU4ODZlNmZjYTJjZDg5NTBlL3RhYmxlcmFuZ2U6NWEwNzY5NzU0OTEwNGY3NTg4NmU2ZmNhMmNkODk1MGVfMi0zLTEtMS0x_237498b0-cd1f-4c14-ab1f-a3149e2f889f"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhMDc2OTc1NDkxMDRmNzU4ODZlNmZjYTJjZDg5NTBlL3RhYmxlcmFuZ2U6NWEwNzY5NzU0OTEwNGY3NTg4NmU2ZmNhMmNkODk1MGVfMy0xLTEtMS0x_27114f7c-1ad8-4474-972a-e40991f4b5e7"
      unitRef="usd">293400000</lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition>
    <lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhMDc2OTc1NDkxMDRmNzU4ODZlNmZjYTJjZDg5NTBlL3RhYmxlcmFuZ2U6NWEwNzY5NzU0OTEwNGY3NTg4NmU2ZmNhMmNkODk1MGVfMy0zLTEtMS0x_5b79a27d-b47d-48b5-a156-ef8961879f4f"
      unitRef="usd">348900000</lly:DebtSecuritiesAvailableforsaleUnrealizedGainPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhMDc2OTc1NDkxMDRmNzU4ODZlNmZjYTJjZDg5NTBlL3RhYmxlcmFuZ2U6NWEwNzY5NzU0OTEwNGY3NTg4NmU2ZmNhMmNkODk1MGVfNC0xLTEtMS0x_202cc4ad-9793-4668-9cc7-54e312c51645"
      unitRef="usd">208100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjVhMDc2OTc1NDkxMDRmNzU4ODZlNmZjYTJjZDg5NTBlL3RhYmxlcmFuZ2U6NWEwNzY5NzU0OTEwNGY3NTg4NmU2ZmNhMmNkODk1MGVfNC0zLTEtMS0x_faacf704-8d1f-4c7a-87ae-5bf88f885678"
      unitRef="usd">11400000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTMyMjk_59c1868c-f99e-4424-b3ab-036ce4e6388f"
      unitRef="number">0.97</us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ4MTQ_9cceb8fc-1b97-4856-bef4-fc4666ae72a5">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity related to our available-for-sale securities was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;49.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;137.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross gains on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized gross losses on sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfMi0xLTEtMS0x_3c651f8f-7729-47a9-b5a2-5d8c70ec4dda"
      unitRef="usd">49600000</lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities>
    <lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfMi0zLTEtMS0x_98d740cb-e609-4aed-a578-8046f7708adf"
      unitRef="usd">14000000.0</lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities>
    <lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfMi01LTEtMS0x_58edee61-1d0d-4e36-82bd-9c18b8120324"
      unitRef="usd">137300000</lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities>
    <lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfMi03LTEtMS0x_4df6f231-2e73-4d6f-9766-16a22bfd5632"
      unitRef="usd">246800000</lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities>
    <lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfMy0xLTEtMS0x_83c2cc34-14b0-434d-950d-71cc051071c6"
      unitRef="usd">400000</lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain>
    <lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfMy0zLTEtMS0x_c57ca2f5-c19e-4581-b7bb-4731b05d8725"
      unitRef="usd">400000</lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain>
    <lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfMy01LTEtMS0x_679140e2-9f25-4ea9-a044-5dfa5948f417"
      unitRef="usd">2200000</lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain>
    <lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfMy03LTEtMS0x_7d26cd83-b046-487b-a6c4-ec5f35c19a1a"
      unitRef="usd">4000000.0</lly:AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain>
    <lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfNC0xLTEtMS0x_5e3ffca0-4a22-452a-80d7-0b2532003138"
      unitRef="usd">300000</lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss>
    <lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfNC0zLTEtMS0x_a74493d9-fc1a-4f3e-8d62-b2ca929a3eb8"
      unitRef="usd">200000</lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss>
    <lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfNC01LTEtMS0x_3434894a-e0d0-4257-857a-0c5e235c3508"
      unitRef="usd">1100000</lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss>
    <lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RhYmxlOjYzNWIzY2ZmMjg2ODQ1ZmM5ZDJkNjExYjVjOTM2MDlkL3RhYmxlcmFuZ2U6NjM1YjNjZmYyODY4NDVmYzlkMmQ2MTFiNWM5MzYwOWRfNC03LTEtMS0x_685c3cb2-25bc-4d90-830c-3b7628c76835"
      unitRef="usd">8200000</lly:AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss>
    <us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized
      contextRef="ie526750480d147ff852c5266a9af6876_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ1MjM_0b5818f3-44ed-4276-8bdd-cec32f57b76c"
      unitRef="usd">617400000</us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized>
    <us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized
      contextRef="ie146f46cbfc341289d8af574772b4b88_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82NC9mcmFnOmVlYWQwMDJkM2MwYTQwNTJiMTEzNzk3MThhYThhYjk0L3RleHRyZWdpb246ZWVhZDAwMmQzYzBhNDA1MmIxMTM3OTcxOGFhOGFiOTRfMTQ1MzA_3e309e13-fec0-4bc2-8619-baa7817aa83d"
      unitRef="usd">754900000</us-gaap:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82Ny9mcmFnOjc0Y2Y2MmRkZDdmNDQxNjM5NjJlODA2ZmI1MDcxNDg2L3RleHRyZWdpb246NzRjZjYyZGRkN2Y0NDE2Mzk2MmU4MDZmYjUwNzE0ODZfOTA2_4efd0885-a71d-411f-84d1-fa548ec87e77">Income Taxes &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate was 10.9 percent for the three months ended September&#160;30, 2021, compared with 15.9 percent for the three months ended September 30, 2020. The lower effective tax rate for the three months ended September 30, 2021 was primarily due to the income tax impact of a debt extinguishment loss and unfavorable mark-to-market adjustments on investments in equity securities, partially offset by a lower net discrete tax benefit compared to the three months ended September 30, 2020. The effective tax rate was 10.7 percent for the nine months ended September&#160;30, 2021, compared with 14.4 percent for the nine months ended September 30, 2020. The lower effective tax rate for the nine months ended September 30, 2021 was primarily due to the income tax impacts of a net inventory impairment charge related to our COVID-19 antibodies and a debt extinguishment loss, as well as higher acquired IPR&amp;amp;D charges and lower favorable mark-to-market adjustments on investments in equity securities compared to the nine months ended September 30, 2020, partially offset by a lower net discrete tax benefit compared to the nine months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. examination of tax years 2016-2018 began in the fourth quarter of 2019 and remains ongoing. The resolution of this audit period will likely extend beyond the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82Ny9mcmFnOjc0Y2Y2MmRkZDdmNDQxNjM5NjJlODA2ZmI1MDcxNDg2L3RleHRyZWdpb246NzRjZjYyZGRkN2Y0NDE2Mzk2MmU4MDZmYjUwNzE0ODZfNTQ_739d46a7-1d61-4943-8dce-512857968b47"
      unitRef="number">0.109</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82Ny9mcmFnOjc0Y2Y2MmRkZDdmNDQxNjM5NjJlODA2ZmI1MDcxNDg2L3RleHRyZWdpb246NzRjZjYyZGRkN2Y0NDE2Mzk2MmU4MDZmYjUwNzE0ODZfMTAy_04650a8e-dbd2-4ef8-a0d4-47ead92fe7ad"
      unitRef="number">0.159</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82Ny9mcmFnOjc0Y2Y2MmRkZDdmNDQxNjM5NjJlODA2ZmI1MDcxNDg2L3RleHRyZWdpb246NzRjZjYyZGRkN2Y0NDE2Mzk2MmU4MDZmYjUwNzE0ODZfMTc0_a44a4760-b79e-46f4-a4e0-9debc701bb04"
      unitRef="number">0.107</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF82Ny9mcmFnOjc0Y2Y2MmRkZDdmNDQxNjM5NjJlODA2ZmI1MDcxNDg2L3RleHRyZWdpb246NzRjZjYyZGRkN2Y0NDE2Mzk2MmU4MDZmYjUwNzE0ODZfMjIw_6a044663-9185-4b44-992e-0da0b21ff8b0"
      unitRef="number">0.144</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RleHRyZWdpb246MjdjMThmNzdiMTJmNGFiOTg4NTJhMmNiZTczZmYxNThfNTY4_ed146df8-c285-4623-b480-d8e9261e179d">Retirement Benefits&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net pension and retiree health benefit (income) cost included the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic benefit cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;92.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;277.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;84.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;253.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(237.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(229.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(712.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(671.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;121.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;366.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;62.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;188.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic benefit income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;37.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(36.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(109.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(44.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(30.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(90.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RleHRyZWdpb246MjdjMThmNzdiMTJmNGFiOTg4NTJhMmNiZTczZmYxNThfNTc4_bf1492e2-f519-4982-970f-ab86640d1808">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net pension and retiree health benefit (income) cost included the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic benefit cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;92.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;277.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;84.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;253.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(237.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(229.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(712.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(671.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;121.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;366.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;62.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;188.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Retiree Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of net periodic benefit income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;37.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(36.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(109.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(44.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(30.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(90.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i176730f8aadd46128632c5ba433875c6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNC0xLTEtMS0x_2170b97d-ec07-4a2b-ad5d-306df2ffb360"
      unitRef="usd">92500000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i26ed7f2fc0cc4fc2b518e980d510d435_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNC0zLTEtMS0x_fa06dd48-5208-4f28-be37-449682f657a1"
      unitRef="usd">81700000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i6f0d0b356cce49a8934e6af36a6e9f3f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNC01LTEtMS0x_14885291-dbfa-40bd-99ee-552ac10ab210"
      unitRef="usd">277800000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i9e32aff16cce45f1bbc5d66e0afc2090_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNC03LTEtMS0x_25498fcf-619a-4cba-a90e-9c6aa45f32c5"
      unitRef="usd">243400000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i176730f8aadd46128632c5ba433875c6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNS0xLTEtMS0x_c5b00772-d1d4-4a88-a5cf-ebb79ce6e866"
      unitRef="usd">84500000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i26ed7f2fc0cc4fc2b518e980d510d435_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNS0zLTEtMS0x_81e58652-fc81-4487-a6f7-188ef7b3aad1"
      unitRef="usd">106600000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i6f0d0b356cce49a8934e6af36a6e9f3f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNS01LTEtMS0x_ef673883-bc99-4e80-98e6-b7369a46732b"
      unitRef="usd">253600000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i9e32aff16cce45f1bbc5d66e0afc2090_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNS03LTEtMS0x_d26c7feb-63fb-4e96-a5c2-73af660705c5"
      unitRef="usd">319000000.0</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i176730f8aadd46128632c5ba433875c6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNi0xLTEtMS0x_53036c34-e90d-47c7-8d02-426fe762163b"
      unitRef="usd">237500000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i26ed7f2fc0cc4fc2b518e980d510d435_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNi0zLTEtMS0x_7339e453-ce09-4310-9a5c-0a5c28c751b8"
      unitRef="usd">229500000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i6f0d0b356cce49a8934e6af36a6e9f3f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNi01LTEtMS0x_02b23bae-d414-4953-ad18-b0d4a41e3851"
      unitRef="usd">712700000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i9e32aff16cce45f1bbc5d66e0afc2090_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNi03LTEtMS0x_17397a91-bde0-4f97-afaa-1f71fe59eb5b"
      unitRef="usd">671400000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i176730f8aadd46128632c5ba433875c6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNy0xLTEtMS0x_65acb032-20f4-41a0-a0a2-efd48fbc5627"
      unitRef="usd">1000000.0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i26ed7f2fc0cc4fc2b518e980d510d435_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNy0zLTEtMS0x_6fd5f106-5c2b-41c9-9af7-6936456da6ef"
      unitRef="usd">1100000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i6f0d0b356cce49a8934e6af36a6e9f3f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNy01LTEtMS0x_e05669f4-0bcb-432f-be03-f2d4d87e0bb9"
      unitRef="usd">3200000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i9e32aff16cce45f1bbc5d66e0afc2090_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfNy03LTEtMS0x_7d080bd7-a9c9-405f-bacc-2b87bfb271c2"
      unitRef="usd">3200000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i176730f8aadd46128632c5ba433875c6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfOC0xLTEtMS0x_1dfc4c06-624f-4962-b417-54fef41820ae"
      unitRef="usd">-121900000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i26ed7f2fc0cc4fc2b518e980d510d435_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfOC0zLTEtMS0x_ac0d8f3d-3575-4d66-b16f-d10b42667d64"
      unitRef="usd">-58400000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i6f0d0b356cce49a8934e6af36a6e9f3f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfOC01LTEtMS0x_310e531d-331d-488e-a6b7-39ef3ebb70e2"
      unitRef="usd">-366300000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i9e32aff16cce45f1bbc5d66e0afc2090_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfOC03LTEtMS0x_8b65f93f-4ba1-4d56-a2c8-7bafe73abe9e"
      unitRef="usd">-286500000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i176730f8aadd46128632c5ba433875c6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfMTAtMS0xLTEtMQ_2ae7a7a6-3a80-4d04-a463-4c2dc5a54ba8"
      unitRef="usd">62400000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i26ed7f2fc0cc4fc2b518e980d510d435_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfMTAtMy0xLTEtMQ_164876c2-fc06-4cc9-8f24-dc0cb990596e"
      unitRef="usd">18300000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i6f0d0b356cce49a8934e6af36a6e9f3f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfMTAtNS0xLTEtMQ_4b7dee25-f881-4100-907d-9db2289233fe"
      unitRef="usd">188200000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i9e32aff16cce45f1bbc5d66e0afc2090_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjRkMTg3YTdlODM0ZDQ2MzdhMDM4N2FiMzRmOWI4OTdjL3RhYmxlcmFuZ2U6NGQxODdhN2U4MzRkNDYzN2EwMzg3YWIzNGY5Yjg5N2NfMTAtNy0xLTEtMQ_39541f23-53fa-4bb5-94eb-648f6c6a918f"
      unitRef="usd">180700000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i6733dbedc8dc49a5a3099a9d0ba22916_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNC0xLTEtMS0x_b0d97473-dd12-4b1b-89e2-79b11767a0bf"
      unitRef="usd">12400000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ifbc6413f2deb444f9703aae3ad14ffef_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNC0zLTEtMS0x_0ce61c49-2667-47b1-9aca-1f63ea0e9b65"
      unitRef="usd">10200000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i07abba9f0ad143a1bd6ac13320789ca2_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNC01LTEtMS0x_668b23d3-0ba9-41b2-a8bd-98034b92f199"
      unitRef="usd">37000000.0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i9c740c841315439ab33499536b4e70a2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNC03LTEtMS0x_c831e5f9-d653-4906-b1b3-1b02a5573885"
      unitRef="usd">30600000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i6733dbedc8dc49a5a3099a9d0ba22916_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNS0xLTEtMS0x_612ab707-d677-4cf2-b710-04e2140f4632"
      unitRef="usd">8100000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ifbc6413f2deb444f9703aae3ad14ffef_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNS0zLTEtMS0x_bc542ae2-fefc-4bb5-bacb-832e29bd5dd8"
      unitRef="usd">10900000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i07abba9f0ad143a1bd6ac13320789ca2_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNS01LTEtMS0x_99f65d77-e75f-4589-833a-122efe698d4b"
      unitRef="usd">24400000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i9c740c841315439ab33499536b4e70a2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNS03LTEtMS0x_7f3e8531-7e80-4da7-a9b2-24495184c895"
      unitRef="usd">32800000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i6733dbedc8dc49a5a3099a9d0ba22916_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNi0xLTEtMS0x_7a0cb6fe-5215-44fc-a306-bf34a710a254"
      unitRef="usd">36500000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ifbc6413f2deb444f9703aae3ad14ffef_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNi0zLTEtMS0x_b9ac9b8d-acee-40c9-b44c-1894d8eead31"
      unitRef="usd">40300000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i07abba9f0ad143a1bd6ac13320789ca2_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNi01LTEtMS0x_3af34503-a0c3-4765-b35c-0e5f45806680"
      unitRef="usd">109600000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i9c740c841315439ab33499536b4e70a2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNi03LTEtMS0x_bb49484c-8e55-4aa1-a76c-f3b1531832c3"
      unitRef="usd">115100000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i6733dbedc8dc49a5a3099a9d0ba22916_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNy0xLTEtMS0x_2021705c-209f-4407-9714-4161490d820a"
      unitRef="usd">-14900000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ifbc6413f2deb444f9703aae3ad14ffef_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNy0zLTEtMS0x_9820dc5d-0816-4966-849c-ba4d948b49d5"
      unitRef="usd">-21900000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i07abba9f0ad143a1bd6ac13320789ca2_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNy01LTEtMS0x_2d21bfda-a43d-43d9-9f10-1e7b17833123"
      unitRef="usd">-44700000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i9c740c841315439ab33499536b4e70a2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfNy03LTEtMS0x_f3562612-ec8c-4eb2-a4bc-d66332db3db4"
      unitRef="usd">-51600000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i6733dbedc8dc49a5a3099a9d0ba22916_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfOC0xLTEtMS0x_d4995a4e-e0dc-4f05-b64e-67cb9871f58a"
      unitRef="usd">-800000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="ifbc6413f2deb444f9703aae3ad14ffef_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfOC0zLTEtMS0x_fbdb5fe8-9b4b-4628-ad51-4c8537142bf8"
      unitRef="usd">-700000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i07abba9f0ad143a1bd6ac13320789ca2_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfOC01LTEtMS0x_b77035bf-acb9-429a-bf89-c5889e2856f3"
      unitRef="usd">-2400000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i9c740c841315439ab33499536b4e70a2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfOC03LTEtMS0x_79260b10-aa49-47d8-9075-5c0bc7c038bc"
      unitRef="usd">-2100000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i6733dbedc8dc49a5a3099a9d0ba22916_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfMTAtMS0xLTEtMQ_5c96aa8e-c809-4e4a-9417-140f6db21fc0"
      unitRef="usd">-30100000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ifbc6413f2deb444f9703aae3ad14ffef_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfMTAtMy0xLTEtMQ_e9299ff3-eece-4e86-831f-9b7a66479463"
      unitRef="usd">-40400000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i07abba9f0ad143a1bd6ac13320789ca2_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfMTAtNS0xLTEtMQ_bb856d25-28ac-4499-81dd-c134516cb45c"
      unitRef="usd">-90500000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i9c740c841315439ab33499536b4e70a2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83MC9mcmFnOjI3YzE4Zjc3YjEyZjRhYjk4ODUyYTJjYmU3M2ZmMTU4L3RhYmxlOjdlMmU3NWNjNDNlNDRkZWZiZDE2ZjVjYWYwZmUzYWY1L3RhYmxlcmFuZ2U6N2UyZTc1Y2M0M2U0NGRlZmJkMTZmNWNhZjBmZTNhZjVfMTAtNy0xLTEtMQ_746240e3-f531-42d5-8d78-fae5f5481f39"
      unitRef="usd">-101200000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMjk0NTQ_0b0d96d7-e047-42a0-8465-548e4a95a69c">Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the final outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated condensed balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently and previously marketed products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Alimta Patent Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alimta (pemetrexed) is protected by a vitamin regimen patent until November 2021, plus pediatric exclusivity through May 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, we settled a lawsuit we filed against Eagle Pharmaceuticals, Inc. (Eagle) in response to its application to market a product using an alternative form of pemetrexed. Per the settlement agreement, Eagle has a limited initial entry into the market with its product starting February 2022 (up to an approximate three-week supply) and subsequent unlimited entry starting April 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;European Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In Europe, Alimta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was protected by the vitamin regimen patent through June 2021. Despite the recent patent expiration, a number of legal proceedings that were initiated prior to expiration are ongoing&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Emgality Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, we were&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; named as a defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA, Inc. (collectively, Teva) in the U.S. District Court for the District of Massachusetts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;seeking a ruling that various claims in nine different Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in adults. Trial is expected in March 2022. In June 2021, we were named as a defendant in a second litigation filed by Teva in the U.S. District Court for the District of Massachusetts seeking a ruling that two of Teva&#x2019;s patents, which are directed toward use of the active ingredient in Emgality to treat migraine, would be infringed by our continued sales of Emgality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separately, the U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) granted our request to initiate an&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;inter partes review&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(IPR) to reexamine the validity of the nine Teva patents asserted against us in the litigation. In February 2020, the PTAB ruled in our favor and found that the claims asserted against us in six of Teva's nine patents were invalid. In March 2020, the PTAB ruled against us on the remaining three Teva patents, finding that we failed to show that the remaining three patents were unpatentable based on the subset of invalidity arguments available in an IPR proceeding. In April 2020, we appealed the PTAB&#x2019;s March 2020 ruling, and Teva appealed the PTAB&#x2019;s February 2020 ruling to the U.S. Court of Appeals for the Federal Circuit. In August 2021, the appeals court affirmed all nine of the PTAB's decisions. Neither Lilly nor Teva appealed the rulings and accordingly those decisions are final, and the parties have agreed to a stipulation which removes the six invalidated patents from the district court litigation. This IPR matter is now closed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Jardiance Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, Boehringer Ingelheim (BI), our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court of Delaware alleging infringement arising from submissions of Abbreviated New Drug Applications (ANDA) by a number of generic companies seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, the generic companies' ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. This litigation has been stayed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Taltz Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, we petitioned the High Court of Ireland to declare invalid the patent that Novartis Pharma AG (Novartis) purchased from Genentech, Inc. in 2020. Novartis responded by filing a claim against us alleging patent infringement related to our commercialization of Taltz and seeking damages for past infringement and an injunction against future infringement. This matter is ongoing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021 and June 2021, Novartis petitioned the Court of Rome Intellectual Property Division and the Commercial Court of Vienna, respectively, in preliminary injunction infringement proceedings against us related to our commercialization of Taltz. In June 2021, the Court of Rome Intellectual Property Division dismissed Novartis&#x2019; preliminary injunction action. Novartis has appealed the ruling and in October 2021 the panel hearing Novartis' appeal appointed a technical expert to assess the merits of the case. Both matters are ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Zyprexa Canada Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the mid-2000&#x2019;s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012, the Canadian Federal Court of Appeals denied our appeal of a lower court's decision that certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trade-Mark Act, and common law. In March 2021, the Ontario Superior Court granted our motion for summary judgement, thereby dismissing Apotex&#x2019;s case. Apotex appealed that ruling to the Court of Appeal for Ontario in April 2021 and a hearing is scheduled for February 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Liability Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Actos&#xae;  Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are named along with Takeda Chemical Industries, Ltd. and Takeda affiliates (collectively, Takeda) as a defendant in four purported product liability class actions in Canada related to Actos, which we commercialized with Takeda in Canada until 2009, including one in Ontario filed December 2011 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), one in Quebec filed July 2012 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Whyte et al. v. Eli Lilly et al.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), one in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Saskatchewan filed November 2017 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Weiler v. Takeda Canada Inc. et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), and one in Alberta filed January 2013 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Epp v. Takeda Canada Inc. et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). In general, plaintiffs in these actions alleged that Actos caused or contributed to their bladder cancer. An agreement to settle these actions became effective in May 2021, and the settlement claims administration process is ongoing. The lawsuits have been dismissed or discontinued.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Byetta&#xae; Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are named as a defendant in approximately 570 Byetta product liability lawsuits in the U.S. which were initiated in March 2009 and involve approximately 805 plaintiffs. Approximately 55 of these lawsuits, covering about 285 plaintiffs, are filed in California state court and coordinated in a Los Angeles Superior Court. Approximately 515 of the lawsuits, covering about 515 plaintiffs, are filed in federal court, the majority of which are coordinated in a multi-district litigation (MDL) in the U.S. District Court for the Southern District of California. Two lawsuits, representing approximately two plaintiffs, have also been filed in various state courts. Approximately 565 of the lawsuits, involving approximately 800 plaintiffs, contain allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer); while six plaintiffs allege Byetta caused or contributed to pancreatitis. In addition, one case alleges that Byetta caused or contributed to ampullary cancer. The federal and state trial courts granted summary judgment in favor of us and our co-defendants on the claims alleging pancreatic cancer. The plaintiffs appealed those rulings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, the U.S. Court of Appeals for the Ninth Circuit reversed the U.S. District Court for the Southern District of California's grant of summary judgment in the MDL based on that court's discovery rulings and remanded the cases back to the U.S. District Court for further proceedings. In March 2021, the U.S. District Court granted summary judgment for the defendants. In April 2021, the plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Ninth Circuit, but we have now been dismissed from that appeal. Certain plaintiffs have agreed to dismiss their lawsuits in exchange for a waiver of costs, and individual plaintiffs have begun dismissing their claims based upon this agreement. Approximately 160 of the MDL pancreatic lawsuits have been dismissed as of October 2021. In the state court actions, in November 2018, the California Court of Appeal reversed the Los Angeles County Superior Court of California&#x2019;s grant of summary judgment based on that court's discovery rulings and remanded for further proceedings. In April 2021, the Los Angeles County Superior Court of California granted summary judgment for the defendants and the parties await entry of the order of judgment.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are aware of approximately 20 additional claimants who have not yet filed suit. These additional claims allege damages for pancreatic cancer or thyroid cancer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Cialis Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are named as a defendant in approximately 350 Cialis product liability lawsuits in the U.S. which were first initiated in August 2015. These cases, many of which were originally filed in various federal courts, contain allegations that Cialis caused or contributed to the plaintiffs' cancer (melanoma). In December 2016, the Judicial Panel on Multidistrict Litigation (JPML) granted the plaintiffs' petition to have filed cases and an unspecified number of future cases coordinated into a federal multidistrict litigation (MDL) in the U.S. District Court for the Northern District of California, alongside an existing coordinated proceeding involving Viagra&#xae;. The JPML ordered the transfer of the existing cases to the now-renamed MDL &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In April 2020, the MDL court granted summary judgment to the defendants on all of the claims brought against them by the plaintiffs. In May 2020, plaintiffs filed an appeal in the U.S. Court of Appeals for the Ninth Circuit. The plaintiffs&#x2019; appeal was administratively closed until August 2021 pending completion of a procedure to resolve the claims in this litigation. The court has entered an extension until February 2022 to finalize resolution of all claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Jardiance Product Liability &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;First initiated in January 2019, we and Boehringer Ingelheim Pharmaceuticals, Inc., a subsidiary of BI, have been named as a defendant in approximately 95 product liability lawsuits in the U.S., mostly in Stamford Superior Court in Connecticut, alleging that Jardiance caused or contributed to plaintiffs&#x2019; Fournier&#x2019;s gangrene.  Our agreement with BI calls for BI to defend and indemnify us against any damages, costs, expenses, and certain other losses with respect to product liability claims in accordance with the terms of the agreement. All pending cases have been paused to allow for settlement negotiations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Environmental Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than 10 sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;340B Litigation and Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges the HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies. We seek a declaratory judgment that the defendants violated the Administrative Procedures Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. In March 2021, the court entered an order preliminarily enjoining the government&#x2019;s enforcement of the administrative dispute resolution process against us. In May 2021, HRSA notified us that it determined that our  policy was contrary to the 340B statute. In response, in May 2021, we filed a motion for preliminary injunction and temporary restraining order requesting that the U.S. District Court for the Southern District of Indiana enjoin defendants from taking any action against us relating to the 340B drug pricing program until after the court issues a final judgment on the aforementioned litigation. In May 2021, the court denied our motion for a temporary restraining order but deferred resolution of our motion for preliminary injunction. In June 2021, the defendants withdrew the HHS December 30, 2020 advisory opinion. In July 2021, the court held oral argument on the parties&#x2019; cross motions for summary judgment, the defendants&#x2019; motion to dismiss, and our motion for preliminary injunction related to HRSA&#x2019;s May 2021 enforcement letter. This matter is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administrative Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program. As described above, the U.S. District Court for the Southern District of Indiana has entered a preliminary injunction enjoining the government&#x2019;s enforcement of this administrative dispute resolution process against us.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, we, along with Sanofi-Aventis U.S., LLC (Sanofi), Novo Nordisk Inc. (Novo Nordisk), and AstraZeneca Pharmaceuticals LP, were named as a defendant in a purported class action lawsuit filed in the U.S. District Court for the Western District of New York by Mosaic Health, Inc. alleging antitrust and unjust enrichment claims related to the defendants' 340B distribution programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received a civil investigative subpoena in February 2021 from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program. We are cooperating with this subpoena. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Branchburg Manufacturing Facility &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, we received a subpoena from the United States Department of Justice requesting the production of certain documents relating to our manufacturing site in Branchburg, New Jersey. We are cooperating with the subpoena.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Brazil Litigation &#x2013; Cosmopolis Facility &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Labor Attorney Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a lawsuit brought by the Labor Attorney for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the labor court judge ruled against Lilly Brasil, ordering it to undertake several actions of unspecified financial impact, including paying lifetime health coverage for the employees and contractors who worked at the Cosmopolis facility more than six months during the affected years and their children born during and after this period. We appealed this decision. In July 2018, the appeals court affirmed the labor court's ruling with a liquidated award of&#160;300&#160;million&#160;Brazilian real (for moral damages, donation of equipment, and creation of a foundation) which, adjusted for inflation and interest using the current Central Bank of Brazil's special system of clearance and custody rate (SELIC), is approximately 950&#160;million Brazilian real (approximately $175&#160;million as of September 30, 2021). The appeals court restricted the broad health coverage awarded by the labor court to health problems that claimants could show arose from exposure to the alleged contamination. In August 2019, Lilly Brasil filed an appeal to the superior labor court. In September 2019, the appeals court stayed a number of elements of its prior decision, including the obligation to provide health coverage for contractors, their children, and children of employees who worked at the Cosmopolis facility, pending the determination of Lilly Brasil&#x2019;s appeal to the superior labor court. The cost of any such health coverage has not been determined. In June 2021, the appeals court published its decision on the admissibility of Lilly Brasil&#x2019;s appeal, admitting the majority of the elements of the appeal to proceed; elements not proceeding are subject to an interlocutory appeal to the appeals court filed in June 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, the Labor Attorney filed an application in the labor court for enforcement of the healthcare coverage granted by the appeals court in its July 2018 ruling and requested restrictions on Lilly Brasil&#x2019;s assets in Brazil. In July 2019, the labor court issued a ruling requiring either a freeze of Lilly Brasil&#x2019;s immovable property or, alternatively, a security deposit or lien of 500 million Brazilian real. Lilly Brasil filed a writ of mandamus challenging this ruling&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; but the court has stayed its decision on this writ and instead directed the parties to attend conciliation hearings, a process that concluded unsuccessfully in September 2020. Consequently, the partial stay of the proceedings relating to Lilly Brasil's application to appeal in the main proceedings has been lifted and in June 2021, the court reduced the security deposit or lien to 100&#160;million Brazilian real from the 500&#160;million Brazilian real referred to above&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Labor Attorney's application for preliminary enforcement of the July 2018 healthcare coverage ruling was granted. As the conciliation hearings have been unsuccessful, we have filed a brief to strike the Labor Attorney&#x2019;s application to enforce the previous healthcare coverage. Lilly Brasil is currently awaiting a determination as to whether its application seeking leave to appeal to the superior labor court has been successful.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Individual Former Employee Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also named in approximately 30&#160;lawsuits filed in the same labor court by individual former employees making similar claims. These lawsuits are each at various stages in the litigation process, with judgments being handed down in approximately half of the lawsuits, nearly all of which are on appeal in the labor courts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;China NDRC Antitrust Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The competition authority in China has investigated our distributor pricing practices in China in connection with a broader inquiry into pharmaceutical industry pricing. We have cooperated with this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Eastern District of Pennsylvania Pricing (Average Manufacturer Price) Inquiry&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2014, we, along with another pharmaceutical manufacturer, were named as co-defendants in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. Trial is scheduled for April 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Health Choice Alliance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are named as a defendant in a lawsuit filed in June 2017 in the U.S. District Court for the Eastern District of Texas seeking damages under the federal anti-kickback statute and state and federal false claims acts for certain patient support programs related to our products Humalog, Humulin, and Forteo. In September 2019, the U.S. District Court granted the U.S. Department of Justice&#x2019;s motion to dismiss the relator&#x2019;s second amended complaint. In January 2020, the relator appealed the District Court&#x2019;s dismissal to the U.S. Court of Appeals for the Fifth Circuit. In July 2021, the U.S. Court of Appeals for the Fifth Circuit affirmed the dismissal of the lawsuit.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also named as a defendant in two similar lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively. In November 2020, the Texas state court action was stayed pending a final determination with respect to the aforementioned federal lawsuit. In April 2021, the New Jersey state court action was dismissed with prejudice and in June 2021, the relator filed a notice of appeal to the Appellate Division of the New Jersey Superior Court, appealing the state court&#x2019;s decision.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pricing Litigation, Investigations, and Inquiries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, we, along with Sanofi and Novo Nordisk were named as defendants in a consolidated purported class action lawsuit,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re. Insulin Pricing Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in the U.S. District Court for the District of New Jersey relating to insulin pricing seeking damages under various state consumer protection laws and the Federal Racketeer Influenced and Corrupt Organization Act (federal RICO Act). Separately, in February 2018, we, along with Sanofi and Novo Nordisk, were named as defendants in&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in the same court, seeking damages under various state consumer protection laws, common law fraud, unjust enrichment, and the federal RICO Act. In both&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; In re. Insulin Pricing Litigation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; MSP Recovery Claims&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; litigation, the court dismissed claims under the federal RICO Act and certain state laws. In April 2021, the plaintiffs in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re. Insulin Pricing Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; amended their complaint to allege additional state law claims for civil conspiracy and violations of state RICO statutes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, we, along with Sanofi, Novo Nordisk, CVS, Express Scripts, and Optum, have been sued in a purported class action, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;FWK Holdings, LLC v. Novo Nordisk Inc., et al., &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;filed in the same court in November 2020, for alleged violations of the federal RICO Act as well as the New Jersey RICO Act and antitrust law. That same group of defendants, along with Medco Health and United Health Group, also have been sued in other purported class actions in the same court, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rochester Drug Co-Operative Inc. v. Eli Lilly &amp;amp; Co. et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Value Drug Co. v. Eli Lilly &amp;amp; Co. et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;both initiated in March 2020, for alleged violations of the federal RICO Act. In September 2020, the U.S. District Court for the District of New Jersey granted plaintiffs&#x2019; motion to consolidate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;FWK Holdings, LLC v. Novo Nordisk Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rochester Drug Co-Operative Inc. v. Eli Lilly &amp;amp; Co. et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Value Drug Co. v. Eli Lilly &amp;amp; Co. et al. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the U.S. District Court for the District of New Jersey dismissed the three antitrust claims alleged by plaintiffs in the consolidated litigation and denied dismissal of the RICO claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Minnesota Attorney General&#x2019;s Office initiated litigation against us, Sanofi, and Novo Nordisk,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;State of Minnesota v. Sanofi-Aventis U.S. LLC et al.,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;in the U.S. District Court for the District of New Jersey, alleging unjust enrichment, violations of various Minnesota state consumer protection laws, and the federal RICO Act. In March 2021, the U.S. District Court for the District of New Jersey dismissed with prejudice the Minnesota Attorney General&#x2019;s federal RICO claims and false advertising claims under state law; the consumer fraud and other related state law claims remain ongoing. Additionally, in May 2019, the Kentucky Attorney General&#x2019;s Office filed a complaint against us, Sanofi, and Novo Nordisk,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commonwealth of Kentucky v. Novo Nordisk, Inc. et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in Kentucky state court, alleging violations of the Kentucky consumer protection law, false advertising, and unjust enrichment. In November 2019, Harris County in Texas initiated litigation against us, Sanofi, Novo Nordisk, Express Scripts, CVS, Optum, and Aetna, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;County of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Harris Texas v. Eli Lilly &amp;amp; Co., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in federal court in the Southern District of Texas alleging violations of the federal RICO Act, the state deceptive trade practices-consumer protection act, and common law claims such as fraud, unjust enrichment, and civil conspiracy. Harris County also alleged violations of federal and state antitrust law, but voluntarily dismissed them. This lawsuit relates to our insulin products as well as Trulicity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the City of Miami, Florida initiated litigation against us, Sanofi, Novo Nordisk, ESI, CVS/Caremark/Aetna, and Optum, asserting state law antitrust, common law fraud, money had and received, unjust enrichment, and civil conspiracy claims. In June 2021, the Mississippi Attorney General&#x2019;s Office initiated litigation against us, Sanofi, Novo Nordisk, Evernorth/ESI, CVS/Caremark, and United/Optum in the Hinds County, Mississippi Chancery Court, alleging state law consumer protection, unjust enrichment, and civil conspiracy claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investigations, Subpoenas, and Inquiries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received a subpoena from the New York a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nd Vermont Attorney General Offices and civil investigative demands from the Washington, New Mexico, and Colorado Attorney General Offices relating to the pricing and sale of our insulin products. The Offices of the Attorney General in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada have requested information relating to the pricing and sale of our insulin products. We also received interrogatories and a subpoena from the California Attorney General's Office regarding our competition in the long-acting insulin market, which was subsequently withdrawn in June 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received a&#x202f;request in January 2019 from the House of Representatives&#x2019; Committee on Oversight and Reform seeking commercial information and business records related to the pricing of insulin products, among other issues. We also received requests from the Senate Finance Committee and the Senate Committee on Health, Education, Labor, and Pensions, and separate requests from the House Committee on Energy and Commerce majority and minority members.&#x202f; Those requests sought pricing and other commercial information regarding Lilly&#x2019;s insulin products. In January 2021, the Senate Finance Committee released a report summarizing the findings of its investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are cooperating with all of these aforementioned investigations, subpoenas, and inquiries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Research Corporation Technologies, Inc. &lt;/span&gt;&lt;/div&gt;In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <lly:LossContingencyNumberOfPatents
      contextRef="i3396e46f9d1e40d387eef70e8d15804f_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfNDUyNQ_095b6c2d-7ac3-41ee-81d8-75d61cc896c0"
      unitRef="patent">9</lly:LossContingencyNumberOfPatents>
    <lly:LossContingencyNumberOfPatents
      contextRef="ifba4f334917d401c815c949e200f615c_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfNDg1NA_5381c53d-7f9c-4197-bb15-1d1347be4c98"
      unitRef="patent">2</lly:LossContingencyNumberOfPatents>
    <lly:LossContingencyNumberOfPatents
      contextRef="i3396e46f9d1e40d387eef70e8d15804f_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfNTE3OQ_095b6c2d-7ac3-41ee-81d8-75d61cc896c0"
      unitRef="patent">9</lly:LossContingencyNumberOfPatents>
    <lly:LossContingencyNumberOfPatentsClaimsDismissed
      contextRef="i04488b288a30423980051e6f31d6daef_D20200201-20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfNTMzMA_e33f9a88-361d-4bb1-ab5d-eda6abe08931"
      unitRef="patent">6</lly:LossContingencyNumberOfPatentsClaimsDismissed>
    <lly:LossContingencyNumberOfPatents
      contextRef="i9a8ded4399f14dd3a19c466a1b1af3e9_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfNTM0Mw_52cc950a-c1ae-4dae-bc8a-96fb3ef1ced3"
      unitRef="patent">9</lly:LossContingencyNumberOfPatents>
    <lly:LossContingencyNumberOfPatentsRuledUnpatentable
      contextRef="ieee62783e4544f66ab4860b55a43cd90_D20200301-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfNTQyNw_f8a16e9f-b087-41e2-b6e6-fae725707624"
      unitRef="patent">3</lly:LossContingencyNumberOfPatentsRuledUnpatentable>
    <lly:LossContingencyNumberOfPatentsRuledUnpatentable
      contextRef="ieee62783e4544f66ab4860b55a43cd90_D20200301-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfNTQ5NA_0fc9de65-d2cb-449a-8a40-9469cabbde68"
      unitRef="patent">3</lly:LossContingencyNumberOfPatentsRuledUnpatentable>
    <lly:LossContingencyNumberOfDecisionsAffirmed
      contextRef="i7c00bf1eb48e4add853803f501de39e3_I20210831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfODc5NjA5MzA1OTYxOQ_68ad7dd7-d02a-4be1-9d45-66e6caf674b9"
      unitRef="decision">9</lly:LossContingencyNumberOfDecisionsAffirmed>
    <lly:LossContingencyNumberOfPatentsClaimsDismissed
      contextRef="ifa01b284a88a485895b7e8d41c34e4e9_D20210801-20210831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfODc5NjA5MzA1OTU3OA_ac68cdd3-9c50-4775-b3d8-00f0d3a6af76"
      unitRef="patent">6</lly:LossContingencyNumberOfPatentsClaimsDismissed>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ie7da18cbbc67441ea99ca54c41121ad6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfODcwOQ_f2cc5a9b-e9d5-4475-9bab-47b5179b4f87"
      unitRef="lawsuit">4</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="if922480499654c8fa72000e69a03bbe5_I20111231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfODg1MA_f722d776-da07-4a84-aa13-10b7ba59295b"
      unitRef="lawsuit">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i9ec7a80a2fc74972819c8c8d4ae943cb_I20120731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfODk1Ng_96ed2e32-fa7a-4462-978a-bff927f9972e"
      unitRef="lawsuit">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ia2d0b9f9d00c4789a57ac22dffd8de57_I20171130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfOTAyMQ_65d15133-7749-4bb9-bce0-27c727bf69c1"
      unitRef="lawsuit">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="id492c2aa322440ef91df2d2864ae3436_I20130131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfOTEwMw_0a5cae28-cfa9-43c7-9fbe-0fa736b2496e"
      unitRef="lawsuit">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i02631251065446e8b80c3ef3bde18d1e_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfOTU2MA_c3075e80-f89f-4d67-8dda-f5d9ea8ec624"
      unitRef="lawsuit">570</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="id08a7fa5ef244fbdb2e5f2a1bf85908a_D20090301-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfOTYzMw_e1c7fb4d-358c-445d-8416-fcc6e5149a92"
      unitRef="plaintiff">805</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i5a6d539b9e9b4a2e9a56aa47022fef97_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfOTY2Mg_250676b7-f725-4c10-882b-5824b7a87148"
      unitRef="lawsuit">55</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i57962c6f806042039b9a5e06a4c746f8_D20090301-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfOTY5OQ_e57a5551-47e6-43d4-aec4-a76fd7a152fb"
      unitRef="plaintiff">285</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i5cebe969b12a4a35a83f8a3e3a6c1d34_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfOTgxMw_ef37dffc-3110-48a0-a3bc-2f04633e1c50"
      unitRef="lawsuit">515</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i6a303e3d333446bd9c148cdb72de62b9_D20090301-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfOTg0OA_1b2409ab-84a8-4514-844d-4513965b062b"
      unitRef="plaintiff">515</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ie6b528e1289547a7a6c8125628509fe4_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTAwMzQ_9a64edf0-7be5-482f-8dde-30106e7eebf7"
      unitRef="lawsuit">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i823025d06a794591a0b79f3627915cb6_D20090301-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTAwNzQ_fa1fd377-470e-414b-9602-9ce7730718ed"
      unitRef="plaintiff">2</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ide3640818e464610a65948e49215fb32_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTAxNDk_0770b833-e545-4037-8234-e4653c297124"
      unitRef="lawsuit">565</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="iec6231ab796440cea08cae552c4f7aec_D20090301-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTAxOTM_3439b255-3030-4f26-b499-343128d17337"
      unitRef="plaintiff">800</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i4e401371e97c43e0b9c5ea15f0b54e42_D20090301-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTAzNDM_9f5f3a2a-e72a-4eda-bed2-6836fabe8cc1"
      unitRef="plaintiff">6</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i7b351247f73c46c28ff4f882e37804b1_D20090301-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTA0MjM_5934b226-9381-440a-abbe-ead339453207"
      unitRef="plaintiff">1</us-gaap:LossContingencyNumberOfPlaintiffs>
    <lly:LossContingencyNumberOfClaimants
      contextRef="i02631251065446e8b80c3ef3bde18d1e_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTE2OTk_fbd3adfb-1d61-46a4-943b-7d2f9b9ccee5"
      unitRef="claimant">20</lly:LossContingencyNumberOfClaimants>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="id877b0b6a111490cbd371689fd76bb41_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTE5MzQ_f0c188e5-952b-4354-aaff-c46bc0f5debf"
      unitRef="lawsuit">350</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i0974ec7e0d754316996a9ed48591b15f_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTMyMzA_90d866dc-68bd-4235-8f87-62bc5e998da3"
      unitRef="lawsuit">95</us-gaap:LossContingencyPendingClaimsNumber>
    <lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup
      contextRef="ic2caaa0461b646bfa03a4e4b72b0fd0c_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTM4NzQ_427293de-a345-42b3-96c1-b71f2439c166"
      unitRef="site">10</lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i4c05f03242a6456dbd827f3bfc73638e_D20180701-20180731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTgyOTY_64850384-66d0-48ad-a837-0a69a3b3f7f5"
      unitRef="brl">300000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ib5389c2f3f2b4fecaa12712374100b27_D20210930-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTg1NDQ_4262cb8c-9fc8-426d-b604-8dbd7a67c7c0"
      unitRef="brl">950000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ib5389c2f3f2b4fecaa12712374100b27_D20210930-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfODc5NjA5MzA1MTY5Mg_e0fc94ae-255f-41c8-abdd-43a9269a8bad"
      unitRef="usd">175000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ic5db0916c42c432ab0d7c4f60ea69486_D20190701-20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMTk4OTQ_7d83f542-f817-4251-939d-a34b982f09c5"
      unitRef="brl">500000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i0b7f344f3e4a4d4489bf483eb893bcbc_D20210601-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMjAzNTk_6b0efc85-7a20-4ff2-bce4-83188c2e33e8"
      unitRef="brl">100000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ic5db0916c42c432ab0d7c4f60ea69486_D20190701-20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMjAzODY_356d98c5-41d5-418b-850a-38ecf0088cd6"
      unitRef="brl">500000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i3fa1d97abf9842288bcab6b2233d933e_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMjA5NDQ_49456823-c18c-404a-a3b9-2621e4046b3f"
      unitRef="lawsuit">30</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i67de38ae9b6847fc8362e05564887711_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMjI4MTE_64ee885e-8fba-4f20-add9-deecd9a1669c"
      unitRef="lawsuit">2</us-gaap:LossContingencyPendingClaimsNumber>
    <lly:LitigationClaimsDismissedNumber
      contextRef="i2330339854444106911984ac8d431494_D20210701-20210731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83My9mcmFnOmNlZWM1ZmEwNjZiMzRmM2Y4N2Y0ZGFmOWJiMjQwNDJiL3RleHRyZWdpb246Y2VlYzVmYTA2NmIzNGYzZjg3ZjRkYWY5YmIyNDA0MmJfMjU1NTM_67db22f0-917a-46e9-970c-fd8f1dd32233"
      unitRef="claim">3</lly:LitigationClaimsDismissedNumber>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RleHRyZWdpb246ZTZhYmQyYzIxYjVhNDE0YWExYTA4MGI1NTAzN2ExYjNfMTI0MQ_5cb13fb3-3598-477f-8b16-70984c0fab06">Other Comprehensive Income (Loss)&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended September&#160;30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at July 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,516.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,569.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(210.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,287.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;86.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;89.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;104.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;114.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,524.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,465.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(190.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,172.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at July 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,722.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,454.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(520.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,682.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,692.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,444.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(434.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,555.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the activity related to each component of other comprehensive income (loss) during the nine months ended September&#160;30, 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,427.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,751.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(332.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,496.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(96.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;132.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;54.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;258.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;269.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(96.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;285.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;142.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;323.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,524.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,465.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(190.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,172.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,678.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,638.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,523.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(222.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,692.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,444.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(434.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,555.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tax benefit (expense) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation gains/losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(39.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(92.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized net gains/losses on securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit pension and retiree health benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(28.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(79.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(37.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit (provision) for income taxes allocated to other comprehensive income (loss) items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(71.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(206.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 6), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated condensed statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassifications out of accumulated other comprehensive loss were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:11pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Details about Accumulated Other Comprehensive Loss Components&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Affected Line Item in the Consolidated Condensed Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="30" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of retirement benefit items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service benefits, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(13.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(41.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial losses, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;122.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;368.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;108.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;327.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(22.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(68.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;86.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;258.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;89.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;269.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RleHRyZWdpb246ZTZhYmQyYzIxYjVhNDE0YWExYTA4MGI1NTAzN2ExYjNfMTI1OQ_e5cd7595-aced-4c82-ad3c-9a5226a985d8">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended September&#160;30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at July 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,516.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,569.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(210.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,287.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;86.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;89.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;104.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;114.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,524.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,465.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(190.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,172.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at July 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,722.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,454.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(520.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,682.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,692.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,444.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(434.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,555.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the activity related to each component of other comprehensive income (loss) during the nine months ended September&#160;30, 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,427.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,751.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(332.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,496.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(96.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;132.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;54.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;258.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;269.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(96.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;285.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;142.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;323.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,524.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,465.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(190.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,172.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts presented net of taxes)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Gains&#160;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized Net Gains (Losses) on&#160;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Defined Benefit Pension and Retiree&#160;Health Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Effective Portion of Cash&#160;Flow Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,678.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,638.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,523.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(222.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,692.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,444.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(434.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,555.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Tax benefit (expense) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation gains/losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(39.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(92.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized net gains/losses on securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined benefit pension and retiree health benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(28.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(79.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective portion of cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(37.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit (provision) for income taxes allocated to other comprehensive income (loss) items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(71.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(206.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibeb5ba7c9ba14c15ba0052fa193204e3_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfMi0xLTEtMS0x_bc82db66-ddf0-4f1d-b2c5-49a808a51551"
      unitRef="usd">-1516200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i55fb2a4e7d5a40df8b249f3933bb08b6_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfMi0zLTEtMS0x_16dff8d1-7270-4307-ad51-9f4b898e38bf"
      unitRef="usd">9100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i44dd2692507f4266b4a6a0fbf0fee907_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfMi01LTEtMS0x_56d79f14-543e-454e-860f-85c1a08b0e1d"
      unitRef="usd">-4569900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic193e7bc5e094826be326aee4fe41f2e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfMi03LTEtMS0x_bdebd0f0-a793-43d1-a952-c21aadd58432"
      unitRef="usd">-210100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc4a62ea3c3045fcb1975315d8b1874c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfMi0xMS0xLTEtMQ_57f72c12-8533-4296-b7bf-e4eb5c13cddb"
      unitRef="usd">-6287100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ibdb47e6e63294d44a8f97f9e50e54a83_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNC0xLTEtMS0x_c3c342cc-f7fa-494b-a99b-9eedf3ed9fdc"
      unitRef="usd">-8000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i75e7048b106947fda1b1b5e4eabdc0fc_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNC0zLTEtMS0x_e2986626-e4cb-42c7-89c1-8253486aa1e3"
      unitRef="usd">-2400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if4b8f930c8cb4479ac83208582a7d734_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNC01LTEtMS0x_d5bbe636-ec5a-408c-b2bd-4e0d3de45517"
      unitRef="usd">18600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i6fcde9e91e224331bee5a8adc7892978_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNC03LTEtMS0x_bff91be6-b66d-4b2c-a1cc-3a264c61fd81"
      unitRef="usd">16800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNC0xMS0xLTEtMQ_8d1d1e22-7d33-4062-91bf-a5e0c8e6ca47"
      unitRef="usd">25000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ibdb47e6e63294d44a8f97f9e50e54a83_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNS0xLTEtMS0x_1dedbe8b-70f1-4fed-9cb4-ac1a2333a377"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i75e7048b106947fda1b1b5e4eabdc0fc_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNS0zLTEtMS0x_c84d0f3d-832a-46a2-a87d-4f69bcdaa200"
      unitRef="usd">-100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if4b8f930c8cb4479ac83208582a7d734_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNS01LTEtMS0x_4a51c01a-2541-4544-b18b-856782924751"
      unitRef="usd">-86000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i6fcde9e91e224331bee5a8adc7892978_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNS03LTEtMS0x_4418e64e-66e7-4983-8302-22a03e527d04"
      unitRef="usd">-3300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNS0xMS0xLTEtMQ_97841230-9183-4522-bc0d-9eb83b4d91dc"
      unitRef="usd">-89400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibdb47e6e63294d44a8f97f9e50e54a83_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNi0xLTEtMS0x_87eecd91-982c-4a82-9a7c-4be38637430d"
      unitRef="usd">-8000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i75e7048b106947fda1b1b5e4eabdc0fc_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNi0zLTEtMS0x_c10d91cd-570d-43ca-b293-e24986c038b0"
      unitRef="usd">-2300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if4b8f930c8cb4479ac83208582a7d734_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNi01LTEtMS0x_a8cd0474-2469-4865-936a-3b87cf55db02"
      unitRef="usd">104600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6fcde9e91e224331bee5a8adc7892978_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNi03LTEtMS0x_adec5957-b47f-4ef2-80c5-43905274c7ff"
      unitRef="usd">20100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfNi0xMS0xLTEtMQ_cbb6ea19-21e6-4d35-853b-7bb5851dc2c0"
      unitRef="usd">114400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie6bf89817cf74679b6916eddd60558c9_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfOC0xLTEtMS0x_424b82ce-edb4-4ade-a36e-9a20cca3b490"
      unitRef="usd">-1524200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibd2e85aa71f446bdbb141da8010fbe3d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfOC0zLTEtMS0x_96528146-5dfa-4bed-b134-ab9616293625"
      unitRef="usd">6800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic375cded995a4df69d3eae9edc6766c7_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfOC01LTEtMS0x_a5e9a54b-7210-49f5-afef-43bce483f8b1"
      unitRef="usd">-4465300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4d2760fb44974a73a735787c71ae8f1a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfOC03LTEtMS0x_87532302-1214-4879-aae3-00c72ba1e0a0"
      unitRef="usd">-190000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b11f523dfe64ce792a038f20fbc68b5_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjIyNDNmMmY1MjMyZDQ2ZGRhNzQ2NDMxYjNjZDZmOGZlL3RhYmxlcmFuZ2U6MjI0M2YyZjUyMzJkNDZkZGE3NDY0MzFiM2NkNmY4ZmVfOC0xMS0xLTEtMQ_01600922-26f9-4d08-8bcc-6bee5083d41c"
      unitRef="usd">-6172700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a35afc361544badb9c16d04e8aad497_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfMi0xLTEtMS0x_3a334729-0907-4c53-bbb4-585e6da67b47"
      unitRef="usd">-1722500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i717939ea3d4e4bb3b1b65e0a974da3c2_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfMi0zLTEtMS0x_d98b659d-4a61-4408-be3c-9487ae930beb"
      unitRef="usd">15100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i37fc3dd032964801aa1348f510cb122b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfMi01LTEtMS0x_4f3a428c-1306-4143-a64d-bfc4d67c9cfc"
      unitRef="usd">-4454900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8bee3c9d23994e78baa2eba95869bd9b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfMi03LTEtMS0x_db656229-47c2-4d1d-acb8-5955cb04e124"
      unitRef="usd">-520600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib1106ce810ad4da5852f6b633b316eee_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfMi0xMS0xLTEtMQ_3771fb33-6336-45af-9da7-e2850b7fcfe4"
      unitRef="usd">-6682900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i8dc5691b17b74c35ad24aafdbf59f3fe_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNC0xLTEtMS0x_af343cd7-56fb-4a7f-bf70-9472e2e95ce0"
      unitRef="usd">30300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ic3759b3a7e2f43dcb3def496f0e66523_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNC0zLTEtMS0x_d9af46f3-4b3b-4b77-8f17-b1a41ae1e0a6"
      unitRef="usd">800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i2b09b2d2f1f840c7ae5d5461b2c17a11_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNC01LTEtMS0x_ae122a7a-4ac3-4ebc-ab06-034904ab001f"
      unitRef="usd">-19600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="idbffb928c8ef4db9847f4474b9b3c4f7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNC03LTEtMS0x_8ab64a08-841d-4ea5-b2ad-aa0473244596"
      unitRef="usd">82900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNC0xMS0xLTEtMQ_556f6614-6171-4841-81ee-7785658a30db"
      unitRef="usd">94400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i8dc5691b17b74c35ad24aafdbf59f3fe_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNS0xLTEtMS0x_1fbd7b32-2744-4134-98d4-285698521e0a"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ic3759b3a7e2f43dcb3def496f0e66523_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNS0zLTEtMS0x_e7e577a7-b3a2-4cec-b0aa-a8dd46f32444"
      unitRef="usd">200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i2b09b2d2f1f840c7ae5d5461b2c17a11_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNS01LTEtMS0x_478b17d7-8a70-4e20-953f-6e24d4366af0"
      unitRef="usd">-30300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="idbffb928c8ef4db9847f4474b9b3c4f7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNS03LTEtMS0x_eeb1e19d-fbbf-430a-8332-4d4d6812f231"
      unitRef="usd">-3300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNS0xMS0xLTEtMQ_ffc4c76b-2c1d-4387-a913-52af2eb06c62"
      unitRef="usd">-33400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8dc5691b17b74c35ad24aafdbf59f3fe_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNi0xLTEtMS0x_526540b0-ca9d-4206-8971-c131009d4b45"
      unitRef="usd">30300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic3759b3a7e2f43dcb3def496f0e66523_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNi0zLTEtMS0x_a628088b-4168-4394-917c-9d4d70001a48"
      unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2b09b2d2f1f840c7ae5d5461b2c17a11_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNi01LTEtMS0x_9076d29e-7ea2-4631-b626-b540769fdf27"
      unitRef="usd">10700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="idbffb928c8ef4db9847f4474b9b3c4f7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNi03LTEtMS0x_b0409580-ff2e-41dd-a6b3-1bd626b8e96a"
      unitRef="usd">86200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfNi0xMS0xLTEtMQ_ab8e7a4b-db27-4192-b8f4-23728e192df0"
      unitRef="usd">127800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i749e85ac79ee42a29981a1a54fe12f89_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfOC0xLTEtMS0x_c47ae6da-0c66-44d7-b5b1-3e60bdc9ac2b"
      unitRef="usd">-1692200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2e49dd86e464c6b8eb00c81c2ba5106_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfOC0zLTEtMS0x_209bfee5-184b-42f5-903d-429144364cd8"
      unitRef="usd">15700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i28164fe940424f16b215cb55adf86237_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfOC01LTEtMS0x_90776d92-56fe-4183-8216-966c45bf95e7"
      unitRef="usd">-4444200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i95f3c6593b4b487dae8900c3ac61ac05_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfOC03LTEtMS0x_181ac25d-ea79-4ec4-9cdf-332132d07138"
      unitRef="usd">-434400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i92bb29baa2584750986eee75a3d6e4ce_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOmUyNjUxNjNmYTE5MDRkMTA4NzA2MjI1ZDYyMjZmNjAwL3RhYmxlcmFuZ2U6ZTI2NTE2M2ZhMTkwNGQxMDg3MDYyMjVkNjIyNmY2MDBfOC0xMS0xLTEtMQ_87b883de-d858-497c-a39d-63c2831d769a"
      unitRef="usd">-6555100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id65902a544ed43ceb02d93ffc0a552e7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfMS0xLTEtMS0x_9b735024-ed27-416f-b212-ee6d676421ad"
      unitRef="usd">-1427500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a29af9f964348b0945d6e3a688d0920_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfMS0zLTEtMS0x_52c493e6-a0a2-4b62-9869-277d91a0d597"
      unitRef="usd">14800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id528bf4c135048229335007002573a24_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfMS01LTEtMS0x_9d94d35e-94a9-4bf5-8330-142c11107b71"
      unitRef="usd">-4751000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib1814bfd7e734e99af54e8b90a4f5ba1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfMS03LTEtMS0x_ca0837b8-266d-4535-bd64-6cbccd83619b"
      unitRef="usd">-332700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic30630769098404a82485baedba6de39_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfMS05LTEtMS0x_e1fd0f79-fd77-4e40-b363-631ee8355a0a"
      unitRef="usd">-6496400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i343f9384f69a4fbea834e4b74393c357_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfMy0xLTEtMS0x_d0f72129-c031-446d-a569-dbb2c8abaa0f"
      unitRef="usd">-96700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i55f74de7b4534040af7ed40631285711_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfMy0zLTEtMS0x_f97de92f-0724-4621-9c45-04dd1fd3a633"
      unitRef="usd">-8800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i42d644c1be1b47929fd7f33b4aa7934f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfMy01LTEtMS0x_516c9c2b-8ae9-4e99-ac37-91fc95cb53c4"
      unitRef="usd">27200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ibb7a26b32e694ddf89ed67424b0f6153_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfMy03LTEtMS0x_05cad9f1-1d16-41e0-8d79-487287a234ed"
      unitRef="usd">132800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfMy05LTEtMS0x_029f2d11-a516-456c-906d-ef407e41392b"
      unitRef="usd">54500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i343f9384f69a4fbea834e4b74393c357_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNC0xLTEtMS0x_c362c8f9-12fb-41f4-a01f-28373fcbd00f"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i55f74de7b4534040af7ed40631285711_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNC0zLTEtMS0x_ae7f02dd-2f2b-4dea-b6a8-6bd28fc64c1a"
      unitRef="usd">-800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i42d644c1be1b47929fd7f33b4aa7934f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNC01LTEtMS0x_e7e9bc60-d018-4f10-b6d3-89e953f721b9"
      unitRef="usd">-258500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ibb7a26b32e694ddf89ed67424b0f6153_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNC03LTEtMS0x_4560a933-70f8-4c28-9bf8-0f77c49a209e"
      unitRef="usd">-9900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNC05LTEtMS0x_71ea9410-0220-45c5-85d2-a10e9432c2cc"
      unitRef="usd">-269200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i343f9384f69a4fbea834e4b74393c357_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNS0xLTEtMS0x_472c6449-aa0a-440d-9237-3f80da4385fa"
      unitRef="usd">-96700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i55f74de7b4534040af7ed40631285711_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNS0zLTEtMS0x_d029409f-f751-44a2-bc06-5535026e333f"
      unitRef="usd">-8000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i42d644c1be1b47929fd7f33b4aa7934f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNS01LTEtMS0x_35a3730c-1835-46df-b425-2ffe5db41e3d"
      unitRef="usd">285700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibb7a26b32e694ddf89ed67424b0f6153_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNS03LTEtMS0x_4583179b-e41f-43c8-a65c-3a79f7157f2e"
      unitRef="usd">142700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNS05LTEtMS0x_b7226736-911a-4f66-9cc8-1284b33dfe01"
      unitRef="usd">323700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie6bf89817cf74679b6916eddd60558c9_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNy0xLTEtMS0x_80696c50-6683-435c-b281-9a04beb8372b"
      unitRef="usd">-1524200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibd2e85aa71f446bdbb141da8010fbe3d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNy0zLTEtMS0x_aadb9bea-da60-4739-97aa-56e400145022"
      unitRef="usd">6800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic375cded995a4df69d3eae9edc6766c7_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNy01LTEtMS0x_1ba3dc94-1128-4b82-9866-b35ef8661ef3"
      unitRef="usd">-4465300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4d2760fb44974a73a735787c71ae8f1a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNy03LTEtMS0x_83e25b2e-59c9-4dd4-9e72-03b372bee538"
      unitRef="usd">-190000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b11f523dfe64ce792a038f20fbc68b5_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjUxYTRmMjUzYTU1MzQ2ZmI4YmJkMzdkMTA3ZWUyMmI2L3RhYmxlcmFuZ2U6NTFhNGYyNTNhNTUzNDZmYjhiYmQzN2QxMDdlZTIyYjZfNy05LTEtMS0x_076b82dc-8f16-4705-bef9-5e65574147d1"
      unitRef="usd">-6172700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d711cf47db44ea8a7769cdcc03215c2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfMS0xLTEtMS0x_979e7d64-79bd-4532-86cd-557b1fbfdf77"
      unitRef="usd">-1678000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1398a4cb6b3b4f82aaf46f5f2990e359_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfMS0zLTEtMS0x_776ad6fe-d440-409e-8444-11d041dcebfa"
      unitRef="usd">4900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7b2773f7cce247f2b474587bc25ee417_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfMS01LTEtMS0x_a7b518dc-0189-4dbe-8e1b-1d2f64a124d7"
      unitRef="usd">-4638600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i11592af1b8584d8e941ac285b2b9ff5f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfMS03LTEtMS0x_849377d2-1ca2-471d-8ba0-c4eb62fcb928"
      unitRef="usd">-211900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if60b5c4e32da4c9aaf3a96926acf3f56_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfMS05LTEtMS0x_70caa9c0-2837-4af1-8712-80ed19480c15"
      unitRef="usd">-6523600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i9f358682845c429a9e682d2659872229_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfMy0xLTEtMS0x_2474e5bb-28ef-4a7f-b8d3-64a148f64c06"
      unitRef="usd">-14200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ifd8c50c7162047369d212f2103eba93f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfMy0zLTEtMS0x_723675e8-3189-4bd7-bcb3-8d5f870490a0"
      unitRef="usd">7600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ia57652e4c70f423c8b2fd6f637a90a05_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfMy01LTEtMS0x_75d07e2f-a7c8-4f17-9b9b-877fb3122efb"
      unitRef="usd">4600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ib297cf9f9edb4c749f2a81b2e539ced2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfMy03LTEtMS0x_5d879d3a-827a-4f35-afc5-0f4a8e1b491a"
      unitRef="usd">-232300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfMy05LTEtMS0x_1916fbb9-8a59-407b-8733-f4dcca4afa76"
      unitRef="usd">-234300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i9f358682845c429a9e682d2659872229_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNC0xLTEtMS0x_02d94fee-b549-4887-aa42-18d4dfc6250d"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ifd8c50c7162047369d212f2103eba93f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNC0zLTEtMS0x_2b08f677-1200-4c3a-8bff-15e2594ff7cf"
      unitRef="usd">-3200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ia57652e4c70f423c8b2fd6f637a90a05_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNC01LTEtMS0x_fb02626f-7e14-4066-94fb-ab0c52fbedb9"
      unitRef="usd">-189800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ib297cf9f9edb4c749f2a81b2e539ced2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNC03LTEtMS0x_f2afb616-21ef-4453-b591-16b10aba64c8"
      unitRef="usd">-9800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNC05LTEtMS0x_d7f66a9a-8511-40c6-b853-1b4ac4a5ce02"
      unitRef="usd">-202800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9f358682845c429a9e682d2659872229_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNS0xLTEtMS0x_4f80a304-1055-4dbb-bf35-0ac3b9b59e61"
      unitRef="usd">-14200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifd8c50c7162047369d212f2103eba93f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNS0zLTEtMS0x_f74afc4c-a609-4029-aef4-cb9d08be8d36"
      unitRef="usd">10800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia57652e4c70f423c8b2fd6f637a90a05_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNS01LTEtMS0x_5f949dd6-75e7-4dbc-a558-4695f0f3dcae"
      unitRef="usd">194400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib297cf9f9edb4c749f2a81b2e539ced2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNS03LTEtMS0x_125fcf60-dc3c-4408-908d-c58cc02a5523"
      unitRef="usd">-222500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNS05LTEtMS0x_63eb3c32-c51e-4ed2-b807-bc1635508dda"
      unitRef="usd">-31500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i749e85ac79ee42a29981a1a54fe12f89_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNy0xLTEtMS0x_33f7f16b-926a-4986-b8c8-34493f599c7f"
      unitRef="usd">-1692200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2e49dd86e464c6b8eb00c81c2ba5106_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNy0zLTEtMS0x_ab208e75-ded4-4b7e-abc1-4112b1304735"
      unitRef="usd">15700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i28164fe940424f16b215cb55adf86237_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNy01LTEtMS0x_64327bf8-3879-4cc4-86e1-f6c1a38234a6"
      unitRef="usd">-4444200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i95f3c6593b4b487dae8900c3ac61ac05_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNy03LTEtMS0x_3889d7a1-8e48-4097-b080-461356e86dab"
      unitRef="usd">-434400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i92bb29baa2584750986eee75a3d6e4ce_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjJmOWFiNDgzOTBlNjQzYWM4YTAxMjZiNmU4MTc5MzQ4L3RhYmxlcmFuZ2U6MmY5YWI0ODM5MGU2NDNhYzhhMDEyNmI2ZTgxNzkzNDhfNy05LTEtMS0x_771d334b-3928-4aa2-8e4d-aca68698d4ae"
      unitRef="usd">-6555100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ibdb47e6e63294d44a8f97f9e50e54a83_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfMi0xLTEtMS0x_232db922-502a-4573-b111-e325a95fd032"
      unitRef="usd">39000000.0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i8dc5691b17b74c35ad24aafdbf59f3fe_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfMi0zLTEtMS0x_bc7c4185-2620-4934-af09-8e3f06c661b6"
      unitRef="usd">-46000000.0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i343f9384f69a4fbea834e4b74393c357_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfMi01LTEtMS0x_95a71e86-c7e4-428f-acf2-354dec50106e"
      unitRef="usd">92300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i9f358682845c429a9e682d2659872229_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfMi03LTEtMS0x_db4b2ac6-962c-47df-a15d-aacfdc9f2f53"
      unitRef="usd">-34900000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i75e7048b106947fda1b1b5e4eabdc0fc_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfMy0xLTEtMS0x_2dda60f3-7312-45b1-bd6d-d7754a2cfeaf"
      unitRef="usd">-800000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ic3759b3a7e2f43dcb3def496f0e66523_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfMy0zLTEtMS0x_cbab30d5-e4a2-4516-8cd8-a022e49dcfc7"
      unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i55f74de7b4534040af7ed40631285711_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfMy01LTEtMS0x_af62592b-7872-46c0-9a65-73c8f59e02c1"
      unitRef="usd">-3800000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ifd8c50c7162047369d212f2103eba93f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfMy03LTEtMS0x_121e090b-aa11-491b-bf5c-4cca6f9e7791"
      unitRef="usd">3000000.0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="if4b8f930c8cb4479ac83208582a7d734_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNC0xLTEtMS0x_d4cf792b-0047-4a9f-9211-56361103e845"
      unitRef="usd">28200000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i2b09b2d2f1f840c7ae5d5461b2c17a11_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNC0zLTEtMS0x_036b5f89-f89e-4fc1-bdbf-f0bc35811532"
      unitRef="usd">-11800000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i42d644c1be1b47929fd7f33b4aa7934f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNC01LTEtMS0x_bd73ceb2-0c6c-4ac0-a978-0599ef8fb87c"
      unitRef="usd">79700000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ia57652e4c70f423c8b2fd6f637a90a05_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNC03LTEtMS0x_8bc262b6-91df-4507-b17e-2041cc1d159e"
      unitRef="usd">32800000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i22630c35f56443229b86ee022e4155d1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNS0xLTEtMS0x_7ed68ed3-b1aa-40b4-a78c-3422fc1a8174"
      unitRef="usd">5400000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i5b485bf17c5749a699e26a1df2e648da_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNS0zLTEtMS0x_5c45e8b1-dd0b-402e-b44d-a53beec8af32"
      unitRef="usd">22900000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i6ff88e97ce21499da1d1b1bdb8a2824f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNS01LTEtMS0x_ae7cf025-c511-44c1-a253-67c574363b90"
      unitRef="usd">37900000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="if57b47926a4847e78d8dcd2326b16c65_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNS03LTEtMS0x_c853b8af-7509-4733-b673-2e2432fe3772"
      unitRef="usd">-59100000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNi0xLTEtMS0x_142a2e0b-be00-44b3-b771-a1dc37e2f55e"
      unitRef="usd">71800000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNi0zLTEtMS0x_9f3fd565-9860-4ccb-b0b9-33d64a8ed781"
      unitRef="usd">-34700000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNi01LTEtMS0x_3651aa0b-540f-4b03-bd80-2b69cfbb63d6"
      unitRef="usd">206100000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjkxNzgyMGVjOTI2YjQ1NzJhOGM2MThiM2Q4N2E5NDI2L3RhYmxlcmFuZ2U6OTE3ODIwZWM5MjZiNDU3MmE4YzYxOGIzZDg3YTk0MjZfNi03LTEtMS0x_9a4c9e3e-9460-4c77-8bd8-53bcd86529ae"
      unitRef="usd">-58200000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RleHRyZWdpb246ZTZhYmQyYzIxYjVhNDE0YWExYTA4MGI1NTAzN2ExYjNfMTI1NQ_98266f8d-d636-45c6-b9cf-868d90bfdf1f">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassifications out of accumulated other comprehensive loss were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:11pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Details about Accumulated Other Comprehensive Loss Components&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Affected Line Item in the Consolidated Condensed Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="30" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of retirement benefit items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service benefits, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(13.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(41.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial losses, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;122.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;368.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;108.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;327.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(22.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(68.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;86.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;258.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;89.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;269.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5dbc75b54c4a4c39a56bbd8e3006acba_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNC0yLTEtMS0x_c1169f81-4864-4629-a39d-0c2f639894c6"
      unitRef="usd">-13900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i412a43d01f8c4978b95b1d9b22b6028e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNC00LTEtMS0x_e5b4f9e2-9017-49f5-9a3f-dc717f645309"
      unitRef="usd">-20800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic8ed2c03cd8446b992f8ed65b4226a3e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNC02LTEtMS0x_55de871f-9dd4-486d-8d7c-1a4d33030751"
      unitRef="usd">-41500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia29720c84e08498b8a3c6e661a3fe7bd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNC04LTEtMS0x_bdf8e188-4288-433f-8277-bfe0bda72e8f"
      unitRef="usd">-48400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i15dc1b0ac6eb41bab90c9964ded2067d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNS0yLTEtMS0x_81739f40-ada2-4bce-9917-718e31f083ae"
      unitRef="usd">122700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9ecbb90470a94e7780adb982e83ad4eb_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNS00LTEtMS0x_3d00776d-cb2c-4283-9611-612148fdf713"
      unitRef="usd">59100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6c3769918b9d406e90beab010e76b7de_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNS02LTEtMS0x_bfdccb59-7481-472f-a569-13febb08ca3b"
      unitRef="usd">368700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3be6ddfb286c465fa67388157f156b71_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNS04LTEtMS0x_8f13bfc7-b788-4b5f-9390-ea16e1442680"
      unitRef="usd">288600000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3b999b38b45f48d6b4eacb839d5ae8ef_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNi0yLTEtMS0x_1e10b9e2-ab6b-48c6-9701-4cf7162a0f6d"
      unitRef="usd">108800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4e909ad38be242f4935ee1c7e0dfc3c7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNi00LTEtMS0x_bb5cb8ea-c940-4008-8164-7eb485cbb784"
      unitRef="usd">38300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="idf900552e5704e3b83f6dd3f56cfb8b1_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNi02LTEtMS0x_64e9d6de-1443-4a80-8789-0286ad05d77f"
      unitRef="usd">327200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibc20efde344e4966b2390b23bdfad980_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNi04LTEtMS0x_5e231d70-b933-41ea-b9a2-a36baf4ed6d6"
      unitRef="usd">240200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3b999b38b45f48d6b4eacb839d5ae8ef_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNy0yLTEtMS0x_7c99322d-55d1-4c42-a11c-971027677235"
      unitRef="usd">22800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4e909ad38be242f4935ee1c7e0dfc3c7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNy00LTEtMS0x_2a6d8ee2-2685-4c14-90a3-7cce1b5a8b86"
      unitRef="usd">8000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idf900552e5704e3b83f6dd3f56cfb8b1_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNy02LTEtMS0x_70016eba-1893-421e-a5da-b9b39d4d354b"
      unitRef="usd">68700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibc20efde344e4966b2390b23bdfad980_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfNy04LTEtMS0x_d9f24fc9-a347-4d0f-ac01-58cc46785772"
      unitRef="usd">50400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i3b999b38b45f48d6b4eacb839d5ae8ef_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfOC0yLTEtMS0x_4922d58d-33c9-4d44-9e95-5bc8cecdde7b"
      unitRef="usd">86000000.0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4e909ad38be242f4935ee1c7e0dfc3c7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfOC00LTEtMS0x_a288d8fe-af2f-4006-a6e3-bd04329fb297"
      unitRef="usd">30300000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idf900552e5704e3b83f6dd3f56cfb8b1_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfOC02LTEtMS0x_0ca74d28-6e8b-4153-84d1-8f820bdf3ced"
      unitRef="usd">258500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibc20efde344e4966b2390b23bdfad980_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfOC04LTEtMS0x_03c85923-6d6a-4c58-b962-fa260bd3ea30"
      unitRef="usd">189800000</us-gaap:ProfitLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i846634e73e214b8b9dde808125858a45_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfMTAtMi0xLTEtMQ_994eedaf-2ae8-43fe-8013-6df851af3980"
      unitRef="usd">3400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifed88205905a4275ba8c331b5dbd8547_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfMTAtNC0xLTEtMQ_69183b46-5510-4f21-a06b-5aacc92a8613"
      unitRef="usd">3100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iaaec30f04bf644fea6c5f2229258f4b8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfMTAtNi0xLTEtMQ_5452179a-71e4-44cf-8397-23ea1153a25f"
      unitRef="usd">10700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i129d769168bb4388b55fa2891a6051bc_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfMTAtOC0xLTEtMQ_31887db6-ecef-4c63-bb7b-972cd4129d3f"
      unitRef="usd">13000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="i9611b430044e49a384caf7309cee05ff_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfMTItMi0xLTEtMQ_2e13cce3-b65d-4b35-b59e-0dcf6f813a8e"
      unitRef="usd">89400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9d84b8a802d54abdb0af6d412798b456_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfMTItNC0xLTEtMQ_1db15d88-c5c3-4c8f-b441-77dc6217c361"
      unitRef="usd">33400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3e9e954fc084405785c8bdfb174f2726_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfMTItNi0xLTEtMQ_455b6925-0f60-4fd0-a225-48bb8b12a2d0"
      unitRef="usd">269200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i99b24dcf85424c689a8236968bfe8b4d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF83OS9mcmFnOmU2YWJkMmMyMWI1YTQxNGFhMWEwODBiNTUwMzdhMWIzL3RhYmxlOjdjYTczZjVjYzk4MTRiMjk4NTY5MjViMDBhOTIyZmY5L3RhYmxlcmFuZ2U6N2NhNzNmNWNjOTgxNGIyOTg1NjkyNWIwMGE5MjJmZjlfMTItOC0xLTEtMQ_c7470ca3-4d67-4e1f-a7e4-7f75bbfe6b7a"
      unitRef="usd">202800000</us-gaap:ProfitLoss>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RleHRyZWdpb246YTkxYmY0ZTA5NjM5NDdiYzk0NDU4ZTZhODVmYmM0ZmZfMTAx_8cfecba8-6799-403d-87c9-52dd3b58d769">Other&#x2013;Net, (Income) Expense&lt;div style="margin-bottom:12pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&#x2013;net, (income) expense consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;83.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;258.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(18.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment (gains) losses on equity securities (Note 6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;246.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(270.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(905.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(72.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(217.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt extinguishment loss (Note 6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;405.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;405.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(20.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(34.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;635.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(158.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;124.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(694.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RleHRyZWdpb246YTkxYmY0ZTA5NjM5NDdiYzk0NDU4ZTZhODVmYmM0ZmZfMTE1_88ecc9db-23da-4963-b77a-ff7b7b77a4c0">&lt;div style="margin-bottom:12pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&#x2013;net, (income) expense consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;83.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;258.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(18.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net investment (gains) losses on equity securities (Note 6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;246.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(270.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(905.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(72.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(217.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt extinguishment loss (Note 6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;405.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;405.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(20.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(34.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#x2013;net, (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;635.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(158.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;124.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(694.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InterestExpense
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfMi0xLTEtMS0x_a4516220-3b3e-49c2-8226-fb935850581d"
      unitRef="usd">83600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfMi0zLTEtMS0x_4f421098-df74-49fb-8cd2-5aa9d50b42c7"
      unitRef="usd">89600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfMi01LTEtMS0x_9e611f64-6a83-458d-ae29-67f1b003d1e3"
      unitRef="usd">258400000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfMi03LTEtMS0x_1764fb86-f729-4101-b07c-ceb608f6c624"
      unitRef="usd">270400000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfMy0xLTEtMS0x_278fdc92-3b2b-45da-b9ec-76355df9a9a3"
      unitRef="usd">7000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfMy0zLTEtMS0x_ffea9cc5-5e57-4c84-aef4-5832097e6258"
      unitRef="usd">5800000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfMy01LTEtMS0x_d9951f22-324f-4333-8235-9e2eb10036cf"
      unitRef="usd">18000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfMy03LTEtMS0x_a864eb38-faa2-48d6-968c-20e128832c13"
      unitRef="usd">27200000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNC0xLTEtMS0x_cff2340f-0dd7-4a76-9122-5e2d2a2538fc"
      unitRef="usd">-246800000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNC0zLTEtMS0x_082b5797-ad24-4e75-b16f-5313b81365b9"
      unitRef="usd">141700000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNC01LTEtMS0x_b24efc0a-8c64-4d51-b59d-bbe1e4f7b058"
      unitRef="usd">270100000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNC03LTEtMS0x_048d4178-26e8-47ca-9719-22a8cedce2c7"
      unitRef="usd">905100000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNS0xLTEtMS0x_05e3ff50-718c-4db5-9490-4f879ba2da66"
      unitRef="usd">-72600000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNS0zLTEtMS0x_09fc8de2-29c1-4597-8741-b94fad82a7e6"
      unitRef="usd">-114000000.0</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNS01LTEtMS0x_5d0e229d-1fa1-4c5d-b0ef-90bedf761cc0"
      unitRef="usd">-217100000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNS03LTEtMS0x_6ea7a29b-14de-4572-bc54-bbbc1647edff"
      unitRef="usd">-194500000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNi0xLTEtMS0zMDY3NA_07ad1f5c-2459-4b8d-b562-0d5deff063d2"
      unitRef="usd">-405200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNi0zLTEtMS0zMDY4MQ_7fea2162-cfda-4900-834f-c8815a049832"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNi01LTEtMS0zMDY4OQ_22373340-21bb-4a86-993d-6a305920aa70"
      unitRef="usd">-405200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNi03LTEtMS0zMDY5Ng_637eb5b8-09db-4795-ade5-b49888574fed"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNi0xLTEtMS0x_79f3f5b3-5e92-49e3-b05e-0348c4e1e4cf"
      unitRef="usd">20100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNi0zLTEtMS0x_16a2949f-fde2-4fdf-851a-0d109cf9fa4d"
      unitRef="usd">-13000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNi01LTEtMS0x_213b587b-fdaf-4150-9851-5d3b7b2d2319"
      unitRef="usd">34100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNi03LTEtMS0x_a7554cf8-1171-4ca7-ae50-a55278b0e659"
      unitRef="usd">-161500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNy0xLTEtMS0x_046e082c-e351-40c8-9a3f-1d9c3ee046a9"
      unitRef="usd">-635900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNy0zLTEtMS0x_71500839-3f67-4d7e-b14c-e1fa16e405bc"
      unitRef="usd">158900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNy01LTEtMS0x_6babaacd-4739-4451-ba0e-593ac3e5d9d7"
      unitRef="usd">-124300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3467b50d6cef4d2e9034bad66520881a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF84NS9mcmFnOmE5MWJmNGUwOTYzOTQ3YmM5NDQ1OGU2YTg1ZmJjNGZmL3RhYmxlOjY4OWY1MjliYzNiOTQyYzQ5MDg5ZThmNWFmYTBmZTBjL3RhYmxlcmFuZ2U6Njg5ZjUyOWJjM2I5NDJjNDkwODllOGY1YWZhMGZlMGNfNy03LTEtMS0x_6768ab30-c670-4893-9576-0327eddc9dcd"
      unitRef="usd">694900000</us-gaap:NonoperatingIncomeExpense>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtMTMtMS0xLTE_7bfab548-476d-464d-b4f0-7f48f5e144be"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtMTMtMS0xLTE_7bfab548-476d-464d-b4f0-7f48f5e144be"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtMTUtMS0xLTE_2bef079f-6b48-4928-a3b6-b6990292d907"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtMTUtMS0xLTE_2bef079f-6b48-4928-a3b6-b6990292d907"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOS0xNS0xLTEtMQ_0d17fa04-e5b1-4fd4-b3d0-b5a50e67f519"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOS0xNS0xLTEtMQ_0d17fa04-e5b1-4fd4-b3d0-b5a50e67f519"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNy0xMy0xLTEtMQ_1e99a41f-b073-458d-8bf2-86a4fd6bb7f1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNy0xMy0xLTEtMQ_1e99a41f-b073-458d-8bf2-86a4fd6bb7f1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtMTUtMS0xLTE_4439dc84-d22d-4752-923a-26a9bc5cdf2b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtMTUtMS0xLTE_4439dc84-d22d-4752-923a-26a9bc5cdf2b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy0xMy0xLTEtMQ_ff7fe7bf-ba9f-4686-897f-21f2098bcd8a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy0xMy0xLTEtMQ_ff7fe7bf-ba9f-4686-897f-21f2098bcd8a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy0xNS0xLTEtMQ_cf430d6f-18f9-497d-bc39-23d0fb10324b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy0xNS0xLTEtMQ_cf430d6f-18f9-497d-bc39-23d0fb10324b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOC0xNS0xLTEtMQ_e5260fcd-2cb4-4b54-bb00-7081c06c9b68"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOC0xNS0xLTEtMQ_e5260fcd-2cb4-4b54-bb00-7081c06c9b68"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtMTMtMS0xLTE_6d009de1-88d9-4000-b2d9-620f045c6496"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtMTMtMS0xLTE_6d009de1-88d9-4000-b2d9-620f045c6496"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtMTUtMS0xLTE_6bfefc11-3f8e-46b8-8bab-7377c0bd95f0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtMTUtMS0xLTE_6bfefc11-3f8e-46b8-8bab-7377c0bd95f0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjEtMTUtMS0xLTE_4a039bb4-7d57-4cc6-8345-e8a588bc0e9d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjEtMTUtMS0xLTE_4a039bb4-7d57-4cc6-8345-e8a588bc0e9d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOS0xMy0xLTEtMQ_cb23c7b5-c41a-4e13-ae27-b624034d3d92"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOS0xMy0xLTEtMQ_cb23c7b5-c41a-4e13-ae27-b624034d3d92"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy0xMy0xLTEtMQ_b2dd5832-acf7-498f-805b-6e6692197d01"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy0xMy0xLTEtMQ_b2dd5832-acf7-498f-805b-6e6692197d01"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtMTMtMS0xLTE_c9e80bc4-8a71-4fb6-87d4-1656f4ee2264"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtMTMtMS0xLTE_c9e80bc4-8a71-4fb6-87d4-1656f4ee2264"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjItMTUtMS0xLTE_7abe819a-50fc-4c27-8850-eae51083415c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjItMTUtMS0xLTE_7abe819a-50fc-4c27-8850-eae51083415c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjItMTMtMS0xLTE_f6b0cbf1-8ea9-4e3c-8fda-d4606c6d2fea"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjItMTMtMS0xLTE_f6b0cbf1-8ea9-4e3c-8fda-d4606c6d2fea"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtMTMtMS0xLTE_46112e1c-12d7-46c8-be5f-d81e03cd4a21"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtMTMtMS0xLTE_46112e1c-12d7-46c8-be5f-d81e03cd4a21"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtMTMtMS0xLTE_b13827a8-af2d-4a7d-87ea-2fb03492aaf7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtMTMtMS0xLTE_b13827a8-af2d-4a7d-87ea-2fb03492aaf7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNy0xNS0xLTEtMQ_ec16c59e-9d22-4e6d-b90e-d91e2ddf8102"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNy0xNS0xLTEtMQ_ec16c59e-9d22-4e6d-b90e-d91e2ddf8102"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtMTUtMS0xLTE_bc0dde86-46f2-4741-980a-39ace0aca559"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtMTUtMS0xLTE_bc0dde86-46f2-4741-980a-39ace0aca559"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy0xNS0xLTEtMQ_11779181-5463-4bed-be4b-1ac758305555"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy0xNS0xLTEtMQ_11779181-5463-4bed-be4b-1ac758305555"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjAtMTMtMS0xLTE_ae12d3ca-246d-4b32-8d5d-2b62d86d16c2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjAtMTMtMS0xLTE_ae12d3ca-246d-4b32-8d5d-2b62d86d16c2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjAtMTUtMS0xLTE_42356bcd-102e-4951-908b-9fbe63c054f2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjAtMTUtMS0xLTE_42356bcd-102e-4951-908b-9fbe63c054f2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtMTMtMS0xLTE_7e106991-453e-4af5-b4d7-11292ad1f604"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtMTMtMS0xLTE_7e106991-453e-4af5-b4d7-11292ad1f604"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtMTUtMS0xLTE_52d0cae5-5189-43c9-a3ba-a9fa5a6931fe"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtMTUtMS0xLTE_52d0cae5-5189-43c9-a3ba-a9fa5a6931fe"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjEtMTMtMS0xLTE_eed90e6f-7db6-4694-8923-b3ee18dc613a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjEtMTMtMS0xLTE_eed90e6f-7db6-4694-8923-b3ee18dc613a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOC0xMy0xLTEtMQ_4a20c478-f442-4f2e-b927-524ce344d68c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOC0xMy0xLTEtMQ_4a20c478-f442-4f2e-b927-524ce344d68c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtMTUtMS0xLTE_2cdb2d62-671e-48fd-a8a2-6a96a76d2aa9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtMTUtMS0xLTE_2cdb2d62-671e-48fd-a8a2-6a96a76d2aa9"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of September&#160;30, 2021, there were $500.0 million remaining under our $8.00 billion share repurchase program authorized in June 2018 and $5.00 billion  remaining under our $5.00 billion share repurchase program authorized in May 2021. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtMTMtMS0xLTE_7bfab548-476d-464d-b4f0-7f48f5e144be"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtMTUtMS0xLTE_2bef079f-6b48-4928-a3b6-b6990292d907"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOS0xNS0xLTEtMQ_0d17fa04-e5b1-4fd4-b3d0-b5a50e67f519"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNy0xMy0xLTEtMQ_1e99a41f-b073-458d-8bf2-86a4fd6bb7f1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTYtMTUtMS0xLTE_4439dc84-d22d-4752-923a-26a9bc5cdf2b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy0xMy0xLTEtMQ_ff7fe7bf-ba9f-4686-897f-21f2098bcd8a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMy0xNS0xLTEtMQ_cf430d6f-18f9-497d-bc39-23d0fb10324b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOC0xNS0xLTEtMQ_e5260fcd-2cb4-4b54-bb00-7081c06c9b68"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtMTMtMS0xLTE_6d009de1-88d9-4000-b2d9-620f045c6496"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMTQtMTUtMS0xLTE_6bfefc11-3f8e-46b8-8bab-7377c0bd95f0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjEtMTUtMS0xLTE_4a039bb4-7d57-4cc6-8345-e8a588bc0e9d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOS0xMy0xLTEtMQ_cb23c7b5-c41a-4e13-ae27-b624034d3d92"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy0xMy0xLTEtMQ_b2dd5832-acf7-498f-805b-6e6692197d01"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtMTMtMS0xLTE_c9e80bc4-8a71-4fb6-87d4-1656f4ee2264"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjItMTUtMS0xLTE_7abe819a-50fc-4c27-8850-eae51083415c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjItMTMtMS0xLTE_f6b0cbf1-8ea9-4e3c-8fda-d4606c6d2fea"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtMTMtMS0xLTE_46112e1c-12d7-46c8-be5f-d81e03cd4a21"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtMTMtMS0xLTE_b13827a8-af2d-4a7d-87ea-2fb03492aaf7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfNy0xNS0xLTEtMQ_ec16c59e-9d22-4e6d-b90e-d91e2ddf8102"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTYtMTUtMS0xLTE_bc0dde86-46f2-4741-980a-39ace0aca559"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMy0xNS0xLTEtMQ_11779181-5463-4bed-be4b-1ac758305555"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjAtMTMtMS0xLTE_ae12d3ca-246d-4b32-8d5d-2b62d86d16c2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjAtMTUtMS0xLTE_42356bcd-102e-4951-908b-9fbe63c054f2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMTQtMTMtMS0xLTE_7e106991-453e-4af5-b4d7-11292ad1f604"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjUtMTUtMS0xLTE_52d0cae5-5189-43c9-a3ba-a9fa5a6931fe"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfMjEtMTMtMS0xLTE_eed90e6f-7db6-4694-8923-b3ee18dc613a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjc2ZmI2NThjMmFiNTRkNmQ5ODJjNTEyODg5YjVkYTUwL3RhYmxlcmFuZ2U6NzZmYjY1OGMyYWI1NGQ2ZDk4MmM1MTI4ODliNWRhNTBfOC0xMy0xLTEtMQ_4a20c478-f442-4f2e-b927-524ce344d68c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RhYmxlOjY5ODVjZjMzMjQ2OTQ5YTg5Mjk1ZWVhODM2NmY3NmZhL3RhYmxlcmFuZ2U6Njk4NWNmMzMyNDY5NDlhODkyOTVlZWE4MzY2Zjc2ZmFfMjUtMTUtMS0xLTE_2cdb2d62-671e-48fd-a8a2-6a96a76d2aa9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ4YWYzNGUxMjcxMzQwMGM4NThmN2EyOTE4M2U1NjgwL3NlYzo0OGFmMzRlMTI3MTM0MDBjODU4ZjdhMjkxODNlNTY4MF8zMS9mcmFnOjNmMTdjYzEwZGU1YjQyOGM5YjU0OWJlMDMyMDNlNmIwL3RleHRyZWdpb246M2YxN2NjMTBkZTViNDI4YzliNTQ5YmUwMzIwM2U2YjBfODc5NjA5MzAyMzkwMw_1309e489-82dc-4971-8c72-1b071c7b3cbc"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657090051656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 22, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-6351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELI LILLY AND COMPANY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">IN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">35-0470950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Lilly Corporate Center<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Indianapolis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">46285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">276-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">956,592,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000059478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock (no par value)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock (no par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member', window );">1.000% Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.000% Notes due 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member', window );">7 1/8% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">7 1/8% Notes due 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member', window );">1.625% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member', window );">2.125% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Notes due 2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member', window );">0.625% Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.625% Notes due 2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A5000NotesDue2033Member', window );">0.500% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.500% Notes due 2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member', window );">6.77%&#160;Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">6.77%&#160;Notes due 2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member', window );">1.625% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member', window );">1.700% Notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.700% Notes due 2049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY49A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member', window );">1.125% Notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.125% Notes due 2051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member', window );">1.375% Notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Notes due 2061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A5000NotesDue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A5000NotesDue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657094104504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Operations - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue (Note 2)</a></td>
<td class="nump">$ 6,772.8<span></span>
</td>
<td class="nump">$ 5,740.6<span></span>
</td>
<td class="nump">$ 20,318.5<span></span>
</td>
<td class="nump">$ 17,099.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs, expenses, and other:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">1,430.8<span></span>
</td>
<td class="nump">1,326.4<span></span>
</td>
<td class="nump">5,262.6<span></span>
</td>
<td class="nump">3,763.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,708.9<span></span>
</td>
<td class="nump">1,465.4<span></span>
</td>
<td class="nump">5,066.5<span></span>
</td>
<td class="nump">4,247.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Marketing, selling, and administrative</a></td>
<td class="nump">1,577.9<span></span>
</td>
<td class="nump">1,569.1<span></span>
</td>
<td class="nump">4,839.6<span></span>
</td>
<td class="nump">4,567.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development (Note 3)</a></td>
<td class="nump">174.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">498.3<span></span>
</td>
<td class="nump">294.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringSettlementAndImpairmentProvisions', window );">Asset impairment, restructuring, and other special charges (Note 5)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">101.4<span></span>
</td>
<td class="nump">211.6<span></span>
</td>
<td class="nump">161.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense (Note 11)</a></td>
<td class="nump">635.9<span></span>
</td>
<td class="num">(158.9)<span></span>
</td>
<td class="nump">124.3<span></span>
</td>
<td class="num">(694.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CostOfSalesOperatingExpensesAndOtherNet', window );">Costs, expenses, and other</a></td>
<td class="nump">5,527.5<span></span>
</td>
<td class="nump">4,303.4<span></span>
</td>
<td class="nump">16,002.9<span></span>
</td>
<td class="nump">12,339.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">1,245.3<span></span>
</td>
<td class="nump">1,437.2<span></span>
</td>
<td class="nump">4,315.6<span></span>
</td>
<td class="nump">4,760.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes (Note 7)</a></td>
<td class="nump">135.2<span></span>
</td>
<td class="nump">228.8<span></span>
</td>
<td class="nump">460.0<span></span>
</td>
<td class="nump">683.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,110.1<span></span>
</td>
<td class="nump">$ 1,208.4<span></span>
</td>
<td class="nump">$ 3,855.6<span></span>
</td>
<td class="nump">$ 4,076.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="nump">$ 4.25<span></span>
</td>
<td class="nump">$ 4.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="nump">$ 4.23<span></span>
</td>
<td class="nump">$ 4.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used in calculation of earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">906.7<span></span>
</td>
<td class="nump">907.2<span></span>
</td>
<td class="nump">907.7<span></span>
</td>
<td class="nump">907.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">910.8<span></span>
</td>
<td class="nump">911.4<span></span>
</td>
<td class="nump">911.7<span></span>
</td>
<td class="nump">911.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CostOfSalesOperatingExpensesAndOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of sales, operating expenses, and other-net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CostOfSalesOperatingExpensesAndOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringSettlementAndImpairmentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restructuring charges, remediation cost, and asset impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringSettlementAndImpairmentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657179821464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,110.1<span></span>
</td>
<td class="nump">$ 1,208.4<span></span>
</td>
<td class="nump">$ 3,855.6<span></span>
</td>
<td class="nump">$ 4,076.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax (Note 10)</a></td>
<td class="nump">114.4<span></span>
</td>
<td class="nump">127.8<span></span>
</td>
<td class="nump">323.7<span></span>
</td>
<td class="num">(31.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 1,224.5<span></span>
</td>
<td class="nump">$ 1,336.2<span></span>
</td>
<td class="nump">$ 4,179.3<span></span>
</td>
<td class="nump">$ 4,045.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657084461032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Condensed Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents (Note 6)</a></td>
<td class="nump">$ 3,788.2<span></span>
</td>
<td class="nump">$ 3,657.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments (Note 6)</a></td>
<td class="nump">37.1<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $24.1 (2021) and $25.9 (2020)</a></td>
<td class="nump">5,914.3<span></span>
</td>
<td class="nump">5,875.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">1,110.7<span></span>
</td>
<td class="nump">1,053.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">3,907.4<span></span>
</td>
<td class="nump">3,980.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">3,050.6<span></span>
</td>
<td class="nump">2,871.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">17,808.3<span></span>
</td>
<td class="nump">17,462.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments (Note 6)</a></td>
<td class="nump">3,350.5<span></span>
</td>
<td class="nump">2,966.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,884.1<span></span>
</td>
<td class="nump">3,766.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangibles, net</a></td>
<td class="nump">7,887.7<span></span>
</td>
<td class="nump">7,450.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">2,625.6<span></span>
</td>
<td class="nump">2,830.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $9,962.8 (2021) and $9,570.7 (2020)</a></td>
<td class="nump">8,920.4<span></span>
</td>
<td class="nump">8,681.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">3,710.4<span></span>
</td>
<td class="nump">3,475.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">48,187.0<span></span>
</td>
<td class="nump">46,633.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term borrowings and current maturities of long-term debt</a></td>
<td class="nump">1,563.0<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,566.8<span></span>
</td>
<td class="nump">1,606.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation</a></td>
<td class="nump">836.6<span></span>
</td>
<td class="nump">997.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_SalesRebatesAndDiscounts', window );">Sales rebates and discounts</a></td>
<td class="nump">7,185.6<span></span>
</td>
<td class="nump">5,853.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">770.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">203.5<span></span>
</td>
<td class="nump">495.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">2,326.5<span></span>
</td>
<td class="nump">2,750.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">13,682.0<span></span>
</td>
<td class="nump">12,481.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Other Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">15,522.4<span></span>
</td>
<td class="nump">16,586.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Accrued retirement benefits (Note 8)</a></td>
<td class="nump">3,878.8<span></span>
</td>
<td class="nump">4,094.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term income taxes payable</a></td>
<td class="nump">3,768.5<span></span>
</td>
<td class="nump">3,837.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">1,632.5<span></span>
</td>
<td class="nump">2,099.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">1,748.7<span></span>
</td>
<td class="nump">1,707.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total other liabilities</a></td>
<td class="nump">26,550.9<span></span>
</td>
<td class="nump">28,326.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Eli Lilly and Company Shareholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">598.2<span></span>
</td>
<td class="nump">598.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">6,758.0<span></span>
</td>
<td class="nump">6,778.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">9,639.4<span></span>
</td>
<td class="nump">7,830.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesHeldInEmployeeTrust', window );">Employee benefit trust</a></td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss (Note 10)</a></td>
<td class="num">(6,172.7)<span></span>
</td>
<td class="num">(6,496.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Cost of common stock in treasury</a></td>
<td class="num">(52.7)<span></span>
</td>
<td class="num">(55.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Eli Lilly and Company shareholders&#8217; equity</a></td>
<td class="nump">7,757.0<span></span>
</td>
<td class="nump">5,641.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">197.1<span></span>
</td>
<td class="nump">183.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">7,954.1<span></span>
</td>
<td class="nump">5,825.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 48,187.0<span></span>
</td>
<td class="nump">$ 46,633.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_SalesRebatesAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales rebates and discounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_SalesRebatesAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesHeldInEmployeeTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesHeldInEmployeeTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657081423400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Condensed Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrentAbstract', window );"><strong>Receivables, Net, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowances for doubtful accounts</a></td>
<td class="nump">$ 24.1<span></span>
</td>
<td class="nump">$ 25.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, accumulated depreciation</a></td>
<td class="nump">$ 9,962.8<span></span>
</td>
<td class="nump">$ 9,570.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657090381720">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Equity - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Employee Benefit Trust</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th" colspan="2"><div>Common Stock in Treasury</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 598.8<span></span>
</td>
<td class="nump">$ 6,685.3<span></span>
</td>
<td class="nump">$ 4,920.4<span></span>
</td>
<td class="num">$ (3,013.2)<span></span>
</td>
<td class="num">$ (6,523.6)<span></span>
</td>
<td class="num">$ (60.8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 92.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,076.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">95.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Cash dividend declared</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,345.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,627)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,627)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(497.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,627<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (500.0)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under employee stock plans, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under employee stock plans, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="num">(206.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(19.0)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">956,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 598.1<span></span>
</td>
<td class="nump">6,698.8<span></span>
</td>
<td class="nump">7,154.0<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(6,555.1)<span></span>
</td>
<td class="num">$ (55.7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">169.1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">956,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 598.1<span></span>
</td>
<td class="nump">6,629.4<span></span>
</td>
<td class="nump">6,617.2<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(6,682.9)<span></span>
</td>
<td class="num">$ (55.7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">179.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,208.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Cash dividend declared</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(671.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under employee stock plans, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under employee stock plans, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5.2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">956,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 598.1<span></span>
</td>
<td class="nump">6,698.8<span></span>
</td>
<td class="nump">7,154.0<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(6,555.1)<span></span>
</td>
<td class="num">$ (55.7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">169.1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,825.2<span></span>
</td>
<td class="nump">$ 598.2<span></span>
</td>
<td class="nump">6,778.5<span></span>
</td>
<td class="nump">7,830.2<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(6,496.4)<span></span>
</td>
<td class="num">$ (55.7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">183.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,855.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">25.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Cash dividend declared</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,542.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,467)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(498.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,467<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (500.0)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under employee stock plans, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under employee stock plans, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="num">(287.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(5.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(11.7)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,954.1<span></span>
</td>
<td class="nump">$ 598.2<span></span>
</td>
<td class="nump">6,758.0<span></span>
</td>
<td class="nump">9,639.4<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(6,172.7)<span></span>
</td>
<td class="num">$ (52.7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">197.1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 598.1<span></span>
</td>
<td class="nump">6,669.2<span></span>
</td>
<td class="nump">8,530.1<span></span>
</td>
<td class="num">(3,013.2)<span></span>
</td>
<td class="num">(6,287.1)<span></span>
</td>
<td class="num">$ (52.7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">219.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,110.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(22.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under employee stock plans, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under employee stock plans, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,954.1<span></span>
</td>
<td class="nump">$ 598.2<span></span>
</td>
<td class="nump">$ 6,758.0<span></span>
</td>
<td class="nump">$ 9,639.4<span></span>
</td>
<td class="num">$ (3,013.2)<span></span>
</td>
<td class="num">$ (6,172.7)<span></span>
</td>
<td class="num">$ (52.7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 197.1<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of September&#160;30, 2021, there were $500.0 million remaining under our $8.00 billion share repurchase program authorized in June 2018 and $5.00 billion  remaining under our $5.00 billion share repurchase program authorized in May 2021.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657079832936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Equity (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividend declared per share (in dollars per share)</a></td>
<td class="nump">$ 0.74<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock repurchase program, remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
<td class="nump">$ 8,000,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657192714952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,110.1<span></span>
</td>
<td class="nump">$ 1,208.4<span></span>
</td>
<td class="nump">$ 3,855.6<span></span>
</td>
<td class="nump">$ 4,076.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,101.9<span></span>
</td>
<td class="nump">956.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Change in deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(709.8)<span></span>
</td>
<td class="nump">66.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt extinguishment loss (Note 6)</a></td>
<td class="nump">405.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">405.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267.5<span></span>
</td>
<td class="nump">220.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Net investment gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(271.1)<span></span>
</td>
<td class="num">(909.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development (Note 3)</a></td>
<td class="nump">174.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">498.3<span></span>
</td>
<td class="nump">294.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net of acquisitions and divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(548.1)<span></span>
</td>
<td class="num">(232.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other non-cash operating activities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504.7<span></span>
</td>
<td class="nump">212.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by Operating Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,104.2<span></span>
</td>
<td class="nump">4,684.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Net purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,018.4)<span></span>
</td>
<td class="num">(933.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sales and maturities of short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.6<span></span>
</td>
<td class="nump">118.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27.9)<span></span>
</td>
<td class="num">(11.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfLongtermInvestments', window );">Proceeds from sales of noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">537.2<span></span>
</td>
<td class="nump">574.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Purchases of noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(710.1)<span></span>
</td>
<td class="num">(223.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for acquisitions, net of cash acquired (Note 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(747.4)<span></span>
</td>
<td class="num">(849.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_PurchasedInProcessResearchAndDevelopment', window );">Purchases of in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(460.6)<span></span>
</td>
<td class="num">(276.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
<td class="nump">16.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used for Investing Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,383.3)<span></span>
</td>
<td class="num">(1,584.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,313.5)<span></span>
</td>
<td class="num">(2,017.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Net change in short-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Net change in short-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(914.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,410.8<span></span>
</td>
<td class="nump">2,062.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,905.3)<span></span>
</td>
<td class="num">(276.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(500.0)<span></span>
</td>
<td class="num">(500.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(295.3)<span></span>
</td>
<td class="num">(200.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Used for Financing Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,604.8)<span></span>
</td>
<td class="num">(1,845.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131.1<span></span>
</td>
<td class="nump">1,257.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at January&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,657.1<span></span>
</td>
<td class="nump">2,337.5<span></span>
</td>
<td class="nump">$ 2,337.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents at September 30</a></td>
<td class="nump">$ 3,788.2<span></span>
</td>
<td class="nump">$ 3,595.3<span></span>
</td>
<td class="nump">$ 3,788.2<span></span>
</td>
<td class="nump">$ 3,595.3<span></span>
</td>
<td class="nump">$ 3,657.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PurchasedInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PurchasedInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657080019656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the consolidated condensed financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/0000059478/000005947821000083/lly-20201231.htm" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2020. We issue our financial statements by filing them with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis; that is, based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657081702248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated condensed statements of operations:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,189.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,281.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,579.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,762.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">583.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,739.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,772.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,740.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,318.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,099.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $62.1 million and $136.1 million during the three and nine months ended September&#160;30, 2021, respectively, and $31.5 million and $101.5 million during the three and nine months ended September 30, 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to certain of our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trajenta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustments to Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to increase (decrease) revenue recognized as a result of changes in estimates for our most significant United States (U.S.) sales returns, rebates, and discounts liability balances for products shipped in previous periods were less than 1 percent of U.S. revenue during each of the three and nine months ended September&#160;30, 2021, and approximately (1) percent and 1 percent of U.S. revenue for the three and nine months ended September 30, 2020, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">278.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021 and 2020, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disaggregation of Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product for the three months ended September 30, 2021 and 2020:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,201.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">398.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,600.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">347.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">279.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">626.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">221.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">169.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">390.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">193.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">114.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">78.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">192.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">65.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">177.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Diabetes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,143.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,131.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,274.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,798.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,783.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">297.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">457.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">135.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">335.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">84.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">168.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">253.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">114.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Oncology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">65.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Oncology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">730.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">675.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,406.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">422.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">170.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">593.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">194.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">212.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">406.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Immunology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Immunology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">616.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">388.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,004.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">99.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">140.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">132.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Neuroscience</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">144.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">305.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">450.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 Antibodies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">215.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">217.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">91.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">200.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">137.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">130.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">354.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">282.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">637.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,989.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,783.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,772.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,161.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,579.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,740.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)   </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to Emergency Use Authorization (EUA).</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product for the nine months ended September 30, 2021 and 2020:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.298%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,465.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,122.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,588.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,565.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,009.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">842.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,851.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,907.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">566.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,058.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">633.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">290.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">923.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">423.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">226.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">650.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">185.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">302.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">488.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Diabetes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,284.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,276.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,560.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,663.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,868.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,530.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">911.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">714.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,626.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">582.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">363.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">945.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">266.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">496.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">762.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">357.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">403.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">340.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">340.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Oncology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">169.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">253.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Oncology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,201.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,130.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,332.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,780.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,803.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,071.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">493.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,565.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">236.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">572.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">809.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Immunology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Immunology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,323.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,080.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,404.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,761.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">454.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">484.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">313.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">415.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">264.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">292.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">154.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Neuroscience</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">453.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">974.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,427.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,356.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 Antibodies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">949.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">226.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,176.2</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">330.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">287.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">617.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">541.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">538.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">164.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">260.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,373.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,220.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,593.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,647.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,635.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,683.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,318.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,631.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,468.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,099.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy, and Trijardy XR.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to EUA.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:51.159%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.948%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.101%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,989.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,161.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,635.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,631.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,098.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,629.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,984.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">595.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,832.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,919.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">400.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,285.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">689.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,936.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,768.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,772.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,740.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,318.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,099.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue is attributed to the countries based on the location of the customer.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657081340168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021 and February 2020, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail) and Dermira, Inc. (Dermira), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated condensed financial statements from the date of acquisition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired assets in development which are further discussed in this note below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired in-process research and development (IPR&amp;D) was immediately expensed because the compound had no alternative future use. We recognized acquired IPR&amp;D charges of $174.0 million and $498.3 million for the three and nine months ended September&#160;30, 2021, respectively, and $294.1 million for the nine months ended September 30, 2020. There were no acquired IPR&amp;D charges recognized in the three months ended September 30, 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions of Businesses</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Prevail Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail&#8217;s portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson&#8217;s disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our access to Prevail information was limited prior to the acquisition. As a consequence, we are in the process of determining fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at January 22, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to PR001.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is not deductible for tax purposes. </span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 6 for a discussion on the estimation of the CVR liability. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included as this acquisition did not have a material impact on our consolidated condensed statements of operations for the three and nine months ended September 30, 2021 and 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Dermira Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we acquired all shares of Dermira for a purchase price of approximately $849.3 million, net of cash acquired. Under the terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the FDA. We also acquired Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the nine months ended September&#160;30, 2021, we sold the rights to Qbrexza. See Note 5 for additional information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $86.8 million, other intangibles of $1.20 billion primarily related to lebrikizumab, deferred income tax liabilities of $49.5 million, and long-term debt of $375.5 million. After the acquisition, we repaid $276.2 million of long-term debt assumed as part of our acquisition of Dermira.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our asset acquisitions during the nine months ended September&#160;30, 2021 and 2020:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s) or Therapy</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biosciences, Inc. </span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential in vivo therapies for genetic disorders</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merus N.V. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CD3-engaging T-cell re-directing bispecific antibodies for the potential treatment of cancer</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asahi Kasei Pharma Corporation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AK1780, an orally bioavailable P2X7 receptor antagonist for the potential treatment of chronic pain conditions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigel Pharmaceuticals, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiNA Therapeutics Limited</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Protomer Technologies Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glucose-sensing insulin program</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kumquat Biosciences Inc. </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical small molecules that stimulate tumor-specific immune responses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">55.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lycia Therapeutics, Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Several potential modalities across a spectrum of therapeutic areas and diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ProQR Therapeutics N.V.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for genetic disorders in the liver and nervous system</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26.7</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sitryx Therapeutics Limited</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for autoimmune diseases</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbCellera Biologics Inc. (AbCellera)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Petra Pharma Corporation (Petra)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutant-selective PI3K</span><span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#945;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> inhibitor that could lead to potential new medicine </span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evox Therapeutics Limited</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets for the potential treatment of neurological disorders</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2020</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> We recognized an acquired IPR&amp;D expense of $25.0 million in May 2020 upon closing of the transaction. </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021 and February 2020, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail) and Dermira, Inc. (Dermira), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated condensed financial statements from the date of acquisition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired assets in development which are further discussed in this note below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired in-process research and development (IPR&amp;D) was immediately expensed because the compound had no alternative future use. We recognized acquired IPR&amp;D charges of $174.0 million and $498.3 million for the three and nine months ended September&#160;30, 2021, respectively, and $294.1 million for the nine months ended September 30, 2020. There were no acquired IPR&amp;D charges recognized in the three months ended September 30, 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions of Businesses</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Prevail Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160&#160;million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail&#8217;s portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson&#8217;s disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA). </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our access to Prevail information was limited prior to the acquisition. As a consequence, we are in the process of determining fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at January 22, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to PR001.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is not deductible for tax purposes. </span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 6 for a discussion on the estimation of the CVR liability. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma information has not been included as this acquisition did not have a material impact on our consolidated condensed statements of operations for the three and nine months ended September 30, 2021 and 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Dermira Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Transaction</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we acquired all shares of Dermira for a purchase price of approximately $849.3 million, net of cash acquired. Under the terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the FDA. We also acquired Qbrexza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the nine months ended September&#160;30, 2021, we sold the rights to Qbrexza. See Note 5 for additional information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $86.8 million, other intangibles of $1.20 billion primarily related to lebrikizumab, deferred income tax liabilities of $49.5 million, and long-term debt of $375.5 million. After the acquisition, we repaid $276.2 million of long-term debt assumed as part of our acquisition of Dermira.</span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our asset acquisitions during the nine months ended September&#160;30, 2021 and 2020:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s) or Therapy</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biosciences, Inc. </span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential in vivo therapies for genetic disorders</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merus N.V. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CD3-engaging T-cell re-directing bispecific antibodies for the potential treatment of cancer</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asahi Kasei Pharma Corporation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AK1780, an orally bioavailable P2X7 receptor antagonist for the potential treatment of chronic pain conditions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigel Pharmaceuticals, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiNA Therapeutics Limited</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Protomer Technologies Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glucose-sensing insulin program</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kumquat Biosciences Inc. </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical small molecules that stimulate tumor-specific immune responses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">55.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lycia Therapeutics, Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Several potential modalities across a spectrum of therapeutic areas and diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ProQR Therapeutics N.V.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for genetic disorders in the liver and nervous system</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26.7</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sitryx Therapeutics Limited</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for autoimmune diseases</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbCellera Biologics Inc. (AbCellera)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Petra Pharma Corporation (Petra)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutant-selective PI3K</span><span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#945;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> inhibitor that could lead to potential new medicine </span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evox Therapeutics Limited</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets for the potential treatment of neurological disorders</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2020</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> We recognized an acquired IPR&amp;D expense of $25.0 million in May 2020 upon closing of the transaction. </span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657080083864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations and Other Arrangements</a></td>
<td class="text">Collaborations and Other Arrangements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Boehringer Ingelheim Diabetes Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim&#8217;s oral diabetes products: Jardiance,  Glyxambi, Synjardy, Trijardy XR, Trajenta, and Jentadueto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as our basal insulin, Basaglar. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. Jentadueto is included in the Trajenta product family. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the net amount of significant milestones capitalized (deferred) at September 30, 2021 and December 31, 2020 for the compounds included in this collaboration: </span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Milestones Capitalized (Deferred) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as of:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Family</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">141.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">95.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(154.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In  connection with the regulatory approvals of Jardiance and Trajenta, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. In connection with the regulatory approvals of Basaglar, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Jardiance product family, we and Boehringer Ingelheim share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue. Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family. Beginning January 1, 2021, the royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds. We pay to Boehringer Ingelheim a royalty on net sales for Basaglar in the U.S. We record our sales of Basaglar to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and our net product revenue recognized with respect to Basaglar:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.015%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Family</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">390.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,058.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">192.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">650.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">279.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Olumiant</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to its Janus tyrosine kinase (JAK) inhibitor compound, now known as Olumiant (baricitinib), and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double digit royalty payments on global net sales with rates ranging up to 20 percent. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. In 2020, the agreement was amended to include the treatment of COVID-19, with Incyte obtaining the right to receive an additional royalty ranging up to the low teens on global net sales for the treatment of COVID-19 that exceed a specified aggregate global net sales threshold. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, milestone payments of $210.0 million were capitalized as intangible assets as of September 30, 2021 and December 31, 2020 and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, Incyte is eligible to receive up to $100.0 million of additional payments from us contingent upon certain success-based regulatory milestones. Incyte is also eligible to receive up to $150.0 million of potential sales-based milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Olumiant, including sales of baricitinib that were made pursuant to EUA, to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. The following table summarizes our net product revenue recognized with respect to Olumiant:</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:49.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.690%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">406.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">809.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 antibodies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a worldwide license and collaboration agreement with AbCellera to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab, for which we hold development and commercialization rights. AbCellera has the right to receive tiered royalty payments on global net sales of bamlanivimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera are recorded as cost of sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a license and collaboration agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including etesevimab, for which we hold development and commercialization rights outside of mainland China and the Special Administrative Regions of Hong Kong and Macau, and for which Junshi Biosciences currently maintains all rights in mainland China and the Special Administrative Regions of Hong Kong and Macau. Junshi Biosciences has the right to receive royalty payments in the mid-teens on our net sales of etesevimab. Junshi Biosciences also has the right to receive certain development, success-based regulatory and sales-based milestones. In connection with the regulatory authorizations of etesevimab (for administration with bamlanivimab) as well as achievement of a sales-based milestone, milestone payments of $95.0 million were capitalized as intangible assets as of September&#160;30, 2021 and are being amortized to cost of sales over the estimated useful life of etesevimab. As of September&#160;30, 2021, Junshi Biosciences is eligible to receive up to $100.0 million of potential sales-based milestones. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to EUAs, we recognized $217.1 million and $1.18 billion of net product revenue associated with our sales of our COVID-19 antibodies during the three and nine months ended September&#160;30, 2021, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sintilimab Injection</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Innovent Biologics, Inc. (Innovent) to jointly develop and commercialize sintilimab injection in China, where it is branded and trademarked as Tyvyt. In 2019, we and Innovent began co-commercializing Tyvyt in China. In 2020, we obtained an exclusive license for sintilimab injection from Innovent for geographies outside of China. Innovent, with collaboration from us, has filed the initial registration of sintilimab injection in the U.S., and we will pursue initial registration of sintilimab injection in other markets and all other subsequent registrations of sintilimab injection. We have exclusive commercialization rights outside of China.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a regulatory approval for Tyvyt in China in the second quarter of 2021, we capitalized a milestone payment of $40.0 million as an intangible asset which is being amortized to cost of sales through the term of the collaboration.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, Innovent is eligible to receive up to $825.0 million for geographies outside of China and up to $195.0 million in China in success-based regulatory and sales-based milestones. Innovent is also eligible to receive tiered double digit royalties on net sales for geographies outside of China. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our sales of Tyvyt to third parties as net product revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. We report as collaboration and other revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties. The following table summarizes our revenue recognized in China with respect to Tyvyt:</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:49.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyvyt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">340.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tanezumab</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain and cancer pain. In October 2021, we and Pfizer discontinued the global clinical development program of tanezumab for the treatment of osteoarthritis pain and cancer pain following the receipt of a Complete Response Letter from the FDA and a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lebrikizumab</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Dermira, we have a worldwide licensing agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively Roche), which provides us the global development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future global net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of September&#160;30, 2021, Roche is eligible to receive up to $180.0 million of payments from us contingent upon the achievement of success-based regulatory milestones and up to $1.03 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Dermira, we have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of September&#160;30, 2021, we are eligible to receive additional payments of $85.0 million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $1.25 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December 31, 2020, $15.3 million and $29.7 million, respectively, were recorded as contract liabilities on the consolidated condensed balance sheets and are expected to be recognized as collaboration and other revenue over the remaining Phase III development period. During the three and nine months ended September&#160;30, 2021 and 2020, milestones received and collaboration and other revenue recognized were not material. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Petra</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Petra, we are required to make milestone payments to Petra shareholders contingent upon the occurrence of certain future events linked to the success of the mutant-selective PI3K</span><span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#945;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> inhibitor. Our more significant, near term milestones include a development milestone of approximately $205&#160;million in 2022 contingent upon initiation of its Phase I trial and a further development milestone of approximately $164&#160;million in 2023 contingent upon achieving clinical proof of concept.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657080015944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Impairment, Restructuring, and Other Special Charges<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock', window );">Asset Impairment, Restructuring, and Other Special Charges</a></td>
<td class="text">Asset Impairment, Restructuring, and Other Special Charges<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below. </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:51.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment (recovery) and other special charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">200.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total asset impairment, restructuring, and other special charges</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">211.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairment, restructuring, and other special charges recognized during the nine months ended September&#160;30, 2021 were primarily related to an intangible asset impairment of $108.1&#160;million resulting from the sale of the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance costs recognized during the three and nine months ended September&#160;30, 2020 were incurred as a result of actions taken worldwide to reduce our cost structure. Substantially all of the severance costs incurred during the three and nine months ended September&#160;30, 2020 have been paid. </span></div>We recognized a net inventory impairment charge related to our COVID-19 antibodies of $435.1&#160;million during the nine months ended September 30, 2021 in cost of sales in our consolidated condensed statements of operations. As part of our response to the COVID-19 pandemic, and at the request of the U.S. and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic has continued to evolve during 2021, we incurred a net inventory impairment charge primarily due to the combination of changes to current and forecasted demand from U.S. and international governments, including changes to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657080090856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity investments are accounted for using three different methods depending on the type of equity investment:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review equity investments other than public equity investments for indications of impairment and observable price changes on a regular basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At September&#160;30, 2021, we had outstanding foreign currency forward commitments to purchase 707.3 million U.S. dollars and sell 604.5 million euro, commitments to purchase 2.54 billion euro and sell 2.98 billion U.S. dollars, commitments to purchase 151.6 million U.S. dollars and sell 980.0 million Chinese yuan, commitments to purchase 144.7 million U.S. dollars and sell 16.13 billion Japanese yen, and commitments to purchase 155.5 million British pounds and sell 212.6 million U.S. dollars, which all have settlement dates within 180 days.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes had carrying amounts of $8.08 billion and $6.02 billion as of September&#160;30, 2021 and December&#160;31, 2020, respectively, of which $5.95 billion and $4.50 billion have been designated as, and are effective as, economic hedges of net investments in certain of our foreign operations as of September&#160;30, 2021 and December&#160;31, 2020, respectively. At September&#160;30, 2021, we had outstanding cross-currency swaps with notional amounts of $2.69 billion swapping U.S. dollars to euro and $1.00 billion swapping Swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed-rate debt to foreign-denominated fixed-rate debt, have also been designated as, and are effective as, economic hedges of net investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated condensed statements of cash flows. At September&#160;30, 2021, substantially all of our total long-term debt is at a fixed rate. We have converted approximately 12 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss), and upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt. As of September&#160;30, 2021, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $1.75 billion, which have settlement dates ranging between 2023 and 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we issued euro-denominated notes consisting of &#8364;600.0&#160;million of 0.50 percent fixed-rate notes due in September 2033, with interest to be paid annually. The net proceeds from the offering will be used to fund, in whole or in part, eligible projects designed to advance one or more of our environmental, social, and governance objectives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we issued euro-denominated notes consisting of &#8364;500.0&#160;million of 1.125 percent fixed-rate notes due in September 2051 and &#8364;700.0&#160;million of 1.375 percent fixed-rate notes due in September 2061, with interest to be paid annually, and British pound-denominated notes consisting of &#163;250.0&#160;million of 1.625 percent fixed-rate notes due in September 2043, with interest to be paid annually. We paid $1.91&#160;billion of the net cash proceeds from the offering to purchase and redeem certain higher interest rate U.S. dollar-denominated notes with an aggregate principal amount of $1.50&#160;billion, resulting in a debt extinguishment loss of $405.2&#160;million. This loss was included in other-net, (income) expense in our consolidated statement of operations during the three and nine months ended September 30, 2021. The $1.50&#160;billion principal amount of higher interest rate U.S. dollar-denominated notes that were redeemed primarily included $541.8&#160;million of 3.95 percent notes due 2049, $408.7&#160;million of 4.15 percent notes due 2059, and $219.4&#160;million of 3.375 percent notes due 2029. We used the remaining net proceeds from the offering to prefund certain 2022 debt maturities and for general corporate purposes. </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Effect of Risk-Management Instruments on the Consolidated Condensed Statements of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"/><td style="width:59.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.221%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(60.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">65.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.3)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">181.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125.1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021 and 2020, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"/><td style="width:59.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.231%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.075%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.231%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">119.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">268.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">170.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the next 12&#160;months, we expect to reclassify $16.4&#160;million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other&#8211;net, (income) expense. During the three and nine months ended September&#160;30, 2021 and 2020, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize certain fair value information at September&#160;30, 2021 and December&#160;31, 2020 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:34.624%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,373.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,373.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,373.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,373.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">37.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">129.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">129.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">129.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">129.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">219.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">215.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">219.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">219.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">110.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">107.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">110.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">110.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">105.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">105.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">105.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,482.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">420.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,482.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,482.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">556.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">725.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,350.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">373.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,966.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:38.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17,085.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18,354.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18,354.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,595.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,038.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,038.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(23.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(23.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(23.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liability:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(70.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(70.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(70.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. Fair values are not readily available for certain equity investments measured under the measurement alternative. As of September 30, 2021, we had approximately $781 million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to 10 years. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liability relates to our liability arising in connection with the CVR issued as a result of the Prevail acquisition. The fair value of the CVR liability was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant's view of the expected cash payment associated with the first potential regulatory approval of a Prevail compound in the applicable countries based on probabilities of technical success, timing of the potential approval events for the compounds, and an estimated discount rate. See Note 3 for additional information related to the CVR arrangement. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of September&#160;30, 2021:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:40.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&#160;Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More&#160;Than<br/>10 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net gains (losses) recognized in our consolidated condensed statements of operations for equity securities were $(246.8)&#160;million and $270.1 million for the three and nine months ended September&#160;30, 2021, respectively, and $141.7 million and $905.1 million for the three and nine months ended September 30, 2020, respectively. The net gains/losses recognized during the three and nine months ended September&#160;30, 2021 and 2020 on equity securities sold during the respective periods were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded during the three and nine months ended September&#160;30, 2021 and 2020 were not material.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.249%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">293.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">208.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the three and nine months ended September&#160;30, 2021 and 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately 97 percent&#160;of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of September&#160;30, 2021, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:60.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">137.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable Factoring Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and, risk related to, the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $617.4 million and $754.9 million&#160;of accounts receivable as of September&#160;30, 2021 and December 31, 2020, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated condensed results of operations for the three and nine months ended September&#160;30, 2021 and 2020&#160;were&#160;not material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657080137160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was 10.9 percent for the three months ended September&#160;30, 2021, compared with 15.9 percent for the three months ended September 30, 2020. The lower effective tax rate for the three months ended September 30, 2021 was primarily due to the income tax impact of a debt extinguishment loss and unfavorable mark-to-market adjustments on investments in equity securities, partially offset by a lower net discrete tax benefit compared to the three months ended September 30, 2020. The effective tax rate was 10.7 percent for the nine months ended September&#160;30, 2021, compared with 14.4 percent for the nine months ended September 30, 2020. The lower effective tax rate for the nine months ended September 30, 2021 was primarily due to the income tax impacts of a net inventory impairment charge related to our COVID-19 antibodies and a debt extinguishment loss, as well as higher acquired IPR&amp;D charges and lower favorable mark-to-market adjustments on investments in equity securities compared to the nine months ended September 30, 2020, partially offset by a lower net discrete tax benefit compared to the nine months ended September 30, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. examination of tax years 2016-2018 began in the fourth quarter of 2019 and remains ongoing. The resolution of this audit period will likely extend beyond the next 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657080062056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Benefits</a></td>
<td class="text">Retirement Benefits<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health benefit (income) cost included the following components:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">92.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">277.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">84.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">253.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(237.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(712.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(671.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">121.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">366.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">188.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.578%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit income:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(109.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(14.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(44.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit income</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(30.1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(90.5)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657080129624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the final outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated condensed balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently and previously marketed products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Alimta Patent Litigation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alimta (pemetrexed) is protected by a vitamin regimen patent until November 2021, plus pediatric exclusivity through May 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we settled a lawsuit we filed against Eagle Pharmaceuticals, Inc. (Eagle) in response to its application to market a product using an alternative form of pemetrexed. Per the settlement agreement, Eagle has a limited initial entry into the market with its product starting February 2022 (up to an approximate three-week supply) and subsequent unlimited entry starting April 2022.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Litigation</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was protected by the vitamin regimen patent through June 2021. Despite the recent patent expiration, a number of legal proceedings that were initiated prior to expiration are ongoing</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Emgality Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, we were</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> named as a defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA, Inc. (collectively, Teva) in the U.S. District Court for the District of Massachusetts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">seeking a ruling that various claims in nine different Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in adults. Trial is expected in March 2022. In June 2021, we were named as a defendant in a second litigation filed by Teva in the U.S. District Court for the District of Massachusetts seeking a ruling that two of Teva&#8217;s patents, which are directed toward use of the active ingredient in Emgality to treat migraine, would be infringed by our continued sales of Emgality.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, the U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) granted our request to initiate an&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes review</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(IPR) to reexamine the validity of the nine Teva patents asserted against us in the litigation. In February 2020, the PTAB ruled in our favor and found that the claims asserted against us in six of Teva's nine patents were invalid. In March 2020, the PTAB ruled against us on the remaining three Teva patents, finding that we failed to show that the remaining three patents were unpatentable based on the subset of invalidity arguments available in an IPR proceeding. In April 2020, we appealed the PTAB&#8217;s March 2020 ruling, and Teva appealed the PTAB&#8217;s February 2020 ruling to the U.S. Court of Appeals for the Federal Circuit. In August 2021, the appeals court affirmed all nine of the PTAB's decisions. Neither Lilly nor Teva appealed the rulings and accordingly those decisions are final, and the parties have agreed to a stipulation which removes the six invalidated patents from the district court litigation. This IPR matter is now closed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Jardiance Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, Boehringer Ingelheim (BI), our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court of Delaware alleging infringement arising from submissions of Abbreviated New Drug Applications (ANDA) by a number of generic companies seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, the generic companies' ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. This litigation has been stayed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Taltz Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we petitioned the High Court of Ireland to declare invalid the patent that Novartis Pharma AG (Novartis) purchased from Genentech, Inc. in 2020. Novartis responded by filing a claim against us alleging patent infringement related to our commercialization of Taltz and seeking damages for past infringement and an injunction against future infringement. This matter is ongoing. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021 and June 2021, Novartis petitioned the Court of Rome Intellectual Property Division and the Commercial Court of Vienna, respectively, in preliminary injunction infringement proceedings against us related to our commercialization of Taltz. In June 2021, the Court of Rome Intellectual Property Division dismissed Novartis&#8217; preliminary injunction action. Novartis has appealed the ruling and in October 2021 the panel hearing Novartis' appeal appointed a technical expert to assess the merits of the case. Both matters are ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Zyprexa Canada Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the mid-2000&#8217;s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012, the Canadian Federal Court of Appeals denied our appeal of a lower court's decision that certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trade-Mark Act, and common law. In March 2021, the Ontario Superior Court granted our motion for summary judgement, thereby dismissing Apotex&#8217;s case. Apotex appealed that ruling to the Court of Appeal for Ontario in April 2021 and a hearing is scheduled for February 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Actos&#174;  Product Liability</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named along with Takeda Chemical Industries, Ltd. and Takeda affiliates (collectively, Takeda) as a defendant in four purported product liability class actions in Canada related to Actos, which we commercialized with Takeda in Canada until 2009, including one in Ontario filed December 2011 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), one in Quebec filed July 2012 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Whyte et al. v. Eli Lilly et al.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), one in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Saskatchewan filed November 2017 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Weiler v. Takeda Canada Inc. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and one in Alberta filed January 2013 (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Epp v. Takeda Canada Inc. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In general, plaintiffs in these actions alleged that Actos caused or contributed to their bladder cancer. An agreement to settle these actions became effective in May 2021, and the settlement claims administration process is ongoing. The lawsuits have been dismissed or discontinued.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Byetta&#174; Product Liability</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in approximately 570 Byetta product liability lawsuits in the U.S. which were initiated in March 2009 and involve approximately 805 plaintiffs. Approximately 55 of these lawsuits, covering about 285 plaintiffs, are filed in California state court and coordinated in a Los Angeles Superior Court. Approximately 515 of the lawsuits, covering about 515 plaintiffs, are filed in federal court, the majority of which are coordinated in a multi-district litigation (MDL) in the U.S. District Court for the Southern District of California. Two lawsuits, representing approximately two plaintiffs, have also been filed in various state courts. Approximately 565 of the lawsuits, involving approximately 800 plaintiffs, contain allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer); while six plaintiffs allege Byetta caused or contributed to pancreatitis. In addition, one case alleges that Byetta caused or contributed to ampullary cancer. The federal and state trial courts granted summary judgment in favor of us and our co-defendants on the claims alleging pancreatic cancer. The plaintiffs appealed those rulings. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the U.S. Court of Appeals for the Ninth Circuit reversed the U.S. District Court for the Southern District of California's grant of summary judgment in the MDL based on that court's discovery rulings and remanded the cases back to the U.S. District Court for further proceedings. In March 2021, the U.S. District Court granted summary judgment for the defendants. In April 2021, the plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Ninth Circuit, but we have now been dismissed from that appeal. Certain plaintiffs have agreed to dismiss their lawsuits in exchange for a waiver of costs, and individual plaintiffs have begun dismissing their claims based upon this agreement. Approximately 160 of the MDL pancreatic lawsuits have been dismissed as of October 2021. In the state court actions, in November 2018, the California Court of Appeal reversed the Los Angeles County Superior Court of California&#8217;s grant of summary judgment based on that court's discovery rulings and remanded for further proceedings. In April 2021, the Los Angeles County Superior Court of California granted summary judgment for the defendants and the parties await entry of the order of judgment.   </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of approximately 20 additional claimants who have not yet filed suit. These additional claims allege damages for pancreatic cancer or thyroid cancer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cialis Product Liability</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in approximately 350 Cialis product liability lawsuits in the U.S. which were first initiated in August 2015. These cases, many of which were originally filed in various federal courts, contain allegations that Cialis caused or contributed to the plaintiffs' cancer (melanoma). In December 2016, the Judicial Panel on Multidistrict Litigation (JPML) granted the plaintiffs' petition to have filed cases and an unspecified number of future cases coordinated into a federal multidistrict litigation (MDL) in the U.S. District Court for the Northern District of California, alongside an existing coordinated proceeding involving Viagra&#174;. The JPML ordered the transfer of the existing cases to the now-renamed MDL </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In April 2020, the MDL court granted summary judgment to the defendants on all of the claims brought against them by the plaintiffs. In May 2020, plaintiffs filed an appeal in the U.S. Court of Appeals for the Ninth Circuit. The plaintiffs&#8217; appeal was administratively closed until August 2021 pending completion of a procedure to resolve the claims in this litigation. The court has entered an extension until February 2022 to finalize resolution of all claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Jardiance Product Liability </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in January 2019, we and Boehringer Ingelheim Pharmaceuticals, Inc., a subsidiary of BI, have been named as a defendant in approximately 95 product liability lawsuits in the U.S., mostly in Stamford Superior Court in Connecticut, alleging that Jardiance caused or contributed to plaintiffs&#8217; Fournier&#8217;s gangrene.  Our agreement with BI calls for BI to defend and indemnify us against any damages, costs, expenses, and certain other losses with respect to product liability claims in accordance with the terms of the agreement. All pending cases have been paused to allow for settlement negotiations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Proceedings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than 10 sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">340B Litigation and Investigations</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges the HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies. We seek a declaratory judgment that the defendants violated the Administrative Procedures Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. In March 2021, the court entered an order preliminarily enjoining the government&#8217;s enforcement of the administrative dispute resolution process against us. In May 2021, HRSA notified us that it determined that our  policy was contrary to the 340B statute. In response, in May 2021, we filed a motion for preliminary injunction and temporary restraining order requesting that the U.S. District Court for the Southern District of Indiana enjoin defendants from taking any action against us relating to the 340B drug pricing program until after the court issues a final judgment on the aforementioned litigation. In May 2021, the court denied our motion for a temporary restraining order but deferred resolution of our motion for preliminary injunction. In June 2021, the defendants withdrew the HHS December 30, 2020 advisory opinion. In July 2021, the court held oral argument on the parties&#8217; cross motions for summary judgment, the defendants&#8217; motion to dismiss, and our motion for preliminary injunction related to HRSA&#8217;s May 2021 enforcement letter. This matter is ongoing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administrative Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program. As described above, the U.S. District Court for the Southern District of Indiana has entered a preliminary injunction enjoining the government&#8217;s enforcement of this administrative dispute resolution process against us.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we, along with Sanofi-Aventis U.S., LLC (Sanofi), Novo Nordisk Inc. (Novo Nordisk), and AstraZeneca Pharmaceuticals LP, were named as a defendant in a purported class action lawsuit filed in the U.S. District Court for the Western District of New York by Mosaic Health, Inc. alleging antitrust and unjust enrichment claims related to the defendants' 340B distribution programs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a civil investigative subpoena in February 2021 from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program. We are cooperating with this subpoena. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Branchburg Manufacturing Facility </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received a subpoena from the United States Department of Justice requesting the production of certain documents relating to our manufacturing site in Branchburg, New Jersey. We are cooperating with the subpoena.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Brazil Litigation &#8211; Cosmopolis Facility </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Labor Attorney Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a lawsuit brought by the Labor Attorney for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the labor court judge ruled against Lilly Brasil, ordering it to undertake several actions of unspecified financial impact, including paying lifetime health coverage for the employees and contractors who worked at the Cosmopolis facility more than six months during the affected years and their children born during and after this period. We appealed this decision. In July 2018, the appeals court affirmed the labor court's ruling with a liquidated award of&#160;300&#160;million&#160;Brazilian real (for moral damages, donation of equipment, and creation of a foundation) which, adjusted for inflation and interest using the current Central Bank of Brazil's special system of clearance and custody rate (SELIC), is approximately 950&#160;million Brazilian real (approximately $175&#160;million as of September 30, 2021). The appeals court restricted the broad health coverage awarded by the labor court to health problems that claimants could show arose from exposure to the alleged contamination. In August 2019, Lilly Brasil filed an appeal to the superior labor court. In September 2019, the appeals court stayed a number of elements of its prior decision, including the obligation to provide health coverage for contractors, their children, and children of employees who worked at the Cosmopolis facility, pending the determination of Lilly Brasil&#8217;s appeal to the superior labor court. The cost of any such health coverage has not been determined. In June 2021, the appeals court published its decision on the admissibility of Lilly Brasil&#8217;s appeal, admitting the majority of the elements of the appeal to proceed; elements not proceeding are subject to an interlocutory appeal to the appeals court filed in June 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Labor Attorney filed an application in the labor court for enforcement of the healthcare coverage granted by the appeals court in its July 2018 ruling and requested restrictions on Lilly Brasil&#8217;s assets in Brazil. In July 2019, the labor court issued a ruling requiring either a freeze of Lilly Brasil&#8217;s immovable property or, alternatively, a security deposit or lien of 500 million Brazilian real. Lilly Brasil filed a writ of mandamus challenging this ruling</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> but the court has stayed its decision on this writ and instead directed the parties to attend conciliation hearings, a process that concluded unsuccessfully in September 2020. Consequently, the partial stay of the proceedings relating to Lilly Brasil's application to appeal in the main proceedings has been lifted and in June 2021, the court reduced the security deposit or lien to 100&#160;million Brazilian real from the 500&#160;million Brazilian real referred to above</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Labor Attorney's application for preliminary enforcement of the July 2018 healthcare coverage ruling was granted. As the conciliation hearings have been unsuccessful, we have filed a brief to strike the Labor Attorney&#8217;s application to enforce the previous healthcare coverage. Lilly Brasil is currently awaiting a determination as to whether its application seeking leave to appeal to the superior labor court has been successful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Individual Former Employee Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also named in approximately 30&#160;lawsuits filed in the same labor court by individual former employees making similar claims. These lawsuits are each at various stages in the litigation process, with judgments being handed down in approximately half of the lawsuits, nearly all of which are on appeal in the labor courts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">China NDRC Antitrust Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The competition authority in China has investigated our distributor pricing practices in China in connection with a broader inquiry into pharmaceutical industry pricing. We have cooperated with this investigation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Eastern District of Pennsylvania Pricing (Average Manufacturer Price) Inquiry</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2014, we, along with another pharmaceutical manufacturer, were named as co-defendants in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. Trial is scheduled for April 2022.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Health Choice Alliance </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are named as a defendant in a lawsuit filed in June 2017 in the U.S. District Court for the Eastern District of Texas seeking damages under the federal anti-kickback statute and state and federal false claims acts for certain patient support programs related to our products Humalog, Humulin, and Forteo. In September 2019, the U.S. District Court granted the U.S. Department of Justice&#8217;s motion to dismiss the relator&#8217;s second amended complaint. In January 2020, the relator appealed the District Court&#8217;s dismissal to the U.S. Court of Appeals for the Fifth Circuit. In July 2021, the U.S. Court of Appeals for the Fifth Circuit affirmed the dismissal of the lawsuit.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also named as a defendant in two similar lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively. In November 2020, the Texas state court action was stayed pending a final determination with respect to the aforementioned federal lawsuit. In April 2021, the New Jersey state court action was dismissed with prejudice and in June 2021, the relator filed a notice of appeal to the Appellate Division of the New Jersey Superior Court, appealing the state court&#8217;s decision.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pricing Litigation, Investigations, and Inquiries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we, along with Sanofi and Novo Nordisk were named as defendants in a consolidated purported class action lawsuit,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re. Insulin Pricing Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the U.S. District Court for the District of New Jersey relating to insulin pricing seeking damages under various state consumer protection laws and the Federal Racketeer Influenced and Corrupt Organization Act (federal RICO Act). Separately, in February 2018, we, along with Sanofi and Novo Nordisk, were named as defendants in&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the same court, seeking damages under various state consumer protection laws, common law fraud, unjust enrichment, and the federal RICO Act. In both</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re. Insulin Pricing Litigation </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> MSP Recovery Claims</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> litigation, the court dismissed claims under the federal RICO Act and certain state laws. In April 2021, the plaintiffs in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re. Insulin Pricing Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> amended their complaint to allege additional state law claims for civil conspiracy and violations of state RICO statutes.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, we, along with Sanofi, Novo Nordisk, CVS, Express Scripts, and Optum, have been sued in a purported class action, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al., </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filed in the same court in November 2020, for alleged violations of the federal RICO Act as well as the New Jersey RICO Act and antitrust law. That same group of defendants, along with Medco Health and United Health Group, also have been sued in other purported class actions in the same court, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Value Drug Co. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">both initiated in March 2020, for alleged violations of the federal RICO Act. In September 2020, the U.S. District Court for the District of New Jersey granted plaintiffs&#8217; motion to consolidate </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FWK Holdings, LLC v. Novo Nordisk Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rochester Drug Co-Operative Inc. v. Eli Lilly &amp; Co. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Value Drug Co. v. Eli Lilly &amp; Co. et al. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the U.S. District Court for the District of New Jersey dismissed the three antitrust claims alleged by plaintiffs in the consolidated litigation and denied dismissal of the RICO claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Minnesota Attorney General&#8217;s Office initiated litigation against us, Sanofi, and Novo Nordisk,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of Minnesota v. Sanofi-Aventis U.S. LLC et al.,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the U.S. District Court for the District of New Jersey, alleging unjust enrichment, violations of various Minnesota state consumer protection laws, and the federal RICO Act. In March 2021, the U.S. District Court for the District of New Jersey dismissed with prejudice the Minnesota Attorney General&#8217;s federal RICO claims and false advertising claims under state law; the consumer fraud and other related state law claims remain ongoing. Additionally, in May 2019, the Kentucky Attorney General&#8217;s Office filed a complaint against us, Sanofi, and Novo Nordisk,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commonwealth of Kentucky v. Novo Nordisk, Inc. et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Kentucky state court, alleging violations of the Kentucky consumer protection law, false advertising, and unjust enrichment. In November 2019, Harris County in Texas initiated litigation against us, Sanofi, Novo Nordisk, Express Scripts, CVS, Optum, and Aetna, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">County of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Harris Texas v. Eli Lilly &amp; Co., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in federal court in the Southern District of Texas alleging violations of the federal RICO Act, the state deceptive trade practices-consumer protection act, and common law claims such as fraud, unjust enrichment, and civil conspiracy. Harris County also alleged violations of federal and state antitrust law, but voluntarily dismissed them. This lawsuit relates to our insulin products as well as Trulicity. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the City of Miami, Florida initiated litigation against us, Sanofi, Novo Nordisk, ESI, CVS/Caremark/Aetna, and Optum, asserting state law antitrust, common law fraud, money had and received, unjust enrichment, and civil conspiracy claims. In June 2021, the Mississippi Attorney General&#8217;s Office initiated litigation against us, Sanofi, Novo Nordisk, Evernorth/ESI, CVS/Caremark, and United/Optum in the Hinds County, Mississippi Chancery Court, alleging state law consumer protection, unjust enrichment, and civil conspiracy claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigations, Subpoenas, and Inquiries</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a subpoena from the New York a</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd Vermont Attorney General Offices and civil investigative demands from the Washington, New Mexico, and Colorado Attorney General Offices relating to the pricing and sale of our insulin products. The Offices of the Attorney General in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada have requested information relating to the pricing and sale of our insulin products. We also received interrogatories and a subpoena from the California Attorney General's Office regarding our competition in the long-acting insulin market, which was subsequently withdrawn in June 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a&#8239;request in January 2019 from the House of Representatives&#8217; Committee on Oversight and Reform seeking commercial information and business records related to the pricing of insulin products, among other issues. We also received requests from the Senate Finance Committee and the Senate Committee on Health, Education, Labor, and Pensions, and separate requests from the House Committee on Energy and Commerce majority and minority members.&#8239; Those requests sought pricing and other commercial information regarding Lilly&#8217;s insulin products. In January 2021, the Senate Finance Committee released a report summarizing the findings of its investigation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are cooperating with all of these aforementioned investigations, subpoenas, and inquiries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Research Corporation Technologies, Inc. </span></div>In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657181096584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text">Other Comprehensive Income (Loss)<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended September&#160;30, 2021 and 2020:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at July 1, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,516.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,569.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(210.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,287.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">104.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">114.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,524.2)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,465.3)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(190.0)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,172.7)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at July 1, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,722.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,454.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(520.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,682.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,692.2)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,444.2)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(434.4)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,555.1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the activity related to each component of other comprehensive income (loss) during the nine months ended September&#160;30, 2021 and 2020: </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:37.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.610%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,427.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,751.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(332.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,496.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(96.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">132.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">258.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(96.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">285.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">142.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">323.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,524.2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,465.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(190.0)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,172.7)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"><tr><td style="width:1.0%"/><td style="width:38.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.457%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,678.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,638.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,523.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,692.2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,444.2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(434.4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,555.1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense) </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(39.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(92.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized net gains/losses on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(28.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(79.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(37.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(71.8)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(206.1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 6), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated condensed statements of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-bottom:1pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.304%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.532%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other Comprehensive Loss Components</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Condensed Statements of Operations</span></td></tr><tr style="height:11pt"><td colspan="30" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(41.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">122.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">368.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">327.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(22.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(68.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">258.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657081439480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other&#8211;Net, (Income) Expense<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other&#8211;Net, (Income) Expense</a></td>
<td class="text">Other&#8211;Net, (Income) Expense<div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense consisted of the following:</span></div><div style="margin-bottom:7pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.116%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">258.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment (gains) losses on equity securities (Note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(270.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(905.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(72.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(217.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment loss (Note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">405.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">405.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(34.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">635.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158.9)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">124.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(694.9)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI http://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI http://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657080016536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text">Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated condensed financial statements from the date of acquisition.Upon each acquisition, the cost allocated to acquired in-process research and development (IPR&amp;D) was immediately expensed because the compound had no alternative future use.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Description of Derivative Risk Management</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.</span></div>We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other&#8211;net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657079775896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of disaggregation of revenue</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue recognized in our consolidated condensed statements of operations:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,189.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,281.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,579.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,762.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other revenue </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">583.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,739.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,772.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,740.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,318.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,099.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration and other revenue associated with prior period transfers of intellectual property was $62.1 million and $136.1 million during the three and nine months ended September&#160;30, 2021, respectively, and $31.5 million and $101.5 million during the three and nine months ended September 30, 2020, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product for the three months ended September 30, 2021 and 2020:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,201.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">398.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,600.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">347.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">279.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">626.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">221.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">169.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">390.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">193.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">114.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">78.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">192.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">65.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">177.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Diabetes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,143.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,131.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,274.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,798.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,783.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">297.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">457.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">135.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">335.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">84.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">168.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">253.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">114.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Oncology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">65.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Oncology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">730.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">675.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,406.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">422.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">170.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">593.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; (3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">194.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">212.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">406.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Immunology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Immunology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">616.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">388.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,004.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">99.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">140.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">132.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Neuroscience</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">144.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">305.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">450.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 Antibodies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">215.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">217.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">91.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">200.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">137.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">130.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">354.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">282.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">637.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,989.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,783.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,772.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,161.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,579.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,740.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and Trijardy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> XR.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)   </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to Emergency Use Authorization (EUA).</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by product for the nine months ended September 30, 2021 and 2020:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.298%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outside U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trulicity</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,465.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,122.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,588.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,565.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humalog</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,009.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">842.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,851.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,907.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jardiance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">566.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,058.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Humulin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">633.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">290.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">923.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">423.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">226.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">650.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Diabetes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">185.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">302.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">488.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Diabetes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,284.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,276.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,560.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,663.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,868.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,530.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Alimta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">911.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">714.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,626.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Verzenio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">582.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">363.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">945.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cyramza</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">266.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">496.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">762.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Erbitux</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">357.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">403.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tyvyt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">340.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">340.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Oncology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">169.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">253.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Oncology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,201.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,130.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,332.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,780.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,803.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Taltz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,071.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">493.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,565.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Olumiant </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">236.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">572.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">809.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Immunology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Immunology</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,323.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,080.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,404.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,761.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroscience:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cymbalta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">454.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">484.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emgality</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">313.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">415.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zyprexa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">264.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">292.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Neuroscience</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">154.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">235.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Neuroscience</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">453.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">974.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,427.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,356.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">COVID-19 Antibodies </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">949.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">226.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,176.2</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Forteo</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">330.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">287.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">617.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cialis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">541.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">538.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">164.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">260.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,373.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,220.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,593.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,647.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,635.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,683.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,318.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,631.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,468.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,099.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Humalog revenue includes insulin lispro.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jardiance revenue includes Glyxambi,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Synjardy, and Trijardy XR.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to EUA.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue by geographical area:</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:51.159%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.948%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.101%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#8212;to unaffiliated customers </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,989.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,161.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,635.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,631.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,098.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,629.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,984.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">595.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,832.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,919.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">400.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,285.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other foreign countries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">689.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,936.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,768.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,772.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,740.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,318.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,099.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue is attributed to the countries based on the location of the customer.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of amounts recorded for contract liabilities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract liability balances:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">278.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657081336312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of the amounts recognized for assets acquired and liabilities assumed</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at January 22, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition date fair value of consideration transferred </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Fair value of CVR liability</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired IPR&amp;D intangibles primarily relate to PR001.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is not deductible for tax purposes. </span></div>(3) See Note 6 for a discussion on the estimation of the CVR liability.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock', window );">Schedule of asset acquisitions</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our asset acquisitions during the nine months ended September&#160;30, 2021 and 2020:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Counterparty</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compound(s) or Therapy</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Month</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase of Development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired IPR&amp;D Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precision Biosciences, Inc. </span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential in vivo therapies for genetic disorders</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merus N.V. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CD3-engaging T-cell re-directing bispecific antibodies for the potential treatment of cancer</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asahi Kasei Pharma Corporation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AK1780, an orally bioavailable P2X7 receptor antagonist for the potential treatment of chronic pain conditions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rigel Pharmaceuticals, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase I</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiNA Therapeutics Limited</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Protomer Technologies Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glucose-sensing insulin program</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kumquat Biosciences Inc. </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical small molecules that stimulate tumor-specific immune responses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">55.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lycia Therapeutics, Inc. </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Several potential modalities across a spectrum of therapeutic areas and diseases</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ProQR Therapeutics N.V.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for genetic disorders in the liver and nervous system</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26.7</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sitryx Therapeutics Limited</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets that could lead to potential new medicines for autoimmune diseases</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbCellera Biologics Inc. (AbCellera)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neutralizing antibodies for the treatment and prevention of COVID-19</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Petra Pharma Corporation (Petra)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutant-selective PI3K</span><span style="color:#000000;font-family:'Book Antiqua',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#945;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> inhibitor that could lead to potential new medicine </span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evox Therapeutics Limited</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical targets for the potential treatment of neurological disorders</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2020</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable. </span></div>(2) We recognized an acquired IPR&amp;D expense of $25.0 million in May 2020 upon closing of the transaction.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657079809640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of significant milestones and revenue recognized</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the net amount of significant milestones capitalized (deferred) at September 30, 2021 and December 31, 2020 for the compounds included in this collaboration: </span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Milestones Capitalized (Deferred) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as of:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Family</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">141.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">95.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(154.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In  connection with the regulatory approvals of Jardiance and Trajenta, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. In connection with the regulatory approvals of Basaglar, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and our net product revenue recognized with respect to Basaglar:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.015%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product Family</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jardiance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">390.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,058.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basaglar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">192.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">650.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trajenta</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">279.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The following table summarizes our net product revenue recognized with respect to Olumiant:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:49.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.690%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olumiant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">406.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">809.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The following table summarizes our revenue recognized in China with respect to Tyvyt:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:49.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyvyt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">125.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">340.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657181060344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Impairment, Restructuring, and Other Special Charges (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">The components of the charges included in asset impairment, restructuring, and other special charges</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below. </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:51.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment (recovery) and other special charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">200.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total asset impairment, restructuring, and other special charges</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">211.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657082182920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of effects of risk-management instruments were recognized in other&#8211;net, (income) expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following effects of risk-management instruments were recognized in other&#8211;net, (income) expense:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"/><td style="width:59.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.221%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from hedged fixed-rate debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(60.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect from interest rate contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swaps</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">110.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">65.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.3)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">181.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125.1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"/><td style="width:59.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.231%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.075%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.231%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">119.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">268.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">170.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"/><td style="width:59.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.231%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.075%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.231%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign currency-denominated notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">119.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">268.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">170.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Forward-starting interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Cross-currency interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary certain fair value information, assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize certain fair value information at September&#160;30, 2021 and December&#160;31, 2020 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:34.624%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,373.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,373.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,373.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,373.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">37.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">129.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">129.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">129.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">129.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">219.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">215.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">219.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">219.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">110.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">107.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">110.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">110.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">105.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">105.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">105.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,482.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">420.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,482.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,482.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">556.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">725.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,350.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,097.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments without readily determinable fair values </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">373.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent investments</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,966.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Summary certain fair value information, liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:38.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17,085.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18,354.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18,354.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,595.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,038.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,038.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair value, by balance sheet grouping</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(23.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(23.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(23.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liability:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(70.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(70.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(70.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-management instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as fair value hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as net investment hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate contracts designated as cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary the contractual maturities of our investments in debt securities measured at fair value</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of September&#160;30, 2021:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:40.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturities by Period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&#160;Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-5<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6-10<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More&#160;Than<br/>10 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Summary of the fair value of available-for-sale securities in an unrealized gain or loss position</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.249%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross gains</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gross losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized gain position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">293.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of securities in an unrealized loss position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">208.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Activity related to our available-for-sale securities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to our available-for-sale securities was as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:60.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">137.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross gains on sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized gross losses on sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657081549256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Schedule of net pension and retiree health benefit (income) cost</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension and retiree health benefit (income) cost included the following components:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">92.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">277.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">84.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">253.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(237.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(712.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(671.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">121.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">366.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">188.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.578%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retiree Health Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of net periodic benefit income:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(109.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(14.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(44.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit income</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(30.1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(90.5)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657078108328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of components of other comprehensive income (loss)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended September&#160;30, 2021 and 2020:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at July 1, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,516.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,569.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(210.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,287.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">104.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">114.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,524.2)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,465.3)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(190.0)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,172.7)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at July 1, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,722.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,454.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(520.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,682.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,692.2)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,444.2)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(434.4)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,555.1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the activity related to each component of other comprehensive income (loss) during the nine months ended September&#160;30, 2021 and 2020: </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:37.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.610%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,427.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,751.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(332.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,496.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(96.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">132.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">258.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(96.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">285.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">142.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">323.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,524.2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,465.3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(190.0)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,172.7)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"><tr><td style="width:1.0%"/><td style="width:38.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.457%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts presented net of taxes)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Gains&#160;(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized Net Gains (Losses) on&#160;Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Portion of Cash&#160;Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,678.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,638.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,523.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net other comprehensive income (loss)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,692.2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,444.2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(434.4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,555.1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax benefit (expense) </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains/losses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(39.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(92.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized net gains/losses on securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and retiree health benefit plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(28.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(79.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective portion of cash flow hedges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(37.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) for income taxes allocated to other comprehensive income (loss) items</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(71.8)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(206.1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Schedule of reclassifications out of accumulated other comprehensive loss</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassifications out of accumulated other comprehensive loss were as follows:</span></div><div style="margin-bottom:1pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.304%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.532%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Details about Accumulated Other Comprehensive Loss Components</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Affected Line Item in the Consolidated Condensed Statements of Operations</span></td></tr><tr style="height:11pt"><td colspan="30" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of retirement benefit items:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service benefits, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(41.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial losses, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">122.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">368.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">327.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(22.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(68.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">86.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">258.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net of tax</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657081451752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other&#8211;Net, (Income) Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of other&#8211;net, (income) expense</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other&#8211;net, (income) expense consisted of the following:</span></div><div style="margin-bottom:7pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.116%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">258.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment (gains) losses on equity securities (Note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">246.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(270.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(905.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement benefit plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(72.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(217.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment loss (Note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">405.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">405.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(34.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#8211;net, (income) expense</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">635.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158.9)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">124.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(694.9)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657082258408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Summary of Revenue Recognized) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 6,772.8<span></span>
</td>
<td class="nump">$ 5,740.6<span></span>
</td>
<td class="nump">$ 20,318.5<span></span>
</td>
<td class="nump">$ 17,099.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">6,189.0<span></span>
</td>
<td class="nump">5,281.1<span></span>
</td>
<td class="nump">18,579.5<span></span>
</td>
<td class="nump">15,762.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CollaborationandOtherRevenueMember', window );">Collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">583.8<span></span>
</td>
<td class="nump">459.5<span></span>
</td>
<td class="nump">1,739.0<span></span>
</td>
<td class="nump">1,337.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Collaboration and other revenue associated with prior period transfers of intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 62.1<span></span>
</td>
<td class="nump">$ 31.5<span></span>
</td>
<td class="nump">$ 136.1<span></span>
</td>
<td class="nump">$ 101.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CollaborationandOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CollaborationandOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657077562264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Adjustments to Revenue) (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Sales returns, rebates, and discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent', window );">Revenue, information used to determine revenue recognized, change in accounting estimate, percent (less than - 2021)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657079775896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue (Contract Liabilities) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">$ 278.4<span></span>
</td>
<td class="nump">$ 276.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657085525496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Disaggregation of Revenue by Product) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 6,772.8<span></span>
</td>
<td class="nump">$ 5,740.6<span></span>
</td>
<td class="nump">$ 20,318.5<span></span>
</td>
<td class="nump">$ 17,099.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">3,989.6<span></span>
</td>
<td class="nump">3,161.4<span></span>
</td>
<td class="nump">11,635.1<span></span>
</td>
<td class="nump">9,631.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">2,783.3<span></span>
</td>
<td class="nump">2,579.3<span></span>
</td>
<td class="nump">8,683.4<span></span>
</td>
<td class="nump">7,468.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_DiabetesMember', window );">Diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">3,274.1<span></span>
</td>
<td class="nump">2,783.0<span></span>
</td>
<td class="nump">9,560.6<span></span>
</td>
<td class="nump">8,530.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_DiabetesMember', window );">Diabetes | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">2,143.0<span></span>
</td>
<td class="nump">1,798.5<span></span>
</td>
<td class="nump">6,284.0<span></span>
</td>
<td class="nump">5,663.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_DiabetesMember', window );">Diabetes | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,131.1<span></span>
</td>
<td class="nump">984.5<span></span>
</td>
<td class="nump">3,276.6<span></span>
</td>
<td class="nump">2,868.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrulicityMemberMember', window );">Trulicity&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,600.1<span></span>
</td>
<td class="nump">1,106.6<span></span>
</td>
<td class="nump">4,588.2<span></span>
</td>
<td class="nump">3,565.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrulicityMemberMember', window );">Trulicity&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,201.4<span></span>
</td>
<td class="nump">791.2<span></span>
</td>
<td class="nump">3,465.7<span></span>
</td>
<td class="nump">2,673.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrulicityMemberMember', window );">Trulicity&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">398.8<span></span>
</td>
<td class="nump">315.4<span></span>
</td>
<td class="nump">1,122.5<span></span>
</td>
<td class="nump">892.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogMember', window );">Humalog&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">626.7<span></span>
</td>
<td class="nump">656.9<span></span>
</td>
<td class="nump">1,851.3<span></span>
</td>
<td class="nump">1,907.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogMember', window );">Humalog&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">347.3<span></span>
</td>
<td class="nump">390.1<span></span>
</td>
<td class="nump">1,009.0<span></span>
</td>
<td class="nump">1,070.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogMember', window );">Humalog&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">279.4<span></span>
</td>
<td class="nump">266.9<span></span>
</td>
<td class="nump">842.3<span></span>
</td>
<td class="nump">837.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">390.4<span></span>
</td>
<td class="nump">310.8<span></span>
</td>
<td class="nump">1,058.9<span></span>
</td>
<td class="nump">840.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">221.2<span></span>
</td>
<td class="nump">163.3<span></span>
</td>
<td class="nump">566.8<span></span>
</td>
<td class="nump">453.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">169.2<span></span>
</td>
<td class="nump">147.5<span></span>
</td>
<td class="nump">492.1<span></span>
</td>
<td class="nump">387.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumulinMember', window );">Humulin&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">286.7<span></span>
</td>
<td class="nump">305.9<span></span>
</td>
<td class="nump">923.8<span></span>
</td>
<td class="nump">935.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumulinMember', window );">Humulin&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">193.4<span></span>
</td>
<td class="nump">214.0<span></span>
</td>
<td class="nump">633.5<span></span>
</td>
<td class="nump">642.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumulinMember', window );">Humulin&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">93.4<span></span>
</td>
<td class="nump">91.9<span></span>
</td>
<td class="nump">290.3<span></span>
</td>
<td class="nump">292.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">192.8<span></span>
</td>
<td class="nump">248.2<span></span>
</td>
<td class="nump">650.1<span></span>
</td>
<td class="nump">842.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">114.7<span></span>
</td>
<td class="nump">178.5<span></span>
</td>
<td class="nump">423.3<span></span>
</td>
<td class="nump">638.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">78.1<span></span>
</td>
<td class="nump">69.7<span></span>
</td>
<td class="nump">226.8<span></span>
</td>
<td class="nump">203.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember', window );">Other Diabetes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">177.4<span></span>
</td>
<td class="nump">154.6<span></span>
</td>
<td class="nump">488.3<span></span>
</td>
<td class="nump">439.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember', window );">Other Diabetes | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">65.0<span></span>
</td>
<td class="nump">61.4<span></span>
</td>
<td class="nump">185.7<span></span>
</td>
<td class="nump">185.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember', window );">Other Diabetes | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">112.2<span></span>
</td>
<td class="nump">93.1<span></span>
</td>
<td class="nump">302.6<span></span>
</td>
<td class="nump">254.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OncologyMember', window );">Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,406.1<span></span>
</td>
<td class="nump">1,333.4<span></span>
</td>
<td class="nump">4,332.4<span></span>
</td>
<td class="nump">3,803.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OncologyMember', window );">Oncology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">730.9<span></span>
</td>
<td class="nump">682.5<span></span>
</td>
<td class="nump">2,201.7<span></span>
</td>
<td class="nump">2,023.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OncologyMember', window );">Oncology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">675.3<span></span>
</td>
<td class="nump">650.9<span></span>
</td>
<td class="nump">2,130.7<span></span>
</td>
<td class="nump">1,780.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_AlimtaMember', window );">Alimta&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">457.0<span></span>
</td>
<td class="nump">578.0<span></span>
</td>
<td class="nump">1,626.6<span></span>
</td>
<td class="nump">1,677.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_AlimtaMember', window );">Alimta&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">297.2<span></span>
</td>
<td class="nump">291.9<span></span>
</td>
<td class="nump">911.9<span></span>
</td>
<td class="nump">933.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_AlimtaMember', window );">Alimta&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">159.8<span></span>
</td>
<td class="nump">286.1<span></span>
</td>
<td class="nump">714.7<span></span>
</td>
<td class="nump">743.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_VerzenioMember', window );">Verzenio&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">335.5<span></span>
</td>
<td class="nump">234.4<span></span>
</td>
<td class="nump">945.8<span></span>
</td>
<td class="nump">631.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_VerzenioMember', window );">Verzenio&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">199.6<span></span>
</td>
<td class="nump">158.9<span></span>
</td>
<td class="nump">582.1<span></span>
</td>
<td class="nump">430.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_VerzenioMember', window );">Verzenio&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">135.9<span></span>
</td>
<td class="nump">75.5<span></span>
</td>
<td class="nump">363.7<span></span>
</td>
<td class="nump">201.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CyramzaMember', window );">Cyramza&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">253.4<span></span>
</td>
<td class="nump">252.7<span></span>
</td>
<td class="nump">762.5<span></span>
</td>
<td class="nump">748.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CyramzaMember', window );">Cyramza&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">84.8<span></span>
</td>
<td class="nump">94.5<span></span>
</td>
<td class="nump">266.3<span></span>
</td>
<td class="nump">277.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CyramzaMember', window );">Cyramza&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">168.6<span></span>
</td>
<td class="nump">158.2<span></span>
</td>
<td class="nump">496.3<span></span>
</td>
<td class="nump">470.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ErbituxMember', window );">Erbitux&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">134.3<span></span>
</td>
<td class="nump">136.4<span></span>
</td>
<td class="nump">403.7<span></span>
</td>
<td class="nump">396.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ErbituxMember', window );">Erbitux&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">114.0<span></span>
</td>
<td class="nump">122.5<span></span>
</td>
<td class="nump">357.7<span></span>
</td>
<td class="nump">356.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ErbituxMember', window );">Erbitux&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">20.3<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="nump">45.9<span></span>
</td>
<td class="nump">40.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">125.6<span></span>
</td>
<td class="nump">84.4<span></span>
</td>
<td class="nump">340.2<span></span>
</td>
<td class="nump">205.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember', window );">Other Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">100.3<span></span>
</td>
<td class="nump">47.5<span></span>
</td>
<td class="nump">253.6<span></span>
</td>
<td class="nump">144.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember', window );">Other Oncology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">35.3<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
<td class="nump">83.7<span></span>
</td>
<td class="nump">26.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember', window );">Other Oncology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">65.1<span></span>
</td>
<td class="nump">32.7<span></span>
</td>
<td class="nump">169.9<span></span>
</td>
<td class="nump">118.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ImmunologyMember', window );">Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,004.9<span></span>
</td>
<td class="nump">627.1<span></span>
</td>
<td class="nump">2,404.2<span></span>
</td>
<td class="nump">1,761.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ImmunologyMember', window );">Immunology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">616.2<span></span>
</td>
<td class="nump">346.8<span></span>
</td>
<td class="nump">1,323.3<span></span>
</td>
<td class="nump">995.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ImmunologyMember', window );">Immunology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">388.7<span></span>
</td>
<td class="nump">280.3<span></span>
</td>
<td class="nump">1,080.9<span></span>
</td>
<td class="nump">766.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TaltzMember', window );">Taltz&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">593.1<span></span>
</td>
<td class="nump">454.5<span></span>
</td>
<td class="nump">1,565.4<span></span>
</td>
<td class="nump">1,293.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TaltzMember', window );">Taltz&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">422.2<span></span>
</td>
<td class="nump">326.2<span></span>
</td>
<td class="nump">1,071.6<span></span>
</td>
<td class="nump">942.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TaltzMember', window );">Taltz&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">170.9<span></span>
</td>
<td class="nump">128.3<span></span>
</td>
<td class="nump">493.8<span></span>
</td>
<td class="nump">350.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">194.0<span></span>
</td>
<td class="nump">14.5<span></span>
</td>
<td class="nump">236.5<span></span>
</td>
<td class="nump">39.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">212.9<span></span>
</td>
<td class="nump">147.5<span></span>
</td>
<td class="nump">572.6<span></span>
</td>
<td class="nump">407.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember', window );">Other Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
<td class="nump">29.7<span></span>
</td>
<td class="nump">21.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember', window );">Other Immunology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">13.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember', window );">Other Immunology | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">14.5<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember', window );">Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">450.2<span></span>
</td>
<td class="nump">470.7<span></span>
</td>
<td class="nump">1,427.8<span></span>
</td>
<td class="nump">1,356.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember', window );">Neuroscience | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">144.6<span></span>
</td>
<td class="nump">140.4<span></span>
</td>
<td class="nump">453.1<span></span>
</td>
<td class="nump">354.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember', window );">Neuroscience | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">305.5<span></span>
</td>
<td class="nump">330.3<span></span>
</td>
<td class="nump">974.7<span></span>
</td>
<td class="nump">1,002.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_EmgalityMember', window );">Emgality&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">140.0<span></span>
</td>
<td class="nump">91.5<span></span>
</td>
<td class="nump">415.7<span></span>
</td>
<td class="nump">252.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_EmgalityMember', window );">Emgality&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">99.9<span></span>
</td>
<td class="nump">81.4<span></span>
</td>
<td class="nump">313.5<span></span>
</td>
<td class="nump">229.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_EmgalityMember', window );">Emgality&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">40.1<span></span>
</td>
<td class="nump">10.1<span></span>
</td>
<td class="nump">102.2<span></span>
</td>
<td class="nump">23.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CymbaltaMember', window );">Cymbalta&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">132.0<span></span>
</td>
<td class="nump">186.6<span></span>
</td>
<td class="nump">484.3<span></span>
</td>
<td class="nump">576.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CymbaltaMember', window );">Cymbalta&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">7.0<span></span>
</td>
<td class="nump">11.1<span></span>
</td>
<td class="nump">30.3<span></span>
</td>
<td class="nump">30.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CymbaltaMember', window );">Cymbalta&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">125.1<span></span>
</td>
<td class="nump">175.5<span></span>
</td>
<td class="nump">454.0<span></span>
</td>
<td class="nump">546.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ZyprexaMember', window );">Zyprexa&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">101.7<span></span>
</td>
<td class="nump">112.7<span></span>
</td>
<td class="nump">292.8<span></span>
</td>
<td class="nump">307.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ZyprexaMember', window );">Zyprexa&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">13.0<span></span>
</td>
<td class="nump">21.2<span></span>
</td>
<td class="nump">28.3<span></span>
</td>
<td class="nump">41.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ZyprexaMember', window );">Zyprexa&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">88.7<span></span>
</td>
<td class="nump">91.5<span></span>
</td>
<td class="nump">264.5<span></span>
</td>
<td class="nump">266.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember', window );">Other Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">76.5<span></span>
</td>
<td class="nump">79.9<span></span>
</td>
<td class="nump">235.0<span></span>
</td>
<td class="nump">219.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember', window );">Other Neuroscience | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">24.7<span></span>
</td>
<td class="nump">26.7<span></span>
</td>
<td class="nump">81.0<span></span>
</td>
<td class="nump">53.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember', window );">Other Neuroscience | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">51.6<span></span>
</td>
<td class="nump">53.2<span></span>
</td>
<td class="nump">154.0<span></span>
</td>
<td class="nump">165.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">637.7<span></span>
</td>
<td class="nump">526.4<span></span>
</td>
<td class="nump">2,593.5<span></span>
</td>
<td class="nump">1,647.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">354.9<span></span>
</td>
<td class="nump">193.2<span></span>
</td>
<td class="nump">1,373.0<span></span>
</td>
<td class="nump">595.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember', window );">Other | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">282.7<span></span>
</td>
<td class="nump">333.2<span></span>
</td>
<td class="nump">1,220.5<span></span>
</td>
<td class="nump">1,052.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 Antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1,176.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 Antibodies | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">215.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">949.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 Antibodies | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">226.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ForteoMember', window );">Forteo&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">200.9<span></span>
</td>
<td class="nump">266.9<span></span>
</td>
<td class="nump">617.8<span></span>
</td>
<td class="nump">791.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ForteoMember', window );">Forteo&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">109.6<span></span>
</td>
<td class="nump">144.6<span></span>
</td>
<td class="nump">330.1<span></span>
</td>
<td class="nump">386.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ForteoMember', window );">Forteo&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">91.3<span></span>
</td>
<td class="nump">122.3<span></span>
</td>
<td class="nump">287.7<span></span>
</td>
<td class="nump">405.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CialisMember', window );">Cialis&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">130.9<span></span>
</td>
<td class="nump">162.5<span></span>
</td>
<td class="nump">538.7<span></span>
</td>
<td class="nump">486.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CialisMember', window );">Cialis&#174; | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="num">(6.5)<span></span>
</td>
<td class="nump">15.1<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
<td class="nump">64.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CialisMember', window );">Cialis&#174; | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">137.4<span></span>
</td>
<td class="nump">147.3<span></span>
</td>
<td class="nump">541.8<span></span>
</td>
<td class="nump">421.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">88.8<span></span>
</td>
<td class="nump">97.0<span></span>
</td>
<td class="nump">260.8<span></span>
</td>
<td class="nump">369.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">36.3<span></span>
</td>
<td class="nump">33.5<span></span>
</td>
<td class="nump">96.5<span></span>
</td>
<td class="nump">144.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OtherProductMember', window );">Other | Outside U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 52.4<span></span>
</td>
<td class="nump">$ 63.6<span></span>
</td>
<td class="nump">$ 164.3<span></span>
</td>
<td class="nump">$ 225.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_DiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_DiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TrulicityMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TrulicityMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_HumalogMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_HumalogMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_JardianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_JardianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_HumulinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_HumulinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_BasaglarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_BasaglarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherDiabetesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherDiabetesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_AlimtaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_AlimtaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_VerzenioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_VerzenioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CyramzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CyramzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ErbituxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ErbituxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TYVYTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TYVYTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TaltzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TaltzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OlumiantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OlumiantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_EmgalityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_EmgalityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CymbaltaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CymbaltaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ZyprexaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ZyprexaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherProductTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherProductTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ForteoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ForteoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CialisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CialisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OtherProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OtherProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657084245384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Disaggregation of Revenue by Geographical Area) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 6,772.8<span></span>
</td>
<td class="nump">$ 5,740.6<span></span>
</td>
<td class="nump">$ 20,318.5<span></span>
</td>
<td class="nump">$ 17,099.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">3,989.6<span></span>
</td>
<td class="nump">3,161.4<span></span>
</td>
<td class="nump">11,635.1<span></span>
</td>
<td class="nump">9,631.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,098.6<span></span>
</td>
<td class="nump">1,046.7<span></span>
</td>
<td class="nump">3,629.6<span></span>
</td>
<td class="nump">2,984.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">595.0<span></span>
</td>
<td class="nump">660.1<span></span>
</td>
<td class="nump">1,832.2<span></span>
</td>
<td class="nump">1,919.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">400.3<span></span>
</td>
<td class="nump">289.1<span></span>
</td>
<td class="nump">1,285.0<span></span>
</td>
<td class="nump">796.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember', window );">Other foreign countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 689.4<span></span>
</td>
<td class="nump">$ 583.2<span></span>
</td>
<td class="nump">$ 1,936.7<span></span>
</td>
<td class="nump">$ 1,768.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lly_OtherForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657094791992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($) </div>
<div>right </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 498,300,000<span></span>
</td>
<td class="nump">$ 294,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">747,400,000<span></span>
</td>
<td class="nump">849,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,884,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,884,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,766,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,905,300,000<span></span>
</td>
<td class="nump">$ 276,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember', window );">Prevail Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 22.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="nump">$ 747,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights', window );">Consideration transferred, number of contingent value rights | right</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare', window );">Contingent value right, additional price per share (up to) (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent value right, additional price per share, aggregate amount</a></td>
<td class="nump">$ 160,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction', window );">Contingent value right, monthly reduction (in cents per share) | $ / shares</a></td>
<td class="nump">$ 0.083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 118,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired IPR&amp;D</a></td>
<td class="nump">824,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income taxes assumed</a></td>
<td class="nump">$ 98,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_DermiraInc.Member', window );">Dermira</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 849,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income taxes assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt', window );">Long-term debt assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Contingent Value Right, Additional Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Number Of Contingent Value Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_DermiraInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_DermiraInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657082222248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Assets Acquired and Liabilities Assumed) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,884.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,766.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 747.4<span></span>
</td>
<td class="nump">$ 849.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember', window );">Prevail Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">$ 90.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquired IPR&amp;D</a></td>
<td class="nump">824.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">118.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(98.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="num">(31.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Acquisition date fair value of consideration transferred</a></td>
<td class="nump">903.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired</a></td>
<td class="num">(90.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability', window );">Fair value of CVR liability</a></td>
<td class="num">(65.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid, net of cash acquired</a></td>
<td class="nump">$ 747.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657090159144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Asset Acquisitions) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="9">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 498,300,000<span></span>
</td>
<td class="nump">$ 294,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_PrecisionBiosciencesIncMember', window );">Precision Biosciences, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_MerusNVMember', window );">Merus N.V.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_AsahiKaseiPharmaCorporationMember', window );">Asahi Kasei Pharma Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_RigelPharmaceuticalsIncMember', window );">Rigel Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_MiNATherapeuticsLimitedMember', window );">MiNA Therapeutics Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_ProtomerTechnologiesIncMember', window );">Protomer Technologies Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_KumquatBiosciencesIncMember', window );">Kumquat Biosciences Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_LyciaTherapeuticsIncMember', window );">Lycia Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_ProQRTherapeuticsNVMember', window );">ProQR Therapeutics N.V.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="nump">$ 26,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_SitryxTherapeuticsLimitedMember', window );">Sitryx Therapeutics Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_AbCelleraBiologicsInc.Member', window );">AbCellera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_JunshiBiosciencesMember', window );">Junshi Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_PetraPharmaCorporationMember', window );">Petra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=lly_EvoxTherapeuticsMember', window );">Evox Therapeutics Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquired IPR&amp;D Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_PrecisionBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_PrecisionBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_MerusNVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_MerusNVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_AsahiKaseiPharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_AsahiKaseiPharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_RigelPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_RigelPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_MiNATherapeuticsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_MiNATherapeuticsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_ProtomerTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_ProtomerTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_KumquatBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_KumquatBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_LyciaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_LyciaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_ProQRTherapeuticsNVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_ProQRTherapeuticsNVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_SitryxTherapeuticsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_SitryxTherapeuticsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_AbCelleraBiologicsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_AbCelleraBiologicsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_JunshiBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_JunshiBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_PetraPharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_PetraPharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_EvoxTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_EvoxTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657086133848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 6,772.8<span></span>
</td>
<td class="nump">$ 5,740.6<span></span>
</td>
<td class="nump">$ 20,318.5<span></span>
</td>
<td class="nump">$ 17,099.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">278.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">400.3<span></span>
</td>
<td class="nump">289.1<span></span>
</td>
<td class="nump">1,285.0<span></span>
</td>
<td class="nump">796.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">390.4<span></span>
</td>
<td class="nump">310.8<span></span>
</td>
<td class="nump">1,058.9<span></span>
</td>
<td class="nump">840.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember', window );">Trajenta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">96.1<span></span>
</td>
<td class="nump">91.7<span></span>
</td>
<td class="nump">279.9<span></span>
</td>
<td class="nump">261.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_BasaglarMember', window );">Basaglar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">192.8<span></span>
</td>
<td class="nump">248.2<span></span>
</td>
<td class="nump">650.1<span></span>
</td>
<td class="nump">842.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_OlumiantMember', window );">Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">406.9<span></span>
</td>
<td class="nump">162.0<span></span>
</td>
<td class="nump">809.1<span></span>
</td>
<td class="nump">446.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember', window );">COVID-19 Antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1,176.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">217.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_TYVYTMember', window );">Tyvyt&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">125.6<span></span>
</td>
<td class="nump">$ 84.4<span></span>
</td>
<td class="nump">340.2<span></span>
</td>
<td class="nump">$ 205.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember', window );">Lebrikizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">15.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember', window );">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Jardiance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">141.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember', window );">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Trajenta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">95.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember', window );">Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Basaglar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="num">(154.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (154.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(168.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementTermsMember', window );">Royalty Agreement Terms | Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsPercent', window );">Collaborative arrangement, rights and obligations, percentage (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember', window );">Milestone Payments, Capitalized as Intangible Assets | Junshi Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">95.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember', window );">Milestone Payments, Capitalized as Intangible Assets | Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember', window );">Milestone Payments, Capitalized as Intangible Assets | Tyvyt&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember', window );">Milestone Payments, Development and Regulatory | Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember', window );">Milestone Payments, Development and Regulatory | Lebrikizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember', window );">Milestone Payments, Sales-based | Junshi Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember', window );">Milestone Payments, Sales-based | Olumiant&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember', window );">Milestone Payments, Sales-based | Lebrikizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">1,250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember', window );">Milestone Payments, Contingent Upon Initiation of Phase I Trial | Petra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">205.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember', window );">Milestone Payments, Contingent Upon Achieving Clinical Proof of Concept | Petra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">164.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=lly_InnoventBiologicsIncMember', window );">Innovent Biologics, Inc. | Milestone Payments, Success-based Regulatory and Sales-based | Tyvyt&#174; | Non-CHINA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">825.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=lly_InnoventBiologicsIncMember', window );">Innovent Biologics, Inc. | Milestone Payments, Success-based Regulatory and Sales-based | Tyvyt&#174; | China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">195.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=lly_RocheMember', window );">Roche | Milestone Payments, Development and Regulatory | Lebrikizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=lly_RocheMember', window );">Roche | Milestone Payments, Sales-based | Lebrikizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations', window );">Potential achievements</a></td>
<td class="nump">$ 1,030.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,030.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CollaborativeArrangementRightsAndObligationsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CollaborativeArrangementRightsAndObligationsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CollaborativeArrangementRightsAndObligationsRightsObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Terms or rights and obligations under collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CollaborativeArrangementRightsAndObligationsRightsObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_JardianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_JardianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TrajentaBIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TrajentaBIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_BasaglarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_BasaglarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_OlumiantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_OlumiantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_TYVYTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_TYVYTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_LebrikizumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_LebrikizumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_JunshiBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_JunshiBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=lly_PetraPharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=lly_PetraPharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lly_InnoventBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lly_InnoventBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lly_NonCHINAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lly_NonCHINAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lly_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lly_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657090046824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Impairment, Restructuring, and Other Special Charges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 144.4<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 154.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges', window );">Asset impairment (recovery) and other special charges</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(43.0)<span></span>
</td>
<td class="nump">200.1<span></span>
</td>
<td class="nump">7.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringSettlementAndImpairmentProvisions', window );">Total asset impairment, restructuring, and other special charges</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 101.4<span></span>
</td>
<td class="nump">211.6<span></span>
</td>
<td class="nump">$ 161.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Intangible asset impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Impairment Charges (Recoveries) And Other Special Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringSettlementAndImpairmentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restructuring charges, remediation cost, and asset impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringSettlementAndImpairmentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657077852600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Narrative) (Details)<br> &#165; in Millions, &#165; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="4"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1', window );">Maximum remaining maturity of foreign currency derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax', window );">Derivatives used in net investment hedge, net of tax</a></td>
<td class="nump">$ 5,950.0<span></span>
</td>
<td class="nump">$ 5,950.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,950.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DescriptionOfDerivativeActivityVolumePercent', window );">Percentage of long-term fixed-rate notes to floating rates through the use of interest rate swaps converted</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt extinguishment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 405.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 405.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet', window );">Pretax net losses on cash flow hedges expected to be reclassified during the next 12 months</a></td>
<td class="nump">$ 16.4<span></span>
</td>
<td class="nump">16.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments', window );">Alternative investments, unfunded commitments</a></td>
<td class="nump">781.0<span></span>
</td>
<td class="nump">781.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 781.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod', window );">Alternative investments, unfunded commitments, payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Equity securities, net unrealized gains (losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(246.8)<span></span>
</td>
<td class="nump">$ 141.7<span></span>
</td>
<td class="nump">$ 270.1<span></span>
</td>
<td class="nump">$ 905.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets', window );">Available-for-sale, percentage of nonperforming assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized', window );">Amount of receivable derecognized</a></td>
<td class="nump">617.4<span></span>
</td>
<td class="nump">617.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 617.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">754.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUsDollarSellEuroMember', window );">Buy U.S. Dollars Sell Euros</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">707.3<span></span>
</td>
<td class="nump">707.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">707.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 604,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyEuroSellUsDollarMember', window );">Buy Euros Sell U.S. Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,540,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">2,980.0<span></span>
</td>
<td class="nump">2,980.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,980.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSDollarSellChineseYuanMember', window );">Buy US Dollar Sell Chinese Yuan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">151.6<span></span>
</td>
<td class="nump">151.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 980.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSdollarSellJapaneseYenMember', window );">Buy U.S. Dollars Sell Japanese Yen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">144.7<span></span>
</td>
<td class="nump">144.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 16,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyBritishPoundandSellUSDollarsMember', window );">Buy British Pounds and Sell U.S. Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 155,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">212.6<span></span>
</td>
<td class="nump">212.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapU.S.DollarsToEuroMember', window );">Swap U.S. Dollars to Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">2,690.0<span></span>
</td>
<td class="nump">2,690.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,690.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapSwissFrancsToU.S.DollarsMember', window );">Swap Swiss Francs to U.S. Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">1,000.0<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="nump">8,080.0<span></span>
</td>
<td class="nump">$ 8,080.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,080.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,020.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Payment for debt extinguishment</a></td>
<td class="nump">1,910.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt, amount</a></td>
<td class="nump">1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt extinguishment loss</a></td>
<td class="nump">$ 405.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 0.500% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 1.125% Notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.125%<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 1.375% Notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.375%<span></span>
</td>
<td class="nump">1.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.375%<span></span>
</td>
<td class="nump">1.375%<span></span>
</td>
<td class="nump">1.375%<span></span>
</td>
<td class="nump">1.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 1.625% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.625%<span></span>
</td>
<td class="nump">1.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.625%<span></span>
</td>
<td class="nump">1.625%<span></span>
</td>
<td class="nump">1.625%<span></span>
</td>
<td class="nump">1.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 3.95% Notes Due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.95%<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt, amount</a></td>
<td class="nump">$ 541.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 4.15% Notes Due 2059</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.15%<span></span>
</td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.15%<span></span>
</td>
<td class="nump">4.15%<span></span>
</td>
<td class="nump">4.15%<span></span>
</td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt, amount</a></td>
<td class="nump">$ 408.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember', window );">Foreign Currency Denominated Debt | 3.375% Notes Due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt, amount</a></td>
<td class="nump">$ 219.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Cash Flow Hedging | Forward-starting interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 1,750.0<span></span>
</td>
<td class="nump">$ 1,750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DescriptionOfDerivativeActivityVolumePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of Derivative Activity Volume Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DescriptionOfDerivativeActivityVolumePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the percentage of nonperforming assets that the underlying assets in the security represent and which were considered as one of the potential factors in reaching a conclusion that the available-for-sale investments are not other-than-temporarily impaired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unfunded commitments for which the entity is obligated, to those certain investments for which net asset value per share is calculated (including by unit, membership interest, or other equity (ownership interest) unit measure) (alternative investments).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL6742756-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of cumulative translation adjustment attributable to gain (loss) on foreign currency derivatives that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUsDollarSellEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUsDollarSellEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyEuroSellUsDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyEuroSellUsDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSDollarSellChineseYuanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSDollarSellChineseYuanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSdollarSellJapaneseYenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyUSdollarSellJapaneseYenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_BuyBritishPoundandSellUSDollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_BuyBritishPoundandSellUSDollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapU.S.DollarsToEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_SwapU.S.DollarsToEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_SwapSwissFrancsToU.S.DollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_SwapSwissFrancsToU.S.DollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=lly_ForeignCurrencyDenominatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A5000NotesDue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A5000NotesDue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A1125NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A1125NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A1375NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A1375NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A1625NotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A1625NotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A395NotesDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A395NotesDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A415NotesDue2059Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A415NotesDue2059Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lly_A3375NotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lly_A3375NotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657082270056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Effect of Risk-Management Instruments) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DerivativeInstrumentsGainLossRecognized', window );">Total</a></td>
<td class="nump">$ 65.0<span></span>
</td>
<td class="num">$ (80.3)<span></span>
</td>
<td class="nump">$ 181.2<span></span>
</td>
<td class="num">$ (125.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lly_HedgedFixedRateDebtMember', window );">Foreign currency-denominated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges</a></td>
<td class="nump">119.0<span></span>
</td>
<td class="num">(181.1)<span></span>
</td>
<td class="nump">268.8<span></span>
</td>
<td class="num">(186.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges</a></td>
<td class="nump">66.7<span></span>
</td>
<td class="num">(110.4)<span></span>
</td>
<td class="nump">170.8<span></span>
</td>
<td class="num">(55.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">22.5<span></span>
</td>
<td class="num">(58.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Forward-starting interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges</a></td>
<td class="nump">19.4<span></span>
</td>
<td class="nump">99.6<span></span>
</td>
<td class="nump">149.3<span></span>
</td>
<td class="num">(231.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Foreign currency-denominated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_FairValueHedgeAbstract', window );"><strong>Fair value hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Effect from hedged fixed-rate debt</a></td>
<td class="num">(10.1)<span></span>
</td>
<td class="num">(14.0)<span></span>
</td>
<td class="num">(60.5)<span></span>
</td>
<td class="nump">110.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Interest rate contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_FairValueHedgeAbstract', window );"><strong>Fair value hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Effect from interest rate contracts</a></td>
<td class="nump">10.1<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="nump">60.5<span></span>
</td>
<td class="num">(110.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Cross-currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="num">(30.2)<span></span>
</td>
<td class="nump">58.1<span></span>
</td>
<td class="num">(54.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Foreign currency exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_CashFlowHedgeAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments</a></td>
<td class="nump">$ 50.8<span></span>
</td>
<td class="num">$ (54.2)<span></span>
</td>
<td class="nump">$ 110.6<span></span>
</td>
<td class="num">$ (82.8)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_CashFlowHedgeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Flow Hedge [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_CashFlowHedgeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DerivativeInstrumentsGainLossRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative Instruments, Gain (Loss) Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DerivativeInstrumentsGainLossRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_FairValueHedgeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Hedge [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_FairValueHedgeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lly_HedgedFixedRateDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lly_HedgedFixedRateDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657174134008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Fair Value of Financial Instruments) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Noncurrent investments</a></td>
<td class="nump">$ 3,350.5<span></span>
</td>
<td class="nump">$ 2,966.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,373.8<span></span>
</td>
<td class="nump">2,097.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">37.1<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments without readily determinable fair values</a></td>
<td class="nump">556.3<span></span>
</td>
<td class="nump">373.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Noncurrent investments</a></td>
<td class="nump">3,350.5<span></span>
</td>
<td class="nump">2,966.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="num">(17,085.4)<span></span>
</td>
<td class="num">(16,595.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">11.3<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">129.9<span></span>
</td>
<td class="nump">78.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">219.7<span></span>
</td>
<td class="nump">137.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">110.7<span></span>
</td>
<td class="nump">106.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">19.7<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Other securities, current investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">15.5<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">105.6<span></span>
</td>
<td class="nump">110.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">1,482.8<span></span>
</td>
<td class="nump">1,664.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Equity method investments</a></td>
<td class="nump">725.8<span></span>
</td>
<td class="nump">471.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,373.8<span></span>
</td>
<td class="nump">2,097.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">11.1<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">129.0<span></span>
</td>
<td class="nump">74.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">215.0<span></span>
</td>
<td class="nump">126.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">107.9<span></span>
</td>
<td class="nump">101.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">19.6<span></span>
</td>
<td class="nump">23.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Other securities, current investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">15.5<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">21.6<span></span>
</td>
<td class="nump">31.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Cost | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">420.5<span></span>
</td>
<td class="nump">311.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,373.8<span></span>
</td>
<td class="nump">2,097.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="num">(18,354.9)<span></span>
</td>
<td class="num">(19,038.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,373.8<span></span>
</td>
<td class="nump">2,097.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="num">(18,354.9)<span></span>
</td>
<td class="num">(19,038.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including current portion</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">11.3<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">129.9<span></span>
</td>
<td class="nump">78.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | U.S. government and agency securities | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">11.3<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">129.9<span></span>
</td>
<td class="nump">78.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | U.S. government and agency securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | U.S. government and agency securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">219.7<span></span>
</td>
<td class="nump">137.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Corporate debt securities | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Corporate debt securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">219.7<span></span>
</td>
<td class="nump">137.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Corporate debt securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">110.7<span></span>
</td>
<td class="nump">106.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Mortgage-backed securities | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Mortgage-backed securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">110.7<span></span>
</td>
<td class="nump">106.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Mortgage-backed securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">19.7<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Asset-backed securities | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Asset-backed securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">19.7<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Asset-backed securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Other securities, current investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">15.5<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Other securities, current investments | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Other securities, current investments | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Other securities, current investments | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, debt securities</a></td>
<td class="nump">8.9<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Other securities, noncurrent investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">105.6<span></span>
</td>
<td class="nump">110.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Other securities, noncurrent investments | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Other securities, noncurrent investments | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Other securities, noncurrent investments | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">105.6<span></span>
</td>
<td class="nump">110.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">1,482.8<span></span>
</td>
<td class="nump">1,664.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Marketable equity securities | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">1,482.8<span></span>
</td>
<td class="nump">1,664.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Marketable equity securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Marketable equity securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lly_OtherEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lly_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lly_EquityMethodAndOtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lly_EquityMethodAndOtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657078121784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Risk Management Instruments) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability, other noncurrent liabilities</a></td>
<td class="num">$ (70.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">$ 41.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(25.7)<span></span>
</td>
<td class="num">(15.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability, other noncurrent liabilities</a></td>
<td class="num">(70.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability, other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability, other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability, other noncurrent liabilities</a></td>
<td class="num">(70.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">41.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(25.7)<span></span>
</td>
<td class="num">(15.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign currency exchange contracts | Not Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign currency exchange contracts | Not Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">41.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(25.7)<span></span>
</td>
<td class="num">(15.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Foreign currency exchange contracts | Not Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Carrying Amount | Interest rate contracts | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">87.2<span></span>
</td>
<td class="nump">158.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Estimate of Fair Value Measurement | Interest rate contracts | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">87.2<span></span>
</td>
<td class="nump">158.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Estimate of Fair Value Measurement | Interest rate contracts | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Estimate of Fair Value Measurement | Interest rate contracts | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">87.2<span></span>
</td>
<td class="nump">158.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Estimate of Fair Value Measurement | Interest rate contracts | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Carrying Amount | Interest rate contracts | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">77.3<span></span>
</td>
<td class="nump">38.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Carrying Amount | Cross-currency interest rate swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">10.8<span></span>
</td>
<td class="nump">34.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(23.0)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Interest rate contracts | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">77.3<span></span>
</td>
<td class="nump">38.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Interest rate contracts | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Interest rate contracts | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">77.3<span></span>
</td>
<td class="nump">38.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Interest rate contracts | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">10.8<span></span>
</td>
<td class="nump">34.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(23.0)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">10.8<span></span>
</td>
<td class="nump">34.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(23.0)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Carrying Amount | Cross-currency interest rate swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">18.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">38.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(17.0)<span></span>
</td>
<td class="num">(92.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(9.5)<span></span>
</td>
<td class="num">(97.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">18.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">38.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(17.0)<span></span>
</td>
<td class="num">(92.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(9.5)<span></span>
</td>
<td class="num">(97.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">18.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">38.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(17.0)<span></span>
</td>
<td class="num">(92.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="num">(9.5)<span></span>
</td>
<td class="num">(97.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedges | Estimate of Fair Value Measurement | Cross-currency interest rate swaps | Designated as Hedging Instrument | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Other receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657082031784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Contractual Maturities) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 501.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less&#160;Than 1 Year</a></td>
<td class="nump">21.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">1-5 Years</a></td>
<td class="nump">157.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">6-10 Years</a></td>
<td class="nump">153.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">More&#160;Than 10 Years</a></td>
<td class="nump">$ 168.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657077477944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Unrealized Gains and Losses) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gross gains</a></td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="nump">$ 20.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized gross losses</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition', window );">Fair value of securities in an unrealized gain position</a></td>
<td class="nump">293.4<span></span>
</td>
<td class="nump">348.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair value of securities in an unrealized loss position</a></td>
<td class="nump">$ 208.1<span></span>
</td>
<td class="nump">$ 11.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Unrealized Gain Position</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657077526616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Realized Gains and Losses) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities', window );">Proceeds from sales</a></td>
<td class="nump">$ 49.6<span></span>
</td>
<td class="nump">$ 14.0<span></span>
</td>
<td class="nump">$ 137.3<span></span>
</td>
<td class="nump">$ 246.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain', window );">Realized gross gains on sales</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss', window );">Realized gross losses on sales</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 8.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for Sale Securities and Equity Securities, FV-NI, Realized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale Securities and Equity Securities, FV-NI, Realized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale of Equity and Available for Sale Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657081460808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate, percentage</a></td>
<td class="nump">10.90%<span></span>
</td>
<td class="nump">15.90%<span></span>
</td>
<td class="nump">10.70%<span></span>
</td>
<td class="nump">14.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657094266328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Benefits (Components of Net Periodic Benefit Cost) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 92.5<span></span>
</td>
<td class="nump">$ 81.7<span></span>
</td>
<td class="nump">$ 277.8<span></span>
</td>
<td class="nump">$ 243.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">84.5<span></span>
</td>
<td class="nump">106.6<span></span>
</td>
<td class="nump">253.6<span></span>
</td>
<td class="nump">319.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(237.5)<span></span>
</td>
<td class="num">(229.5)<span></span>
</td>
<td class="num">(712.7)<span></span>
</td>
<td class="num">(671.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit', window );">Recognized actuarial loss</a></td>
<td class="nump">121.9<span></span>
</td>
<td class="nump">58.4<span></span>
</td>
<td class="nump">366.3<span></span>
</td>
<td class="nump">286.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">62.4<span></span>
</td>
<td class="nump">18.3<span></span>
</td>
<td class="nump">188.2<span></span>
</td>
<td class="nump">180.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Retiree Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">12.4<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="nump">37.0<span></span>
</td>
<td class="nump">30.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">8.1<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
<td class="nump">24.4<span></span>
</td>
<td class="nump">32.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(36.5)<span></span>
</td>
<td class="num">(40.3)<span></span>
</td>
<td class="num">(109.6)<span></span>
</td>
<td class="num">(115.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost</a></td>
<td class="num">(14.9)<span></span>
</td>
<td class="num">(21.9)<span></span>
</td>
<td class="num">(44.7)<span></span>
</td>
<td class="num">(51.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit', window );">Recognized actuarial loss</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="num">$ (30.1)<span></span>
</td>
<td class="num">$ (40.4)<span></span>
</td>
<td class="num">$ (90.5)<span></span>
</td>
<td class="num">$ (101.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss), recognized immediately as component of net periodic benefit (cost) credit, for change in value of benefit obligation or plan assets from experience different from that assumed, change in actuarial assumption, or consequence of temporarily deviating from substantive plan. Includes, but is not limited to, amount in excess of ten percent of greater of fair value of plan assets or benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657084725512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Details)<br> R$ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="1">151 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>BRL (R$) </div>
<div>claimant </div>
<div>lawsuit </div>
<div>site</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>claimant </div>
<div>lawsuit </div>
<div>site</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>patent </div>
<div>decision</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>claim</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>BRL (R$) </div>
<div>patent</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>patent</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>patent</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>BRL (R$)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>BRL (R$)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>lawsuit </div>
<div>plaintiff </div>
<div>site </div>
<div>claimant</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>patent</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Jan. 31, 2013 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Jul. 31, 2012 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Dec. 31, 2011 </div>
<div>lawsuit</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember', window );">Unfavorable Regulatory Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup', window );">Number of sites jointly and severally liable for cleanup (fewer than) | site</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ActosMember', window );">Actos | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyNumberOfClaimants', window );">Number of claimants | claimant</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Pancreatic Cancer or Thyroid Cancer | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="nump">565<span></span>
</td>
<td class="nump">565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Pancreatitis | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Ampullary Cancer | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Los Angeles | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Southern District of California | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="nump">515<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_ByettaMember', window );">Byetta | Various State Domiciles | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_CialisMember', window );">Cialis&#174; | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_JardianceMember', window );">Jardiance | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_HumalogHumulinAndForteoMember', window );">Humalog, Humulin and Forteo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lly_InsulinMember', window );">Insulin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LitigationClaimsDismissedNumber', window );">Number of claims dismissed | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_DrReddysLabMember', window );">Dr Reddy's Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm', window );">Limited initial market entry, supply term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember', window );">Emgality Patent Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyNumberOfPatents', window );">Number of patents | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyNumberOfPatentsClaimsDismissed', window );">Number of patents, claims dismissed | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyNumberOfPatentsRuledUnpatentable', window );">Number of patents ruled unpatentable | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_LossContingencyNumberOfDecisionsAffirmed', window );">Number of decisions affirmed | decision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember', window );">Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al. | Actos | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_WhyteEtAlVEliLillyEtAlMember', window );">Weiler v. Takeda Canada Inc. et al. | Actos | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_WeilerVTakedaCanadaIncEtAlMember', window );">Weiler v. Takeda Canada Inc. et al. | Actos | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=lly_EppVTakedaCanadaIncEtAlMember', window );">Epp v. Takeda Canada Inc. et al. | Actos | Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BR', window );">Brazil | Employee Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending lawsuits</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded, value</a></td>
<td class="nump">R$ 950<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">R$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">R$ 500<span></span>
</td>
<td class="nump">R$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LitigationClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation, Claims Dismissed, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LitigationClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfClaimants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Claimants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfClaimants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfDecisionsAffirmed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Decisions Affirmed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfDecisionsAffirmed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Patents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfPatentsClaimsDismissed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Patents, Claims Dismissed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfPatentsClaimsDismissed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfPatentsRuledUnpatentable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Patents Ruled Unpatentable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfPatentsRuledUnpatentable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ActosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ActosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=lly_ProductLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=lly_ProductLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_ByettaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_ByettaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PlaintiffAllegationsAxis=lly_PancreaticCancerOrThyroidCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PlaintiffAllegationsAxis=lly_PancreaticCancerOrThyroidCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PlaintiffAllegationsAxis=lly_PancreatitisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PlaintiffAllegationsAxis=lly_PancreatitisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_PlaintiffAllegationsAxis=lly_AmpullaryCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_PlaintiffAllegationsAxis=lly_AmpullaryCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DomicileOfLitigationAxis=lly_LosAngelesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DomicileOfLitigationAxis=lly_LosAngelesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DomicileOfLitigationAxis=lly_SouthernDistrictOfCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DomicileOfLitigationAxis=lly_SouthernDistrictOfCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DomicileOfLitigationAxis=lly_VariousStateDomicilesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DomicileOfLitigationAxis=lly_VariousStateDomicilesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_CialisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_CialisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_JardianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_JardianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_HumalogHumulinAndForteoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_HumalogHumulinAndForteoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lly_InsulinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lly_InsulinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_DrReddysLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_DrReddysLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_EmgalityPatentLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_WhyteEtAlVEliLillyEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_WhyteEtAlVEliLillyEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_WeilerVTakedaCanadaIncEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_WeilerVTakedaCanadaIncEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_EppVTakedaCanadaIncEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_EppVTakedaCanadaIncEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lly_EmployeeLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lly_EmployeeLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657094465704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (AOCI) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,825.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="nump">$ 94.4<span></span>
</td>
<td class="nump">54.5<span></span>
</td>
<td class="num">$ (234.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">89.4<span></span>
</td>
<td class="nump">33.4<span></span>
</td>
<td class="nump">269.2<span></span>
</td>
<td class="nump">202.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">114.4<span></span>
</td>
<td class="nump">127.8<span></span>
</td>
<td class="nump">323.7<span></span>
</td>
<td class="num">(31.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">7,954.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,954.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(6,287.1)<span></span>
</td>
<td class="num">(6,682.9)<span></span>
</td>
<td class="num">(6,496.4)<span></span>
</td>
<td class="num">(6,523.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(6,172.7)<span></span>
</td>
<td class="num">(6,555.1)<span></span>
</td>
<td class="num">(6,172.7)<span></span>
</td>
<td class="num">(6,555.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Gains&#160;(Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(1,516.2)<span></span>
</td>
<td class="num">(1,722.5)<span></span>
</td>
<td class="num">(1,427.5)<span></span>
</td>
<td class="num">(1,678.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(8.0)<span></span>
</td>
<td class="nump">30.3<span></span>
</td>
<td class="num">(96.7)<span></span>
</td>
<td class="num">(14.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="num">(8.0)<span></span>
</td>
<td class="nump">30.3<span></span>
</td>
<td class="num">(96.7)<span></span>
</td>
<td class="num">(14.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(1,524.2)<span></span>
</td>
<td class="num">(1,692.2)<span></span>
</td>
<td class="num">(1,524.2)<span></span>
</td>
<td class="num">(1,692.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized Net Gains (Losses) on&#160;Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">9.1<span></span>
</td>
<td class="nump">15.1<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(2.4)<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="num">(8.8)<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="num">(2.3)<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">15.7<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">15.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(4,569.9)<span></span>
</td>
<td class="num">(4,454.9)<span></span>
</td>
<td class="num">(4,751.0)<span></span>
</td>
<td class="num">(4,638.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">18.6<span></span>
</td>
<td class="num">(19.6)<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">86.0<span></span>
</td>
<td class="nump">30.3<span></span>
</td>
<td class="nump">258.5<span></span>
</td>
<td class="nump">189.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">104.6<span></span>
</td>
<td class="nump">10.7<span></span>
</td>
<td class="nump">285.7<span></span>
</td>
<td class="nump">194.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(4,465.3)<span></span>
</td>
<td class="num">(4,444.2)<span></span>
</td>
<td class="num">(4,465.3)<span></span>
</td>
<td class="num">(4,444.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember', window );">Effective Portion of Cash&#160;Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(210.1)<span></span>
</td>
<td class="num">(520.6)<span></span>
</td>
<td class="num">(332.7)<span></span>
</td>
<td class="num">(211.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">16.8<span></span>
</td>
<td class="nump">82.9<span></span>
</td>
<td class="nump">132.8<span></span>
</td>
<td class="num">(232.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amount reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive income (loss)</a></td>
<td class="nump">20.1<span></span>
</td>
<td class="nump">86.2<span></span>
</td>
<td class="nump">142.7<span></span>
</td>
<td class="num">(222.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">$ (190.0)<span></span>
</td>
<td class="num">$ (434.4)<span></span>
</td>
<td class="num">$ (190.0)<span></span>
</td>
<td class="num">$ (434.4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657082229352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Tax Effect) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit (provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">$ (71.8)<span></span>
</td>
<td class="nump">$ 34.7<span></span>
</td>
<td class="num">$ (206.1)<span></span>
</td>
<td class="nump">$ 58.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Gains&#160;(Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit (provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">(39.0)<span></span>
</td>
<td class="nump">46.0<span></span>
</td>
<td class="num">(92.3)<span></span>
</td>
<td class="nump">34.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized net gains/losses on securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit (provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Defined Benefit Pension and Retiree&#160;Health Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit (provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">(28.2)<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="num">(79.7)<span></span>
</td>
<td class="num">(32.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember', window );">Effective portion of cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Benefit (provision) for income taxes allocated to other comprehensive income (loss) items</a></td>
<td class="num">$ (5.4)<span></span>
</td>
<td class="num">$ (22.9)<span></span>
</td>
<td class="num">$ (37.9)<span></span>
</td>
<td class="nump">$ 59.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657078370488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Reclassification) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="nump">$ 20.1<span></span>
</td>
<td class="num">$ (13.0)<span></span>
</td>
<td class="nump">$ 34.1<span></span>
</td>
<td class="num">$ (161.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total before tax</a></td>
<td class="nump">1,245.3<span></span>
</td>
<td class="nump">1,437.2<span></span>
</td>
<td class="nump">4,315.6<span></span>
</td>
<td class="nump">4,760.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="num">(135.2)<span></span>
</td>
<td class="num">(228.8)<span></span>
</td>
<td class="num">(460.0)<span></span>
</td>
<td class="num">(683.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Total reclassifications, net of tax</a></td>
<td class="nump">89.4<span></span>
</td>
<td class="nump">33.4<span></span>
</td>
<td class="nump">269.2<span></span>
</td>
<td class="nump">202.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Defined Benefit Pension and Retiree&#160;Health Benefit Plans | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total before tax</a></td>
<td class="nump">108.8<span></span>
</td>
<td class="nump">38.3<span></span>
</td>
<td class="nump">327.2<span></span>
</td>
<td class="nump">240.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="num">(22.8)<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
<td class="num">(68.7)<span></span>
</td>
<td class="num">(50.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Total reclassifications, net of tax</a></td>
<td class="nump">86.0<span></span>
</td>
<td class="nump">30.3<span></span>
</td>
<td class="nump">258.5<span></span>
</td>
<td class="nump">189.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember', window );">Prior service benefits, net | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="num">(13.9)<span></span>
</td>
<td class="num">(20.8)<span></span>
</td>
<td class="num">(41.5)<span></span>
</td>
<td class="num">(48.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Actuarial losses, net | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="nump">122.7<span></span>
</td>
<td class="nump">59.1<span></span>
</td>
<td class="nump">368.7<span></span>
</td>
<td class="nump">288.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Other, net of tax | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="nump">$ 10.7<span></span>
</td>
<td class="nump">$ 13.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139657180653944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other&#8211;Net, (Income) Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 83.6<span></span>
</td>
<td class="nump">$ 89.6<span></span>
</td>
<td class="nump">$ 258.4<span></span>
</td>
<td class="nump">$ 270.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(7.0)<span></span>
</td>
<td class="num">(5.8)<span></span>
</td>
<td class="num">(18.0)<span></span>
</td>
<td class="num">(27.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net investment gains</a></td>
<td class="nump">246.8<span></span>
</td>
<td class="num">(141.7)<span></span>
</td>
<td class="num">(270.1)<span></span>
</td>
<td class="num">(905.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Retirement benefit plans</a></td>
<td class="num">(72.6)<span></span>
</td>
<td class="num">(114.0)<span></span>
</td>
<td class="num">(217.1)<span></span>
</td>
<td class="num">(194.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt extinguishment loss (Note 6)</a></td>
<td class="nump">405.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">405.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense</a></td>
<td class="num">(20.1)<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="num">(34.1)<span></span>
</td>
<td class="nump">161.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other&#8211;net, (income) expense</a></td>
<td class="nump">$ 635.9<span></span>
</td>
<td class="num">$ (158.9)<span></span>
</td>
<td class="nump">$ 124.3<span></span>
</td>
<td class="num">$ (694.9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>63
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MJ)MQTZXS5VUGT$QG,/C$*GD08*_ZD5GB=\OQR4*\JX3IU4$OZERAQ80WM'8
M]LX \A"T]&?[^G#/1N?_M;[_SZV?B('[4L%-/CR3[V.5LI(.I0'^NKP5DJNI
M_O="=K_/[C?9_9GLU_215D<*WGYFD@+TSE8];8:PR:!7P,=-&$7(B=?NXWA0
M3%@0^9X3GL)V)@QY&,9.<(K;FS@8>4DR:O:$<- 3#A;EW#(AU92AS[6><NJ)
M5!E@\D#Y^8*<89\]7)139]=35Y""6F=B&QZ-6?G8,[2TP# *'7^BI0D+4(BF
MDN]-&(Y"/%+\A&O4<XU^4#J"$IX>&@4S54<%JW6!VFA')I_(BYUD0ML"\\/
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MRC5 _7['U$;8O>@&^OO:S;]02P,$%     @ VDA;4Q3TAL?S @  O@@  !@
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MA ; \P6''JLW.D#SR3+X U!+ P04    " #:2%M3UN]#RK '  #N'P  &
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M+U95TCAXQD\&-,.9;]ZT:H= )P*Z?K0P$S_7#]!VNS:3[5B;MW%[XKJV*Z+
M]CH]+XI-75BE[44-/QO)R3D23[2V_7 MJV^QS4P#:Q'K[$ XZZ79.2 U9KV
MOA@P?2 ,%6-@>YD\> A M_6JBOM%?=8(=98H<=P^3,P!97R"^Z-S8/'OCHXJ
M[)A9]=1$/*YV]LNZ:LF2%5:["G _PC3_B&0E:@A25=^QO<#7-1/L4"_78XW-
M+ANI3K#AP&"4JN/87LAGZ=)"XM=B+2'5J2"5.&# N "*NX'G]V-!EV-^OV@-
MF#H0"PH2L)T2>B[OY:8'PCCNKPP=*UQ7A_;S1JX]&A[F?1@'M,$T#@FZG&N+
M;0ZX,99BVCS8Q\\ Y( 5V TF!M#$"JFP'58&MXL7FW1@]G1FJH*4T_[PZ')
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M,6-\'57L_,9)F$5D#.@AS?R58:9HKC:D>H2%=G9)BF(RO1#(^'7$*3&4C4L
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MTR&'0FA2VA,'(EF.4:$?"2,+#ASG(;1$E8(;4IC%\A&3#85:<)7&T\DIBX4
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MT:<L#<#W,X/("!]H@^;WBY[]!U!+ P04    " #:2%M3Z 10)YL0  "0.
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6R]6VUSV[:R_BL8-],3S\BT
M),N.G2:9<9SFU&G3>.+TY,[<N1\@$I+0D(0"@G'47W^?71!\D2A927WZQ19)
MO.S[/KL@G]T9^ZE8*.7$URS-B^<'"^>63X^/BWBA,EE$9JER/)D9FTF'2SL_
M+I96R80G9>GQ>#@\.\ZDS@]>/.-[-_;%,U.Z5.?JQHJBS#)I5R]5:NZ>'XP.
MPHWW>KYP=./XQ;.EG*M;Y?Y8WEA<'=>K)#I3>:%-+JR:/3^X'#U].:'Q/. _
M6MT5K=^".)D:\XDNKI/G!T,B2*4J=K2"Q+\OZDJE*2T$,CY7:Q[46]+$]N^P
M^FOF';Q,9:&N3/I1)V[Q_.#\0"1J)LO4O3=WOZB*GU-:+S9IP7_%735V>"#B
MLG FJR:#@DSG_K_\6LEAGPGC:L*8Z?8;,96OI),OGEES)RR-QFKT@UGEV2!.
MYZ246V?Q5&.>>P%N4CDU5I*,"B'S1+QS"V7%I;4RGRO(WQ7/CAVVH@G'<;7L
M2[_L>,NR%^*MR=VB$#_GB4JZ\X]!8DWG.-#Y<KQSP5NUC,3)<"#&P_%HQWHG
M-=\GO-[)EO7>V;G,]5_,]D!<@7>3ZD1Z2X$0;JPJP+J_86;BM<YE'FN9BEO<
M]&(1_WLY+9R%8?W?#HHF-443IFCRT)IX@&7%1P4FG<H%KO!,Y\Z(N)GY1?%$
MPQ,+G>E46B';"V!\HK[ QY<\,C99IBS)2_^E1&++N8AQGR2LBDA<=9<FS]1.
MJP*6O<+F<5HF2I &I(T7O&"U.&TVP"C[23F=S_D17#REWX_]1/JYM"8SQ##T
MU5J=1B\7JT*#L!Q+.JEIYB&MF)<SC"PMK@=^1PW=ZFE)RT3BPP+4=%GV K/J
M<ZFM@F^F"MZ:8U A[D 2_;=F)5.W$L8223/MCHJ%Q."E7/$: P@J)T9P(<HE
M3 T2%B:.2VM5'I-21*PLZ,S%K 1U2D .M#GH_J02$CO-*,HX5@61Q)>R*!#.
M==Z56HLN]15!O2 1ZVQ:VJ+B: :Q,:T5>6'YN&U#>&I=KFPD;I42OQNGQ%@@
M.PB9F=++96U"8SJ6J"]IW]C,X7[@@/=T+%VW6BJ>WA9S)-XM%2T$M59D%[Q=
M; IL!IV3K*!7L%%*B-'3O*XLDKI52V,=QFJ6LR9ZBJ7BO%"+A/Q':'CX0.00
M(E&3KQJ))* >.QB[+CMZX.57VGZ!0=MWVBU(68OUV5-%_+7$(AU+WB$!\@]:
M8X5A<"R2T335<^F\ 8"V2/PLL6AW6UV(,M>?01?XS259C[=LHC S$$BAL=M,
MQR2V#6G!_I%_"NPQI=0=B9=&+<@]H,=K_$TAP4R\TG*JX-.B$V<HGM!.O5,6
MDGQ>S%,S)?><6\6[$BM_&D2>=+4CE$A!.IPA6!O231*VQZ@ES"^AX,+.0\M4
MD20H?-TLP60?@3_^<#X>/?D)4K:@K]X!#IR4L2N>BC?2XB[<<R#^G:Z^RFRJ
M!^)VE?^)^ZN!^& U_Q+_\YXNY)^41[SDW]!/6 I8_?&'T9/)3VVG)+4 8&!/
MG1<E[' @7N)RCE@;]6Y$*[8V8X;66:YI#?2+F42H@L6T:-'%QKQ ]\:T#V25
M<IHJ;Q85FH-J"IY'/N,# :FG;6!U@(2RY%([UF<B'@-"*?+@0[)YI'FXWA3J
M"+F>N7REXNKNB.\..0)XE59Z7^- %UUM/Q6_@[*W#0U7;1I>U30\'AVR+F9/
M 0$\YZ^9\S[2-LEJQ/UX?"@>B=%D%(WH_^E9-&Z$^OCD4%R<XLEH-(G.:C5C
M]]-)-"0JSL[]_T/8)26)O$*Q'$&(<:OF92J=L2LAEU#2%YER[&PH\.81S*_)
M3W4LRR2R[)V"U;05(DF4#K% DY(YE?C,2>;EXQ04;!T/9IA0>%W+E&W FG+N
M2022R$)*ZB@C^E:F@H!ZV4#45(C@B6>%8JA-/!^47 F>(:C+*5)]#0)Z6=F'
M<JAU.+XX%%UXU)?CR%,T$;?T2-*[1\B1;@%CYT X50 16QPBY$91.(1_3]"Z
M87?H5D3%K!(E!4H&0\IJDS3IS'MGS7C$IOIA,SS6@9G5TQO*R0L;@U/DAHQB
MD$RUK;%SVT^A-D=KLA:06(MRN4QY&Y2$%&Q<91,$>SAT4.S%-NJK\Z4@"](B
M;$7L1M]/>.V-_SC=KZO@M2TX RCLR)\>0@)VRA1AB0%C/C>DZ1;<VTB=GJL
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M&'2,S4R)/ XJ?>*54'R2Z*J_5R>,CKQH(@5H!WC=+^I>_0=Z/$"O0KX4%"V
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ML,:7#CDVP/N5M6$_88##M]/L;U!+ P04    " #:2%M3 *&W6@T;  "27P
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M)'=A=UUN")^;BY#\7(0UW0:BM*FM6N[DT0A(D)'=;KB*6[@'7-UADXE.C0$
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M1F&OMGQ+2JO?F>A1WQ\GMVSQ94 JT<=X8CYXR-PFOY/NAN'[:4!R>JG/"]B
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MS/;\<X=86N74 -\W65::!YK 7L/_\G\!4$L#!!0    ( -I(6U,JQ3*5A0,
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MHX1<W_K[B=@VMMO,"IIW_*WP6F(7!+!?6BN[27 PO+^6_P)02P,$%     @
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M_UC6<,D+M:&P";UX3[!?PB)1ESW3M>;&\AT(1:MT&L16BW9"ZW B/5Y$,*@
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M.]YPJ#^?(88A!G,>@#,CVP23P B2?L/(A8+125<;X$;TM*]KO2)3U<"72UU
M9%4F!Z_/#U/20=Q>A7-40?J/PB1.BA$& ]J[2=, %1#;!5\$EO\66P\CO8$H
M84MA#[C@)4X7YBLIEXL?$J% *4K3,F]0L.9S-&$T]^]@R-XT/4(M!S[;Y.#T
M]S>GAXRN/<:!8$LC:,8DK:J0F\ZC(-S;<+I#,*-]&#,L=N)@][\6.["9<\,2
M<K6KOL)W.])*$BQB#.%.20ED.J?(G;2[[RQU:.V7#2:$SR1W3* *!K6V7P-
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M&8!L#+/( 8<>TNGJ1(G!Q?TN96A+!.8O)P%,* J?1/5R5:JE!.EKU0[&)-E
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M?# -4!G$6\K$G.JR58)C'^(&V79K@'/P[ABYL2(1%,$2>("LL+7"-O%P<$S
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M4QA0G;NX]"B=\.&5==TA:^_GNH=0SN:P94#LMPJC7<S>2*55$B9!I1I$FWL
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MI&NNDZ]8[))^95D6_(5<+;2S=;A(A&YT'L4;7UH(R"7)R874O)X\/7H=G<>
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M=DI1/]4 OQ'P\EU?9_6CCUR(WFCN=X@N./B'*M=8<W:W">#Z_E1@Y^SK=[U
MBCEYMOW;63&"M19O?(>#L*AWW%'O 6[@S[Y1')._3>CTVTF]!]I^&UV\O<.'
M^+)(+]K1>3G*MX_NDXA10!';7ND3'"%GXK!-"9U'R%;*L!>FJG1;=VK4UN+
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M+[WZQ_GW<B'X 7\$.$4OX-6CV?-G#_BG(NT?7;VFWWV=UV!#2OKG2F-)'1^
M[Q<U>"WY R=P/P3\R_\"4$L#!!0    ( -I(6U/#%%52E@<  ' 8   9
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M2EQQ&^E,T&6  0E#SWEB4DQ :#>(SBX]@2*KK: M(CZG&>'&L \:\4)":XP
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M4J.E\U_$EEFLBZE:-2E#4A-E%VS(XA5NH%P8B(2J$<:B].3!)CVWDPF4D#=
MNI(XPZO8@;B@7,]G5A@B7[>PP(1C/T*_87_ VK=7\VN00^I,+B3V'WP)/B^]
MD7E>@LI$5:F7BJ,&L'5-'!"PZ]@-MW&VZ\E@.($K-_+=K"9O<,2QMV@F)/,[
MZ?'<IJ2Y/H/DQZ94D%X,EB1%3[ T)CNT$1E3_\:1^_(<#IW#:Y.##Q]$G&FC
M3$H4"N'[3I4Q5*CK:)I$Q*1V)?9"!$UJ><Y^*-4^LY-I-&+79?ZI!+ZMFJE+
M9GNIRT$=5#VFS5*)VB5J;F4EKF6.I#44KR,+S2G "2Q_#@#Y]78=2[X3S9H4
M=RA],'8K5KE)^*;[QM9@W.&,#O6VS.LFO#'".-)=M;LFG[,RQ<2Y!\>HCN^/
MM[M9#;7];U.Z7UZ0':*GPLQN TH->3;0$[=V$-,M3=U#A]?1E-U);]>/_P\+
MP_CS5"%_+HC^9WD<@DBS!7U\  U1B=@9UT1J-V\ZH?>^ UKD5?Y.5-VCAD^%
M2G%!YUH12$@9C0[O[Z\NNX.C9Z&$4KG+, =D7()WVD$<M[E]8:(#]M8GP/7G
MM_\9N/4^:*2"<P'S^W2Z'=YTV$V)(<9WZP^[%13Z:G3-OO[J:#SYYDG@_GHV
MGP$SF([1PMZLS-^AT!=$58O25IG'FZU.2AS:$XXAPD$MG2:28M/ODZU^'X86
M36AH'FO&[#":;D9NBS$T%4U"K*@WU6/^/K/UUMQ "WBRHB:;;,\\F"X.V ."
M O-%H0 6C7+_@-?;^C*%-*?A^]M17K2O/E*;I\TG_JSZLGU:7OU_ (3&]."0
MS26V]J,I9CM;?7-7-]X4X3MW83SZ0+C,D'EA:0'>+PVR4M_0 <T_/L[^ %!+
M P04    " #:2%M31GS:T/,$  "G#   &0   'AL+W=O<FMS:&5E=',O<VAE
M970R,RYX;6R]5]]OVS80_E<((0\)$,B2+#MVD!A(TA7+@+1!DVT/PQYHZ2QQ
MI4B-I.*X?WWO2%EVTB3K-FPO)D7R[K[O?I$^6VOSV=8 CCTV4MGSJ':N/1V-
M;%%#PVVL6U"XL]*FX0X_336RK0%>>J%&CK(DF8X:+E2T./-KMV9QICLGA8);
MPVS7--QL+D'J]7F41MN%3Z*J'2V,%F<MK^ .W,_MK<&OT:"E% TH*[1B!E;G
MT45Z>IG3>7_@%P%KNS=GQ&2I]6?ZN"[/HX0 @83"D0:.PP-<@92D"&'\V>N,
M!I,DN#_?:G_ON2.7);=PI>6OHG3U>32+6 DKWDGW2:]_A)[/A/056EK_R];]
MV21B16>=;GIA1- (%4;^V/OA>P2R7B#SN(,AC_(==WQQ9O2:&3J-VFCBJ7II
M!"<4!>7.&=P5*.<6R$;RI3:<?&095R7[Z&HP[,(8KBI _SO+#N_Y4H(].ALY
MM$F2HZ+7?QGT9Z_HG[,;K5QMV0^JA/*I_ BQ#H"S+>#+[$V%=]#&;)P<LRS)
MTC?TC0<'C+V^\2OZ/IJ**_'%\S]F5^@$+47)0\J@-VX-6/1!6- K]EXHK@K!
M);O#Q=X_OUTLK3.88;^_@2@?$.4>4?X:0RR\LI- UJRHE%B)@BN'T<<0.*T@
MA,G  Z@.<"PT'OKRW+O!F6^:HHH_M2TOX#QJB:=Y@&AQ7P-S%&^VI)KMZQ4-
M6(:9P11V"M[H#A&]#K#@K7!<$BIVB$4"QD!YQ+AC&#_TVA(S;!M$S^8=%/UJ
MZE<3A@W'VRMTTZ*UTC*A"MEA%N$$=P1:V4_>4_8!D=WL,%SM8W@W8#A,$8=%
M[*<86UUVA6/O.4+?O 3M6U@_<5,*S !@A]D1.V!IGL8IC9-IG+%[P_^@;&&'
MXR,VG^!.FN;QE%URRRO)#5J?Y'%"**:S,!ZQ:X5,E.K[U%JXVA,W4'62.VTV
MC+>MT0]<$NP]!.2XK<7CG?M9RS<A+QM> EN#@2<!X>1*A]4M*,C<6G AI;BA
MF M548"-\X>=1G VQ)I+GP-&=U6 Z, TM!/BM!>,^.^2VCKH11J8XH"]NPQ4
M*.%-&7B@"5]W3 J^%%(X 6]0^1[D&-8DFQ\%WOOKI%7[UMA77LSN*0D-M*%%
MA/((I4%S3/::/Q ,4*\5Q,KHQHM9QXT+@)XG]A/<0"A6O2M;8H846S!"E\>^
M-'&SK\Z!>.Q3]?X;IKPRX!M8",^EAMJ@.F1XC;^R!M'X*MPE'% 9=BW*PF,K
MS- 4]^L4P^9(IX^"VF#[:%OIS>"ESS#DKL^) A >M0Z',4,S\.C"9>\=:<#I
MV)?1/P<^5./_CILPKQ"S7E-\0C?=ZZ.Z,W^577M]/;#$)&L1 24FP7ZY"[ 5
MM3(J F37AO86"H),4G[TB]]C9EN3IT@''?[D)G_6+#_@Q?+6_K-.ZWNK;Z>[
MV8[0 1O/DSBG,4WB&377XV0RB^<XF^5)/-ZUTW2>X8$LGV'OG4X2[+>S/,,#
M@S_F4UR;I_$)RT[FJ"&;TOQ?\WF)P$?9-8+NP0.6)U./-IUF<4*HD[F_)/)\
M^E]9O]\\;,ATFDWPOB%'!0^BOS(<LV2"B%YZG8SV'H\-F,H_D:D%80\)[\AA
M=7B%7X3'Y^YX>,+?<%,)+ ,)*Q1-XI-)Q$QX%H</IUO_%%UJAP];/ZWQGP08
M.H#[*XU5UG^0@>&_R>(K4$L#!!0    ( -I(6U/9HB;HVP(  ,\&   9
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MD8&NE3T+M3=&S_G\<:R-T04W(:VIJN@#O)]H;=H;<K \D#[^&U!+ P04
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M,J4QBLH>H.\[*<UA8P6:P3S[ U!+ P04    " #:2%M3[V0M)@X"  "!!
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M78J:C>=#5%<B/1L0?SD?F=ES98F "G'Q^!;'V70#WSE.-V%FMMJA!,&L\8T
MXP/PO-+:G1P_AL.KD[\"4$L#!!0    ( -I(6U/MVA4HAQ,  -J4   9
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M@G!#<UT5I5^EI;]#4UX,%;(E"OL2*NJNFNQ,G$IVU<N1^14'"Z23JTXP/'H
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M?<(87#,U&%SG\E'Q?5KQOUNO-L=E=GKLHYSZPN:&CV+K)YL;IY)=8[P_WV)
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MP>":X65J$US%E5%-&^JG*CF<[.Q+[3TYZ@\RB<3G-><1"Y> HG\@"SLA@$*
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M!6#L; :@ H#V!> "@/<%D ) ]@4$!2!X"VAO ;0+0'M?#YT"T-D7T"T W;>
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M3@W,]X_*=%E^D1:P?7/OXG]02P,$%     @ VDA;4^?D*DTR P  U@D  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S@N>&ULI59;;]HP%/XK5K2'5FK)E< J
M0*+0:7VH5I5='J8]F.1 K"5V9AMH__V.G30#$EBUO8#M?-^Y?#ZVSV@GY$^5
M 6CR7.1<C9U,Z_+&=56204%53Y3 \<M*R()JG,JUJTH)-+6D(G<#SXO=@C+N
M3$9V[5%.1F*C<\;A41*U*0HJ7VXA%[NQXSNO"T]LG6FSX$Y&)5W# O27\E'B
MS&VLI*P KIC@1,)J[$S]F[NAP5O 5P8[M3<F)I.E$#_-Y#X=.YX)"')(M+%
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M]1B=S& +DO($NDJIHKZW5',=;B>8Y'9_<RI$O(?PHZ@7':+F'2B_US\$W76
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MK&-9=1'51(O2/I-+H?'1M<,,&R^0!H#?5T+HUXEQT+1RD]]02P,$%     @
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M[?8&>\%:R[6\U,8];\]( C'3,WI[MKP7B TALH^9T^0K8LK-^0UV5^0II%=
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M;=^O6=YG6U=I6\ "CFRT+0&B$.?9;=M>4C-@$X +4<-%R[[/,O4C0M) K'0
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MQ!*_9+F.](5L#_#BJ?$B]7BM.'Z40> !:SPKE^\\X36/3H(U, B\;L;4/P@
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M2X!ZOF%,'F_*"=I#IME_4$L#!!0    ( -I(6U/#*ND-)@@  %XO   9
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;+6:;7/BMA;'OXJ&NW.[.Y,)R$]
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M;!L<(G'-']ZQ*B KM[?F45;\CQXJK#%!ZT,F>%P-EC.(PZ3\&WRK$M$:(.W
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MELA/ EU5CQB"9(.NF0A3QDJ>>">Y1.P;G$R,EC$:?4*<E\<8C78@>NTPCC$
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M;"]W;W)K<VAE971S+W-H965T-3 N>&ULS5=;;]LV%/XKA%<,#K!8-UNV,]M
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M&U82=\IU8>#U<-PSP!"&T\ .S08DC0')H $+6*FW6NTA1\+WVHF<<HY&3U0
MBL8F)Y+>5 *Y%%Y'?-(3[W:47\6S'.(YTYPVFM-!S?HL12-2'Z #>UIJ6)I>
M:<[3W@2QWU%J(/*#WA+WHW"$+ZTP=G^T#NZ_ZZU[AU+W#E=(KSG;NVCDAW:W
MP@UA-UCNR=V=VQ"'O<#N^+0TT46RRM..!TZKDRJ [70+R]&:'DM1G:#-:-,F
MW^GFL#-^CV_GV#"^4&VU[MQ^T%<]^6/&=G)?1#EL92K7CN7"LZK-K6X$/>@^
M;D6%[ KUY5[^-0"F N3S+95O5GVC$C1_-F;_ %!+ P04    " #:2%M3='C-
M95T#   !%@  #0   'AL+W-T>6QE<RYX;6S=6-%NVC 4_94HG:9.FAI"1B K
M(&U(E29M4Z7V86^5(0Y8<IS,,1WT<;]2[6U?L4_9E\PW#@E07T;[L,*":.Q[
M?,\]OKY.7/J%6G)Z-:-4.8N4BV+@SI3*WWI>,9G1E!1G64Z%1I),ID3IKIQZ
M12XIB0MP2KG7;K5"+R5,N,.^F*<7J2J<2387:N#V:I-C;A_B@>N';US'T(VR
MF [<F].77^>9.G_AF/O)ZY.3UEGKYM7Y-G):0:]<STK<V21NB/[F&.ZE:)<D
ME+J[!S7*BY'V]M.[4S!*'MG)?W__B6AND)VJNRT[\:\?"&\-[*;U$=I[C/;^
M(:U75>ZPGV2B*># -08=EZ34N25\X(X(9V/)P"LA*>-+8VZ#89+Q3#I*[QPM
MQ =+<6=@W_1@4U4\*1.9+&.;".;ON!J^!:QZ()!Q7@MLN\8P[.=$*2K%A>Z4
M@TOC \BIVM?+7"N<2K+TVQVW<2AO.L@XDS&5=1C?79F&?4X3D"/9= 9WE>4>
M@$IEJ6[$C$PS04H-*X^JH6DGE/,K>.)\23:X%\G:BI9E(NJF%E0U#8WI /\Z
MF^%>I^T\B=?)V6VFWL_U=$39ATJAEY(F;%'V%TDM &/W<7:2YWSYCK.I2*F9
M_-X!AWVR\G-FF61W.AJ4RD0;J'2=6RH5FZQ;ODF27].%6I73(L$UMX]0\[_-
M\Y0**@E?%ZUK_Y"S_&3%0?>Y))=/E6W!5HW5,>+017:.061X#"*/HB9[QR R
M.@*1W6=[:CY&I'_X(@\SCUYU6EL[$FX<"&NK P?O@?L9#OB\">J,YXPK)JK>
MC,4Q%0_.A9I>D;'^_W:#7X^/:4+F7%W7X,!MVI]HS.9I5(^ZA$14HYKV1YB>
M']:G?AV+B9@N:#RJNG(Z+IN.;NBHU04.V\A%>=D1S,=@=@0P+ ZF /,Q7EB<
M_VD^/70^!L.T]:Q(#_7IH3[&RX:,R@\6Q^X3Z<L^TR@*@C#$,CH:616,L+R%
M(7SM;)@V\,#B0*3'Y1I?;;Q"=M<!MJ:[*@2;*5Z)V$SQ7 -BSQMX1)%]M;$X
MX(&M E8[$-\>!VK*[A,$L*J8-FP'XT@480C4HKU&PQ#)3@@?^_I@NR0(HLB.
M &97$ 08 KL11S %H %#@J!\#VZ]C[S5>\IK?O0=_@%02P,$%     @ VDA;
M4Y>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(
M,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5
MN %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;
M+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%
MR=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M    " #:2%M3T+NV'E0$  "Z(@  #P   'AL+W=O<FMB;V]K+GAM;,6:77/:
M.!1 _XK&3V2FL^"OM,V4SB2AV64FFS*DF]>.L"^@1I98229I?OW*=FCE%N[L
MRX4GL"SD8PGIZ%[[PY,VCPNM']ES)94=1VOG-A?#H2W64''[A]Z \F>6VE3<
M^4.S&MJ- 5[:-8"KY# 9C<Z'%1<J^OAAU];,#,,#[:!P0BM?V!0\"'BR/\\W
MAVPKK%@(*=SW<=1^EQ"Q2BA1B1<HQ]$H8G:MG_[21KQHY;B\+XR6<AS%W8D'
M,$X4OQ7?-Y!?^,*V)8XOYMR#C*/SD6]P*8QU;8VV?>X9M^ K=T>UTS=".C 3
M[N!/H^N-4*NF&7\7P^ VVG[8?7:=>&'^3S?JY5(4,-%%78%R73\:D V@LFNQ
ML1%3O()Q=*VW8-B,KZ"Y*7^5:=G=H/-D07>9"^%/F&G9,E+R**NE*/W52^8/
M2E#6?[MO</Q/ \@$@4Q."/DU"2!3!#(]">05EUP5P +(#(',3@C9Z\D<@<Q/
M.=QI 'F.0)Z?$C(+(-\BD&]/"9D'D.\0R'>TD%?<"LOTDLT,6%^UK1&@O4?0
MWM.BS6$+JNXMU2-LK1[1XEP6_];^HFUYR(3Z@UP@4O*%-MT9QE7)/KNU=]RE
M,5RM0DS,(#&Q0BZM]2U/JPT7IJGZALW!.E,7KC:BCXDY)":6R(U0?B$67+*I
M:O":ZKVAQMP1$\MCJ@I= ?O"GZ''A*DB)G;%')PPS4[%L2M0L!3][L($$=,;
MPOF_%OCQ[/<7)H28V C=W+S6E=_WK[T-_"Z9O8[KX%;W,#$EQ,1.:#&_WH&?
MIX,.[XQ]>MXT^@H1,37$Q&[8JRTVF'G?_C+@">:,A-@9KPIC Q\,2;!G(1?F
MC838&Z'+]L*A\09YP(%(K;=-3C!;),2V0*76Q\2\D1![8Z_4]HXY9I+D^";9
MRX@I)2%6"KIZ]P<<DTQR#,GL7[V;+@TQ,<DDQ)+YL33>UU7%S?=F,=^5S:$(
M,3'1),<)0MC@LOQ66]?-'J?9[\%)BHDF/99HFGV/X85CMX*W:4!OP[,P_Y%B
MWDF)O?,#<R(L7ZT,K#IQOXY]B(D9*"4V$(K93WFA.2]J _4L?L=-H\RMG^Z#
M"3@N0DS,0"FQ@?J8K38M:PL-E"Q<D%),02FQ@O9@LJ LQ,0LE)('-MCN*,S/
MI9B%4F(+X;NC'B9FH9380@=V1[NY%&)B%DJ)+70 \]-R"7ZIUV%Z&[-01FRA
M Y@W_C_ 'K@,,3$+9<06.H Y%_:1_<W#F9YA%LJ(+70 <V?X$!.S4':*K!D;
M_*,,<"E>0DSTV<MIXJ!Y"PEEB(E9*".V4)CF>_6X[(5 &2:?C%@^>\.T)B+2
MZI=<:8;))Z-_\O(S^;>_%S'I9,?(KQT,)$,W9IAT,F+IX)CA0[8<DTY.+!T<
M,WS,EF/2R8FE@X;EDS#TR3'IY*UTAKMW)4H_!Q64=_X2UI<77!8SPYJ/[J%/
MEC=IVF4MY;4O^ZQN-2]WKU[L7AOY^!]02P,$%     @ VDA;4XHQ=E_/ 0
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ME2[J8SYK?X5//P%02P$"% ,4    " #:2%M3!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( -I(6U-Q
M;\+@[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( -I(6U.97)PC$ 8  )PG   3              "  <P!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ VDA;4^5501*I!P
MTS$  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( -I(6U,^=(.1C@4  +L5   8              " @>P/
M  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #:2%M3%/2&
MQ_,"  "^"   &               @(&P%0  >&PO=V]R:W-H965T<R]S:&5E
M=#,N>&UL4$L! A0#%     @ VDA;4];O0\JP!P  [A\  !@
M ("!V1@  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( -I(
M6U-)[???:@(  &4%   8              " @;\@  !X;"]W;W)K<VAE971S
M+W-H965T-2YX;6Q02P$"% ,4    " #:2%M3E:I,94 *   T.0  &
M        @(%?(P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%
M  @ VDA;4['RI<KE @  8@@  !@              ("!U2T  'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( -I(6U.:=MK9=@<  'H?   8
M              " @? P  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"
M% ,4    " #:2%M3'/(:'O0%  #W#0  &               @(&<.   >&PO
M=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ VDA;4Y;T)_Q:#0
M:",  !D              ("!QCX  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX
M;6Q02P$"% ,4    " #:2%M3_$\5@>T.  #+2   &0              @(%7
M3   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( -I(6U/H
M!% GFQ   ) X   9              " @7M;  !X;"]W;W)K<VAE971S+W-H
M965T,3(N>&UL4$L! A0#%     @ VDA;4]0L5QVU P  1PD  !D
M     ("!36P  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M" #:2%M3 *&W6@T;  "27P  &0              @($Y<   >&PO=V]R:W-H
M965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( -I(6U,JQ3*5A0,  (L)   9
M              " @7V+  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L!
M A0#%     @ VDA;4STBXO6% P  ?0@  !D              ("!.8\  'AL
M+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #:2%M38>&V>OPE
M   4>   &0              @('UD@  >&PO=V]R:W-H965T<R]S:&5E=#$W
M+GAM;%!+ 0(4 Q0    ( -I(6U/#%%52E@<  ' 8   9              "
M@2BY  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ VDA;
M4U@PU53^ @  O@8  !D              ("!]<   'AL+W=O<FMS:&5E=',O
M<VAE970Q.2YX;6Q02P$"% ,4    " #:2%M34,C[C3X%  #O#   &0
M        @($JQ   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0
M   ( -I(6U.K?7.5!@L  $L<   9              " @9_)  !X;"]W;W)K
M<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ VDA;4U2<,Q?2!@  !!$
M !D              ("!W-0  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q0
M2P$"% ,4    " #:2%M31GS:T/,$  "G#   &0              @('EVP
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( -I(6U/9HB;H
MVP(  ,\&   9              " @0_A  !X;"]W;W)K<VAE971S+W-H965T
M,C0N>&UL4$L! A0#%     @ VDA;4W*+_NQ@"@  %"H  !D
M ("!(>0  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #:
M2%M3E&> R)0#  "?"   &0              @(&X[@  >&PO=V]R:W-H965T
M<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( -I(6U.BGMISK08  )P6   9
M          " @8/R  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#
M%     @ VDA;4_I"9FP1 P  L08  !D              ("!9_D  'AL+W=O
M<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #:2%M3W-Z_GF8#  #Q
M"P  &0              @(&O_   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM
M;%!+ 0(4 Q0    ( -I(6U.R/V*\J@(  *0'   9              " @4P
M 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ VDA;4^]D
M+28. @  @00  !D              ("!+0,! 'AL+W=O<FMS:&5E=',O<VAE
M970S,2YX;6Q02P$"% ,4    " #:2%M3[=H5*(<3  #:E   &0
M    @(%R!0$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    (
M -I(6U-5XAPOL@,  -0.   9              " @3 9 0!X;"]W;W)K<VAE
M971S+W-H965T,S,N>&UL4$L! A0#%     @ VDA;4Z4S#+85!0  %Q4  !D
M             ("!&1T! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"
M% ,4    " #:2%M3"WQ@DK$#  !9#   &0              @(%E(@$ >&PO
M=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( -I(6U-AI$@J. 4
M !8=   9              " @4TF 0!X;"]W;W)K<VAE971S+W-H965T,S8N
M>&UL4$L! A0#%     @ VDA;4Z"S/ V="   Q3<  !D              ("!
MO"L! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #:2%M3
MY^0J33(#  #6"0  &0              @(&0- $ >&PO=V]R:W-H965T<R]S
M:&5E=#,X+GAM;%!+ 0(4 Q0    ( -I(6U,ZH&_"B0H  )I"   9
M      " @?DW 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%
M  @ VDA;4TA'5$Y8!0  Z1<  !D              ("!N4(! 'AL+W=O<FMS
M:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #:2%M3X_7H6]X,  ")>
M&0              @(%(2 $ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+
M 0(4 Q0    ( -I(6U-.8[.#O@D  &Q8   9              " @5U5 0!X
M;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ VDA;4XN_.'=5
M @  O@4  !D              ("!4E\! 'AL+W=O<FMS:&5E=',O<VAE970T
M,RYX;6Q02P$"% ,4    " #:2%M3\$^-5I,"  "T!@  &0
M@('>80$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( -I(
M6U.#J0KUY (  )<(   9              " @:AD 0!X;"]W;W)K<VAE971S
M+W-H965T-#4N>&UL4$L! A0#%     @ VDA;4[T])*90 @  R@8  !D
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M=#4P+GAM;%!+ 0(4 Q0    ( -I(6U-WGSG9Q00  ,05   9
M  " @1N# 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @
MVDA;4XE: O>J P  > P  !D              ("!%X@! 'AL+W=O<FMS:&5E
M=',O<VAE970U,BYX;6Q02P$"% ,4    " #:2%M3='C-95T#   !%@  #0
M            @ 'XBP$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( -I(6U.7
MBKL<P    !,"   +              "  8"/ 0!?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( -I(6U/0N[8>5 0  +HB   /              "  6F0 0!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " #:2%M3BC%V7\\!   S'P  &@
M        @ 'JE $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " #:2%M3,N&!X<<!   2'P  $P              @ 'QE@$ 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     /  \ %L0  #IF $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>821</ContextCount>
  <ElementCount>326</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>157</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>17</UnitCount>
  <MyReports>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Condensed Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations</Role>
      <ShortName>Consolidated Condensed Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Condensed Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Condensed Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets</Role>
      <ShortName>Consolidated Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Condensed Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity</Role>
      <ShortName>Consolidated Condensed Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Condensed Statements of Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical</Role>
      <ShortName>Consolidated Condensed Statements of Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Consolidated Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows</Role>
      <ShortName>Consolidated Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2115104 - Disclosure - Collaborations and Other Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangements</Role>
      <ShortName>Collaborations and Other Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2118105 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges</Role>
      <ShortName>Asset Impairment, Restructuring, and Other Special Charges</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130107 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2132108 - Disclosure - Retirement Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefits</Role>
      <ShortName>Retirement Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2135109 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2137110 - Disclosure - Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLoss</Role>
      <ShortName>Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2142111 - Disclosure - Other???Net, (Income) Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherNetIncomeExpense</Role>
      <ShortName>Other???Net, (Income) Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/BasisofPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Revenue</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Acquisitions</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - Collaborations and Other Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangementsTables</Role>
      <ShortName>Collaborations and Other Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/CollaborationsandOtherArrangements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2319304 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables</Role>
      <ShortName>Asset Impairment, Restructuring, and Other Special Charges (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstruments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2333306 - Disclosure - Retirement Benefits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsTables</Role>
      <ShortName>Retirement Benefits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefits</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2338307 - Disclosure - Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</Role>
      <ShortName>Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLoss</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2343308 - Disclosure - Other???Net, (Income) Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherNetIncomeExpenseTables</Role>
      <ShortName>Other???Net, (Income) Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherNetIncomeExpense</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Revenue (Summary of Revenue Recognized) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails</Role>
      <ShortName>Revenue (Summary of Revenue Recognized) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Revenue (Adjustments to Revenue) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails</Role>
      <ShortName>Revenue (Adjustments to Revenue) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Revenue (Contract Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueContractLiabilitiesDetails</Role>
      <ShortName>Revenue (Contract Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Revenue (Disaggregation of Revenue by Product) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails</Role>
      <ShortName>Revenue (Disaggregation of Revenue by Product) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Revenue (Disaggregation of Revenue by Geographical Area) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails</Role>
      <ShortName>Revenue (Disaggregation of Revenue by Geographical Area) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RevenueTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Acquisitions (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Acquisitions (Assets Acquired and Liabilities Assumed) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions (Assets Acquired and Liabilities Assumed) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Acquisitions (Asset Acquisitions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails</Role>
      <ShortName>Acquisitions (Asset Acquisitions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AcquisitionsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Collaborations and Other Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails</Role>
      <ShortName>Collaborations and Other Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/CollaborationsandOtherArrangementsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails</Role>
      <ShortName>Asset Impairment, Restructuring, and Other Special Charges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Financial Instruments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Financial Instruments (Effect of Risk-Management Instruments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Effect of Risk-Management Instruments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Financial Instruments (Fair Value of Financial Instruments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Fair Value of Financial Instruments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Financial Instruments (Risk Management Instruments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Risk Management Instruments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2427415 - Disclosure - Financial Instruments (Contractual Maturities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails</Role>
      <ShortName>Financial Instruments (Contractual Maturities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2428416 - Disclosure - Financial Instruments (Unrealized Gains and Losses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails</Role>
      <ShortName>Financial Instruments (Unrealized Gains and Losses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2429417 - Disclosure - Financial Instruments (Realized Gains and Losses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails</Role>
      <ShortName>Financial Instruments (Realized Gains and Losses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2431418 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/IncomeTaxes</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Retirement Benefits (Components of Net Periodic Benefit Cost) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>Retirement Benefits (Components of Net Periodic Benefit Cost) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/RetirementBenefitsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2436420 - Disclosure - Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/ContingenciesDetails</Role>
      <ShortName>Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/Contingencies</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2439421 - Disclosure - Other Comprehensive Income (Loss) (AOCI) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (AOCI) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2440422 - Disclosure - Other Comprehensive Income (Loss) (Tax Effect) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Tax Effect) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - Other Comprehensive Income (Loss) (Reclassification) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Reclassification) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="lly-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2444424 - Disclosure - Other???Net, (Income) Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/OtherNetIncomeExpenseDetails</Role>
      <ShortName>Other???Net, (Income) Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lilly.com/role/OtherNetIncomeExpenseTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="lly-20210930.htm">lly-20210930.htm</File>
    <File>lly-20210930.xsd</File>
    <File>lly-20210930_cal.xml</File>
    <File>lly-20210930_def.xml</File>
    <File>lly-20210930_lab.xml</File>
    <File>lly-20210930_pre.xml</File>
    <File>lly-9302021x10qxexhibit311.htm</File>
    <File>lly-9302021x10qxexhibit312.htm</File>
    <File>lly-9302021x10qxexhibit32.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>69
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lly-20210930.htm": {
   "axisCustom": 2,
   "axisStandard": 21,
   "contextCount": 821,
   "dts": {
    "calculationLink": {
     "local": [
      "lly-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lly-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lly-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lly-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lly-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lly-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 517,
   "entityCount": 1,
   "hidden": {
    "http://www.lilly.com/20210930": 1,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 6
   },
   "keyCustom": 27,
   "keyStandard": 299,
   "memberCustom": 103,
   "memberStandard": 50,
   "nsprefix": "lly",
   "nsuri": "http://www.lilly.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.lilly.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Revenue",
     "role": "http://www.lilly.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Acquisitions",
     "role": "http://www.lilly.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115104 - Disclosure - Collaborations and Other Arrangements",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangements",
     "shortName": "Collaborations and Other Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118105 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges",
     "role": "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges",
     "shortName": "Asset Impairment, Restructuring, and Other Special Charges",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Financial Instruments",
     "role": "http://www.lilly.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130107 - Disclosure - Income Taxes",
     "role": "http://www.lilly.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132108 - Disclosure - Retirement Benefits",
     "role": "http://www.lilly.com/role/RetirementBenefits",
     "shortName": "Retirement Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135109 - Disclosure - Contingencies",
     "role": "http://www.lilly.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137110 - Disclosure - Other Comprehensive Income (Loss)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLoss",
     "shortName": "Other Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142111 - Disclosure - Other\u2013Net, (Income) Expense",
     "role": "http://www.lilly.com/role/OtherNetIncomeExpense",
     "shortName": "Other\u2013Net, (Income) Expense",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Condensed Statements of Operations",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations",
     "shortName": "Consolidated Condensed Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation (Policies)",
     "role": "http://www.lilly.com/role/BasisofPresentationPolicies",
     "shortName": "Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Revenue (Tables)",
     "role": "http://www.lilly.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Acquisitions (Tables)",
     "role": "http://www.lilly.com/role/AcquisitionsTables",
     "shortName": "Acquisitions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - Collaborations and Other Arrangements (Tables)",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangementsTables",
     "shortName": "Collaborations and Other Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319304 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Tables)",
     "role": "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables",
     "shortName": "Asset Impairment, Restructuring, and Other Special Charges (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333306 - Disclosure - Retirement Benefits (Tables)",
     "role": "http://www.lilly.com/role/RetirementBenefitsTables",
     "shortName": "Retirement Benefits (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338307 - Disclosure - Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables",
     "shortName": "Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343308 - Disclosure - Other\u2013Net, (Income) Expense (Tables)",
     "role": "http://www.lilly.com/role/OtherNetIncomeExpenseTables",
     "shortName": "Other\u2013Net, (Income) Expense (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - Revenue (Summary of Revenue Recognized) (Details)",
     "role": "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails",
     "shortName": "Revenue (Summary of Revenue Recognized) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i3751844cca5948b7a2fad81b7407b645_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Condensed Statements of Comprehensive Income (Loss)",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss",
     "shortName": "Consolidated Condensed Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i61a4e12edfa84ace81f68212f895f984_D20210701-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Revenue (Adjustments to Revenue) (Details)",
     "role": "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails",
     "shortName": "Revenue (Adjustments to Revenue) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i61a4e12edfa84ace81f68212f895f984_D20210701-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lly:RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ie526750480d147ff852c5266a9af6876_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Revenue (Contract Liabilities) (Details)",
     "role": "http://www.lilly.com/role/RevenueContractLiabilitiesDetails",
     "shortName": "Revenue (Contract Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Revenue (Disaggregation of Revenue by Product) (Details)",
     "role": "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
     "shortName": "Revenue (Disaggregation of Revenue by Product) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "if41782491b964242bf0779976ed75cfc_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Revenue (Disaggregation of Revenue by Geographical Area) (Details)",
     "role": "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
     "shortName": "Revenue (Disaggregation of Revenue by Geographical Area) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ia3c0a13a33a349aa92d5012e4b636a7a_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Acquisitions (Narrative) (Details)",
     "role": "http://www.lilly.com/role/AcquisitionsNarrativeDetails",
     "shortName": "Acquisitions (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i34f0affb1412406985b955e8954cdf8e_I20210131",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ie526750480d147ff852c5266a9af6876_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Acquisitions (Assets Acquired and Liabilities Assumed) (Details)",
     "role": "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Acquisitions (Assets Acquired and Liabilities Assumed) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i34f0affb1412406985b955e8954cdf8e_I20210131",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Acquisitions (Asset Acquisitions) (Details)",
     "role": "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails",
     "shortName": "Acquisitions (Asset Acquisitions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i6b575113de824b30a1c74f39db88aefd_D20210101-20210131",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Collaborations and Other Arrangements (Details)",
     "role": "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
     "shortName": "Collaborations and Other Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "if5010b2b7e5545ed8348dbdee8d74c25_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Asset Impairment, Restructuring, and Other Special Charges (Details)",
     "role": "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails",
     "shortName": "Asset Impairment, Restructuring, and Other Special Charges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Financial Instruments (Narrative) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ie526750480d147ff852c5266a9af6876_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Condensed Balance Sheets",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets",
     "shortName": "Consolidated Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ie526750480d147ff852c5266a9af6876_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:DerivativeInstrumentsGainLossRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Financial Instruments (Effect of Risk-Management Instruments) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
     "shortName": "Financial Instruments (Effect of Risk-Management Instruments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:DerivativeInstrumentsGainLossRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ie526750480d147ff852c5266a9af6876_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Financial Instruments (Fair Value of Financial Instruments) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
     "shortName": "Financial Instruments (Fair Value of Financial Instruments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "iab73c3bd3fe34c699b5cb054ccb42a6b_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "iab73c3bd3fe34c699b5cb054ccb42a6b_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Financial Instruments (Risk Management Instruments) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails",
     "shortName": "Financial Instruments (Risk Management Instruments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "iab73c3bd3fe34c699b5cb054ccb42a6b_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ie526750480d147ff852c5266a9af6876_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427415 - Disclosure - Financial Instruments (Contractual Maturities) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails",
     "shortName": "Financial Instruments (Contractual Maturities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ie526750480d147ff852c5266a9af6876_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ie526750480d147ff852c5266a9af6876_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428416 - Disclosure - Financial Instruments (Unrealized Gains and Losses) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails",
     "shortName": "Financial Instruments (Unrealized Gains and Losses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ie526750480d147ff852c5266a9af6876_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429417 - Disclosure - Financial Instruments (Realized Gains and Losses) (Details)",
     "role": "http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails",
     "shortName": "Financial Instruments (Realized Gains and Losses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "lly:ProceedsfromSaleofEquityandAvailableforSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431418 - Disclosure - Income Taxes (Details)",
     "role": "http://www.lilly.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i176730f8aadd46128632c5ba433875c6_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Retirement Benefits (Components of Net Periodic Benefit Cost) (Details)",
     "role": "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "Retirement Benefits (Components of Net Periodic Benefit Cost) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i176730f8aadd46128632c5ba433875c6_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic2caaa0461b646bfa03a4e4b72b0fd0c_I20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "lly:LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup",
      "reportCount": 1,
      "unitRef": "site",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436420 - Disclosure - Contingencies (Details)",
     "role": "http://www.lilly.com/role/ContingenciesDetails",
     "shortName": "Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "id08a7fa5ef244fbdb2e5f2a1bf85908a_D20090301-20210930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNumberOfPlaintiffs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plaintiff",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ie146f46cbfc341289d8af574772b4b88_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439421 - Disclosure - Other Comprehensive Income (Loss) (AOCI) (Details)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
     "shortName": "Other Comprehensive Income (Loss) (AOCI) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ie526750480d147ff852c5266a9af6876_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Condensed Balance Sheets (Parenthetical)",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical",
     "shortName": "Consolidated Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ie526750480d147ff852c5266a9af6876_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440422 - Disclosure - Other Comprehensive Income (Loss) (Tax Effect) (Details)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails",
     "shortName": "Other Comprehensive Income (Loss) (Tax Effect) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - Other Comprehensive Income (Loss) (Reclassification) (Details)",
     "role": "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails",
     "shortName": "Other Comprehensive Income (Loss) (Reclassification) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i9611b430044e49a384caf7309cee05ff_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444424 - Disclosure - Other\u2013Net, (Income) Expense (Details)",
     "role": "http://www.lilly.com/role/OtherNetIncomeExpenseDetails",
     "shortName": "Other\u2013Net, (Income) Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i612deeb868604a2c937e486f25fce6f6_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Condensed Statements of Equity",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity",
     "shortName": "Consolidated Condensed Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i612deeb868604a2c937e486f25fce6f6_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Condensed Statements of Equity (Parenthetical)",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical",
     "shortName": "Consolidated Condensed Statements of Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i369d527a3a544d0e92b64c7679d350bd_D20200701-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "i77c9c7d940cb4f60984ea34283b3aa2b_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Consolidated Condensed Statements of Cash Flows",
     "role": "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows",
     "shortName": "Consolidated Condensed Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation",
     "role": "http://www.lilly.com/role/BasisofPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20210930.htm",
      "contextRef": "ic43f823a6cce4f7791eb66cfb7601752_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 157,
   "tag": {
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BRAZIL",
        "terseLabel": "Brazil"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "lly_A1.000NotesDueJune22022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.000% Notes Due June 2, 2022 [Member]",
        "label": "1.000% Notes Due June 2, 2022 [Member]",
        "terseLabel": "1.000% Notes due 2022"
       }
      }
     },
     "localname": "A1.000NotesDueJune22022Member",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.625NotesDueJune22026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625% Notes Due June 2, 2026 [Member]",
        "label": "1.625% Notes Due June 2, 2026 [Member]",
        "terseLabel": "1.625% Notes due 2026"
       }
      }
     },
     "localname": "A1.625NotesDueJune22026Member",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.700Notesdue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.700% Notes due 2049 [Member]",
        "label": "1.700% Notes due 2049 [Member]",
        "terseLabel": "1.700% Notes due 2049"
       }
      }
     },
     "localname": "A1.700Notesdue2049Member",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1125NotesDue2051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.125% Notes Due 2051",
        "label": "1.125% Notes Due 2051 [Member]",
        "terseLabel": "1.125% Notes due 2051"
       }
      }
     },
     "localname": "A1125NotesDue2051Member",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CoverPage",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1375NotesDue2061Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.375% Notes Due 2061",
        "label": "1.375% Notes Due 2061 [Member]",
        "terseLabel": "1.375% Notes due 2061"
       }
      }
     },
     "localname": "A1375NotesDue2061Member",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CoverPage",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1625NotesDue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625% Notes Due 2043",
        "label": "1.625% Notes Due 2043 [Member]",
        "terseLabel": "1.625% Notes due 2043"
       }
      }
     },
     "localname": "A1625NotesDue2043Member",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CoverPage",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A2.125NotesDueJune32030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.125% Notes Due June 3, 2030 [Member]",
        "label": "2.125% Notes Due June 3, 2030 [Member]",
        "terseLabel": "2.125% Notes due 2030"
       }
      }
     },
     "localname": "A2.125NotesDueJune32030Member",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A3375NotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.375% Notes Due 2029",
        "label": "3.375% Notes Due 2029 [Member]",
        "terseLabel": "3.375% Notes Due 2029"
       }
      }
     },
     "localname": "A3375NotesDue2029Member",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A395NotesDue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.95% Notes Due 2049",
        "label": "3.95% Notes Due 2049 [Member]",
        "terseLabel": "3.95% Notes Due 2049"
       }
      }
     },
     "localname": "A395NotesDue2049Member",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A415NotesDue2059Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.15% Notes Due 2059",
        "label": "4.15% Notes Due 2059 [Member]",
        "terseLabel": "4.15% Notes Due 2059"
       }
      }
     },
     "localname": "A415NotesDue2059Member",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A5000NotesDue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".5000% Notes Due 2033",
        "label": ".5000% Notes Due 2033 [Member]",
        "terseLabel": "0.500% Notes due 2033"
       }
      }
     },
     "localname": "A5000NotesDue2033Member",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CoverPage",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A6.77NotesDueJanuary12036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "label": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "terseLabel": "6.77%\u00a0Notes due 2036"
       }
      }
     },
     "localname": "A6.77NotesDueJanuary12036Member",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A625Notesdue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".625% Notes due 2031 [Member]",
        "label": ".625% Notes due 2031 [Member]",
        "terseLabel": "0.625% Notes due 2031"
       }
      }
     },
     "localname": "A625Notesdue2031Member",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A718NotesDueJune12025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "label": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "terseLabel": "7 1/8% Notes due 2025"
       }
      }
     },
     "localname": "A718NotesDueJune12025Member",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AbCelleraBiologicsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AbCellera Biologics Inc. [Member]",
        "label": "AbCellera Biologics Inc. [Member]",
        "terseLabel": "AbCellera"
       }
      }
     },
     "localname": "AbCelleraBiologicsInc.Member",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge And Foreign Currency Adjustment, Including Portion Attributable To Noncontrolling Interest [Member]",
        "terseLabel": "Other, net of tax"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeAndForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AcquiredInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT)",
        "label": "Acquired in-process research and development",
        "terseLabel": "Acquired in-process research and development (Note 3)"
       }
      }
     },
     "localname": "AcquiredInProcessResearchAndDevelopment",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_ActosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actos",
        "label": "Actos [Member]",
        "terseLabel": "Actos"
       }
      }
     },
     "localname": "ActosMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AlimtaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alimta [Member]",
        "label": "Alimta [Member]",
        "terseLabel": "Alimta\u00ae"
       }
      }
     },
     "localname": "AlimtaMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AmpullaryCancerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ampullary Cancer",
        "label": "Ampullary Cancer [Member]",
        "terseLabel": "Ampullary Cancer"
       }
      }
     },
     "localname": "AmpullaryCancerMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AsahiKaseiPharmaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asahi Kasei Pharma Corporation",
        "label": "Asahi Kasei Pharma Corporation [Member]",
        "terseLabel": "Asahi Kasei Pharma Corporation"
       }
      }
     },
     "localname": "AsahiKaseiPharmaCorporationMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_AssetImpairmentChargesRecoveriesAndOtherSpecialCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Impairment Charges (Recoveries) And Other Special Charges",
        "label": "Asset Impairment Charges (Recoveries) And Other Special Charges",
        "terseLabel": "Asset impairment (recovery) and other special charges"
       }
      }
     },
     "localname": "AssetImpairmentChargesRecoveriesAndOtherSpecialCharges",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for Sale Securities and Equity Securities, FV-NI, Realized Gain",
        "label": "Available for Sale Securities and Equity Securities, FV-NI, Realized Gain",
        "terseLabel": "Realized gross gains on sales"
       }
      }
     },
     "localname": "AvailableforSaleSecuritiesandEquitySecuritiesFVNIRealizedGain",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale Securities and Equity Securities, FV-NI, Realized Loss",
        "label": "Available for sale Securities and Equity Securities, FV-NI, Realized Loss",
        "terseLabel": "Realized gross losses on sales"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesandEquitySecuritiesFVNIRealizedLoss",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_BasaglarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basaglar [Member]",
        "label": "Basaglar [Member]",
        "terseLabel": "Basaglar\u00ae",
        "verboseLabel": "Basaglar"
       }
      }
     },
     "localname": "BasaglarMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Contingent Value Right, Additional Price Per Share",
        "label": "Business Acquisition, Contingent Value Right, Additional Price Per Share",
        "terseLabel": "Contingent value right, additional price per share (up to) (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentValueRightAdditionalPricePerShare",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs",
        "label": "Business Acquisition, Contingent Value Right, Regulatory Approval Delay, Monthly Reduction",
        "terseLabel": "Contingent value right, monthly reduction (in cents per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Number Of Contingent Value Rights",
        "label": "Business Combination, Consideration Transferred, Number Of Contingent Value Rights",
        "terseLabel": "Consideration transferred, number of contingent value rights"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredNumberOfContingentValueRights",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities), Net",
        "terseLabel": "Other assets and liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilitiesNet",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_BuyBritishPoundandSellUSDollarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy British Pound and Sell US Dollars [Member]",
        "label": "Buy British Pound and Sell US Dollars [Member]",
        "terseLabel": "Buy British Pounds and Sell U.S. Dollars"
       }
      }
     },
     "localname": "BuyBritishPoundandSellUSDollarsMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyEuroSellUsDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Forward Commitment to Buy euro Sell US dollar",
        "label": "Buy Euro Sell Us Dollar [Member]",
        "terseLabel": "Buy Euros Sell U.S. Dollars"
       }
      }
     },
     "localname": "BuyEuroSellUsDollarMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyUSDollarSellChineseYuanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy US Dollar Sell Chinese Yuan",
        "label": "Buy US Dollar Sell Chinese Yuan [Member]",
        "terseLabel": "Buy US Dollar Sell Chinese Yuan"
       }
      }
     },
     "localname": "BuyUSDollarSellChineseYuanMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyUSdollarSellJapaneseYenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Buy US dollar Sell Japanese Yen [Member]",
        "label": "Buy US dollar Sell Japanese Yen [Member]",
        "terseLabel": "Buy U.S. Dollars Sell Japanese Yen"
       }
      }
     },
     "localname": "BuyUSdollarSellJapaneseYenMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_BuyUsDollarSellEuroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Forward commitment to Buy US dollar Sell euro",
        "label": "Buy Us Dollar Sell Euro [Member]",
        "terseLabel": "Buy U.S. Dollars Sell Euros"
       }
      }
     },
     "localname": "BuyUsDollarSellEuroMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ByettaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Byetta",
        "label": "Byetta [Member]",
        "terseLabel": "Byetta"
       }
      }
     },
     "localname": "ByettaMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_COVID19AntibodiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Antibodies",
        "label": "COVID-19 Antibodies [Member]",
        "terseLabel": "COVID-19 Antibodies"
       }
      }
     },
     "localname": "COVID19AntibodiesMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CashFlowHedgeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow Hedge [Abstract]",
        "label": "Cash Flow Hedge [Abstract]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "CashFlowHedgeAbstract",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Casseres Et Al. V. Takeda Pharmaceutical North America, Inc., Et Al.",
        "label": "Casseres Et Al. V. Takeda Pharmaceutical North America, Inc., Et Al. [Member]",
        "terseLabel": "Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al."
       }
      }
     },
     "localname": "CasseresEtAlVTakedaPharmaceuticalNorthAmericaIncEtAlMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CialisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cialis [Member]",
        "label": "Cialis [Member]",
        "terseLabel": "Cialis\u00ae"
       }
      }
     },
     "localname": "CialisMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CollaborationandOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and Other Revenue [Member]",
        "label": "Collaboration and Other Revenue [Member]",
        "verboseLabel": "Collaboration and other revenue"
       }
      }
     },
     "localname": "CollaborationandOtherRevenueMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CollaborativeArrangementRightsAndObligationsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.",
        "label": "Collaborative Arrangement, Rights and Obligations Percent",
        "terseLabel": "Collaborative arrangement, rights and obligations, percentage (up to)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsPercent",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_CollaborativeArrangementRightsAndObligationsRightsObligations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms or rights and obligations under collaborative arrangements.",
        "label": "Collaborative Arrangement, Rights and Obligations, Rights (Obligations)",
        "terseLabel": "Potential achievements"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsRightsObligations",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_CostOfSalesOperatingExpensesAndOtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of sales, operating expenses, and other-net",
        "label": "Cost of sales, operating expenses, and other-net",
        "totalLabel": "Costs, expenses, and other"
       }
      }
     },
     "localname": "CostOfSalesOperatingExpensesAndOtherNet",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_CymbaltaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cymbalta [Member]",
        "label": "Cymbalta [Member]",
        "terseLabel": "Cymbalta\u00ae"
       }
      }
     },
     "localname": "CymbaltaMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_CyramzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cyramza [Member]",
        "label": "Cyramza [Member]",
        "terseLabel": "Cyramza\u00ae"
       }
      }
     },
     "localname": "CyramzaMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DebtSecuritiesAvailableforsaleUnrealizedGainPosition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale, Unrealized Gain Position",
        "label": "Debt Securities, Available-for-sale, Unrealized Gain Position",
        "terseLabel": "Fair value of securities in an unrealized gain position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforsaleUnrealizedGainPosition",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DerivativeInstrumentsGainLossRecognized": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instruments, Gain (Loss) Recognized",
        "label": "Derivative Instruments, Gain (Loss) Recognized",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossRecognized",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_DermiraInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dermira, Inc. [Member]",
        "label": "Dermira, Inc. [Member]",
        "terseLabel": "Dermira"
       }
      }
     },
     "localname": "DermiraInc.Member",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DescriptionOfDerivativeActivityVolumePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of Derivative Activity Volume Percent",
        "label": "Description of Derivative Activity Volume Percent",
        "terseLabel": "Percentage of long-term fixed-rate notes to floating rates through the use of interest rate swaps converted"
       }
      }
     },
     "localname": "DescriptionOfDerivativeActivityVolumePercent",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_DiabetesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diabetes [Member]",
        "label": "Diabetes [Member]",
        "terseLabel": "Diabetes"
       }
      }
     },
     "localname": "DiabetesMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DomicileOfLitigationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domicile Of Litigation",
        "label": "Domicile Of Litigation [Axis]",
        "terseLabel": "Domicile of Litigation [Axis]"
       }
      }
     },
     "localname": "DomicileOfLitigationAxis",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_DomicileOfLitigationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domicile Of Litigation",
        "label": "Domicile Of Litigation [Domain]",
        "terseLabel": "Domicile of Litigation [Domain]"
       }
      }
     },
     "localname": "DomicileOfLitigationDomain",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DrReddysLabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr Reddy's Lab [Member]",
        "label": "Dr Reddy's Lab [Member]",
        "terseLabel": "Dr Reddy's Lab"
       }
      }
     },
     "localname": "DrReddysLabMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EmgalityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emgality [Member]",
        "label": "Emgality [Member]",
        "terseLabel": "Emgality\u00ae"
       }
      }
     },
     "localname": "EmgalityMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EmgalityPatentLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emgality Patent Litigation [Member]",
        "label": "Emgality Patent Litigation [Member]",
        "terseLabel": "Emgality Patent Litigation"
       }
      }
     },
     "localname": "EmgalityPatentLitigationMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EmployeeLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Litigation [Member]",
        "label": "Employee Litigation [Member]",
        "terseLabel": "Employee Litigation"
       }
      }
     },
     "localname": "EmployeeLitigationMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EppVTakedaCanadaIncEtAlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Epp V. Takeda Canada Inc. Et Al.",
        "label": "Epp V. Takeda Canada Inc. Et Al. [Member]",
        "terseLabel": "Epp v. Takeda Canada Inc. et al."
       }
      }
     },
     "localname": "EppVTakedaCanadaIncEtAlMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EquityMethodAndOtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method and Other Investments [Member]",
        "label": "Equity Method And Other Investments [Member]",
        "verboseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodAndOtherInvestmentsMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ErbituxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Erbitux [Member]",
        "label": "Erbitux [Member]",
        "terseLabel": "Erbitux\u00ae"
       }
      }
     },
     "localname": "ErbituxMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_EvoxTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evox Therapeutics",
        "label": "Evox Therapeutics [Member]",
        "terseLabel": "Evox Therapeutics Limited"
       }
      }
     },
     "localname": "EvoxTherapeuticsMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_FairValueHedgeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Hedge [Abstract]",
        "label": "Fair Value Hedge [Abstract]",
        "terseLabel": "Fair value hedges:"
       }
      }
     },
     "localname": "FairValueHedgeAbstract",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period",
        "label": "Fair Value, Investments, Entities That Calculate Net Asset Value Per Share, Unfunded Commitments, Payment Period",
        "terseLabel": "Alternative investments, unfunded commitments, payment period"
       }
      }
     },
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitmentsPaymentPeriod",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_ForeignCurrencyDenominatedDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Denominated Debt [Member]",
        "label": "Foreign Currency Denominated Debt [Member]",
        "terseLabel": "Foreign Currency Denominated Debt"
       }
      }
     },
     "localname": "ForeignCurrencyDenominatedDebtMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ForteoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forteo [Member]",
        "label": "Forteo [Member]",
        "terseLabel": "Forteo\u00ae"
       }
      }
     },
     "localname": "ForteoMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HedgedFixedRateDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedged Fixed-Rate Debt [Member]",
        "label": "Hedged Fixed Rate Debt [Member]",
        "terseLabel": "Foreign currency-denominated notes"
       }
      }
     },
     "localname": "HedgedFixedRateDebtMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HumalogHumulinAndForteoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humalog, Humulin, And Forteo",
        "label": "Humalog, Humulin, And Forteo [Member]",
        "terseLabel": "Humalog, Humulin and Forteo"
       }
      }
     },
     "localname": "HumalogHumulinAndForteoMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HumalogMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humalog [Member]",
        "label": "Humalog [Member]",
        "terseLabel": "Humalog\u00ae"
       }
      }
     },
     "localname": "HumalogMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_HumulinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humulin [Member]",
        "label": "Humulin [Member]",
        "terseLabel": "Humulin\u00ae"
       }
      }
     },
     "localname": "HumulinMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunology [Member]",
        "label": "Immunology [Member]",
        "terseLabel": "Immunology"
       }
      }
     },
     "localname": "ImmunologyMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_InnoventBiologicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innovent Biologics, Inc.",
        "label": "Innovent Biologics, Inc. [Member]",
        "terseLabel": "Innovent Biologics, Inc."
       }
      }
     },
     "localname": "InnoventBiologicsIncMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_InsulinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insulin",
        "label": "Insulin [Member]",
        "terseLabel": "Insulin"
       }
      }
     },
     "localname": "InsulinMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_JardianceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jardiance [Member]",
        "label": "Jardiance [Member]",
        "terseLabel": "Jardiance"
       }
      }
     },
     "localname": "JardianceMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_JunshiBiosciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Junshi Biosciences",
        "label": "Junshi Biosciences [Member]",
        "terseLabel": "Junshi Biosciences"
       }
      }
     },
     "localname": "JunshiBiosciencesMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_KumquatBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kumquat Biosciences Inc.",
        "label": "Kumquat Biosciences Inc. [Member]",
        "terseLabel": "Kumquat Biosciences Inc."
       }
      }
     },
     "localname": "KumquatBiosciencesIncMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_LebrikizumabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lebrikizumab [Member]",
        "label": "Lebrikizumab [Member]",
        "terseLabel": "Lebrikizumab"
       }
      }
     },
     "localname": "LebrikizumabMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_LitigationClaimsDismissedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation, Claims Dismissed, Number",
        "label": "Litigation, Claims Dismissed, Number",
        "terseLabel": "Number of claims dismissed"
       }
      }
     },
     "localname": "LitigationClaimsDismissedNumber",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LosAngelesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Los Angeles",
        "label": "Los Angeles [Member]",
        "terseLabel": "Los Angeles"
       }
      }
     },
     "localname": "LosAngelesMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term",
        "label": "Loss Contingency, Claims Settled And Dismissed, Limited Initial Market Entry, Supply Term",
        "terseLabel": "Limited initial market entry, supply term"
       }
      }
     },
     "localname": "LossContingencyClaimsSettledAndDismissedLimitedInitialMarketEntrySupplyTerm",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lly_LossContingencyNumberOfClaimants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Claimants",
        "label": "Loss Contingency, Number Of Claimants",
        "terseLabel": "Number of claimants"
       }
      }
     },
     "localname": "LossContingencyNumberOfClaimants",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LossContingencyNumberOfDecisionsAffirmed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Decisions Affirmed",
        "label": "Loss Contingency, Number Of Decisions Affirmed",
        "terseLabel": "Number of decisions affirmed"
       }
      }
     },
     "localname": "LossContingencyNumberOfDecisionsAffirmed",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LossContingencyNumberOfPatents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Patents",
        "label": "Loss Contingency, Number Of Patents",
        "terseLabel": "Number of patents"
       }
      }
     },
     "localname": "LossContingencyNumberOfPatents",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LossContingencyNumberOfPatentsClaimsDismissed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Patents, Claims Dismissed",
        "label": "Loss Contingency, Number Of Patents, Claims Dismissed",
        "terseLabel": "Number of patents, claims dismissed"
       }
      }
     },
     "localname": "LossContingencyNumberOfPatentsClaimsDismissed",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LossContingencyNumberOfPatentsRuledUnpatentable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Patents Ruled Unpatentable",
        "label": "Loss Contingency, Number Of Patents Ruled Unpatentable",
        "terseLabel": "Number of patents ruled unpatentable"
       }
      }
     },
     "localname": "LossContingencyNumberOfPatentsRuledUnpatentable",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup",
        "label": "Loss Contingency, Number Of Sites Jointly And Severally Liable For Cleanup",
        "terseLabel": "Number of sites jointly and severally liable for cleanup (fewer than)"
       }
      }
     },
     "localname": "LossContingencyNumberOfSitesJointlyAndSeverallyLiableForCleanup",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lly_LyciaTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lycia Therapeutics, Inc.",
        "label": "Lycia Therapeutics, Inc. [Member]",
        "terseLabel": "Lycia Therapeutics, Inc."
       }
      }
     },
     "localname": "LyciaTherapeuticsIncMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities [Member]",
        "label": "Marketable Securities [Member]",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "MarketableSecuritiesMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MerusNVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merus N.V.",
        "label": "Merus N.V. [Member]",
        "terseLabel": "Merus N.V."
       }
      }
     },
     "localname": "MerusNVMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MiNATherapeuticsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MiNA Therapeutics Limited",
        "label": "MiNA Therapeutics Limited [Member]",
        "terseLabel": "MiNA Therapeutics Limited"
       }
      }
     },
     "localname": "MiNATherapeuticsLimitedMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Capitalized As Intangible Assets",
        "label": "Milestone Payments, Capitalized As Intangible Assets [Member]",
        "terseLabel": "Milestone Payments, Capitalized as Intangible Assets"
       }
      }
     },
     "localname": "MilestonePaymentsCapitalizedAsIntangibleAssetsMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Contingent Upon Achieving Clinical Proof Of Concept",
        "label": "Milestone Payments, Contingent Upon Achieving Clinical Proof Of Concept [Member]",
        "terseLabel": "Milestone Payments, Contingent Upon Achieving Clinical Proof of Concept"
       }
      }
     },
     "localname": "MilestonePaymentsContingentUponAchievingClinicalProofOfConceptMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsContingentUponInitiationOfPhaseITrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Contingent Upon Initiation Of Phase I Trial",
        "label": "Milestone Payments, Contingent Upon Initiation Of Phase I Trial [Member]",
        "terseLabel": "Milestone Payments, Contingent Upon Initiation of Phase I Trial"
       }
      }
     },
     "localname": "MilestonePaymentsContingentUponInitiationOfPhaseITrialMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsDevelopmentAndRegulatoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Development and Regulatory [Member]",
        "label": "Milestone Payments, Development and Regulatory [Member]",
        "terseLabel": "Milestone Payments, Development and Regulatory"
       }
      }
     },
     "localname": "MilestonePaymentsDevelopmentAndRegulatoryMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member]",
        "label": "Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative [Member]",
        "terseLabel": "Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative"
       }
      }
     },
     "localname": "MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsSalesBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Sales-based [Member]",
        "label": "Milestone Payments, Sales-based [Member]",
        "terseLabel": "Milestone Payments, Sales-based"
       }
      }
     },
     "localname": "MilestonePaymentsSalesBasedMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Success-based Regulatory And Sales-based",
        "label": "Milestone Payments, Success-based Regulatory And Sales-based [Member]",
        "terseLabel": "Milestone Payments, Success-based Regulatory and Sales-based"
       }
      }
     },
     "localname": "MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_NeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue to unaffiliated customers, Neuroscience",
        "label": "Neuroscience [Member]",
        "terseLabel": "Neuroscience"
       }
      }
     },
     "localname": "NeuroscienceMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_NonCHINAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-CHINA",
        "label": "Non-CHINA [Member]",
        "terseLabel": "Non-CHINA"
       }
      }
     },
     "localname": "NonCHINAMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OlumiantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Olumiant [Member]",
        "label": "Olumiant [Member]",
        "terseLabel": "Olumiant\u00ae"
       }
      }
     },
     "localname": "OlumiantMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue to unaffiliated customers, Oncology",
        "label": "Oncology [Member]",
        "terseLabel": "Oncology"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherDiabetesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Diabetes [Member]",
        "label": "Other Diabetes [Member]",
        "terseLabel": "Other Diabetes"
       }
      }
     },
     "localname": "OtherDiabetesMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Equity Securities [Member]",
        "label": "Other Equity Securities [Member]",
        "terseLabel": "Other securities, noncurrent investments"
       }
      }
     },
     "localname": "OtherEquitySecuritiesMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherForeignCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Foreign Countries [Member]",
        "label": "Other Foreign Countries [Member]",
        "terseLabel": "Other foreign countries"
       }
      }
     },
     "localname": "OtherForeignCountriesMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Immunology [Member]",
        "label": "Other Immunology [Member]",
        "terseLabel": "Other Immunology"
       }
      }
     },
     "localname": "OtherImmunologyMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherNeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Neuroscience [Member]",
        "label": "Other Neuroscience [Member]",
        "terseLabel": "Other Neuroscience"
       }
      }
     },
     "localname": "OtherNeuroscienceMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Oncology [Member]",
        "label": "Other Oncology [Member]",
        "terseLabel": "Other Oncology"
       }
      }
     },
     "localname": "OtherOncologyMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Product [Member]",
        "label": "Other Product [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_OtherProductTotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Product, Total [Member]",
        "label": "Other Product, Total [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductTotalMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PancreaticCancerOrThyroidCancerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pancreatic Cancer Or Thyroid Cancer",
        "label": "Pancreatic Cancer Or Thyroid Cancer [Member]",
        "terseLabel": "Pancreatic Cancer or Thyroid Cancer"
       }
      }
     },
     "localname": "PancreaticCancerOrThyroidCancerMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PancreatitisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pancreatitis",
        "label": "Pancreatitis [Member]",
        "terseLabel": "Pancreatitis"
       }
      }
     },
     "localname": "PancreatitisMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PetraPharmaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Petra Pharma Corporation",
        "label": "Petra Pharma Corporation [Member]",
        "terseLabel": "Petra"
       }
      }
     },
     "localname": "PetraPharmaCorporationMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PlaintiffAllegationsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiff Allegations",
        "label": "Plaintiff Allegations [Axis]",
        "terseLabel": "Plaintiff Allegations [Axis]"
       }
      }
     },
     "localname": "PlaintiffAllegationsAxis",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_PlaintiffAllegationsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiff Allegations",
        "label": "Plaintiff Allegations [Domain]",
        "terseLabel": "Plaintiff Allegations [Domain]"
       }
      }
     },
     "localname": "PlaintiffAllegationsDomain",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PrecisionBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Precision Biosciences, Inc.",
        "label": "Precision Biosciences, Inc. [Member]",
        "terseLabel": "Precision Biosciences, Inc."
       }
      }
     },
     "localname": "PrecisionBiosciencesIncMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PrevailTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prevail Therapeutics Inc.",
        "label": "Prevail Therapeutics Inc. [Member]",
        "terseLabel": "Prevail Therapeutics Inc."
       }
      }
     },
     "localname": "PrevailTherapeuticsIncMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ProQRTherapeuticsNVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ProQR Therapeutics N.V.",
        "label": "ProQR Therapeutics N.V. [Member]",
        "terseLabel": "ProQR Therapeutics N.V."
       }
      }
     },
     "localname": "ProQRTherapeuticsNVMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ProceedsfromSaleofEquityandAvailableforSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Sale of Equity and Available for Sale Securities",
        "label": "Proceeds from Sale of Equity and Available for Sale Securities",
        "terseLabel": "Proceeds from sales"
       }
      }
     },
     "localname": "ProceedsfromSaleofEquityandAvailableforSaleSecurities",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_ProductLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Liability",
        "label": "Product Liability [Member]",
        "terseLabel": "Product Liability"
       }
      }
     },
     "localname": "ProductLiabilityMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ProtomerTechnologiesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Protomer Technologies Inc.",
        "label": "Protomer Technologies Inc. [Member]",
        "terseLabel": "Protomer Technologies Inc."
       }
      }
     },
     "localname": "ProtomerTechnologiesIncMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_PurchasedInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of CASH paid for research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore, written off in the period of acquisition (CASH FLOWS).",
        "label": "Purchased in-process research and development",
        "negatedTerseLabel": "Purchases of in-process research and development"
       }
      }
     },
     "localname": "PurchasedInProcessResearchAndDevelopment",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent",
        "label": "Revenue, Information Used To Determine Revenue Recognized, Change In Accounting Estimate, Percent",
        "terseLabel": "Revenue, information used to determine revenue recognized, change in accounting estimate, percent (less than - 2021)"
       }
      }
     },
     "localname": "RevenueInformationUsedToDetermineRevenueRecognizedChangeInAccountingEstimatePercent",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lly_RigelPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rigel Pharmaceuticals, Inc.",
        "label": "Rigel Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Rigel Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "RigelPharmaceuticalsIncMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_RocheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche [Member]",
        "label": "Roche [Member]",
        "terseLabel": "Roche"
       }
      }
     },
     "localname": "RocheMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SalesRebatesAndDiscounts": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales rebates and discounts",
        "label": "Sales rebates and discounts",
        "terseLabel": "Sales rebates and discounts"
       }
      }
     },
     "localname": "SalesRebatesAndDiscounts",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lly_SitryxTherapeuticsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sitryx Therapeutics Limited [Member]",
        "label": "Sitryx Therapeutics Limited [Member]",
        "terseLabel": "Sitryx Therapeutics Limited"
       }
      }
     },
     "localname": "SitryxTherapeuticsLimitedMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SouthernDistrictOfCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Southern District Of California",
        "label": "Southern District Of California [Member]",
        "terseLabel": "Southern District of California"
       }
      }
     },
     "localname": "SouthernDistrictOfCaliforniaMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SwapSwissFrancsToU.S.DollarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap Swiss Francs To U.S. Dollars [Member]",
        "label": "Swap Swiss Francs To U.S. Dollars [Member]",
        "terseLabel": "Swap Swiss Francs to U.S. Dollars"
       }
      }
     },
     "localname": "SwapSwissFrancsToU.S.DollarsMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_SwapU.S.DollarsToEuroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap U.S. Dollars To Euro [Member]",
        "label": "Swap U.S. Dollars To Euro [Member]",
        "terseLabel": "Swap U.S. Dollars to Euro"
       }
      }
     },
     "localname": "SwapU.S.DollarsToEuroMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TYVYTMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TYVYT",
        "label": "TYVYT [Member]",
        "terseLabel": "Tyvyt\u00ae"
       }
      }
     },
     "localname": "TYVYTMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TaltzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taltz [Member]",
        "label": "Taltz [Member]",
        "terseLabel": "Taltz\u00ae"
       }
      }
     },
     "localname": "TaltzMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TrajentaBIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trajenta (BI) [Member]",
        "label": "Trajenta (BI) [Member]",
        "terseLabel": "Trajenta"
       }
      }
     },
     "localname": "TrajentaBIMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_TrulicityMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trulicity [Member] [Member]",
        "label": "Trulicity [Member] [Member]",
        "terseLabel": "Trulicity\u00ae"
       }
      }
     },
     "localname": "TrulicityMemberMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_VariousStateDomicilesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Various State Domiciles",
        "label": "Various State Domiciles [Member]",
        "terseLabel": "Various State Domiciles"
       }
      }
     },
     "localname": "VariousStateDomicilesMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_VerzenioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verzenio [Member]",
        "label": "Verzenio [Member]",
        "terseLabel": "Verzenio\u00ae"
       }
      }
     },
     "localname": "VerzenioMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_WeilerVTakedaCanadaIncEtAlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weiler V. Takeda Canada Inc. Et Al.",
        "label": "Weiler V. Takeda Canada Inc. Et Al. [Member]",
        "terseLabel": "Weiler v. Takeda Canada Inc. et al."
       }
      }
     },
     "localname": "WeilerVTakedaCanadaIncEtAlMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_WhyteEtAlVEliLillyEtAlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Whyte Et Al. V. Eli Lilly Et Al.",
        "label": "Whyte Et Al. V. Eli Lilly Et Al. [Member]",
        "terseLabel": "Weiler v. Takeda Canada Inc. et al."
       }
      }
     },
     "localname": "WhyteEtAlVEliLillyEtAlMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_ZyprexaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zyprexa [Member]",
        "label": "Zyprexa [Member]",
        "terseLabel": "Zyprexa\u00ae"
       }
      }
     },
     "localname": "ZyprexaMember",
     "nsuri": "http://www.lilly.com/20210930",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r167",
      "r299",
      "r302",
      "r560",
      "r607",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r167",
      "r299",
      "r302",
      "r560",
      "r607",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r168",
      "r169",
      "r299",
      "r303",
      "r609",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r168",
      "r169",
      "r299",
      "r303",
      "r609",
      "r617",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/ContingenciesDetails",
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r40",
      "r527"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r6",
      "r28",
      "r171",
      "r172"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowances of $24.1 (2021) and $25.9 (2020)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r24",
      "r565",
      "r591"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r61",
      "r67",
      "r75",
      "r76",
      "r77",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Defined Benefit Pension and Retiree\u00a0Health Benefit Plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r60",
      "r67",
      "r75",
      "r76",
      "r77",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Actuarial losses, net"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r62",
      "r67",
      "r75",
      "r76",
      "r77",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to prior service cost (credit) component of defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Prior Service Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Prior service benefits, net"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r38",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r55",
      "r67",
      "r75",
      "r76",
      "r77",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign Currency Translation Gains\u00a0(Losses)"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": {
     "auth_ref": [
      "r67",
      "r75",
      "r76",
      "r77",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]",
        "terseLabel": "Effective portion of cash flow hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r56",
      "r67",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Effective Portion of Cash\u00a0Flow Hedges"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r57",
      "r58",
      "r59",
      "r67",
      "r75",
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized net gains/losses on securities",
        "verboseLabel": "Unrealized Net Gains (Losses) on\u00a0Securities"
       }
      }
     },
     "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r31",
      "r64",
      "r66",
      "r67",
      "r593",
      "r614",
      "r615"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss (Note 10)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r75",
      "r76",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r63",
      "r67",
      "r75",
      "r76",
      "r77",
      "r122",
      "r123",
      "r124",
      "r456",
      "r610",
      "r611",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r400",
      "r401",
      "r402",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r35",
      "r173",
      "r199"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowances for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r63",
      "r67",
      "r75",
      "r76",
      "r77",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails",
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]",
        "terseLabel": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for asset acquisition.",
        "label": "Asset Acquisition [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "AssetAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r187",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r116",
      "r157",
      "r160",
      "r165",
      "r197",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r451",
      "r457",
      "r508",
      "r525",
      "r527",
      "r563",
      "r590"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r10",
      "r52",
      "r116",
      "r197",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r451",
      "r457",
      "r508",
      "r525",
      "r527"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized gross gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r181"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Unrealized gross losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r182",
      "r185",
      "r584"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "6-10 Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r182",
      "r184",
      "r583"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "1-5 Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "auth_ref": [
      "r182",
      "r186",
      "r585"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "More\u00a0Than 10 Years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r182",
      "r183",
      "r582"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Less\u00a0Than 1 Year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r175",
      "r179",
      "r205",
      "r571"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r176",
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "verboseLabel": "Short-term investments, debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r176",
      "r205"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "verboseLabel": "Noncurrent investments, debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the percentage of nonperforming assets that the underlying assets in the security represent and which were considered as one of the potential factors in reaching a conclusion that the available-for-sale investments are not other-than-temporarily impaired.",
        "label": "Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets",
        "terseLabel": "Available-for-sale, percentage of nonperforming assets"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r389",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r389",
      "r393",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Business acquisition, share price (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r433",
      "r434",
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Purchase price"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r438"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Contingent value right, additional price per share, aggregate amount"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r432",
      "r435",
      "r437"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "negatedLabel": "Contingent consideration liability, other noncurrent liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability": {
     "auth_ref": [
      "r429",
      "r430"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability",
        "negatedTerseLabel": "Fair value of CVR liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred tax liabilities",
        "terseLabel": "Deferred income taxes assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r430"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt",
        "terseLabel": "Long-term debt assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Acquisition date fair value of consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "negatedTerseLabel": "Cash acquired"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r36",
      "r112"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents (Note 6)"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r107",
      "r112",
      "r113"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and Cash Equivalents at September 30",
        "periodStartLabel": "Cash and cash equivalents at January\u00a01"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r107",
      "r509"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r130",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Change in Accounting Estimate [Line Items]",
        "terseLabel": "Change in Accounting Estimate [Line Items]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r130",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r490"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails": {
       "order": 3.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "negatedLabel": "Effect from interest rate contracts"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r490"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails": {
       "order": 4.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "negatedLabel": "Effect from hedged fixed-rate debt"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r114",
      "r116",
      "r137",
      "r138",
      "r139",
      "r141",
      "r143",
      "r148",
      "r149",
      "r150",
      "r197",
      "r242",
      "r246",
      "r247",
      "r248",
      "r251",
      "r252",
      "r278",
      "r279",
      "r280",
      "r281",
      "r508",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r444",
      "r445",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborations and Other Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r47",
      "r229",
      "r572",
      "r598"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r238",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common Stock (no par value)"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividend declared per share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r122",
      "r123",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesHeldInEmployeeTrust": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.",
        "label": "Common Stock, Shares Held in Employee Trust",
        "negatedLabel": "Employee benefit trust"
       }
      }
     },
     "localname": "CommonStockSharesHeldInEmployeeTrust",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r27",
      "r527"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r71",
      "r73",
      "r74",
      "r85",
      "r577",
      "r603"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r71",
      "r73",
      "r84",
      "r450",
      "r461",
      "r576",
      "r602"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r83",
      "r94",
      "r575",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of amounts recorded for contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r288",
      "r289",
      "r300"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/RevenueContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r338",
      "r383",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r87",
      "r560"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs, expenses, and other:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CrossCurrencyInterestRateContractMember": {
     "auth_ref": [
      "r338",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.",
        "label": "Cross Currency Interest Rate Contract [Member]",
        "terseLabel": "Cross-currency interest rate swaps"
       }
      }
     },
     "localname": "CrossCurrencyInterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "terseLabel": "Short-term borrowings and current maturities of long-term debt"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r19",
      "r21",
      "r22",
      "r115",
      "r121",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r272",
      "r273",
      "r274",
      "r275",
      "r520",
      "r564",
      "r566",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r253",
      "r272",
      "r273",
      "r518",
      "r520",
      "r521"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r44",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r45",
      "r115",
      "r121",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r272",
      "r273",
      "r274",
      "r275",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Summary the contractual maturities of our investments in debt securities measured at fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r190",
      "r207",
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Fair value of securities in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsUnrealizedGainsandLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r408",
      "r409"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "verboseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r408",
      "r409"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit": {
     "auth_ref": [
      "r315",
      "r353",
      "r377"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss), recognized immediately as component of net periodic benefit (cost) credit, for change in value of benefit obligation or plan assets from experience different from that assumed, change in actuarial assumption, or consequence of temporarily deviating from substantive plan. Includes, but is not limited to, amount in excess of ten percent of greater of fair value of plan assets or benefit obligation.",
        "label": "Defined Benefit Plan, Actuarial Gain (Loss), Immediate Recognition as Component in Net Periodic Benefit (Cost) Credit",
        "negatedLabel": "Recognized actuarial loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r315",
      "r354",
      "r378",
      "r383",
      "r384"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of prior service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r315",
      "r352",
      "r376",
      "r383",
      "r384"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r315",
      "r319",
      "r351",
      "r375",
      "r383",
      "r384"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r349",
      "r373",
      "r383",
      "r384"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r317",
      "r350",
      "r374",
      "r383",
      "r384"
     ],
     "calculation": {
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r110",
      "r155"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotionalAmount": {
     "auth_ref": [
      "r464",
      "r465",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative asset.",
        "label": "Derivative Asset, Notional Amount",
        "terseLabel": "Derivative asset, notional amount"
       }
      }
     },
     "localname": "DerivativeAssetNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsNoncurrent": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "DerivativeAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r54",
      "r473",
      "r476",
      "r480",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r471",
      "r473",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "negatedTerseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "negatedTerseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r464",
      "r465",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "Derivative liability, notional amount"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r465",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r120",
      "r463",
      "r466",
      "r471",
      "r472",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Description of Derivative Risk Management"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r299",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of disaggregation of revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r284",
      "r587"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "negatedTerseLabel": "Cash dividend declared"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r13",
      "r42"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r86",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r135",
      "r137",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r494",
      "r495",
      "r578",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r86",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r137",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r494",
      "r495",
      "r578",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r509"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate, percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r75",
      "r76",
      "r77",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r134",
      "r147",
      "r198",
      "r283",
      "r284",
      "r400",
      "r401",
      "r402",
      "r415",
      "r416",
      "r493",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r516",
      "r610",
      "r611",
      "r612",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r196"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "negatedLabel": "Net investment gains",
        "terseLabel": "Equity securities, net unrealized gains (losses)"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity investments without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r262",
      "r272",
      "r273",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Extinguishment of debt, amount"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r496",
      "r497",
      "r498",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary certain fair value information, assets"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r496",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Fair value, by balance sheet grouping"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r262",
      "r272",
      "r273",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r383",
      "r497",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r262",
      "r272",
      "r273",
      "r496",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r262",
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r262",
      "r338",
      "r340",
      "r345",
      "r383",
      "r497",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r262",
      "r272",
      "r273",
      "r338",
      "r340",
      "r345",
      "r383",
      "r497",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r262",
      "r272",
      "r273",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r383",
      "r497",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments": {
     "auth_ref": [
      "r502"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unfunded commitments for which the entity is obligated, to those certain investments for which net asset value per share is calculated (including by unit, membership interest, or other equity (ownership interest) unit measure) (alternative investments).",
        "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments",
        "terseLabel": "Alternative investments, unfunded commitments"
       }
      }
     },
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary certain fair value information, liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r262",
      "r272",
      "r273",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r383",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r187",
      "r188",
      "r193",
      "r194",
      "r195",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r208",
      "r209",
      "r210",
      "r211",
      "r270",
      "r282",
      "r492",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r54",
      "r338",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign currency exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r473",
      "r479"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "negatedLabel": "Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r91",
      "r110",
      "r177"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedLabel": "Net investment gains"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Activity related to our available-for-sale securities"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r110",
      "r276",
      "r277"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Debt extinguishment loss (Note 6)",
        "negatedTerseLabel": "Debt extinguishment loss"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r215",
      "r216",
      "r527",
      "r562"
     ],
     "calculation": {
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails",
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r471",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r110",
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Intangible asset impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r81",
      "r157",
      "r159",
      "r161",
      "r164",
      "r166",
      "r561",
      "r573",
      "r580",
      "r605"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Total before tax",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r117",
      "r412",
      "r413",
      "r414",
      "r417",
      "r419",
      "r423",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r118",
      "r133",
      "r134",
      "r156",
      "r410",
      "r418",
      "r421",
      "r606"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedNetLabel": "Tax benefit",
        "terseLabel": "Income taxes (Note 7)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Change in deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedTerseLabel": "Other changes in operating assets and liabilities, net of acquisitions and divestitures"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r217",
      "r219"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Other intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r79",
      "r154",
      "r517",
      "r519",
      "r579"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.",
        "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
        "negatedLabel": "Pretax net losses on cash flow hedges expected to be reclassified during the next 12 months"
       }
      }
     },
     "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r54",
      "r338",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest rate contracts"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Forward-starting interest rate swaps"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r51",
      "r527"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r90",
      "r153"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r34",
      "r116",
      "r197",
      "r508",
      "r527",
      "r568",
      "r596"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r43",
      "r116",
      "r197",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r452",
      "r457",
      "r458",
      "r508",
      "r525",
      "r526",
      "r527"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r22",
      "r23",
      "r116",
      "r197",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r452",
      "r457",
      "r458",
      "r508",
      "r525",
      "r526"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total other liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Other Liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r22",
      "r261",
      "r271",
      "r272",
      "r273",
      "r566",
      "r592"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "negatedTerseLabel": "Long-term debt, including current portion",
        "terseLabel": "Long-term debt, including current portion"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Investments (Note 6)",
        "totalLabel": "Noncurrent investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets",
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r45",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r237",
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r237",
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r229",
      "r232",
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded, value"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r237",
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of pending lawsuits"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Maximum Remaining Maturity of Foreign Currency Derivatives",
        "terseLabel": "Maximum remaining maturity of foreign currency derivatives"
       }
      }
     },
     "localname": "MaximumRemainingMaturityOfForeignCurrencyDerivatives1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r50",
      "r116",
      "r197",
      "r242",
      "r246",
      "r247",
      "r248",
      "r251",
      "r252",
      "r508",
      "r567",
      "r595"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MortgageBackedSecuritiesMember": {
     "auth_ref": [
      "r178",
      "r338",
      "r340",
      "r383",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities collateralized by mortgage loans.",
        "label": "Collateralized Mortgage Backed Securities [Member]",
        "terseLabel": "Mortgage-backed securities"
       }
      }
     },
     "localname": "MortgageBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Used for Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Used for Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r107",
      "r108",
      "r111"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Provided by Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r69",
      "r72",
      "r77",
      "r82",
      "r111",
      "r116",
      "r125",
      "r127",
      "r128",
      "r129",
      "r130",
      "r133",
      "r134",
      "r140",
      "r157",
      "r159",
      "r161",
      "r164",
      "r166",
      "r197",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r495",
      "r508",
      "r574",
      "r600"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net investment hedges"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.",
        "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component",
        "terseLabel": "Retirement benefit plans"
       }
      }
     },
     "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Outside U.S."
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r284",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations": {
       "order": 6.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": -1.0
      },
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedLabel": "Other\u2013net, (income) expense (Note 11)",
        "negatedTotalLabel": "Other\u2013net, (income) expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/BasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r67",
      "r75",
      "r76",
      "r78",
      "r510",
      "r512",
      "r516"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss) before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r56",
      "r64",
      "r474",
      "r477",
      "r489"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r64",
      "r68",
      "r478"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "lly_DerivativeInstrumentsGainLossRecognized",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r481"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsEffectofRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r70",
      "r73",
      "r75",
      "r76",
      "r78",
      "r83",
      "r283",
      "r510",
      "r515",
      "r516",
      "r575",
      "r601"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax (Note 10)",
        "totalLabel": "Net other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofComprehensiveIncomeLoss",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r65",
      "r75",
      "r83",
      "r410",
      "r420",
      "r422",
      "r510",
      "r513",
      "r516",
      "r575",
      "r601"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "negatedTerseLabel": "Benefit (provision) for income taxes allocated to other comprehensive income (loss) items"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherDebtSecuritiesMember": {
     "auth_ref": [
      "r189",
      "r206",
      "r338",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as other.",
        "label": "Other Debt Obligations [Member]",
        "terseLabel": "Other securities, current investments"
       }
      }
     },
     "localname": "OtherDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r310",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "Other\u2013Net, (Income) Expense"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r42",
      "r527"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r37",
      "r599"
     ],
     "calculation": {
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other Long-term Investments",
        "verboseLabel": "Equity method investments"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income) expense",
        "terseLabel": "Other\u2013net, (income) expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails",
      "http://www.lilly.com/role/OtherNetIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other non-cash operating activities, net"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r312",
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r366",
      "r370",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Retiree Health Benefit Plans"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r96",
      "r99"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other investing activities, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "terseLabel": "Payment for debt extinguishment"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Cash paid for acquisitions, net of cash acquired (Note 3)",
        "terseLabel": "Cash paid, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "terseLabel": "Acquired IPR&amp;D Expense"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetAcquisitionsDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireLongtermInvestments": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.",
        "label": "Payments to Acquire Long-term Investments",
        "negatedTerseLabel": "Purchases of noncurrent investments"
       }
      }
     },
     "localname": "PaymentsToAcquireLongtermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r98",
      "r440",
      "r441",
      "r442"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Net purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedTerseLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r337",
      "r339",
      "r345",
      "r362",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r383",
      "r385",
      "r386",
      "r387",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Retirement Benefits"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r24",
      "r313",
      "r314",
      "r336",
      "r383"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "terseLabel": "Accrued retirement benefits (Note 8)"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r311",
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r366",
      "r370",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r387",
      "r388",
      "r393",
      "r394",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "verboseLabel": "Defined Benefit Pension Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails",
      "http://www.lilly.com/role/FinancialInstrumentsRiskManagementInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Not measured at fair value.",
        "label": "Portion at Other than Fair Value Measurement [Member]",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "PortionAtOtherThanFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r7",
      "r9",
      "r213",
      "r214"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r101",
      "r105"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfLongtermInvestments": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.",
        "label": "Proceeds from Sale of Long-term Investments",
        "terseLabel": "Proceeds from sales of noncurrent investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfLongtermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-term Investments",
        "terseLabel": "Proceeds from sales and maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Net change in short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product revenue"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r69",
      "r72",
      "r77",
      "r106",
      "r116",
      "r125",
      "r133",
      "r134",
      "r157",
      "r159",
      "r161",
      "r164",
      "r166",
      "r197",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r450",
      "r453",
      "r454",
      "r460",
      "r461",
      "r495",
      "r508",
      "r580"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "verboseLabel": "Total reclassifications, net of tax"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r222",
      "r527",
      "r586",
      "r597"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $9,962.8 (2021) and $9,570.7 (2020)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables, Net, Current [Abstract]",
        "terseLabel": "Receivables, Net, Current [Abstract]"
       }
      }
     },
     "localname": "ReceivablesNetCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r67",
      "r75",
      "r76",
      "r78",
      "r510",
      "r514",
      "r516"
     ],
     "calculation": {
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Net amount reclassified from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Schedule of reclassifications out of accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayments of long-term debt",
        "terseLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedTerseLabel": "Net change in short-term borrowings"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r405",
      "r559",
      "r628"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]",
        "terseLabel": "Asset Impairment, Restructuring, and Other Special Charges"
       }
      }
     },
     "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialCharges"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringSettlementAndImpairmentProvisions": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of restructuring charges, remediation cost, and asset impairment loss.",
        "label": "Restructuring, Settlement and Impairment Provisions",
        "terseLabel": "Asset impairment, restructuring, and other special charges (Note 5)",
        "totalLabel": "Total asset impairment, restructuring, and other special charges"
       }
      }
     },
     "localname": "RestructuringSettlementAndImpairmentProvisions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r30",
      "r284",
      "r403",
      "r527",
      "r594",
      "r613",
      "r615"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r134",
      "r198",
      "r400",
      "r401",
      "r402",
      "r415",
      "r416",
      "r493",
      "r610",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r366",
      "r370",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r366",
      "r370",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r151",
      "r152",
      "r158",
      "r162",
      "r163",
      "r167",
      "r168",
      "r170",
      "r298",
      "r299",
      "r560"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r301",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r80",
      "r116",
      "r151",
      "r152",
      "r158",
      "r162",
      "r163",
      "r167",
      "r168",
      "r170",
      "r197",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r508",
      "r580"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Revenue (Note 2)"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyGeographicalAreaDetails",
      "http://www.lilly.com/role/RevenueDisaggregationofRevenuebyProductDetails",
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyAgreementTermsMember": {
     "auth_ref": [
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the royalty agreement under research and development arrangements.",
        "label": "Royalty Agreement Terms [Member]",
        "terseLabel": "Royalty Agreement Terms"
       }
      }
     },
     "localname": "RoyaltyAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Collaboration and other revenue associated with prior period transfers of intellectual property"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueSummaryofRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns and Allowances [Member]",
        "terseLabel": "Sales returns, rebates, and discounts"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r67",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of components of other comprehensive income (loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.lilly.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.",
        "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), cash flow hedges"
       }
      }
     },
     "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfChangeInAccountingEstimateTable": {
     "auth_ref": [
      "r130",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summarization of the nature of changes in accounting estimates, including changes that occur in interim periods. Changes in accounting estimate have the effect of adjusting the carrying amounts of existing assets or liabilities or altering the subsequent accounting for existing or future assets or liabilities. Changes in accounting estimates are a necessary consequence of assessments, in conjunction with the periodic presentation of financial statements, of the present status and expected future benefits and obligations associated with assets and liabilities. Changes in accounting estimates result from new or better information. Examples of items for which estimates are necessary are uncollectible receivables, inventory obsolescence, service lives and salvage values of depreciable assets, warranty obligations, and regulatory reviews.",
        "label": "Schedule of Change in Accounting Estimate [Table]",
        "terseLabel": "Schedule of Change in Accounting Estimate [Table]"
       }
      }
     },
     "localname": "ScheduleOfChangeInAccountingEstimateTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RevenueAdjustmentstoRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of significant milestones and revenue recognized"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r372",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of effects of risk-management instruments were recognized in other\u2013net, (income) expense"
       }
      }
     },
     "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Schedule of net pension and retiree health benefit (income) cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/RetirementBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss), net investment hedges"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of other\u2013net, (income) expense"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/OtherNetIncomeExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of the amounts recognized for assets acquired and liabilities assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included.",
        "label": "Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block]",
        "terseLabel": "Schedule of asset acquisitions"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r223",
      "r224",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "The components of the charges included in asset impairment, restructuring, and other special charges"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "lly_CostOfSalesOperatingExpensesAndOtherNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Marketing, selling, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/AssetImpairmentRestructuringandOtherSpecialChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r20",
      "r569",
      "r570",
      "r589"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments (Note 6)"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r114",
      "r116",
      "r137",
      "r138",
      "r139",
      "r141",
      "r143",
      "r148",
      "r149",
      "r150",
      "r197",
      "r242",
      "r246",
      "r247",
      "r248",
      "r251",
      "r252",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r508",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r49",
      "r75",
      "r76",
      "r77",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r134",
      "r147",
      "r198",
      "r283",
      "r284",
      "r400",
      "r401",
      "r402",
      "r415",
      "r416",
      "r493",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r516",
      "r610",
      "r611",
      "r612",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossReclassificationDetails",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossTaxEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r147",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r26",
      "r27",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of stock under employee stock plans, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r26",
      "r27",
      "r283",
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of stock under employee stock plans, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r26",
      "r27",
      "r284",
      "r398",
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Stock repurchase program, remaining authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r27",
      "r32",
      "r33",
      "r116",
      "r174",
      "r197",
      "r508",
      "r527"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Eli Lilly and Company shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r76",
      "r116",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r197",
      "r198",
      "r284",
      "r400",
      "r401",
      "r402",
      "r415",
      "r416",
      "r448",
      "r449",
      "r459",
      "r493",
      "r508",
      "r510",
      "r511",
      "r516",
      "r611",
      "r612",
      "r642"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets",
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity",
      "http://www.lilly.com/role/OtherComprehensiveIncomeLossAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Eli Lilly and Company Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized": {
     "auth_ref": [
      "r541"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition.",
        "label": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized",
        "terseLabel": "Amount of receivable derecognized"
       }
      }
     },
     "localname": "TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r187",
      "r188",
      "r193",
      "r194",
      "r195",
      "r270",
      "r282",
      "r492",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTax": {
     "auth_ref": [
      "r511"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of cumulative translation adjustment attributable to gain (loss) on foreign currency derivatives that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.",
        "label": "Derivatives used in Net Investment Hedge, Net of Tax",
        "terseLabel": "Derivatives used in net investment hedge, net of tax"
       }
      }
     },
     "localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r48",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Common Stock in Treasury"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r27",
      "r283",
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of treasury shares"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r27",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Purchase of treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "auth_ref": [
      "r27",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period.",
        "label": "Treasury Stock, Shares, Retired",
        "negatedTerseLabel": "Retirement of treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesRetired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r48",
      "r286",
      "r287"
     ],
     "calculation": {
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Cost of common stock in treasury"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r283",
      "r284",
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Purchase of treasury shares"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrustForBenefitOfEmployeesMember": {
     "auth_ref": [
      "r363",
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trust created by the entity that exists for the benefit of its employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management.",
        "label": "Trust for Benefit of Employees [Member]",
        "terseLabel": "Employee Benefit Trust"
       }
      }
     },
     "localname": "TrustForBenefitOfEmployeesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangements [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r119",
      "r338",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government and agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnfavorableRegulatoryActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A enacted or proposed action, ruling or regulation that is likely to or possibly will have an adverse effect on the entity's financial position or results of operations, excluding tax matters.",
        "label": "Unfavorable Regulatory Action [Member]",
        "terseLabel": "Unfavorable Regulatory Action"
       }
      }
     },
     "localname": "UnfavorableRegulatoryActionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Summary of the fair value of available-for-sale securities in an unrealized gain or loss position"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r136",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Shares used in calculation of earnings per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r135",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.lilly.com/role/ConsolidatedCondensedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 17
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e777-108305"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL6283291-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "http://asc.fasb.org/topic&trid=49130413"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "http://asc.fasb.org/topic&trid=2122503"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r629": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r630": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r631": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r632": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r633": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r634": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r635": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r636": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r637": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r638": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r639": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r640": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r641": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>70
<FILENAME>0000059478-21-000216-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000059478-21-000216-xbrl.zip
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M ]FM96$W"$X:*L$]<2PM#'_2V:$GY<%4W:&&7G8#SNUG83>(DA'67.<XC%2
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MCI+"-FO.$B#V+'/X"A!D\I%75FZ)8X$(Z^\7W"8I;()@BQQ(8IE-YZ'Y'"?
MEC5 2K4CK="M<?/UHCV+AAY:C^(CX:\=&)6E#I]/L0S\F'C]0\4[I(*->E5A
MY%8S-8N@/5,*/74T#=Q[8KLOAK(D>+5VIR0R=%\;%S-A[J&K>1"HI?@JJ<%]
M8(%M.H\4GHM"RHV'<Q/0]<JP2BL0,.^@?FB'++#-]M)L]SW,HDIID+(+2:DY
M:$G68Z/U#Q+LV<LQ9X,:G6L,0^L5R82I*$(4BI#6GJ4YP7OW^'!RR>NO#&TS
M9:53#',>CF  ZDPI-T=0]X(@9?T]I5NQCMWG :UKP\8>9<A)0Y48._1!!5!
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M>'Y]7M\;-6PT=3B&'$<J*3$#>F2+G)#F&8*4(N^D*GR7U+#-P &R7FJ.F;P
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M2:-8AOHC7T7SW1=&V$8U,&</2JTQP[ 4;A$D8\S78R]Q_5VCG3+"-DO,:?"
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M?^>GA[,]Z@-D#CV:3%TPY']E*)G<AE:0D+6O7P+RBN"MQ ';=*8I;$$KF )
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MQ!849E:!G"&JDI"Q-,5VW28%?[HQTE;$\\_G9Y=G)W[^R/6KT[/CLR>'6])
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M^<Y=H8/.TL\L='J@U.%\+KOUZ*[LSG:FNWC0]TS2)>P.N!0#->>R ^,ME )
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M8L$E7D6W_(CPZ3U$Q*$@HH'#RC6J5(@ %4KRJ1%SZ9U4"BWQVJ/E1T1\/T;
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MHAENK/(=.GPCAXI%N*'I.])%U4+J![,TH);C(':3C9+WYL(W4T.N$:+4"OJ
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M8AXQ<9Z,F"_H#"XT5A,BH.9$R"&70$F)(]CJ04##Z+'"S*<*<[3..05D/K^
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M6'Q&*10SI%:SCTY,"!%R3LDN<?'CK_7N?PYW<'OV0O\YW)[NWM[E^_U,G=D
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M7XZMR=H6G.<F$:JDXM#XW)SIA[UE"JMCZR6M\UR4'7O/G%9]M & D*E4&]F
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M+S%YN!0;)W(I^99JE7Z BU-2 "$GJBZ(@$VK:.,!T(#+\6<;BL-F*8<,G*6
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MP5(=B?T(_17E^B5:JY@W9J%IT6>HV)(WI8J8T,9:_ 5!?Y!LN'#6Q(_9. Z
MQ&2P10;K4NF3-W%DP\L!CFOABUZ*E "MF@Q@0LJA9N)&-D%SR<61+RX'.*Z%
M495"#K@VU<P.:LP%L_.Q*,%JHJ%C7*6\)."X?,XQ??/M7+87WWE_:[JWAO.J
MM.I#*_:7?#.;O_B7(L'_Z^09_VI8#R9M-CO8G1W(K;4VG^T\EK;?)YS\+T=T
M=_;ZH7O\^IE?/^27]UX__Z&\?/3R9WCVZ[.W&S\\?;/^LKY9?_OS[^L_K,/&
MYM;.AKMW]&CS'JR[IW;CY8O?'_J-[6=O9^;1#_=WUM\^WE[??.#7-]?-^MWO
M7SZZ^Q2>O^2M]9>OWCRZN[&]L?D,UN_GM^M/RD[=N;_[Z.7&SOHFOWSV]M[O
MSW]X:I^]_/GHT0_KX=G+I^;1KS]NK]]=/UKOK]MYH)_S>.O9SIOM1R^K>[[S
MP.F]O%S?N3_=V'S\:F/GY_#H[H\O-S;UWNZ^T-?_\NK9YM-WK]'/.GSNGL:-
MM\]WGKU\9O4SCI[]^L!N_/"S>W[W%:SOK%N];WAT=WNZ\>OCK8W-[]OZRWL'
MZYM/#]:?F#</-^_]!FA\45DS21S2!&J-D^PA3"1C4*53C11>&T?TKT9T\V<=
MT?5W(QI9XQ6+G>3,90(:<R;D]%%TO7H2:H02QQ']RQ$],F_Z_SJ:!^L__]9:
MZEM7VH2PM G$K! MJ4V<;<XHTZR<<1S0SSO]&41%N!B)39V>HHYH 1U1YR?D
M16SF&JT?[(@^T]'[Y>7SE^MOUU_^[!YM_AR>;;X(^AGV^:^_;#VZN^XV=I[Y
MC9WG6Y^,Z,M7L/&K?N;;]:.-N\_"QMUM??XK_3Z_;#__5;_3VV?N^<)B]S^&
MJ#HXA^S=!&O3*%IRFV03:-)W7A5G2V)CQP']RP'=?/8!1"%:Z\36B76L(QIK
MGI"$-N%LI6_J!'2#'=&K<?I'=\R;C2?O("K!1=,J3US5; \48$*DN2F9;*N)
MM5#,0QW0J_/Y]P;4VI2*S782('H=4&%%*-#$8DT:"TS0_X8ZH%>#T(T/!U2J
MC344F11V;@(2=4 U34VX6'&]F[\U;AS0OW3Y)Q\,J&&;&AJ82" [@<;J\IZ5
MC@8,FOY3"[:, _K7Q.GI!UFI%LF&JM(E3'U$E3WEI,-J8X@-1)R+,([H7ZNE
M9Q_J3_"%:X:)^CQ/( 4W42:*$Q>Q4 V5FZ.ACNA5,:>?/QA11]),4J44";)R
M49<GZ!6H%$LQKJ@4-6FH(WIU>>D]<F_[N8)@57^:I(D^9)YD:FZ2(VI,C42I
M#9:*7A%$%V'T/8A65L44W20F*Q/(C2>847_$$C%%=HAC8OI,8KK]81AU/D12
M=J\<24>T!#LI)M.D-)+HJPG01N[T6;GTGM.KOC054IXT "6C34>5BDN3X*#V
M%=X<<QT']*\A^N #[M0BF4K-3K)@47KOZT0='R<,4>6G.GV3P1:=KI([G8UH
MHH:JXS7):\R<0 053-!4TC<-J4$LJ"@=ZHA>)7=Z;T3%FMY@0+.\US"*+>B(
M<II8J\0)V;9H!LOOKS+5GXTH69]=0N6@K?-[3$J>DBB_;V2\DE/$-K+1S\Z&
MO"?J:P-O.+:)S4W#:-$!I>K+Q*FR;V2-=S!8P725$W9GW"E2DU:MG?B6U>DC
M9>7W2)/D4ZJ&N(1FQA']?)GD;$2#8U-1PB38K!CUM70)BA,L#0/&XFT;;&*Z
M2GY_%D91K&-?-6Y"3_7D57YRX(FCZ#A'MK&._/X<=/0,HPE)LBTX":;5"53E
M]CD',Q'%K379@PTCP?]LM?D]Q53)^9HH3"I85'YO_01%1U41"IKJV7,9+$2O
M<@[T#*)43=]:V6?HFVK0!"KJL\&)+UC%8,40RJVU[>GNJ\=_O61JL5ZJ/^_6
MVL%LF(NDMN4_CX^>_\I[I!%PW3U[L^$V7JYO?O_J^>8OTXV[#^#96T5F-\S.
MT]_7WS[X7>_1/7NI*+U;P\;+VV'][>VC];>O?E___3?K31'0S)0=UTZA5)/6
MY":63+(*85^IWEJ;S5GF_^]6/V3P7Q^M4CO]S?[L<%YE__C'+4%>K+GCZ>OO
M_EO_.NGRD;%Y]0:7K =C:@ZY)73%9B\A9O/;X@/>O6;_X*B;<F>Z.]F2Z8NM
M@V_!?9/"WL&_?Y_RP=:WUIC_?6OQU._^>W\/=[_[;YK_2]_@^/'Q^WSR;GVI
MW02WIR]VOZW2=ROH.RRV,IP^@19?=E)GV]NXMR_?GC[X-T_W][;QZ-OIKL)'
M)HL7_7L'YR_T_FAV<##;^;;?VVN9'TPK;I]\R.+SCB^?W'8IW^3@^YT?Z! =
M\.D'GWRI;Q9?ZE\'_.FUDK\IYL\OFV_LNVO_6KSW_/0))^/G]PYN+5ZG7ZJ/
MTO^[Y6]]]+U/OHG=.UC;GVU/>>U_+=:*FG^?7#^8[7WK/KFXA]QWB'QKUNSB
M(\[NX5^+<3JG(?H]G5[76YS-OSW]@#;;/9@TW)EN'WW[?V_/I[C]?_]K'W?W
M)_LRG[;CR_O3M_*M!;7!XL??C[]STE<O#'8R!M;U$7RZ\6#SWMVU)YNW-^\]
M6?L0,TMSDT_NW7GZ^,'F [W#VQMWU^[]?W?^<WOCAWMK=QZMKS]X\N3!HXTK
MOW%WKAO_%34T[+XXF.W^U]K=;^Y\L^9,@/*G-WOB1!U:BM!_7]:]YW/=^_W9
M?&>MK\7=G>UN'.[HF]2UDR6ZFBYZ-W50<>0\QEH%6E_X(!1[_Y84C4W!_=%J
M_K5=[,NQ6:;?WIW5P[X">?-H3VZ==(6YGOSSYJ%[KLRF:F*NFD&>A@UW?_O1
MYL;+C1_6WSQS#]X^VKRO>865!=U[\^SMCU-E/J_YAU^ __/C]G.W_9I>SMR&
M)NV-S5?^V:]/P[I;-\_>WG_Y[.5Z6/]U7?/2\^EZ?X^=!T?/;-8<MFY^0R:O
MPX(3<0)]"DDT]T2:& F2/'DR)MWZSIK)SXM4<F:%[_[<3:\(0.<#_X5CIRDB
M\4!?_>;@VS9](SPYF!_*'V'JYT.<Z]?=/GHL>[/YP<V#E_LM43(Q>3L)46@"
M!NT$T=1)*#E4",Z@\)78J.'V_A\::7.NX)IV_G1SK52QB.G+;)T5J[0SM@D:
MQY.8"D4;%MOJ;WWW#LX?1X)/(L/Q2*[]=#C?/\3= Z7V:T^D]C'^/__+1O-O
MZY7#KMGP#_[GVJRM'6S)DF9.O>O#N8)#]M?NO:E;N/M"UF[7@W[3MGBX[@AH
MSIM"^Q"O_<^I_=:.M[RLR2X+7WQR?=_Y& ]DLJ-ON=4];\)X-#D2G$]D]X]\
M\:?%?=T[WJ!STQQQ\_9O6$UCACQ)7?2!T[\(Q4U\T,@9;2XI4@?EWL%B%]6Q
M,WGS7VM]\#_URB& \XP\K]U_\/#>VL;3]>_O/;Y,QG=OL<7L_G1;]-UU%&\:
MSNZNPV\@Y QQC_"MSR::K&DYI4DP'@+8&B/GOBW13J(/GR#K7,PO7AZTW#4Q
MOX\Q]%A>3/</E#\<;.B5FX>C\%M*$G)0>B<UF0G4OG2_ZX@$T7@*)2FJ;GUW
M[^&#M8</'CY\MM#-ZO$_W=YX=GY0756 @C]$T3_NO4'-^-WV/>V?V7P-]]?V
M]Z3V7;J\-MU=FQ[LKRE'Z#GVG^?QD'!<_AE(M0O2-P7RN:I=7_*V[IL0SU=#
M^Z*;C=_8XKZD-/=G=;C34IK;>].+:9^&M$_&?+9W,?C\N#[R"3S-9<M;O:7:
M=U8?R-Y\]KI[P(>T[3@*]NW><^7[BQKTHO_-G=GA[L'\Z,Z,AQD4[T_IAZ=Q
M_>T+MW'WQ=MU]\O6LTV>ZFO,L\U7]ME;_4RG][QSSS[_00/DYHN3U_RBGQ5V
MGV_.WCZZ^\P\NKO^]OFO][<VW ,-I(^W'FW^\E*_W]OG+_75F[^\>O;KQM:C
M^_GWAYNWSR93G5@!\!/@DB:06"9J/3OAY"NY+#%'S<L/=GF*N_BGA.\$\E^&
MYFUIG\2/X]!Q?CAO3G=4*6W([VN/9SNX^U7 /B:W7_>=5M-#/W; 37SSX*1=
MQ'&+A@'SVJMVO0?O7,];YVVK91*CJ1/P"'T1*$UJ-)A3Y1*R:B\?)OU<JQ+,
M7WK?P)/*/Q9AO-=H9KV[Q]K+P_ETGZ>+"HZ2H#'0+*?5'GSS^)LGWZS=V]G;
MGAWUWBNK@\CI^R1C <SY"]R=OEW\_,\1D$MIM ^STMK&[)M_?HK)/YV1?D\I
MP>75$C[[3:ZFE'";>2[[^R?_/-0;L(/,WU]33_CYZ#>24C$[F-34X@3$T*08
M_2N;F"0:XX-QM[Y[.-W>/EJ[<Q(09.W. @\?)^3_NOPBXHFY[NC#1_/-V>^[
M-\]FO_\6LF,=/&5*)N($*%)?4DM]OY>M8).IK;S3+'NS[>G^%5CJBU7LB2D7
MQ.?1_"=]IJ:<8<K7K[+GV]^$?2LNRD1"G[)E [W909Q0=<"!^W'=?ZY!K\SG
M?IJI2;>?3_<&6V7X*C.9WQ*Z .!3W[06)N"PJ(7Z;G5;6M\)' *IVT%T.5Q[
MJ?5\2?8?)Z9=PUU>>SO=4_#PHN:Z-U=?G.[A]IJ\D7IX,'W=?ZV\0O;/56B]
MQ%FN\WVSLZ+Q__E?V=GT[_VU ]F6O:W9KJSM+M3Z?ZU-3QL[K^%<\/C+_^,2
MW:EGK=OZ23?3@>QOX$PP&,HDA>Y M?5N>,E,/)L0)*-+/6]YFSYVGW^>$/3+
M,\W#F7+VGSHZ!ES*^2KSN-^RL<[7AI-HHIMHH)-))K56BX$XM59+Q%O?N11U
M!,TGU9CS+DZ[G"CPV<4D\T5 D+GPVMZ?+I)Q_Z#3Y3$?K#[Y]CS?+5_/Y!+8
M\'<FE[S[QN7SS==\T>12_,::<.%OZ_,WWOI+GEVZB*K$7V$V?0ZS*N&/[X>E
MGA1>OCW<503U9]WZ;G-ZL+W(SO>P;JW=Z3V"K[\,<ZE?>(Z+[/SD:(?TBZWV
ME]TXF>Y>&/==\'FTN_;KUE1_\_A=_+J@(N,?C<>%5:L^'HPOGZ<)+1D&9@HF
M0-;<(PP!)!G-2^Q*^TP^/XG\1];1PFT&F<^/IV:>O]S:7K_[[.CYKS^'];?Z
M^KM/C]9_^''ZZ.X]?5WUS^_VC5/K1\_OUH^F9O9V'OWP]/>-E\H)[KYZJWS
M;&P^^/W9S@/0^PT;;_G58N/4VQ]?;5B]Q_=F1:O/KE@O$]6>/ %;T@2#Z?O,
M?4Z)/96FD+TSV]F9[:X].9C55VO_V)VM[>%\[35N'\H_EV^F=*GA>A+IC@/=
MB-5S8/7>&5:C#2%QG"2)I:^(P@DZ[R?5Q09L:I06;WWW\.$GZY]&3)ZCC">:
MB3ZMX)V&U],\-=C5>%<-V[/9[QBP24LT<36;":26)]A[[Q>+53@X'W)G!?+[
MVK/9_-5)D#T=[TN:"E]^3(NX#-&BM2KS#7,N#GN%M'G.CJH?:<$%8_;H?5J@
MXTZMICHQ$4A#;:$)E9 G1-76?IP*@K_UG0HYM>/:QNQ =3<?2E\K[VY:\/U*
MH(Z$X$M1>D8(O"F0?>I+I#,H2GN7XXAYXIDX835<Q"X(P8C*<Z%RI 27"MPS
M2E!:#2R2)]#Z'A&/98(U:7@UU66D$&-*(R7X&-->DP[ZYJID@4*>P-A^G)A5
M1#,&&2G!!6/V[0>5@H"]>5)0WFKM!%QQDQ**#C5E8VQ029;;K>_2FOU7_H@2
M?#))NNK!]RN!.E*"+T7I&25H(;C:3S^PGOT$C"AQ3>@FOE S.4+PD(\IP8C*
M\Z!RI 27"MPS2N"B!E<L?I*:TE@0AQ.R_7Q%(@<5(3;?EH$2+-',027EL]:)
MD#I\-:V8V$)?697 !3)IY ,7#%CS/A]@-EA;=!.BII'62YQD@[YWH#<8$T<
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MPUN@?/T+0L BNRD>H*R,:U:&R2=0K<IC666EP#]";.6@N#$X9&_$_FD</*9
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M*]#ADLXM$;6TK+[7*5')1UT TO.NW?I2\M3ND0U_L#6(6<](]/=GRFTP#C.
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MLVKC([EB'BZ#;4GA9SGX4(&?N<#/1"Y_$)A)BA&+$LPF%1VR409D3& Z$=A
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MDGU5[E'N4>Y1#J$6)C?\5S6B*N N'IN9/#:[O=T#WQNFN'U6PCO!M$8R28)
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ML9P98KQ2/IOHM9=+O*U2T:JBU1+1RO%L [72.D^!)?PE@O6:":X!\)>*5D\
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M2$_ "TV<%)%0GTR2("!3BQ1CZ_(-JT<Y.E_%M)@Z1AUC5<=XLJDFC1$@'BU
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M*"3+C-W89EMP^=2U=7T)II4(%=0QGFSH9!'J^+"Q\'.DJT1P,62;AL)]*#=
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MZ*?!:>U-E-$:L,IX$4!JDYCVWLMDKT:_16]\5FA\:&B<B6\ZQHVECA-9\FJ
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MU8: XYQX$*EDK!CJLL8=3.5JF)%R2]UGDLH-,63M&V*L']3-WXAUAKKY3[0
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MM3W *G*?"P&2&U0+KM&2^ZP2/-F-6@=TJ<!YL=:-\-Y"T$1XX0DDEXF%[$@
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M>RG?^^WC,WUPLUCSQ77;X]/:3MTLIYZ7_>3Q@Y-ZY^?3WD.NN;$G3$&]6$@
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MPX%2WPWCP^=+J"3&G',,!5 W :]]P>P23Q3_T.?NK(L@YKS<66=0KFM_X;P
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MXJNR4**M7>?D@H/7'H\/?$=.SNCLP*&C"!!R0HIH70&TOJ::>X_ )H#UPB.
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M\C&W;KGCM8_IQJB5.RO"I4?A5HKPLQCC.RO"NX_Q$C6([I"G_@ E$SF*TN:
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MW?'81NI]QF.CV&L5%0>6&2R.GQ?E,H?],H?#-MS6#A;L5[90M9HOGYPW*&
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M31*$, $:0*Z715Y!/OBO)8Z,5:_,D2_4(LSIELID"1=YHZ8<"?_?(B]&S;"
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M_F-%D*,5QH,) <&HI#QGB>OE7-]NE>L;%W-]ETUY70\"IK!S]M1*=W5HYR_
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M)1MCJ1&WTB/'=43!&BH(K)"((9]B:DKHSTW1>5-TWA2=/Q6;D32AG+Y:P7G
MT>3F,UY)90(3V(4;LQDU.O1..G3&5$0)\T;FYHZ4"<09J$]-DT-$<^VY<<;A
MG"G+&ZJB;UF?-5CQ9OKL5J=#C3Y[,'TVHR$*RH?(0941[ SB23"D+9$H&>N8
MTM2!5@-]1K8NIO\T@+!1H T@?"1 R'-_-!RDCXD'&@UF'+PY*07%6A-[8Q:B
M1H'>28'.&(8<M]0K0Y&A,B#N$D968(\\850*Q8)1*A>(\!4\;FNJSVX<RTSE
M/\\@EOER*;&@]4.N)8!QG?UX>4[!I6%Q>K,I6:EYGR&8>_# 7\ZI+2LURY2J
MTZ#>5:O5CL-))EN=)U6_WZBQFZBQL_G8H&68J101EHD@KK@'')@4\O :=U2"
M1TN><6QPM89Z4+2W=,M+#\6>IQ99O2H_/&Z,*]>XP&^-WGALO3&+A\7 L ]4
MHJ"L1QRSA+2+#B5.8L"<*>'LQ@O.5O 4_-CLWF>+ >XMH-/LV<?:L[.8C\,)
M!Q$PXL0YQ U6"+R8B(ARB@JAH\_9WJ!RMTACZ;][7;$^L8M&5SR6KIB%-[#3
MQ"C.44PZ'WK!;]J#I?<Z"$V-X4'XC1=JA:9XNGW[[>9B[?='N6+VUN41MPPU
MU;4)]$*TZ9E%G>_WV.X>9N69H\!'2P%;* C[*XY&G5B7,\Y,P9^9!GBX3B75
MST+;[[Z:BP)%G13F"2--8P1X2"PR";2]M)$80035#C_C*-!][]_'/3"\VWAO
M>:#XK:C^^SUP?/:J?_TRU!H5_Y J?A:P"]%91Y5#0N0"XNAS EO&]R$JKKG!
M)J:-%^",W7<"6Z-NOR-UVR#M-8VW-NKV,=3M+-;*G?#".H=89("H 5<CETA
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MP:I59K6RLU\1@#A9TVKM-ZMMELU#Z5%7%MT.<N_#:H=5"G 0LSFJ7-ER2H#
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MWL2)JS=90=)5W_KR=R79\S+?LD5ZA].O7GC^<N+4[Z';3\GD"+%&^?/"D8\
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M \E:/7N],/OD\-2>#%?:O2)MX*]E#=-M3PZ\)NLRN]SL(*H$=NJ8=U[MZHS
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M'JS1VA#..991L! <:<3A@<1!@%[4AB78?B .+H>J# 83B:T#]Q"6(">V<&S
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MB$L*8-$0BZ*+P1CEI78<P.***-U)-8,389J)T9Q>JJ+T!2;,J:7AJO."5<<
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M>KC=:68';A4FK()Y-UL1#%V[HKSJ'Q?&B@KLU4V%PN>"9C,5;*:OZU>DAH4
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M/*>*>.48)<E87D?CU%<.5!9C<Z\*^<N;WM^]0809.(\AY[+E5+:]7B$D#F\
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M)W$O#+2H@E[8*2JA#[NCI"B$HE(LJ4"I)@/TDD!:X:3Q"35E6CU 7%+^R(0
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M<;G1DVMR-*@8:ZKSODARD*Q/NEL+&&K[O^4@PW>UNJ R]UUQ]9H;L"AC:U7
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MT4$C?9AZ(H-I1F[.4K.N,:]P[M; OH%]2\<^ZX&#9V<9'' *J=<E1<$2J3H
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MA= -$19,.,933P0AGLYYA:E1:LBB7,@-(8IQBEUBQ3E($@,^0[[W$-=IH,-
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M04HPM>;(VMQ[:"R-@-X2F.* N96'.6^(L6=)^UZX["B90*@+Q90M:CPCV6G
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M!SS<'#PL!%A8<K:B>Z.SU/NJHL(:K4)3L7J/(@8&/ QX6-8H$NL;2VA\E"&
MY90"69VTJ;:F!/'<$]0'#"P!!A:B)9A-B!6,@A2:!1&(%2(T"R*Z4DW,N98P
MW @#!);C1O#:> QM;TF!:B0)(5CGV==</)P[%6. P#+<" O1D% 8C<U5<39>
M 3MH*) ;*#B7:Q*;=3 #!>Y$5<L&[_]>#GL@<JW,Q&R4MGPV;R1J1]%[)YC
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M-5:QF2F.->?V^.^ME691O.Z"M/^F0>%_'U5[?9#'&3UM,K3-KP_*@_<_?-4
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M\Z7HBO6)(39\C.MV]0!R>IT*KBS]*\?U3KNQ%8>SFPY"#)B[+,S-XQ"2R'G
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MEKC$\_\KYL+7QZZ1:>5BTBK;A!A,!D83#KEB)P?987%AU^ZP:[MQ 6'&,B.
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MRZUI&:-#8Y1+LW)IM@ZCQ!OIC0T*,TNYX,RD(+3VN5^D,":D8I0\LE%RKDI
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MH!'GBB.CJ$618V-(XDY$!4:5N2J!I//*R]7P\QANJGLI+]T%B"=77@I / Y
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MBC_G*M.(R%+R%B-N*05[@UJD<5 (.RH8R Q&F,[VQN9>4)4J>MU16![*05$
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M&A=5R^+'N.C$WM1A[+O^ ,147?QH5=-I$JN=S6RW+';4C-&JIW351N1ZASD
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MI5<'._0]CRF R2V0502D!R$):1X(G*S@.GJMHE(U]@.MQK"3D5N'J 53 <A
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M&65RSE^(TUG_L-JC:<^.0F\\.XJ3WB >VD'O9#(&0,R -NW-CNP,7M*?YM?
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M+FJ%J8E& KH#Q,Q<,VUB(GH[O_2^6WSV?>]D#C9(9?]4D/1+S%6'HS]JHB6
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ML$A,A90\8@2@@VN+D67.(YHPEXS!62(PX <Y$T!N$3ZD91@><6",@:;I@O$
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M<':?=!2WE@?W+->C36ZK)O3QYKL%K93#3EI""#?8 QXI(K5)04GG..F<L[<
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MVN/\GT$_@:UW$/,J9<]N.5OMAU9L9&')&S_H:%SEW'\!O3H/>UI'&6<8,%O
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MEPQ?"MD@K2O(^L,TF ?'^L4)4KP0C5S5SJ#>LUS1!4/XQ0Y+1[AJD+"["TS
M!Y-CN.A!T8@&(((EK:2,!VXV"L>]C'.]']Z\^./5L^I\N&0&U^G=[P33QM/$
M$G4<I-Y:0A6A3'&PT!Q5>?=7X?>59>7=[K_%W4]VG^=@O*3>:8],\AK!7P$Y
MB3G2 $S*2N65QSG)ZX+=WUO>^(L[Y'^?N46.)J';(NNY15X_]V+WXU.Q<_*4
M[.R]%3L?WD><O.$V(BI$0IS EK$N!,29-13@4CL;-K:).IT3N+A;JJK?-_%P
MNA#5(#]6H>#%X[E$7_J^"9F"(FK#*5W%5D^L4<;:RE6E_^5OPY8$5?*@CMC-
M2P=]:=@^V1]] ?LMLP@4$[.M0!:EH>9\+\4>V<D\"^3,ZTK,YJ)*N9P;WG@Z
MFBS'UCC+E>9+4EWLM+)2-8'/A>JS.HQ8A7G+FN8<R\-RZ4;_:6M\I:+7#1K#
MK4HR_)S+)E;I?BU-;W-)(ZO/JT8_RX.8*8F74@HW9P&*RH%:14YGIU][$6=>
M^LNL896Q/BFF1M;&)T=^_]3D<M @5XG626I-U'954&YQ\0^/8/$F^]DVFK;:
MLC:AQU!*Z.MLN?-GL5F^/9TY)MK,B47G;CW3^3CJ)Y9S')_,OY*GTBIOR2X(
M, ,_UGESI?LZ3'$P\D=5\&9A&1<G.$]&:99A;4-JU0 ;(5FV1UMR-TM-J W2
M-C;D;;XB2Z#:,+YRYM2;IBDSJ1%F<=W@TGE'S,R,=C_JV@55!8H+DE6&VO",
M_3&9Q"I1NCI3%^P7<]IV+/'P# CU+:L<E_PJ]DN(+GO,8CR)9^[(_L'!Z'/)
MACML6G6/QMD&SW$4V[3)M&!J@D:9]VB();B0TZT'_4K\KZ #>A$<-D1Z3CUG
MU#H<E.=)X@@:-]>%4Y&8Q@(RG05T=SK@)_YZ[Z_W*FB6!*<H::) !Q0$&69"
MSL]T1M.$C0<+2*SB3%NM_FVM/ 1[7\;](F&9!<,>'$UFJ5X5"/8;<_N*J=NY
M#M"-^S=#E,T'R!?/222M- T[:0[WTX<+K$U9O<K2 S !%2CTQW&F%359TQGP
MI]-8^6E\Z7B;+U+W:)YL-H5@DT8)&A7EH%22P5F9/TA'@[HHHZ6,4%QEH&4L
MR_D%F_.[9@,2QMU@9XO09,&=WMX2_YDL ',>]$+MW$'APFE=*"]..:T'_53<
M+\/%4ZJ=[S*.X<C'IC7.&9 %M[P"9&&G$N,\L<@M#YQKXQ+7+#IMF//.US:)
M;-C09&>3W!%D?7QZLKOWZ;UT.(+!*I"R--,\)II;V('9RHC6GD;&HLXYY%<T
M6V>AI>XX>YQ[X_7SM^^9D,%H+\ ^S?V?B79("VP1T]$GC&%_!+GZ.#MW;XR;
M=+^,5CESZ2Y/C-4Y_UL/T'QQ@4;RM*:]A.3+:7XK=.NYCKQ*RVX<[G9&*%B2
MQBIT7W&@M:J-V@?8YJP0J5$^0$.(J31: Q7\4UPQE;:%UCZ:ZCG4AUO\7!@@
M5HQ]2>O)M ^S;+S"K%4,@B5;UY8C^\M^K++IIHMWSYEW)403\U3FQ^0Y)O#\
MJ)ROQJ.(.>>M-B.I>UF%YU[43H4UC\@VW&.94GP>.KU)E3-+E@2CK$M&<TJU
M=MXZZ2AE+!@XW+HJYULX+41Q@!LNI*8,>9)[:&%N<UL4@ZBD),*?TK%,37/6
M83$K;%[(3YSDKHUMH73';0K&4U'K@RIA?@*P.; -]V)#43.[1=YCI=0-]/86
M5WVNE&E<&_.DC%K+KVLUF@3N# WY3OL5$6'()9RG]BI89>DT*?H0$#<C6<6?
M,>_N,5HFOFC-^_&S/#S;!Z3N[3[_^UGOZ2PWM*JZ6T<DVJL3$9I\<'LTW:_\
MBCF+H<PEGP_S%+^Z\&&6L%K.[Z8,(^]T7^VNZK?PPM?E^'#Q.BI>'/(E%3P[
MGHXK]I^E'#[8_+!P\&%]\1*O+^=SDRP% YDGYO7;E7Z/?@^]L*<SD@&*AY/C
MP6>;.3O_K%?\AZ>U%K33ROXOG\8?>Z^JY5W'7;?$:\Q/Y9C;X85%#LOYX8OT
MT'?5=_R*&LIBQF'5I[@7OV8_QQ:\.X[^4ZNG<4F"!_7U8*OA2WFHSL:;#;&9
M;1U4"X^LSG>?5 DTUZ7D>@66TW#4GS1QF(.JYG61?7RIUFFR7Z)O!0RF=<EA
MDYCIP=[J-U5E+8S*7G)8]"D@3U5[DF$EIV;F#(J&MZS?>+9*#&C^6;ZN'?BC
MVC5E:YEK;\;J>GD:A>$\IPK[_1A*?E9>@!D9%3U5\=%E]5=9_7S]L_HOS-)?
MSNIWF+" A28FIVXI(R,V7@L5'2%PG4=)!EJ7<S_;'V4)>CH85(0ZZWC,7,0%
MNJ*DO@X2JLL@VJIC>B]^S6[YV@QO:(+GQ0;SG@C3/OK4]Y\*XWU=T]OJE%!R
M5>OO)K#5YIT.<F%#";8W#/#PA+*W!&S[7 XUJQYJUQQEC6U6%9'K]P>C#YOY
M17:>5*'YE[F4:G1F3L%Y9/IG4 ;4&?4S+\FIFL_RPS+*T9Q<:0*;+B=LPE5"
MR9VHCX0JJCDOBZQ9_>J?MU,YX](X9Y>N;WM9BOZ7_=1FW#M=+7N%GR^FC,X'
MLF@TW>E!O]I#^  .PM/.C].B>47OAU0A,FVC<5)SE;QFDD8LA.1:*T7.(.:]
M6<^9SC?2]HV\XCM[+]Y+'J/6(B(-AV)NIH61#<' 21)],)9(:?P9_?8:5\9I
M_T@%J1FCYJ4S"RWW\I?F#2&(.0=^JVOM@)+H;1] ;VR/ MA+\7-5_S\CT6C=
M:?[E L/5\ZZHK6JRJ9+O4 "BI2$W %4?"*=:4Q35N@[?-IE-#47!HL=W%:_5
M$FE!<U(T.+*J+\3JQ6N/9MYDH]SR<!P_9M+@>$;PM('>BQJA9& <Y*,(</ES
M':).RT-:I/';K"_1)#NU!CQ'\R9=_S81C%XN$/]@5=NWIL4U'H2YGWQSB2YI
MLZ90*LE!\4+VI'68\,;V>KO]EYBYU1FE]14"M4OH%ST=BVX.FX]",.WJ.I/S
MJ^(WZ_*3-7"-%/J:C%23K(3V3F_(A_!Z7$+K7Z8)J &LG;G2K^?4.$97GT?+
MW6/A1P=5?Y]IG#^T&:?3RQKC_P:# <Z'PK:;!D>@BM3I+<]&X_'1X;3W>OS!
M#OLG=G:@_= <#W^_>O8ZO_/C5M;Q,S='2=1;+-3.)4^7VY;+'KB%?;D^&VWG
MS9^]OV/=7JDZOC<S_U@_%]=DWHK:+?=YJYEHF]JB]8T'W) E/E3W3;_);FKH
M./,?O92UG\W3I!5S]K7EC5,4"S>:[J_#<^U=B" /8-S4*[<6Z[-BXS] TN*@
MI6&T.+1FNF;MUSCM(FDVW0(!<K6]\U:^J#_?FD0 UO"8FSE7ZA*-F=>](B[,
M_:U:C:]F*]X\J>)\*L0?&64.^V#"501/%5%A4U1<_:X\Q-J]-?D^_!M/!Y/1
M&4?HYM+Y^>R_;S9[+[Z"I06:VAL_[A\V_1=?'TZ/#MK<^"5G_QS>H\VUV.TO
M__V_O=]&@U"E#N>C$T[54VQ035SKCL9\[@A/IUW,"C*6K/="ZE>7<"UN[=4H
M-8%G/AB4!*U%VW8!R.:$42!2.>QEI]4P/HQ'%5'U7(U:V$$[,?A1FX>UCBW6
M[_R:?[Y9>=5.[YHZFKIRYTQ6*1GKL)G^'OG]PLW5>Y[9'I^-T.N*)@5F5UBX
M8&_-B2K^CSTXS)0B6XT^]S"'_SHL7$GK;19M_98I*Y"+="0S-M<KB]VI@$7C
M=[N&"=?$,TZW@)B'+EJV]EH\ZJL![D-8,.NP2C=#DH=8M0Y*KD%4>4VYG]LB
MYU9R%/5W*?!$&<.,&2TX_(]@:0@QFENO V>$&U[7^:BFSF>IEN.2$:C21&)F
M,%26W/-FT-]]Z G&NK?S7JK@*$T8&:(LXC(:9!3V* 6=2 @L9T)O;$_WQS&N
MZ \\4\H6VOR6VMU%D[*N*YC[6P>++0=J;NA3$=YR7CUL([.+!*D50JM9CW;Z
MPV&<C*;V%$?C+ I34SG.3_/V>LQH;C=G]L\I'^+Z^ EG]&+S:<]<@N@,E^ #
M5(%6"W9M1W6+*FV%XV]1X6I\BO,%N<B[>*[C<)FS_T90O12BO.1V71A7(^LY
MU:;$=FWX',?PE$OCJ[9;:N8#>3(#@#+_XD%=T:C@E,]D'$N%:L,ZWGLZ\Z_4
M#OB:ZJW.MOF_\#"._*?C"^6NB;VV,B<?E] ]*^[H+Y4-"\]Z-O,E-;;F77Y0
M1_QL;*UP=$N<3ALKLQ^<(3";I_?=YFH>Z>7L@KQ1?K/C,2#2L]R+Y'B>*'%I
M*%Y<WE->J.*;JMU0A:T[3H=V/=3Y>LJC]( ]VQYR_O63KY[W:I7\(2T^V(H+
M_:X;O6DE+W^=W7.V$"T?)9NMC!#0I,'T[Y=$<!OBO (%K9*XPF99,5+.8F U
M/I>,[YSK?FY(;-GKO;4D@\7YMMIW,<_[G&=XMAR!FX7;X?-H ->I>M4L&"4'
M=?^*)E^U.F<F36KG/-Y<IWBV?)%[N4#6]Z?'#]V.\2)BGD8K>%:3&NWTX2Z;
MO9=P=U"UKPUK;UX5*/OIF<UG\/C33S6.M9SLF4!G7&+W\W-[]G1614SASYBK
MWD)-UU-13E]ZV\S*]4Y/?B?S0<$_AX?]V].YEU8D-[/(M1@_G5J;S99?^:>R
M.(WH_M8?AF:;;RZ,\ME^Z4!_/$O<:B2YI0.=EL4KKU57,[&J9D(\@IJ)BVH@
MEFHF@L".8DR4XI(;+;5S1":!4S1167>OG1"N'.I=S)][4S.XWTXJ72X4R#&B
M84#UQ%+YWY/[;/APFE-_UBG%WK^J 8O:]'<XU42B LE)"U06VU2$F%FE)O.)
M_&LG^X!;TPQ.>5([\6O?CS;KU"J8A@VCLV^SW)JB2?TJYWW=IF+545T5OC57
M.:LC1C80YYB[V1IK[_G6,U#V,J45F,Z%)KT^,;.!\,7V&_,O?L[4[24R..>7
MZP\KY^.LJ]:U9O!OG<P_VR>%/G \^I#3@_OU,UBU=^:C/C7E_\R.N7'\D+MV
MYTYJ1^.%6N6F?!RL:I3UODQV7@\NGV9QVJYBS#SW#1=5W2[-5K7L<^;"M=20
M%@0PZP#,/*F?X&(34&+F*_O;Z&A2GMC?,9MU54_'S_/.;=GL[D^GL53COP:-
M8)+O6![4W[G_U\$LRRQK/W%<$<*W=DO^ILO,T=EF'.<4XW"JRU&S@S++Z-*F
MV<R-<_-'%8M)Z="W8B/5\VQ)Z9N8VT/W7A:6^MB:1^-YJK^P,,&F==,+N'>=
MB5287"K1^#-WN)XE/$_JQ,@5]ZX6=>'*+V"S?CBN,:(L5(N9,[\+QVKUQT$Q
MW2=;]1,$L<^\L;.;3*IF"6VAJ];FC/6?2T4Q_.;4C*>D\U0WN7.7$1YA+GHM
M])"QU)-5+?WZ)TTN?NH/*XJUFCQV+4KO+U-P=*K+2LU,,2VD&4L5%?VELWRR
M>);WF[/\T7,-_ V3+W[99Z.<'%+MKKWH]X<PQ \E1[9XWJZ@@#_@HUZM@UZL
M4[92"8DL7%#G-I]K&5R5!]8=]RZ[D#_\_6SOQZLFFL/2G(QRWRGX<:DN7\H!
MSK_)*KXO3M2&A_EL*VLT+)B_V$RS9H#)*<63ZIU6B?N\WG0&X7.:Z+JDM&D/
MG1%HZ_0>Z?V2$S\:XLF#T>>Z.'ZY:6BM+]2,70U9<M-F=#H:?<I!N6(!SYFT
M\_&]$,2:^1,626]/W6S&FUD#6W%?V<]5M^F\W+E+9CWWZJ!JSWRY.,LV?1_A
M\!H=P[%SO-7[$ZS>8:&];![7H3TN]+GSI-=VEFP_575@%0U882FO^I?,:,$W
M:P9RET\;^"1?.SN02K7S:-KB$<L4!K!Q7.Y^#'AVD&];#MJLHPU#FR*L\(.=
MM3B5HZ/:*LT)L-5[VIN.JWE-ETBR)W%Z-C1^1Q:Z/-M"SX,L\,2U38S'W+6
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M"=Z2F%WKLN=_)OC9-^T&VPWVAH,EE[OL!7D@#YCNH2_5\/Z'IX5@;=(#I)P
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M9T!SB9+<5FKAVM0(=5UEU]<IV0G_70O_W,>8%+?)<X^LQ#F,2@VRH+HB[TS
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M_O;D[=?7O[XZ>??\ WN[]PG#9VFGWVX/Q6APAE(D,+6("\60(X2@R*BP1J2
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MQ#8"S9$MZGBRH9JZ[!B!*CNAHRD0@>L^#9Z\U$QG0V\=X4((:&F'"W'P%)*
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M5.EX7(-]@L%O412V]4ATQ_!):.N*"W12S%#411[-57G7S$!J5-5!5,%!L<Q
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M7.,D7&66W'Y6$"^F\-\@NGI9+^I#.0&%\/GO*,514A)NLN"Q>F43DHVBI%Z
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MR@-I0F:23TJ09Q0E8 V*4@5(@PWX,V!RZI-\+(V8;4"4"+-TTH0NP+4@"D/
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MOX\C0"?"AZTT>3L-=R5;308V'R9+*#68WP^8S(SA>8 :?XR>5W2%[ZU($99
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M<G5*LQ%)HN^D0O:%#5AP&I$,..&S@!MH'1(?Z0[PO&)2YQSER!-Q"W%5Q?!
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M@XQC ^D,AT5_F:) 7M$FQYL[ K47PE;C S$\NDQFYEA"9!3A"].LMB$\H)[
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MR5]9OV)-.$%1Z?(8M)FUR><YY88OP$-3)G"4.8W\3=?(_9@-')9QB.H!7X0
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MXJSUZMIFP$[:V=ZBL\U077D;K0?K%H>BW12'+?&HH@Z-TV'-B60)[NAZGK8
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M:^50#6I7A5M(T.\)S5!184H@24EZQ<O#$GHM36@0^>C?#"60NFH/%H8=$WB
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M"HDT8F46.TH3RJOR>;IWQK,,<2Q]I2PYEB8!_I4FP32-DJ(*-7G$"PM\7R=
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M%T65[4Y4$XN!LB-F1 :\O!,?X!,@$GKM/.L2,8\;OI"A1%?U1@":7VGENT6
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M@*H''DJ_HK9SNT>KLG(6X=<5D\OSB&&*T=?H>SDA'HB"A%? Q[545E62!/X
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M_5/3AJ8B :>KVBWTC5"USO"["7=11HAJJ(JV80^-FU7Q*>]YFR98B@:4RDC
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M(R])BLA+@XCFW:F4- Y0*5DU%D6>-#N+MC?>W79>HPL;;BV.L+N9_-CBH7;
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M4%W[\%8M/CIM-B/Z/Q^/*FTT</K =;K0"OS0S#A2)'V0^:XBN-!CH<=K4<O
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MSX4P'"=)YJI#]W18<R))LC--Z\O5#Q<P0I3W(DMVI@]7*AL[&OB<$E-,0^V
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MA &U%U6L?R:3/Q(!!NB'6=\5S!KPZ2^WQ7@H);1)8*O1%(-TB<VAO'5'TJL
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MBRU_Q*]Z01C2)!&4?J&TH@0G;[DJ@C],U$KRT8WH(?CKJ2=\GQHZJ="82B1
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M/R15@L[*MV:>K!'Z:# *C(FR]$<N:=JUALG6B4_GAP,9W1@QU!/^G06: )"
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MWTS(JZX_11&U>B!?'S)8W<0"C]OY!,3R3Y0$D;<"&ST!B\T0T(NT0Y[X<.?
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M+9LN5XP2M\XEJYK,!JBY'8"L_16'Y*.%-;X-L8-40X?OF&&A5Z-TW&H> SK
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MZ9U$M]:=JDIZ,Y3)7;#,,E=TM!JIF/Y2M>0W8+FSQ#YZ_\/_ 5!+ P04
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M@!ZXVK:=.8\GPNT%LL;P/PM;Q@8TQ;3S)'F1B 3MB64I$F6,#-HQQF5+/AW
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M"4*NE6A421<5@RP9NFYC;]W$!FAC(@0OF2.,HWDI/;4D,&>(3Z8D;KF0=:.
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MM8A<!PDIE)NXWN'B'$L2L*'$^^ $0_EXH^+UWT(U/I>Z!B.JZ:&NU7P-I]_
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M ?EV#7$(-?8E_C2)/ >K I+$"31 653$!4X)<SIHD3@Z;FV2&AZ&<^^4#KB
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MKQ?C_NG9]#M..;O[V_&?K,C"T42)-I81"0:(9UD1Q1PWE#&AO?S_3_\DJ'#
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MM&S?';DBTS?JF?>X5N\DRE753]]=5JK^*0Y&$TA__GXZGL'UAZ/A%'Z?OAE
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MRYJ2G:?5EDU(J-QA[^,8OOG^X,L9C/U7F$W[<?)V&)=M]3ED%W@F"BQ:9MH
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MD,9._8&>HP(\$!S:)_^;B+BR\XI+WZM_?_O^9.F8H87!I$9W#-<X(A53Q!L
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M(,M8<AD%H9MHP7I,QZ(*E:3>XL;-1UH*:F8]#V (EZ76C^&B%:SBA#-GF-(
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MYY%NA,2N=YRYT*NQKW*)US_3<)2FMS!\ V.(ZY!S"G%F@02;)"X8W4G/2KF
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M_7-M?@=Q$@@2>) E#H*(QP1BGV 8DL /"$7<"WP3-C :?6XTH>0$I:!@*RG
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MH2M<'Z+8QS .<0RIZP0.9W$0<*TJ.IVCS(U$ZISR6L2+YB] "0N^K#0#PMW
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M/^!TE:[N+C?K^RQ7<N^NN7S(-JNUN_#".$X(3F"D_D H03!)0@^&)").0KS
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M!#Z'C-( *K-=<HWCJ!(;?B+YQTUBK0TS_2'GQD*[;;/'2EBPQ-^*3:J[ 60
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ML3=6MFHH=[@U 94F*ANLT066RH W6W5 H\_I Q_FVR\68+6[/W..0--NX%B
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MYZ;4HH6_'L58@W.B-*8&ME+>BZ9<8".SZ@-:K$$EMCWF,0')*@-I#3PI$YE
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MSKH(7?=/6.A 0XW]R@4Z-PQS*-__8Y.NG[<EZ&+'(Y$3J8KYB$#D"&EC<B>
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M<O=9F:!;^?E!FEZRQ>V['P_:")*EMF0JPTA;0*LHS7B<4 PC*C4[2<DA"X(
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M"%8T@XI)I.(@0X&T:DC7M\C2S)I63E,'?9#4Z6B^%]-AC\X'4A,SRAZDS].
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M,%:0"*E@0B7/D@3K9UVY!.2=5E_:XUZ)^]>_X"@,__9):C?[5:W)+VV#>;>
MO-M.V$7F)\-W8MJHVQ<U#8N,BU'_H6W<?Q!^HJRO4;AYC=N[23!K '\4.$\C
M^>-N,H[CG@X*_L]\=[=YW'V55.3KGV^E:0B:%Z9:YW!">F^,HI6,6!H@%ID.
M;@PB2K1GI&@*4Q['*%.$Q]PJHG^Q)$OCOJ8#8G>NY9^U+F!;*P-$1QN@3(I#
M%?IWS&4=OW=V##G+CDQM9#T==;[?BT8-T-4#'*6;5+KX(\Z+X?1*HN.EF950
M+P;M*;E>?L-+B';?>O/MYI[FQ4K%#"<BH3"(B)G]J\U';'+Y51@IK@3/@LBI
M6/GD*@LER+V4X(]:3L<LC=.(NE#;!3C-0UL.$(VDHS,03$ U3U=Z 1HYH^QI
MBCCW85_S?RN[;I52G&&A]&.?20)1F!#(<!C"2$D:90$-0H3=^D.=6<GJRSUK
M^Z=*K$NGAM8HVCWTER#SDG,]^X'R,*/S"(:)AV[6:[WP%,TCA8?'8AY_W#UW
MZLW/>T;7.]H4F7+)A4@1-VT*]'\R(B%-0@$CE,0R($&$N74!]/&ME_:F;Z7[
MZU_"#/W-/OGE"6#]C_=E,$S\1+>"C:A4?@*"?4;/>#!FRM"Q!\4IU>:TWCVI
M,T\NF"T5YK2@W=26,Y^X,)_\X[ZH1(5*NQUI"N. 2H@XH1#+1,"0AA*GD6*8
M.,TX>[[$TJCHD-D\OK#G!)"VEL<E\$QN=#@A,SZ_^YGRTV1S?WR9,I7S:I[-
MU'[^2?=<M(_Y+J][J[VA99U %3(6$\X32+&,M'T1!)"82=J<R4R$)#.Q!MM,
MM.>W7]J#?9 0&!&=<]!. -C_4%\.R\0/M",B3KEGYQ6_.//LQ*UGRSL[KU8W
MZZSG4^Y.P3_SM2QWFT)^H3^K4X(W]"'?U5U8K\L/V@@K;G.V;@K26B.0"A1Q
M*6&4*3- AR"(XU0_WQ(KB3*6!,PJ:V2L $M[^/<Z@%:)*]!1 ] 2'!1I"DCM
M+?!16S3LK$P-_,3T,H3Y]0G,1[@_XYX/:R=IZDV8R94:LQE^O*U+ .SQR4;=
M=C;/[1*EN_[=1?<9V4;J.\W7U;G69ON-KN7A",R,D#S\]DFCT(S6P#%!D5((
MHD2_8Y#*%&0R1C#D)$8*$4H177V76[:Q[C#E+(3+,]<59;I'[B!;]XS_JAI!
M"\J]"HY]J=QWQ\[UG!;QB5\U1L3.V?T5V&L#U68+2VKF9Q\D]]C::C1J?GM>
MN8LQ;S.LT3 ]ZY(U_DXC@V+\3HK'M?RLWLIM_EV_IO6CW)EQL'?2RVX]M=SJ
M[]V]F<![78AG9=8?S?>J[6Y\R$=46,04*0:E&7B)*(FUT1X&,) BRU0BPP!E
M3L&VV41?FKG?:FZZ$\AJ>DQI?MSFY;^@5HW>UG&L_( %^%-N)=A*OKDM*H,H
M+\"FDYQ:5,FI>9.<*L<DI\[X3;*,-B[R^S%U%+/SU>BHW1U= PZ*/VEO<="]
MRJA]WOCB"K0 -%WCP22YM?/OG-\0['SBSQO:G7U;GH6,YY?@@CP7,Z5>BK>/
MIC.2%B+?B"J/KBJ[?DU+*4QNC2;:VDM/E0Q"C!3D<8;-<3B&5& .*8]1&A+$
M8IFXG46YBK"XUYS1 #(C)N =.4<DR[AMA>UIUI0 3_V>, +JUT(E_E6;ZUO]
MM4&\<<G!]79KIF.9GZ\ 57KC@39.E<QWCSZ:0UR.IO],'3<QYD_B&073R?R>
M<7=RC_)?IU'R:;.3I7B441"'39PRR3(69G%8#RE!,@D@29&$84HRCC,FX\ J
M[_?\$DOCM.!7+>:_@4I0H"4%1E3[:/ 9'(>#[9>C,S$AG<)E1+C\#$#V ?'+
M@9HIY#T.,*?8=C\6/='K,Q?.%I_N%[P;@1[XY#CK[ZO<Y=OJC?E%;]F-ODE;
MYZ 21$4B8$I"!)'2[Q\:10I2)-(PS%B2Q4YU#N<66AKK'>0$1E!@)!U9[G 6
M6SNCS0=B$S/A.+"<#:XA)+R:56<7F]5X&E+YJ8DT^/EICZ!6,<9!FI (DH1Q
M;1X%$60B15 $L6(RRB3"\>HPK-[;(8@3?>R7G^Z)N#%K3'.0Y/GX:$$T8G%H
M-/]!T8L>#RWS4.C2HZ +R:AM$J(=/987]+A[H/ZIS/6]JC]W @'E5_/39_7Y
M<6=.#,IZ0'9^>[>B$4DBDW0I&#8'YER35T@"F'!*E(IDF"HG"\>O>$NSB]R;
MWNI_:\8(2T#[*[/GV&X[]GRY39R88_<]5CN:'?58/5*N&TK3?%SI9TY@6@WW
M83BCI3]NG@9]KPSN6<19>7X:>)^^#29:9=P[XV9;38+X6840:R-9O-F4NW_*
MW=U&-,TUN&(AH9F B# )4<8#2"67,)1!0A!%C.!]2>^-_0O!9FTKAC@N\KV9
MUPO63_VN4:3F=<<\*:L=L"-G;X#.0[FMN*"25[-H+;%AW7(':J']-RUQ <DK
M,UHM/"O?N4#QE,6<KAW;8/):"/V%J\^"/V^_;#??<ZW8BA/),A0$FH_2#*(@
MYI!)DD*)(JR(,M7(5I;IT$)+LS&;_HJ-L)T6JZW KNTGS^#;SS8^49N88<8#
M-J(Y93\:%W2I/'/CF=M5]JOWO&_EP.?'F2MU#[F/F[)\KT6LS:9';3E]?FA,
MIO*U5)NMK#]W0W_(\MV/W9;J-;2IM?U9U2::C$M]I59?KW3[H="/KBQWJS3-
MXH@G%$:I,%D;,H0X"#',F"8;29 V@B*7$-V$LBXMJM?T;F25/J#./00[HY&;
M+33E]FH[-:!4;VK B##S>B)(4L$@);%^:2"94&4US6!IVSO#>Z<*VK:[J[=U
M.9MJ9Q<O9*LF?MDU#^$KH^<OP% X.*@*#KJV&]E\OE*WKCDXJ =:_?S9W3-L
M@E=S?4IY9[7R9P#^J7,PQY(7CC/^4#P\[LJ/\KM<1TUF"4I3F6 >P2A*0X@4
M11"G",,@#4,2*8XCMZJ&GK66QO#?\MLB5SFGQ:[IOOR9E7+[O4H,K\77Q&(4
M )'E.#8;Q.WHVQ..$]-OM]%J+>@5:!#SF,OC@,DTTW9/K/<RLW//*WYV$F[/
M)>X1BK=-;MB'HDI)W^>=KW@0L  '""),B/8C8@E9&C!(>$!5'":9#)AM=.+<
M(DOCCU9.T!&TJ2NQ3 KJA70X(.$#J*E/\<=@Y!2'& )A5 SB[$UGBS\,J=6-
M/0Q^=IS9<'Q.__0\_[=B*^M*=V/RM-4H*Q0%8:2I "J%(LT&J83:UV0PDE0C
MH"1-A!417"+$THCB_;XUO#DX.=26FRI&6H#'O1)@K;4 #XT:;B;'J-VRLT6F
MWH.I.<BF_/R@!3!J[$L&_5DOEZ#HU:P9)<BL]LXE4#TUA"ZZU]@SG":GEW&D
M6&(B;YKV($KT?VB6)#!6*J48B53_YG9FL\S\Z.;(P2TC^AE:MB<PB\MXME5_
MQ/G*8$ZS[7G*G/G*Y\1_?E[B)1^Y;;YSLZE&"&_EM[O-=G<CM_<?#HU=5E3&
M(5<!@5F6F&1DF4&"< )5$@9(121C)!Z1SV&U^$(3.K[H&]W14E9U]*61&YJY
M&=U^.&XVB-U.V!D=_H"=:5QP(R_8;4 C,?AVP/2#!:;.)H431EYM"+N59S4:
MG,!X:B6X73R2IV11F@2W9AB8-C9VVWU*U6M92)7ORE.3\+A,0AR$*>1IH*D+
M9V9:%TZA8 S3F"0ACYQBM&,%69K9T4E(:Z5VY*NQ.V))83/@/#&KG8!XHH&$
MEX+EE][&"C,OXUT(V3,2O/1^HV<JW\GUVI3JT^*G273CL: 9Y)K?( I8"%G$
M)8PY08Q':1*GCDY3]_9+X[#&=ZA$!(V,S@.5N_#9>E%C09G'E[+#8\PTY1-J
M7S),N7N[N6<IGU#EQ"CE4Y^ZM-E>F\Y?&4MUS*1\_;/S6WV$$>CG-B$I@TF0
M$H@BE4#&]/-,&"4RRD(:(Z=J*E<!EO:P=[N;[6MONBI< ?:S^P>WXZ31^V1G
MSDR)_L2LXA_X"YK"N:$W46LW2R%>J$&;&T3GVZPYWL?=?C'=U]9?[C:%_/18
M97=@$DD5$P+#S(1\A4@@"8B",8M#1%A$! MLK9>G-U\:G57R@4I 4$MH;[D\
M V[8;KD$CHGYQ0$))YOEG,JC+)9G-YO-7CFG1M=:.?N9L3UL3%=%OJM:@WV3
MN]VZ\F*T;_-!FT+YMNJ*8?+SC<=3KHC,:,R5A"99!2*B.,24)E!D-%.$8:J-
M%[?.-B[++^W!KOK5@WPOZ178=O6YJMJK5OUW0?D@JQ:K_(YN;V4)7IEN1"!Q
MS)=SW"T9I8QFF$&",@411A&D<1A"+&06\3A5&7*J6IAPM^9J+P+HZ#V;=*OL
M3,OI-F#R^-@1Q@?1*[@/PH.#]#Y;((U!S7-C)"<19FZ7- :>YTV41MUE9&LE
MSA_O']?F /"3W!V.'OY.\\(D*'PH^/I1F&:7FVU5++_;;7/VN*MZ_VY.)X^W
MB=XQQ2D.%8RDZ<\;!@3B$&4PP$D<81(B%$>.4T F$];E 9]G6D@G/4CK"HR*
M95UU(LM?P*;XZU_"-/C;(<_$L=O3=-L>RC +$AS!B&5F2G&&]%N2!9 F:11D
M*$XP)RZ&S3(V?0XCJ+/EA=[R6[/E_[ZN=EQO^/@1,=/MM=V[=AD[./%[^?KS
MFP]7H*-J]<@V=6)7P"HE< _$N3JQ"4H<IM\<OZW+IA-WWF9GD\/^K#W:]"NZ
MM[G^EN^V/W_<:!^!/LC'7<[+C_E]KD5L"";-$A;R+(8R5;%^F6#M<J4,P5#&
M3 J.LSBV&DEKL=;2W@:UN* K+V@$MN_N/(1O/X%[1FWJD/MYP$;TQ1Y"SKY!
MMD<$9^J4?1&23@VS+;'IZ9P]=(?96FA;JM+MI6U[R3C7KDJI,.>P6WEG\BR^
MRT/!\ W]L0HS)2EG"H8T-(8ZHMH_8P2F<1:H@,52^V\C\E,'EK7ZNL^?F=HD
MFX!7#ZUG_0O0AME1EPU U]6W63\%NTT3V>)=1=M/OUI7S0%R4U_M9JL/[9F=
MP>UC"^;A[+H*^DA4<-1AX<IT3O!G[5HBX]5D'5IS5KO3$H"GQJ/M92.#4-6T
MVA5)9":#!$/-/Q%$@:20!93"6(HHS"0+E,!.W;NKVRXX>.[JR-<P63K=SLI/
M[2![FB%]6D&_3F9]ZWD=PB-UGCEOQ_]Z@4'P<5/</JV/4%$4<:Y2R+-40!2G
M^L$3*H$J#0.I'SZ6J,PM4GMNJ>7%6=_]]Z-)_[NO&BJ.+T0YBZW#&_M"O&9Y
M51L9)ZPO&<+!_XOYU&+SOY%[5#[Y*N[[O!LYE-O=ZIN\K2)!<G.K/9&[G--U
M4R&)48JSD,601TC["$*%D+(D@1R14,A49,(,U!AV#GI765KDI2NA8XEI/YK]
M7. -HXF)P T>:PJP4K_O^=<WZ#S[^K>GSWW_"K,\]%9*MD^\W8<O/O=]JQW?
M0HK& S:#>\IK\7\?:UJYX' H$8ADINI5A6D D<(24A0);5KHOQ(12Q0YY6)/
M+_+2B*A1$[3!B:9<ILKTJ.ND9'T,_ ])U[N[P^<,(*,/":?Z/C@?%BY@EZ?V
MB3K'A<\VV^@+#@IW3@<;E4%79Q.2>I%3PXEW::K3PZG$?JE3Q(FWH><T<>J5
MW4\5]6W?_./#I^LV$4E$),0"08)H8OK%*<A2+& D$.:*J3"B5ADISV^]M!>&
ME@Y6XMF?<SW!:OA <#P"$Y/I7OD1IWU/4+ _W!N/QDQG><-?":<#N]/Z]IS/
M/;E@MN.XTX)V3]_.?,+=??ZRW8A'OBNO"_%-;K_G7):M^QR$C*<BAD$LM/O,
M @4IEBGDRC2!R4(5<*O:G-Y5ED9"C:"5E=I(.L*+/@_JL!?M!:J)V6H42D[.
M]" *%SO3YU>8S9D>5++K3 ]_>)PSW>OV<)31),Y2F @SPCI&,60LS6 L(IYF
M,9&IM.HN8+/8TJC@C$/BZ)MZ\"K_/_$'YW/@9G>]EN,TC7%W)G!4.N4>4E]T
MITGIK>F9O7DP5N&['P^R*.7*M+/.%.(P2GAJLND%Q))@R)F*&241PF[=;7M7
M6QI]M,)6+TEQ$->Y?JP'8#O^\ ;;Q 1RA%A'4M"(ZK44;!@1WY5?/2O.7>@U
MK/R)NBZ+B\9WSOY0F+JQ.NA2\]-7NI/59##Q1>HOF/8U;^4J%A0EH8Q@C#(3
M#0DE9*9/"A4D"4+3EU(AUW[9=DLOC5YJ^4#>OF6W^E?W%MB6L-OQS#1@3DPZ
M56W+0>JK@]UB!&_F 0IPD-UOBVLWO+PWMK9<?O9VUFZPG&IB[7B'L<RUS;_3
M7?Y=F@%&6\IW-_I&C:L?X)C%*@LAST(%$>$<XD3&D L>\2A$F0RD&U>=7VQI
M['20%;3".H91K""VY24_P$W.1",P&T$ZPV!XIIF>!6<FEF'5GU.)Q37CR,-^
MR/O'G+)\G>]^KC*M-THPTTP22(@HY=K^B024:9@P@M* "-F6/=BQR@@IK)Z9
MXRJ(B>GF(#'@79'!NI7YJBEY*/17Y7&[-9]L_\VY)GG,QMDQU52;,0^![5O%
M=<2_ IV].=+@"NQU\,=N%P#HE?3&R#$K%UX U%.*O.16XYCSX^')_;1_GE<8
M<\'22$),3")X&!%(4FU^H2A+LYAS$A/F4H%Q<A4G0VNV@HR:VT83VFD\[2CK
M8I0F)J6.?/4$VUI"?Y33"X!74CF]TJRTT:OL4V+H_[![9DR5//[A_OZQV*PW
MMS^;,Q0I!&:"(AB+(#/M_A'$4F+(:"+#E&6<":LCJK,K+,VWJFL9#E+:)XJ<
M!K#_.?<"R\3/^%-$1N30G(;&/I7F8HAFRJAQA\HIPZ87AIY$F]/7S99OTRMV
M-^VF_X,7SYO>U\-4S<@U;][<T=T;NN95LN(GN:M*Z:H/?Y';;W=T*W\KU&,A
MI-#6UWV^:^JV1(J2( X"R!C6IA!'"A(5Z5^S*$,JPEBF?.28:D\B+HU4K]=Z
ME:*.OG3JZ*[ 8R.\*9;7TH^HKIM@?^U,LY?=M8DY_WB6=F?#6@W!3JL(]CI6
MC>CJ3JW552:B#RI%S33+9H_?6.SQ)7.X/6_#5..[?8GY4E._/</<,RS<]THC
M4[BD7K.\J_IJZCN__OE;*<6'XO-#Y7<7M]=<\UHEWHJ%2C$:",@S1B$B-(0D
M0@G$6:C]YU1E.$U=G&3[I9?F.1L^,**#5G8STV O-S@([ICO9;\7=BP^#<(3
ML_-)<%\9R?7;]1<WF-W3PYP1\YLL9K_\O*ECSK \2R1SO\.EYZK[D.&GC7&,
MZ/KZ?O-8[%924U>*N8*4Q!%$2.\$#1&#QK% 2/,8SZ)QAZMG5ER:P=HY+>P<
M<A2-S(!60H\]:CV'NNMYJP<LYSMT_7B L1477/?#>,'IZP T$QW!GEOUA<YA
M!T X?Q@[=.&%GGC=L>:Z$)T0YC\E-6/\Q.?BJ^F$:_J;ZP]\VA3;]M?7M,S+
M9I073E00X:I[-(;:&5>0*:&MKE"Q-$AH*I33#%)ODBV-QKINW%[Z*@&T*_^X
MP5[^MM/1WYYSDV9TLR_8G_%.LR\LI_&5+Y;N95QD7Z">]8R]+>!^2G0=IE%B
MQNJ4;Q]E%*"XB>43&L4X)2%4 3&'PAQ#S"6'":4BS12/ F%=2'UFC:61:_BK
M%O/?0"4H$(\2&%'MST3.(3E\8.0!GXEY[0B:MPTT(\Z-SF%D?W+D :N9SHY.
M8N;GW&@ A)Z3HW-7SG9V-"!Z]_1HZ*-C!T+?T!\?A-[_7.6\^@XT0P*%-C29
MQ +B( H@RF@$&0I3B&*BJ! "I2)UFPU]9J6E$5\MK.F^"X[%=1Z\V ]P/Q-Z
MA6UB/AR-V(BAT@-H7#!?^MR=9QXU/:#@\ZG30Q=<T#)5VUI2.\W:IBI-^*[)
M[=)_3#B.$B@DU<R0AA)BB@-(:$RQD@D6H5-EYOFEED8-=0+$]B#JB%:IIS&U
M<Q+](#4Q&]0@=:2\,L>G5^"-[^2Y833\-TT]O=S\;5-[U3[9.+7_BG$D\>9.
M;[S\4%QS;B)HV@M[5^[R>[J3KW^:4H?K'WFYRA 2*1,2\CC6OE-@YKT*@J'*
MTD0$7&2172L8ET671ARUS" OP$%JT(IMCK>,X. /([ICG,IJ"^S8Q3>P$_.,
M%TR=2<<%)*_T8[7PK$3D L532G*Z=D1?9U.J^;1];/4H8"'2@ 4<AA)I9T:2
M%+(LSF!  QF00*:$"NN^SN=661K]'#<N=F"9?BS[:<4;0A/SB LX;CV=AY2_
MO*?SV17FZ^D\I.113^?!#[N';,T@EGW)$/]9.S^?U1>]4K$KWZQI?E^^S<O[
MO"RE6'&J)$IX"-/4=)6)M!=#3#<(F0B.M0.3X<RJ!X3SRDNCA%I:L%'@H9;W
M"O!*8B!:D>T#F6Y[,!P"G@S9B:G$R TZ@E\U 1#P68$O+<RU^.#MU##;1Y$G
M@WNFV+)?V)UBSZ.@ZXE(N]UOMCCU*#6[T>MQ-QCGE?ZGS&_O=E)<?Y=;>BO;
MM:H$VO+SXZ[<T4(T)X9\)5&8XBS53FF<1! 1G$"&5 !CG,A4A%+2U*E9O]/J
M2WLK5$*!5]JG*BMY?W%S1MV0M_-*)\-SXG=!*S=H! >'-VXM.^@(?P4J\?VY
MJ:-0\^JONDDPJ^,Z"IRG'NRXFXQCM'=T6^A;E6T9P-M\_:B77J4!5W&*. PP
M0Q QGD$2QS$,6,8E2Q CD7+AKC/K+(VE&K$JGA*;]9IN2_"@'ZV*LQPIZQRT
M=N3D ;"IS^8:";LE2XV4_MAF  :OO')NK5D99$#AIUPQ]/%17N^U-J76)C.J
M.DT.9$JCC$4PBHUC*SF"F&$*M?TB,R32A"$7Q_;HYDM[_K5\H!'0R7DZ1LS*
M#1V-P_2>9@O!B,2C9U@X^8JC,9G/'1S\>K@Z>2=U[O?CCB^9TU4[*>P3;^ST
M9\:9)TUW^>:[%/- 22&Y)FX<0R223#.1HM#T+<1!1I+4;NC,R;LOC8I,K=I#
M,]!@*[_+XM&QD>HQ=G96QVA$)B:E=K*#_Z;M)S7V:E8<KS"K,7%2N:<FQ.D/
MC:V0>SJWJAD*\693[E91$F6*:)!B9EIAF9[K5(8*BBR)5<1"*1*GL0V]JRWM
M>6X'DG MFVL!7!^H=@^V-Z@F?M!/3>R[V@]S>=.'W8BJ-PM,/%>\]:TX<[6;
MA?+/*]UL+AK=+>#0N. ?4MQJMZ9Y=V$L)9(1@4(R#I'B,21*.R0)$EQ)'L0R
M=<KS.;_4TDC#& &'OB_@3LLZHO+_'*YVU.$'K8EYPP!UD!(T8DXQY&40#=]5
M^^>6F[M*?T#M$U7Y0U=<6H5_:*9>_IWFA3D)>OVS6>JK7%?.8'F7/U0I);%$
ME#(4P#"),411JIT'(2*82I6F,DF9AF5<:;Z+&$LCF/9!Z<HY*EMPY*[86B]3
M8STQ/8V!^8(J_C$H353:[R3*"]7[CX'K?!. 47=SC].^^?S[A[<AN2YV.=N(
M?!]P0T&J8HDE5&$B(4(9A5BE'(8L#4-.8XSMC*6>-99&8I68,"3@(*A]Q/(<
MCL-!7 _H3$P[)X 9$=,]AY!]:-<#4C-%>%V^2DZ1W@$(>@*^YZZ<+>X[('HW
M_#OT45]1I6N^>Z3;G*Y;AOUP?R]%3G?RJ^2;VR*OYJ*;WN\/FT*:83O:'/VB
M*5H+Q9O[&)_US59?M5N1...8R4P[F)G0MB%5$(=46XEAJO\7!"@0RFU^Q=0B
M6STZLPZ[:+3X'RD ;54%:ZWGI<$NSWL]-E[V OOWDB&WO;K Z M>&8U_N0)[
MI4%':T"KX1JUWJ9LQGCCK>K[^[XRVO\":OVGC.)-LU,3!P(]"_W"L<1IMF X
M'#G1NN[6N9GU]LTTD*EZS%Q_I_G:%$BJS;:D:_E;L95T;;C2R/EE4U9RK7C&
MI>"9TK9Z9.*< 8,$"6V_BQ3'- OBB&%;TWV, $NSZZLN3]^KML@;!<J]-H9B
M: $>]TJ 6\-1#XT:]I;MJ%T:=@RFQG[R%P+;@8/\^EW0:@"U"M#H8)I3[\&O
M7A!?Y@'?WN>8>A-F<DBFV0PGU^42)'O\FE&WG<WIN43IKD=TT7U&GJ1MBM]:
M'YT+D04*Q3#CH7FEF,G$E&<P31"F#%,1,ZNBU!/W7MK;PF1&YT*"WW[]]JOC
M$5D',,LSL7$P3'T(MC'_/\6AUW-U_9YR=>X_[['6<\6>G6.=^,BXY_*#?ED4
MM[E^^NL^A-KT?/>#KQ]-+O_?-QOQ9[Y>KP@5:9@D"60DCB'2#R@D5"$8J3#-
M9)JP,(M='EB;11?W)%=]7O*]Y/JM5TC'I!DKL.T>=M\03LP"!W'KP2)UEQSP
M:B\S:(4^7]#@S! N&'FE#JN%9^44%RB>DHW3M2,[ZVC?=ROO9%%69U5\<V\&
M@GQ6-_3'2I*8!%0RB&)3]1.1 %+"*<R4H@QE,0N%<!G#T;.6$^?,,'?C2%3-
M/496QWXY/<#:$8TGN*8^5#I"JA9S'Q\T3*-]=2VQ]E1VNVW.'G?&W@6[#?A"
M_7;ILH#+;Y^<GO7F;8\SK/BSKC@6EXSEDWH ^7_FN[LWC^5.WWE[&# =4DY#
M&J0P)'&FS1E31XB$:8U!(Y;Q+%-)L/HNMVQCW:2K;SV7QZ2[ZI1/2RWN^#&X
M_0#;,HLGT";GE@:M/[6@H)5TDIG<5I!XYH^^%6=F$ OEGW.(S45>9X6]SPM:
M\./Y5"@+E8PPAY*8P]J <<TFB$(69(RE,<$D33S,"CNQ]-)LEOTXJVJ"E=IL
MP5YHWX/"3FV$9:AD$GBGCJ3T#PIS@MG7H+ >Q.88%'9J^24,"NN!Q7)06-\=
MQK'9S;8:*O'SVV[#_U5-GEB)Q-0NL@2F24 @P@F&5"D%,Y+P "E,N8C=4DR>
M+[*\I!!SEFK\ 3.E=E. THAJ3N]VC>QNW'0"5CL.&@G5/%S3"@<JZ:[JL3;^
MV.2\[EY9X\0RL[+#>36?LD#/)Z?M"G7-RLI^6M$HX7&**>1!A(U3I(T7G@H8
M\TRE,8TSY=9<Q56 I<5[FZY%C_7K%?!F4*W)+-+<(=L^(_M&+/]GFMY1^_VQ
M(Y4I49^8<AP[2+5=<?YH5?%XM#06Q1?I*+478I%-I9Y"-+:OU+/[C*/%:\X?
M[ZN!T^)YHE9Y+?[O8UT;IJVR?;96T<2ZOVRV5:96)X)XL_FDX3(NZ&:M5[W]
M4&AJDF7;WR"E/.("$4APED(49APRA2*8(8YY%LI,_\>%4V>5?FF$?'V4P#OJ
M_&W>W;=C[,7NZ<1TW]$;G,KV+<%!]SJ$W\GY!7L(0(/!L\#^,0R@Q6&"1(07
MV4&OKYIY-9CU/?4BF_/T)?<R0HRN:Y';K0E!F/.8&_JC,Y92R[=*0T1-T1Y4
M@7Z=(9(IB 62,!"24HY#I"AW[)?2M][2WD*MN&!'?XP_/AD"V>[5X1&ZB<E^
MCUIS,FMFIW6$K?C=:_6%#2Z^BR=ZUYR[]L$&@!.E"U:77=HBH7M;K5 S$PPG
M(<$B36$6:$Y!&(60"9Y!F2H6R#@0C) V&'DSIB7"R65'A"=O9LLV*_9B7D(U
M_;#;4LWE*,Y%-:VDAP/:*W 0=8K6!KV83-3#X/2:+]2LH!> \UT)^B]S+W!Z
MO]G*_+:HI[WQGV]EL;G/B]KL8JU;)LS41OTM@D1BS3,9)I Q%4%%J0JS+)-9
M8-4!WW;!I5DPC<R@%1ITI 9&;/MJ&2N\^PEF"A0G9IA! $>T,[#[YEK7&?E&
M=*:Z(@_(.A41N<#44S1D=9O9BH1<E.H6!3E=-\X$?/U8:N>W+*_Y?S_F=5E1
M]>-6RK>;>^WYKE(>A)'B&*8L$-J[C -($\D@%X)D)&6<R,C%NQQ<<6GLW H,
M.A)?@59F\$<MM6,?K&'<[:Q KVA.S-*7 NEL#EJ#X]4@'%YU5I/0&H2G1J']
MA>YFX742!,&GS4Z6;Q]E%,1Q.T2 J"3B1&.*A28;1!FD(D8PH4$LI,I(HJQ"
M63UK+(U>@E^UG/\&*D&!>)3 B&IOIIQ#<MC&\X#/Q(1AD-E#\[:!9H0I=PXC
M>^O- U8S&6PG,?-CFPV T&..G;MR-@ML0/2NT37TT;'E#]N'S5:;;L>%WNVI
MM.E.K%U@S7-) A%F0MM8YFA:;W? * K32#I-*.];;6D$N!<6".-/'/IWN-8_
M]"%L9TUYPVUB8CQ ]J3OPP1GJ5:8>"Z Z%MQY@(("^6?%T#87#2.1TROFRH9
M\6U>\O6F?-1?JQOY8_=:2_VO%6&,IU*D,%"80<03 7&():0H0$&F8A2&3LV+
M>U=;&H\T^=ET#3JM5=TXI!]=.P[QAMG4,3/3-:D2%'0D!7\864$EK$<2L0+%
M*XGTKS@KB5@I_Y1$["X:G7*W>=0/QQ?ZTR0OO&F/^S*.9,(C2)3)(]"V",1I
M&,$X2W@:BD 2937!K7^9I=%&*R5XJ,5TSE\[!:4=55P.T,0<L<>FD?"JB0-[
M/++KQ\!W3M6II>9.?NI1]T264M^GQY[Z/VRE?D\:/U3_O)959*<0U_<FK^E_
M:F<84<:$BC#D(0D@"F0"248H5"J5 <U0PF.K'H,NBRZ-&;HR UH(0#O"NA[Y
M6V!N1QJ^D9R80KKB7H&]P!6>US9XCD@"L ?(<R: Q<(SIP/80_$\)\#A6O<(
M\+O[6VH20;YH/ZG8?=0>TFUURW8\0<Q2DB !E6EMA0@-(8M8 JF*0Q3'3 7<
MJK_5\%)+8YU66E"+"P[RV@<\!\ =C@W[@VQB>CF/UH@X\0!L]N%B?_#-%#6^
M!$:G&+(=,CVAY($;S!91ME.D&UBVO.+"N%#=$.R?5>VJ%)^+KR;^M,V+V]>T
MS#O!C(0AAK5G!Y,H,N.ZJ82,:(\O4HB1A$G,TVQ4J,A2@*71[K?'^WNZ_0FX
MW.Y,58LZ-)7."[79WC<6#*W4&QE6LMT<QTC3!)#/%GRZ:KH/@E9\H#EGKP"H
M- !_W%0U1-.&IAQ1G"9:92O$RP2P'"$Z&]-RO<]EN4UO-O?,I$V9@5I?-NN<
M_UQA'*1*8@R%=FTA"@.A+<L$09J03+'01,&<V._\4DOCN7T23E?4<;E+)W"U
M(RX_:$U,42>! K68X(_F_R=AI&%X)LE7.K'<BR0JG5?[7(92SQ47UZ1791\G
MVB*V?JI2$4."P33CFDAB3"!)N#+3AP4301Q+P4;6D_>OO#1>Z18/UZ4RQPU
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MGXI_V7S0&4XXR3(DH=))"@DF$E)"%)1)$@G%D2%,IP9M/<:>&GONJP^6,F[
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M]Y2_;CK=2/=[3-+ /-SL0=_4Z0;LM"JFKJG7#:@UNRG(V$ZGN62GWB#=Z8,
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M >J;*%T.\U(54;:-W6$#\N",W&-U1FZ^5]B/J$*_#VXL]SWF>!R*//((*_5
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MU5AK=:_P2%*%XSB&BF02$ELU)D\IAE'.8YZD*4^DTQ;!R9.GYG 6PKGT .\
MK)WHKX)A\/U11P2\CF.=U;;76:S#)XUV$.NL LU36.<OZ-GA:K62?\P7BQG5
ME*%,$2@8U9#$>019E@J;*J<P48PGB5=-YOK!4UMVM5R>C9]JF-S,JC[*#[S8
M.O7V;XMTI&38?D;UP\=M1'2DTDD'H>._]UMT;[[96I_/\\UC4;Q=V]//MU]6
MS\OM+,.$XHPCR+BM9I3&'/*4YI!%2J8"(\%RKPZ2EX>:VL(\E-0>UK5MN6\
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MA!1PW+H9 T![4A=CB#$N?2*:;YVYZ^__^@_U;\S_<+91__H/_P]02P,$%
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M>M<'S!7AI)++Y21K+I&G#,X$$HKB$6+M(V(LTZ)X+D,GB:[=;V^'E)>6&.U
MTJ- S-LY/2VDU?0+O@FKL&%K@L&C+CP#U^0O*\$TN)P9L.P54XB!ER[.<'>_
MO1UB7EIZM -)CP(Q]6!Z\3JL\*Q97$VT]8PAQ=<9%2/RI2 36?]9B!V#/D=V
M6@W(CI>V*R)[:9G1X^4Z"EA\O BSV8^72Y+&<DEAEK=,N5J1O2[0KBE_37ZV
M]38X5,B9T1W XMY+V\'BI>5 CY?K*&#QTP4NSFA__-.B^6UU_KJY^!SF5Q/C
M4 2M(GE2(H#B"B&XP %)4D*:Z+WN(E>^\^7M8/+2DI^GRWD4</EXCK/9EGJT
M+,N4*3#C%(XIIS0$HKB6*$BIF'3H3[O-\/B=[<#Q<C*A)TIU%)BX;A&UOO[S
M\9S$N'QWN:IM1VL(/ZDP=M[J*A@*WKFL-W>,K,T2+9E#9UDY+?C]-@WM,/-R
M<J8=2WU@#+TB^>0JHY]GX6S"HN>6! !"RD3[9Y;@%"N@E>;:2X/RR=9_WX;+
MO=>U0\;+R9\>+\N1U*__/%VF,/L/#(N?Z2?+B3#2,%4D&"]*;35G()(,0#AT
MAB'SCI]VRK;GQ>V \7(2JEW(=U00N:[&OV8BRRP,"@\F)P,*#0<7M0(C>5)"
M483>41OB1Z]N!Y.7DV3M1L;C<$J(C468O9UG_/IO>#61Y&#'(@CI@3M0MNZ-
MSD<H7HK(F9#<8Q=^R/W7M@/(B\NMGB#;H6LXKK-ZMW9P>Z&'.Y,M%P@L:T8
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M+.9D(I?O<;&NW[R1B-8Y.R4"H W$!T\&0JB][HLU5@3#C.MGM]Q'T; .?Q_
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MM%GV4Q#4AKIA3W"&-HBGJFM$]O A:S]>+J=SK&?QZXZ]5<PWO=]29-*SQ.L
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M46?13QWS-TD;AWD["0 M0'6\-@8^=7^_P"_DRGPB!S1\QLO5-"W?SM.V.ZO
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MQ-#5A+T@;"C6@O7U2F95/"&8AZ1,,(QK[66;'C<;R>GB_#U4U?<;>ATL]P[
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M:4\2206DCKD(&6L<OI4IV/CYL=.D@]N"PX780<)AB,3-']?3S%/11@J7P95
MP@PY0PC,@V6>URD9*'R;"4^#LM%)[[514VGCX:*#37&3"+]B^A?M=-)_.'MU
M/KN8+D^D84(BF8FHBP$E78(HZWAHF1DZX1B/K=)QSY#V\ILL[ F;1RLUA]!A
M5Z!<R?8>,T8K76A;0S#<UTH08BO0*60P:R^#"HJU:;SP)%DO_V'RT& \5'<=
M /'OX:_)^<7Y%ZS^4WVF&.HHKN6O3^7!XX_KB0[\Q EBHQ0&L00-RL<,ON@
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M5A!I7VV1N-QES4[:HX^&M:8ZZL+JW<X7OP\)UWLH9%.\2A*X<K4G/+'@F,_
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M]4]QNEC=L:39.=8MLO&I[\TSW[32]^M:_H^U;V'2B#&%#-G7ZH&@&3AK.-C
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M.1A34S-1%' U^"TIH#=.9Z:;5WP<VF>WZ[?2@Q9^#*7)GO"Y58>[+#@9[>)
MI?KN%BV'8'0"*[G0,96B2YOTV._79W<GG!S49W<7I?6$R W]7+5GP4@9H&!]
M-!E0@8\F@@U1!U%<4(V>3/\F?79W@L(.?79WT4NG$+OJY^K(AT##$4P(%%#9
MFA#,1H(0C!?&4PRQS;RKWZ3/[M 0VT<OG4+LJI^KL+R(4"2@DV3Z%47O)!@'
M(:")W$MM<IM<VF_29W=HB.VCEYX@-DAC X?*H=4<2 AUV)(1$"@,!VF25LK$
M8!)K"\JC]=GMNG/.@('*T7'1P::XN>2YY/ZZA:6U3&HR$B8X"XHG!"^M!9M+
M4$;[8&+K:J4[!'7B-1X?(H_6E>ROKPYA=ZOEI&#>A4*.BZO%T(K.)G R&CJ\
M@LDY"E/D<9"W8P/1KM_QM '?GEKK"G^W9'FUET@*B5F2CF"&D5^3.7CG,V!A
MP0IC:*>UNOMXG*I.',Z.,'B@YH9N$C4P&&_MK<24SD0Y,$\!G'(B@=,A ^=D
M])/P0IK6=9L;"7OY104-(;FG_OI!Y>N+!4EGL7@S.X^3RRNJ6JE#HB.>Z*?%
MA/2[[@]VR?6O$UZ%A9)!R=K5QR,"O+<1O Y&FN*]NS\">""D[D'LR[^C&0:]
MK?5\***/V(?OJA+M(IS]/2RO>Z,/V8/OR27:]-_;GJMC]-YS,5*8H@R(K FJ
M+M3A3!BK;?0\&N&B;IPW:=![;]O.^B=>*>Z(4X@H/*CL&02*V*!PG3*=!=PV
MXGY;"CN)LP]%SKZC#W924 ?-:Y_FZV:[UR;ED^FG*?Y/#/-K*9]DXS+WQ".R
MFL$UFD%DJ8 UDD>KN$$UQB":Y^CN)!X_+D@'568'(?BVW+XJM"8Q^^UT/KOX
M?OJ>W.S*]\UUQXD7H6"=(^BRXJ!2K8G3*8(QWJN@H]"Y33'08"QT$MR/!>AA
M5?S2L%W977/^#:?W&(^,!Q,+!XV<&*\U@5%G!89SJ;514LDV#<D'8Z&3+,&H
MV!Y,Q2\-VP^YM2KFQ(A;J[(%%0AYP1>*)(L*TMJBLFPS>OXPNCO)%HR*XL.4
M.1AT6V<!_IS.,9Q-_@_FVF=V$::Y]IH=.A'PW"IM<@$[\7:45OP)D=<)7TS4
M I4BR/AAS6&Y'%R=^*#8T5JE-4L'W(TQ7Z5T<7YQ5G-;?ZMO;>_JY#66V1R_
MA;].D@TQ\A@@.<9 88C@<S2 RN0@I>>:'V?"XE[D=YQ(V 5SSQG,]JKM\,C?
MENE5C^YKIK.W/(E41_DF)#_'<?)SN()Z.<RU#$S+-EM]$/([SCF,@>?]53LB
MGNEX/+G'X!7[Q,F"V+^[83_/%I.JX1,>N(BL=NG3=:!O];-<D X88\$F9KR\
M/^SV@0^P[]H=IP;VP=U15-"!R7R$Q_4NN[N/KGDL4<K@37W[YXE'NWKA62QP
MIHPK4B:CVYSX^U#;<5Q_B$%LKK@7$P=].4(4]/0:C>:1]14!.5/[,^4,1?)(
MULU%,FRUT2&SS!;N5%!MVARUB("J>?\\G]'^RXNZ:>N>F97+D;DDZMNV_FZZ
MX42'PK(K'))T==*XK4VLL@,4D@LLI=C['7@V'K%[+=YQK+(+.FZ?L>V5,+(?
M]S@7Q.*#V>+_^/CA]K8_"<600"V"=2:16+6 4+0#[M!QSJT7/F^!MH.(Z#BB
MV!=UQU-*1^A;[,)H/6Q.G'42R1,AHYSK32TY*>2^)M!2630%8Y!R1_3M3$3'
M<<40Z&NKE"Y]N ]3^K&&X[B/=W;[OS[<[WJ4EH$\JNOOW^#G&CZ6Q<@XA88V
M.@8J\5#G3QO@(F@7"DK/VA2U/$'4X2U8'WSZ&XGR-?V;?Y[$:*UC)8-(!%^5
M@P)G,8-DQ7EG?$R-.NT_1=6X/M50^'C8A74@/?1N0?8/\S9\9%![TC)0>PHV
M46MOHJW.<,U"61W 95G 2F.*0FN4:9.^;FA6WI6"Z;+[]7J-JT:OD^G%9/K]
MTX]UZ??B1*!$+ID&7;M5*"8-1(H2P%L,1C,5=5!-V-^>QGY-SB[8>3 PH8V.
MNC1 7W Y64^$PBF6R7(? [3A(X<;H.<H&\@ O:5/3S&OU_A\%J;U:<BGY2G.
M/\\(3/>I6/V+33ZT4$IY50R$$#V0YC6X$B3(.J #=4K<M2FS&8J#@P=GX711
M=_Y3:R\VG>)!!>N$Y9!7=[-*9HB%?B(_P297LJ2MT$1R^U(\=L/[$1#[8.S6
M,93]0BSFJB'&,'9S_:D6UG,3E;W9T"**M(99R%;2<2IB;3E'I[;T+M57G"DW
MZM[7BPW]FDXQ7YSAI_(1K]9Z0P1<:N]F%S&N<PQ1@LV1=I%4 H(C-T0X21\-
M+-O0QF1N2>!O8B%WP>-]"]E"E2_$(+Z9G?^83>O-WZPR_QGGDUF>I%M"V#_8
M/62U%F9U3UX'LKQU=3J)+W?6--^0MR$DRHRIQ), PT6@6$5Y\(XCJ.1S4D'P
M9F/DMR=R./NYP0;<VN&7/:Q*\#+6"=\FN@PJU.UMC( 2!#-99RM<FQDD.Y$Y
MKBUMA;#'S>70FNN@-NE&:I6=.M1EU6&7:6YD\1&"S E4+@&"CA:<\()K^D6(
M-IT\-],S+M : F VN#:ZQ-2Z^:1VS%EM-53'@B(L)<&G+,#EC R%UMJU:0GR
M&$7CXFH(;3\+H#U$WP&$UD'\Y0Z[L^FN!V8;Y94D9S2B(=^T-GF4MD#QB5F!
M#D.CIO_/4=8;I/;1_^:,RC#*V!M</W$>9P/!Z[F :Q.3+JN4F+*U<E1 ?6A<
MNRKZ5?MY)2R[/:)]4,3M0>RXY41-0-A:91T8O8?>Q8US\<=U?Z>8O9'"<5 %
MR;\P*D!DY,JBDE)&8V3"-G>/6Y$W+O*.YZD-KZLN ?@5YS\G"6NRH)9B>94<
MHSU$@129>Z08BBE(7# 5DN&IM+GU?9*LWO)Y!\/@6:#MJY,N 78U5';%C9!>
MA'HT!"Y(3C[4EITQ@DYT,*B4);(V>:"GZ1I[N._Q(;:W5KK$V+N_?F!:8LT0
M7<RGGU:.[&6KQ9. BGEN.6#4=1Q"U!"R02BFI.!5C/)HUSJ/4SGVZ-_CXV\@
MC0W8;G)(/+XZG\V7D_^STN"G\GD^F<UOV?0W1.1D>:+J/ W!(_#5Y8LH 9PG
MCE-0.?$2O3H:,K>A=]P7@&-@=' M=FD[7]5>H?-).*NO,FIM_(?S<^*,=L<7
M3+/OT]6;QU<W=TT?IINOFM;RX#HQ*\G;-M'7Q^%*@]?. =/.1J-X3'BL4J1A
M.1NW)] H^!\/&9W:]<W\G10,)FBK(.<Z9EK4"=/T?\!C*!1CII#]L;S:S12.
M._AG#.P.H*G!&KX.6?!PW:P[3?8J^[K[WQ]>E/ $/<.5&9Q/EJNWW*^F^<YZ
M&VNOF1&6,XBRSEI,K+[*"-5Y5):GZ%,4;7*X.Y%YJ&7::K&;,A^,T0L9$6PB
MK"L".<3D(OG63)C"I%"^S:W<;G2.7FS0"&?WK55#[759I'67P[VKKS9^9F +
MUKA>:@> "<NBJ2.6LBH6E/8&(MI"SE.R*J*+F-KD8H]JR*I7>6>)R[R]5RIR
M(S+($NK=3GT;7MNLJ%R2\1R35FV"B,WTO"3#M MN[ANF ;0Q8HB[F"]/OI):
M5C>'?\/9]WGX<3I)X7*BN$G&I> 9V,SKH#+NP/.4(3@9O0PH9-IJS!>M<@M.
M]+O[4'J2C'&1-(1^9T,+>VS$X/?[+*SOLBDB+386 489$DO*$GS4$:(M):-7
M)=SO&G((8AXC8QS$#*C>V="R'A$P:78Q7<Y_G;S^<J(SV=)5Z7RH=R96N\I^
M[2=!#IK5+,CP5,R_P/0?WV<__]_U%R\!LO[-"A\K9-RL-R(,AE':[" )CFPD
M_I@L)]\OAV6%Q64-'Q;&K>,>E*\="@,Z.F<364[! Z=X@$>W52.OK:S#P_7'
MO;$<^" Y4+Q=@>-6,52.,1CFZXML20#/@J+%'"3$( CC10:6MKK@V0,B8Q?
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MM?;D<JP5Q6XH8@3KZ^AZ9A(X8Q0P^A4=A7K6-O:M-Y$U+K#:H>&^.SB8:CK
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M'Y:?S\)T,8@144:9B)R#5:5>]M7VWD+7(9%1,FNR]:J-Q]Z>MW$?*_6QA7J
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M3_<&[3R:(UO_1?TEA@7^?__/_P]02P,$%     @ VDA;4X9W(! ="   MBD
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M%.2CD'+N<Z22C*9SR$+WU6:A?B19N*0&UA[6.YF3NU3-)&=C'FPD@REN2*I
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M/U)C%46%IBRO2=\.JZDR%N_3<SVT92(T]$>!R@G:FYEPLQ1VHB"'1Q".FUT
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M4$L! A0#%     @ VDA;4WS>_G'M:0, <7(L !               ( !
M &QL>2TR,#(Q,#DS,"YH=&U02P$"% ,4    " #:2%M3%-#;2CP4  #0V0
M$               @ $;:@, ;&QY+3(P,C$P.3,P+GAS9%!+ 0(4 Q0    (
M -I(6U.OV)*#Z1T   \E 0 4              "  85^ P!L;'DM,C R,3 Y
M,S!?8V%L+GAM;%!+ 0(4 Q0    ( -I(6U/B(?+GU&,  "LT!  4
M      "  :"< P!L;'DM,C R,3 Y,S!?9&5F+GAM;%!+ 0(4 Q0    ( -I(
M6U/\,TOC^?0  +SU"0 4              "  :8 ! !L;'DM,C R,3 Y,S!?
M;&%B+GAM;%!+ 0(4 Q0    ( -I(6U/J4@-"/8T  !M0!@ 4
M  "  ='U! !L;'DM,C R,3 Y,S!?<')E+GAM;%!+ 0(4 Q0    ( -I(6U.&
M=R 0'0@  +8I   >              "  4"#!0!L;'DM.3,P,C R,7@Q,'%X
M97AH:6)I=#,Q,2YH=&U02P$"% ,4    " #:2%M3D/(?E0T(  "=*0  '@
M            @ &9BP4 ;&QY+3DS,#(P,C%X,3!Q>&5X:&EB:70S,3(N:'1M
M4$L! A0#%     @ VDA;4XDFQK_;!   MQL  !T              ( !XI,%
M &QL>2TY,S R,#(Q>#$P<7AE>&AI8FET,S(N:'1M4$L%!@     )  D 9P(
' /B8!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
